# 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases: Developed by the task force on the management of peripheral arterial and aortic diseases of the European Society of Cardiology (ESC) _Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN), and the European Society of Vascular Medicine (ESVM)_

Lucia Mazzolai, Gisela Teixido-Tura, Stefano Lanzi, Vinko Boc, Eduardo Bossone, Marianne Brodmann, Alessandra Bura-Rivière, Julie De Backer, Sebastien Deglise, Alessandro Della Corte [... Show more](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#)

[Author Notes](javascript:;)

_European Heart Journal_, ehae179, [https://doi.org/10.1093/eurheartj/ehae179](https://doi.org/10.1093/eurheartj/ehae179)

Published:

30 August 2024

-   [![pdf](https://academic.oup.com//oup.silverchair-cdn.com/UI/app/svg/pdf.svg)PDF](https://academic.oup.com/eurheartj/advance-article-pdf/doi/10.1093/eurheartj/ehae179/58966255/ehae179.pdf)
-   [Cite](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#)
    
-   [_Permissions Icon_ Permissions](https://s100.copyright.com/AppDispatchServlet?publisherName=OUP&publication=1522-9645&title=2024%20ESC%20Guidelines%20for%20the%20management%20of%20peripheral%20arterial%20and%20aortic%20diseases%3A%20Developed%20by%20the%20task%20force%20on%20the%20management%20of%20peripheral%20arterial%20and%20aortic%20diseases%20of%20the%20European%20Society%20of%20Cardiology%20%28ESC%29%20Endorsed%20by%20the%20European%20Association%20for%20Cardio-Thoracic%20Surgery%20%28EACTS%29%2C%20the%20European%20Reference%20Network%20on%20Rare%20Multisystemic%20Vascular%20Diseases%20%28VASCERN%29%2C%20and%20the%20European%20Society%20of%20Vascular%20Medicine%20%28ESVM%29&publicationDate=2024-08-30&volumeNum=&issueNum=&author=Mazzolai%2C%20Lucia%3B%20Teixido-Tura%2C%20Gisela&startPage=1&endPage=163&contentId=10.1093%2Feurheartj%2Fehae179&oa=&copyright=%C2%A9%20The%20European%20Society%20of%20Cardiology%202024.%20All%20rights%20reserved.%20For%20permissions%2C%20please%20email%3A%20journals.permissions%40oup.com.&orderBeanReset=True)

[Guidelines](javascript:;), [Acute aortic syndrome](javascript:;), [Aortic aneurysm](javascript:;), [Aortic atherosclerosis](javascript:;), [Aortic dissection](javascript:;), [Aortic surgery](javascript:;), [Carotid artery disease](javascript:;), [Chronic limb-threatening ischaemia](javascript:;), [Endovascular repair](javascript:;), [Exercise](javascript:;), [Genetic aortic diseases](javascript:;), [Intramural haematoma](javascript:;), [Lower extremity artery disease](javascript:;), [Penetrating atherosclerotic ulcer](javascript:;), [Peripheral arterial disease](javascript:;), [Polyvascular disease](javascript:;), [Renal artery disease](javascript:;)

Topic:

-   [aorta](javascript:;)
-   [aortic aneurysm](javascript:;)
-   [aortic diseases](javascript:;)
-   [peripheral vascular diseases](javascript:;)
-   [aneurysm](javascript:;)
-   [follow-up](javascript:;)
-   [surgical procedures, operative](javascript:;)
-   [diagnosis](javascript:;)
-   [diagnostic imaging](javascript:;)
-   [guidelines](javascript:;)
-   [mortality](javascript:;)
-   [surgery specialty](javascript:;)
-   [revascularization](javascript:;)
-   [surveillance, medical](javascript:;)
-   [medical management](javascript:;)
-   [european society of cardiology](javascript:;)
-   [acute aortic syndrome](javascript:;)

## Table of contents

-   1\. Preamble 
    
-   2\. Introduction 
    
-   3\. What is new 
    
-   4\. Epidemiology and risk factors 
    
-    4.1. Epidemiology 
    
-    4.2. Risk factors 
    
-   5\. Evaluation of peripheral arteries and aorta 
    
-    5.1. Clinical history and examination, and laboratory assessment, in patients with peripheral arterial and aortic diseases 
    
-    5.2. Functional and quality of life assessment in patients with peripheral arterial and aortic diseases 
    
-    5.3. Vascular examination of peripheral arteries 
    
-     5.3.1. Duplex ultrasound 
    
-     5.3.2. Digital subtraction angiography, computed tomography angiography, and magnetic resonance angiography 25
    
-    5.4. Evaluation of the aorta 
    
-     5.4.1. Aortic measurements 
    
-     5.4.2. Normal aortic values 
    
-     5.4.3. Chest X-ray and electrocardiogram 
    
-     5.4.4. Echocardiography 
    
-     5.4.5. Duplex ultrasound imaging of the abdominal aorta 
    
-     5.4.6. Cardiovascular computed tomography 
    
-     5.4.7. Cardiovascular magnetic resonance 
    
-     5.4.8. Positron emission tomography 
    
-     5.4.9. Intravascular ultrasound 
    
-     5.4.10. Digital subtraction aortography 
    
-   6\. Screening for carotid, peripheral arterial, and aortic diseases 
    
-    6.1. Screening for carotid and peripheral arterial diseases 
    
-     6.1.1. Lower-extremity peripheral arterial disease 
    
-     6.1.2. Carotid artery stenosis 
    
-     6.1.3. Multisite artery disease 
    
-    6.2. Screening for aortic diseases 
    
-     6.2.1. Screening for abdominal aortic aneurysm 
    
-     6.2.2. Screening for thoracic aortic aneurysm 
    
-   7\. Optimal medical treatment 
    
-    7.1. Lifestyle, exercise, patient education 
    
-     7.1.1. Diet 
    
-     7.1.2. Physical activity 
    
-     7.1.3. Smoking 
    
-     7.1.4. Patient education 
    
-     7.1.5. Risk scoring models in secondary prevention 
    
-    7.2. Principles of pharmacological medical therapy 
    
-     7.2.1. Antithrombotic therapy 
    
-     7.2.2. Antihypertensive therapy 
    
-      7.2.2.1. Renovascular hypertension 
    
-     7.2.3. Lipid-lowering therapy 
    
-      7.2.3.1. Statins 
    
-      7.2.3.2. Ezetimibe 
    
-      7.2.3.3. Proprotein convertase subtilisin/kexin type 9 inhibitors 
    
-      7.2.3.4. Bempedoic acid 
    
-      7.2.3.5. Hypertriglyceridaemia 
    
-     7.2.4. Diabetes and pre-diabetes conditions 
    
-     7.2.5. Other pharmacological therapy 
    
-   8\. Peripheral arterial disease 
    
-    8.1. Lower-extremity peripheral arterial disease 
    
-     8.1.1. Peripheral arterial disease syndromes 
    
-      8.1.1.1. Clinical presentation and diagnosis 
    
-       8.1.1.1.1. Diagnostic tests 
    
-       8.1.1.1.2. Imaging methods 
    
-      8.1.1.2. Medical treatment 
    
-       8.1.1.2.1. Exercise therapy 
    
-       8.1.1.2.2. Pharmacological treatment 
    
-       8.1.1.2.3. Aorto-iliac lesion revascularization 
    
-       8.1.1.2.4. Femoro-popliteal lesion revascularization 
    
-       8.1.1.2.5. Below-the-knee artery revascularization 
    
-      8.1.1.3. Follow-up 
    
-     8.1.2. Chronic limb-threatening ischaemia 
    
-      8.1.2.1. Clinical presentation and diagnosis 
    
-       8.1.2.1.1. Definition 
    
-       8.1.2.1.2. Initial assessment and risk of amputation 
    
-       8.1.2.1.3. Imaging 
    
-       8.1.2.1.4. Mortality risk assessment 
    
-      8.1.2.2. Medical treatment 
    
-      8.1.2.3. Interventional treatment 
    
-       8.1.2.3.1. Revascularization 
    
-       8.1.2.3.2. Spinal cord stimulation 
    
-       8.1.2.3.3. Amputation 
    
-      8.1.2.4. Follow-up 
    
-     8.1.3. Acute limb ischaemia 
    
-      8.1.3.1. Clinical presentation and diagnosis 
    
-       8.1.3.1.1. Clinical examination 
    
-       8.1.3.1.2. Imaging and functional tests 
    
-      8.1.3.2. Medical treatment 
    
-      8.1.3.3. Surgical and interventional treatment 
    
-      8.1.3.4. Follow-up 
    
-    8.2. Extracranial carotid and vertebral artery disease 
    
-     8.2.1. Clinical presentation and diagnosis 
    
-      8.2.1.1. Clinical presentation 
    
-      8.2.1.2. Diagnosis 
    
-     8.2.2. Asymptomatic carotid artery stenosis 
    
-      8.2.2.1. Medical treatment 
    
-       8.2.2.1.1. Lipid-lowering therapy 
    
-       8.2.2.1.2. Antihypertensive therapy 
    
-       8.2.2.1.3. Glucose-lowering therapy 
    
-       8.2.2.1.4. Antithrombotic therapy 
    
-      8.2.2.2. Interventional treatment 
    
-       8.2.2.2.1. Open surgery vs. medical therapy 
    
-       8.2.2.2.2. Carotid revascularization: surgery vs. stenting 
    
-     8.2.3. Symptomatic carotid artery stenosis 
    
-      8.2.3.1. Medical treatment 
    
-       8.2.3.1.1. Lipid-lowering therapy 
    
-       8.2.3.1.2. Antihypertensive therapy 
    
-       8.2.3.1.3. Glucose-lowering therapy 
    
-       8.2.3.1.4. Antithrombotic therapy 
    
-      8.2.3.2. Interventional treatment 
    
-       8.2.3.2.1. Open surgery 
    
-       8.2.3.2.2. Endovascular therapy vs. open surgery 
    
-       8.2.3.2.3. Vertebral arteries 
    
-      8.2.3.3. Follow-up 
    
-    8.3. Other arterial locations 
    
-     8.3.1. Subclavian artery disease 
    
-      8.3.1.1. Clinical presentation and diagnosis 
    
-      8.3.1.2. Treatment strategy (medical and interventional) 
    
-      8.3.1.3. Follow-up 
    
-     8.3.2. Renal artery disease 
    
-      8.3.2.1. Clinical presentation and diagnosis 
    
-       8.3.2.1.1. Epidemiology 
    
-       8.3.2.1.2. Clinical presentation 
    
-       8.3.2.1.3. Diagnosis of renal artery disease 
    
-       8.3.2.1.4. Prognosis 
    
-      8.3.2.2. Treatment strategy (medical and interventional) 
    
-       8.3.2.2.1. Medical therapy 
    
-       8.3.2.2.2. Revascularization 
    
-      8.3.2.3. Follow-up 
    
-     8.3.3. Visceral artery disease 
    
-      8.3.3.1. Acute mesenteric ischaemia 
    
-       8.3.3.1.1. Clinical presentation and diagnosis 
    
-       8.3.3.1.2. Treatment strategy 
    
-       8.3.3.1.3. Follow-up 
    
-      8.3.3.2. Chronic mesenteric artery disease 
    
-       8.3.3.2.1. Clinical presentation and diagnosis 
    
-       8.3.3.2.2. Treatment strategy 
    
-       8.3.3.2.3. Follow-up 
    
-   9\. Aorta 
    
-    9.1. Atheromatous disease of the aorta 
    
-     9.1.1. General concepts 
    
-     9.1.2. Treatment 
    
-      9.1.2.1. Primary prevention 
    
-      9.1.2.2. Secondary prevention 
    
-    9.2. Aortic aneurysms 
    
-     9.2.1. General concepts 
    
-      9.2.1.1. Definitions 
    
-     9.2.2. Thoracic aortic aneurysms 
    
-      9.2.2.1. Aetiology, risk factors, and natural history 
    
-      9.2.2.2. Ascending thoracic aorta and arch aneurysms 
    
-      9.2.2.3. Descending thoracic aorta and thoracoabdominal aorta aneurysms 
    
-      9.2.2.4. Surveillance 
    
-     9.2.3. Abdominal aortic aneurysms 
    
-      9.2.3.1. General concepts 
    
-      9.2.3.2. Aetiology, risk factors, and natural history 
    
-      9.2.3.3. Surveillance 
    
-     9.2.4. Optimal medical treatment of aortic aneurysms 
    
-     9.2.5. Surgical management of aortic aneurysms 
    
-      9.2.5.1. Surgical treatment of aortic root and ascending aorta 
    
-      9.2.5.2. Surgical treatment of aortic arch aneurysms 
    
-      9.2.5.3. Surgical treatment of the thoracic descending aorta 
    
-       9.2.5.3.1. General considerations 
    
-       9.2.5.3.2. Open repair 
    
-       9.2.5.3.3. Endovascular repair 
    
-      9.2.5.4. Surgical treatment of thoracoabdominal aorta aneurysms 
    
-       9.2.5.4.1. General considerations 
    
-       9.2.5.4.2. Open repair 
    
-       9.2.5.4.3. Endovascular repair 
    
-      9.2.5.5. Surgical treatment of abdominal aorta aneurysms 
    
-       9.2.5.5.1. General considerations 
    
-       9.2.5.5.2. Pre-operative cardiovascular evaluation and choice of treatment 
    
-       9.2.5.5.3. Open abdominal aorta aneurysm repair 
    
-       9.2.5.5.4. Endovascular abdominal aorta aneurysm repair 
    
-     9.2.6. Endoleaks 
    
-     9.2.7. Long-term follow-up after aortic repair 
    
-      9.2.7.1. Follow-up after thoracic aortic aneurysm treatment 
    
-      9.2.7.2. Follow-up after abdominal aortic aneurysm treatment 
    
-    9.3. Acute thoracic aortic syndromes 
    
-     9.3.1. General concepts 
    
-      9.3.1.1. Epidemiology and risk factors 
    
-       9.3.1.1.1. Sex differences 
    
-       9.3.1.1.2. Chronobiology 
    
-       9.3.1.1.3. Outcomes 
    
-      9.3.1.2. Clinical presentation 
    
-      9.3.1.3. Diagnostic work-up 
    
-      9.3.1.4. Therapeutic intervention in acute aortic dissection 
    
-       9.3.1.4.1. Initial treatment 
    
-       9.3.1.4.2. Type A aortic dissection interventional treatment 
    
-       9.3.1.4.3. Acute type B aortic dissection interventional treatment 
    
-       9.3.1.4.4. Chronic type B aortic dissection interventional treatment 
    
-       9.3.1.4.5. Management during pregnancy 
    
-     9.3.2. Intramural haematoma 
    
-      9.3.2.1. Diagnostic work-up 
    
-      9.3.2.2. Clinical outcomes 
    
-      9.3.2.3. Geographical variations 
    
-      9.3.2.4. Management 
    
-       9.3.2.4.1. Type A intramural haematoma 
    
-       9.3.2.4.2. Type B intramural haematoma 
    
-     9.3.3. Penetrating atherosclerotic ulcer 
    
-      9.3.3.1. Diagnosis 
    
-      9.3.3.2. Treatment 
    
-     9.3.4. Aortic pseudo-aneurysm 
    
-     9.3.5. Traumatic aortic injury 
    
-      9.3.5.1. Diagnosis and therapeutic interventions 
    
-      9.3.5.2. Long-term surveillance in traumatic aortic injury 
    
-     9.3.6. Iatrogenic aortic injuries 
    
-     9.3.7. Long-term follow-up of acute aortic syndrome 
    
-      9.3.7.1. Follow-up after invasive treatment 
    
-      9.3.7.2. Follow-up under medical treatment (chronic type B aortic dissection, intramural haematoma, penetrating atherosclerotic ulcer) 
    
-   10\. Genetic and congenital diseases of the aorta 
    
-    10.1. Genetic and chromosomal diseases 
    
-     10.1.1. Turner syndrome 
    
-      10.1.1.1. Diagnosis, clinical presentation, and natural history 
    
-      10.1.1.2. Medical treatment 
    
-      10.1.1.3. Surgery of aortic aneurysms 
    
-      10.1.1.4. Pregnancy and physical exercise 
    
-     10.1.2. Vascular Ehlers–Danlos syndrome 
    
-      10.1.2.1. Diagnosis, clinical presentation, and natural history 
    
-      10.1.2.2. Surveillance and imaging 
    
-      10.1.2.3. Medical treatment 
    
-      10.1.2.4. Surgical treatment 
    
-      10.1.2.5. Pregnancy 
    
-     10.1.3. Marfan syndrome 
    
-      10.1.3.1. Diagnosis, clinical presentation, and natural history 
    
-      10.1.3.2. Imaging surveillance 
    
-      10.1.3.3. Medical treatment 
    
-      10.1.3.4. Aortic surgery 
    
-      10.1.3.5. Pregnancy and physical exercise 
    
-     10.1.4. Other syndromic and non-syndromic heritable thoracic aortic diseases and/or arterial disorders 
    
-      10.1.4.1. Loeys–Dietz syndrome 
    
-       10.1.4.1.1. Diagnosis, clinical presentation, and natural evolution 
    
-      10.1.4.2. ACTA2-related heritable thoracic aortic disease 
    
-    10.2. Aortic disease associated with bicuspid aortic valves 
    
-    10.3. Coarctation of the aorta and aortic arch variants 
    
-     10.3.1. Coarctation of the aorta 
    
-      10.3.1.1. Diagnostic work-up 
    
-      10.3.1.2. Treatment and follow-up 
    
-     10.3.2. Aortic arch anatomic variants 
    
-     10.3.3. Aberrant subclavian artery and Kommerell’s diverticulum 
    
-   11\. Polyvascular peripheral arterial disease and peripheral arterial disease in patients with cardiac diseases 
    
-    11.1. Polyvascular disease 
  
-     11.1.1. Epidemiology and prognosis 
    
-     11.1.2. Screening for atherosclerosis in other arterial territories 
    
-      11.1.2.1. Screening for coronary artery disease in patients with symptomatic peripheral arterial disease 
    
-      11.1.2.2. Screening for peripheral arterial disease in patients with coronary artery disease 
    
-      11.1.2.3. Screening for coronary artery disease in patients with carotid stenosis 
    
-      11.1.2.4. Screening for carotid stenosis in patients with coronary artery disease 
    
-     11.1.3. Management of patients with polyvascular disease 
    
-    11.2. Peripheral arterial disease and heart failure 
    
-    11.3. Peripheral arterial disease and AF 
    
-    11.4. Peripheral arterial disease and aortic stenosis 
    
-   12\. Key messages 
    
-   13\. Gaps in evidence 
    
-   14\. Sex differences 
    
-   15\. ‘What to do’ and ‘What not to do’ messages from the guidelines 
    
-   16\. Evidence tables 
    
-   17\. Data availability statement 
    
-   18\. Author information 
    
-   19\. Appendix 
    
-   20\. References 
    

## Tables of Recommendations

-   Recommendation Table 1 — Recommendations for clinical and laboratory, and for functional and quality of life, assessment in patients with peripheral arterial and aortic disease (see also Evidence Table 1) 
    
-   Recommendation Table 2 — Recommendations for diagnostic tests in patients with peripheral arterial disease 
    
-   Recommendation Table 3 — Recommendations for imaging of the aorta (see also Evidence Table 2) 
    
-   Recommendation Table 4 — Recommendations for thoracic aortic measurements 
    
-   Recommendation Table 5 — Recommendations for peripheral arterial disease screening (see also Evidence Table 3) 
    
-   Recommendation Table 6 — Recommendations for abdominal aortic aneurysm screening 
    
-   Recommendation Table 7 — Recommendations for lifestyle, physical activity, and patient education (see also Evidence Table 4) 
    
-   Recommendation Table 8 — Recommendations for antihypertensive therapy in patients with peripheral and aortic disease 
    
-   Recommendation Table 9 — Recommendations for lipid-lowering therapy in patients with peripheral arterial and aortic diseases 
    
-   Recommendation Table 10 — Recommendations for the medical management of patients with peripheral arterial and aortic diseases and diabetes 
    
-   Recommendation Table 11 — Recommendations for diagnostic tests in patients with peripheral arterial disease and diabetes, renal failure, and wounds 
    
-   Recommendation Table 12 — Recommendations for imaging in patients with peripheral arterial disease 
    
-   Recommendation Table 13 — Recommendations for exercise therapy in patients with peripheral arterial disease (see also Evidence Table 5) 
    
-   Recommendation Table 14 — Recommendations for antithrombotic therapy in patients with peripheral arterial disease (see also Evidence Table 6) 
    
-   Recommendation Table 15 — Recommendations for interventional treatment of asymptomatic and symptomatic peripheral arterial disease (general) 
    
-   Recommendation Table 16 — Recommendations for interventional treatment of patients with symptomatic peripheral arterial disease (per arterial bed) 
    
-   Recommendation Table 17 — Recommendations in patients with peripheral arterial disease: follow-up of patients with peripheral arterial disease 
    
-   Recommendation Table 18 — Recommendations for the management of chronic limb-threatening ischaemia 
    
-   Recommendation Table 19 — Recommendations for medical treatment in patients with chronic limb-threatening ischaemia (see also Evidence Table 7) 
    
-   Recommendation Table 20 — Recommendations for interventional treatment of chronic limb-threatening ischaemia 
    
-   Recommendation Table 21 — Recommendations for follow-up in patients with chronic limb-threatening ischaemia 
    
-   Recommendation Table 22 — Recommendations for the management of patients presenting with acute limb ischaemia (see also Evidence Table 8) 
    
-   Recommendation Table 23 — Recommendations for carotid artery stenosis assessment 
    
-   Recommendation Table 24 — Recommendations for antithrombotic treatment in patients with carotid stenosis 
    
-   Recommendation Table 25 — Recommendations for interventional treatment in patients with asymptomatic carotid artery stenosis 
    
-   Recommendation Table 26 — Recommendations for evaluation and medical treatment in patients with symptomatic carotid artery stenosis 
    
-   Recommendation Table 27 — Recommendations for interventions in patients with symptomatic carotid artery stenosis 
    
-   Recommendation Table 28 — Recommendations for follow-up in patients with carotid artery stenosis 
    
-   Recommendation Table 29 — Recommendations for the management of subclavian artery stenosis (see also Evidence Table 9) 
    
-   Recommendation Table 30 — Recommendations for diagnostic strategies for renal artery disease 
    
-   Recommendation Table 31 — Recommendations for treatment strategies for renal artery disease (see also Evidence Table 10) 
    
-   Recommendation Table 32 — Recommendations in patients with visceral artery stenosis 
    
-   Recommendation Table 33 — Recommendations for primary and secondary prevention in aortic atheromatous plaques 
    
-   Recommendation Table 34 — Recommendations for initial evaluation of thoracic aortic aneurysm and abdominal aortic aneurysm 
    
-   Recommendation Table 35 — Recommendation for the surveillance of patients with thoracic aortic aneurysms (non-heritable thoracic aortic disease) 
    
-   Recommendation Table 36 — Recommendations for surveillance of patients with abdominal aortic aneurysm 
    
-   Recommendation Table 37 — Recommendations for medical treatment in patients with thoracic aorta or abdominal aortic aneurysms 
    
-   Recommendation Table 38 — Recommendations for surgery in aortic root and ascending aorta dilatation associated with tricuspid aortic valve (see also Evidence Table 11) 
    
-   Recommendation Table 39 — Recommendations for surgery in aortic arch aneurysms 
    
-   Recommendation Table 40 — Recommendations for the management of patients presenting with descending thoracic aortic and thoracoabdominal aortic aneurysms 
    
-   Recommendation Table 41 — Recommendations for the management of patients presenting with abdominal aortic aneurysm 
    
-   Recommendation Table 42 — Recommendations for the management of patients presenting with endoleaks 
    
-   Recommendation Table 43 — Recommendations for follow-up after treatment of aortic aneurysms (see also Evidence Table 12) 
    
-   Recommendation Table 44 — Recommendations for diagnostic work-up of acute aortic syndromes 
    
-   Recommendation Table 45 — Recommendation for medical treatment in acute aortic syndromes 
    
-   Recommendation Table 46 — Recommendations for intervention in type A acute aortic dissection 
    
-   Recommendation Table 47 — Recommendations for aortic repair strategies in type A acute aortic dissection 
    
-   Recommendation Table 48 — Recommendations for the management of malperfusion in the setting of acute aortic dissection 
    
-   Recommendation Table 49 — Recommendations for the management of patients presenting with acute type B aortic dissection 
    
-   Recommendation Table 50 — Recommendations for the management of patients presenting with chronic type B aortic dissection 
    
-   Recommendation Table 51 — Recommendations for the management of intramural haematoma 
    
-   Recommendation Table 52 — Recommendations for the management of penetrating atherosclerotic ulcer 
    
-   Recommendation Table 53 — Recommendations for traumatic aortic injury 
    
-   Recommendation Table 54 — Recommendations for follow-up after treatment of acute aortic syndrome 
    
-   Recommendation Table 55 — Recommendations for the management of patients with heritable thoracic aortic disease 
    
-   Recommendation Table 56 — Recommendations for genetic testing and aortic screening in aortic disease 
    
-   Recommendation Table 57 — Recommendations for imaging in women with Turner syndrome 
    
-   Recommendation Table 58 — Recommendations for aortic surgery in women with Turner syndrome 
    
-   Recommendation Table 59 — Recommendations for medical treatment in patients with vascular Ehlers–Danlos syndrome (see also Evidence Table 13) 
    
-   Recommendation Table 60 — Recommendations for vascular imaging in Marfan syndrome 
    
-   Recommendation Table 61 — Recommendations for medical treatment in Marfan syndrome (see also Evidence Table 14) 
    
-   Recommendation Table 62 — Recommendations for aortic surgery in Marfan syndrome 
    
-   Recommendation Table 63 — Recommendations for pregnancy in women with Marfan syndrome 
    
-   Recommendation Table 64 — Recommendations for physical exercise in patients with Marfan syndrome 
    
-   Recommendation Table 65 — Recommendations for imaging follow-up in Loeys–Dietz syndrome 
    
-   Recommendation Table 66 — Recommendations for aortic root surgery in Loeys–Dietz syndrome 
    
-   Recommendation Table 67 — Recommendations for imaging and surgery in ACTA2-related heritable thoracic aortic disease (see also Evidence Table 11) 
    
-   Recommendation Table 68 — Recommendations for bicuspid aortic valve-associated aortopathy management 
    
-   Recommendation Table 69 — Recommendations for evaluation and medical treatment of patients with coarctation of the aorta 
    
-   Recommendation Table 70 — Recommendations for screening and management of polyvascular disease and peripheral arterial disease with cardiac diseases (see also Evidence Table 15) 
    

## List of tables

-   Table 1 Classes of recommendations 
    
-   Table 2 Levels of evidence 
    
-   Table 3 New recommendations 
    
-   Table 4 Revised recommendations 
    
-   Table 5 Main aortic imaging techniques 
    
-   Table 6 High-risk populations for carotid artery stenosis 
    
-   Table 7 Peripheral arterial disease categorized according to clinical presentation 
    
-   Table 8 Assessment of the risk of amputation: the Wound, Ischaemia, and foot Infection classification 
    
-   Table 9 Clinical categories of acute limb ischaemia 
    
-   Table 10 Peak systolic velocity criteria for grading internal carotid artery stenosis 
    
-   Table 11 High-risk features associated with increased risk of stroke in patients with asymptomatic internal carotid artery stenosis on optimal medical treatment 
    
-   Table 12 High-risk peri-operative features for carotid endarterectomy 
    
-   Table 13 Clinical signs suggestive of renal artery disease 
    
-   Table 14 Grading of atherosclerotic aortic plaques 
    
-   Table 15 Overview of factors favouring open vs. endovascular repair in thoracoabdominal aortic aneurysm 
    
-   Table 16 High-risk features of intramural haematoma type A and B 
    
-   Table 17 Need for assessment of associated atherosclerotic disease in additional vascular territories in symptomatic patients with coronary artery disease, peripheral arterial disease, or carotid stenosis 
    
-   Table 18 ‘What to do’ and ‘What not to do’ 
    

## List of figures

-   Figure 1 Central illustration: from diagnosis to treatment, a holistic multidisciplinary peripheral arterial and aortic diseases approach 
    
-   Figure 2 Estimated specific prevalence of peripheral arterial disease, by sex, in people aged 40 years and older 
    
-   Figure 3 Main risk factors associated with atherosclerosis in peripheral arterial and aortic diseases 
    
-   Figure 4 Haemodynamic assessment of peripheral arterial disease 
    
-   Figure 5 Anatomy and aortic segments and upper normal values for aortic dimensions 
    
-   Figure 6 Conventional measurements of the aorta at different levels by echocardiography or duplex ultrasound (A, B, C), cardiovascular computed tomography or cardiovascular magnetic resonance (D, E, F) 
    
-   Figure 7 Cardiovascular risk modification and healthy lifestyle interventions and targets in patients with peripheral arterial and aortic diseases 
    
-   Figure 8 Cardiovascular risk in patients with peripheral arterial disease 
    
-   Figure 9 Diagnostic algorithm for peripheral arterial disease 
    
-   Figure 10 Optimal medical treatment in patients with peripheral arterial disease 
    
-   Figure 11 Treatment algorithm in peripheral arterial disease without wounds 
    
-   Figure 12 Treatment algorithm in peripheral arterial disease with wounds 
    
-   Figure 13 Exercise training characteristics and benefits in patients with peripheral arterial disease 
    
-   Figure 14 Long-term antithrombotic therapy in patients with symptomatic peripheral arterial disease 
    
-   Figure 15 Patients with chronic symptomatic PAD after endovascular revascularization 
    
-   Figure 16 Management of acute limb ischaemia 
    
-   Figure 17 North American Symptomatic Carotid Endarterectomy Trial/European Carotid Surgery Trial methods 
    
-   Figure 18 Algorithm of carotid artery stenosis management 
    
-   Figure 19 Diagnostic and treatment algorithm for renal artery stenosis 
    
-   Figure 20 Algorithm of chronic mesenteric ischaemia management 
    
-   Figure 21 Thoracic and abdominal aortic aneurysms: aetiology, screening and diagnostic methods 
    
-   Figure 22 Classification of thoracoabdominal and abdominal aortic aneurysms 
    
-   Figure 23 Risk factors for thoracic and abdominal aneurysm rupture 
    
-   Figure 24 Surveillance of patients with **non-heritable** thoracic aortic disease and abdominal aortic aneurysms 
    
-   Figure 25 Peri-operative algorithm for the management of patients with surgically treated aortic root and ascending aortic aneurysm 
    
-   Figure 26 Algorithm for individual decision-making process in the treatment of patients with abdominal aortic aneurysm 
    
-   Figure 27 Algorithm for follow-up after thoracic endovascular aortic aneurysm repair, and management of endoleaks and their classification 
    
-   Figure 28 Anatomical and temporal classification of acute aortic syndrome 
    
-   Figure 29 Aortic dissection classification system based on the 2020 Society for Vascular Surgery/Society of Thoracic Surgeons Reporting Standards and the European update of the Stanford classification—Type Entry Malperfusion classification 
    
-   Figure 30 Multiparametric diagnostic work-up of acute aortic syndrome 
    
-   Figure 31 Medical management of acute aortic syndrome 
    
-   Figure 32 Complications in acute aortic syndromes, clinical evidence associated with malperfusion syndrome, and in-hospital mortality associated with these complications 
    
-   Figure 33 Interventional treatment algorithm in acute aortic dissection 
    
-   Figure 34 Mechanisms and clinical management of aortic branch obstruction in acute aortic dissection 
    
-   Figure 35 High-risk features in penetrating atherosclerotic ulcer and management of patients with type B penetrating atherosclerotic ulcer 
    
-   Figure 36 Classification and treatment of traumatic aortic injuries 
    
-   Figure 37 Aetiology, risk factors, and classification of iatrogenic aortic injuries 
    
-   Figure 38 Algorithm for follow-up after acute aortic syndrome 
    
-   Figure 39 Algorithm for genetic and imaging screening in patients with thoracic aortic disease 
    
-   Figure 40 Algorithm for surveillance in women (≥15 years) with Turner syndrome 
    
-   Figure 41 Algorithm for imaging surveillance in patients with syndromic and non-syndromic heritable thoracic aortic disease 
    
-   Figure 42 Suggested thresholds for prophylactic aortic root/ascending replacement in Loeys–Dietz syndrome 
    
-   Figure 43 Bicuspid aortic valve, valvulo-aortopathy nomenclature 
    
-   Figure 44 Criteria for significant coarctation/re-coarctation of the aorta and management algorithm 
    
-   Figure 45 Reported rate ranges of other localizations of atherosclerosis in patients with a specific arterial disease 
    

## Abbreviations and acronyms

 -   <sup>18</sup>F–NaF
    
    Fluorine-18–sodium fluoride
    
 -   6MWD
    
    Six-minute walking distance
    
 -   6MWT
    
    Six-minute walk test
    
 -   AA
    
    Abdominal aorta
    
 -   AAA
    
    Abdominal aortic aneurysm
    
 -   AAD
    
    Acute aortic dissection
    
 -   AAE
    
    Aortic adverse events
    
 -   AAL
    
    Ascending aortic length
    
 -   AAS
    
    Acute aortic syndrome
    
 -   ABI
    
    Ankle–brachial index
    
 -   ACAS
    
    Asymptomatic Carotid Atherosclerosis Study
    
 -   ACB
    
    Asymptomatic Cervical Bruit Study
    
 -   ACC/AHA
    
    American College of Cardiology and American Heart Association
    
 -   ACEI
    
    Angiotensin-converting enzyme inhibitor
    
 -   ACS
    
    Acute coronary syndrome
    
 -   ACST
    
    Asymptomatic Carotid Surgery Trial
    
 -   _ACTA2_
    
    Alpha-actin gene
    
 -   AD
    
    Aortic dissection
    
 -   ADAM
    
    American Aneurysm Detection and Management
    
 -   ADD-RS
    
    Aortic dissection detection-risk score
    
 -   AF
    
    Atrial fibrillation
    
 -   AHI
    
    Aortic height index
    
 -   ALI
    
    Acute limb ischaemia
    
 -   AMI
    
    Acute mesenteric ischaemia
    
 -   AP
    
    Antero-posterior
    
 -   ARB
    
    Angiotensin receptor blocker
    
 -   ARR
    
    Absolute risk reduction
    
 -   ASCVD
    
    Atherosclerotic cardiovascular disease
    
 -   ASE
    
    American Society of Echocardiography
    
 -   ASI
    
    Aortic size index
    
 -   BASIL
    
    Bypass versus Angioplasty in Severe Ischaemia of the Leg trial
    
 -   BAV
    
    Bicuspid aortic valve
    
 -   BB
    
    Beta-blocker
    
 -   BEST-CLI
    
    Best Endovascular versus Best Surgical Therapy for Patients with Critical Limb Ischemia trial
    
 -   b.i.d.
    
    Bis in die (twice daily)
    
 -   BMI
    
    Body mass index
    
 -   BP
    
    Blood pressure
    
 -   b.p.m.
    
    Beats per minute
    
 -   BSA
    
    Body surface area
    
 -   BTK
    
    Below-the-knee
    
 -   CABG
    
    Coronary artery bypass grafting
    
 -   CAD
    
    Coronary artery disease
    
 -   CANTOS
    
    Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
    
 -   CANVAS
    
    Canagliflozin Cardiovascular Assessment Study
    
 -   CAS
    
    Carotid artery stenting
    
 -   CCA
    
    Common carotid artery
    
 -   CCB
    
    Calcium channel blocker
    
 -   CCT
    
    Cardiovascular computed tomography
    
 -   CDT
    
    Catheter-based thrombectomy
    
 -   cdTLR
    
    Clinically driven target lesion revascularization
    
 -   CEA
    
    Carotid endarterectomy
    
 -   CEUS
    
    Contrast-enhanced ultrasound
    
 -   CHA<sub>2</sub>DS<sub>2</sub>\-VASc
    
    Congestive heart failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled), vascular disease, age 65 to 74 and sex category (female)
    
 -   CI
    
    Confidence interval
    
 -   cIMT
    
    Carotid intima media thickness
    
 -   CK
    
    Creatinine kinase
    
 -   CKD
    
    Chronic kidney disease
    
 -   CLTI
    
    Chronic limb-threatening ischaemia
    
 -   CMI
    
    Chronic mesenteric ischaemia
    
 -   CMR
    
    Cardiovascular magnetic resonance
    
 -   CoA
    
    Coarctation of the aorta
    
 -   COMPASS
    
    Cardiovascular Outcomes for People Using Anticoagulation Strategies
    
 -   COPD
    
    Chronic obstructive pulmonary disease
    
 -   CP
    
    Carotid plaque
    
 -   CREDENCE
    
    Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation
    
 -   CREST-2
    
    Carotid Revascularization Endartectomy vs. Stenting Trial 2
    
 -   CRP
    
    C-reactive protein
    
 -   CS
    
    Carotid artery stenosis
    
 -   CSA/h
    
    Cross-sectional area-to-height ratio
    
 -   CT
    
    Computed tomography
    
 -   CTA
    
    Computed tomography angiography
    
 -   CV
    
    Cardiovascular
    
 -   CVD
    
    Cardiovascular disease
    
 -   CVRF
    
    Cardiovascular risk factor
    
 -   DAPT
    
    Dual antiplatelet therapy
    
 -   DBP
    
    Diastolic blood pressure
    
 -   DD
    
    D-dimer
    
 -   DISSECT
    
    Duration, Intimal tear, Size, Segmental Extent, Clinical complications, Thrombosis
    
 -   DPI
    
    Dual pathway inhibition
    
 -   DSA
    
    Digital subtraction angiography
    
 -   DTA
    
    Descending thoracic aorta
    
 -   DUS
    
    Duplex ultrasound
    
 -   DWI
    
    Diffusion-weighted imaging
    
 -   ECG
    
    Electrocardiogram
    
 -   ECST
    
    European Carotid Surgery Trial
    
 -   eGFR
    
    Estimated glomerular filtration rate
    
 -   EMPA-REG OUTCOME
    
    (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients
    
 -   ESC
    
    European Society of Cardiology
    
 -   ESH
    
    European Society of Hypertension
    
 -   ESRD
    
    End-stage renal disease
    
 -   EUCLID
    
    Examining Use of tiCagreLor In peripheral artery Disease
    
 -   FDA
    
    (United States) Food and Drug Administration
    
 -   FDG
    
    Fluorodeoxyglucose
    
 -   FDR
    
    First-degree relative
    
 -   FET
    
    Frozen elephant trunk
    
 -   FID
    
    Focal intimal disruption
    
 -   FL
    
    False lumen
    
 -   GERAADA
    
    German Registry of Acute Aortic Dissection Type A
    
 -   GFR
    
    Glomerular filtration rate
    
 -   GLP-1RA
    
    Glucagon-like peptide-1 receptor agonist
    
 -   GSV
    
    Great saphenous vein
    
 -   HADS
    
    Hospital anxiety and depression score
    
 -   HbA1c
    
    Glycated haemoglobin
    
 -   HBET
    
    Home-based exercise training
    
 -   HF
    
    Heart failure
    
 -   HITS
    
    High-intensity transient signal
    
 -   HOME
    
    Hyperinsulinaemia: the Outcomes of its Metabolic Effects
    
 -   HR
    
    Hazard ratio
    
 -   HRQoL
    
    Health-related quality of life
    
 -   hs-CRP
    
    High-sensitivity C-reactive protein
    
 -   HSR
    
    High surgical risk
    
 -   HTAD
    
    Heritable thoracic aortic disease
    
 -   IC
    
    Intermittent claudication
    
 -   ICA
    
    Internal carotid artery
    
 -   ID
    
    Intimal disruption
    
 -   IL
    
    Interleukin
    
 -   ILT
    
    Intensive lipid-lowering therapy
    
 -   IMA
    
    Inferior mesenteric artery
    
 -   IMH
    
    Intramural haematoma
    
 -   IMPROVE-AD
    
    The Improving outcomes in vascular disease—aortic dissection trial
    
 -   IMPROVE-IT
    
    IMProved Reduction of Outcomes: Vytorin Efficacy International Trial
    
 -   IPE
    
    Icosapent ethyl
    
 -   IRAD
    
    International Registry of Acute Aortic Dissection
    
 -   ISTH
    
    International Society on Thrombosis and Haemostasis
    
 -   i.v.
    
    Intravenous
    
 -   IVUS
    
    Intravascular ultrasound
    
 -   LDL-C
    
    Low-density lipoprotein cholesterol
    
 -   LEADER
    
    Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results trial
    
 -   LSA
    
    Left subclavian artery
    
 -   LV
    
    Left ventricular
    
 -   MACE
    
    Major adverse cardiac event
    
 -   MAD
    
    Multisite artery disease
    
 -   MALE
    
    Major adverse limb event
    
 -   MAP
    
    Mean arterial pressure
    
 -   MESA
    
    Multi-Ethnic Study of Atherosclerosis
    
 -   MFS
    
    Marfan syndrome
    
 -   MHV
    
    Mechanical heart valve
    
 -   MI
    
    Myocardial infarction
    
 -   MRA
    
    Magnetic resonance angiography
    
 -   MRI
    
    Magnetic resonance imaging
    
 -   MWD
    
    Maximal walking distance
    
 -   NASCET
    
    North American Symptomatic Carotid Endarterectomy Trial
    
 -   OAC
    
    Oral anticoagulation
    
 -   o.d.
    
    Once daily
    
 -   OMT
    
    Optimal medical treatment
    
 -   OR
    
    Odds ratio
    
 -   PAAD
    
    Peripheral arterial and aortic diseases
    
 -   PA
    
    Popliteal aneurysm
    
 -   PAD
    
    Peripheral arterial disease
    
 -   PAU
    
    Penetrating atherosclerotic ulcer
    
 -   PC-AKI
    
    Post-contrast acute kidney injury
    
 -   PCSK9
    
    Proprotein convertase subtilisin/kexin type 9
    
 -   PET
    
    Positron emission tomography
    
 -   PET-CT
    
    PET-computed tomography
    
 -   PFWD
    
    Pain-free walking distance
    
 -   PROM
    
    Patient-reported outcome measure
    
 -   PSV
    
    Peak systolic velocity
    
 -   PSVr
    
    Peak systolic velocity ratio
    
 -   PVD
    
    Polyvascular disease
    
 -   QoL
    
    Quality of life
    
 -   RAR
    
    Renal-aortic peak flow velocity ratio
    
 -   RAS
    
    Renal artery stenosis
    
 -   RCT
    
    Randomized controlled trial
    
 -   REACH
    
    The REduction of Atherothrombosis for Continued Health
    
 -   REDUCE-IT
    
    Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial
    
 -   ROMS
    
    Retrograde open mesenteric stenting
    
 -   ROPAC
    
    Registry Of Pregnancy And Cardiac disease
    
 -   RPE
    
    Rate of perceived exertion
    
 -   RR
    
    Relative risk
    
 -   SAMMPRIS
    
    Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis trial
    
 -   SAPPHIRE
    
    Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy trial
    
 -   SAPT
    
    Single antiplatelet therapy
    
 -   SBP
    
    Systolic blood pressure
    
 -   SCI
    
    Spinal cord ischaemia
    
 -   SCS
    
    Spinal cord stimulation
    
 -   SET
    
    Supervised exercise training
    
 -   SF-36
    
    Short-form 36-item health questionnaire
    
 -   SGLT2i
    
    Sodium-glucose co-transporter-2 inhibitor
    
 -   SMA
    
    Superior mesenteric artery
    
 -   SMART
    
    Secondary Manifestation of ARTerial disease
    
 -   SOCRATES
    
    Acute Stroke or Transient Ischaemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes trial
    
 -   SCORE2
    
    Systematic Coronary Risk Evaluation 2
    
 -   SCORE2-Diabetes
    
    Systematic Coronary Risk Evaluation 2 - diabetes
    
 -   SCORE2-OP
    
    Systematic Coronary Risk Evaluation 2–Older Persons
    
 -   SPACE-2
    
    Stent Protected Angioplasty versus Carotid Endarterectomy study
    
 -   SPPB
    
    Short physical performance battery
    
 -   SRUCC
    
    Society of Radiologists in Ultrasound
    
 -   SS
    
    Subclavian stenosis
    
 -   SSFP
    
    Steady-state free precession
    
 -   STJ
    
    Sinotubular junction
    
 -   STS/AATS
    
    Society of Thoracic Surgeons/American Association for Thoracic Surgery
    
 -   SUSTAIN-6
    
    Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes
    
 -   SVS
    
    Society for Vascular Surgery
    
 -   T1DM
    
    Type 1 diabetes mellitus
    
 -   T2DM
    
    Type 2 diabetes mellitus
    
 -   TAA
    
    Thoracic aortic aneurysm
    
 -   TAAA
    
    Thoracoabdominal aortic aneurysm
    
 -   TAAD
    
    Type A aortic dissection
    
 -   TAD
    
    Thoracic aortic disease
    
 -   TAI
    
    Traumatic aortic injury
    
 -   TAV
    
    Tricuspid aortic valve
    
 -   TAVI
    
    Transcatheter aortic valve implantation
    
 -   TBAD
    
    Type B aortic dissection
    
 -   TBI
    
    Toe–brachial index
    
 -   TCAR
    
    Transcarotid artery revascularization
    
 -   TcPO<sub>2</sub>
    
    Transcutaneous oxygen pressure
    
 -   TOE
    
    Transoesophageal echocardiography
    
 -   TEM
    
    Type entry malperfusion classification
    
 -   TEVAR/EVAR
    
    Thoracic endovascular aortic aneurysm repair
    
 -   TFCAS
    
    Transfemoral carotid artery stenting
    
 -   THALES
    
    Acute Stroke or Transient Ischaemic Attack Treated with Ticagrelor and acetylsalicylic acid for Prevention of Stroke and Death trial
    
 -   TIA
    
    Transient ischaemic attack
    
 -   TIMI
    
    Thrombolysis in myocardial infarction
    
 -   TP
    
    Toe pressure
    
 -   TS
    
    Turner syndrome
    
 -   TTE
    
    Transthoracic echocardiography
    
 -   UEAD
    
    Upper-limb artery disease
    
 -   UKPDS
    
    United Kingdom Prospective Diabetes Study: clinical and therapeutic implications for type 2 diabetes
    
 -   uTBAD
    
    Uncomplicated type B aortic dissection
    
 -   VascuQoL
    
    Vascular quality of life questionnaire
    
 -   VAST
    
    Vertebral Artery Stenting Trial
    
 -   vEDS
    
    Vascular Ehlers–Danlos syndrome
    
 -   VIST
    
    Vertebral Artery Ischaemia Stenting Trial
    
 -   VKA
    
    Vitamin K antagonist
    
 -   WELCH
    
    Walking Estimated Limitation Calculated by History
    
 -   WIfI
    
    Wound, Ischaemia, foot Infection classification
    
 -   WIQ
    
    Walking Impairment Questionnaire
    

## 1\. Preamble

Guidelines evaluate and summarize available evidence with the aim of assisting health professionals in proposing the best diagnostic or therapeutic approach for an individual patient with a given condition. Guidelines are intended for use by health professionals and the European Society of Cardiology (ESC) makes its guidelines freely available.

ESC Guidelines do not override the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient or the patient’s caregiver where appropriate and/or necessary. It is also the health professional’s responsibility to verify the rules and regulations applicable in each country to drugs and devices at the time of prescription and to respect the ethical rules of their profession.

ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated when warranted by new evidence. ESC Policies and Procedures for formulating and issuing ESC Guidelines can be found on the ESC website ([https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines](https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines)). This guideline updates and replaces the previous peripheral arterial disease and aortic disease guidelines from 2017 and 2014, respectively.

The Members of this task force were selected by the ESC to include professionals involved with the medical care of patients with this pathology as well as patient representatives and methodologists. The selection procedure included an open call for authors and aimed to include members from across the whole of the ESC region and from relevant ESC Subspecialty Communities. Consideration was given to diversity and inclusion, notably with respect to gender and country of origin. The task force performed a critical review and evaluation of the published literature on diagnostic and therapeutic approaches including assessment of the risk–benefit ratio. The strength of every recommendation and the level of evidence supporting them were weighed and scored according to pre-defined scales as outlined in _[Tables 1](javascript:;)_ and _[2](javascript:;)_ below. Patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs) were also evaluated as the basis for recommendations and/or discussion in these guidelines. The task force followed ESC voting procedures and all approved recommendations were subject to a vote and achieved at least 75% agreement among voting members. Members of the task force with declared interests on specific topics were asked to abstain from voting on related recommendations.

Table 1

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479845777)

Classes of recommendations

![Classes of recommendations](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179t1.jpeg?Expires=1728479087&Signature=OyEmdd8uEczIGBN46qWk6lTnqG4j32MDN1ahth0DkcHBdaNi6l94X-jQAsmAoEVBp5UEGhU2Au95zP~nlU0T3OYcqaTiGbAuXh8t4phqOQ66sE9CrWy-z7AXg~F2XwuRptuB-qwYQ2J2jZgSqXjpVihGIOELqdIAsVm6-77Y1pPM4HN9iyPriAuDWQURbyraHgDz9fRIpxjBEzgbHwxAk49h8yKwDerUY8EgXBS8tse~1E49Ws9RDhMw7TqxvNhabTtGhzyP6ciFfCxeqYaksg9AE-U9eZdGCKA7vU~KW~z9AWBKDoQ6C0sMEX9skMJF1Ac5Av9kSLpC5CPjeiKV2g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Table 2

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479845778)

Levels of evidence

![Levels of evidence](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179t2.jpeg?Expires=1728479087&Signature=ac29Sy0PZXzUmooYS8fm7rCWlRYl-~ypCttg-YpVlKwRKgB0bQF9epBGLNaW2uHwurTbNBO42yZ~PAbtCjyZfkvpX1yhnLbFZEs0~MPeVxzxCmuKdyGs40f~SLXpxQYPh614NZOJxN0U3uQAGV1IGQ4xcDsqXmeF7AiCTkOaPSL~6CSFfyvCw8CznkIWV73BGGvHB9lBp86XU~Cnl~K0wSBlgnpbTfZbtGXq6-noUet6yayZ64frJZDVL9zdy8-YgTUooec2SlqilM72Ug7SV~Boc0tehvgR7DoSGbCsSv8JXSIUa9G81rYU3GCrm0fbUeMJblvwRK~y9NpuoSkxww__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

The experts of the writing and reviewing panels provided declaration of interest forms for all relationships that might be perceived as real or potential sources of conflicts of interest. Their declarations of interest were reviewed according to the ESC declaration of interest rules which can be found on the ESC website ([http://www.escardio.org/guidelines](http://www.escardio.org/guidelines)) and have been compiled in a report published in a supplementary document with the guidelines. Funding for the development of ESC Guidelines is derived entirely from the ESC with no involvement of the healthcare industry.

The ESC Clinical Practice Guidelines (CPG) Committee supervises and co-ordinates the preparation of new guidelines and is responsible for the approval process. In addition to review by the CPG Committee, ESC Guidelines undergo multiple rounds of double-blind peer review by external experts, including members from across the whole of the ESC region, all National Cardiac Societies of the ESC and from relevant ESC Subspecialty Communities. After appropriate revisions, the guidelines are signed off by all the experts in the task force. The finalized document is signed off by the CPG Committee for publication in the _European Heart Journal_.

ESC Guidelines are based on analyses of published evidence, chiefly on clinical trials and meta-analyses of trials, but potentially including other types of studies. Evidence tables summarizing key information from relevant studies are generated early in the guideline development process to facilitate the formulation of recommendations, to enhance comprehension of recommendations after publication, and reinforce transparency in the guidelines development process. The tables are published in their own section of ESC Guidelines and reference specific recommendation tables.

Off-label use of medication may be presented in this guideline if a sufficient level of evidence shows that it can be considered medically appropriate for a given condition. However, the final decisions concerning an individual patient must be made by the responsible health professional giving special consideration to:

-   The specific situation of the patient. Unless otherwise provided for by national regulations, off-label use of medication should be limited to situations where it is in the patient’s interest with regard to the quality, safety, and efficacy of care, and only after the patient has been informed and has provided consent.
    
-   Country-specific health regulations, indications by governmental drug regulatory agencies, and the ethical rules to which health professionals are subject, where applicable.
    

## 2\. Introduction

Peripheral arterial and aortic diseases (PAAD) are highly prevalent and significantly increase cardiovascular (CV) mortality and morbidity in the general population,<sup><a href="javascript:;" reveal-id="ehae179-B1" data-open="ehae179-B1" class="link link-ref link-reveal xref-bibr">1</a>,<a href="javascript:;" reveal-id="ehae179-B2" data-open="ehae179-B2" class="link link-ref link-reveal xref-bibr">2</a></sup> consequently, intensive preventive strategies are needed. However, patients with PAAD are generally underdiagnosed and undertreated<sup><a href="javascript:;" reveal-id="ehae179-B3" data-open="ehae179-B3" class="link link-ref link-reveal xref-bibr">3</a>,<a href="javascript:;" reveal-id="ehae179-B4" data-open="ehae179-B4" class="link link-ref link-reveal xref-bibr">4</a></sup> compared with patients with coronary artery disease (CAD).<sup><a href="javascript:;" reveal-id="ehae179-B5" data-open="ehae179-B5" class="link link-ref link-reveal xref-bibr">5</a></sup> Common risk factors in PAAD often coexist, requiring a multidisciplinary approach for effective management.<sup><a href="javascript:;" reveal-id="ehae179-B5" data-open="ehae179-B5" class="link link-ref link-reveal xref-bibr">5</a></sup> Early diagnosis is crucial for better outcomes. These guidelines address PAAD, updating and merging the 2017 peripheral arterial diseases and 2014 aortic diseases guidelines. The focus is primarily on atherosclerotic arterial diseases, but they also address some non-atherosclerotic genetic conditions. While not exhaustive, these 2024 guidelines offer guidance on diagnosis, surveillance, and treatment. A number of new and revised recommendations are summarized in _[Tables 3](javascript:;)_ and _[4](javascript:;)_, respectively. Readers should consider non-atherosclerotic conditions and refer to specific documents.<sup><a href="javascript:;" reveal-id="ehae179-B6 ehae179-B7 ehae179-B8 ehae179-B9" data-open="ehae179-B6 ehae179-B7 ehae179-B8 ehae179-B9" class="link link-ref link-reveal xref-bibr">6–9</a></sup>

A general approach to PAAD is provided in the central illustration (_[Figure 1](javascript:;)_).

![Central illustration: from diagnosis to treatment, a holistic multidisciplinary peripheral arterial and aortic diseases approach.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f1.jpeg?Expires=1728479087&Signature=pxtrKAjj-3KiqkYd0J3ovJ6HEE8D7QnGEJQVLCjQSDOmWtOpZT2kVzNnyezfnFAWbszwINTUy5HQk~31BSo-HNw06KjVpoGm1cCDRy3NdlfYwZByB30V0wSwYo8bDYmL0h0i-JARxwvbGG3T3U9kOQWPuuFcW8GePykOou5WCSxt7CT2juKrKLBzAmQ0MoU6ixxpZagr69JH5EOIDUcYgWtxiZUJl80mAogmLqgLpod5QevmaTxx73dFuB1y0d9pt9tLbP~71t43D4oPq2TRnaQtL0axofb1FmsnxOch6n~lyrNBqfF2hN59ghcYDZQtWpP6TUraKmsQKl~ux2Gwhg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 1

Central illustration: from diagnosis to treatment, a holistic multidisciplinary peripheral arterial and aortic diseases approach.

CV, cardiovascular; CVRFs, cardiovascular risk factors; MACE, major adverse cardiac event; MALE, major adverse limb event; PAAD, peripheral arterial and aortic diseases; QoL, quality of life.

[Open in new tab](https://academic.oup.com/view-large/figure/479845787/ehae179f1.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f1.jpeg?Expires=1728479087&Signature=qV1YrLTLyJaZYJzWy0GCdBuWEoTSVmzPg17SFB36SJQNYT3soo9-TEIeZUm4WAg72xlw2gvW07tQNnVexY-GWlGFB7~0tjSUTBeIyt3~DY-dgvdrqezmaORh-D-QflGpgqmsHcaqh~vLYOzZbYKo1TdB0qggjuoXfe3pSw1IwcyaftdV42hbCtfBDRY0bZSUszo7Ut3lxBba6~w5dIegfQno2CC2~KvnXu02DpGCPXM5QMG6hDVAd7XGQVvrD24nbcZufVds9yuct763M0jM33XBE7Jhj1~kx36gjAKHxhEiaCNzH2oqvLsbe6py0ewL9VrzSuFrB4qyATfWXG7hSA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479845787&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

In the management of PAAD, the following aspects must be highlighted:

-   **_Shared decision-making_** to involve patients, explore treatment options, assess patient values, and reach decisions collaboratively.
    
-   **_Multidisciplinary approach (_**_[Figure 1](javascript:;)_**_) in expert and high-volume PAAD centres for complex patients or procedures_**. These centres provide diverse services, including diagnosis, treatment planning, minimally invasive procedures, open surgery, post-operative and outpatient care, and ideally, research and innovation. They should provide continuous clinical service (24/7) and have access to digital imaging. These guidelines recognize variations in healthcare systems, population sizes, and needs, impacting the definition of ‘high volume’ in PAAD care across countries.
    

## 3\. What is new

Table 3

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479845791)

New recommendations

![New recommendations](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179t3.jpeg?Expires=1728479087&Signature=eQjJIR7x6txSj0pQNaAGe3ad5gkJCI~aouIMLoo1hacxKev4xYUpAMu6f0g4Io0zPMBXXQhQQoA1HgLlQj4lc2DgBQTw57gZzN3xZIlYrxIq9ufSvhevjWKlDh7PiFMX-zHaIixWcV1VAHMvRk-tZ7HYkFwqayGuJq-NRsS2Id32jEbHk440vD~9uUw2bIDRiU7qcvqeOUUWhpCKTuuLYOYMuca60-CyIK-A7VvAVxonRNbzV0SRCsaR8EsCuN3w9GJz4FrdD6RM56O43V3PEPiQr41Iiq0ry~aJKUcPnHdoOeoS3giIb1dsDeBj-qZm2eZGmsVl51zdWKZxRpbXpw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Table 4

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479845792)

Revised recommendations

![Revised recommendations](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179t4.jpeg?Expires=1728479087&Signature=Vl85R6XDLv7AlU~eSFUmHJkieWtgv8TeUnI9T13Mmx8u84QRt7x2RIHF6R-4rhtShFk5lESatLtwYL4OL~TuqNr7c~J9V92JceCr9RONs3komvFhDE6TPvx4WWFPri9GKG~Q4pFb-d6Aw58MSdi5i5G~XGJL2GLYGlMoy565lDKBB~C8RDWdbmVl2e7syApc8I7KweBuqNKz~Iz1aacJKqDBYR0n2fuNFgzOFfwkOm79f-CWX69kgIJtUaaP6MYjVSvoNeqlMXleKS-wMzXQJBkAjH2kmBhfRtTnc6O1HlvUKYc62PSDwiB-fnJPabKAx4FSKT8VLhRQ01coO4C7~A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

## 4\. Epidemiology and risk factors

### 4.1. Epidemiology

Peripheral arterial disease (PAD) is prevalent worldwide and affects 113 million people aged 40 and older, of which 42.6% are in countries with a low-to-middle sociodemographic index. Global prevalence is 1.52%, increases with age (14.91% in those aged 80–84 years), and is higher in females than in males (18.03% vs. 10.56%, in the same age group).<sup><a href="javascript:;" reveal-id="ehae179-B10 ehae179-B11 ehae179-B12 ehae179-B13" data-open="ehae179-B10 ehae179-B11 ehae179-B12 ehae179-B13" class="link link-ref link-reveal xref-bibr">10–13</a></sup>

PAD prevalence rose by 72% from 1990 to 2019, considering a 45% growth rate in the world population.<sup><a href="javascript:;" reveal-id="ehae179-B10" data-open="ehae179-B10" class="link link-ref link-reveal xref-bibr">10</a>,<a href="javascript:;" reveal-id="ehae179-B11" data-open="ehae179-B11" class="link link-ref link-reveal xref-bibr">11</a>,<a href="javascript:;" reveal-id="ehae179-B14" data-open="ehae179-B14" class="link link-ref link-reveal xref-bibr">14</a></sup> The overall global age-standardized prevalence is about 1470 per 100 000 persons (_[Figure 2](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B14" data-open="ehae179-B14" class="link link-ref link-reveal xref-bibr">14</a></sup>

![Estimated specific prevalence of peripheral arterial disease, by sex, in people aged 40 years and older.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f2.jpeg?Expires=1728479087&Signature=zBjMmxamrzsEBOs4ksiNraG0xrGZHEmC7IOnQ7Lk2DJ416vOw46n27UHaHZZ7lrXGizO0kl--SMZfCTW~GI8zwGH9x5-7EX5ZAQKx6Xbv3rFWuaHchwBA397XcYjgMNtuZoD4jRlRzxL~hbvzcMWstf57qHCg2xwqY84JzOJ5WJ7MwEZAKT9OkbbhMt5go085T1JPSS2h94OpZskiwSdlpUhn~omPHR3cuuspXVAGcE8-sHRqK5bosPp8fSZ3M4cvPD3VTQQ1bjkH8AgG~0moFeB95Aj~au0uhCun9TI7Is5GXZ5QZN00yee2wkupjZDZOl9QFAGl3rtAodc6LrbRA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 2

Estimated specific prevalence of peripheral arterial disease, by sex, in people aged 40 years and older.

Adapted from<sup><a href="javascript:;" reveal-id="ehae179-B12" data-open="ehae179-B12" class="link link-ref link-reveal xref-bibr">12</a></sup> under the terms of the Open access Creative Commons CC-BY license.

[Open in new tab](https://academic.oup.com/view-large/figure/479845797/ehae179f2.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f2.jpeg?Expires=1728479087&Signature=0tA~klCtTztkYnALrYKZ5jdstOK3fZOD0I-oPOlo75NnIjnSBNdWuGqfQv259anCTh6-X3rxDtZat5be3Q-P1cQvotNBISms77G1JIl4fkUnSuwoKoQ~gTf1I33HnzloP7lz250vax1STu504mpbgLSeabOqx5cVt44xmdBzjWqT5gU7EEFTMXug-zVwvtTJXGyRqmJyRvr9OniaQFeV3hZLkk4URxCjv~l4ySQVbUA0FuF~IvDGgqNIhN1icnHyCZi9Ewei6dRKp6fwb28nL2Iq2vTj98rxq~qUOtzu8hIcotXauNfmAvdnyYRnQznw2rh14QXq0QWpkJeiiEsLKA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479845797&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Ischaemic cerebral disease, mainly linked to carotid stenosis (65% of cases), has a prevalence of 77.19 million, marking a 95% increase from 1990 to 2019.<sup><a href="javascript:;" reveal-id="ehae179-B15" data-open="ehae179-B15" class="link link-ref link-reveal xref-bibr">15</a></sup>

The overall prevalence of aortic disease including aneurysm and dissections is estimated at around 1% to 3% in the general population, with up to 10% prevalence in older age groups. European studies show a decrease in abdominal aortic aneurysm (AAA) prevalence in screened men >65 years of age, at 1.3%–3.3%,<sup><a href="javascript:;" reveal-id="ehae179-B16" data-open="ehae179-B16" class="link link-ref link-reveal xref-bibr">16</a>,<a href="javascript:;" reveal-id="ehae179-B17" data-open="ehae179-B17" class="link link-ref link-reveal xref-bibr">17</a></sup> contrasting with the United States of America’s 5% found in screened male smokers.<sup><a href="javascript:;" reveal-id="ehae179-B16" data-open="ehae179-B16" class="link link-ref link-reveal xref-bibr">16</a>,<a href="javascript:;" reveal-id="ehae179-B17" data-open="ehae179-B17" class="link link-ref link-reveal xref-bibr">17</a></sup> Globally, in 2019, there were 172 000 aortic aneurysm-related deaths (82.1% increase from 1990).<sup><a href="javascript:;" reveal-id="ehae179-B10" data-open="ehae179-B10" class="link link-ref link-reveal xref-bibr">10</a></sup>

### 4.2. Risk factors

Main PAAD risk factors are summarized in _[Figure 3](javascript:;)_. Traditional risk factors in tools like Framingham, Reynolds, Atherosclerotic Cardiovascular Disease (ASCVD) risk estimator Plus (United States of America), SCORE2 (Systematic Coronary Risk Evaluation 2, age 40–69 years), SCORE2-Diabetes (Systematic Coronary Risk Evaluation 2 - diabetes), and SCORE2-OP (Systematic Coronary Risk Evaluation 2–Older Persons) (Europe)<sup><a href="javascript:;" reveal-id="ehae179-B18" data-open="ehae179-B18" class="link link-ref link-reveal xref-bibr">18</a></sup> also contribute to PAAD’s pathophysiology and development. More details are available in [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179_supplementary_data.pdf?Expires=1728479087&Signature=yLyH980QM156IeuIcUZSEzWy76j01TnWXcoDQ4ZTMz8G6FY7KOUPe9CAN7trJOkJECG-MYpuU27tCqsQRlxJWP9-UJADAWuzJcW~SADGmrFdrHAUX5nbWspT4OuxID7JLGOkIlBiisNgnknrjguhxEfXL5Xw0cXwVZVePRasNLB4SfkHnsWLikAdvK6MVUoOQNMydHIdMmimWPB1bNHA5j3nyW3UOqv9pjaVjPKJEzXCZ6aaFRjvIWIKfxk82niB8OyLIent5oFpBBoSLW0Ckf~Ali3l~PgKo1Sjda8tTFnwWwkWqacxm99FgYZDufGtlJ09OC6EtvqBoL0eEKbk9w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Section 1.1](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179_supplementary_data.pdf?Expires=1728479087&Signature=yLyH980QM156IeuIcUZSEzWy76j01TnWXcoDQ4ZTMz8G6FY7KOUPe9CAN7trJOkJECG-MYpuU27tCqsQRlxJWP9-UJADAWuzJcW~SADGmrFdrHAUX5nbWspT4OuxID7JLGOkIlBiisNgnknrjguhxEfXL5Xw0cXwVZVePRasNLB4SfkHnsWLikAdvK6MVUoOQNMydHIdMmimWPB1bNHA5j3nyW3UOqv9pjaVjPKJEzXCZ6aaFRjvIWIKfxk82niB8OyLIent5oFpBBoSLW0Ckf~Ali3l~PgKo1Sjda8tTFnwWwkWqacxm99FgYZDufGtlJ09OC6EtvqBoL0eEKbk9w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_, and the _2021 ESC Guidelines on CV disease prevention in clinical practice_.<sup><a href="javascript:;" reveal-id="ehae179-B19" data-open="ehae179-B19" class="link link-ref link-reveal xref-bibr">19</a></sup>

![Main risk factors associated with atherosclerosis in peripheral arterial and aortic diseases.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f3.jpeg?Expires=1728479087&Signature=22sw6WpmEioIEaXRMNFX4n2r3tNN~fOFApEvVDgWlcp9Q21BdXgpaE11-dKX37AxpoBACfR8k0IiLB2tNN1SstPYLgf50K8L5-kCpe91j628w7fxtFvnPqtq02PBL81ckXM6BCzt07-Ftz0YCa4~VVBk1fLF47lP~Uh~Lfmg9MyCX1BLQyegkSHpUnblSlzhCK2GfIuhaRCdYII8eLLfPHEhCxJ9Go0IkwFcFFFT9FCRS8-~ZeJLfZEUYeWEi6s7zZtUC93M0Fdx6X~gZL4rBuqqMrfbgGBNZgteZW-Mfi~SDtJj1n5TFPx78rk32cm5LrZTnjykvCVyIM6jaxbdvQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 3

Main risk factors associated with atherosclerosis in peripheral arterial and aortic diseases.

PAAD, peripheral arterial and aortic diseases.

[Open in new tab](https://academic.oup.com/view-large/figure/479845802/ehae179f3.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f3.jpeg?Expires=1728479087&Signature=Zkt~hQ-Cvp6g2yAn8D0NHmhZiM4wiiOyc53MrXexbwL56GPH-Mhdq046I6FTmVHWQPjjQq4u-vNvFPmfDPoFD2FvwsJ7IdLVIsC23BilHroyNn0mm8Wimgfi74~FNXexlbBouaSzj3V3NOaJcEO1w-vBs5QowNsrjQd5yOQhO6WGChWZhMjNdWzmQuxQmPWCHWV8UpXJKyeJNGoDaWfnTKWg~OnHTI8DhWwp89DuQHkV9gaMye4ZrUGrfpXAZf-acr7uiyWJyFBZtY~011IXbQbhZ2Ablt1TaNPwx4yxVWFYsB2mWUuNrhZ7RAu-Z5X9-pNJRN7I9vgSsWZF7nJUGQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479845802&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Low-density lipoprotein cholesterol (LDL-C) is a pivotal factor in atherosclerosis,<sup><a href="javascript:;" reveal-id="ehae179-B19" data-open="ehae179-B19" class="link link-ref link-reveal xref-bibr">19</a></sup> with diabetes and tobacco exposure significantly amplifying PAD risk by 2–4 times each.<sup><a href="javascript:;" reveal-id="ehae179-B20" data-open="ehae179-B20" class="link link-ref link-reveal xref-bibr">20</a></sup> Both men and women face a similar risk of PAD, but women have distinct risk factors (_[Figure 3](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B21" data-open="ehae179-B21" class="link link-ref link-reveal xref-bibr">21</a></sup> Hypertension and male sex are major risk factors for AAA, whereas diabetes mellitus lowers its incidence by 25%.<sup><a href="javascript:;" reveal-id="ehae179-B22 ehae179-B23 ehae179-B24" data-open="ehae179-B22 ehae179-B23 ehae179-B24" class="link link-ref link-reveal xref-bibr">22–24</a></sup> Thoracic aortic aneurysm (TAA) or dissection share atherosclerotic risk factors, yet monogenic or polygenic diseases like Marfan syndrome (MFS), more prevalent in younger individuals, also contribute.<sup><a href="javascript:;" reveal-id="ehae179-B24" data-open="ehae179-B24" class="link link-ref link-reveal xref-bibr">24</a>,<a href="javascript:;" reveal-id="ehae179-B25" data-open="ehae179-B25" class="link link-ref link-reveal xref-bibr">25</a></sup> Inflammation as a risk factor can be observed in PAAD<sup><a href="javascript:;" reveal-id="ehae179-B26" data-open="ehae179-B26" class="link link-ref link-reveal xref-bibr">26</a></sup> and the potential for inflammation to be a modifiable risk factor is indicated by research related to colchicine and the effects demonstrated by canakinumab (a monoclonal antibody that reduces inflammation by inhibiting interleukin-1 beta).<sup><a href="javascript:;" reveal-id="ehae179-B27" data-open="ehae179-B27" class="link link-ref link-reveal xref-bibr">27</a>,<a href="javascript:;" reveal-id="ehae179-B28" data-open="ehae179-B28" class="link link-ref link-reveal xref-bibr">28</a></sup>

## 5\. Evaluation of peripheral arteries and aorta

To be consistent with existing literature, the term PAD is used to refer to lower-extremity atherosclerotic arterial disease.

### 5.1. Clinical history and examination, and laboratory assessment, in patients with peripheral arterial and aortic diseases

Clinical evaluation encompassing history (including family history), review of symptoms, and physical examination are the first steps in diagnosing and assessing patients with PAAD. Pulse palpation, femoral, carotid, and abdominal bruit auscultation, heart auscultation, and observation of the legs and feet need to be part of the vascular examination.

Clinical signs, beyond aiding diagnosis, offer prognostic insights. Carotid bruits double the risk of myocardial infarction (MI) and CV death,<sup><a href="javascript:;" reveal-id="ehae179-B29" data-open="ehae179-B29" class="link link-ref link-reveal xref-bibr">29</a>,<a href="javascript:;" reveal-id="ehae179-B30" data-open="ehae179-B30" class="link link-ref link-reveal xref-bibr">30</a></sup> while a brachial systolic blood pressure (SBP) difference of more than 15 mmHg raises CV death risk by 50%.<sup><a href="javascript:;" reveal-id="ehae179-B31" data-open="ehae179-B31" class="link link-ref link-reveal xref-bibr">31</a></sup> Hence, bilateral arm blood pressure (BP) measurement is recommended.<sup><a href="javascript:;" reveal-id="ehae179-B32" data-open="ehae179-B32" class="link link-ref link-reveal xref-bibr">32</a></sup> Lab assessments should include lipid profile (including lipoprotein\[a\] at least once in a lifetime),<sup><a href="javascript:;" reveal-id="ehae179-B33" data-open="ehae179-B33" class="link link-ref link-reveal xref-bibr">33</a></sup> fasting glycaemia, glycated haemoglobin (HbA1c), renal function, blood count, coagulation studies, liver function, electrolytes, and inflammatory markers (C-reactive protein \[CRP\] and erythrocyte sedimentation rate). Additional evaluations, like thyroid function tests, are advised as needed.

### 5.2. Functional and quality of life assessment in patients with peripheral arterial and aortic diseases

Patients with PAD have decreased walking performance and self-reported physical and mental health-related quality of life (HRQoL).<sup><a href="javascript:;" reveal-id="ehae179-B34 ehae179-B35 ehae179-B36 ehae179-B37 ehae179-B38 ehae179-B39 ehae179-B40" data-open="ehae179-B34 ehae179-B35 ehae179-B36 ehae179-B37 ehae179-B38 ehae179-B39 ehae179-B40" class="link link-ref link-reveal xref-bibr">34–40</a></sup> Muscle strength and balance are also impaired,<sup><a href="javascript:;" reveal-id="ehae179-B41 ehae179-B42 ehae179-B43 ehae179-B44 ehae179-B45" data-open="ehae179-B41 ehae179-B42 ehae179-B43 ehae179-B44 ehae179-B45" class="link link-ref link-reveal xref-bibr">41–45</a></sup> leading to a faster decline in functional (physical functioning) performance in both symptomatic and asymptomatic patients.<sup><a href="javascript:;" reveal-id="ehae179-B46" data-open="ehae179-B46" class="link link-ref link-reveal xref-bibr">46</a>,<a href="javascript:;" reveal-id="ehae179-B47" data-open="ehae179-B47" class="link link-ref link-reveal xref-bibr">47</a></sup> Depression is associated with greater impairment in functional performance.<sup><a href="javascript:;" reveal-id="ehae179-B48" data-open="ehae179-B48" class="link link-ref link-reveal xref-bibr">48</a>,<a href="javascript:;" reveal-id="ehae179-B49" data-open="ehae179-B49" class="link link-ref link-reveal xref-bibr">49</a></sup> Impaired functional status is related to decreased self-reported HRQoL,<sup><a href="javascript:;" reveal-id="ehae179-B50" data-open="ehae179-B50" class="link link-ref link-reveal xref-bibr">50</a>,<a href="javascript:;" reveal-id="ehae179-B51" data-open="ehae179-B51" class="link link-ref link-reveal xref-bibr">51</a></sup> and predicts further mobility loss and CV mortality.<sup><a href="javascript:;" reveal-id="ehae179-B52" data-open="ehae179-B52" class="link link-ref link-reveal xref-bibr">52</a>,<a href="javascript:;" reveal-id="ehae179-B53" data-open="ehae179-B53" class="link link-ref link-reveal xref-bibr">53</a></sup> Very poor HRQoL has been found in patients with chronic limb-threatening ischaemia (CLTI).<sup><a href="javascript:;" reveal-id="ehae179-B54" data-open="ehae179-B54" class="link link-ref link-reveal xref-bibr">54</a></sup>

Different questionnaires are available assessing different facets (functional, mental, and social status) of patient-reported outcome measures (PROMs).<sup><a href="javascript:;" reveal-id="ehae179-B34 ehae179-B35 ehae179-B36" data-open="ehae179-B34 ehae179-B35 ehae179-B36" class="link link-ref link-reveal xref-bibr">34–36</a>,<a href="javascript:;" reveal-id="ehae179-B38" data-open="ehae179-B38" class="link link-ref link-reveal xref-bibr">38</a></sup> The Short-form 36-item health questionnaire (SF-36) (including physical- and mental health-related items) is the most used generic questionnaire in PAD.<sup><a href="javascript:;" reveal-id="ehae179-B35" data-open="ehae179-B35" class="link link-ref link-reveal xref-bibr">35</a>,<a href="javascript:;" reveal-id="ehae179-B36" data-open="ehae179-B36" class="link link-ref link-reveal xref-bibr">36</a>,<a href="javascript:;" reveal-id="ehae179-B38" data-open="ehae179-B38" class="link link-ref link-reveal xref-bibr">38</a></sup> The Edinburgh Claudication Questionnaire is a modified version of the initially developed Rose questionnaire and has a sensitivity of 91% and a specificity of 99% in comparison with a physician-based diagnosis.<sup><a href="javascript:;" reveal-id="ehae179-B55" data-open="ehae179-B55" class="link link-ref link-reveal xref-bibr">55</a>,<a href="javascript:;" reveal-id="ehae179-B56" data-open="ehae179-B56" class="link link-ref link-reveal xref-bibr">56</a></sup> The Walking Impairment Questionnaire (WIQ), the Walking Estimated Limitation Calculated by History (WELCH), and the Vascular quality of life (VascuQoL) questionnaire are the most used PAD-specific questionnaires.<sup><a href="javascript:;" reveal-id="ehae179-B34 ehae179-B35 ehae179-B36" data-open="ehae179-B34 ehae179-B35 ehae179-B36" class="link link-ref link-reveal xref-bibr">34–36</a>,<a href="javascript:;" reveal-id="ehae179-B38" data-open="ehae179-B38" class="link link-ref link-reveal xref-bibr">38</a></sup>

Treadmill testing, using standardized criteria, is the gold standard to assess walking performance.<sup><a href="javascript:;" reveal-id="ehae179-B37" data-open="ehae179-B37" class="link link-ref link-reveal xref-bibr">37</a>,<a href="javascript:;" reveal-id="ehae179-B57 ehae179-B58 ehae179-B59 ehae179-B60 ehae179-B61 ehae179-B62" data-open="ehae179-B57 ehae179-B58 ehae179-B59 ehae179-B60 ehae179-B61 ehae179-B62" class="link link-ref link-reveal xref-bibr">57–62</a></sup> Patients are asked to walk until maximal pain levels, defining the maximal walking distance (MWD). Patients are also asked to indicate the point at which pain begins, defining the pain-free walking distance (PFWD). Constant-load protocols have poorer reliability than graded protocols.<sup><a href="javascript:;" reveal-id="ehae179-B60 ehae179-B61 ehae179-B62 ehae179-B63 ehae179-B64" data-open="ehae179-B60 ehae179-B61 ehae179-B62 ehae179-B63 ehae179-B64" class="link link-ref link-reveal xref-bibr">60–64</a></sup> Additionally, the six-minute walk test (6MWT) should be performed to assess functional walking performance.<sup><a href="javascript:;" reveal-id="ehae179-B62" data-open="ehae179-B62" class="link link-ref link-reveal xref-bibr">62</a>,<a href="javascript:;" reveal-id="ehae179-B65" data-open="ehae179-B65" class="link link-ref link-reveal xref-bibr">65</a></sup> For muscular lower-limb strength assessment,<sup><a href="javascript:;" reveal-id="ehae179-B66" data-open="ehae179-B66" class="link link-ref link-reveal xref-bibr">66</a></sup> isokinetic dynamometry has good test–retest reliability.<sup><a href="javascript:;" reveal-id="ehae179-B67" data-open="ehae179-B67" class="link link-ref link-reveal xref-bibr">67</a></sup> Alternatively, the Short physical performance battery (SPPB) test should be used.<sup><a href="javascript:;" reveal-id="ehae179-B62" data-open="ehae179-B62" class="link link-ref link-reveal xref-bibr">62</a>,<a href="javascript:;" reveal-id="ehae179-B64" data-open="ehae179-B64" class="link link-ref link-reveal xref-bibr">64</a>,<a href="javascript:;" reveal-id="ehae179-B68" data-open="ehae179-B68" class="link link-ref link-reveal xref-bibr">68</a>,<a href="javascript:;" reveal-id="ehae179-B69" data-open="ehae179-B69" class="link link-ref link-reveal xref-bibr">69</a></sup> The SPPB has good test–retest reliability.<sup><a href="javascript:;" reveal-id="ehae179-B64" data-open="ehae179-B64" class="link link-ref link-reveal xref-bibr">64</a></sup>

Few data exist on HRQoL, functional assessment, and exercise capacity in patients with aortic diseases.<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B71" data-open="ehae179-B71" class="link link-ref link-reveal xref-bibr">71</a></sup> Those with acute aortic dissection (AAD), as well as patients who had aortic valve or thoracic aortic surgery, may present with depression and anxiety, leading to mental health issues<sup><a href="javascript:;" reveal-id="ehae179-B72" data-open="ehae179-B72" class="link link-ref link-reveal xref-bibr">72</a>,<a href="javascript:;" reveal-id="ehae179-B73" data-open="ehae179-B73" class="link link-ref link-reveal xref-bibr">73</a></sup> that can also be assessed with the SF-36 questionnaire or the hospital anxiety and depression score (HADS).<sup><a href="javascript:;" reveal-id="ehae179-B72" data-open="ehae179-B72" class="link link-ref link-reveal xref-bibr">72</a></sup> Patients with MFS have reduced HRQoL and a significant decline over time in physical HRQoL.<sup><a href="javascript:;" reveal-id="ehae179-B74" data-open="ehae179-B74" class="link link-ref link-reveal xref-bibr">74</a>,<a href="javascript:;" reveal-id="ehae179-B75" data-open="ehae179-B75" class="link link-ref link-reveal xref-bibr">75</a></sup> Assessing HRQoL in aortic disease patients is crucial for understanding well-being, disease impact, and treatment effects. This involves PROMs, including surveys, symptom assessment, functional evaluation, psychological well-being (HADS), social and occupational function, and medication/treatment side effects. It also covers healthcare utilization and patient satisfaction, informing care and enhancing aortic disease management.

Recommendation Table 1

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479845814)

Recommendations for clinical and laboratory, and for functional and quality of life, assessment in patients with peripheral arterial and aortic disease (see also Evidence Table 1)

![Recommendations for clinical and laboratory, and for functional and quality of life, assessment in patients with peripheral arterial and aortic disease (see also Evidence Table 1)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt1.jpeg?Expires=1728479087&Signature=1z2GFUMvoIu13TC0c1NuzBA3XdqdPK~aLs7XlikDdtDYij2q4TwWUycSIp3itGSYaFnYGtAjPrwaB7aZ0g2zWjg6Plu1R44uYbr-WAGmANzZVj~NH3~WxMWS2q9-SuDHiIuO9SE3wzeCY-0~YHG~hRl5I1HyTNE11diSvQRjSbixBJmgo5-QgNjeK6BJ2E6JKbpC74eU2j4aGSV6~JvMTlO2S89WViuqt9iiyVqrkATuTzY8eRjplykgxb4zbWbwyMqtxbZgrfrBhNpxvRxM-Ow-CN8T5zMTw7P~NcYQSAz4PJGpdCdow28vT3oMeIwkyDJh6NGPBKL8xTw1qFbbMA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 5.3. Vascular examination of peripheral arteries

The ankle-brachial index (ABI)<sup><a href="javascript:;" reveal-id="ehae179-B78" data-open="ehae179-B78" class="link link-ref link-reveal xref-bibr">78</a>,<a href="javascript:;" reveal-id="ehae179-B79" data-open="ehae179-B79" class="link link-ref link-reveal xref-bibr">79</a></sup> is a low-cost, easy, and largely used tool, used both at rest or after exercise<sup><a href="javascript:;" reveal-id="ehae179-B80 ehae179-B81 ehae179-B82 ehae179-B83 ehae179-B84" data-open="ehae179-B80 ehae179-B81 ehae179-B82 ehae179-B83 ehae179-B84" class="link link-ref link-reveal xref-bibr">80–84</a></sup> for PAD diagnosis and surveillance (_[Figure 4](javascript:;)_). Both oscillometric and Doppler methods have shown good concordance.<sup><a href="javascript:;" reveal-id="ehae179-B78" data-open="ehae179-B78" class="link link-ref link-reveal xref-bibr">78</a></sup>

![Haemodynamic assessment of peripheral arterial disease.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f4.jpeg?Expires=1728479087&Signature=lsnPRaiyWI61Mh6uVbRDsS2WlgLrstmJqzWdP3EGa-qcKIVMahSiorh-iq7PnIDIO-7UokQiTlQFs2FMyIX0l22rMO74ZqU9X4PsvDEEDRzRsK-H7kw0NCUzDT13kkNLedUAN4hg460PwOVCY4ZUpcZ2N-LRAi2g7pRxAncrZCBcfMO5vhhd1oTsqZcNAgVlCS62DPrtk-mVgLS8WqTAcuOpZsC1MjGGk5ahJ8R3B~l6tSVoXj90I-paH1iSyvHPP1l6boxqGytW1O1iL5~ELGJ2ax~diUEqU9LJOrQJ4GSyEE6YzudNJgu-ehRatokl8yL1z86FloJB~c3c5rA6eA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 4

Haemodynamic assessment of peripheral arterial disease.

ABI, ankle–brachial index; CLTI, chronic limb-threatening ischaemia; PAD, peripheral arterial disease; TBI, toe–brachial index; TcPO<sub>2</sub>, transcutaneous oxygen pressure.

[Open in new tab](https://academic.oup.com/view-large/figure/479845817/ehae179f4.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f4.jpeg?Expires=1728479087&Signature=4n0lR2IdUkZNdwvNQt43JWnnaIAqJ1tPQXJWBRfbpryPy62NczIv8nv9pnV8MY8LOO9-J7yyjpjUZTcPiiNIqZRlINpdnkNhQmzx4DAIx-M4zzna1HTbUROiG-S7zsA7jTmBFinUmoe7G1zP7-L3nJngH3b8S8xl-JB7M-QkYwwmPOP4tRJdU4e23-4KsxoOIFeszVKUlVFQIDt4OJyufT205zjZesjgTh-4~IPzneRbpMW5h~KubkvFciADgchSTdxoLrNM0ewY9z9KQtjMmUIGLuR32uVOuePqJNazw9uy6bXGQZ8Wr2rEsGomKcDEZBk-Hrdge3XBEl9Mi7VIEg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479845817&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Resting ABI has a 68%–84% sensitivity and an 84%–99% specificity for PAD diagnosis (_[Figure 4](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B79" data-open="ehae179-B79" class="link link-ref link-reveal xref-bibr">79</a></sup> An ABI ≤0.90 confirms PAD diagnosis.<sup><a href="javascript:;" reveal-id="ehae179-B79" data-open="ehae179-B79" class="link link-ref link-reveal xref-bibr">79</a>,<a href="javascript:;" reveal-id="ehae179-B85 ehae179-B86 ehae179-B87" data-open="ehae179-B85 ehae179-B86 ehae179-B87" class="link link-ref link-reveal xref-bibr">85–87</a></sup> For values >1.40, the term ‘non-compressible arteries’ should be used.

Ankle–brachial index >1.40, seen in arterial stiffness (diabetes, severe kidney failure, or advanced age), correlates with increased CV events and mortality risk.<sup><a href="javascript:;" reveal-id="ehae179-B88" data-open="ehae179-B88" class="link link-ref link-reveal xref-bibr">88</a>,<a href="javascript:;" reveal-id="ehae179-B89" data-open="ehae179-B89" class="link link-ref link-reveal xref-bibr">89</a></sup> For ABI >1.40, assessing resting toe–brachial index (TBI) is recommended.<sup><a href="javascript:;" reveal-id="ehae179-B79" data-open="ehae179-B79" class="link link-ref link-reveal xref-bibr">79</a>,<a href="javascript:;" reveal-id="ehae179-B90 ehae179-B91 ehae179-B92 ehae179-B93 ehae179-B94 ehae179-B95" data-open="ehae179-B90 ehae179-B91 ehae179-B92 ehae179-B93 ehae179-B94 ehae179-B95" class="link link-ref link-reveal xref-bibr">90–95</a></sup>

Toe–brachial index addresses medium-calibre artery rigidity<sup><a href="javascript:;" reveal-id="ehae179-B96" data-open="ehae179-B96" class="link link-ref link-reveal xref-bibr">96</a></sup> measuring pressure on the hallux, second, or third toe using laser Doppler probe or plethysmography.<sup><a href="javascript:;" reveal-id="ehae179-B97" data-open="ehae179-B97" class="link link-ref link-reveal xref-bibr">97</a>,<a href="javascript:;" reveal-id="ehae179-B98" data-open="ehae179-B98" class="link link-ref link-reveal xref-bibr">98</a></sup> Sensitivity and specificity for PAD diagnosis range from 45% to 100% and 17% to 100%, respectively.<sup><a href="javascript:;" reveal-id="ehae179-B91" data-open="ehae179-B91" class="link link-ref link-reveal xref-bibr">91</a></sup> The usual pathological threshold for TBI is ≤0.70 (_[Figure 4](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B99" data-open="ehae179-B99" class="link link-ref link-reveal xref-bibr">99</a></sup>

Used within the Framingham risk score, ABI enables the upgrading of risk estimation in ‘low-risk’ women and men,<sup><a href="javascript:;" reveal-id="ehae179-B77" data-open="ehae179-B77" class="link link-ref link-reveal xref-bibr">77</a>,<a href="javascript:;" reveal-id="ehae179-B88" data-open="ehae179-B88" class="link link-ref link-reveal xref-bibr">88</a></sup> it allows CV risk assessment in diverse ethnic groups independently of risk factors,<sup><a href="javascript:;" reveal-id="ehae179-B77" data-open="ehae179-B77" class="link link-ref link-reveal xref-bibr">77</a>,<a href="javascript:;" reveal-id="ehae179-B89" data-open="ehae179-B89" class="link link-ref link-reveal xref-bibr">89</a></sup> and is inexpensive and minimally time-consuming.<sup><a href="javascript:;" reveal-id="ehae179-B100" data-open="ehae179-B100" class="link link-ref link-reveal xref-bibr">100</a></sup> Trained physicians have better reproducibility than inexperienced ones.<sup><a href="javascript:;" reveal-id="ehae179-B101" data-open="ehae179-B101" class="link link-ref link-reveal xref-bibr">101</a>,<a href="javascript:;" reveal-id="ehae179-B102" data-open="ehae179-B102" class="link link-ref link-reveal xref-bibr">102</a></sup>

In patients with exertional limb pain relieved by rest and a resting ABI >0.90, exercise testing with post-exercise ABI measurements or exercise oximetry has been proposed to diagnose lower-limb arterial stenoses.<sup><a href="javascript:;" reveal-id="ehae179-B103 ehae179-B104 ehae179-B105" data-open="ehae179-B103 ehae179-B104 ehae179-B105" class="link link-ref link-reveal xref-bibr">103–105</a></sup>

The post-exercise ABI is determined 1 min after the cessation of a standardized treadmill exercise.<sup><a href="javascript:;" reveal-id="ehae179-B106" data-open="ehae179-B106" class="link link-ref link-reveal xref-bibr">106</a></sup> The physician measures bilateral ankle BP, starting with the symptomatic leg, using the ankle artery used for the reference resting ABI measurement. Brachial SBP should simultaneously be measured to enable calculation of the post-exercise ABI.<sup><a href="javascript:;" reveal-id="ehae179-B104" data-open="ehae179-B104" class="link link-ref link-reveal xref-bibr">104</a></sup>

Discrepancies in PAD diagnosis exist between exercise criteria, such as a fall in absolute ankle BP >30 mmHg or a drop of >20% in the post-exercise ABI.<sup><a href="javascript:;" reveal-id="ehae179-B104" data-open="ehae179-B104" class="link link-ref link-reveal xref-bibr">104</a></sup> Recent studies identified numerous false positives in a healthy population when using a post-exercise ABI drop of >20% as the diagnostic threshold, as commonly proposed.<sup><a href="javascript:;" reveal-id="ehae179-B103" data-open="ehae179-B103" class="link link-ref link-reveal xref-bibr">103</a></sup>

Measurement of transcutaneous oxygen pressure (TcPO<sub>2</sub>) is a means of evaluating tissue viability and is proposed as a diagnostic criterion of CLTI (_[Figure 4](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B107" data-open="ehae179-B107" class="link link-ref link-reveal xref-bibr">107</a></sup> TcPO<sub>2</sub> is affected by local and general factors such as skin thickness, probe temperature, inflammation, and oedema,<sup><a href="javascript:;" reveal-id="ehae179-B108" data-open="ehae179-B108" class="link link-ref link-reveal xref-bibr">108</a>,<a href="javascript:;" reveal-id="ehae179-B109" data-open="ehae179-B109" class="link link-ref link-reveal xref-bibr">109</a></sup> resulting in misleading values.

Resting TcPO<sub>2</sub> >30 mmHg is a favourable indicator of wound healing;<sup><a href="javascript:;" reveal-id="ehae179-B110 ehae179-B111 ehae179-B112" data-open="ehae179-B110 ehae179-B111 ehae179-B112" class="link link-ref link-reveal xref-bibr">110–112</a></sup> however, resting TcPO<sub>2</sub> <10 mmHg is associated with bad prognosis for wound healing and amputation in CLTI patients treated with bone marrow-derived stem cells.<sup><a href="javascript:;" reveal-id="ehae179-B107" data-open="ehae179-B107" class="link link-ref link-reveal xref-bibr">107</a></sup> When performed at successive levels on an ischaemic limb, TcPO<sub>2</sub> measurement may help to determine amputation level.<sup><a href="javascript:;" reveal-id="ehae179-B113 ehae179-B114 ehae179-B115" data-open="ehae179-B113 ehae179-B114 ehae179-B115" class="link link-ref link-reveal xref-bibr">113–115</a></sup>

Exercise transcutaneous oximetry has also been proposed.<sup><a href="javascript:;" reveal-id="ehae179-B116" data-open="ehae179-B116" class="link link-ref link-reveal xref-bibr">116</a>,<a href="javascript:;" reveal-id="ehae179-B117" data-open="ehae179-B117" class="link link-ref link-reveal xref-bibr">117</a></sup> This seems of interest to detect proximal (buttock) claudication<sup><a href="javascript:;" reveal-id="ehae179-B105" data-open="ehae179-B105" class="link link-ref link-reveal xref-bibr">105</a></sup> or unsuspected exercise-induced hypoxaemia<sup><a href="javascript:;" reveal-id="ehae179-B118" data-open="ehae179-B118" class="link link-ref link-reveal xref-bibr">118</a></sup> in patients with intermittent claudication (IC).<sup><a href="javascript:;" reveal-id="ehae179-B117" data-open="ehae179-B117" class="link link-ref link-reveal xref-bibr">117</a></sup>

#### 5.3.1. Duplex ultrasound

Duplex ultrasound (DUS) is a first step in the vascular work-up for PAD screening and diagnosis, allowing a dynamic, non-invasive, radiation- and contrast-free examination. It localizes vascular lesions and quantifies their extent and severity through velocity criteria.<sup><a href="javascript:;" reveal-id="ehae179-B119 ehae179-B120 ehae179-B121" data-open="ehae179-B119 ehae179-B120 ehae179-B121" class="link link-ref link-reveal xref-bibr">119–121</a></sup> In combination with ABI or TBI, DUS permits determining the haemodynamic relevance of arterial lesions<sup><a href="javascript:;" reveal-id="ehae179-B122" data-open="ehae179-B122" class="link link-ref link-reveal xref-bibr">122</a>,<a href="javascript:;" reveal-id="ehae179-B123" data-open="ehae179-B123" class="link link-ref link-reveal xref-bibr">123</a></sup> and estimation of ABI.<sup><a href="javascript:;" reveal-id="ehae179-B124" data-open="ehae179-B124" class="link link-ref link-reveal xref-bibr">124</a></sup> DUS has a sensitivity of 88% and specificity of 95% for >50% stenosis detection.<sup><a href="javascript:;" reveal-id="ehae179-B125" data-open="ehae179-B125" class="link link-ref link-reveal xref-bibr">125</a></sup> Post-exercise DUS can reveal borderline arterial lesions if initial findings are inconclusive.<sup><a href="javascript:;" reveal-id="ehae179-B122" data-open="ehae179-B122" class="link link-ref link-reveal xref-bibr">122</a>,<a href="javascript:;" reveal-id="ehae179-B126" data-open="ehae179-B126" class="link link-ref link-reveal xref-bibr">126</a>,<a href="javascript:;" reveal-id="ehae179-B127" data-open="ehae179-B127" class="link link-ref link-reveal xref-bibr">127</a></sup>

Duplex ultrasound distinguishes atherosclerotic (even subclinical disease) from non-atherosclerotic lesions, but its reliability relies on the sonographer’s expertise.<sup><a href="javascript:;" reveal-id="ehae179-B122" data-open="ehae179-B122" class="link link-ref link-reveal xref-bibr">122</a></sup> Cross-sectional imaging is advisable for revascularization planning. ABI and DUS are recommended for PAD patient follow-up post-revascularization.<sup><a href="javascript:;" reveal-id="ehae179-B128" data-open="ehae179-B128" class="link link-ref link-reveal xref-bibr">128</a></sup>

More recent techniques, such as flow imaging, 3D echography, ultrafast ultrasound, and shear wave elastography, as well as the use of contrast-enhanced ultrasound (CEUS), could further improve DUS performance.<sup><a href="javascript:;" reveal-id="ehae179-B129" data-open="ehae179-B129" class="link link-ref link-reveal xref-bibr">129</a></sup>

#### 5.3.2. Digital subtraction angiography, computed tomography angiography, and magnetic resonance angiography

Detailed information about these techniques can be found in the [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179_supplementary_data.pdf?Expires=1728479087&Signature=yLyH980QM156IeuIcUZSEzWy76j01TnWXcoDQ4ZTMz8G6FY7KOUPe9CAN7trJOkJECG-MYpuU27tCqsQRlxJWP9-UJADAWuzJcW~SADGmrFdrHAUX5nbWspT4OuxID7JLGOkIlBiisNgnknrjguhxEfXL5Xw0cXwVZVePRasNLB4SfkHnsWLikAdvK6MVUoOQNMydHIdMmimWPB1bNHA5j3nyW3UOqv9pjaVjPKJEzXCZ6aaFRjvIWIKfxk82niB8OyLIent5oFpBBoSLW0Ckf~Ali3l~PgKo1Sjda8tTFnwWwkWqacxm99FgYZDufGtlJ09OC6EtvqBoL0eEKbk9w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Section 1.2](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179_supplementary_data.pdf?Expires=1728479087&Signature=yLyH980QM156IeuIcUZSEzWy76j01TnWXcoDQ4ZTMz8G6FY7KOUPe9CAN7trJOkJECG-MYpuU27tCqsQRlxJWP9-UJADAWuzJcW~SADGmrFdrHAUX5nbWspT4OuxID7JLGOkIlBiisNgnknrjguhxEfXL5Xw0cXwVZVePRasNLB4SfkHnsWLikAdvK6MVUoOQNMydHIdMmimWPB1bNHA5j3nyW3UOqv9pjaVjPKJEzXCZ6aaFRjvIWIKfxk82niB8OyLIent5oFpBBoSLW0Ckf~Ali3l~PgKo1Sjda8tTFnwWwkWqacxm99FgYZDufGtlJ09OC6EtvqBoL0eEKbk9w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_ (_[Table S1](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179_supplementary_data.pdf?Expires=1728479087&Signature=yLyH980QM156IeuIcUZSEzWy76j01TnWXcoDQ4ZTMz8G6FY7KOUPe9CAN7trJOkJECG-MYpuU27tCqsQRlxJWP9-UJADAWuzJcW~SADGmrFdrHAUX5nbWspT4OuxID7JLGOkIlBiisNgnknrjguhxEfXL5Xw0cXwVZVePRasNLB4SfkHnsWLikAdvK6MVUoOQNMydHIdMmimWPB1bNHA5j3nyW3UOqv9pjaVjPKJEzXCZ6aaFRjvIWIKfxk82niB8OyLIent5oFpBBoSLW0Ckf~Ali3l~PgKo1Sjda8tTFnwWwkWqacxm99FgYZDufGtlJ09OC6EtvqBoL0eEKbk9w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). Digital subtraction angiography (DSA) remains mostly limited to revascularization procedures. Computed tomography angiography (CTA) offers better spatial resolution than magnetic resonance angiography (MRA) and better calcification visualization; however, it can also overestimate stenosis severity due to the blooming effect. MRA allows arterial wall and lumen assessment as well as tissue and organ perfusion distal to or surrounding the explored arterial territory.

Recommendation Table 2

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479845834)

Recommendations for diagnostic tests in patients with peripheral arterial disease

![Recommendations for diagnostic tests in patients with peripheral arterial disease](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt2.jpeg?Expires=1728479087&Signature=WGrPHSersnW1dEZx2U90LZwtRT5Wx66AwHeqp4XgkPkvhA5TXwuVj8IF-eHZQ8ZbWtRIaadvumV2yhm6fW4PQwbjxlDj-dhq~-RTIs4fIMW7-tllNDrUqCu1iIzwVYU4BRSEqe9YHpwqQTZi~8pCPUgYXJlnoE41ngOOvw8lXCcKUd20cELwCJljlOIgxWa37J6qnBE5M0sppVr8b0x~w2jBOiGWVBerjYfbG7JzY8xXe4XKleEyTugPS0XMzfVofOIVhp8lhrXWvjZdGBkb7MV1fbWZl~ERjSII00L0kmcn2vm-eT4Wy84XG8slJhP2h7fLxvXVsoy4apnj8CyiSw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 5.4. Evaluation of the aorta

The aorta can be divided into different anatomical regions (from proximal to distal) for reporting purposes. The main anatomical aortic regions are the aortic root, ascending aorta, aortic arch, descending thoracic aorta (DTA), abdominal aorta (AA), infrarenal aorta, and the iliac arteries (_[Figure 5](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B134" data-open="ehae179-B134" class="link link-ref link-reveal xref-bibr">134</a>,<a href="javascript:;" reveal-id="ehae179-B135" data-open="ehae179-B135" class="link link-ref link-reveal xref-bibr">135</a></sup>

![Anatomy and aortic segments and upper normal values for aortic dimensions.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f5.jpeg?Expires=1728479087&Signature=a50bBwx3-tK9KnNFcU5aS3WUqSwowcw7Ic5yGJZS~hTGyJSt-h5YOygPDpELf7YDhHEvSXkCTxRObgSuPxplf8rv2spvSoszR15w77llFvc~YXAhlCYJnDwd5JCJNyMA8tCKbnyq5~pOIMG-F4V79Gjq-mVvbMMgC37SiiyT57OTHenGUr3CD2b3Y2nf6b4M43mqQmcMAg4A4zZ7m8Kq0PjFpIPTo2S8Ot0bEpEFUSfQYSxK2TdItOjEI-SAWRkdrSa8NXgIpk8mfkuhM9QW9rHbA8rDZz4y31xWwMsJGpEpOJoPb6aViJYPs4~rG-i~zKRRm~v-KSNr9oGxL0vUCA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 5

Anatomy and aortic segments and upper normal values for aortic dimensions.

Numbers represent the 11 aortic segments based on the Society for Vascular Surgery/Society of Thoracic Surgeons (SVS/STS) classification for surgical and endovascular purposes.<sup><a href="javascript:;" reveal-id="ehae179-B136" data-open="ehae179-B136" class="link link-ref link-reveal xref-bibr">136</a></sup> Z-scores can be calculated for aortic root and ascending aorta. Calculation of z-scores can be performed following these links: [https://www.marfan.fr/accueil/z-score-calculus/](https://www.marfan.fr/accueil/z-score-calculus/) or [https://marfan.org/dx/z-score-adults](https://marfan.org/dx/z-score-adults).

[Open in new tab](https://academic.oup.com/view-large/figure/479845837/ehae179f5.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f5.jpeg?Expires=1728479087&Signature=CMih0gdNiH0UiL6vRryB-KLji~3qKuMdePSvxMh9UzaXnBJ1wY-mtqoGMTUR8Szp5HZe~sst3SBVXqGolLGFWGOnYBNS09oEKWf1uW57QCB~BaXMY642mMxkSxtaz2f408UzlRCUfjYlWjOzfK9Xh8xAPOcXqW~4zYGnHxnaYGFdQXpLM-VaffWf8NYqn-LOpK1fyEoxrRMtJ6SU1y2NEG~hgzmFfr-5SChzZMPt9msShzHnDpOCOpf4Z6D1gmQiKMKmBzGdi-BysnC98o6TJRLoiL6dYk0NFz0KNO9uDUEOHczjTsj79wbKNLF1XA0YlO24NUsQ1gNwMTQTEl7MEA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479845837&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

#### 5.4.1. Aortic measurements

The main imaging techniques used for aortic evaluation are illustrated in _[Table 5](javascript:;)_.

Table 5

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479845840)

Main aortic imaging techniques

|  | TTE/DUS | TOE | CCT | CMR |
| --- | --- | --- | --- | --- |
| **Availability** | ++++ | +++ | ++ | + |
| **Cost** | + | ++ | +++ | ++++ |
| **Time requirement** | + | +++ | +++ | ++++ |
| **Radiation** | 0 | 0 | +++ | 0 |
| **Spatial resolution** | 1 mm | 1 mm | 0.6 mm | 1–2 mm |
| **Temporal resolution** | 20 msec | 20 msec | 80 msec | 30 msec |
| **Nephrotoxicity** | 0 | 0 | +++ | + |
| **Accuracy** | ++ | ++++ | ++++ | ++++ |
| **Serial examination** | ++++ | ++ | ++ | ++++ |
| **Aortic wall visualization** | ++ | +++ | ++++ | ++++ |
| **Aortic valve function** | +++ | ++++ | + | ++++ |
| **RV/LV function** | +++ | +++ | +++<sup><a href="javascript:;" reveal-id="tblfn258" data-open="tblfn258" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup> | ++++ |
| **Aortic root assessment** | +++ | +++ | ++++ | ++++ |
| **Aortic arch assessment** | ++ | +++ | ++++ | ++++ |
| **Thoracic aorta assessment** | + | ++ | ++++ | ++++ |
| **Abdominal aorta assessment** | +++ | \- | ++++ | ++++ |

CCT, cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; LV, left ventricle; RV right ventricle; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography.

<sup>a</sup>CCT can be used to evaluate left and right ventricular function only if retrospective gating is used.

© ESC 2024

Evaluating aortic dilation and progression depends on standardized measurements. In echocardiography, aortic diameters should be measured using the leading-to-leading edge method during end-diastole (as systole sees about a 2 mm aortic expansion) in all segments (_[Figure 6](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B137" data-open="ehae179-B137" class="link link-ref link-reveal xref-bibr">137</a>,<a href="javascript:;" reveal-id="ehae179-B138" data-open="ehae179-B138" class="link link-ref link-reveal xref-bibr">138</a></sup>

![Conventional measurements of the aorta at different levels by echocardiography or duplex ultrasound (A, B, C), cardiovascular computed tomography or cardiovascular magnetic resonance (D, E, F).](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f6.jpeg?Expires=1728479087&Signature=CLu1G11fMzm1kl5QJdyBwmTqAmBPFQKvdiGYpglK2SJvAk5JArDNFm5LvXuy1kYulcF32GjLzlKVmduZ9x8M91f4uDtcQhD0qp3xrPqjIA3QlOH8jA~RMh~L9NbwrNMMgl1D~eNm4rf1jf4Hcp8DHZvMH0so~UlVxCP32u~~LDIGCX6nVg0qHujv8Mr6O4EfkrCwNF0c35M~4evup1B~tnTcN1XZlLx96WQ6rDj0bfewh2smt8dFNzKhToh4HH7P9H189pNoieVB3lMriomVz0RYcSU8JjqmA7pJfkWLTKFWOXrf0R38ahBCWr1u1TK93473KM~vlboW4WTlf8k5Pw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 6

Conventional measurements of the aorta at different levels by echocardiography or duplex ultrasound (_A_, _B_, _C_), cardiovascular computed tomography or cardiovascular magnetic resonance (_D_, _E_, _F_).

(_A_) Echocardiographic measurements of the aortic root and ascending aorta using the leading-to-leading edge methodology. (_B_) The outer-to-outer convention in the abdominal aorta in cases with aortic wall disease in a longitudinal view. This method can be used in a non-circular section as an alternative. (_C_) The outer-to-outer antero-posterior diameter of the abdominal aorta in a cross-sectional view. Evaluation of the aortic root using the cusp-to-cusp diameter (_D_) and the cusp-to-commissure convention (_E_); (_F_) measurement of the ascending aorta and the descending aorta with the double-oblique technique. AoR, aortic root; ASC, proximal ascending aorta.

[Open in new tab](https://academic.oup.com/view-large/figure/479845842/ehae179f6.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f6.jpeg?Expires=1728479087&Signature=o02-wOFCSqZWf4EKs2pyZXLCpDSBu~pU7vr7Lvy~QxOhGubKz-Bvl~G9IQeF1WBdbGSAi0fIQKFcpol-AiH-wXm98exm-lQeSzTpD4mF1aIbVIH3sXaTXH5kzY3ztAeJPBQZuMr17DYWjxcJxrk2qaTsCuNENBZ4QQi2eQVjtx8Q2v1WqAdaBd4869JevOAzeNIpKcr0mlYlKmaLIPd-9puCt-UaujUOgQqYAfQkgiNad7zY-kb6~p6a~8FhOmwMQvqXb4ZW~gSCap~x8NqyXYYvimSW7a07t-0HNF6cGz3aexARNE2LChM~UKwQbVhbvveZaba3jA876s2sRFebnw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479845842&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Most studies supporting prophylactic surgery have used this approach. Furthermore, better agreement exists between echo’s leading-to-leading edge and cardiovascular computed tomography (CCT)/cardiovascular magnetic resonance (CMR)’s inner-to-inner edge during end-diastole.<sup><a href="javascript:;" reveal-id="ehae179-B137" data-open="ehae179-B137" class="link link-ref link-reveal xref-bibr">137</a>,<a href="javascript:;" reveal-id="ehae179-B139" data-open="ehae179-B139" class="link link-ref link-reveal xref-bibr">139</a>,<a href="javascript:;" reveal-id="ehae179-B140" data-open="ehae179-B140" class="link link-ref link-reveal xref-bibr">140</a></sup> However, when the aortic wall thickens (e.g. atheroma, thrombus, intramural haematoma \[IMH\], or aortitis) or in cases of aortic dissection (AD), also report the outer-to-outer diameter (_[Figure 6](javascript:;)_).

Given the high incidence of atherosclerotic plaques/thrombi in the AA, the outer-to-outer convention should be preferred (also presenting the best agreement with CCT and CMR) (_[Figure 6](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B141" data-open="ehae179-B141" class="link link-ref link-reveal xref-bibr">141</a>,<a href="javascript:;" reveal-id="ehae179-B142" data-open="ehae179-B142" class="link link-ref link-reveal xref-bibr">142</a></sup>

Regarding CCT and CMR, measurements must be performed using the inner-to-inner edge method (_[Figure 6](javascript:;)_) in end-diastole (fewer motion artefacts).<sup><a href="javascript:;" reveal-id="ehae179-B137" data-open="ehae179-B137" class="link link-ref link-reveal xref-bibr">137</a>,<a href="javascript:;" reveal-id="ehae179-B143" data-open="ehae179-B143" class="link link-ref link-reveal xref-bibr">143</a>,<a href="javascript:;" reveal-id="ehae179-B144" data-open="ehae179-B144" class="link link-ref link-reveal xref-bibr">144</a></sup>

The aortic root is measured in the parasternal long axis by transthoracic echocardiography (TTE),<sup><a href="javascript:;" reveal-id="ehae179-B137" data-open="ehae179-B137" class="link link-ref link-reveal xref-bibr">137</a>,<a href="javascript:;" reveal-id="ehae179-B139" data-open="ehae179-B139" class="link link-ref link-reveal xref-bibr">139</a>,<a href="javascript:;" reveal-id="ehae179-B140" data-open="ehae179-B140" class="link link-ref link-reveal xref-bibr">140</a>,<a href="javascript:;" reveal-id="ehae179-B145" data-open="ehae179-B145" class="link link-ref link-reveal xref-bibr">145</a></sup> since the short axis underestimates the diameter due to possible plane obliquity. By CMR or CCT, the cusp-to-cusp diameter best correlates with echocardiography (_[Figure 6](javascript:;)_). A diameter difference >5 mm (among root diameters within the same imaging modality) indicates root asymmetry, frequent in bicuspid aortic valve (BAV) or genetic aortopathies, which is important to be determined since it generates underestimations.<sup><a href="javascript:;" reveal-id="ehae179-B146" data-open="ehae179-B146" class="link link-ref link-reveal xref-bibr">146</a></sup> While 3D echocardiography is a potential surveillance alternative in these cases (especially if CMR/CCT is limited for serial follow-up), validation studies are lacking.<sup><a href="javascript:;" reveal-id="ehae179-B147" data-open="ehae179-B147" class="link link-ref link-reveal xref-bibr">147</a></sup>

In end-diastole, measure the ascending aorta by moving the transducer 1–2 intercostal spaces up in the parasternal long axis. Echocardiography provides information on aortic arch or DTA enlargement, but diagnostic certainty (precise measurement of the diameters) is lacking. CCT or CMR uses the double-oblique technique to measure aortic diameters, reporting antero-posterior and perpendicular dimensions for accurate assessment.<sup><a href="javascript:;" reveal-id="ehae179-B148" data-open="ehae179-B148" class="link link-ref link-reveal xref-bibr">148</a></sup> It is recommended to report aortic measurements by specific segments based on anatomical landmarks and to relate the largest diameter to a nearby anatomical structure for reference.

Changes in aortic diameter require a ≥3 mm increase in echocardiography, which should be confirmed with CCT/CMR and compared with baseline measurements. For accurate assessment, stick to the same imaging technique, centre, methodology, and side-by-side comparisons.<sup><a href="javascript:;" reveal-id="ehae179-B137" data-open="ehae179-B137" class="link link-ref link-reveal xref-bibr">137</a>,<a href="javascript:;" reveal-id="ehae179-B140" data-open="ehae179-B140" class="link link-ref link-reveal xref-bibr">140</a></sup>

#### 5.4.2. Normal aortic values

When evaluating aortic dimensions and clinical relevance, consider factors like aortic region, anthropometric measurements, patient history, and underlying medical conditions. Factors influencing aortic and peripheral artery size in the normal population include age, sex, ethnicity, body surface area (BSA), and, particularly, height.<sup><a href="javascript:;" reveal-id="ehae179-B149" data-open="ehae179-B149" class="link link-ref link-reveal xref-bibr">149</a></sup>

Body surface area is the most used method to normalize aortic dimensions based on an individual’s body size, thus an ascending thoracic aorta >22 mm/m<sup>2</sup> or a DTA >16 mm/m<sup>2</sup> is considered aortic dilatation.<sup><a href="javascript:;" reveal-id="ehae179-B150 ehae179-B151 ehae179-B152" data-open="ehae179-B150 ehae179-B151 ehae179-B152" class="link link-ref link-reveal xref-bibr">150–152</a></sup> However, extremes of low or high body weight pose limitations. In such cases, surgical thresholds may involve indexing aortic diameter by height (an aorta height index >32.1 mm/m is associated with a 12% yearly risk of aortic adverse events \[AAE\]),<sup><a href="javascript:;" reveal-id="ehae179-B153" data-open="ehae179-B153" class="link link-ref link-reveal xref-bibr">153</a></sup> aortic cross-sectional area to patient height (a ratio ≥10 cm<sup>2</sup>/m implies reduced long-term survival),<sup><a href="javascript:;" reveal-id="ehae179-B154" data-open="ehae179-B154" class="link link-ref link-reveal xref-bibr">154</a></sup> or aortic length (from the aortic annulus to the innominate artery, considering a length >11 cm a threshold for surgery).<sup><a href="javascript:;" reveal-id="ehae179-B155" data-open="ehae179-B155" class="link link-ref link-reveal xref-bibr">155</a></sup>

To correlate measured diameter with the expected one based on age, sex, and body surface, use nomograms or z-score calculation formulas, especially in heritable thoracic aortic disease (HTAD). [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179_supplementary_data.pdf?Expires=1728479087&Signature=yLyH980QM156IeuIcUZSEzWy76j01TnWXcoDQ4ZTMz8G6FY7KOUPe9CAN7trJOkJECG-MYpuU27tCqsQRlxJWP9-UJADAWuzJcW~SADGmrFdrHAUX5nbWspT4OuxID7JLGOkIlBiisNgnknrjguhxEfXL5Xw0cXwVZVePRasNLB4SfkHnsWLikAdvK6MVUoOQNMydHIdMmimWPB1bNHA5j3nyW3UOqv9pjaVjPKJEzXCZ6aaFRjvIWIKfxk82niB8OyLIent5oFpBBoSLW0Ckf~Ali3l~PgKo1Sjda8tTFnwWwkWqacxm99FgYZDufGtlJ09OC6EtvqBoL0eEKbk9w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Figure S1](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179_supplementary_data.pdf?Expires=1728479087&Signature=yLyH980QM156IeuIcUZSEzWy76j01TnWXcoDQ4ZTMz8G6FY7KOUPe9CAN7trJOkJECG-MYpuU27tCqsQRlxJWP9-UJADAWuzJcW~SADGmrFdrHAUX5nbWspT4OuxID7JLGOkIlBiisNgnknrjguhxEfXL5Xw0cXwVZVePRasNLB4SfkHnsWLikAdvK6MVUoOQNMydHIdMmimWPB1bNHA5j3nyW3UOqv9pjaVjPKJEzXCZ6aaFRjvIWIKfxk82niB8OyLIent5oFpBBoSLW0Ckf~Ali3l~PgKo1Sjda8tTFnwWwkWqacxm99FgYZDufGtlJ09OC6EtvqBoL0eEKbk9w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_ and _[Table S2](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179_supplementary_data.pdf?Expires=1728479087&Signature=yLyH980QM156IeuIcUZSEzWy76j01TnWXcoDQ4ZTMz8G6FY7KOUPe9CAN7trJOkJECG-MYpuU27tCqsQRlxJWP9-UJADAWuzJcW~SADGmrFdrHAUX5nbWspT4OuxID7JLGOkIlBiisNgnknrjguhxEfXL5Xw0cXwVZVePRasNLB4SfkHnsWLikAdvK6MVUoOQNMydHIdMmimWPB1bNHA5j3nyW3UOqv9pjaVjPKJEzXCZ6aaFRjvIWIKfxk82niB8OyLIent5oFpBBoSLW0Ckf~Ali3l~PgKo1Sjda8tTFnwWwkWqacxm99FgYZDufGtlJ09OC6EtvqBoL0eEKbk9w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_, presents nomograms developed for echocardiography, applicable also to CCT and CMR.<sup><a href="javascript:;" reveal-id="ehae179-B156" data-open="ehae179-B156" class="link link-ref link-reveal xref-bibr">156</a>,<a href="javascript:;" reveal-id="ehae179-B157" data-open="ehae179-B157" class="link link-ref link-reveal xref-bibr">157</a></sup> Calculation of z-scores can be performed following these links: [https://www.marfan.fr/accueil/z-score-calculus/](https://www.marfan.fr/accueil/z-score-calculus/) or [https://marfan.org/dx/z-score-adults/](https://marfan.org/dx/z-score-adults/); reference values used for their estimation may vary depending on age and other factors. However, z-scores are limited by the fact that not all ethnic groups are equally represented (mostly white) and over- or underweight can lead to an over- or underestimation.<sup><a href="javascript:;" reveal-id="ehae179-B158" data-open="ehae179-B158" class="link link-ref link-reveal xref-bibr">158</a></sup>

Moreover, with ageing and loss of elastic properties, the aorta tends to enlarge. Aortic growth in adults is about 0.9 mm per 10 years in males and 0.7 mm per 10 years in females, which may be influenced by BP, physical activity, and genetic factors.

Recommendation Table 3

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479845854)

Recommendations for imaging of the aorta (see also Evidence Table 2)

![Recommendations for imaging of the aorta (see also Evidence Table 2)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt3.jpeg?Expires=1728479087&Signature=lxuU2Q5gJ2aKGAlUQBbprmRm8yj-pxuVOZ1TuiVpZ13XMJDhtnzdgNUQY2Pe6cwf8VfB46MuCjOtANEfj0KpyGBJayCtO7ebxRlHlHl~Z8inBsALBKR0~IMaQC7EVPGW3bYFQaWhFQISrWi6AVykNP3QyulzGUPy71l2BJyqg2asgAlnr3FLggc4TgvOklLMV8oyAevd2dk3gTP5GNF-4xxTnMaKS631~NXbAEnIfTC~Anuw14cOPLqO3PdwmvIgT20a3NWKl9Ss~-FSleLkaaifwiByWgriO1ruvkXLsG7HuVZ1nQMMv46IhIT63S25qMk6A-h6BRizeP7whoViDA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 5.4.3. Chest X-ray and electrocardiogram

Chest X-ray obtained for other indications in asymptomatic patients or in cases of acute aortic syndrome (AAS) suspicion may detect abnormalities of aortic size/contour that need to be confirmed by another imaging technique. It presents limited sensitivity (64%) and specificity (86%) in the diagnosis of aortic diseases;<sup><a href="javascript:;" reveal-id="ehae179-B162" data-open="ehae179-B162" class="link link-ref link-reveal xref-bibr">162</a></sup> thus, a normal chest X-ray may not rule out the diagnosis of AAS.<sup><a href="javascript:;" reveal-id="ehae179-B162 ehae179-B163 ehae179-B164" data-open="ehae179-B162 ehae179-B163 ehae179-B164" class="link link-ref link-reveal xref-bibr">162–164</a></sup> On the contrary, chest X-ray may identify other causes of chest pain (e.g. pleural effusion or pneumothorax).

Electrocardiogram (ECG) might be useful to rule out other causes of chest pain (e.g. MI) or AAS complications (coronary occlusion/dissection) but it is not useful for AAS diagnosis.

#### 5.4.4. Echocardiography

It is considered the first-line imaging technique in the evaluation of aortic disease, assessing all echocardiographic windows and the aortic valve. It provides key anatomic information (i.e. dilatation, atherosclerotic lesions, or dissection) for the ascending aorta, arch, and AA; however, it is not useful to assess the exact diameters of the aortic arch and DTA (requiring confirmation with CCT/CMR). Also, the distal ascending aorta and proximal arch (blind spot) are inadequately visualized due to left mainstem bronchus interposition.

Transthoracic echocardiography can identify AAS complications (e.g. aortic regurgitation, tamponade, or wall motion abnormalities), but its diagnostic accuracy for AAS is limited (sensitivity: 78%–100% for type A, 31%–55% for type B). Contrast enhancement improves diagnosis.<sup><a href="javascript:;" reveal-id="ehae179-B165" data-open="ehae179-B165" class="link link-ref link-reveal xref-bibr">165</a></sup> Transoesophageal echocardiography (TOE) is highly accurate (sensitivity: up to 99%, specificity: 89% for AAS), except with absolute contraindications like oesophageal issues, bleeding, recent gastro-oesophageal surgery, or respiratory distress. TOE is convenient for bedside and intraoperative use but less suitable for long-term surveillance, which requires evaluation with CCT/CMR.

Recommendation Table 4

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479845861)

Recommendations for thoracic aortic measurements

![Recommendations for thoracic aortic measurements](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt4.jpeg?Expires=1728479088&Signature=NVEV7EFG1fjG1dyV6dlk5lDc6at9YkAA1isulATuZmdRORXI-lfy6AobBilHmBi0ULGoA3h4h27Rubul5KrPOXrUxzNIVdVDTPZpnMUd3Kb-DzdBGQ917fsUxdNh8H0yrk9zUPWRYM5mS9couFqyuBtgbQ6dPZLBKvoM~sQet9Npbvv0OnxE7UH-jVf0b~t-XPdG~1kFhVSA7Tc2BCZGHzp1Vu27J9fE2hjQc0RpyHAnZeOYQoHQjZoACpAAm5tIt5XvhBpknrv-YEwvJC4OSpQOtu2Wk-d~h8P49cEhlX-vpWkl0ZI0zC1HS-d4VFOyLgKKOqd6JYYQpVnt4VpVgw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 5.4.5. Duplex ultrasound imaging of the abdominal aorta

After scanning both transversally and longitudinally, the antero-posterior (AP) diameter in a cross-sectional view of the AA should be measured. Ensure the DUS beam is perpendicular to the AA axis, forming a circular vessel section. If the AA is sinuous or dilated, achieving equal AP and transverse diameters may be challenging. In such instances, calculate the mean ellipse diameter or measure the AA diameter in a clear longitudinal view with a perpendicular diameter (_[Figure 6](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B122" data-open="ehae179-B122" class="link link-ref link-reveal xref-bibr">122</a></sup> The outer-to-outer (_[Figure 6](javascript:;)_) method is the one recommended by the American Institute of Ultrasound in Medicine, the American College of Cardiology/American Heart Association (ACC/AHA), and the European Society of Cardiology (ESC), since it is more reliable in cases of atherosclerotic plaque or intravascular thrombus and best correlates with CCT and CMR. However, the most effective methodology is under debate and further studies are needed to determine the best convention.<sup><a href="javascript:;" reveal-id="ehae179-B169" data-open="ehae179-B169" class="link link-ref link-reveal xref-bibr">169</a></sup>

Normal diameters of the AA are reported in _[Figure 5](javascript:;)_ and [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179_supplementary_data.pdf?Expires=1728479088&Signature=jsMN1psOaEf3KpW8UiQOwnEDCNM0eDJ9FhgPq~GNXqLItMAEdFx6foOGTBTeCpJhrfS5f9C1WsT6JBJ-OF2VSZCY4hMS9gJl7FbAOywEXjZ7FkQ8D8eMHICtPb1wzBA3uZZtBKMZczJqU~L965QcGSWu4bY5onpcoRMSzjgnNpdPf9L4pLKg-a0ahzhjNRwGHt5NoJ7ErFgx3duCbchEi0MsV0cDIkqzsUCeNEtwo8kpBYcJAps4DqCXaYZS5CPCAIpG4RbHZce70W~XP9IUuUZszMeWmEvwL5IF-0Kt0kkQwtSCyF6kopinSbFrVRYLZmYxxNRPbjwJpR0g1P88ZQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Section 1.3](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179_supplementary_data.pdf?Expires=1728479088&Signature=jsMN1psOaEf3KpW8UiQOwnEDCNM0eDJ9FhgPq~GNXqLItMAEdFx6foOGTBTeCpJhrfS5f9C1WsT6JBJ-OF2VSZCY4hMS9gJl7FbAOywEXjZ7FkQ8D8eMHICtPb1wzBA3uZZtBKMZczJqU~L965QcGSWu4bY5onpcoRMSzjgnNpdPf9L4pLKg-a0ahzhjNRwGHt5NoJ7ErFgx3duCbchEi0MsV0cDIkqzsUCeNEtwo8kpBYcJAps4DqCXaYZS5CPCAIpG4RbHZce70W~XP9IUuUZszMeWmEvwL5IF-0Kt0kkQwtSCyF6kopinSbFrVRYLZmYxxNRPbjwJpR0g1P88ZQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_.

#### 5.4.6. Cardiovascular computed tomography

Cardiovascular computed tomography, due to its quick acquisition, wide availability, high reproducibility, and suitability for emergency departments, is the primary imaging method for aortic disease diagnosis, prognosis, and therapy planning (sensitivity 100%, specificity 98% for AAS).<sup><a href="javascript:;" reveal-id="ehae179-B170 ehae179-B171 ehae179-B172" data-open="ehae179-B170 ehae179-B171 ehae179-B172" class="link link-ref link-reveal xref-bibr">170–172</a></sup> ‘Double or triple rule-out’ protocols concurrently assess the aorta, pulmonary, and coronary arteries.<sup><a href="javascript:;" reveal-id="ehae179-B173" data-open="ehae179-B173" class="link link-ref link-reveal xref-bibr">173</a>,<a href="javascript:;" reveal-id="ehae179-B174" data-open="ehae179-B174" class="link link-ref link-reveal xref-bibr">174</a></sup>

Electrocardiogram triggering is crucial to prevent motion artefacts (especially in the aortic root and ascending aorta), which can distort measurements or resemble dissection flaps, facilitating coronary artery assessment. The standard protocol comprises non-enhanced scans (for calcification, IMH, or surgical material), contrast-enhanced CCT angiography, and a late scan (to visualize contrast leakage or aortic wall late enhancement suggestive of inflammation or infection).<sup><a href="javascript:;" reveal-id="ehae179-B175" data-open="ehae179-B175" class="link link-ref link-reveal xref-bibr">175</a></sup>

Iodinated contrast agents carry potential allergic reactions and post-contrast acute kidney injury (PC-AKI) risks.<sup><a href="javascript:;" reveal-id="ehae179-B176" data-open="ehae179-B176" class="link link-ref link-reveal xref-bibr">176</a></sup> In these cases, opt for contrast-free CCT for accurate aortic diameter measurement (also for CMR-intolerant patients). Moreover, excessive radiation caution is crucial, particularly in young females, when performing CCT for monitoring chronic aortic diseases.<sup><a href="javascript:;" reveal-id="ehae179-B177" data-open="ehae179-B177" class="link link-ref link-reveal xref-bibr">177</a></sup>

#### 5.4.7. Cardiovascular magnetic resonance

Cardiovascular magnetic resonance comprehensively evaluates the aorta, including shape, diameter, tissue characteristics (inflammation, infection, atheroma, bleeding),<sup><a href="javascript:;" reveal-id="ehae179-B178" data-open="ehae179-B178" class="link link-ref link-reveal xref-bibr">178</a></sup> lesion extent, side branches, adjacent structures, and mural thrombus. It assesses ventricular and valve function, quantifies flow, and employs cine steady-state free precession (SSFP) or ECG-gated angio-CMR for the aortic root, while non-gated sequences suffice for the rest. Recently, 4D flow sequences<sup><a href="javascript:;" reveal-id="ehae179-B179" data-open="ehae179-B179" class="link link-ref link-reveal xref-bibr">179</a></sup> have been developed to evaluate complex intravascular flows,<sup><a href="javascript:;" reveal-id="ehae179-B180" data-open="ehae179-B180" class="link link-ref link-reveal xref-bibr">180</a>,<a href="javascript:;" reveal-id="ehae179-B181" data-open="ehae179-B181" class="link link-ref link-reveal xref-bibr">181</a></sup> complex flow parameters (wall shear stress, pulse wave velocity, or kinetic energy), or flow quantification at different levels in one unique acquisition (useful in AD or congenital diseases).<sup><a href="javascript:;" reveal-id="ehae179-B182" data-open="ehae179-B182" class="link link-ref link-reveal xref-bibr">182</a>,<a href="javascript:;" reveal-id="ehae179-B183" data-open="ehae179-B183" class="link link-ref link-reveal xref-bibr">183</a></sup>

Cardiovascular magnetic resonance obviates ionizing radiation and iodinated contrast (3D contrast CMR), making it ideal for young patients, women, and pregnancy. Caution is warranted, especially with non-macrocyclic gadolinium, for estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m² ([Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179_supplementary_data.pdf?Expires=1728479088&Signature=jsMN1psOaEf3KpW8UiQOwnEDCNM0eDJ9FhgPq~GNXqLItMAEdFx6foOGTBTeCpJhrfS5f9C1WsT6JBJ-OF2VSZCY4hMS9gJl7FbAOywEXjZ7FkQ8D8eMHICtPb1wzBA3uZZtBKMZczJqU~L965QcGSWu4bY5onpcoRMSzjgnNpdPf9L4pLKg-a0ahzhjNRwGHt5NoJ7ErFgx3duCbchEi0MsV0cDIkqzsUCeNEtwo8kpBYcJAps4DqCXaYZS5CPCAIpG4RbHZce70W~XP9IUuUZszMeWmEvwL5IF-0Kt0kkQwtSCyF6kopinSbFrVRYLZmYxxNRPbjwJpR0g1P88ZQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Section 1.2](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179_supplementary_data.pdf?Expires=1728479088&Signature=jsMN1psOaEf3KpW8UiQOwnEDCNM0eDJ9FhgPq~GNXqLItMAEdFx6foOGTBTeCpJhrfS5f9C1WsT6JBJ-OF2VSZCY4hMS9gJl7FbAOywEXjZ7FkQ8D8eMHICtPb1wzBA3uZZtBKMZczJqU~L965QcGSWu4bY5onpcoRMSzjgnNpdPf9L4pLKg-a0ahzhjNRwGHt5NoJ7ErFgx3duCbchEi0MsV0cDIkqzsUCeNEtwo8kpBYcJAps4DqCXaYZS5CPCAIpG4RbHZce70W~XP9IUuUZszMeWmEvwL5IF-0Kt0kkQwtSCyF6kopinSbFrVRYLZmYxxNRPbjwJpR0g1P88ZQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). CMR is increasingly used in patients with intracardiac devices (pacemakers/implantable cardioverter defibrillators, CMR- and non-CMR-compatible devices) with proper monitoring, but not for those with cochlear implants or intracranial clips.<sup><a href="javascript:;" reveal-id="ehae179-B184" data-open="ehae179-B184" class="link link-ref link-reveal xref-bibr">184</a>,<a href="javascript:;" reveal-id="ehae179-B185" data-open="ehae179-B185" class="link link-ref link-reveal xref-bibr">185</a></sup>

In the acute setting, CMR use is limited because of low availability, difficulties in monitoring unstable patients, and longer acquisition times.<sup><a href="javascript:;" reveal-id="ehae179-B166" data-open="ehae179-B166" class="link link-ref link-reveal xref-bibr">166</a>,<a href="javascript:;" reveal-id="ehae179-B186" data-open="ehae179-B186" class="link link-ref link-reveal xref-bibr">186</a></sup>

#### 5.4.8. Positron emission tomography

Positron emission tomography (PET) usually uses <sup>18</sup>F-fluorodeoxyglucose (FDG), allowing non-invasive assessments of metabolic activity (inflammation/infection) and treatment response.<sup><a href="javascript:;" reveal-id="ehae179-B187" data-open="ehae179-B187" class="link link-ref link-reveal xref-bibr">187</a>,<a href="javascript:;" reveal-id="ehae179-B188" data-open="ehae179-B188" class="link link-ref link-reveal xref-bibr">188</a></sup> Although different tracers have been tested to identify calcification, fibrosis and/or thrombus formation, most PET studies have focused on vasculitis.

The relationship between FDG-PET images and AAA progression is controversial. However, fluorine-18–sodium fluoride (<sup>18</sup>F–NaF) PET-computed tomography (PET-CT), a marker of active vascular calcification and high-risk plaques, has shown a correlation between increased tracer uptake, AAA growth, and CV events.<sup><a href="javascript:;" reveal-id="ehae179-B189" data-open="ehae179-B189" class="link link-ref link-reveal xref-bibr">189</a></sup>

PET-CT has shown better diagnostic accuracy in identifying lesions and detecting graft infection or infectious aortic diseases.<sup><a href="javascript:;" reveal-id="ehae179-B190 ehae179-B191 ehae179-B192 ehae179-B193" data-open="ehae179-B190 ehae179-B191 ehae179-B192 ehae179-B193" class="link link-ref link-reveal xref-bibr">190–193</a></sup> High radiation exposure, high costs, and limited availability are the main limitations of PET.

#### 5.4.9. Intravascular ultrasound

Intravascular ultrasound (IVUS) provides high-resolution imaging for artery and vein diseases, aiding complex aortic disease management by distinguishing true and false lumens and guiding stent placement. It is operator-dependent, costly, and less accessible, but seems to provide better measurements for acute aortic syndromes.<sup><a href="javascript:;" reveal-id="ehae179-B194" data-open="ehae179-B194" class="link link-ref link-reveal xref-bibr">194</a></sup>

#### 5.4.10. Digital subtraction aortography

Non-invasive imaging modalities have replaced DSA in first-line diagnostic testing, both in suspected AAS or known chronic AD; however, DSA might be useful if findings in non-invasive techniques are ambiguous or incomplete. It is primarily used for the percutaneous treatment of CAD, aortic visceral branches, or for monitoring thoracic endovascular aortic aneurysm repair (TEVAR/EVAR) implantation.

## 6\. Screening for carotid, peripheral arterial, and aortic diseases

### 6.1. Screening for carotid and peripheral arterial diseases

#### 6.1.1. Lower-extremity peripheral arterial disease

Due to elevated CV risk in chronic PAD, early diagnosis, prevention, and robust cardiovascular risk factor (CVRF) control are essential, even in asymptomatic cases. ‘Intermediary CV risk’ individuals may be reclassified as ‘high or very high risk’, prompting adapted prevention. ABI is the preferred first-line test for asymptomatic individuals aged ≥65 years,<sup><a href="javascript:;" reveal-id="ehae179-B14" data-open="ehae179-B14" class="link link-ref link-reveal xref-bibr">14</a>,<a href="javascript:;" reveal-id="ehae179-B195" data-open="ehae179-B195" class="link link-ref link-reveal xref-bibr">195</a></sup> especially women.<sup><a href="javascript:;" reveal-id="ehae179-B196" data-open="ehae179-B196" class="link link-ref link-reveal xref-bibr">196</a></sup> Screening might also be beneficial at a younger age in case of CVRFs, but data are still lacking. Clinical examination, functional status, and walking capacity assessment are recommended to detect ‘masked PAD’.<sup><a href="javascript:;" reveal-id="ehae179-B77" data-open="ehae179-B77" class="link link-ref link-reveal xref-bibr">77</a></sup>

In diabetes, early PAD (and foot neuropathy) diagnosis is crucial. Effective CVRF management and treatment can prevent CV disease, foot wounds, and amputation.<sup><a href="javascript:;" reveal-id="ehae179-B197" data-open="ehae179-B197" class="link link-ref link-reveal xref-bibr">197</a></sup> In patients with diabetes and normal resting ABI, TBI measurement should be considered.

The prevalence of popliteal aneurysms (PAs) is high in patients with AAA and subaneurysmal aortic dilatation, warranting screening. PAs are correlated with iliac and femoral artery diameters.<sup><a href="javascript:;" reveal-id="ehae179-B76" data-open="ehae179-B76" class="link link-ref link-reveal xref-bibr">76</a></sup> In patients needing transfemoral access, screening for iliofemoral artery disease may be considered.<sup><a href="javascript:;" reveal-id="ehae179-B198" data-open="ehae179-B198" class="link link-ref link-reveal xref-bibr">198</a></sup>

#### 6.1.2. Carotid artery stenosis

Due to the low prevalence of ≥70% asymptomatic carotid artery stenosis (CS) in the general population (0%–3.1%), widespread screening is not recommended since it does not reduce stroke risk and might lead to inappropriate stress and invasive procedures.<sup><a href="javascript:;" reveal-id="ehae179-B199" data-open="ehae179-B199" class="link link-ref link-reveal xref-bibr">199</a>,<a href="javascript:;" reveal-id="ehae179-B200" data-open="ehae179-B200" class="link link-ref link-reveal xref-bibr">200</a></sup> Conversely, screening for significant CS in a highly selected population might be cost-effective, especially if prevalence is ≥20% (_[Table 6](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B201" data-open="ehae179-B201" class="link link-ref link-reveal xref-bibr">201</a></sup> When the degree of asymptomatic CS is ≥70%, the 5 year ipsilateral stroke risk is significantly increased (14.6%) and revascularization may be beneficial.<sup><a href="javascript:;" reveal-id="ehae179-B202" data-open="ehae179-B202" class="link link-ref link-reveal xref-bibr">202</a></sup> Selective screening aims to prevent CV events, rather than identifying candidates for an intervention.<sup><a href="javascript:;" reveal-id="ehae179-B203" data-open="ehae179-B203" class="link link-ref link-reveal xref-bibr">203</a></sup>

Table 6

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479845889)

High-risk populations for carotid artery stenosis

| Population | Prevalence of carotid stenosis (%) |
| --- | --- |
| \>60 years + CVRFs (hypertension, CAD, current smoking, first-degree family history of stroke)<sup><a href="javascript:;" reveal-id="ehae179-B210" data-open="ehae179-B210" class="link link-ref link-reveal xref-bibr">210</a></sup> | Two CVRFs: 14%  
Three CVRFs: 16%  
Four CVRFs: 67% |
| Hypertension + cardiac disease<sup><a href="javascript:;" reveal-id="ehae179-B211" data-open="ehae179-B211" class="link link-ref link-reveal xref-bibr">211</a></sup> | 22% |
| HD<sup><a href="javascript:;" reveal-id="ehae179-B212" data-open="ehae179-B212" class="link link-ref link-reveal xref-bibr">212</a></sup> | 
-   In HD patients, prevalence of carotid stenosis is high, and is associated with high peri-operative and long-term stroke or death rates
    
-   Carotid stenosis is a predictor of death in patients with long-term dialysis and aged ≥70 years at time of surgery
    
-   Lower risk if previous renal transplant.
    

 |
| PAD<sup><a href="javascript:;" reveal-id="ehae179-B213" data-open="ehae179-B213" class="link link-ref link-reveal xref-bibr">213</a></sup> | 23.2% |
| Severe CAD (before CABG) | 

-   Almost 20%<sup><a href="javascript:;" reveal-id="ehae179-B214" data-open="ehae179-B214" class="link link-ref link-reveal xref-bibr">214</a></sup>
    
-   Carotid bruit and T2DM: increased predictive value<sup><a href="javascript:;" reveal-id="ehae179-B215" data-open="ehae179-B215" class="link link-ref link-reveal xref-bibr">215</a></sup>
    
-   Carotid stenosis = risk factors for peri-operative stroke.<sup><a href="javascript:;" reveal-id="ehae179-B215" data-open="ehae179-B215" class="link link-ref link-reveal xref-bibr">215</a></sup>
    

 |
| Carotid bruit<sup><a href="javascript:;" reveal-id="ehae179-B216" data-open="ehae179-B216" class="link link-ref link-reveal xref-bibr">216</a></sup> | 31% |
| Previous neck irradiation<sup><a href="javascript:;" reveal-id="ehae179-B217" data-open="ehae179-B217" class="link link-ref link-reveal xref-bibr">217</a></sup> | 21.7% (70%–99% stenosis) |

CABG, coronary artery bypass grafting; CAD, coronary artery disease; CVRFs, cardiovascular risk factors; HD, haemodialysis; PAD, peripheral arterial disease; T2DM, type 2 diabetes mellitus.

© ESC 2024

#### 6.1.3. Multisite artery disease

Multisite artery disease (MAD) is defined as the presence of atherosclerosis in two or more vascular beds.<sup><a href="javascript:;" reveal-id="ehae179-B204" data-open="ehae179-B204" class="link link-ref link-reveal xref-bibr">204</a></sup> This is a common condition in patients with atherosclerotic diseases. Although associated with worse clinical outcomes, screening for asymptomatic disease in additional vascular sites did not seem to improve outcomes.<sup><a href="javascript:;" reveal-id="ehae179-B77" data-open="ehae179-B77" class="link link-ref link-reveal xref-bibr">77</a></sup> More recently, screening for coronary calcifications (coronary artery calcium \[CAC\] score) and screening for carotid and femoral plaques have been shown to be of potential assistance in CV risk reclassification of ‘presumed moderate-risk patients’ into a higher-risk category, leading to more aggressive prevention strategies.<sup><a href="javascript:;" reveal-id="ehae179-B205 ehae179-B206 ehae179-B207 ehae179-B208 ehae179-B209" data-open="ehae179-B205 ehae179-B206 ehae179-B207 ehae179-B208 ehae179-B209" class="link link-ref link-reveal xref-bibr">205–209</a></sup>

Recommendation Table 5

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479845892)

Recommendations for peripheral arterial disease screening (see also Evidence Table 3)

![Recommendations for peripheral arterial disease screening (see also Evidence Table 3)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt5.jpeg?Expires=1728479088&Signature=iZVw0WKP6yyp5mOr0xyDNbbMze7shCNKLUHBuwaF-jjCVtCkpridGbn8TIdUBhdTlaBX-QrqeXOHGJPNNaCZ4gVL~YOfdEOMEH1Pe6R5ZKqqQBmEKNeQ2GBBsSs62FBfKu5jJ3HwPCyB4fuOcFPfhp7awHcqoazrLalJEkox1UyTLoqpcx33L9wUfnytb8IMRN5SVh5WT6KiJHT9eHLh8siOE5XmFboqe5oLtd~bYF9-k-UmKQxKQJYLisZybqSSlOCfqeR3H1qoYfgFL1gYFpciIybhO-0SD5qygyiVmKvllKaxirLaEJ8hpLjE4sHmLRHz7Afl9l9e5r59eubV5A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 6.2. Screening for aortic diseases

#### 6.2.1. Screening for abdominal aortic aneurysm

Abdominal aortic aneurysm screening by DUS is effective in reducing rupture-related mortality in populations with high AAA prevalence (especially male smokers aged ≥65 years).<sup><a href="javascript:;" reveal-id="ehae179-B221 ehae179-B222 ehae179-B223 ehae179-B224" data-open="ehae179-B221 ehae179-B222 ehae179-B223 ehae179-B224" class="link link-ref link-reveal xref-bibr">221–224</a></sup> However, no such effect has been found in a single large study in which AAA prevalence was low (current or former smoking women aged 65–74 years, or with a history of CAD).<sup><a href="javascript:;" reveal-id="ehae179-B225" data-open="ehae179-B225" class="link link-ref link-reveal xref-bibr">225</a></sup>

Screening for AAA by non-contrast computed tomography (CT) was not found to be effective over 5 years in males aged 65–74 years in a Danish trial.<sup><a href="javascript:;" reveal-id="ehae179-B226" data-open="ehae179-B226" class="link link-ref link-reveal xref-bibr">226</a></sup> Longer-term follow-up is planned, and as the technique involves ionizing radiation, no recommendation is made in relation to CT at present.

Screening may be considered in populations at intermediate risk, such as men aged >75 years, or women aged >75 years who are hypertensive, smokers, or both, since almost all women in a contemporary population-based study who had ruptured AAA and were aged >75 years were either smokers or hypertensive.<sup><a href="javascript:;" reveal-id="ehae179-B227" data-open="ehae179-B227" class="link link-ref link-reveal xref-bibr">227</a>,<a href="javascript:;" reveal-id="ehae179-B228" data-open="ehae179-B228" class="link link-ref link-reveal xref-bibr">228</a></sup>

Screening for AAA is recommended in first-degree relatives (FDRs) of patients with AAA (especially siblings), as they are at increased risk of AAA when >50 years of age.<sup><a href="javascript:;" reveal-id="ehae179-B229" data-open="ehae179-B229" class="link link-ref link-reveal xref-bibr">229</a></sup> The risk associated with family history is uncertain, but a population-based study estimated a relative risk of around 2.<sup><a href="javascript:;" reveal-id="ehae179-B230" data-open="ehae179-B230" class="link link-ref link-reveal xref-bibr">230</a></sup> Screening should be repeated periodically if initial assessment is reassuring and performed at a relatively young age.<sup><a href="javascript:;" reveal-id="ehae179-B231" data-open="ehae179-B231" class="link link-ref link-reveal xref-bibr">231</a></sup>

Opportunistic screening (during TTE) identified AAA in about 2% of subjects, thus it may be considered in high-prevalence populations (males ≥65 or women ≥75 years of age).<sup><a href="javascript:;" reveal-id="ehae179-B232" data-open="ehae179-B232" class="link link-ref link-reveal xref-bibr">232</a></sup> Additionally, opportunistic screening detects AAA in patients with symptomatic/asymptomatic PAD (with a 12% cumulative incidence in symptomatic PAD), making it worthwhile in this population.<sup><a href="javascript:;" reveal-id="ehae179-B233" data-open="ehae179-B233" class="link link-ref link-reveal xref-bibr">233</a></sup>

Recommendation Table 6

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479845900)

Recommendations for abdominal aortic aneurysm screening

![Recommendations for abdominal aortic aneurysm screening](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt6.jpeg?Expires=1728479088&Signature=R3rutoZ9hdusyHTbXL6dNIBcij~S3BU6NAhM3pQfwuZHIcmep3LfDW3JQO3i3uk9EPaFkmbUamHzhAIzu9agD~ChgS6xfLQNy-zw4OuYBBnHgDRc5qW08RZ-vfy1mVzMb5vZR6ZQ7dEZIwEnJ3XrJJ1KTdPQkgtXGljdm2Uq4AuJ-h0qxs7oy19h6UQgY4aveomwTyo1fl3K8YwYIvCUnYgjHB7wIQN2v-~frPRj-cC44V9rUn2Giucl6K5-5VmjbWqdoDYv6uvhAgrC0v0ydXLBkRZCz-nH3Nl0iQoTOmdlJk2796WYnN0ayIwFqa-v0J1WlsBemMl9U~V37AH1FA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 6.2.2. Screening for thoracic aortic aneurysm

Screening for TAA is described in detail in _Section [10.1](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#ehae179-s9.1)_ and _Section [10.2](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#ehae179-s9.2)_.

## 7\. Optimal medical treatment

Optimal medical treatment (OMT), including lifestyle measures and pharmacological treatment, is recommended for all patients with PAAD (_[Figure 7](javascript:;)_).

![Cardiovascular risk modification and healthy lifestyle interventions and targets in patients with peripheral arterial and aortic diseases.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f7.jpeg?Expires=1728479088&Signature=uqyNF3JEBf-1wAzXyDAczF~x9PA8EDV94P08TWTFJ0dsVt2OYQb7rC17f2apQvJ4B5U14DJZZGJp0yci8Gtx1JsoALqBSji-Vt1gsH19uqIjk2xSpAOZRKWytGqNy83gPe6ycgZuWPYeIahVnLQeUug11KyWlWlv-Q9urPpWrGaPzb5Xr0Xh-FLr7YETGok7gytiSGw-LOsa8Ga9COKpQRxKLKJniS2NGo6qHai5PmE36Ui3PUKQoY4XfTbTwWkjw4auVrr52safLw4fhSzpew4JvwwyDr5-X6hA1-f6WNfbwTsndKxwpcU60uUI1R7Ryvq7no0bsBarkaoy278OiA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 7

Cardiovascular risk modification and healthy lifestyle interventions and targets in patients with peripheral arterial and aortic diseases.

ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker; BMI, body mass index; LDL, low-density lipoprotein; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor; HbA1c, glycated haemoglobin.

[Open in new tab](https://academic.oup.com/view-large/figure/479845905/ehae179f7.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f7.jpeg?Expires=1728479088&Signature=GX27TqAxfuwBz~CeJTMyZHYfFKb9yJul~7j~x9QWSr55lOa-dZtDrsM3ZF3kJP6t3T6xqVd7WImzZadr-iy9sTxuBcUDRAMAgFOpWbBRYEwacOptdtpn4LpHr330ewlbFSk17uwjHsiOLsXZoQUddeqfMf8b~mkLQ4JZCehweMZANrTD4mKEcJLZMhTpl~bp-LXWkjfjLJR4xtisnxVCpXrSBQKhxGjOnEh38KuljgZgvjLcMtCfndi8jpIfBOZ-gNcU3K3VcU5ybfxzJ2BcpGq9PZRr8WFD8BYevpsNTzx4pF1u9j3ex6Q-56dhCK0ctdk8OZMsn8i7rkEG0P3LoQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479845905&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

### 7.1. Lifestyle, exercise, patient education

Apart from genetic-related TAA, hypertension and ASCVD are the main causative factors for PAAD. As lifestyle factors are strongly related to ASCVD,<sup><a href="javascript:;" reveal-id="ehae179-B11" data-open="ehae179-B11" class="link link-ref link-reveal xref-bibr">11</a></sup> patients with PAAD should strive to maintain a healthy lifestyle. The _2021 ESC Guidelines on cardiovascular prevention_<sup><a href="javascript:;" reveal-id="ehae179-B19" data-open="ehae179-B19" class="link link-ref link-reveal xref-bibr">19</a></sup> give comprehensive guidance on risk factors for ASCVD and their treatment.

#### 7.1.1. Diet

A Mediterranean diet rich in legumes, dietary fibre, nuts, fruits, and vegetables proves crucial and efficacious for primary and CV prevention in PAAD.<sup><a href="javascript:;" reveal-id="ehae179-B238" data-open="ehae179-B238" class="link link-ref link-reveal xref-bibr">238</a></sup> It has demonstrated notable reductions in cholesterol and BP,<sup><a href="javascript:;" reveal-id="ehae179-B239 ehae179-B240 ehae179-B241 ehae179-B242 ehae179-B243 ehae179-B244 ehae179-B245 ehae179-B246 ehae179-B247" data-open="ehae179-B239 ehae179-B240 ehae179-B241 ehae179-B242 ehae179-B243 ehae179-B244 ehae179-B245 ehae179-B246 ehae179-B247" class="link link-ref link-reveal xref-bibr">239–247</a></sup> and holds potential protective benefits against PAAD development.<sup><a href="javascript:;" reveal-id="ehae179-B248" data-open="ehae179-B248" class="link link-ref link-reveal xref-bibr">248</a>,<a href="javascript:;" reveal-id="ehae179-B249" data-open="ehae179-B249" class="link link-ref link-reveal xref-bibr">249</a></sup> In a large cohort with 17.5 years of follow-up, adherence to a Mediterranean diet was associated with reduced AAA risk in current and ex-smokers.<sup><a href="javascript:;" reveal-id="ehae179-B249" data-open="ehae179-B249" class="link link-ref link-reveal xref-bibr">249</a>,<a href="javascript:;" reveal-id="ehae179-B250" data-open="ehae179-B250" class="link link-ref link-reveal xref-bibr">250</a></sup> Malnutrition and metabolic disorders can complicate post-invasive procedure recovery and nutritional support may improve nutritional status and HRQoL.<sup><a href="javascript:;" reveal-id="ehae179-B251" data-open="ehae179-B251" class="link link-ref link-reveal xref-bibr">251</a></sup>

#### 7.1.2. Physical activity

Few patients with chronic symptomatic PAD meet the physical activity guidelines<sup><a href="javascript:;" reveal-id="ehae179-B252" data-open="ehae179-B252" class="link link-ref link-reveal xref-bibr">252</a></sup> for reducing the risk of major adverse cardiac events (MACE).<sup><a href="javascript:;" reveal-id="ehae179-B253" data-open="ehae179-B253" class="link link-ref link-reveal xref-bibr">253</a>,<a href="javascript:;" reveal-id="ehae179-B254" data-open="ehae179-B254" class="link link-ref link-reveal xref-bibr">254</a></sup> Better ambulation, HRQoL, and vascular outcomes have been observed in patients meeting the physical activity time-intensity guidelines.<sup><a href="javascript:;" reveal-id="ehae179-B19" data-open="ehae179-B19" class="link link-ref link-reveal xref-bibr">19</a>,<a href="javascript:;" reveal-id="ehae179-B255" data-open="ehae179-B255" class="link link-ref link-reveal xref-bibr">255</a></sup> Regular physical activity is also relevant in patients with aortic diseases<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B71" data-open="ehae179-B71" class="link link-ref link-reveal xref-bibr">71</a>,<a href="javascript:;" reveal-id="ehae179-B256 ehae179-B257 ehae179-B258 ehae179-B259" data-open="ehae179-B256 ehae179-B257 ehae179-B258 ehae179-B259" class="link link-ref link-reveal xref-bibr">256–259</a></sup> and lowers resting heart rate and BP, thus decreasing the risk of aortic complications.<sup><a href="javascript:;" reveal-id="ehae179-B256" data-open="ehae179-B256" class="link link-ref link-reveal xref-bibr">256</a>,<a href="javascript:;" reveal-id="ehae179-B259" data-open="ehae179-B259" class="link link-ref link-reveal xref-bibr">259</a></sup> Few data exist on the practice of exercise and sports in patients with aortic diseases.<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B71" data-open="ehae179-B71" class="link link-ref link-reveal xref-bibr">71</a>,<a href="javascript:;" reveal-id="ehae179-B256 ehae179-B257 ehae179-B258 ehae179-B259" data-open="ehae179-B256 ehae179-B257 ehae179-B258 ehae179-B259" class="link link-ref link-reveal xref-bibr">256–259</a></sup> Recommendations should be individualized and based on risk stratification.<sup><a href="javascript:;" reveal-id="ehae179-B71" data-open="ehae179-B71" class="link link-ref link-reveal xref-bibr">71</a></sup>

#### 7.1.3. Smoking

Patients with PAAD who smoke should strongly be advised to quit (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179_supplementary_data.pdf?Expires=1728479088&Signature=jsMN1psOaEf3KpW8UiQOwnEDCNM0eDJ9FhgPq~GNXqLItMAEdFx6foOGTBTeCpJhrfS5f9C1WsT6JBJ-OF2VSZCY4hMS9gJl7FbAOywEXjZ7FkQ8D8eMHICtPb1wzBA3uZZtBKMZczJqU~L965QcGSWu4bY5onpcoRMSzjgnNpdPf9L4pLKg-a0ahzhjNRwGHt5NoJ7ErFgx3duCbchEi0MsV0cDIkqzsUCeNEtwo8kpBYcJAps4DqCXaYZS5CPCAIpG4RbHZce70W~XP9IUuUZszMeWmEvwL5IF-0Kt0kkQwtSCyF6kopinSbFrVRYLZmYxxNRPbjwJpR0g1P88ZQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Section 1.1.5](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179_supplementary_data.pdf?Expires=1728479088&Signature=jsMN1psOaEf3KpW8UiQOwnEDCNM0eDJ9FhgPq~GNXqLItMAEdFx6foOGTBTeCpJhrfS5f9C1WsT6JBJ-OF2VSZCY4hMS9gJl7FbAOywEXjZ7FkQ8D8eMHICtPb1wzBA3uZZtBKMZczJqU~L965QcGSWu4bY5onpcoRMSzjgnNpdPf9L4pLKg-a0ahzhjNRwGHt5NoJ7ErFgx3duCbchEi0MsV0cDIkqzsUCeNEtwo8kpBYcJAps4DqCXaYZS5CPCAIpG4RbHZce70W~XP9IUuUZszMeWmEvwL5IF-0Kt0kkQwtSCyF6kopinSbFrVRYLZmYxxNRPbjwJpR0g1P88ZQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). Complete smoking cessation and avoiding second-hand smoke or environmental particle air pollution are crucial in patients with PAAD to reduce the risk of death, AD, acute mesenteric ischaemia (AMI), AAA, and PAD.<sup><a href="javascript:;" reveal-id="ehae179-B119" data-open="ehae179-B119" class="link link-ref link-reveal xref-bibr">119</a>,<a href="javascript:;" reveal-id="ehae179-B260 ehae179-B261 ehae179-B262 ehae179-B263 ehae179-B264 ehae179-B265 ehae179-B266 ehae179-B267" data-open="ehae179-B260 ehae179-B261 ehae179-B262 ehae179-B263 ehae179-B264 ehae179-B265 ehae179-B266 ehae179-B267" class="link link-ref link-reveal xref-bibr">260–267</a></sup> Smokers should be offered structural follow-up support, including nicotine replacement therapy, varenicline, and bupropion, individually or in combination.<sup><a href="javascript:;" reveal-id="ehae179-B19" data-open="ehae179-B19" class="link link-ref link-reveal xref-bibr">19</a>,<a href="javascript:;" reveal-id="ehae179-B268" data-open="ehae179-B268" class="link link-ref link-reveal xref-bibr">268</a>,<a href="javascript:;" reveal-id="ehae179-B269" data-open="ehae179-B269" class="link link-ref link-reveal xref-bibr">269</a></sup> Smoking avoidance also includes cannabis, associated with premature ASCVD.<sup><a href="javascript:;" reveal-id="ehae179-B266" data-open="ehae179-B266" class="link link-ref link-reveal xref-bibr">266</a></sup>

Vaping and e-cigarette use has surged in the past decade, viewed by some as a healthier option than smoked tobacco, though long-term health effects remain unknown.<sup><a href="javascript:;" reveal-id="ehae179-B270" data-open="ehae179-B270" class="link link-ref link-reveal xref-bibr">270</a></sup> E-cigarettes may be considered as an aid to quit tobacco smoking, as a recent Cochrane review found that they increase quit rates as compared with nicotine replacement therapy,<sup><a href="javascript:;" reveal-id="ehae179-B271" data-open="ehae179-B271" class="link link-ref link-reveal xref-bibr">271</a></sup> but their use has been associated with adverse effects on CV, respiratory, immunological, and periodontal health compared with non-users, but with a milder impact than smoked cigarettes.<sup><a href="javascript:;" reveal-id="ehae179-B272 ehae179-B273 ehae179-B274" data-open="ehae179-B272 ehae179-B273 ehae179-B274" class="link link-ref link-reveal xref-bibr">272–274</a></sup> However, their use should be brief and preferably not concurrent with traditional cigarettes.<sup><a href="javascript:;" reveal-id="ehae179-B271" data-open="ehae179-B271" class="link link-ref link-reveal xref-bibr">271</a>,<a href="javascript:;" reveal-id="ehae179-B275" data-open="ehae179-B275" class="link link-ref link-reveal xref-bibr">275</a></sup>

The main limitation of the evidence base remains imprecision due to the small number of randomized controlled trials (RCTs), often with low event rates and follow-up limited to 2 years.

#### 7.1.4. Patient education

While detailed explanations of CVRFs might not always inspire lifestyle changes,<sup><a href="javascript:;" reveal-id="ehae179-B276" data-open="ehae179-B276" class="link link-ref link-reveal xref-bibr">276</a></sup> providing plain language and visual aids is essential for patient understanding.<sup><a href="javascript:;" reveal-id="ehae179-B277" data-open="ehae179-B277" class="link link-ref link-reveal xref-bibr">277</a></sup> Structured programmes, incorporating psychological and behavioural aspects, are pivotal in fostering desired changes.<sup><a href="javascript:;" reveal-id="ehae179-B276" data-open="ehae179-B276" class="link link-ref link-reveal xref-bibr">276</a></sup> Engaging patients’ families, friends, and support networks significantly contributes to perpetuating these changes (particularly in self-care),<sup><a href="javascript:;" reveal-id="ehae179-B276" data-open="ehae179-B276" class="link link-ref link-reveal xref-bibr">276</a></sup> and increases treatment compliance and self-efficacy, reducing hospitalization risk and enriching patient HRQoL.<sup><a href="javascript:;" reveal-id="ehae179-B278" data-open="ehae179-B278" class="link link-ref link-reveal xref-bibr">278</a>,<a href="javascript:;" reveal-id="ehae179-B279" data-open="ehae179-B279" class="link link-ref link-reveal xref-bibr">279</a></sup> When caregivers disconnect from healthcare professionals, they should be recognised to receive better support systems.<sup><a href="javascript:;" reveal-id="ehae179-B280" data-open="ehae179-B280" class="link link-ref link-reveal xref-bibr">280</a>,<a href="javascript:;" reveal-id="ehae179-B281" data-open="ehae179-B281" class="link link-ref link-reveal xref-bibr">281</a></sup> Psychosocial interventions are crucial to navigating complexities with resilience.<sup><a href="javascript:;" reveal-id="ehae179-B282" data-open="ehae179-B282" class="link link-ref link-reveal xref-bibr">282</a></sup>

Advocating active involvement, education, clear communication, and shared decision-making is key for achieving optimal patient outcomes.<sup><a href="javascript:;" reveal-id="ehae179-B276 ehae179-B277 ehae179-B278 ehae179-B279 ehae179-B280 ehae179-B281 ehae179-B282 ehae179-B283" data-open="ehae179-B276 ehae179-B277 ehae179-B278 ehae179-B279 ehae179-B280 ehae179-B281 ehae179-B282 ehae179-B283" class="link link-ref link-reveal xref-bibr">276–283</a></sup>

#### 7.1.5. Risk scoring models in secondary prevention

Recent ESC CV prevention guidelines discuss risk models for developing vascular disease in healthy individuals and ASCVD patients.<sup><a href="javascript:;" reveal-id="ehae179-B19" data-open="ehae179-B19" class="link link-ref link-reveal xref-bibr">19</a></sup> Several registries enabling risk prediction in ASCVD have been developed: REACH (The REduction of Atherothrombosis for Continued Health)<sup><a href="javascript:;" reveal-id="ehae179-B284" data-open="ehae179-B284" class="link link-ref link-reveal xref-bibr">284</a></sup> and SMART (Secondary Manifestation of ARTerial disease)<sup><a href="javascript:;" reveal-id="ehae179-B285" data-open="ehae179-B285" class="link link-ref link-reveal xref-bibr">285</a></sup> which use clinical parameters such as medical history, SBP, and common biomarkers. Addition of carotid ultrasound did not improve the model.<sup><a href="javascript:;" reveal-id="ehae179-B286" data-open="ehae179-B286" class="link link-ref link-reveal xref-bibr">286</a></sup> A new algorithm combining the SMART and REACH models<sup><a href="javascript:;" reveal-id="ehae179-B287" data-open="ehae179-B287" class="link link-ref link-reveal xref-bibr">287</a></sup> enables calculation of lifetime risk and treatment effects. The SMART model has recently been updated and validated<sup><a href="javascript:;" reveal-id="ehae179-B288" data-open="ehae179-B288" class="link link-ref link-reveal xref-bibr">288</a>,<a href="javascript:;" reveal-id="ehae179-B289" data-open="ehae179-B289" class="link link-ref link-reveal xref-bibr">289</a></sup> with the SMART-2 algorithm. These tools are available online as clinical risk calculators (see [www.u-preveotnt.com](https://www.u-prevent.com)) and smartphone apps on the ESC website ([https://www.escardio.org/Education/ESC-Prevention-of-CVD-Programme/Risk-assessment/SMART-Risk-Score](https://www.escardio.org/Education/ESC-Prevention-of-CVD-Programme/Risk-assessment/SMART-Risk-Score)).

Recommendation Table 7

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479845921)

Recommendations for lifestyle, physical activity, and patient education (see also Evidence Table 4)

![Recommendations for lifestyle, physical activity, and patient education (see also Evidence Table 4)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt7.jpeg?Expires=1728479088&Signature=SZXetLaKPuPuhfMflEeIpex7rweEO95RQVsr4julUX0kPw7TMvhoh6F-YrJlsfURISezlhEEjELs~Bd1NDKqhCq4JgntfIpsP0PGkxZJanebzktu1a3NqYEcGAKbG-9PCw1Dy1WlQKFftLVBhtm35qfkrKLim4ZcsvbwYmPQZqNWdMlEnQFhayI~lsUGL3F8ULWUz8~nRAxr3gbVHZGT5mG2PwOwAn9xVqkAdbpOqyokkG7iudafRlvlrjh4~ASdcRlAY3BJT~Cj4bksOhYDDOTTbGpoXdyCP6~yIba8SWHqAVcG2jsKtFlMxb7LOcWSDkWqgiOs6~8V6bSqquXTrg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 7.2. Principles of pharmacological medical therapy

#### 7.2.1. Antithrombotic therapy

Antithrombotic therapy is crucial for patients with symptomatic PAAD at high CV risk. While trials are fewer than in CAD, recent evidence should guide practice. In the absence of specific indications for chronic oral anticoagulation (OAC) in concomitant CV disease, a single antiplatelet agent is the primary long-term treatment for patients with symptomatic PAAD. Combining it with another antiplatelet agent or low-dose anticoagulants depends on the patient’s ischaemic and bleeding risk, as well as therapeutic paths (e.g. endovascular therapy). Recent guidelines<sup><a href="javascript:;" reveal-id="ehae179-B299" data-open="ehae179-B299" class="link link-ref link-reveal xref-bibr">299</a></sup> propose a tool for bleeding risk assessment in PAD patients (OAC<sup><a href="javascript:;" reveal-id="ehae179-B3" data-open="ehae179-B3" class="link link-ref link-reveal xref-bibr">3</a></sup> PAD score).

Antithrombotic strategy is detailed in _Sections [8](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#ehae179-s7)_ and _[9](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#ehae179-s8)_ for each arterial territory.

#### 7.2.2. Antihypertensive therapy

New 2024 ESC Guidelines on hypertension are currently published and should be reviewed for further details.<sup><a href="javascript:;" reveal-id="ehae179-B300" data-open="ehae179-B300" class="link link-ref link-reveal xref-bibr">300</a></sup> Patients with hypertension and PAAD are considered to have target organ damage and are at high CV risk.<sup><a href="javascript:;" reveal-id="ehae179-B300" data-open="ehae179-B300" class="link link-ref link-reveal xref-bibr">300</a></sup>

Different meta-analyses showed that systolic BP treatments reduce CV risk in all ages up to 85 years down to a level of 120–129 mmHg.<sup><a href="javascript:;" reveal-id="ehae179-B301" data-open="ehae179-B301" class="link link-ref link-reveal xref-bibr">301</a>,<a href="javascript:;" reveal-id="ehae179-B302" data-open="ehae179-B302" class="link link-ref link-reveal xref-bibr">302</a></sup> There is no need to increase the BP target in healthy patients up to the age of 85 years.<sup><a href="javascript:;" reveal-id="ehae179-B303" data-open="ehae179-B303" class="link link-ref link-reveal xref-bibr">303</a>,<a href="javascript:;" reveal-id="ehae179-B304" data-open="ehae179-B304" class="link link-ref link-reveal xref-bibr">304</a></sup> To reduce cardiovascular disease (CVD) risk, it is recommended that treated SBP values in most adults be targeted to 120–129 mmHg, provided the treatment is well tolerated. However, in cases where BP-lowering treatment is poorly tolerated and achieving an SBP of 120–129 mmHg is not possible, it is recommended to target an SBP level that is ‘as low as reasonably achievable’ (ALARA principle).<sup><a href="javascript:;" reveal-id="ehae179-B301" data-open="ehae179-B301" class="link link-ref link-reveal xref-bibr">301</a>,<a href="javascript:;" reveal-id="ehae179-B302" data-open="ehae179-B302" class="link link-ref link-reveal xref-bibr">302</a>,<a href="javascript:;" reveal-id="ehae179-B305" data-open="ehae179-B305" class="link link-ref link-reveal xref-bibr">305</a></sup> To avoid overtreatment, out-of-office BP measurements may be helpful when pursuing this target.

If on-treatment SBP is on target, but diastolic blood pressure (DBP) is ≥80 mmHg, intensified treatment may be considered to further reduce the CV risk.<sup><a href="javascript:;" reveal-id="ehae179-B306" data-open="ehae179-B306" class="link link-ref link-reveal xref-bibr">306</a></sup>

Because the CVD benefit of an on-treatment BP target of 120–129 mmHg may not generalize to some groups, setting personalized and more lenient BP targets (e.g. <140/90 mmHg) has to be considered in patients with pre-treatment orthostatic hypotension, age ≥85 years, clinically significant frailty at any age, or a limited lifespan (<3 years).<sup><a href="javascript:;" reveal-id="ehae179-B301" data-open="ehae179-B301" class="link link-ref link-reveal xref-bibr">301</a></sup>

Patients with both PAAD and hypertension face a high or very high CV risk. Antihypertensive medications such as diuretics, beta-blockers (BBs), calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors (ACEIs), and angiotensin receptor blockers (ARBs) are all appropriate options for managing hypertension in PAAD. These agents can be used as monotherapy or in various combinations (excluding ARBs+ACEIs), considering individual patients’ conditions. It is often necessary to implement combination therapy, preferably in the form of a single pill, to effectively achieve the recommended treatment goals. However, ACEIs or ARBs should be considered as first-line antihypertensive therapy to reduce CV events.<sup><a href="javascript:;" reveal-id="ehae179-B300" data-open="ehae179-B300" class="link link-ref link-reveal xref-bibr">300</a>,<a href="javascript:;" reveal-id="ehae179-B307 ehae179-B308 ehae179-B309 ehae179-B310 ehae179-B311 ehae179-B312" data-open="ehae179-B307 ehae179-B308 ehae179-B309 ehae179-B310 ehae179-B311 ehae179-B312" class="link link-ref link-reveal xref-bibr">307–312</a></sup>

Regardless of BP levels and in the absence of contraindications, ACEIs/ARBs may be considered in all patients with PAD to reduce cardiovascular events.<sup><a href="javascript:;" reveal-id="ehae179-B312" data-open="ehae179-B312" class="link link-ref link-reveal xref-bibr">312</a>,<a href="javascript:;" reveal-id="ehae179-B313" data-open="ehae179-B313" class="link link-ref link-reveal xref-bibr">313</a></sup> A meta-analysis suggests that antihypertensive treatment may improve mean walking distance in patients with PAD.<sup><a href="javascript:;" reveal-id="ehae179-B310" data-open="ehae179-B310" class="link link-ref link-reveal xref-bibr">310</a></sup>

Beta-blockers can be prescribed, if necessary, to patients with intermittent claudication, since they do not worsen walking capacity or limb events.<sup><a href="javascript:;" reveal-id="ehae179-B314" data-open="ehae179-B314" class="link link-ref link-reveal xref-bibr">314</a></sup> There is some evidence suggesting a higher amputation rate<sup><a href="javascript:;" reveal-id="ehae179-B315" data-open="ehae179-B315" class="link link-ref link-reveal xref-bibr">315</a></sup> or increased rate of re-intervention<sup><a href="javascript:;" reveal-id="ehae179-B316" data-open="ehae179-B316" class="link link-ref link-reveal xref-bibr">316</a></sup> in patients with CLTI treated with ACEIs, although in one smaller study no effect on limb-related outcomes was observed.<sup><a href="javascript:;" reveal-id="ehae179-B317" data-open="ehae179-B317" class="link link-ref link-reveal xref-bibr">317</a></sup> Thus, they remain a treatment option in hypertensive patients with PAD, especially in those with concomitant CAD.<sup><a href="javascript:;" reveal-id="ehae179-B318" data-open="ehae179-B318" class="link link-ref link-reveal xref-bibr">318</a></sup> BBs were not associated with worsened clinical outcomes in a retrospective study<sup><a href="javascript:;" reveal-id="ehae179-B319" data-open="ehae179-B319" class="link link-ref link-reveal xref-bibr">319</a></sup> on CLTI patients, but it seems prudent to avoid excessively low heart rates in these patients.

##### 7.2.2.1. Renovascular hypertension

Angiotensin-converting enzyme inhibitors and ARBs effectively manage unilateral renal artery stenosis (RAS) by blocking the renin–angiotensin system, potentially reducing renal capillary perfusion pressure.<sup><a href="javascript:;" reveal-id="ehae179-B320 ehae179-B321 ehae179-B322" data-open="ehae179-B320 ehae179-B321 ehae179-B322" class="link link-ref link-reveal xref-bibr">320–322</a></sup> This transiently lowers glomerular filtration rate (GFR) and raises serum creatinine. For bilateral RAS, regular follow-up assessments of renal function and kidney perfusion are advised.

Angiotensin-converting enzyme inhibitors and ARBs additionally (combined with hydrochlorothiazide and/or CCBs if needed) contribute to CV risk reduction in patients with atherosclerotic disease and reduced eGFR.<sup><a href="javascript:;" reveal-id="ehae179-B307" data-open="ehae179-B307" class="link link-ref link-reveal xref-bibr">307</a>,<a href="javascript:;" reveal-id="ehae179-B323" data-open="ehae179-B323" class="link link-ref link-reveal xref-bibr">323</a>,<a href="javascript:;" reveal-id="ehae179-B324" data-open="ehae179-B324" class="link link-ref link-reveal xref-bibr">324</a></sup>

Recommendation Table 8

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479845937)

Recommendations for antihypertensive therapy in patients with peripheral and aortic disease

![Recommendations for antihypertensive therapy in patients with peripheral and aortic disease](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt8.jpeg?Expires=1728479088&Signature=TxrYRLx9LJft5~TL1cp2MmcmsInemaG6QDPV62AJ2tFhCtZkFHycTdEqz6w64B80rzHTqQGVc--W~rqZSLOjBuhRR2eDkZtyLDhcrSZORi~VFdTOj65tIMoQz4JO250zfghjZS7XZ6tHho2~eKe4FZZ5rFXrd39cb74yxnIIw4IdhpoCl1tN1ztiF8cITK0LXrkUaBY0GcdBeov63mwNdJPkEk71CFJdmtI2QrH5cYSWxT7DH17oSeYbCSLRchI5dsSG7G96pknq9lsOZ0DXuCAuEk3dllg-5MWx1LnQQi4pLRqLoVIU1D6HuaMrTMg3SGaRC6rnVB4ZY3mgProFWg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 7.2.3. Lipid-lowering therapy

Patients with symptomatic PAAD are at very high CV risk but are usually inadequately managed compared with patients with CAD.<sup><a href="javascript:;" reveal-id="ehae179-B5" data-open="ehae179-B5" class="link link-ref link-reveal xref-bibr">5</a>,<a href="javascript:;" reveal-id="ehae179-B247" data-open="ehae179-B247" class="link link-ref link-reveal xref-bibr">247</a>,<a href="javascript:;" reveal-id="ehae179-B326 ehae179-B327 ehae179-B328 ehae179-B329 ehae179-B330 ehae179-B331 ehae179-B332" data-open="ehae179-B326 ehae179-B327 ehae179-B328 ehae179-B329 ehae179-B330 ehae179-B331 ehae179-B332" class="link link-ref link-reveal xref-bibr">326–332</a></sup> Both LDL-C reduction by ≥50% from baseline and an LDL-C goal of <1.4 mmol/L (<55 mg/dL) are recommended to obtain a reduction in CV death, MI, and stroke, and to improve walking distance.<sup><a href="javascript:;" reveal-id="ehae179-B242" data-open="ehae179-B242" class="link link-ref link-reveal xref-bibr">242</a>,<a href="javascript:;" reveal-id="ehae179-B333 ehae179-B334 ehae179-B335 ehae179-B336" data-open="ehae179-B333 ehae179-B334 ehae179-B335 ehae179-B336" class="link link-ref link-reveal xref-bibr">333–336</a></sup>

##### 7.2.3.1. Statins

Statins demonstrate mortality and CV event reduction in RCTs for PAD, CS, and severe aortic arch plaques.<sup><a href="javascript:;" reveal-id="ehae179-B243 ehae179-B244 ehae179-B245" data-open="ehae179-B243 ehae179-B244 ehae179-B245" class="link link-ref link-reveal xref-bibr">243–245</a></sup> Even in advanced disease stages, they are linked to lower MACE and mortality.<sup><a href="javascript:;" reveal-id="ehae179-B246" data-open="ehae179-B246" class="link link-ref link-reveal xref-bibr">246</a></sup>

Statins significantly improve CV outcomes in patients with PAD, reducing major adverse limb events (MALE).<sup><a href="javascript:;" reveal-id="ehae179-B244" data-open="ehae179-B244" class="link link-ref link-reveal xref-bibr">244</a>,<a href="javascript:;" reveal-id="ehae179-B327 ehae179-B328 ehae179-B329" data-open="ehae179-B327 ehae179-B328 ehae179-B329" class="link link-ref link-reveal xref-bibr">327–329</a>,<a href="javascript:;" reveal-id="ehae179-B337" data-open="ehae179-B337" class="link link-ref link-reveal xref-bibr">337</a>,<a href="javascript:;" reveal-id="ehae179-B338" data-open="ehae179-B338" class="link link-ref link-reveal xref-bibr">338</a></sup> Meta-analyses show enhanced walking distances.<sup><a href="javascript:;" reveal-id="ehae179-B244" data-open="ehae179-B244" class="link link-ref link-reveal xref-bibr">244</a>,<a href="javascript:;" reveal-id="ehae179-B338" data-open="ehae179-B338" class="link link-ref link-reveal xref-bibr">338</a>,<a href="javascript:;" reveal-id="ehae179-B339" data-open="ehae179-B339" class="link link-ref link-reveal xref-bibr">339</a></sup>

For CS, statin pre-treatment lowers recurrent stroke risk post-transient ischaemic attack (TIA).<sup><a href="javascript:;" reveal-id="ehae179-B19" data-open="ehae179-B19" class="link link-ref link-reveal xref-bibr">19</a>,<a href="javascript:;" reveal-id="ehae179-B340 ehae179-B341 ehae179-B342 ehae179-B343" data-open="ehae179-B340 ehae179-B341 ehae179-B342 ehae179-B343" class="link link-ref link-reveal xref-bibr">340–343</a></sup> While lacking RCTs in renovascular or visceral artery disease, statins benefit cardiorenal events and post-RAS stenting prognosis.<sup><a href="javascript:;" reveal-id="ehae179-B344 ehae179-B345 ehae179-B346" data-open="ehae179-B344 ehae179-B345 ehae179-B346" class="link link-ref link-reveal xref-bibr">344–346</a></sup>

Mixed evidence suggests statins may mitigate AAA and TAA growth.<sup><a href="javascript:;" reveal-id="ehae179-B347 ehae179-B348 ehae179-B349 ehae179-B350 ehae179-B351 ehae179-B352" data-open="ehae179-B347 ehae179-B348 ehae179-B349 ehae179-B350 ehae179-B351 ehae179-B352" class="link link-ref link-reveal xref-bibr">347–352</a></sup> However, since most patients with AAA or TAA present with associated CVRFs, liberal use of lipid-lowering treatment<sup><a href="javascript:;" reveal-id="ehae179-B19" data-open="ehae179-B19" class="link link-ref link-reveal xref-bibr">19</a></sup> should be considered, using an individualized approach with shared decision-making and considering residual CV risk.<sup><a href="javascript:;" reveal-id="ehae179-B353" data-open="ehae179-B353" class="link link-ref link-reveal xref-bibr">353</a></sup> Pre-operative statin use links to increased 5 year survival after TEVAR.<sup><a href="javascript:;" reveal-id="ehae179-B19" data-open="ehae179-B19" class="link link-ref link-reveal xref-bibr">19</a></sup>

Statin use was associated with a mean AAA growth rate reduction and a lower rupture risk.<sup><a href="javascript:;" reveal-id="ehae179-B347 ehae179-B348 ehae179-B349" data-open="ehae179-B347 ehae179-B348 ehae179-B349" class="link link-ref link-reveal xref-bibr">347–349</a>,<a href="javascript:;" reveal-id="ehae179-B352" data-open="ehae179-B352" class="link link-ref link-reveal xref-bibr">352</a>,<a href="javascript:;" reveal-id="ehae179-B354" data-open="ehae179-B354" class="link link-ref link-reveal xref-bibr">354</a></sup>

Some evidence suggests that statins may reduce TAA growth rate and risk of rupture.<sup><a href="javascript:;" reveal-id="ehae179-B350" data-open="ehae179-B350" class="link link-ref link-reveal xref-bibr">350</a>,<a href="javascript:;" reveal-id="ehae179-B351" data-open="ehae179-B351" class="link link-ref link-reveal xref-bibr">351</a>,<a href="javascript:;" reveal-id="ehae179-B355" data-open="ehae179-B355" class="link link-ref link-reveal xref-bibr">355</a></sup>

No benefit on AAA or TAA growth rate was shown with fenofibrate therapy.<sup><a href="javascript:;" reveal-id="ehae179-B356" data-open="ehae179-B356" class="link link-ref link-reveal xref-bibr">356</a>,<a href="javascript:;" reveal-id="ehae179-B357" data-open="ehae179-B357" class="link link-ref link-reveal xref-bibr">357</a></sup>

##### 7.2.3.2. Ezetimibe

Ezetimibe combined with statins benefits selected patients with PAAD, particularly when the target LDL-C level is not met.<sup><a href="javascript:;" reveal-id="ehae179-B335" data-open="ehae179-B335" class="link link-ref link-reveal xref-bibr">335</a></sup> In an IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) subanalysis, involving acute coronary syndrome (ACS) patients with PAD, ezetimibe consistently reduced CV risk, especially in high-risk subgroups.<sup><a href="javascript:;" reveal-id="ehae179-B247" data-open="ehae179-B247" class="link link-ref link-reveal xref-bibr">247</a>,<a href="javascript:;" reveal-id="ehae179-B331" data-open="ehae179-B331" class="link link-ref link-reveal xref-bibr">331</a></sup>

##### 7.2.3.3. Proprotein convertase subtilisin/kexin type 9 inhibitors

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, in addition to statins, reduce CV events in symptomatic atherosclerotic disease patients with LDL-C ≥1.8 mmol/L.<sup><a href="javascript:;" reveal-id="ehae179-B336" data-open="ehae179-B336" class="link link-ref link-reveal xref-bibr">336</a></sup> Adding them to statins further reduces MACE and MALE risk in patients with PAD and improves walking distance;<sup><a href="javascript:;" reveal-id="ehae179-B333" data-open="ehae179-B333" class="link link-ref link-reveal xref-bibr">333</a></sup> however, their potential in TAA/AAA is an emerging area of research.<sup><a href="javascript:;" reveal-id="ehae179-B247" data-open="ehae179-B247" class="link link-ref link-reveal xref-bibr">247</a></sup>

Inclisiran, administered semi-annually, has proved a notable 26% MACE risk reduction in a pooled phase III analysis,<sup><a href="javascript:;" reveal-id="ehae179-B358" data-open="ehae179-B358" class="link link-ref link-reveal xref-bibr">358</a></sup> but its role in PAAD is not firmly established and ongoing RCTs including PAD participants (e.g. [ClinicalTrials.gov](https://ClinicalTrials.gov) NCT05030428) aim to provide insights.

##### 7.2.3.4. Bempedoic acid

Bempedoic acid, acting upstream of statins in cholesterol metabolism, has been shown to reduce cholesterol levels by 17%–28%<sup><a href="javascript:;" reveal-id="ehae179-B359" data-open="ehae179-B359" class="link link-ref link-reveal xref-bibr">359</a>,<a href="javascript:;" reveal-id="ehae179-B360" data-open="ehae179-B360" class="link link-ref link-reveal xref-bibr">360</a></sup> and demonstrated a decrease in the incidence of MACE in statin-intolerant PAD patients.<sup><a href="javascript:;" reveal-id="ehae179-B361" data-open="ehae179-B361" class="link link-ref link-reveal xref-bibr">361</a></sup> However, its impact on aortic diseases and AAA still requires further research.

##### 7.2.3.5. Hypertriglyceridaemia

Beyond LDL-C, evidence shows insulin resistance, elevated triglycerides, and remnant lipoproteins are associated with ASCVD, particularly in PAD.<sup><a href="javascript:;" reveal-id="ehae179-B362 ehae179-B363 ehae179-B364 ehae179-B365" data-open="ehae179-B362 ehae179-B363 ehae179-B364 ehae179-B365" class="link link-ref link-reveal xref-bibr">362–365</a></sup> However, in a meta-analysis and an RCT, fibrates showed no benefit over placebo in reducing MACE in patients with PAD for a composite outcome of non-fatal stroke, non-fatal MI, and vascular death.<sup><a href="javascript:;" reveal-id="ehae179-B366" data-open="ehae179-B366" class="link link-ref link-reveal xref-bibr">366</a></sup> Fibrates showed no benefit over placebo in reducing coronary and cerebrovascular events in patients with PAD in an RCT.<sup><a href="javascript:;" reveal-id="ehae179-B367" data-open="ehae179-B367" class="link link-ref link-reveal xref-bibr">367</a></sup> While the relationship between triglycerides and aortic diseases is complex and not fully understood, some evidence suggests that triglyceride levels may contribute to the development and progression of aortic diseases.

In contrast, icosapent ethyl (IPE) demonstrated a reduction in mortality and morbidity among individuals with hypertriglyceridaemia in the Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial (REDUCE-IT).<sup><a href="javascript:;" reveal-id="ehae179-B368" data-open="ehae179-B368" class="link link-ref link-reveal xref-bibr">368</a></sup> Its impact on patients with PAAD is unexplored,<sup><a href="javascript:;" reveal-id="ehae179-B369" data-open="ehae179-B369" class="link link-ref link-reveal xref-bibr">369</a></sup> although a small pilot RCT suggested an improved ABI in hyperglycaemic haemodialysis patients.<sup><a href="javascript:;" reveal-id="ehae179-B370" data-open="ehae179-B370" class="link link-ref link-reveal xref-bibr">370</a></sup>

Recommendation Table 9

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479845958)

Recommendations for lipid-lowering therapy in patients with peripheral arterial and aortic diseases

![Recommendations for lipid-lowering therapy in patients with peripheral arterial and aortic diseases](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt9.jpeg?Expires=1728479088&Signature=hGjds~Iy70leQ6SpLXjGibA~9eB1uJdkYuTlcJXssqDaGC2c0xvEiMvy21JHvaZP~kSxRgY0D3AEr~IOM11YVLQLj52EN0ue2cW4LlZ5qyXSe8ysduiYV7s74nB0TISX9Yw7kg44G4iTi7ZDMkHRxaL5GRVYP0NgLd99UqRz1jHT89GrZP0Cm9z6V~SXHHpi4kelfsefEDF~RcYglVrcoXELftnChX~-5yrBnz4XxwFmTTegVJQ3MZmUIlpQMGp0vnLD2hdMjzpbfwQ4kF8g~39fc7OfRU10Ry5aJLQ6WJKPhilC5ot4Lr1Rru7YS0aiMlb~SSjzP3rqmKDnzJ4U6g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 7.2.4. Diabetes and pre-diabetes conditions

Screening for diabetes or pre-diabetes is recommended in PAAD. Recent ESC Guidelines on diabetes and CVD<sup><a href="javascript:;" reveal-id="ehae179-B374" data-open="ehae179-B374" class="link link-ref link-reveal xref-bibr">374</a></sup> provide detailed diagnostic criteria and underscore the importance of diagnosing diabetes in ASCVD patients and vice versa. Both Type 1 (T1DM) and Type 2 (T2DM) diabetes mellitus imply significantly increased risk of PAD, carotid stenosis, and polyvascular disease, depending on disease duration and the status of other CVRFs. Diabetes is present in 30% of patients with IC and 50%–70% of those with CLTI.<sup><a href="javascript:;" reveal-id="ehae179-B375" data-open="ehae179-B375" class="link link-ref link-reveal xref-bibr">375</a>,<a href="javascript:;" reveal-id="ehae179-B376" data-open="ehae179-B376" class="link link-ref link-reveal xref-bibr">376</a></sup> Although the prevalence of PAD in patients with diabetes is 20%–30%, only half of them are symptomatic because of peripheral neuropathy with decreased pain sensitivity.<sup><a href="javascript:;" reveal-id="ehae179-B377" data-open="ehae179-B377" class="link link-ref link-reveal xref-bibr">377</a></sup> As already detailed in _Section [4](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#ehae179-s3)_, diabetes implies reduced risk of TAA, AAA, or aortic dissection. However, patients with T2DM and PAAD are in the very high-risk group for stroke, MI, and CV death,<sup><a href="javascript:;" reveal-id="ehae179-B374" data-open="ehae179-B374" class="link link-ref link-reveal xref-bibr">374</a></sup> and for T1DM, an online risk prediction tool has recently been developed.<sup><a href="javascript:;" reveal-id="ehae179-B377 ehae179-B378 ehae179-B379 ehae179-B380" data-open="ehae179-B377 ehae179-B378 ehae179-B379 ehae179-B380" class="link link-ref link-reveal xref-bibr">377–380</a></sup>

For non-pregnant PAAD patients, aiming for an HbA1c level of <53 mmol/mol (7%) to avoid significant hypoglycaemia is appropriate. Consider a higher threshold (<69 mmol/mol \[8.5%\]) for limited life expectancy or when treatment risks outweigh benefits.<sup><a href="javascript:;" reveal-id="ehae179-B374" data-open="ehae179-B374" class="link link-ref link-reveal xref-bibr">374</a></sup>

In PAAD, it is recommended to aim for tight glycaemic control, preferably with agents with proven CV benefits such as sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA), adding metformin and other glucose-lowering agents as necessary.<sup><a href="javascript:;" reveal-id="ehae179-B374" data-open="ehae179-B374" class="link link-ref link-reveal xref-bibr">374</a>,<a href="javascript:;" reveal-id="ehae179-B381 ehae179-B382 ehae179-B383 ehae179-B384" data-open="ehae179-B381 ehae179-B382 ehae179-B383 ehae179-B384" class="link link-ref link-reveal xref-bibr">381–384</a></sup>

The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial and Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) investigated subcutaneous GLP-1RAs liraglutide (≤1.8 mg/day) and semaglutide (0.5 or 1.0 mg/week), respectively, vs. placebo in T2DM patients with high CV risk. Overall, 12.7% of patients in LEADER and 14.0% in SUSTAIN-6 presented with PAD at baseline. Although non-statistically significant due to a lack of power, the effects on MACE showed a consistently beneficial trend in PAD: liraglutide (hazard ratio (HR), 0.77; 95% confidence interval (CI), 0.58–1.01) and semaglutide (HR, 0.61; 95% CI, 0.33–1.13).<sup><a href="javascript:;" reveal-id="ehae179-B381" data-open="ehae179-B381" class="link link-ref link-reveal xref-bibr">381</a></sup>

The (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) investigated the SGLT2i empagliflozin (10 mg or 25 mg per day) vs. placebo in patients with T2DM and high CV risk. Overall, 20.8% of patients presented with PAD at baseline. In these patients, empagliflozin reduced CV death (HR, 0.57; 95% CI, 0.37–0.88) and all-cause mortality (HR, 0.62; 95% CI, 0.44–0.88), and there was a non-significant reduction in limb amputation: 5.5% with empagliflozin vs. 6.3% with placebo (HR, 0.84; 95% CI, 0.54–1.32).<sup><a href="javascript:;" reveal-id="ehae179-B382" data-open="ehae179-B382" class="link link-ref link-reveal xref-bibr">382</a></sup> In the Canagliflozin Cardiovascular Assessment Study (CANVAS)<sup><a href="javascript:;" reveal-id="ehae179-B385" data-open="ehae179-B385" class="link link-ref link-reveal xref-bibr">385</a></sup> investigating canagliflozin, there was an increased risk of amputation, but this was not confirmed in the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial investigating canagliflozin in patients with T2DM and chronic kidney disease (CKD).<sup><a href="javascript:;" reveal-id="ehae179-B386" data-open="ehae179-B386" class="link link-ref link-reveal xref-bibr">386</a></sup> Still, the use of other SLGT2is seems reasonable in PAD patients.

Patients with carotid stenosis were included in trials testing GLP-1RA and SGLT2i, but no analysis on this subpopulation was performed. A meta-analysis of eight trials investigating GLP-1RAs vs. placebo in patients with T2DM reported a reduction in all strokes (HR, 0.84; 95% CI, 0.75–0.93).<sup><a href="javascript:;" reveal-id="ehae179-B387" data-open="ehae179-B387" class="link link-ref link-reveal xref-bibr">387</a></sup> Among patients with T2DM and prior history of MI or non-fatal stroke, GLP-1RAs reduced the incidence of recurrent MACE (HR, 0.86; 95% CI, 0.8–0.92).<sup><a href="javascript:;" reveal-id="ehae179-B388" data-open="ehae179-B388" class="link link-ref link-reveal xref-bibr">388</a></sup> SGLT2is do not appear to reduce stroke in patients with T2DM, but patients with a stroke history experienced similar cardiorenal benefits as the rest of the population.<sup><a href="javascript:;" reveal-id="ehae179-B389" data-open="ehae179-B389" class="link link-ref link-reveal xref-bibr">389</a></sup>

Before the era of GLP-1RAs and SGLT2is, different studies (United Kingdom Prospective Diabetes Study \[UKPDS\] 34<sup><a href="javascript:;" reveal-id="ehae179-B390" data-open="ehae179-B390" class="link link-ref link-reveal xref-bibr">390</a></sup> and Hyperinsulinaemia: the Outcomes of its Metabolic Effects \[HOME\] trials<sup><a href="javascript:;" reveal-id="ehae179-B391" data-open="ehae179-B391" class="link link-ref link-reveal xref-bibr">391</a></sup>) showed that metformin reduced the risk of MALE and MACE in patients with PAD.<sup><a href="javascript:;" reveal-id="ehae179-B391" data-open="ehae179-B391" class="link link-ref link-reveal xref-bibr">391</a>,<a href="javascript:;" reveal-id="ehae179-B392" data-open="ehae179-B392" class="link link-ref link-reveal xref-bibr">392</a></sup> But a recent study with GLP-1RA dulaglutide found the same risk reduction in MACE between patients with and without baseline metformin, calling into question its add-on value.<sup><a href="javascript:;" reveal-id="ehae179-B384" data-open="ehae179-B384" class="link link-ref link-reveal xref-bibr">384</a>,<a href="javascript:;" reveal-id="ehae179-B393" data-open="ehae179-B393" class="link link-ref link-reveal xref-bibr">393</a></sup> However, there are studies suggesting that metformin may reduce AAA growth (see _Section [9.2.4](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#ehae179-s8.2.4)_).

Recommendation Table 10

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479845967)

Recommendations for the medical management of patients with peripheral arterial and aortic diseases and diabetes

![Recommendations for the medical management of patients with peripheral arterial and aortic diseases and diabetes](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt10.jpeg?Expires=1728479088&Signature=nAyVyuJeGCG4v23KuQOf3CwtrjK5jN5ohOdc4bPcinvotEYrlxEDVkGKFN~PusqHk731mBR6FWFi2cqq8~m9lvelK09MEGjb0G-p5563u2Wvxrjaz-o3MqzJNJO~ss232XDQ9KqBOqUXR9ab1G7V8NxwocdklMvTx38iHs~VCyUL2Gr~VyoDtnz7C4jBSH-cyWdPA~r-7mJ8SCCgFoRv8BDgAMiVfabDtSpwLB4h05IO3XbMNxwCYtNan4cS2QjSrLjGSs4lBdpe3zpDtnAnk9lli5cqOICY2FQa-B5oUSK0gw5grAg-DANHzqd1UpXq0Uheys~2Zk5r7GWNkg70yw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 7.2.5. Other pharmacological therapy

Increased attention is focused on inflammation in ASCVD,<sup><a href="javascript:;" reveal-id="ehae179-B413" data-open="ehae179-B413" class="link link-ref link-reveal xref-bibr">413</a></sup> supported by the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS),<sup><a href="javascript:;" reveal-id="ehae179-B414" data-open="ehae179-B414" class="link link-ref link-reveal xref-bibr">414</a></sup> which showed that canakinumab, a monoclonal antibody targeting interleukin (IL)-1β, reduced MACE in high-risk patients with previous MI and increased high-sensitivity (hs)-CRP. Data for patients with PAAD are not reported. Furthermore, low-dose colchicine (0.5 mg/day) has been shown to reduce MACE among those with stable atherosclerosis after recent MI.<sup><a href="javascript:;" reveal-id="ehae179-B415" data-open="ehae179-B415" class="link link-ref link-reveal xref-bibr">415</a></sup> However, the effect of colchicine and other anti-inflammatory drugs in PAAD remains unproven.<sup><a href="javascript:;" reveal-id="ehae179-B416" data-open="ehae179-B416" class="link link-ref link-reveal xref-bibr">416</a></sup>

## 8\. Peripheral arterial disease

### 8.1. Lower-extremity peripheral arterial disease

#### 8.1.1. Peripheral arterial disease syndromes

##### 8.1.1.1. Clinical presentation and diagnosis

Atheromatous lower-extremity PAD is a chronic disease with different clinical manifestations. PAD may be symptomatic or asymptomatic and may or may not be associated with limb wounds. Wound healing and amputation risk may be affected by the concomitant presence of PAD, diabetes, and/or infection;<sup><a href="javascript:;" reveal-id="ehae179-B417" data-open="ehae179-B417" class="link link-ref link-reveal xref-bibr">417</a></sup> therefore, amputation risk assessment should be systematically performed using the Wound, Ischaemia, and foot Infection (WIfI) classification.

PAD presents as:

-   Asymptomatic PAD: suspected by lower-limb pulse abolition or imaging studies performed for other purposes and detected by pathological ABI or TBI.<sup><a href="javascript:;" reveal-id="ehae179-B418" data-open="ehae179-B418" class="link link-ref link-reveal xref-bibr">418</a>,<a href="javascript:;" reveal-id="ehae179-B419" data-open="ehae179-B419" class="link link-ref link-reveal xref-bibr">419</a></sup> These patients do not present with IC or atypical effort-related symptoms. However, attention should be paid to those with wounds, with masked effort-related symptoms due to reduced walking capacity (for reasons other than PAD), or reduced pain sensitivity. ‘Masked PAD’ is defined as PAD without provoked leg pain because of reduced walking capacity for other reasons or reduced pain sensitivity.<sup><a href="javascript:;" reveal-id="ehae179-B420" data-open="ehae179-B420" class="link link-ref link-reveal xref-bibr">420</a></sup>
    
-   Symptomatic (effort-related) PAD: patients with pathological ABI or TBI, presenting with IC, atypical effort-related symptoms, or chronic lower-limb wounds (diabetic foot or non-healing ulceration/gangrene ≥2 weeks) without critically reduced limb perfusion.<sup><a href="javascript:;" reveal-id="ehae179-B417" data-open="ehae179-B417" class="link link-ref link-reveal xref-bibr">417</a>,<a href="javascript:;" reveal-id="ehae179-B421" data-open="ehae179-B421" class="link link-ref link-reveal xref-bibr">421</a></sup> In these patients, IC is characterized by exertional muscle pain and dysfunction in the supply area of the obstructed arterial segment, which is relieved at rest.<sup><a href="javascript:;" reveal-id="ehae179-B422" data-open="ehae179-B422" class="link link-ref link-reveal xref-bibr">422</a></sup> Some patients may present with atypical symptoms or with ‘masked PAD’.<sup><a href="javascript:;" reveal-id="ehae179-B420" data-open="ehae179-B420" class="link link-ref link-reveal xref-bibr">420</a>,<a href="javascript:;" reveal-id="ehae179-B423" data-open="ehae179-B423" class="link link-ref link-reveal xref-bibr">423</a></sup> In women, the prevalence of IC is lower than in men, while atypical symptoms are more common.<sup><a href="javascript:;" reveal-id="ehae179-B424" data-open="ehae179-B424" class="link link-ref link-reveal xref-bibr">424</a></sup>
    
-   CLTI represents the more severe chronic PAD presentation and underlies poor limb outcomes without intervention. In addition to common signs of chronic PAD, patients with CLTI present with a critical haemodynamic status (ankle pressure <50 mmHg, toe pressure \[TP\] <30 mmHg, or TcPO<sub>2</sub> <30 mmHg) responsible for ischaemic rest pain, non-healing chronic (>2 weeks of duration) ulceration, or foot gangrene.<sup><a href="javascript:;" reveal-id="ehae179-B425" data-open="ehae179-B425" class="link link-ref link-reveal xref-bibr">425</a>,<a href="javascript:;" reveal-id="ehae179-B426" data-open="ehae179-B426" class="link link-ref link-reveal xref-bibr">426</a></sup>
    

PAD syndromes can be categorized according to their clinical presentation (_[Table 7](javascript:;)_).

Table 7

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479845978)

Peripheral arterial disease categorized according to clinical presentation

| Clinical characteristics of PAD | Rutherford classification | Fontaine classification |
| --- | --- | --- |
| Category | Signs and symptoms | Stage | Signs and symptoms |
| --- | --- | --- | --- |
| **Asymptomatic PAD** | **0** | Asymptomatic | **I** | Asymptomatic |
| **Symptomatic (effort-related) PAD** | **1** | Mild claudication | **IIa** | Non-disabling intermittent claudication |
| **2** | Moderate claudication | **IIb** | Disabling intermittent claudication |
| **3** | Severe claudication |  |  |
| **Chronic limb-threatening Ischaemia** | **4** | Ischaemic rest pain | **III** | Ischaemic rest pain |
| **5** | Minor tissue loss | **IV** | Ischaemic ulceration or gangrene |
| **6** | Major tissue loss |  |  |

PAD, peripheral arterial disease.

© ESC 2024

The 5 year cumulative incidence of clinical deterioration from asymptomatic PAD to IC is 7%, and 21% from IC to CLTI.<sup><a href="javascript:;" reveal-id="ehae179-B427" data-open="ehae179-B427" class="link link-ref link-reveal xref-bibr">427</a></sup> All patients with PAD are at high risk of MACE, cerebrovascular disease, and MALE (_[Figure 8](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B428 ehae179-B429 ehae179-B430" data-open="ehae179-B428 ehae179-B429 ehae179-B430" class="link link-ref link-reveal xref-bibr">428–430</a></sup> The 5 year cumulative incidence of CV mortality is 9% in asymptomatic PAD and 13% in symptomatic patients. In comparison with symptomatic PAD, CLTI further increases all-cause mortality risk (relative risk \[RR\] 2.26) and the risk of MACE (RR 1.73).<sup><a href="javascript:;" reveal-id="ehae179-B431" data-open="ehae179-B431" class="link link-ref link-reveal xref-bibr">431</a></sup> Health insurance data reveal a major amputation rate of 9% in patients with CLTI and 1% in patients with IC, while considerably higher amputation rates were reported in trials and registries data focusing on patients with CLTI.<sup><a href="javascript:;" reveal-id="ehae179-B432 ehae179-B433 ehae179-B434 ehae179-B435" data-open="ehae179-B432 ehae179-B433 ehae179-B434 ehae179-B435" class="link link-ref link-reveal xref-bibr">432–435</a></sup> Among patients with PAD, development of MALE is associated with poor prognosis, with a three-fold increase in death and a 200-fold increase in subsequent lower-extremity amputation.<sup><a href="javascript:;" reveal-id="ehae179-B429" data-open="ehae179-B429" class="link link-ref link-reveal xref-bibr">429</a></sup>

![Cardiovascular risk in patients with peripheral arterial disease.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f8.jpeg?Expires=1728479088&Signature=fYZRWPvdDuNZrpX8RpAWP9fFnaQbjGGETVdUqT6glsnMbFCf2WE2T9S8Gf6BmHl46vi-yjej5XJ8X10vkQNtLZ5GpZVH4EC-BPx7YJDgGVk1wT4M4gJeGzpLbM8CNDCLQ22skOsuIv2S9vB0QFzAlfTfIQG3qOEqejCEuuO5I~51Vauh7HSUqMU0Np1mh6Gw8HWCNw8lCv~k2CGkg-UaQpaMfJIUw04KHBcaOmXRm9kJqySzgWQzgSgA3l2Y~15CPX0UyNFjGlu-X24u1NKoF27D6xplAiAFGKq48hDAX-NV1RgR8fQOdeMNbYV90hY2GHezy0Iw9yoBwPPAlj9nVw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 8

Cardiovascular risk in patients with peripheral arterial disease.

CV, cardiovascular; MACE, major adverse cardiac event; MALE, major adverse limb event; PAD, peripheral arterial disease.

[Open in new tab](https://academic.oup.com/view-large/figure/479845980/ehae179f8.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f8.jpeg?Expires=1728479088&Signature=LueBLRCMXUdXsjbra4KuHb1mNIkIx0SDAo9q1pP-qP-KUpia4Ph-OTVfujCD9HB2OrXxxlE88ccq5JnfJVOuySxU1vVxEAFvUXiaMEHZtDCHsblO7TDvf~3i-qgoyCGgt-nxqmD-nBZAQM6PGNWWmQWWYjejwEL0S7jU~-VM2iz3jiDqItAniwDdfEXNgw1h8jmeDhAHaxj2-UwDhGZQ1wyijgSg6Xnkag0qMEdqycfVLA1~klfNWgrrIKTYSgFch8kU5LpbpsP60~XuquV~ThzaulCF2e9aq1JS-LzWzsq1v~PXctjvQGpjCSveu5kd3Gg8q-u4LrONyMU2g2ZcwQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479845980&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Prevention of MALE is crucial, and the risk of MACE/MALE increases with the increased number of arterial beds involved.

###### Diagnostic tests

Vascular assessment: ABI, TBI, TcPO<sub>2</sub> measurements (refer to_Section [5.3](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#ehae179-s4.3)_)

Ankle–brachial index is the proposed initial non-invasive diagnostic test to confirm lower-limb decreased perfusion status<sup><a href="javascript:;" reveal-id="ehae179-B90" data-open="ehae179-B90" class="link link-ref link-reveal xref-bibr">90</a>,<a href="javascript:;" reveal-id="ehae179-B436" data-open="ehae179-B436" class="link link-ref link-reveal xref-bibr">436</a>,<a href="javascript:;" reveal-id="ehae179-B437" data-open="ehae179-B437" class="link link-ref link-reveal xref-bibr">437</a></sup> and needs to be reported separately for each leg (see Recommendation Table 2). An ABI ≤0.90 confirms PAD diagnosis.<sup><a href="javascript:;" reveal-id="ehae179-B90" data-open="ehae179-B90" class="link link-ref link-reveal xref-bibr">90</a>,<a href="javascript:;" reveal-id="ehae179-B436" data-open="ehae179-B436" class="link link-ref link-reveal xref-bibr">436</a>,<a href="javascript:;" reveal-id="ehae179-B437" data-open="ehae179-B437" class="link link-ref link-reveal xref-bibr">437</a></sup> In cases of an ABI >0.90 and clinical suspicion of PAD, post-exercise ABI measurements should be considered, along with imaging studies (preferably by treadmill). A post-exercise ABI decrease of >20% may serve as a PAD diagnostic criterion.<sup><a href="javascript:;" reveal-id="ehae179-B438" data-open="ehae179-B438" class="link link-ref link-reveal xref-bibr">438</a>,<a href="javascript:;" reveal-id="ehae179-B439" data-open="ehae179-B439" class="link link-ref link-reveal xref-bibr">439</a></sup>

In cases of abnormally high ABI values (ABI >1.4; see Recommendation Table 2) and patients with CLTI and diabetes<sup><a href="javascript:;" reveal-id="ehae179-B440" data-open="ehae179-B440" class="link link-ref link-reveal xref-bibr">440</a></sup> (see Recommendation Table 11), TP measurements, the calculation of TBI and TcPO<sub>2</sub>, as well as pulse volume recordings or analysis of distal arterial Doppler waveforms, should be considered,<sup><a href="javascript:;" reveal-id="ehae179-B90" data-open="ehae179-B90" class="link link-ref link-reveal xref-bibr">90</a>,<a href="javascript:;" reveal-id="ehae179-B91" data-open="ehae179-B91" class="link link-ref link-reveal xref-bibr">91</a>,<a href="javascript:;" reveal-id="ehae179-B132" data-open="ehae179-B132" class="link link-ref link-reveal xref-bibr">132</a>,<a href="javascript:;" reveal-id="ehae179-B133" data-open="ehae179-B133" class="link link-ref link-reveal xref-bibr">133</a>,<a href="javascript:;" reveal-id="ehae179-B441" data-open="ehae179-B441" class="link link-ref link-reveal xref-bibr">441</a></sup> and ABI can be estimated from distal Doppler waveforms independent of diabetes and media sclerosis.<sup><a href="javascript:;" reveal-id="ehae179-B124" data-open="ehae179-B124" class="link link-ref link-reveal xref-bibr">124</a></sup>

Apart from the assessment of limb perfusion, ABI serves as a surrogate marker for CV and all-cause mortality.<sup><a href="javascript:;" reveal-id="ehae179-B88" data-open="ehae179-B88" class="link link-ref link-reveal xref-bibr">88</a>,<a href="javascript:;" reveal-id="ehae179-B442" data-open="ehae179-B442" class="link link-ref link-reveal xref-bibr">442</a>,<a href="javascript:;" reveal-id="ehae179-B443" data-open="ehae179-B443" class="link link-ref link-reveal xref-bibr">443</a></sup> A diagnostic PAD algorithm is depicted in _[Figure 9](javascript:;)_.

![Diagnostic algorithm for peripheral arterial disease.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f9.jpeg?Expires=1728479088&Signature=xmrffBK5fd1nf7Ai9B2Dlmj5IA2AcuQdmUJvoidnX5GGyhgaKszLSmPacx767QbXafcwRSBbs7xi59eFNR8h8v8Xox5fYw99u-BacDzMEbCqyPP8Gruy5e2aKQe7YuZjbT4HnqWVlCfQqp0~paJlBkah0Xz7sV3zNo9jImZTWgUN1R4H-txzh-04DODj6dU-xyUubLX9XzMsbxTzmNONLUudCy-YVCtO0ik6rqeJ819F-7yBvnA9sfm9annHgORxQmHpBvDZhH062op75x1lp8cCwSeN3YmxA8sjBqYAEVuIEmQRJS4bGFv9cPIYdkXQ3M~PN2Oqwp8k-i~lLy6Zww__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 9

Diagnostic algorithm for peripheral arterial disease.

6MWT, six-minute walk test; ABI, ankle–brachial index; AP, ankle pressure; DUS, duplex ultrasound; PAD, peripheral arterial disease; SPPB, short physical performance battery; TcPO<sub>2</sub>, transcutaneous oxygen pressure; TP, toe pressure; WIfI, Wound, Ischaemia, and foot Infection classification.

[Open in new tab](https://academic.oup.com/view-large/figure/479845987/ehae179f9.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f9.jpeg?Expires=1728479088&Signature=kFXHd1BggK6wNInOYuw1khUTLxJ-hTYIOcZqybxXGz1pLa6qbws-FqDYgQfMi6C82d0YQ2Wqi0sxpaUfVLwB1tUMq5MSYlxdqQTDbydZjtwvnG76tyE4UTwXn8tW6SuOr0HPUHXClwrSKXickgKZgw~skPLVoCwEajaUNAPoC3KqCOynhXukJvfZE9EWPAUlaQbQmsdBKUdSApeTih9~ITERTBCdX-mIwXIIPRnkoC56R5F~c4CkuEM1Ho5FhgSOb6HLpmrKflE2tRdeXXrn-HkXJll5qzhThbhYsS0ot1mKdjqjnCw2Ve7gapvr8rVMUa8SLyz6ZmQswtbP4UngUA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479845987&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Walking impairment questionnaires, assessment of functional and walking capacity

Determining walking impairment, capacity, and functional status in all patients with PAD is mandatory (refer to _Section [5.2](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#ehae179-s4.2)_).

Assessment of amputation risk

In patients with PAD and chronic lower-limb wounds (diabetic foot ulcer, non-healing lower-limb ulceration, or gangrene of ≥2 weeks of duration), even without haemodynamic parameters of critical limb perfusion, the additional presence of comorbidities such as diabetes and/or wound infection may contribute to an increased risk of amputation. The WIfI classification system takes the patients’ limb perfusion, wound size, and the extent of foot infection into account to determine the amputation risk (_[Table 8](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B417" data-open="ehae179-B417" class="link link-ref link-reveal xref-bibr">417</a>,<a href="javascript:;" reveal-id="ehae179-B444 ehae179-B445 ehae179-B446" data-open="ehae179-B444 ehae179-B445 ehae179-B446" class="link link-ref link-reveal xref-bibr">444–446</a></sup>

Table 8

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479845992)

Assessment of the risk of amputation: the Wound, Ischaemia, and foot Infection classification

![Assessment of the risk of amputation: the Wound, Ischaemia, and foot Infection classification](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179t8.jpeg?Expires=1728479088&Signature=IAA7QcmCXwbjarNBFT9U0XG-u-maCyMTL1i6InZDGQAGTWH~USUF~K9IZ3QMSw0QROAtCk51IAos18GhTaKJtaeK~UHAbM-TR~NUPCaKqigygrm6EqUDUzLlIPhDzNlXpaTcNED46XXYSPITGqlXK1r3qLkP~S7DppgYpMFpCvDSF6rtiRiqrB5MAX45u5e-MK7Q7k9xIIo~-UpkY2CmIoDQqh1xV4iprOzGdp0xAmWQoiwJ0B9wI27G31PPDPkMaunaHDEOVMXesgdGyrzJbGlbk9DXl2imW3P5fkdwpqtaPjFsoVwnPysL2Uldv6c27YeNkJuG0fjlC1SjXwx6Lg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

###### Imaging methods

Duplex ultrasound is recommended as the first-line imaging method for PAD screening and diagnosis. CTA and/or MRA are recommended as adjuvant imaging. For details refer to [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179_supplementary_data.pdf?Expires=1728479088&Signature=jsMN1psOaEf3KpW8UiQOwnEDCNM0eDJ9FhgPq~GNXqLItMAEdFx6foOGTBTeCpJhrfS5f9C1WsT6JBJ-OF2VSZCY4hMS9gJl7FbAOywEXjZ7FkQ8D8eMHICtPb1wzBA3uZZtBKMZczJqU~L965QcGSWu4bY5onpcoRMSzjgnNpdPf9L4pLKg-a0ahzhjNRwGHt5NoJ7ErFgx3duCbchEi0MsV0cDIkqzsUCeNEtwo8kpBYcJAps4DqCXaYZS5CPCAIpG4RbHZce70W~XP9IUuUZszMeWmEvwL5IF-0Kt0kkQwtSCyF6kopinSbFrVRYLZmYxxNRPbjwJpR0g1P88ZQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Section 1.4](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179_supplementary_data.pdf?Expires=1728479088&Signature=jsMN1psOaEf3KpW8UiQOwnEDCNM0eDJ9FhgPq~GNXqLItMAEdFx6foOGTBTeCpJhrfS5f9C1WsT6JBJ-OF2VSZCY4hMS9gJl7FbAOywEXjZ7FkQ8D8eMHICtPb1wzBA3uZZtBKMZczJqU~L965QcGSWu4bY5onpcoRMSzjgnNpdPf9L4pLKg-a0ahzhjNRwGHt5NoJ7ErFgx3duCbchEi0MsV0cDIkqzsUCeNEtwo8kpBYcJAps4DqCXaYZS5CPCAIpG4RbHZce70W~XP9IUuUZszMeWmEvwL5IF-0Kt0kkQwtSCyF6kopinSbFrVRYLZmYxxNRPbjwJpR0g1P88ZQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_.

Recommendation Table 11

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479845995)

Recommendations for diagnostic tests in patients with peripheral arterial disease and diabetes, renal failure, and wounds

![Recommendations for diagnostic tests in patients with peripheral arterial disease and diabetes, renal failure, and wounds](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt11.jpeg?Expires=1728479088&Signature=rZ-J5Q3obo8OM982EYb~g5UgHQl~7W-yJ6AECkiOgExuI16zP7XrD6OMBne5Squ0S-D30MF5vybuAaZsqcdIeFFflJignLZt84wHn3VjoVJuyubZt0pRqmCFoB2YSzhmL5m29ssbLE1IgcVjbbJMCDa3iH1sMhMvleg8iKvvg8goOkABQndVb~vuJ7-YvTmcCXWz2wihkk6IwihchOCg2cHwQ77ezmjT-QhvLxRwMbUFZ8m0E5qQZoJVCDC380p2Oj1NEZbGi~JS2UXQ-65HsS~7gV8ije1QPJGHd1nAt-mlU-ULBvIl6Youih1EbqeFDODPy1Li2wWdybCTAaXQkg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 12

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479845996)

Recommendations for imaging in patients with peripheral arterial disease

![Recommendations for imaging in patients with peripheral arterial disease](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt12.jpeg?Expires=1728479088&Signature=AkWdKzIgoAxXPK~xmAhO8l7~mg83v19g8EAQi73YkTaktUDcT~F-cFmt1~PUWbRYn6lQzaygp~CB27I-P8Jx9Upt4Knit-twZzwL7IhphCDnDwf~DIygzwD~JEibCK-pzWYlPd~cawpQCRrPYGsVujOkgcsDrzoo9Uj686Yy~NgM0xDPRUp3jtvbE23~jnv3TNtMusrUY1IVJzfjtb0MwqyRtOwcJO4Or3Z3OreCwrp1MpZpCZE0R1YIDAD~ETZsG7vSN2VpkyuhzRycqF720p1N3GgNaBPAMLpO71hbv0-meRT7-VcgHqpp12uSaSCcXMTjrXRUuit9uTcNX3fA9A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

##### 8.1.1.2. Medical treatment

Patients with PAD should receive comprehensive OMT, including supervised exercise training and lifestyle modification (_[Figures 10](javascript:;)–[12](javascript:;)_). A personalized programme of guidelines-guided pharmacotherapy to reduce MACE and MALE should be prescribed and tightly followed.

![Optimal medical treatment in patients with peripheral arterial disease.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f10.jpeg?Expires=1728479088&Signature=A4AIl~SHu5t9FFIidLyJL7DPONGcUBk0Y~04gm4Hp840d5mcfKDtv15IeYFEZ1StkMA~1DNuigJFP1TqcDO~Y5fG~B3bmQGYyxFccjTkbueVSk7N~VRM75QVGON6upngWIlU5VL3g9ZWKZMQfzF5iMK5xwsGeV~wWtYEDPWsSxBbTduXg7zElA1BQVIpaO-dXgJimBUOfBNtPD-Z3VLqLRf~uoCBgDGi46JMBvopIHXqH5DyslSWqioepNNrzf8qTjxG1qr0njlnBa6YZydg-nJKyokKqIS6fgmiWF5~CTs29m6B4EurDmMrSs0cTty6IXymHxF-Cidazc6eQOrHDg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 10

Optimal medical treatment in patients with peripheral arterial disease.

CV, cardiovascular.

[Open in new tab](https://academic.oup.com/view-large/figure/479845999/ehae179f10.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f10.jpeg?Expires=1728479088&Signature=ZH33LA6AygV27qp8KOF94CXEATM0w4iKIaSg99GbUsjdsOpuMLAE1UuhZXJxigTPUs3oqzAb5xyHGzdmO7SIl-r4EIe6GMvoDu4uQQ8OycDXA8k-806R9Wv05xckP6JEjYBjR3rKwmaezclEzFpevob2GkaadXm03PE997eTxXqwbiWy9Pnk67dO9A557k-Hen3Q0duO~3ZrZ0poGpjdXEOkDTyFN-1C1UZ6j8C7vllpzkOw1ZM9TWeeG4Zv87vq4~T-ag~rBlqLZm4YMxT~WiY7mu4eAWdg0cWsyCCTVYHikUMQU2XXryjrXVn1TvO2hV54RaoVIKLR99Qsx~xuuw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479845999&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

![Treatment algorithm in peripheral arterial disease without wounds.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f11.jpeg?Expires=1728479088&Signature=1Igk0yIT5V5dFAK73GDlqi3ugzfkvYGK3FulSISmdcL5f3pO2l~q7v5Mkfv6XCD5-vqfJKcZS22oOH81nKArpFwxcxm3igRA1S-m2NVVsm7mV2qnU7za~bNlSBt5WmYytNwPaN0ozh0VfHzzFud0TaS4O9nsyOajGF1L948P6SOVzHadzuZh~GEryUebjUNtFgVCbn806pEzD-lINSf~UEX7VnMFv5ejPOLC0WNyKPvOH4RZnmRbsE6~VAHY54PuzuKfZopcNa2JR7muHeTxqxH4kb1u3SvnGe7NORzyefN6VTAtuluC0e2OvsQ4S4gz9CoElhCCuDjy-Rp0VwPJfQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 11

Treatment algorithm in peripheral arterial disease without wounds.

CLTI, chronic limb-threatening ischaemia; PAD, peripheral arterial disease.

[Open in new tab](https://academic.oup.com/view-large/figure/479846000/ehae179f11.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f11.jpeg?Expires=1728479088&Signature=dzHplto4ItMrZL53QehLu~sn45rW8ap55hgUQTNZMn5vKWoimkQDtb7OXQzUz3Wj-fiEKt4Lyh6v87-X11yWqgqRWRkYulwnapIPZLTSOenhUGzCi7qRWNVP3XjTtjSJicslHx9xltfC-rrYN8ptP4rhJV9zfXUvqrk~ngG2NRo0wisg5nBC0aHjkG-CaKjtJ1rH9Zbe2paQuSsBn368QcV7u0Ik8Fsq40ZQ42AVixqHqL6sKLtldSr3iDt11vB5mDeIktpJ55zxlRvDIheb2QV5cozRsCX0SeHQNz-Js5RltkqaOCvNIsBdgv1NV5I~yqUuJsQ6oq9DJBDLimcEUA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846000&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

![Treatment algorithm in peripheral arterial disease with wounds.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f12.jpeg?Expires=1728479088&Signature=buTGcCSehv7wF8QidzgeKVZZUR60Tx7DWzAEExl-q-Jgvj8plOyA0j73eTNY6SrI64Zrx2uKQzQRrGHS-MFfW1f1-jL-p4tybwroiI-jC2U9vM58ItwCvviNNCAcDLKW03HJ-X~Cf3DJED~pmEe9~G-5HGsDMQE9iTCboiSRrlSyAQYOlIhKLB8hYTcqQ7IF50o1he4~J~grDw50zYgg~jVHvJcDYRY2yFiXA2IH5eTfaQk1p9zn2vvDxDoJCWixPOptEZqYQL0GiK4yH4JiFb8nNRxaH2piqyT4j2vpj3-HwDydMfNoMfuala8SQbrpdZ0sAWJpzUlhq1AxcqCF3Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 12

Treatment algorithm in peripheral arterial disease with wounds.

CLTI, chronic limb-threatening ischaemia; PAD, peripheral arterial disease.

[Open in new tab](https://academic.oup.com/view-large/figure/479846001/ehae179f12.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f12.jpeg?Expires=1728479088&Signature=ggLuuAJDswbs7cOd1Ok~XtKvNusxAfmkeHvuVfU7790y92vwo6YDOQPKyy4Pj3BflcTuSHsmvXjDjjp2~KzC2huObEJXRSIh5v~RODTdFnbFeOHaATMf7J~roWdx36Xk0g7mHTtZqJzrAA2O6cecYiN-uqLn7BPHS3aCR0vYO4tQ1hIOppzGpCHH6z99J9T9xLcJslddrSINh9LPsHrusLDKgg73bjVYg8GCJqJuXCm47CmqG9mhiyj8yaaUnJoU2V8LgDlcxDphaPUYf-yfj4wb2aKFewNxT5RPrvgvkwkrpovEuSosGnuEvimgAO-7uBlkZzFAdDc4bvELdicsZg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846001&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Patients with PAD are less likely to receive OMT than patients with CAD.<sup><a href="javascript:;" reveal-id="ehae179-B450 ehae179-B451 ehae179-B452" data-open="ehae179-B450 ehae179-B451 ehae179-B452" class="link link-ref link-reveal xref-bibr">450–452</a></sup> For general lifestyle and pharmacological therapy see _Section [7](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#ehae179-s6)_.

###### Exercise therapy

A consensus document on exercise and PAD has been published recently.<sup><a href="javascript:;" reveal-id="ehae179-B62" data-open="ehae179-B62" class="link link-ref link-reveal xref-bibr">62</a></sup> Symptomatic patients should be medically screened before any supervised exercise training (SET) programme initiation.<sup><a href="javascript:;" reveal-id="ehae179-B37" data-open="ehae179-B37" class="link link-ref link-reveal xref-bibr">37</a>,<a href="javascript:;" reveal-id="ehae179-B62" data-open="ehae179-B62" class="link link-ref link-reveal xref-bibr">62</a></sup> In patients with symptomatic PAD, SET is safe and improves treadmill PFWD, MWD, functional walking as measured by six-minute walking distance (6MWD), HRQoL, and cardiorespiratory fitness (_[Figure 13](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B294" data-open="ehae179-B294" class="link link-ref link-reveal xref-bibr">294</a>,<a href="javascript:;" reveal-id="ehae179-B453 ehae179-B454 ehae179-B455 ehae179-B456 ehae179-B457 ehae179-B458 ehae179-B459 ehae179-B460 ehae179-B461 ehae179-B462 ehae179-B463" data-open="ehae179-B453 ehae179-B454 ehae179-B455 ehae179-B456 ehae179-B457 ehae179-B458 ehae179-B459 ehae179-B460 ehae179-B461 ehae179-B462 ehae179-B463" class="link link-ref link-reveal xref-bibr">453–463</a></sup> Exercise has not been found to improve ABI.<sup><a href="javascript:;" reveal-id="ehae179-B457" data-open="ehae179-B457" class="link link-ref link-reveal xref-bibr">457</a>,<a href="javascript:;" reveal-id="ehae179-B458" data-open="ehae179-B458" class="link link-ref link-reveal xref-bibr">458</a></sup> Ideally, SET should be co-ordinated by vascular physicians, and training sessions supervised by clinical exercise physiologists or physiotherapists.<sup><a href="javascript:;" reveal-id="ehae179-B62" data-open="ehae179-B62" class="link link-ref link-reveal xref-bibr">62</a></sup> In Europe, SET is usually underused.<sup><a href="javascript:;" reveal-id="ehae179-B464" data-open="ehae179-B464" class="link link-ref link-reveal xref-bibr">464</a>,<a href="javascript:;" reveal-id="ehae179-B465" data-open="ehae179-B465" class="link link-ref link-reveal xref-bibr">465</a></sup>

![Exercise training characteristics and benefits in patients with peripheral arterial disease.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f13.jpeg?Expires=1728479088&Signature=BZ3yC3Dxz-PrIaDdvdH6GTGpGTCkUJkUOE8gu4rSMrxtBm5J10jwqRjrY5wq9TIhq1RyZh1n3dkoH5O1yCA2kDm3YhlDEpHpHLNo3Joxc91-q1W8Ru4UE9OtW6tVYUSFJoYNImu1ZRQb7gsVg~2U~LQUDI8VhSCMxHUqLams8aGuEw5n7UzPhlakKfgM2Sv95-w38gBz-tVwk~I6Vic7wycXkVMACfO37nqLnMBfCBBCt3rZUEhvMNj8WMCFAfcZOKvNuUlAhhlizdwcV~F0Bf5~bYUCpmbdbwEvShdsFXR0XtCC9ItlGmonkJ~UXsLLf3C7QpsJnp6Uk29NmvuuFw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 13

Exercise training characteristics and benefits in patients with peripheral arterial disease.

CVR, cardiovascular risk.

[Open in new tab](https://academic.oup.com/view-large/figure/479846005/ehae179f13.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f13.jpeg?Expires=1728479088&Signature=y9XSRjdpGVeXMCr45BJX0NJyf7aW5fituxPm8Bhz~xpsIxxiXHpg2G22kuokZVwTRqh5GjrXdz-26rCAb33vl1TCLWQNTllM3rgzSTB7oJ5cHHUJ6Slh97n0FeRrjK4yJ9W22O2Q4HErNgn4aiv-gQtrFRyZEPlPo8GYIYV3odBhcptMn8LnSemUm~hyIxoFq8Zg-iBdzLg~spei-ChoDAcvGAVv4m-NlsMlaiLt~qVqU8GSOoiQntCJmUEvD4~eXKzgoKy~ez-2Y0bONWZsXEHATKCtw67bx0y6rMHp9NXicXZbE-vHmxGYL~6PhILfPgBnwH8x0bgCYqng058acg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846005&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

When SET is not available, home-based exercise training (HBET) should be proposed (_[Figure 13](javascript:;)_), although it is inferior with regard to improving walking performance.<sup><a href="javascript:;" reveal-id="ehae179-B466 ehae179-B467 ehae179-B468 ehae179-B469" data-open="ehae179-B466 ehae179-B467 ehae179-B468 ehae179-B469" class="link link-ref link-reveal xref-bibr">466–469</a></sup> HBET is safe and its inferiority is reduced if monitoring is implemented.<sup><a href="javascript:;" reveal-id="ehae179-B469" data-open="ehae179-B469" class="link link-ref link-reveal xref-bibr">469</a>,<a href="javascript:;" reveal-id="ehae179-B470" data-open="ehae179-B470" class="link link-ref link-reveal xref-bibr">470</a></sup> Compared with no exercise, HBET improves walking performance.<sup><a href="javascript:;" reveal-id="ehae179-B471" data-open="ehae179-B471" class="link link-ref link-reveal xref-bibr">471</a></sup> SET training frequency should be at least three times per week, for 30–60 min, and the programme last for at least 12 weeks.<sup><a href="javascript:;" reveal-id="ehae179-B37" data-open="ehae179-B37" class="link link-ref link-reveal xref-bibr">37</a>,<a href="javascript:;" reveal-id="ehae179-B58" data-open="ehae179-B58" class="link link-ref link-reveal xref-bibr">58</a>,<a href="javascript:;" reveal-id="ehae179-B59" data-open="ehae179-B59" class="link link-ref link-reveal xref-bibr">59</a>,<a href="javascript:;" reveal-id="ehae179-B454" data-open="ehae179-B454" class="link link-ref link-reveal xref-bibr">454</a>,<a href="javascript:;" reveal-id="ehae179-B472" data-open="ehae179-B472" class="link link-ref link-reveal xref-bibr">472</a>,<a href="javascript:;" reveal-id="ehae179-B473" data-open="ehae179-B473" class="link link-ref link-reveal xref-bibr">473</a></sup> Patients should exercise to moderate-severe claudication pain to improve walking performance.<sup><a href="javascript:;" reveal-id="ehae179-B37" data-open="ehae179-B37" class="link link-ref link-reveal xref-bibr">37</a>,<a href="javascript:;" reveal-id="ehae179-B294" data-open="ehae179-B294" class="link link-ref link-reveal xref-bibr">294</a>,<a href="javascript:;" reveal-id="ehae179-B453" data-open="ehae179-B453" class="link link-ref link-reveal xref-bibr">453</a>,<a href="javascript:;" reveal-id="ehae179-B454" data-open="ehae179-B454" class="link link-ref link-reveal xref-bibr">454</a>,<a href="javascript:;" reveal-id="ehae179-B456 ehae179-B457 ehae179-B458" data-open="ehae179-B456 ehae179-B457 ehae179-B458" class="link link-ref link-reveal xref-bibr">456–458</a>,<a href="javascript:;" reveal-id="ehae179-B474" data-open="ehae179-B474" class="link link-ref link-reveal xref-bibr">474</a></sup> However, prescribing high-pain exercise may hinder programme uptake and adherence. Additionally, it has been reported that improvements in walking performance may be obtained with less severe claudication pain.<sup><a href="javascript:;" reveal-id="ehae179-B455" data-open="ehae179-B455" class="link link-ref link-reveal xref-bibr">455</a>,<a href="javascript:;" reveal-id="ehae179-B460" data-open="ehae179-B460" class="link link-ref link-reveal xref-bibr">460</a></sup> Therefore, a flexible approach is recommended, considering the patient’s needs and preferences.<sup><a href="javascript:;" reveal-id="ehae179-B62" data-open="ehae179-B62" class="link link-ref link-reveal xref-bibr">62</a></sup> Alternative training modalities, such as strength training, arm cranking, cycling, and combinations of different modes, have proven effective in improving walking performance compared with traditional walking training, with limited evidence for HRQoL.<sup><a href="javascript:;" reveal-id="ehae179-B475" data-open="ehae179-B475" class="link link-ref link-reveal xref-bibr">475</a></sup> However, this evidence is low due to small sample size and risk of bias.<sup><a href="javascript:;" reveal-id="ehae179-B475" data-open="ehae179-B475" class="link link-ref link-reveal xref-bibr">475</a></sup> Vigorous intensity exercise training (77%–95% of maximal heart rate or 14–17 on the rate of perceived exertion on Borg’s scale) has been shown to induce the best walking and cardiorespiratory fitness improvements.<sup><a href="javascript:;" reveal-id="ehae179-B294" data-open="ehae179-B294" class="link link-ref link-reveal xref-bibr">294</a>,<a href="javascript:;" reveal-id="ehae179-B457" data-open="ehae179-B457" class="link link-ref link-reveal xref-bibr">457</a></sup> Training programmes should begin at low-to-moderate intensity, gradually advancing to vigorous exercise if well tolerated.<sup><a href="javascript:;" reveal-id="ehae179-B62" data-open="ehae179-B62" class="link link-ref link-reveal xref-bibr">62</a></sup> This approach assesses patient response and minimizes complications.<sup><a href="javascript:;" reveal-id="ehae179-B37" data-open="ehae179-B37" class="link link-ref link-reveal xref-bibr">37</a>,<a href="javascript:;" reveal-id="ehae179-B62" data-open="ehae179-B62" class="link link-ref link-reveal xref-bibr">62</a></sup>

Data on the efficacy of exercise therapy in women compared with men are scarce. Women may respond less well than men,<sup><a href="javascript:;" reveal-id="ehae179-B476" data-open="ehae179-B476" class="link link-ref link-reveal xref-bibr">476</a>,<a href="javascript:;" reveal-id="ehae179-B477" data-open="ehae179-B477" class="link link-ref link-reveal xref-bibr">477</a></sup> although discrepancies among studies exist.<sup><a href="javascript:;" reveal-id="ehae179-B478 ehae179-B479 ehae179-B480 ehae179-B481" data-open="ehae179-B478 ehae179-B479 ehae179-B480 ehae179-B481" class="link link-ref link-reveal xref-bibr">478–481</a></sup>

SET combined with endovascular revascularization significantly improves walking performance, HRQoL, and reduces future revascularization.<sup><a href="javascript:;" reveal-id="ehae179-B482" data-open="ehae179-B482" class="link link-ref link-reveal xref-bibr">482</a>,<a href="javascript:;" reveal-id="ehae179-B483" data-open="ehae179-B483" class="link link-ref link-reveal xref-bibr">483</a></sup>

An exercise therapy algorithm in PAD has been recently described.<sup><a href="javascript:;" reveal-id="ehae179-B62" data-open="ehae179-B62" class="link link-ref link-reveal xref-bibr">62</a></sup>

Recommendation Table 13

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846010)

Recommendations for exercise therapy in patients with peripheral arterial disease (see also Evidence Table 5)

![Recommendations for exercise therapy in patients with peripheral arterial disease (see also Evidence Table 5)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt13.jpeg?Expires=1728479088&Signature=FwjfQYMH~cN7bGkTO1LJ2vr03dp58zN90wKkXmXg-lf5pz7YKAGrko4JJploLsXkc51KsjUTARjVUSSElCYDILhZi8RPNvQ-WI~29rBd4H5piAoA6rdk3IgHqIJKOdKfHqPsQRSIa7dFpIg4JWlnp~XxQhoDl59pUCFHSRN5E00isrtLRtR3eZIrPRFpwrQMxxUGE252D36IK01Po-J0koegU21NDtvOEI9cyhHl7kFD7rofEIRuVKvDlBkjxKvF9AJN1ufy7jQcvEFzjLZRsmmDQR6KUKFEp8KczIk2bdKKwZZ6Uh6f8G0qizswznCebzBAKInJt3tPpDsruEIpTg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

###### Pharmacological treatment

Antithrombotic therapy

_Asymptomatic PAD_

Although patients with PAD are at very high CV risk,<sup><a href="javascript:;" reveal-id="ehae179-B404" data-open="ehae179-B404" class="link link-ref link-reveal xref-bibr">404</a>,<a href="javascript:;" reveal-id="ehae179-B484" data-open="ehae179-B484" class="link link-ref link-reveal xref-bibr">484</a></sup> a trial evaluating the effect of antiplatelet agents in asymptomatic patients with an ABI ≤0.95 did not show an effect on MACE or revascularization.<sup><a href="javascript:;" reveal-id="ehae179-B485" data-open="ehae179-B485" class="link link-ref link-reveal xref-bibr">485</a></sup> Another trial on patients with an ABI ≤0.99 and diabetes also failed to show any difference in MACE or amputation.<sup><a href="javascript:;" reveal-id="ehae179-B486" data-open="ehae179-B486" class="link link-ref link-reveal xref-bibr">486</a></sup> However, these data were not powered to analyse subgroups and do not rule out the possibility that aspirin could provide a benefit in subjects at increased risk of CV events. In a randomized trial evaluating aspirin in the prevention of cancer and CVD in patients with diabetes without known arterial disease, MACE occurred in a significantly lower percentage of participants in the aspirin group than in the placebo group, with more major bleeding events in the aspirin group.<sup><a href="javascript:;" reveal-id="ehae179-B487" data-open="ehae179-B487" class="link link-ref link-reveal xref-bibr">487</a></sup> The effect of antithrombotics in patients with higher-risk PAD (i.e. ABI <0.90 and other CV risk factors) has not been evaluated in randomized trials. Antithrombotic therapy should not be systematically administered in patients with asymptomatic PAD.

_Symptomatic PAD_

In patients with symptomatic PAD, antithrombotic therapy improves CV prognosis.<sup><a href="javascript:;" reveal-id="ehae179-B488 ehae179-B489 ehae179-B490 ehae179-B491 ehae179-B492" data-open="ehae179-B488 ehae179-B489 ehae179-B490 ehae179-B491 ehae179-B492" class="link link-ref link-reveal xref-bibr">488–492</a></sup> Clopidogrel may have a modest advantage over aspirin (_[Figure 14](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B493" data-open="ehae179-B493" class="link link-ref link-reveal xref-bibr">493</a>,<a href="javascript:;" reveal-id="ehae179-B494" data-open="ehae179-B494" class="link link-ref link-reveal xref-bibr">494</a></sup> In the Examining Use of tiCagreLor In peripheral artery Disease (EUCLID) trial, single antiplatelet therapy (SAPT) with ticagrelor showed no superior benefit in the reduction of MACE or major bleeding compared with clopidogrel.<sup><a href="javascript:;" reveal-id="ehae179-B495 ehae179-B496 ehae179-B497" data-open="ehae179-B495 ehae179-B496 ehae179-B497" class="link link-ref link-reveal xref-bibr">495–497</a></sup>

![Long-term antithrombotic therapy in patients with symptomatic peripheral arterial disease.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f14.jpeg?Expires=1728479088&Signature=KiDVKpAysb0YVHBz5k8nzxNqN3VXOPxCn8Jh~oeAVm~-JtSMCzAtXzYi4jUi6JN4bGTTV37-jEZ7i58MBkmt~nTo6NBwZKbeuKVLofoqfqNal2k7lhRlApWLnnHT3cc2sLsrFMj97lLCZfIh7V1abDiWoIPLemS~bsWl68vT71lwhoa8QKmz1uc8fo5mjSqx~9iZIDRulC42wB6bZZqVrAxlhxzxP4JoUy6UkmQI23Fpgc7GTEzRURAJWCD233sCKGgqJYGstb7BcIJ-3dRVVOL135du-fI9Ec-FLzuVSeyolyXNxJLnC0uujT4qSIUb-~vDv1Jc3ryfoH4EmEZLnQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 14

Long-term antithrombotic therapy in patients with symptomatic peripheral arterial disease.

b.i.d., twice daily; OAC, oral anticoagulant; PAD, peripheral arterial disease; ASA, aspirin <sup>a</sup>High-risk limb presentation: previous amputation, chronic limb-threatening ischaemia, previous revascularization, high-risk comorbidities: heart failure, diabetes, vascular disease in two or more vascular beds, moderate kidney dysfunction; eGFR <60 mL/min/1.73 m<sup>2</sup>.

[Open in new tab](https://academic.oup.com/view-large/figure/479846017/ehae179f14.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f14.jpeg?Expires=1728479088&Signature=TxkQdKXbQ9Hm3ikJqYBhEPvV9k2H1azYw97dJ3bVn09p~mZK7qb~CoYOU4nq6qFacsbEC37VZj-XJFq75O2fJYUiP~OURQdviYmwlw4grDuzdotUe0j7TiQ5ldb2JRtRddWZRYKKSlHy4Y--yVWYj6kKXdoaWHtUhvg9~dooqT27ky~L2iFD94fIxjy3glh28hYT5~u-~zf80tznaOjzw-Fn9Rl9c1-BsIa7EWN9LCVpZ7WP84e2XUqj5OvXKlGq9H0-JCQCgyOHt1CWcWhzhb6c1VG80E2akEoxfKI9qWgw1s8UA8Y2bA6gJmeDVXyyJFmlwAtqazeYe8nE91jVVw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846017&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Dual antithrombotic therapy with aspirin and vascular-dose rivaroxaban (2.5 mg b.i.d.) in patients with PAD is more effective than aspirin alone, reducing MACE, MALE, and preventing acute limb ischaemia (ALI), but with increased major bleeding risk.<sup><a href="javascript:;" reveal-id="ehae179-B429" data-open="ehae179-B429" class="link link-ref link-reveal xref-bibr">429</a>,<a href="javascript:;" reveal-id="ehae179-B430" data-open="ehae179-B430" class="link link-ref link-reveal xref-bibr">430</a>,<a href="javascript:;" reveal-id="ehae179-B498" data-open="ehae179-B498" class="link link-ref link-reveal xref-bibr">498</a>,<a href="javascript:;" reveal-id="ehae179-B499" data-open="ehae179-B499" class="link link-ref link-reveal xref-bibr">499</a></sup> Patients with high-risk limb presentation (CLTI, previous amputation, or revascularization) or high-risk comorbidities (heart failure \[HF\], diabetes, or polyvascular disease \[PVD\]) benefit the most.<sup><a href="javascript:;" reveal-id="ehae179-B498" data-open="ehae179-B498" class="link link-ref link-reveal xref-bibr">498</a></sup>

After endovascular therapy, dual antiplatelet therapy (DAPT) for 1–3 months is supported by rare randomized studies.<sup><a href="javascript:;" reveal-id="ehae179-B500" data-open="ehae179-B500" class="link link-ref link-reveal xref-bibr">500</a>,<a href="javascript:;" reveal-id="ehae179-B501" data-open="ehae179-B501" class="link link-ref link-reveal xref-bibr">501</a></sup> DAPT is not associated with reduced CV mortality or MACE,<sup><a href="javascript:;" reveal-id="ehae179-B501" data-open="ehae179-B501" class="link link-ref link-reveal xref-bibr">501</a></sup> but seems to improve patency without increasing bleeding (_[Figure 15](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B502 ehae179-B503 ehae179-B504" data-open="ehae179-B502 ehae179-B503 ehae179-B504" class="link link-ref link-reveal xref-bibr">502–504</a></sup> The combination of aspirin 100 mg and vascular-dose rivaroxaban (2.5 mg b.i.d.), started post-revascularization, showed a moderate but significantly lower incidence of MALE and MACE compared with aspirin alone,<sup><a href="javascript:;" reveal-id="ehae179-B490" data-open="ehae179-B490" class="link link-ref link-reveal xref-bibr">490</a>,<a href="javascript:;" reveal-id="ehae179-B505" data-open="ehae179-B505" class="link link-ref link-reveal xref-bibr">505</a></sup> without an increase in thrombolysis in myocardial infarction (TIMI) major bleedings, but with an increase in International Society on Thrombosis and Haemostasis (ISTH) major bleedings, especially when clopidogrel was given for >1 month.<sup><a href="javascript:;" reveal-id="ehae179-B506" data-open="ehae179-B506" class="link link-ref link-reveal xref-bibr">506</a></sup>

![Patients with chronic symptomatic PAD after endovascular revascularization.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f15.jpeg?Expires=1728479088&Signature=hNeHUOIgNT5xZv67bThXBGUBpafYIHZNt1LpzSsgH3M2tVylmg42b61tFkWPMtvA-JvD4uKOKAVA9mxqlnadCEPbaox2KNLBaxX33gJkhIPjggMfsAhPfSTxzjhLohvkUbaBIZVMx6Btn9chJErMKg0g82Iwjbu99vdjuLG9nE3Es4NKA6kbHIPYO7SyIHoSy-SEB3vz8SNnHXRc5p659R~xpm8iSRbUSBztoQwyhGKdw~brNr1OpkZTe49JZBUGrll2nemOVgrLb97dVCLHU-BoVw4hZTshXl~un97kC9QRTnUM4dfcxvNn5VqkkMldAmY8k9fzshJmQHda5A4nTg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 15

Patients with chronic symptomatic PAD after endovascular revascularization.

b.i.d., twice daily; DAPT, dual antiplatelet therapy; OAC, oral anticoagulant; PAD, peripheral arterial disease; ASA, aspirin; SAPT, single antiplatelet therapy

<sup>a</sup>High bleeding risk: dialysis or a renal impairment glomerular filtration rate <15 mL/min/1.73 m<sup>2</sup>, acute coronary syndrome <30 days, history of intracranial haemorrhage, stroke or TIA, active or clinically significant bleeding.

[Open in new tab](https://academic.oup.com/view-large/figure/479846020/ehae179f15.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f15.jpeg?Expires=1728479088&Signature=nRFwC117V25Dud13iH-UsF0eqbZGD95DRIneCJqZxMAAWDwSpzQDN05Gce25FkueXZND-pp1cHlR9Hvpvpyrh-ow0uf7s1b0GrrUkFaX24AHVvyfu6s2wA-5VbtbMLK9BDrBsVsoQpgvvBh9kyfAGMzVyPNjJqR70Y9BkHfd32UABH5fp94MAb20L9UOMIk22KRuwl6DiRpl-sNL4VXe~TknOkWnTp9XM73H-ewXQkYloKa2OvG28tGeSAwY57jJaj3qOS4STpC2JfscleSnUIh6yMeIQjWuMA17EvJ40CWvGn-drAlHk~vfGs~kqS0RTPz7K0oKs0rHF5tnsQPqmg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846020&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Patients with CLTI are at high risk of MACE and MALE.<sup><a href="javascript:;" reveal-id="ehae179-B429" data-open="ehae179-B429" class="link link-ref link-reveal xref-bibr">429</a>,<a href="javascript:;" reveal-id="ehae179-B431" data-open="ehae179-B431" class="link link-ref link-reveal xref-bibr">431</a>,<a href="javascript:;" reveal-id="ehae179-B507" data-open="ehae179-B507" class="link link-ref link-reveal xref-bibr">507</a></sup> Among CLTI patients, there is no robust evidence favouring a specific antithrombotic strategy for vein graft maintenance. DAPT with clopidogrel and aspirin is not superior to aspirin alone in below-the-knee (BTK) bypass grafts.<sup><a href="javascript:;" reveal-id="ehae179-B508 ehae179-B509 ehae179-B510" data-open="ehae179-B508 ehae179-B509 ehae179-B510" class="link link-ref link-reveal xref-bibr">508–510</a></sup> Vitamin K antagonists (VKAs) may be considered for high-risk conduits with low bleeding risk.<sup><a href="javascript:;" reveal-id="ehae179-B509" data-open="ehae179-B509" class="link link-ref link-reveal xref-bibr">509</a></sup>

Dual antiplatelet therapy could confer benefit for prosthetic conduit (occlusion, revascularization, amputation, or death), without increasing major bleeding.<sup><a href="javascript:;" reveal-id="ehae179-B510" data-open="ehae179-B510" class="link link-ref link-reveal xref-bibr">510</a></sup> VKAs with an international normalized ratio (INR) of 3–4.5 are slightly beneficial in venous conduits, but with a 1.9-fold and 1.3-fold increase in major and fatal bleedings, respectively.<sup><a href="javascript:;" reveal-id="ehae179-B509" data-open="ehae179-B509" class="link link-ref link-reveal xref-bibr">509</a></sup> A study suggested that VKAs could be associated with prolonged patency of at-risk prosthetic grafts due to poor run-off.<sup><a href="javascript:;" reveal-id="ehae179-B511" data-open="ehae179-B511" class="link link-ref link-reveal xref-bibr">511</a></sup>

In patients with another indication for OAC (such as atrial fibrillation \[AF\] or mechanic valve replacement) and PAD, anticoagulation is warranted.<sup><a href="javascript:;" reveal-id="ehae179-B512" data-open="ehae179-B512" class="link link-ref link-reveal xref-bibr">512</a></sup> Additional SAPT post-endovascular therapy should be brief.

Recommendation Table 14

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846024)

Recommendations for antithrombotic therapy in patients with peripheral arterial disease (see also Evidence Table 6)

![Recommendations for antithrombotic therapy in patients with peripheral arterial disease (see also Evidence Table 6)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt14.jpeg?Expires=1728479088&Signature=vzEo8YzfLd5RYaX9KkW~u0HhJ44FwRe4~O1jAV-eZGa80B8Rp6zzR39SIoRWM0puiYlNHCBef6g-AL77N0A9Jpx3Z-PdLMTvXV05eQKQeprU04H61~BFSTFg6NBWa3fhDyXWOJvZVGgcf2lmxzGYaVGH~9dbsF-mCe8o5gMxVIlO8ThY1NvtsJGleAigXBg2TaK9l9CRJqdZ9vZsV3Oca~ANJ9goA8XUWnbExYsiHefiycLzw1GimvQqbLbLXO5j2hN7FfcGby6TlfqJucljvBusD5IdDAiqfobVR~jlYgU-7XeADFEgKUuznt7foBe1hdV0xfBkQlwBQVg7qjvcgw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Pharmacotherapy to decrease walking impairment

Verapamil,<sup><a href="javascript:;" reveal-id="ehae179-B516" data-open="ehae179-B516" class="link link-ref link-reveal xref-bibr">516</a></sup> statins,<sup><a href="javascript:;" reveal-id="ehae179-B517" data-open="ehae179-B517" class="link link-ref link-reveal xref-bibr">517</a>,<a href="javascript:;" reveal-id="ehae179-B518" data-open="ehae179-B518" class="link link-ref link-reveal xref-bibr">518</a></sup> antiplatelet agents, and prostanoids (prostaglandins I<sub>2</sub> and E<sub>1</sub>)<sup><a href="javascript:;" reveal-id="ehae179-B519" data-open="ehae179-B519" class="link link-ref link-reveal xref-bibr">519</a></sup> can alleviate walking impairment in patients with symptomatic PAD. However, drugs like cilostazol, naftidrofuryl, pentoxifylline, buflomedil, carnitine, and propionyl-L-carnitine are suggested to increase walking distance in patients with IC without impacting CV health.<sup><a href="javascript:;" reveal-id="ehae179-B339" data-open="ehae179-B339" class="link link-ref link-reveal xref-bibr">339</a>,<a href="javascript:;" reveal-id="ehae179-B520" data-open="ehae179-B520" class="link link-ref link-reveal xref-bibr">520</a></sup> Their objective benefit is generally limited, ranging from mild to moderate, with considerable variability.<sup><a href="javascript:;" reveal-id="ehae179-B339" data-open="ehae179-B339" class="link link-ref link-reveal xref-bibr">339</a></sup> The additional benefit of these drugs alongside antithrombotics, antihypertensives, and statins remains unknown.

Cilostazol, a phosphodiesterase type III inhibitor, improved MWD compared with placebo and pentoxifylline.<sup><a href="javascript:;" reveal-id="ehae179-B520 ehae179-B521 ehae179-B522" data-open="ehae179-B520 ehae179-B521 ehae179-B522" class="link link-ref link-reveal xref-bibr">520–522</a></sup> In a Cochrane analysis, 100 mg twice daily increased MWD by 76%,<sup><a href="javascript:;" reveal-id="ehae179-B521" data-open="ehae179-B521" class="link link-ref link-reveal xref-bibr">521</a></sup> while another review reported a 25% average improvement.<sup><a href="javascript:;" reveal-id="ehae179-B520" data-open="ehae179-B520" class="link link-ref link-reveal xref-bibr">520</a></sup> Cilostazol also has antiplatelet effects, requiring cautious combination with other anticoagulant and antiplatelet treatments.<sup><a href="javascript:;" reveal-id="ehae179-B522" data-open="ehae179-B522" class="link link-ref link-reveal xref-bibr">522</a></sup> Notably, it increases bleeding complications.<sup><a href="javascript:;" reveal-id="ehae179-B523" data-open="ehae179-B523" class="link link-ref link-reveal xref-bibr">523</a></sup>

Naftidrofuryl oxalate, tested for IC,<sup><a href="javascript:;" reveal-id="ehae179-B524" data-open="ehae179-B524" class="link link-ref link-reveal xref-bibr">524</a></sup> demonstrated a 74% average increase in MWD and improved HRQoL.<sup><a href="javascript:;" reveal-id="ehae179-B524" data-open="ehae179-B524" class="link link-ref link-reveal xref-bibr">524</a>,<a href="javascript:;" reveal-id="ehae179-B525" data-open="ehae179-B525" class="link link-ref link-reveal xref-bibr">525</a></sup> In a systematic review, the average MWD improvement was 60% compared with placebo.<sup><a href="javascript:;" reveal-id="ehae179-B520" data-open="ehae179-B520" class="link link-ref link-reveal xref-bibr">520</a></sup> However, inconsistent results for other medications, such as prostanoids, pentoxifylline, L-arginine, buflomedil, or _Gingko biloba_, preclude their recommendation for patients with IC.<sup><a href="javascript:;" reveal-id="ehae179-B519" data-open="ehae179-B519" class="link link-ref link-reveal xref-bibr">519</a>,<a href="javascript:;" reveal-id="ehae179-B526" data-open="ehae179-B526" class="link link-ref link-reveal xref-bibr">526</a>,<a href="javascript:;" reveal-id="ehae179-B527" data-open="ehae179-B527" class="link link-ref link-reveal xref-bibr">527</a></sup>

###### Aorto-iliac lesion revascularization

Aorto-iliac lesions can be treated by either an endovascular or a surgical approach according to the lesion morphology and patient risk. Long-term patency with a low risk of complications can be achieved by balloon angioplasty with or without stenting in external iliac arteries or primary stenting in common iliac arteries.<sup><a href="javascript:;" reveal-id="ehae179-B528" data-open="ehae179-B528" class="link link-ref link-reveal xref-bibr">528</a></sup> A meta-analysis evaluated outcomes of open surgery vs. an endovascular approach in aorto-iliac lesions (TASC II C-D) and found that short-term morbidity and mortality favours the endovascular approach, but early and mid-term primary patency favours open surgery; however, secondary patency is comparable in all groups.

###### Femoro-popliteal lesion revascularization

If revascularization is indicated, endovascular therapy should be the first choice even for complex lesions, especially in surgical high-risk patients.<sup><a href="javascript:;" reveal-id="ehae179-B119" data-open="ehae179-B119" class="link link-ref link-reveal xref-bibr">119</a>,<a href="javascript:;" reveal-id="ehae179-B529 ehae179-B530 ehae179-B531" data-open="ehae179-B529 ehae179-B530 ehae179-B531" class="link link-ref link-reveal xref-bibr">529–531</a></sup>

Endovascular therapy faces the challenge of sustaining long-term patency and durability in the femoro-popliteal region, particularly post-stent placement in a highly mobile artery. Drug-eluting balloons have improved long-term patency in complex patient cohorts and lesions.<sup><a href="javascript:;" reveal-id="ehae179-B532" data-open="ehae179-B532" class="link link-ref link-reveal xref-bibr">532</a></sup> With regard to paclitaxel-coated devices, a meta-analysis caused a decline in their usage, especially as the United States Food and Drug Administration (FDA) reacted and restricted their use.<sup><a href="javascript:;" reveal-id="ehae179-B533" data-open="ehae179-B533" class="link link-ref link-reveal xref-bibr">533</a></sup> Consequently, data from large national databases were evaluated and the mortality signal could not be confirmed. The FDA revised its position, and drug-eluting treatment is now deemed to be a safe and efficient treatment strategy for femoro-popliteal lesions.<sup><a href="javascript:;" reveal-id="ehae179-B534 ehae179-B535 ehae179-B536 ehae179-B537 ehae179-B538" data-open="ehae179-B534 ehae179-B535 ehae179-B536 ehae179-B537 ehae179-B538" class="link link-ref link-reveal xref-bibr">534–538</a></sup>

An open surgical approach in femoro-popliteal lesions should be considered when an autologous vein (e.g. great saphenous vein \[GSV\]) is available and the patient shows low surgical risk, and in complex lesions after an interdisciplinary team discussion.

###### Below**\-**the**\-**knee artery revascularization

In patients with severe IC in whom endovascular femoro-popliteal treatment is performed, BTK arteries can be treated in the same intervention if there is substantially impaired outflow.<sup><a href="javascript:;" reveal-id="ehae179-B539" data-open="ehae179-B539" class="link link-ref link-reveal xref-bibr">539</a></sup>

Recommendation Table 15

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846037)

Recommendations for interventional treatment of asymptomatic and symptomatic peripheral arterial disease (general)

![Recommendations for interventional treatment of asymptomatic and symptomatic peripheral arterial disease (general)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt15.jpeg?Expires=1728479088&Signature=GV0OsIggidkdnHE872mxa6UPPuFCi1GrBK3FhW6voKv5AZB-ny9I6qFvIsZm6RId55nov14MykKS0wAyr8Vso45-IiWVJrwZILL7gilhkHHjzRjfnnEefxxQCDkH2AvNQNckELjRzvpXXreyi1bFKzH8UlimUZg9qto3i6yjTvdmHS5fssh5ahb5YT640c7~lA8qy1JPdaCVjOZE8xF9T2jicY~imJ54muh-ODjHEDhb4gp4oJzN~fEIw1E3y66mqp5nfPyQuXj28drWFRmgkSiHMTN5Kw6Qa3N-ePs~n7oV6RYmlTtFve~Jay58FMh9jKjBLuFlQgvvn6x53iR71g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 16

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846038)

Recommendations for interventional treatment of patients with symptomatic peripheral arterial disease (per arterial bed)

![Recommendations for interventional treatment of patients with symptomatic peripheral arterial disease (per arterial bed)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt16.jpeg?Expires=1728479088&Signature=2DvrEVsRv32SGG115bEFiqb5uWd3oL253SwhVyqtqNg6ZLKXuyDlTW9bcrNPZ0FdvvWNLl-YxOetbIPxKzAWhr1SAL-pi6B8ezCc7rjSKeKSTgYAF1p0WdzjZaTzuQ1jRv7AteRVifeZAu92ZwYS7y-3reTBwjV4BpCXQlkmHGw1rJvGdRwFgALzsNf~v0sUgutMT7Nlp0s6f~MYJ9TbcQYHVuSc5o6Ci28PBPIamF0YAIAeEsiLh7qPu8eOVDOg7TVJYtWACF92wgDGYF2dP00ILxqC1bab7J~NIXYi1xMMHVvRJjs~W3oDzL204FopvutLTqlyiNdYZbBU1KaLnw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

##### 8.1.1.3. Follow-up

Asymptomatic and symptomatic PAD are at increased risk of leg symptom worsening<sup><a href="javascript:;" reveal-id="ehae179-B427" data-open="ehae179-B427" class="link link-ref link-reveal xref-bibr">427</a></sup> and of CV mortality and morbidity.<sup><a href="javascript:;" reveal-id="ehae179-B419" data-open="ehae179-B419" class="link link-ref link-reveal xref-bibr">419</a>,<a href="javascript:;" reveal-id="ehae179-B431" data-open="ehae179-B431" class="link link-ref link-reveal xref-bibr">431</a>,<a href="javascript:;" reveal-id="ehae179-B551" data-open="ehae179-B551" class="link link-ref link-reveal xref-bibr">551</a></sup> Follow-up post-revascularization is crucial to ensure perfusion improvement, address CVRFs, optimize pharmacological treatment adherence, identify disease progression, and evaluate mental health and functional capacity. Experienced vascular care physicians should conduct follow-up, although specific protocols are currently undefined.<sup><a href="javascript:;" reveal-id="ehae179-B128" data-open="ehae179-B128" class="link link-ref link-reveal xref-bibr">128</a>,<a href="javascript:;" reveal-id="ehae179-B552" data-open="ehae179-B552" class="link link-ref link-reveal xref-bibr">552</a></sup> Data on asymptomatic PAD follow-up are limited.<sup><a href="javascript:;" reveal-id="ehae179-B553" data-open="ehae179-B553" class="link link-ref link-reveal xref-bibr">553</a></sup> For symptomatic PAD or post-intervention, annual follow-up are advised, including ABI/TBI measurement and DUS for new or worsening symptoms.

Recommendation Table 17

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846041)

Recommendations in patients with peripheral arterial disease: follow-up of patients with peripheral arterial disease

![Recommendations in patients with peripheral arterial disease: follow-up of patients with peripheral arterial disease](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt17.jpeg?Expires=1728479088&Signature=EigsBiJjE4UicZwUPvc1SyvmAu4ljJxWuLUxKTX8IUGrPUPvzlzx0NUbiOF1RYHTlFt99e0y3-ckvphfw28DUOX7JFSl1i3DRgC-NXSpXwZCRgzLZ5VQmRcEKUGHW3cvW2~cSTjPCOKwalvZTl5-u844HnfycYwMmwd-16HVY3eXMa9C6u97E7i9BczihfYLIzjW3slOimOBnSJvbCTnGoizKsdTLnEbvoev2TpouH22fk5Qt-LoLXNhlZvK3AmU31bE0n1vop9KhTFwx1111rGQGhrPYcToE3Wml3zOl~Cl2Hswlz2mcGgz0uQdYeHhAvRMeUnC7tbwPK1BXyjuaA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 8.1.2. Chronic limb-threatening ischaemia

##### 8.1.2.1. Clinical presentation and diagnosis

Chronic limb-thretening ischaemia describes chronic lower-limb hypoperfusion responsible for ischaemic rest pain, or non-healing ulceration or gangrene (typically in distal segments).<sup><a href="javascript:;" reveal-id="ehae179-B555" data-open="ehae179-B555" class="link link-ref link-reveal xref-bibr">555</a>,<a href="javascript:;" reveal-id="ehae179-B556" data-open="ehae179-B556" class="link link-ref link-reveal xref-bibr">556</a></sup> Ischaemic rest pain primarily affects the patient’s forefoot and aggravates in a supine position, while lowering of the affected leg eases ischaemic symptoms.

###### Definition

Chronic limb-thretening ischaemia should be considered in the presence of one of the following lower-limb clinical signs or symptoms:

-   Ischaemic rest pain
    
-   Non-healing lower-limb wound of ≥2 weeks’ duration
    
-   Lower-limb gangrene
    

The following haemodynamic criteria may be used to guide diagnosis in patients with suspicion of CLTI:

-   Ankle pressure <50 mmHg
    
-   TP <30 mmHg
    
-   TcPO<sub>2</sub> <30 mmHg
    

###### Initial assessment and risk of amputation

For patients with CLTI, initial diagnostic steps involve clinical examination and limb perfusion assessment through haemodynamic measurements. Regarding haemodynamic assessment in CLTI, standard ABI may be normal or falsely elevated due to non-compressible arteries related to medial sclerosis (common in diabetes or CKD),<sup><a href="javascript:;" reveal-id="ehae179-B557" data-open="ehae179-B557" class="link link-ref link-reveal xref-bibr">557</a></sup> which can be overcome by estimation of ABI based on Doppler waveforms.<sup><a href="javascript:;" reveal-id="ehae179-B124" data-open="ehae179-B124" class="link link-ref link-reveal xref-bibr">124</a></sup> Therefore, standard ankle pressure alone may not be reliable in estimating limb loss risk.<sup><a href="javascript:;" reveal-id="ehae179-B441" data-open="ehae179-B441" class="link link-ref link-reveal xref-bibr">441</a>,<a href="javascript:;" reveal-id="ehae179-B558" data-open="ehae179-B558" class="link link-ref link-reveal xref-bibr">558</a></sup> In addition, a large proportion of patients with ulcers may have below-the-ankle lesions.<sup><a href="javascript:;" reveal-id="ehae179-B440" data-open="ehae179-B440" class="link link-ref link-reveal xref-bibr">440</a></sup> In patients with CLTI, TP, TBI, or TcPO<sub>2</sub> should additionally be obtained.<sup><a href="javascript:;" reveal-id="ehae179-B90" data-open="ehae179-B90" class="link link-ref link-reveal xref-bibr">90</a>,<a href="javascript:;" reveal-id="ehae179-B441" data-open="ehae179-B441" class="link link-ref link-reveal xref-bibr">441</a>,<a href="javascript:;" reveal-id="ehae179-B559" data-open="ehae179-B559" class="link link-ref link-reveal xref-bibr">559</a></sup>

Particularly in patients with CLTI, the WIfI classification system should be applied. In addition to patients’ limb perfusion, the WIfI classification considers the wound size and the extent of foot infection to determine the individual risk of amputation.<sup><a href="javascript:;" reveal-id="ehae179-B417" data-open="ehae179-B417" class="link link-ref link-reveal xref-bibr">417</a>,<a href="javascript:;" reveal-id="ehae179-B444 ehae179-B445 ehae179-B446" data-open="ehae179-B444 ehae179-B445 ehae179-B446" class="link link-ref link-reveal xref-bibr">444–446</a></sup>

###### Imaging

In all patients with CLTI, comprehensive vascular imaging is mandatory to evaluate revascularization options. CLTI commonly affects more than one arterial segment of the lower limbs, involving infra**_\-_**popliteal arteries (BTK and below-the-ankle arteries) in most cases. While non-invasive imaging (DUS, CTA, MRA) provides reliable results for above-the-knee arteries, imaging of BTK arteries, especially below the ankle, may be hampered by severe calcification.<sup><a href="javascript:;" reveal-id="ehae179-B448" data-open="ehae179-B448" class="link link-ref link-reveal xref-bibr">448</a>,<a href="javascript:;" reveal-id="ehae179-B560" data-open="ehae179-B560" class="link link-ref link-reveal xref-bibr">560</a>,<a href="javascript:;" reveal-id="ehae179-B561" data-open="ehae179-B561" class="link link-ref link-reveal xref-bibr">561</a></sup> Therefore, in CLTI additional DSA with dedicated views of the foot should be considered for the assessment of BTK arteries.<sup><a href="javascript:;" reveal-id="ehae179-B560" data-open="ehae179-B560" class="link link-ref link-reveal xref-bibr">560</a></sup> Even in patients who are not candidates for revascularization, DSA should be obtained to prevent unnecessary amputation or to minimize amputation extent.<sup><a href="javascript:;" reveal-id="ehae179-B560" data-open="ehae179-B560" class="link link-ref link-reveal xref-bibr">560</a>,<a href="javascript:;" reveal-id="ehae179-B562" data-open="ehae179-B562" class="link link-ref link-reveal xref-bibr">562</a></sup>

###### Mortality risk assessment

All-cause mortality and event rates of MI are more than two-fold higher in CLTI patients than in unselected patients with an ABI ≤0.90.<sup><a href="javascript:;" reveal-id="ehae179-B431" data-open="ehae179-B431" class="link link-ref link-reveal xref-bibr">431</a></sup>

In CLTI patients undergoing revascularization, the post-revascularization period is particularly associated with an increased risk of MALE and MACE.<sup><a href="javascript:;" reveal-id="ehae179-B563" data-open="ehae179-B563" class="link link-ref link-reveal xref-bibr">563</a></sup> The management of patients with CLTI should therefore include an individual peri-procedural risk assessment. Referring to the peri-procedural risk patients can be categorized as average procedural risk (peri-procedural mortality <5% and 2 year survival >50%) or high procedural risk (peri-procedural mortality ≥5% and 2 year survival ≤50%).<sup><a href="javascript:;" reveal-id="ehae179-B564" data-open="ehae179-B564" class="link link-ref link-reveal xref-bibr">564</a>,<a href="javascript:;" reveal-id="ehae179-B565" data-open="ehae179-B565" class="link link-ref link-reveal xref-bibr">565</a></sup>

Besides revascularization, it also needs to be considered that lower-limb amputation is associated with 30 day mortality rates of up to 22%.<sup><a href="javascript:;" reveal-id="ehae179-B566" data-open="ehae179-B566" class="link link-ref link-reveal xref-bibr">566</a></sup>

Recommendation Table 18

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846059)

Recommendations for the management of chronic limb-threatening ischaemia

![Recommendations for the management of chronic limb-threatening ischaemia](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt18.jpeg?Expires=1728479088&Signature=r5rN8z5TGfoRlOcQ5poGNFBlvJnGJD~BGLJqQ7Jb3LJCEl3zBjM~6R8y4O-zRG6KoXPTsZMwmJ9MI0JvbHcFZd7W8azDwXDG13QETefK-ferEdy9lMpSNqbjIz2-PceyxlDkd1GwJkBCFcX3ftwLMibwzZvJ1idSZjWdc1B4wlZA8T29iqA1BJyW7yMcsOgSj1fuRkf3P9yjde3-muPT8L9LoPyRNBGykwRciayXVilp3OPtQHfJtt98fzK~CnFzu8cqv5CvNN2EVk6b-t6qruqPu5Tu7u1-eMaLcZktcf5DqrYZtSuAc4sYeED3cwovk0nvz~HQ4FjfNxxRxN8l7w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

##### 8.1.2.2. Medical treatment

Chronic limb-thretening ischaemia is associated with a high risk of ischaemic events,<sup><a href="javascript:;" reveal-id="ehae179-B429" data-open="ehae179-B429" class="link link-ref link-reveal xref-bibr">429</a>,<a href="javascript:;" reveal-id="ehae179-B431" data-open="ehae179-B431" class="link link-ref link-reveal xref-bibr">431</a></sup> thus management of patients with CLTI must include OMT.

In addition, rest pain, optimal wound care, and infection control should be managed. A vascular team, including at least a vascular physician, a vascular surgeon, and a radiologist, should be involved to prevent amputation.<sup><a href="javascript:;" reveal-id="ehae179-B568" data-open="ehae179-B568" class="link link-ref link-reveal xref-bibr">568</a></sup> Lower-limb exercise training is contraindicated until ulcers are healed and aggressive offloading should be ensured to allow healing. Depending on infection extent, oral antibiotics may suffice, however, if extensive with systemic signs of inflammation, admission for intravenous (i.v.) antibiotic administration may be required.<sup><a href="javascript:;" reveal-id="ehae179-B569" data-open="ehae179-B569" class="link link-ref link-reveal xref-bibr">569</a>,<a href="javascript:;" reveal-id="ehae179-B570" data-open="ehae179-B570" class="link link-ref link-reveal xref-bibr">570</a></sup>

Good-quality evidence on the advantages of one type of wound dressing over others is lacking, while in selected patients individualized treatments with antimicrobial dressing,<sup><a href="javascript:;" reveal-id="ehae179-B571" data-open="ehae179-B571" class="link link-ref link-reveal xref-bibr">571</a></sup> silver dressing,<sup><a href="javascript:;" reveal-id="ehae179-B572" data-open="ehae179-B572" class="link link-ref link-reveal xref-bibr">572</a></sup> collagen dressing,<sup><a href="javascript:;" reveal-id="ehae179-B573" data-open="ehae179-B573" class="link link-ref link-reveal xref-bibr">573</a></sup> honey- or iodine-based dressings,<sup><a href="javascript:;" reveal-id="ehae179-B574" data-open="ehae179-B574" class="link link-ref link-reveal xref-bibr">574</a></sup> platelet-rich plasma, or negative pressure therapy<sup><a href="javascript:;" reveal-id="ehae179-B575" data-open="ehae179-B575" class="link link-ref link-reveal xref-bibr">575</a>,<a href="javascript:;" reveal-id="ehae179-B576" data-open="ehae179-B576" class="link link-ref link-reveal xref-bibr">576</a></sup> may accelerate wound healing, shorten hospital stay, and prevent amputations. If deep-seated infection is suspected, X-ray or MRA are required to diagnose osteomyelitis, in which case a longer course of antibiotics may be necessary.<sup><a href="javascript:;" reveal-id="ehae179-B577" data-open="ehae179-B577" class="link link-ref link-reveal xref-bibr">577</a></sup> Antibiotics for osteomyelitis treatment may be empirical, however, they should be adapted according to (preferably tissue) cultures.<sup><a href="javascript:;" reveal-id="ehae179-B578 ehae179-B579 ehae179-B580 ehae179-B581" data-open="ehae179-B578 ehae179-B579 ehae179-B580 ehae179-B581" class="link link-ref link-reveal xref-bibr">578–581</a></sup>

Ulcers require assessment of venous aetiology and potential for endovenous therapy, while mixed ulcers require compression therapy after revascularization.<sup><a href="javascript:;" reveal-id="ehae179-B582" data-open="ehae179-B582" class="link link-ref link-reveal xref-bibr">582</a></sup>

Recommendation Table 19

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846065)

Recommendations for medical treatment in patients with chronic limb-threatening ischaemia (see also Evidence Table 7)

![Recommendations for medical treatment in patients with chronic limb-threatening ischaemia (see also Evidence Table 7)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt19.jpeg?Expires=1728479088&Signature=Yk5Ns5SkXUTySNPn0VqqzeCUCPYYUz2aXyeZXDBNN-kVvCMNPhnH~QD0ZYdIfGXgozSUWAiU1WcpL01F9Xk~nBkFkqFo-aOcxbodlWt9k~KJlMYb5gG6-sa3Y3Zd9LRW7-65hTQwqMInlT5kRhW-KLt6uDIeD5h1KJNbPVvEudcY0HpYIlTw6wfNcSoR3mg0x9rgw7lDGYtL2a37fAzKqX8DBKVp1rqWwYPDSxHw5yvfrZ31hMrZVrHhmDZcG955X4Qt8dXu74VOcxGxabrct4k43dV9iw6ogjQb1kITGNfJksJSwp1UekFvZaXgMdk9M9BYr7FX8kZLDP6R5erpYg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

##### 8.1.2.3. Interventional treatment

###### Revascularization

In CLTI, revascularization should be attempted to rapidly restore an inline direct blood flow to the foot.<sup><a href="javascript:;" reveal-id="ehae179-B585 ehae179-B586 ehae179-B587 ehae179-B588" data-open="ehae179-B585 ehae179-B586 ehae179-B587 ehae179-B588" class="link link-ref link-reveal xref-bibr">585–588</a></sup> Three RCTs compared endovascular therapy with open surgery in infra-inguinal arteries. In the Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial, no significant difference was found regarding mortality or amputation-free survival at 2 years.<sup><a href="javascript:;" reveal-id="ehae179-B589" data-open="ehae179-B589" class="link link-ref link-reveal xref-bibr">589</a></sup> However, surgery was associated with a significantly reduced risk of amputation, death, or both after 2 years.<sup><a href="javascript:;" reveal-id="ehae179-B564" data-open="ehae179-B564" class="link link-ref link-reveal xref-bibr">564</a>,<a href="javascript:;" reveal-id="ehae179-B589" data-open="ehae179-B589" class="link link-ref link-reveal xref-bibr">589</a></sup> In the Best Endovascular versus Best Surgical Therapy for Patients with Critical Limb Ischemia (BEST-CLI) trial (median follow-up of 2.7 years), the incidence of MALE or death was lower in patients in which one segment of the GSV was available for surgical revascularization than in patients who underwent endovascular revascularization. In the same trial, outcomes of patients for whom an alternative bypass conduit was needed for surgical revascularization were similar to those of patients who underwent endovascular revascularization.<sup><a href="javascript:;" reveal-id="ehae179-B567" data-open="ehae179-B567" class="link link-ref link-reveal xref-bibr">567</a></sup>

In the BASIL-2 trial, which included patients requiring infra-popliteal, with or without additional further proximal infra-inguinal, revascularization procedures, endovascular revascularization was associated with better amputation-free survival than surgical revascularization, which was primarily due to fewer deaths in this group.<sup><a href="javascript:;" reveal-id="ehae179-B590" data-open="ehae179-B590" class="link link-ref link-reveal xref-bibr">590</a></sup> It is important to consider<sup><a href="javascript:;" reveal-id="ehae179-B591" data-open="ehae179-B591" class="link link-ref link-reveal xref-bibr">591</a></sup> both revascularization options individually in each patient, considering the complexity of the diseased anatomical region.

Multilevel disease

Patients with CLTI commonly present with multilevel disease.<sup><a href="javascript:;" reveal-id="ehae179-B592" data-open="ehae179-B592" class="link link-ref link-reveal xref-bibr">592</a></sup> Especially for complex lesions, comprehensive patient assessment, including the individual patient’s clinical presentation, the lesion morphology, and the peri-procedural risk, needs to be undertaken by a multidisciplinary vascular team to weigh the risks against the benefits of the respective methods of revascularization (endovascular vs. surgical).<sup><a href="javascript:;" reveal-id="ehae179-B590" data-open="ehae179-B590" class="link link-ref link-reveal xref-bibr">590</a>,<a href="javascript:;" reveal-id="ehae179-B593 ehae179-B594 ehae179-B595 ehae179-B596" data-open="ehae179-B593 ehae179-B594 ehae179-B595 ehae179-B596" class="link link-ref link-reveal xref-bibr">593–596</a></sup> A structured approach is essential to achieve rapid and durable restoration of an inline flow to the foot. When possible, the angiosome concept can be considered, targeting the most affected ischaemic area.<sup><a href="javascript:;" reveal-id="ehae179-B597" data-open="ehae179-B597" class="link link-ref link-reveal xref-bibr">597</a></sup> When CLTI leaves no viable revascularization options, transcatheter arterialization of deep veins may be considered.<sup><a href="javascript:;" reveal-id="ehae179-B598" data-open="ehae179-B598" class="link link-ref link-reveal xref-bibr">598</a></sup>

Aorto-iliac disease

An endovascular approach is the first choice, commonly employing bare metal or covered stents.<sup><a href="javascript:;" reveal-id="ehae179-B599 ehae179-B600 ehae179-B601 ehae179-B602 ehae179-B603" data-open="ehae179-B599 ehae179-B600 ehae179-B601 ehae179-B602 ehae179-B603" class="link link-ref link-reveal xref-bibr">599–603</a></sup> Surgery is reserved for extensive obstructions and lesions treated unsuccessfully with an endovascular procedure.<sup><a href="javascript:;" reveal-id="ehae179-B604" data-open="ehae179-B604" class="link link-ref link-reveal xref-bibr">604</a></sup> Hybrid revascularization should be considered in occlusion of the common femoral artery or profunda femoris artery requiring endarterectomy, in addition to inflow and/or outflow disease amenable to endovascular therapy. Hybrid procedures should be encouraged in a one-step modality.<sup><a href="javascript:;" reveal-id="ehae179-B605" data-open="ehae179-B605" class="link link-ref link-reveal xref-bibr">605</a></sup>

Femoro-popliteal disease

Chronic limb-threatening ischaemia is unlikely to be related to isolated superficial femoral artery lesions; femoro-popliteal involvement in combination with aorto-iliac or infra-popliteal disease is frequently found. In 40% of cases, inflow treatment of femoro-popliteal disease is necessary.<sup><a href="javascript:;" reveal-id="ehae179-B606" data-open="ehae179-B606" class="link link-ref link-reveal xref-bibr">606</a></sup> The revascularization strategy should be selected according to lesion complexity.<sup><a href="javascript:;" reveal-id="ehae179-B422" data-open="ehae179-B422" class="link link-ref link-reveal xref-bibr">422</a></sup> If endovascular therapy is chosen, landing zones for potential bypass grafts should be preserved. When bypass surgery is decided, the bypass should be as short as possible, using the saphenous veins.<sup><a href="javascript:;" reveal-id="ehae179-B567" data-open="ehae179-B567" class="link link-ref link-reveal xref-bibr">567</a></sup>

Infra-popliteal disease

Extended infra-popliteal disease is mainly seen in patients with diabetes<sup><a href="javascript:;" reveal-id="ehae179-B607 ehae179-B608 ehae179-B609 ehae179-B610" data-open="ehae179-B607 ehae179-B608 ehae179-B609 ehae179-B610" class="link link-ref link-reveal xref-bibr">607–610</a></sup> and CKD,<sup><a href="javascript:;" reveal-id="ehae179-B611" data-open="ehae179-B611" class="link link-ref link-reveal xref-bibr">611</a>,<a href="javascript:;" reveal-id="ehae179-B612" data-open="ehae179-B612" class="link link-ref link-reveal xref-bibr">612</a></sup> often being associated with superficial femoral artery lesions. In short infra-popliteal lesions, endovascular therapy is the first choice.<sup><a href="javascript:;" reveal-id="ehae179-B593" data-open="ehae179-B593" class="link link-ref link-reveal xref-bibr">593</a></sup> Drug-eluting balloons<sup><a href="javascript:;" reveal-id="ehae179-B607" data-open="ehae179-B607" class="link link-ref link-reveal xref-bibr">607</a></sup> and bare metal stent implantation<sup><a href="javascript:;" reveal-id="ehae179-B613" data-open="ehae179-B613" class="link link-ref link-reveal xref-bibr">613</a></sup> have shown no superiority over plain balloon angioplasty, although drug-eluting stents may be used for relatively short proximal lesions.<sup><a href="javascript:;" reveal-id="ehae179-B614 ehae179-B615 ehae179-B616" data-open="ehae179-B614 ehae179-B615 ehae179-B616" class="link link-ref link-reveal xref-bibr">614–616</a></sup>

###### Spinal cord stimulation

Spinal cord stimulation (SCS) may be considered in treating patients with CLTI and no viable revascularization options. SCS offers modest pain relief and an 11% reduction in amputation rate compared with conservative management at 1 year. No effect was seen in ulcer healing and benefits should be weighed against the high cost and possible complications.<sup><a href="javascript:;" reveal-id="ehae179-B617" data-open="ehae179-B617" class="link link-ref link-reveal xref-bibr">617</a></sup> Recent technological advances in neuromodulation may improve the treatment value of this modality.<sup><a href="javascript:;" reveal-id="ehae179-B618" data-open="ehae179-B618" class="link link-ref link-reveal xref-bibr">618</a></sup>

###### Amputation

Minor amputation, usually up to the forefoot, is often needed for necrotic tissue removal with minor impact on patient mobility. Pre-amputation revascularization enhances wound healing. In cases of extensive necrosis or infectious gangrene, primary major amputation without revascularization may be preferable to avoid complications. Secondary amputation is indicated when revascularization fails, re-intervention is not possible, or limb deterioration persists despite a patent graft and optimal management. BTK amputation allows better mobility with a prosthesis. For bedridden patients, above-the-knee amputation may be the preferred choice.

Recommendation Table 20

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846082)

Recommendations for interventional treatment of chronic limb-threatening ischaemia

![Recommendations for interventional treatment of chronic limb-threatening ischaemia](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt20.jpeg?Expires=1728479088&Signature=KLF0jtI2eYbGssdSjpyF8gSg9AQRmcZeA-nN6IxDbuffIfEkKA1F8B-eeFUuf3CtTdxNd1NCQVi-kNE5DBw5DnMrfgr~RIH3z2KtsnyGYv40rol-zT~VOcUufyj4YdgHIunTlHY7Lc7GNKpeeSMHMonVMKYfvTbV6jIG5U5~gSbfLKGwwztq2-cvBPdr1Ug-tAsoTon~7uIgNPb9JyOrUyyUgn7DAGpk-SSG~qnAmNgDjpPWHcS6jWgUAPWabOOAeb3q9VVWrU2Kz0ILlQLxUJkf2pPMB64Dkxw5xvn2JhGtZVpxSQZo7JjgrfRYFBALGkmT~JNMZa-HgHySr8hqng__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

##### 8.1.2.4. Follow-up

In patients with CLTI, the incidence of CV events is increased.<sup><a href="javascript:;" reveal-id="ehae179-B619" data-open="ehae179-B619" class="link link-ref link-reveal xref-bibr">619</a>,<a href="javascript:;" reveal-id="ehae179-B620" data-open="ehae179-B620" class="link link-ref link-reveal xref-bibr">620</a></sup> Follow-up should focus on general clinical CV condition, prevention of revascularization failure, wound healing, and contralateral limb status. After revascularization, at least an annual appointment with a vascular physician expert in CLTI management is warranted. Due to the lack of evidence, recommendations are largely based on consensus and expert opinions.<sup><a href="javascript:;" reveal-id="ehae179-B128" data-open="ehae179-B128" class="link link-ref link-reveal xref-bibr">128</a></sup>

First-year incidence of vein graft stenosis is 20%;<sup><a href="javascript:;" reveal-id="ehae179-B621" data-open="ehae179-B621" class="link link-ref link-reveal xref-bibr">621</a></sup> however, if uneventful for 12 months, late issues are scarce.<sup><a href="javascript:;" reveal-id="ehae179-B622" data-open="ehae179-B622" class="link link-ref link-reveal xref-bibr">622</a></sup> Clinical examination, ABI (or TBI) measurement, and DUS should be performed within 4–6 weeks and thereafter at 3, 6, 12, and 24 months after bypass surgery.<sup><a href="javascript:;" reveal-id="ehae179-B128" data-open="ehae179-B128" class="link link-ref link-reveal xref-bibr">128</a></sup>

After endovascular treatment, restenosis and occlusion ranges from 5% in the pelvic region to >50% in the infra-popliteal arteries.<sup><a href="javascript:;" reveal-id="ehae179-B623" data-open="ehae179-B623" class="link link-ref link-reveal xref-bibr">623</a>,<a href="javascript:;" reveal-id="ehae179-B624" data-open="ehae179-B624" class="link link-ref link-reveal xref-bibr">624</a></sup> Unlike after surgery, no plateau phase is seen, and the failure rate is constant for at least 5 years. Surveillance includes clinical assessment looking for recurrent symptoms or signs, ABI measurement, and DUS based on the first check-up: if normal, DUS is recommended if symptoms reappear; if abnormal, initial DUS, re-intervention, or closer DUS follow-up on a case-by-case basis are recommended.<sup><a href="javascript:;" reveal-id="ehae179-B128" data-open="ehae179-B128" class="link link-ref link-reveal xref-bibr">128</a></sup> Post-procedural ankle duplex-based estimated ABI of <0.90 predicts suboptimal wound healing, clinically driven target lesion revascularization (cdTLR), and MALE.<sup><a href="javascript:;" reveal-id="ehae179-B625" data-open="ehae179-B625" class="link link-ref link-reveal xref-bibr">625</a></sup>

After revascularization, closer follow-up and wound care are recommended until healing. Thereafter, annual appointments with vascular physicians with expertise in CLTI management should be scheduled to check for symptoms, foot condition, ABI, and CVRFs, including availability for TP and TcPO<sub>2</sub> if needed. Recurrence of symptoms may also be due to the progression of atherosclerotic disease above or below the bypass or angioplasty site.<sup><a href="javascript:;" reveal-id="ehae179-B427" data-open="ehae179-B427" class="link link-ref link-reveal xref-bibr">427</a></sup>

Recommendation Table 21

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846088)

Recommendations for follow-up in patients with chronic limb-threatening ischaemia

![Recommendations for follow-up in patients with chronic limb-threatening ischaemia](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt21.jpeg?Expires=1728479088&Signature=RnfXdP4by14T6SIffBqafbXE6RRA-acd0baBFvegkMG1lRSfOhJ3JEcE7Rj3NnMi3O2qC0pgYoeF6gF8PBkjB-HtH-Lpx~Fig-8SynVxpHEennmRj1IVhCaiN6CKTjLCfbcDlvxw~oQJJAgbjuaGSUylwBH-sZsNZ7SKfDiDgwx4KabedDSTM8PDVccUmOOlab8AgVJ63Ft09LDLCTl5Hi3y6puyOIJqYTm8Aepnibdsr49HyMTJ7Mv-mKOLMnnF9WovJDi9NyhdBhCP~lr9Qey99fqBtBRY~aaa7w5bYeJAfMpoSJb8DE8AFscblwyM-AgwS8lM7r6Ft7tpzaE-TA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 8.1.3. Acute limb ischaemia

##### 8.1.3.1. Clinical presentation and diagnosis

Acute limb ischaemia is caused by an abrupt decrease in arterial limb perfusion. Potential causes are PAD progression, cardiac/aortic embolization, AD, graft thrombosis, aneurysm thrombosis, popliteal artery entrapment syndrome, trauma, phlegmasia cerulea dolens, ergotism, hypercoagulable states, and iatrogenic complications related to vascular procedures. ALI is a medical emergency and timely recognition is crucial to successful treatment.<sup><a href="javascript:;" reveal-id="ehae179-B629 ehae179-B630 ehae179-B631 ehae179-B632" data-open="ehae179-B629 ehae179-B630 ehae179-B631 ehae179-B632" class="link link-ref link-reveal xref-bibr">629–632</a></sup> Patients should be rapidly evaluated by a vascular specialist<sup><a href="javascript:;" reveal-id="ehae179-B633" data-open="ehae179-B633" class="link link-ref link-reveal xref-bibr">633</a></sup> or rapidly transferred to a facility with such resources.

The time constraint is due to the period that skeletal muscle and nerves will tolerate ischaemia—roughly 4–6 h.<sup><a href="javascript:;" reveal-id="ehae179-B634" data-open="ehae179-B634" class="link link-ref link-reveal xref-bibr">634</a></sup> Lower-extremity symptoms can include both pain and loss of function. The longer and the stronger these symptoms are, the less likely the possibility of limb salvage.

###### Clinical examination

The emergency level and the choice of therapeutic strategy depend on the clinical presentation, mainly according to neurological deficits. Clinical assessment must include symptom duration as well as sensory and motor deficit severity to distinguish a threatened from a non**_\-_**viable extremity. Neurological deficits (sensory loss or especially motor deficit) are signs of limb threat and require emergency imaging and revascularization.<sup><a href="javascript:;" reveal-id="ehae179-B635" data-open="ehae179-B635" class="link link-ref link-reveal xref-bibr">635</a></sup> Severe sensory deficit and paralysis suggest the limb may be unsalvageable. Clinical ALI categories are presented in _[Table 9](javascript:;)_.

Table 9

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846095)

Clinical categories of acute limb ischaemia

| Grade | Category | Sensory loss | Motor deficit | Arterial Doppler signal | Venous Doppler signal | Capillary refill | Biomarkers | Prognosis |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **I** | Viable | None | None | Yes | Yes | Yes | Not elevated | No immediate threat |
| **IIA** | Marginally threatened | None or minimal (toes) | None | No | Yes |  |  | Salvageable if promptly treated |
| **IIB** | Immediately threatened | More than toes | Mild-moderate | No | Yes |  |  | Salvageable if promptly revascularized |
| **III** | Irreversible | Profound, anaesthetic | Profound paralysis (rigor) | No | No | No | Massively elevated | Major tissue loss, permanent nerve damage inevitable |

Adapted with permission from.<sup><a href="javascript:;" reveal-id="ehae179-B641" data-open="ehae179-B641" class="link link-ref link-reveal xref-bibr">641</a></sup>

© ESC 2024

###### Imaging and functional tests

The imaging method depends on availability and aims to diagnose clot presence and assess haemodynamic severity. DSA, CTA, DUS, and contrast-enhanced (CE)-MRA are options based on local expertise, availability, and preference.<sup><a href="javascript:;" reveal-id="ehae179-B636" data-open="ehae179-B636" class="link link-ref link-reveal xref-bibr">636</a></sup> DUS helps determine treatment urgency when assessing neurological deficit is challenging. Loss of arterial signal suggests limb threat, while a present signal may indicate the limb is not immediately threatened, allowing for ABI measurement. The absence of both arterial and venous Doppler signals, coupled with extensive motor deficit, suggests the limb may be irreversibly damaged (non-salvageable).<sup><a href="javascript:;" reveal-id="ehae179-B637" data-open="ehae179-B637" class="link link-ref link-reveal xref-bibr">637</a></sup> In addition, biomarkers of muscle damage such as creatinine kinase (CK) or myoglobin may be useful as high levels indicate rhabdomyolysis, risk of amputation,<sup><a href="javascript:;" reveal-id="ehae179-B638" data-open="ehae179-B638" class="link link-ref link-reveal xref-bibr">638</a></sup> kidney failure, and mortality.<sup><a href="javascript:;" reveal-id="ehae179-B639" data-open="ehae179-B639" class="link link-ref link-reveal xref-bibr">639</a></sup> In limb ischaemia, CK and myoglobin elevations may be lower in chronic cases, possibly due to ischaemic pre-conditioning and collateral development.<sup><a href="javascript:;" reveal-id="ehae179-B640" data-open="ehae179-B640" class="link link-ref link-reveal xref-bibr">640</a></sup>

##### 8.1.3.2. Medical treatment

Upon clinical diagnosis, initiate analgesia, anticoagulation, and i.v. fluids. Addressing acidosis and hyperkalaemia may be necessary. Administer i.v. unfractionated heparin (bolus 5000 IU or 70–100 IU per kg body weight, followed by continuous infusion with dose adjustment based on patient response, monitored by activated clotting time or activated partial thromboplastin time) or subcutaneous low molecular weight heparin (e.g. enoxaparin 1 mg per kg twice daily) to prevent further embolization and thrombus propagation.

##### 8.1.3.3. Surgical and interventional treatment

For a salvageable limb, urgent revascularization is essential. Diagnostic imaging, if it will not delay treatment, is recommended to guide therapy. If the limb is deemed unsalvageable, primary amputation or comfort care is indicated.

Different revascularization modalities can be applied, including percutaneous catheter-directed thrombolytic therapy, percutaneous mechanical thrombus extraction or thrombo-aspiration (with or without thrombolytic therapy), or surgical thrombectomy, bypass, and/or arterial repair.<sup><a href="javascript:;" reveal-id="ehae179-B642" data-open="ehae179-B642" class="link link-ref link-reveal xref-bibr">642</a></sup> Moreover, these modalities can be combined, with the strategy determined by factors such as neurological deficit, ischaemia duration, localization, size, aetiology, comorbidities, type of conduit (artery or graft), and therapy-related risks and outcomes. Current endovascular approaches to ALI boast high technical success rates.<sup><a href="javascript:;" reveal-id="ehae179-B626" data-open="ehae179-B626" class="link link-ref link-reveal xref-bibr">626</a></sup> To reduce morbidity and mortality, an endovascular-first approach is often preferred, especially in patients with severe comorbidities. Thrombus extraction, thrombo-aspiration, and surgical thrombectomy are indicated in cases of neurological deficit, while catheter-directed thrombolytic therapy is more appropriate in less severe cases without neurological deficit. Modern catheter-based thrombectomy (CDT) is associated with 12-month amputation rates of <10% in Rutherford IIB.<sup><a href="javascript:;" reveal-id="ehae179-B643" data-open="ehae179-B643" class="link link-ref link-reveal xref-bibr">643</a></sup> A meta-analysis showed that although CDT in the treatment of not immediately threatening ALI showed high angiographic success, the long-term outcomes were relatively poor, with low patency and a substantial risk of major amputation.<sup><a href="javascript:;" reveal-id="ehae179-B644" data-open="ehae179-B644" class="link link-ref link-reveal xref-bibr">644</a></sup> Systemic thrombolysis has no role in the treatment of patients with ALI.

A meta-analysis showed that CDT and surgery have similar limb salvage rates.<sup><a href="javascript:;" reveal-id="ehae179-B645" data-open="ehae179-B645" class="link link-ref link-reveal xref-bibr">645</a></sup> Recent analyses indicate benefits of endovascular approaches in terms of mortality at similar amputation rates.<sup><a href="javascript:;" reveal-id="ehae179-B646" data-open="ehae179-B646" class="link link-ref link-reveal xref-bibr">646</a>,<a href="javascript:;" reveal-id="ehae179-B647" data-open="ehae179-B647" class="link link-ref link-reveal xref-bibr">647</a></sup>

A comparison of percutaneous thrombectomy vs. ultrasound-accelerated thrombolysis for the initial management of ALI showed no difference in terms of amputation, bleeding, clinical success, and adverse events, with primary patency at 30 days of 82% and 71%, respectively.<sup><a href="javascript:;" reveal-id="ehae179-B629" data-open="ehae179-B629" class="link link-ref link-reveal xref-bibr">629</a>,<a href="javascript:;" reveal-id="ehae179-B648" data-open="ehae179-B648" class="link link-ref link-reveal xref-bibr">648</a>,<a href="javascript:;" reveal-id="ehae179-B649" data-open="ehae179-B649" class="link link-ref link-reveal xref-bibr">649</a></sup>

After thrombus removal, in cases of pre-existing arterial lesions, these should be treated by endovascular therapy or open surgery. If surgical treatment is required, it should be ideally performed in a hybrid room with capacity to allow sufficient completion angiographic imaging and initiation of local lysis if any remaining clot is visualized. Lower-extremity four-compartment fasciotomies should be performed in patients with long-lasting ischaemia to prevent post-reperfusion compartment syndrome.<sup><a href="javascript:;" reveal-id="ehae179-B637" data-open="ehae179-B637" class="link link-ref link-reveal xref-bibr">637</a></sup> The management of ALI is summarized in _[Figure 16](javascript:;)_.

![Management of acute limb ischaemia.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f16.jpeg?Expires=1728479088&Signature=EEpzpWa~Ywd7gplpUxWjovYq5Dfdu80HI89QTZpf961OsHHFYTQT3dMK1lotoPDK10d~WCzpHWxWBAfPHcseD~K3EaoBMOM7IZg87JdT0cUenVy139Umu4F4v9mkifQwiLafizNtHv9ur-5hr1lp0nRzlLSQX8B09ZTKpV0~5uiF~if6ewjauPKHyE7WZK2t92MFI8KUdPaJpUUbEo1NQ3Zc~byPVmqd5qk0DoqPOSkySLxIJpSZ0nIM16TEkguPxUi7jbTl4w3KucENw9t0pb9Pexz64VDrDaA~0bZplOhPha8Mp5IyObF1FcqmLPqtb3B~F8WZblA3-4hDWm50Bg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 16

Management of acute limb ischaemia.

ALI, acute limb ischaemia; CTA, computed tomography angiography; DSA, digital subtraction angiography; DUS, duplex ultrasound; MRA, magnetic resonance angiography. <sup>a</sup>Should not delay treatment.

[Open in new tab](https://academic.oup.com/view-large/figure/479846106/ehae179f16.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f16.jpeg?Expires=1728479088&Signature=CbedP8gRZTOjTmLmLFBwoxUqgm-nDVWSKS7TYQvWjpdObnOE4JybVwFDTh7P9fdW~YQumBChgVLwiWjyI97LXd8fngUjOdpeyQ2EvPua4x0u2mnZjnO0~xpON1uRXzOIvOHhqSZe6KujaDoWDQkVN7ankbHdZDSIzACzN5kAc~zCojYALJFaFHaNsEqKhtwNHP~vFCGZYZRUmtyHNjJQuDoJP~zz7k3x5fHMYHNiuwSJI9saZUvTS5tHAkAfCvHS7yy-pvq8kqB4xvAqwTKP1~Xh77bMQA7tKgvePcc4ulsowjuYkH3pjefktb1581BrtTXQ~nTa-U3JtoSRQP4b9Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846106&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

##### 8.1.3.4. Follow-up

After revascularization or amputation, haemodynamic success should be established, aetiology of ALI investigated, and OMT ensured. Statins improve outcomes after revascularization.<sup><a href="javascript:;" reveal-id="ehae179-B552" data-open="ehae179-B552" class="link link-ref link-reveal xref-bibr">552</a>,<a href="javascript:;" reveal-id="ehae179-B630" data-open="ehae179-B630" class="link link-ref link-reveal xref-bibr">630</a></sup> Since ALI is frequently caused by thrombo-embolism, Holter-ECG, echocardiogram, and aortic imaging are useful to allow initiation of appropriate therapy, in particular anticoagulation.<sup><a href="javascript:;" reveal-id="ehae179-B650" data-open="ehae179-B650" class="link link-ref link-reveal xref-bibr">650</a></sup> Additionally, consider other prothrombotic syndromes, such as antiphospholipid syndromes and vasculitis, if clinically suspected. While there is only sparse evidence, the inclusion of PAD patients after revascularization into structured follow-up may improve their functional outcomes.<sup><a href="javascript:;" reveal-id="ehae179-B627" data-open="ehae179-B627" class="link link-ref link-reveal xref-bibr">627</a></sup>

Recommendation Table 22

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846109)

Recommendations for the management of patients presenting with acute limb ischaemia (see also Evidence Table 8)

![Recommendations for the management of patients presenting with acute limb ischaemia (see also Evidence Table 8)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt22.jpeg?Expires=1728479088&Signature=PG-TgliYJ5y4DNysDRlTDR6XxF0pXQzS~SqHKNWY6LBMvIILSV7pRP-4mn~SjAXCDsSKx9y6hA7IFOH9lhJYtn0p~Hdug-g0t-iuQrPvRrHImIixQllOFp5Vgdk4-~2EoMRR95-L7l7ptX3G~JFYt8ZDHO3BFUtgfV5Ty4FA7AZYtfH92-lQQcEAnFwTekD-O7i7fJcOMUmu~L1kJ9L6YfF9htOrQXKoAVfGZAZnh~0HXgXbxSujZdP6eLgnuweNsRwkyf0Oq59BnQCBWFNVSX8GVlJV~USJL6utU50mEIUWD4U8pAffaAvA6PORH~YUxvUtpi5hJ-~k3JVs2go6kQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 8.2. Extracranial carotid and vertebral artery disease

#### 8.2.1. Clinical presentation and diagnosis

##### 8.2.1.1. Clinical presentation

Atherosclerotic CS represents one of the major causes of acute ischaemic stroke (20%).<sup><a href="javascript:;" reveal-id="ehae179-B657" data-open="ehae179-B657" class="link link-ref link-reveal xref-bibr">657</a></sup>

CS may be revealed by a cervical bruit, but also by a TIA or stroke.

##### 8.2.1.2. Diagnosis

Atherosclerotic lesions are primarily located in specific arterial segments, including the carotid bifurcation, siphon, M1 segment of the middle cerebral artery, brachiocephalic trunk, subclavian artery, first and fourth segments of the vertebral artery, or first segment of the basilar artery. Carotid plaques (CP), originating in the intima, offer a better representation of the atherosclerotic process than carotid intima-media thickness (cIMT). CP may be diffuse or focal (protuberant). According to the Mannheim carotid plaque consensus, a CP is defined as a focal structure encroaching into the arterial lumen by ≥0.5 mm or ≥50% of the surrounding vessel.<sup><a href="javascript:;" reveal-id="ehae179-B658" data-open="ehae179-B658" class="link link-ref link-reveal xref-bibr">658</a></sup> The American Society of Echocardiography (ASE) recently proposed a definition that includes any focal thickening considered atherosclerotic in origin and encroaching into the lumen of any carotid artery segment (protuberant-type plaque) or, in the case of diffuse vessel wall atherosclerosis, when cIMT measures ≥1.5 mm in any carotid artery segment.<sup><a href="javascript:;" reveal-id="ehae179-B659" data-open="ehae179-B659" class="link link-ref link-reveal xref-bibr">659</a></sup> Plaques can progress to CS, defined as ≥50% narrowing of the extracranial internal carotid artery (ICA), with stenosis severity estimated using the North American Symptomatic Carotid Endarterectomy Trial (NASCET) method or its non-invasive equivalent assessed by DUS (_[Figure 17](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B122" data-open="ehae179-B122" class="link link-ref link-reveal xref-bibr">122</a>,<a href="javascript:;" reveal-id="ehae179-B660" data-open="ehae179-B660" class="link link-ref link-reveal xref-bibr">660</a></sup> Other methods are described in the [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179_supplementary_data.pdf?Expires=1728479088&Signature=jsMN1psOaEf3KpW8UiQOwnEDCNM0eDJ9FhgPq~GNXqLItMAEdFx6foOGTBTeCpJhrfS5f9C1WsT6JBJ-OF2VSZCY4hMS9gJl7FbAOywEXjZ7FkQ8D8eMHICtPb1wzBA3uZZtBKMZczJqU~L965QcGSWu4bY5onpcoRMSzjgnNpdPf9L4pLKg-a0ahzhjNRwGHt5NoJ7ErFgx3duCbchEi0MsV0cDIkqzsUCeNEtwo8kpBYcJAps4DqCXaYZS5CPCAIpG4RbHZce70W~XP9IUuUZszMeWmEvwL5IF-0Kt0kkQwtSCyF6kopinSbFrVRYLZmYxxNRPbjwJpR0g1P88ZQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Section 1.5](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179_supplementary_data.pdf?Expires=1728479088&Signature=jsMN1psOaEf3KpW8UiQOwnEDCNM0eDJ9FhgPq~GNXqLItMAEdFx6foOGTBTeCpJhrfS5f9C1WsT6JBJ-OF2VSZCY4hMS9gJl7FbAOywEXjZ7FkQ8D8eMHICtPb1wzBA3uZZtBKMZczJqU~L965QcGSWu4bY5onpcoRMSzjgnNpdPf9L4pLKg-a0ahzhjNRwGHt5NoJ7ErFgx3duCbchEi0MsV0cDIkqzsUCeNEtwo8kpBYcJAps4DqCXaYZS5CPCAIpG4RbHZce70W~XP9IUuUZszMeWmEvwL5IF-0Kt0kkQwtSCyF6kopinSbFrVRYLZmYxxNRPbjwJpR0g1P88ZQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_. The European Carotid Surgery Trial (ECST) and the area methods overestimate the severity of the CS and are not recommended.<sup><a href="javascript:;" reveal-id="ehae179-B77" data-open="ehae179-B77" class="link link-ref link-reveal xref-bibr">77</a></sup>

![North American Symptomatic Carotid Endarterectomy Trial/European Carotid Surgery Trial methods.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f17.jpeg?Expires=1728479088&Signature=2flPEDtjzhzr1CDsNTkf2WPF83DrdBNFm3qYRDwD~3HIIXB0YOBfhfyg8S0B6OciIMH2wE8F73KUltdZsI5lOA910S4ySiVys09WRIe3U0PUXMIdjUvy3Bhb5VdvrZmdna3xtQ~vEiuZrrFHFdBccIuBes8Qh-6pen8BRpEy9NxQJoNsyKS5Kq~Bx3uYAs8X~sHRgx7NA6ffvFkgCoKWkLpa9rP1ZhvqISXmq8uiMkLQqzz4P1NtzMwC4YOt1uo-I0MThS295XzF1h1jaMGfezL2D3itJFhp1FKsvNLSPStle901n0XGN1LGBCO-Uj6fcCjZGwaDxCeVwyJVTce7Ag__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 17

North American Symptomatic Carotid Endarterectomy Trial/European Carotid Surgery Trial methods.

ECST, European Carotid Surgery Trial; NASCET, North American Symptomatic Carotid Endarterectomy trial.

[Open in new tab](https://academic.oup.com/view-large/figure/479846117/ehae179f17.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f17.jpeg?Expires=1728479088&Signature=W-dyKJmU8l-jiNWZ7FvNbyYVvFn8McfkctGoqeI9HmKzU66qnCNyc61uHhUklAB81ppXo~IfqtE6TPrTyEwSXT~~xryUO3rWnEAG4uiTsP2OnYUxJ1LzK0ZOpKAc4IgFjicZeef6M-5GdRisKWhZCMVWvXfsupP2jxYK1VINm8ytkJNiLwU8DAAa~dl~-mjmTGN3OQxypNCmQ2IrHwtGTxWTpWwYBUEUXfOGKGs9TGKeYSAYzZXl8EcBLVJ~AQp-biYN9y2nFoVe1jA7Vgof1S37DSPv0p9Mq~JujZ~wd7XFBds0mQI4VXjvxBZYbcT8~luLmfiBG7ia6l5CLDx55w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846117&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Carotid DUS is safe, accurate, and reliable if performed by a skilled vascular specialist. It is the first-line imaging modality for screening, diagnosis, and surveillance of extracranial carotid arteries.<sup><a href="javascript:;" reveal-id="ehae179-B77" data-open="ehae179-B77" class="link link-ref link-reveal xref-bibr">77</a></sup> The degree of stenosis is mostly based on Doppler analysis of blood flow in the common carotid artery (CCA), ICA, and external carotid artery (_[Table 10](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B661" data-open="ehae179-B661" class="link link-ref link-reveal xref-bibr">661</a>,<a href="javascript:;" reveal-id="ehae179-B662" data-open="ehae179-B662" class="link link-ref link-reveal xref-bibr">662</a></sup> Vertebral and subclavian arteries must also be checked. In some cases, indirect signs of severe stenosis have to be evaluated by transcranial and/or ophthalmic artery Doppler. Severe arterial calcification can decrease DUS accuracy.<sup><a href="javascript:;" reveal-id="ehae179-B122" data-open="ehae179-B122" class="link link-ref link-reveal xref-bibr">122</a></sup>

Table 10

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846119)

Peak systolic velocity criteria for grading internal carotid artery stenosis

| % stenosis | Reference | 50%–69% (moderate stenosis) | ≥70% (severe stenosis) |
| --- | --- | --- | --- |
| PSV threshold | SRUCC<sup><a href="javascript:;" reveal-id="ehae179-B662" data-open="ehae179-B662" class="link link-ref link-reveal xref-bibr">662</a></sup>  
\-------------------------  
Gornik _et al._<sup><a href="javascript:;" reveal-id="ehae179-B661" data-open="ehae179-B661" class="link link-ref link-reveal xref-bibr">661</a></sup> | 125–230 cm/s  
  
\-------------------------  
≥180 cm/s  
or  
≥125 cm/s + PSV ICA/CCA ≥2 | \>230 cm/s  
  
\-------------------------  
Overestimation with SRUCC criteria but no consensus |

CCA, common carotid artery; ICA, internal carotid artery; PSV, peak systolic velocity; SRUCC, Society of Radiologists in Ultrasound.

© ESC 2024

Recommendation Table 23

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846120)

Recommendations for carotid artery stenosis assessment

![Recommendations for carotid artery stenosis assessment](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt23.jpeg?Expires=1728479088&Signature=cGAU0c-asKRgAwQv6721JqHI9bJc9NblFKKYIQKPLT0izklSIXiBUkWjGszpCm0vAHN4fojlqsXFYtjx544VvKPCOLIrOTQI~L1MwTOTYT6wl7tRHkQ2fopvkUEY-csMACnhal64QymFhLZ43LGJgSmZF3GFNkVgjL31UjjuiE~WLsSaznCl-QqylzXaE8yyeGa65JBwujwXYIXpFO1LDJgDIIe3ZQg8aCzj8JAstzLihJehM4CR~ROPoX060NcJdXMAhtQj4QoZyilpvoESWdp5qc7AsQudzm6H1m5T1hxlYlT3Qa1Fadrf1cg0SraJHr8PcIBYmMrN~LDTaqBkMw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 8.2.2. Asymptomatic carotid artery stenosis

##### 8.2.2.1. Medical treatment

Optimal medical treatment is based on CVRF correction through lifestyle intervention and pharmacological treatment, with the goal of reducing cerebrovascular and global CV events.<sup><a href="javascript:;" reveal-id="ehae179-B19" data-open="ehae179-B19" class="link link-ref link-reveal xref-bibr">19</a></sup> Concerning hypertension, similar target values as those presented in the general section are recommended for patients with asymptomatic CS.

###### Lipid-lowering therapy

See _Section [7](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#ehae179-s6)_.

###### Antihypertensive therapy

See _Section [7](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#ehae179-s6)_.

###### Glucose-lowering therapy

See _Section [7](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#ehae179-s6)_.

###### Antithrombotic therapy

The clinical benefit of antithrombotic treatment in patients with asymptomatic CS remains unproven.<sup><a href="javascript:;" reveal-id="ehae179-B664" data-open="ehae179-B664" class="link link-ref link-reveal xref-bibr">664</a></sup> The only RCT (the Asymptomatic Cervical Bruit Study \[ACB\]) addressing the issue enrolled only 188 patients per arm, and failed to show superiority of aspirin vs. placebo in reducing TIA, stroke, MI, or death.<sup><a href="javascript:;" reveal-id="ehae179-B665" data-open="ehae179-B665" class="link link-ref link-reveal xref-bibr">665</a></sup> In observational studies, SAPT (mainly low-dose aspirin) was associated with reduced risk of MACE, although data were conflicting for moderate stenosis (i.e. 50%–75%);<sup><a href="javascript:;" reveal-id="ehae179-B664" data-open="ehae179-B664" class="link link-ref link-reveal xref-bibr">664</a></sup> DAPT, combining aspirin and clopidogrel, has no benefit over SAPT.<sup><a href="javascript:;" reveal-id="ehae179-B496" data-open="ehae179-B496" class="link link-ref link-reveal xref-bibr">496</a>,<a href="javascript:;" reveal-id="ehae179-B497" data-open="ehae179-B497" class="link link-ref link-reveal xref-bibr">497</a></sup>

The Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial reported a non-significant decrease in MACE in patients with either history of carotid revascularization or asymptomatic patients with >50% CS and CVRFs allocated to dual antithrombotic therapy (aspirin 100 mg o.d. and rivaroxaban 2.5 mg b.i.d.) vs. aspirin alone or rivaroxaban 5 mg b.i.d. alone. However, specific data on asymptomatic CS were not reported.

Since these patients present a two times higher risk of MI,<sup><a href="javascript:;" reveal-id="ehae179-B30" data-open="ehae179-B30" class="link link-ref link-reveal xref-bibr">30</a></sup> lifelong low-dose aspirin should be considered in asymptomatic CS patients at increased risk for CV events (i.e. diabetic patients) and low bleeding risk<sup><a href="javascript:;" reveal-id="ehae179-B497" data-open="ehae179-B497" class="link link-ref link-reveal xref-bibr">497</a></sup> to reduce stroke and CV risk.<sup><a href="javascript:;" reveal-id="ehae179-B19" data-open="ehae179-B19" class="link link-ref link-reveal xref-bibr">19</a>,<a href="javascript:;" reveal-id="ehae179-B299" data-open="ehae179-B299" class="link link-ref link-reveal xref-bibr">299</a>,<a href="javascript:;" reveal-id="ehae179-B488" data-open="ehae179-B488" class="link link-ref link-reveal xref-bibr">488</a>,<a href="javascript:;" reveal-id="ehae179-B666" data-open="ehae179-B666" class="link link-ref link-reveal xref-bibr">666</a></sup>

Recommendation Table 24

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846134)

Recommendations for antithrombotic treatment in patients with carotid stenosis

![Recommendations for antithrombotic treatment in patients with carotid stenosis](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt24.jpeg?Expires=1728479088&Signature=vicFyMqeFeL8H6suC~xp3LFo-Nz2ttuT-e2xIDKqOLMZUT~GZgEth3Wl0tTnjReuxOEl8bGwYCZebgqsiwdBpjLM2u0t-KmzYcA476sJ3fMuHECl8KIKyltsHWb0BvFDyPELWhP6ZzoIS5DG11k7oL8ZaChXpCA~Ohgw6YR0Ocio-005NS12o01Mxm-NhSzxFGt5gscGSCHHnlHBTk3nnIZirBv053d5Yr5BfOiCF7ZM~9Aia34tUggMxf1eWOWl3ATUVj613RFNuW2pKFFfgiNX4yLYJzHDIGjQJTifdFYWtxzFKMm1Kl-coREQYKLGxVg2d-drtNOr0vZ0gcSv2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

##### 8.2.2.2. Interventional treatment

###### Open surgery vs. medical therapy

The rationale for carotid endarterectomy (CEA) in asymptomatic CS stems from two trials that were published some time ago. The Asymptomatic Carotid Atherosclerosis Study (ACAS) and the Asymptomatic Carotid Surgery Trial 1 (ACST-1) compared CEA with medical therapy in asymptomatic patients with 60%–99% CS.<sup><a href="javascript:;" reveal-id="ehae179-B672 ehae179-B673 ehae179-B674" data-open="ehae179-B672 ehae179-B673 ehae179-B674" class="link link-ref link-reveal xref-bibr">672–674</a></sup> In ACAS, 5 year rates of ipsilateral stroke/death under CEA vs. medical therapy were 5.1% vs. 11.0%. ACST-1 reported 5 year rates of any stroke of 6.4% vs. 11.8%, respectively. In a combined analysis of both trials, CEA conferred less benefit in women at 5 years.<sup><a href="javascript:;" reveal-id="ehae179-B675" data-open="ehae179-B675" class="link link-ref link-reveal xref-bibr">675</a></sup> At 10 years, however, ACST-1<sup><a href="javascript:;" reveal-id="ehae179-B674" data-open="ehae179-B674" class="link link-ref link-reveal xref-bibr">674</a></sup> reported that females benefit following CEA (absolute risk reduction \[ARR\] 5.8%) to the same extent as men (ARR 5.5%).

Medical treatment has advanced following the recruitment of patients in these trials.<sup><a href="javascript:;" reveal-id="ehae179-B672 ehae179-B673 ehae179-B674 ehae179-B675 ehae179-B676" data-open="ehae179-B672 ehae179-B673 ehae179-B674 ehae179-B675 ehae179-B676" class="link link-ref link-reveal xref-bibr">672–676</a></sup> A 60%–70% decline in annual stroke rates was also observed in medically treated patients in both trials over 1995 to 2010.<sup><a href="javascript:;" reveal-id="ehae179-B676" data-open="ehae179-B676" class="link link-ref link-reveal xref-bibr">676</a></sup> This reduction was attributed to better medical treatment and lower smoking incidence. The Stent Protected Angioplasty versus Carotid Endarterectomy study (SPACE-2) compared OMT alone against OMT plus CEA/carotid artery stenting (CAS) in asymptomatic patients with CS ≥70% according to ECST criteria. Due to slow recruitment, the study was underpowered. The 1 year rate of the major secondary endpoint was 2.5% after CEA, 3.0% after CAS, and 0.9% after OMT.<sup><a href="javascript:;" reveal-id="ehae179-B677" data-open="ehae179-B677" class="link link-ref link-reveal xref-bibr">677</a></sup> Incidence of any stroke or death from any cause within 30 days or any ipsilateral ischaemic stroke within 5 years (primary efficacy endpoint) was 2.5% with CEA plus OMT, 4.4% with CAS plus OMT, and 3.1% with OMT alone. Results from the Carotid Revascularization Endartectomy vs. Stenting Trial 2 (CREST-2) are awaited to clarify whether intervention is beneficial in the treatment of asymptomatic CS compared with modern OMT.

The ARR in stroke favouring surgery over OMT was only 4.6% at 10 years in ACST-1, indicating that 95% of asymptomatic patients ultimately underwent unnecessary interventions.<sup><a href="javascript:;" reveal-id="ehae179-B674" data-open="ehae179-B674" class="link link-ref link-reveal xref-bibr">674</a>,<a href="javascript:;" reveal-id="ehae179-B678" data-open="ehae179-B678" class="link link-ref link-reveal xref-bibr">678</a></sup>

A recent meta-analysis confirmed the role of modern OMT in reducing major stroke, combined stroke, and mortality in asymptomatic patients, suggesting that OMT has the potential to reduce the requirement for surgical intervention in patients with asymptomatic carotis stenosis.<sup><a href="javascript:;" reveal-id="ehae179-B679" data-open="ehae179-B679" class="link link-ref link-reveal xref-bibr">679</a></sup>

In conclusion, for invasive treatment of asymptomatic carotid stenosis, the overall risk reduction is low compared with OMT. Current data are not available to assess subgroups that may still benefit from intervention. However, there is a need to target revascularization in a subgroup of patients with clinical and/or imaging features that increase the risk for stroke on OMT (_[Table 11](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B678" data-open="ehae179-B678" class="link link-ref link-reveal xref-bibr">678</a>,<a href="javascript:;" reveal-id="ehae179-B680" data-open="ehae179-B680" class="link link-ref link-reveal xref-bibr">680</a></sup>

Table 11

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846142)

High-risk features associated with increased risk of stroke in patients with asymptomatic internal carotid artery stenosis on optimal medical treatment

<table role="presentation" aria-labelledby="
                        label-42213" aria-describedby="
                        caption-42213"><tbody><tr><td>Clinical<sup><a href="javascript:;" reveal-id="tblfn267" data-open="tblfn267" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup></td><td>Contralateral TIA/stroke<sup><a href="javascript:;" reveal-id="ehae179-B681" data-open="ehae179-B681" class="link link-ref link-reveal xref-bibr">681</a>,<a href="javascript:;" reveal-id="ehae179-B682" data-open="ehae179-B682" class="link link-ref link-reveal xref-bibr">682</a></sup></td></tr><tr><td>Cerebral imaging</td><td>Ipsilateral silent infarction<sup><a href="javascript:;" reveal-id="ehae179-B683 ehae179-B684 ehae179-B685" data-open="ehae179-B683 ehae179-B684 ehae179-B685" class="link link-ref link-reveal xref-bibr">683–685</a></sup></td></tr><tr><td>Ultrasound/CT imaging</td><td>Stenosis progression (&gt;20%)<sup><a href="javascript:;" reveal-id="ehae179-B340" data-open="ehae179-B340" class="link link-ref link-reveal xref-bibr">340</a>,<a href="javascript:;" reveal-id="ehae179-B684" data-open="ehae179-B684" class="link link-ref link-reveal xref-bibr">684</a>,<a href="javascript:;" reveal-id="ehae179-B685" data-open="ehae179-B685" class="link link-ref link-reveal xref-bibr">685</a></sup><br>Spontaneous embolization on transcranial Doppler (HITS)<sup><a href="javascript:;" reveal-id="ehae179-B341" data-open="ehae179-B341" class="link link-ref link-reveal xref-bibr">341</a>,<a href="javascript:;" reveal-id="ehae179-B686" data-open="ehae179-B686" class="link link-ref link-reveal xref-bibr">686</a></sup><br>Impaired cerebral vascular reserve<sup><a href="javascript:;" reveal-id="ehae179-B687" data-open="ehae179-B687" class="link link-ref link-reveal xref-bibr">687</a>,<a href="javascript:;" reveal-id="ehae179-B688" data-open="ehae179-B688" class="link link-ref link-reveal xref-bibr">688</a></sup><br>Large plaques<sup><a href="javascript:;" reveal-id="ehae179-B689" data-open="ehae179-B689" class="link link-ref link-reveal xref-bibr">689</a>,<a href="javascript:;" reveal-id="ehae179-B690" data-open="ehae179-B690" class="link link-ref link-reveal xref-bibr">690</a></sup><br>Echolucent plaques<sup><a href="javascript:;" reveal-id="ehae179-B136" data-open="ehae179-B136" class="link link-ref link-reveal xref-bibr">136</a>,<a href="javascript:;" reveal-id="ehae179-B691" data-open="ehae179-B691" class="link link-ref link-reveal xref-bibr">691</a></sup><br>Increased juxta-luminal black (hypoechogenic) area<sup><a href="javascript:;" reveal-id="ehae179-B689" data-open="ehae179-B689" class="link link-ref link-reveal xref-bibr">689</a>,<a href="javascript:;" reveal-id="ehae179-B690" data-open="ehae179-B690" class="link link-ref link-reveal xref-bibr">690</a></sup></td></tr><tr><td>MRA<sup><a href="javascript:;" reveal-id="tblfn268" data-open="tblfn268" class="link link-ref link-reveal xref-fn js-xref-fn">b</a></sup></td><td>Intraplaque haemorrhage<sup><a href="javascript:;" reveal-id="ehae179-B692" data-open="ehae179-B692" class="link link-ref link-reveal xref-bibr">692</a>,<a href="javascript:;" reveal-id="ehae179-B693" data-open="ehae179-B693" class="link link-ref link-reveal xref-bibr">693</a></sup><br>Lipid-rich necrotic core<sup><a href="javascript:;" reveal-id="ehae179-B694" data-open="ehae179-B694" class="link link-ref link-reveal xref-bibr">694</a>,<a href="javascript:;" reveal-id="ehae179-B695" data-open="ehae179-B695" class="link link-ref link-reveal xref-bibr">695</a></sup></td></tr></tbody></table>

CT, computed tomography; HITS, high-intensity transient signal; MRA, magnetic resonance angiography; TIA, transient ischaemic attack.

<sup>a</sup>Age is not a predictor of poorer outcome.

<sup>b</sup>More than 40 mm<sup>2</sup> on digital analysis.

© ESC 2024

Importantly, ACST-1 found no evidence that age >75 years at baseline was associated with any ipsilateral stroke reduction at 5–10 years.<sup><a href="javascript:;" reveal-id="ehae179-B676 ehae179-B677 ehae179-B678" data-open="ehae179-B676 ehae179-B677 ehae179-B678" class="link link-ref link-reveal xref-bibr">676–678</a>,<a href="javascript:;" reveal-id="ehae179-B696" data-open="ehae179-B696" class="link link-ref link-reveal xref-bibr">696</a></sup> Neither the ACAS nor ACST-1 studies found any evidence that stenosis severity or contralateral occlusion increased late stroke risk.<sup><a href="javascript:;" reveal-id="ehae179-B672" data-open="ehae179-B672" class="link link-ref link-reveal xref-bibr">672</a>,<a href="javascript:;" reveal-id="ehae179-B674" data-open="ehae179-B674" class="link link-ref link-reveal xref-bibr">674</a>,<a href="javascript:;" reveal-id="ehae179-B697" data-open="ehae179-B697" class="link link-ref link-reveal xref-bibr">697</a></sup> In a recent meta-analysis, increasing stenosis was associated with late ipsilateral stroke only in the presence of concomitant high-risk features.<sup><a href="javascript:;" reveal-id="ehae179-B698" data-open="ehae179-B698" class="link link-ref link-reveal xref-bibr">698</a></sup> The general algorithm of CS management is presented in _[Figure 18](javascript:;)_.<sup><a href="javascript:;" reveal-id="ehae179-B552" data-open="ehae179-B552" class="link link-ref link-reveal xref-bibr">552</a></sup>

![Algorithm of carotid artery stenosis management.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f18.jpeg?Expires=1728479088&Signature=UEqCuAei4lk6KBHHNxqZbW6dixicxLJ-le1qDNsVfHlahhKSm8phANGVDjE-esUpoB7tD2mAEB4s8Y0UfIv7ikETjP7x3ObJQOY2MbvVZGqR9RZjDDrOuEYatWzd3GoZqUq~6vTnD4tZ-3RMPbSMkxao0oXHC7WO~aH3vhr6yKRi5jyD3ng~g5QyS81D-iqOpK4-imIVqAiiXyFC2MEE4zjSTvOghMT7sXvIKyVW5HX3MoceCUSF8BuyJrJ3HaEcVu-6n97AKZIIcGvg1xa49n82LOzJqys3vqd9t8TXXSIEf5~xhZ5KBn0JV396Nq7z2rxUEZL~rg3pcJFQ1pdVLQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 18

Algorithm of carotid artery stenosis management.

CAS, carotid artery stenting; CEA, carotid endarterectomy; CTA, computed tomography angiography; MRA, magnetic resonance angiography; OMT, optimal medical treatment; TCAR, transcarotid artery revascularization; TIA, transient ischaemic attack. <sup>a</sup>Assess presence of high-risk features according to _[Table 11](javascript:;)_. If surgery/revascularization is considered, assess the overall risk related to surgery according to _[Table 12](javascript:;)_.

[Open in new tab](https://academic.oup.com/view-large/figure/479846144/ehae179f18.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f18.jpeg?Expires=1728479088&Signature=J1YX6-pFl-6Rboo7rBzQzFFcFhhVx3bFLQjLYx1dmtiOoPfc8fFMhWY6WgpLJqW-NAHJHG7KPU8ZmkdhWJxE1IH0~RTn9WjdgXSlBiTNU-FE8Rc7WwwiTbmBh9O3oBPnQxJHCAdccr-ktV0pAdA4WIEZlgMV0zr1NBVHshnA4Mx5e3o0-pV0~R~6lXEONU6v~n~uwqkS62wvFfbdkXF-hnyaX6aCvfY3GKV4igabjcXeYHtd2sY3CufxcWntxiuzOyPqqk931me8xbh5X3xjvJiTqM8VyT0KICwWb9KbIbJxYTOs0h5n-0q1r3xYP1ULvdNGZBbE90d8rgoWs~8Pjw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846144&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

###### Carotid revascularization: surgery vs. stenting

In a recent meta-analysis update on RCTs in asymptomatic patients comparing CEA vs. CAS, including altogether 7092 patients, CAS was associated with significantly higher rates of 30 day ‘any’ stroke and 30 day death/any stroke, while CEA was associated with significantly higher rates of 30 day MI. No significant differences were seen in 30 day death, 30 day disabling stroke, 30 day death/disabling stroke, or 30 day death/any stroke/MI when CAS was compared with CEA.<sup><a href="javascript:;" reveal-id="ehae179-B699" data-open="ehae179-B699" class="link link-ref link-reveal xref-bibr">699</a></sup> In the largest RCT, ACST-2, post-operative death and major stroke were similar (1.0%) between groups.<sup><a href="javascript:;" reveal-id="ehae179-B700" data-open="ehae179-B700" class="link link-ref link-reveal xref-bibr">700</a>,<a href="javascript:;" reveal-id="ehae179-B701" data-open="ehae179-B701" class="link link-ref link-reveal xref-bibr">701</a></sup>

No significant difference was found in the 5 and 10 year incidence of ipsilateral stroke and any stroke between CEA and CAS.<sup><a href="javascript:;" reveal-id="ehae179-B696" data-open="ehae179-B696" class="link link-ref link-reveal xref-bibr">696</a>,<a href="javascript:;" reveal-id="ehae179-B702" data-open="ehae179-B702" class="link link-ref link-reveal xref-bibr">702</a>,<a href="javascript:;" reveal-id="ehae179-B703" data-open="ehae179-B703" class="link link-ref link-reveal xref-bibr">703</a></sup> The 5 year non-procedural stroke rate in ACST-2 was 2.5% in each group for fatal/disabling stroke, and 5.3% with CAS vs. 4.5% with CEA for any stroke.<sup><a href="javascript:;" reveal-id="ehae179-B700" data-open="ehae179-B700" class="link link-ref link-reveal xref-bibr">700</a>,<a href="javascript:;" reveal-id="ehae179-B701" data-open="ehae179-B701" class="link link-ref link-reveal xref-bibr">701</a></sup>

The Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy (SAPPHIRE) trial randomized symptomatic and asymptomatic patients deemed ‘high-risk for surgery’ to either CEA or CAS (using embolic protection devices).<sup><a href="javascript:;" reveal-id="ehae179-B704" data-open="ehae179-B704" class="link link-ref link-reveal xref-bibr">704</a></sup> Overall, 71% of SAPPHIRE patients were asymptomatic, and in these patients the 30 day rate of death/stroke after CAS was 5.8% vs. 6.1% after CEA<sup><a href="javascript:;" reveal-id="ehae179-B704" data-open="ehae179-B704" class="link link-ref link-reveal xref-bibr">704</a></sup>—both beyond the recommended 3%. If these procedural risk levels reflect contemporary practice, most ‘high-risk for surgery’ asymptomatic patients would be better treated medically.

A small sample size RCT has provided evidence that the use of a double-layer mesh stent can reduce the occurrence of peri-procedural diffusion-weighted imaging (DWI)-detected ischaemic lesion after carotid stents, when compared with conventional stents. At 1 year follow-up the use of a double-layer mesh stent was associated with a significant reduction in the composite endpoint of MACE and in-stent restenosis or occlusion. The clinical benefit of these findings has to be proven.<sup><a href="javascript:;" reveal-id="ehae179-B705" data-open="ehae179-B705" class="link link-ref link-reveal xref-bibr">705</a>,<a href="javascript:;" reveal-id="ehae179-B706" data-open="ehae179-B706" class="link link-ref link-reveal xref-bibr">706</a></sup>

Transcarotid artery revascularization (TCAR) has been introduced recently. Although no RCTs are available, large registry-based analyses report a 99.7% technical success rate and low 30 day complication rates (<3% in 30 day stroke/death and <1% MI).<sup><a href="javascript:;" reveal-id="ehae179-B681" data-open="ehae179-B681" class="link link-ref link-reveal xref-bibr">681</a></sup>

In a large-scale registry the 1 year rate of stroke or death was 6.4% for TCAR, 5.2% for CEA, and 9.7% for transfemoral carotid artery stenting (TFCAS).<sup><a href="javascript:;" reveal-id="ehae179-B707" data-open="ehae179-B707" class="link link-ref link-reveal xref-bibr">707</a></sup>

Properly conducted RCTs comparing TCAR with CEA in asymptomatic patients are required to establish the true place of TCAR in carotid revascularization.<sup><a href="javascript:;" reveal-id="ehae179-B708" data-open="ehae179-B708" class="link link-ref link-reveal xref-bibr">708</a></sup>

Recommendation Table 25

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846153)

Recommendations for interventional treatment in patients with asymptomatic carotid artery stenosis

![Recommendations for interventional treatment in patients with asymptomatic carotid artery stenosis](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt25.jpeg?Expires=1728479088&Signature=Z8UjgypADOXDaYWY~Q8z-YG-NSo3asuAD727rRcBrZ2lX2C6FCATmaPQxk2YOfQMh3z6LtZnLKOFdFbGPnnUVh3ZBUt0AOgkPXIAF0zE3eFyxujfU7IbsIM7h5eJS2k0QDZlpuefMN3-48iBpWfuGFr8t2mG2JWKVXzPYYdEdrofUrqkYvGU4ReRlnIssjJpsk4QKqC63wn7B5e-4G-3-ZFMBTcq5pwnY0PbfscCcksHfeRJXvHFG9CUDaCd53oTodMz6-BopZy6XRbRpIU~nY7TYDAp9jkpz9VjwRAH1D4g9c-iQQgQ27MRr1RgTYrjY1x9CWj-XZFiVpa0gH0zqQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 8.2.3. Symptomatic carotid artery stenosis

##### 8.2.3.1. Medical treatment

###### Lipid-lowering therapy

See _Section [7](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#ehae179-s6)_.

###### Antihypertensive therapy

See _Section [7](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#ehae179-s6)_.

###### Glucose-lowering therapy

See _Section [7](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#ehae179-s6)_.

###### Antithrombotic therapy

Symptomatic CS is associated with a high risk of early recurrence of cerebrovascular ischaemic events.<sup><a href="javascript:;" reveal-id="ehae179-B667 ehae179-B668 ehae179-B669" data-open="ehae179-B667 ehae179-B668 ehae179-B669" class="link link-ref link-reveal xref-bibr">667–669</a>,<a href="javascript:;" reveal-id="ehae179-B683" data-open="ehae179-B683" class="link link-ref link-reveal xref-bibr">683</a></sup> DAPT with low-dose aspirin and clopidogrel is recommended for all patients with symptomatic CS for at least 3 months.<sup><a href="javascript:;" reveal-id="ehae179-B669" data-open="ehae179-B669" class="link link-ref link-reveal xref-bibr">669</a></sup> Those undergoing surgical revascularization can stop clopidogrel after surgery.<sup><a href="javascript:;" reveal-id="ehae179-B711" data-open="ehae179-B711" class="link link-ref link-reveal xref-bibr">711</a></sup> Those undergoing endovascular revascularization should continue DAPT with clopidogrel and low-dose aspirin for 4 weeks after the procedure.<sup><a href="javascript:;" reveal-id="ehae179-B488" data-open="ehae179-B488" class="link link-ref link-reveal xref-bibr">488</a>,<a href="javascript:;" reveal-id="ehae179-B666" data-open="ehae179-B666" class="link link-ref link-reveal xref-bibr">666</a>,<a href="javascript:;" reveal-id="ehae179-B711" data-open="ehae179-B711" class="link link-ref link-reveal xref-bibr">711</a>,<a href="javascript:;" reveal-id="ehae179-B712" data-open="ehae179-B712" class="link link-ref link-reveal xref-bibr">712</a></sup> In patients with stroke related to extracranial arterial disease, aspirin was more effective than VKAs in reducing recurrencies.<sup><a href="javascript:;" reveal-id="ehae179-B687" data-open="ehae179-B687" class="link link-ref link-reveal xref-bibr">687</a>,<a href="javascript:;" reveal-id="ehae179-B713" data-open="ehae179-B713" class="link link-ref link-reveal xref-bibr">713</a></sup> Subgroup analysis from the Acute Stroke or Transient Ischaemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) trial suggested a lower rate of MACE in patients receiving ticagrelor vs. aspirin;<sup><a href="javascript:;" reveal-id="ehae179-B689" data-open="ehae179-B689" class="link link-ref link-reveal xref-bibr">689</a></sup> however, this analysis was underpowered to make any conclusions regarding the benefit of ticagrelor.

A combination of aspirin and clopidogrel in the early phase of symptomatic carotid stenosis reduces asymptomatic cerebral embolization and stroke.<sup><a href="javascript:;" reveal-id="ehae179-B692" data-open="ehae179-B692" class="link link-ref link-reveal xref-bibr">692</a>,<a href="javascript:;" reveal-id="ehae179-B694" data-open="ehae179-B694" class="link link-ref link-reveal xref-bibr">694</a>,<a href="javascript:;" reveal-id="ehae179-B714" data-open="ehae179-B714" class="link link-ref link-reveal xref-bibr">714</a></sup> It also reduces stroke recurrence after a minor stroke/TIA.<sup><a href="javascript:;" reveal-id="ehae179-B667" data-open="ehae179-B667" class="link link-ref link-reveal xref-bibr">667</a>,<a href="javascript:;" reveal-id="ehae179-B668" data-open="ehae179-B668" class="link link-ref link-reveal xref-bibr">668</a></sup>

Recently, the Acute Stroke or Transient Ischaemic Attack Treated with Ticagrelor and acetylsalicylic acid for Prevention of Stroke and Death (THALES) trial showed a 17% reduction in the risk of death or stroke when using ticagrelor and aspirin vs. aspirin alone in patients with minor stroke or high-risk TIA;<sup><a href="javascript:;" reveal-id="ehae179-B715" data-open="ehae179-B715" class="link link-ref link-reveal xref-bibr">715</a></sup> however, bleeding events occurred more frequently in the ticagrelor plus aspirin group.<sup><a href="javascript:;" reveal-id="ehae179-B700" data-open="ehae179-B700" class="link link-ref link-reveal xref-bibr">700</a>,<a href="javascript:;" reveal-id="ehae179-B716" data-open="ehae179-B716" class="link link-ref link-reveal xref-bibr">716</a></sup> Of note, COMPASS data cannot be applied to symptomatic carotid stenosis since these patients were excluded because of intracranial bleeding risk.<sup><a href="javascript:;" reveal-id="ehae179-B499" data-open="ehae179-B499" class="link link-ref link-reveal xref-bibr">499</a></sup>

Recommendation Table 26

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846166)

Recommendations for evaluation and medical treatment in patients with symptomatic carotid artery stenosis

![Recommendations for evaluation and medical treatment in patients with symptomatic carotid artery stenosis](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt26.jpeg?Expires=1728479088&Signature=fJ6pyFvGtr7gmBDuG6VILpo~J~qtxtsjBkuE8iXa8pT7Z0OCk1~O-B6k70-4bl53QQfiIofgdpDh77irq~mK748YpFX4IVib7DjLEuqlpGhsPzVP1LpOk~5SUsPngfTvwcVH-Nxu6ALkUObKTyUmhbbwYX5GcsPtkc70j2tyM9vQ0pJMMzjba2XYpnZg-L2AOmh-KGsIAaAJcQgJv~CA4~S2xsYlNdvP-DFVPdR5Zuytky8tdlZSiDt8AMq6ObjN4ef7cQxNHR90cnmWIaHdlLlOLyk0rrbhDCNx39XqDt0ubwG1YHPu1wLN2xo8CFMy4dFUkmc-njJU7~qkiyHmyw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

##### 8.2.3.2. Interventional treatment

###### Open surgery

Optimal medical treatment is recommended for all symptomatic patients with CS. In recently symptomatic patients with <50% stenosis, CEA (plus OMT) did not prevent stroke. However, surgery reduced stroke risk in patients with moderate (50%–69%) and severe (70%–99%) stenosis. The benefit from surgery increased with increasing severity of stenosis, except for ‘near-occlusion’ lesions (95%–99% stenosis with distal ICA collapse or a narrow calibre lumen with ‘trickle flow’).<sup><a href="javascript:;" reveal-id="ehae179-B660" data-open="ehae179-B660" class="link link-ref link-reveal xref-bibr">660</a>,<a href="javascript:;" reveal-id="ehae179-B717 ehae179-B718 ehae179-B719 ehae179-B720" data-open="ehae179-B717 ehae179-B718 ehae179-B719 ehae179-B720" class="link link-ref link-reveal xref-bibr">717–720</a></sup>

Some features are associated with a higher increase of stroke in symptomatic patients (50%–99% stenosis) medically treated: age (>75 years), symptoms within 14 days, male sex, hemispheric (vs. retinal) symptoms, cortical (vs. lacunar) stroke, increasing comorbidities, irregular stenosis, stenosis severity, contralateral occlusion, tandem intracranial stenosis, and failure to recruit intracranial collaterals.<sup><a href="javascript:;" reveal-id="ehae179-B721" data-open="ehae179-B721" class="link link-ref link-reveal xref-bibr">721</a></sup>

Large-scale registries suggest that CEA can be performed safely in the first 7 days after TIA/minor stroke.<sup><a href="javascript:;" reveal-id="ehae179-B722 ehae179-B723 ehae179-B724" data-open="ehae179-B722 ehae179-B723 ehae179-B724" class="link link-ref link-reveal xref-bibr">722–724</a></sup> However, not all patients benefit from urgent revascularization, and controversy exists over the safety of performing CEA within the first 48 h after symptom onset due to an increased risk of haemorrhagic transformation. Higher-risk patients include those with acute carotid occlusion, a persisting major neurological deficit, an area of middle cerebral artery infarction exceeding one-third, evidence of pre-existing parenchymal haemorrhage, and signs of impaired consciousness.<sup><a href="javascript:;" reveal-id="ehae179-B724" data-open="ehae179-B724" class="link link-ref link-reveal xref-bibr">724</a>,<a href="javascript:;" reveal-id="ehae179-B725" data-open="ehae179-B725" class="link link-ref link-reveal xref-bibr">725</a></sup>

The choice to perform carotid revascularization within 48 h from symptom onset is still debatable.<sup><a href="javascript:;" reveal-id="ehae179-B726" data-open="ehae179-B726" class="link link-ref link-reveal xref-bibr">726</a></sup>

###### Endovascular therapy vs. open surgery

Contemporary RCTs comparing CEA with CAS in symptomatic patients reported a significantly higher risk of 30 day ‘any stroke’ and ‘death/stroke’ following CAS. This is mainly due to higher rates of minor stroke, which were non-disabling and resolved within 6 months.<sup><a href="javascript:;" reveal-id="ehae179-B711" data-open="ehae179-B711" class="link link-ref link-reveal xref-bibr">711</a>,<a href="javascript:;" reveal-id="ehae179-B727" data-open="ehae179-B727" class="link link-ref link-reveal xref-bibr">727</a></sup>

However, the occurrence of a peri-operative stroke is associated with three-fold poorer long-term survival,<sup><a href="javascript:;" reveal-id="ehae179-B727" data-open="ehae179-B727" class="link link-ref link-reveal xref-bibr">727</a></sup> similar to a post-procedural MI (which was more frequent after CEA).<sup><a href="javascript:;" reveal-id="ehae179-B728" data-open="ehae179-B728" class="link link-ref link-reveal xref-bibr">728</a></sup>

In CAS patients, the risk increased in those aged >60 years, especially for those aged >80 years, who are four times more likely to experience a procedural stroke/death. When comparing CAS with CEA, the age-related effect became apparent in patients aged 60–65 years, and CEA is superior to CAS in patients aged >70 years.<sup><a href="javascript:;" reveal-id="ehae179-B729" data-open="ehae179-B729" class="link link-ref link-reveal xref-bibr">729</a>,<a href="javascript:;" reveal-id="ehae179-B730" data-open="ehae179-B730" class="link link-ref link-reveal xref-bibr">730</a></sup>

Elderly CAS patients may experience more peri-operative strokes, mainly minor ipsilateral strokes, possibly due to a higher burden of aortic arch disease. In these cases, operator/institution experience may play a role in determining peri-procedural outcomes. CAS is associated with significantly lower risks for MI, transient cranial nerve injury, and haematoma.<sup><a href="javascript:;" reveal-id="ehae179-B731" data-open="ehae179-B731" class="link link-ref link-reveal xref-bibr">731</a>,<a href="javascript:;" reveal-id="ehae179-B732" data-open="ehae179-B732" class="link link-ref link-reveal xref-bibr">732</a></sup>

Beyond the 30 day peri-operative period, long-term data suggest that outcomes after CAS are similar to those with CEA.<sup><a href="javascript:;" reveal-id="ehae179-B703" data-open="ehae179-B703" class="link link-ref link-reveal xref-bibr">703</a>,<a href="javascript:;" reveal-id="ehae179-B733" data-open="ehae179-B733" class="link link-ref link-reveal xref-bibr">733</a></sup> The predicted magnitude of 30 day risk (according to clinical/anatomical characteristics and operator/centre experience) will thus largely determine whether CEA or CAS is preferable in individual patients.

Post-hoc trial analysis revealed enhanced benefits of CEA when performed within 2 weeks of the ischaemic event,<sup><a href="javascript:;" reveal-id="ehae179-B734" data-open="ehae179-B734" class="link link-ref link-reveal xref-bibr">734</a></sup> with reduced complications compared with CAS performed within 1 week of stroke/TIA. The Carotid Stenosis Trialists’ Collaboration found a higher stroke/death rate (8.3% with CAS vs. 1.3% with CEA) for CAS in patients treated within 1 week of the last symptomatic event.<sup><a href="javascript:;" reveal-id="ehae179-B735" data-open="ehae179-B735" class="link link-ref link-reveal xref-bibr">735</a></sup> These findings support a preference for early CEA in symptomatic patients. However, these trials, initiated over 30 years ago, lack evaluation of current OMT. Initially designed as an alternative for high surgical risk (HSR) patients,<sup><a href="javascript:;" reveal-id="ehae179-B704" data-open="ehae179-B704" class="link link-ref link-reveal xref-bibr">704</a>,<a href="javascript:;" reveal-id="ehae179-B736" data-open="ehae179-B736" class="link link-ref link-reveal xref-bibr">736</a></sup> carotid stenting’s efficacy needs consideration in contemporary practice (_[Table 12](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B735" data-open="ehae179-B735" class="link link-ref link-reveal xref-bibr">735</a></sup>

Table 12

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846180)

High-risk peri-operative features for carotid endarterectomy

| Clinical |
| --- |
| Congestive heart failure (NYHA functional class III/IV) |
| Unstable angina (CCS III/IV) |
| CAD with LM or >1 vessel with 70% stenosis |
| Recent MI (<30 days) |
| Planned open heart surgery (<30 days) |
| LVEF <30% |
| Severe pulmonary disease |
| Severe renal disease |

| Anatomical |
| --- |
| Surgically inaccessible lesions
-   At or above C2
    
-   Below the clavicle
    

 |
| Ipsilateral neck irradiation |
| Spinal immobility of the neck |
| Contralateral carotid artery occlusion (increases risk for stroke) |
| Contralateral laryngeal palsy |
| Tracheostomy |

CAD, coronary artery disease; CCS, Canadian Cardiovascular Society; LM, left main; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association.

© ESC 2024

In conclusion, CEA is still the treatment choice for patients with symptomatic carotid stenosis. However, in patients eligible for carotid revascularization but deemed high surgical risk by a multidiscliplinary team, CAS may be preferred over CEA—the patient must be a suitable candidate for CAS, and the complication rate should not surpass 6%.

At present, TCAR results have been analysed in registries only. In these studies, in-hospital stroke/death has been significantly lower after TCAR compared with transfemoral CAS.<sup><a href="javascript:;" reveal-id="ehae179-B707" data-open="ehae179-B707" class="link link-ref link-reveal xref-bibr">707</a>,<a href="javascript:;" reveal-id="ehae179-B737" data-open="ehae179-B737" class="link link-ref link-reveal xref-bibr">737</a></sup> Similar to the previous results established for CEA, symptomatic patients undergoing TCAR demonstrate similar outcomes if the procedure is performed >48 h after the neurological event.<sup><a href="javascript:;" reveal-id="ehae179-B738" data-open="ehae179-B738" class="link link-ref link-reveal xref-bibr">738</a></sup> However, TCAR has not yet been evaluated in RCTs and has not been compared with CEA or OMT.

###### Vertebral arteries

The evidence on the use of lifestyle modifications and medical therapy in cases of symptomatic vertebral artery stenosis is lacking, but their use is reasonable given the overall CV risk in these patients.

Evidence on the use of preventive strategies and antithrombotic agents is lacking, but their use is reasonable in the presence of other CVRFs.

Surgery on extracranial vertebral stenosis (with transposition to CCA, trans-subclavian vertebral endarterectomy, distal venous bypass) can be performed with low stroke/death rates in experienced centres.<sup><a href="javascript:;" reveal-id="ehae179-B739" data-open="ehae179-B739" class="link link-ref link-reveal xref-bibr">739</a>,<a href="javascript:;" reveal-id="ehae179-B740" data-open="ehae179-B740" class="link link-ref link-reveal xref-bibr">740</a></sup> However, with limited expertise in complex vertebral artery reconstructions, open surgery has been mostly replaced by endovascular interventions.

In a combined analysis of the the Vertebral Artery Ischaemia Stenting Trial (VIST), the Vertebral Artery Stenting Trial (VAST), and the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial,<sup><a href="javascript:;" reveal-id="ehae179-B741" data-open="ehae179-B741" class="link link-ref link-reveal xref-bibr">741</a></sup> no clear benefit was shown for extracranial vertebral artery stenting.

Randomized controlled trials have not assessed surgical techniques like vertebral artery endarterectomy or transposition. While case series exist, they often lack a control group following a consistent medical treatment protocol.<sup><a href="javascript:;" reveal-id="ehae179-B742" data-open="ehae179-B742" class="link link-ref link-reveal xref-bibr">742</a></sup> As a result, the effectiveness of these procedures remains uncertain.

Recommendation Table 27

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846189)

Recommendations for interventions in patients with symptomatic carotid artery stenosis

![Recommendations for interventions in patients with symptomatic carotid artery stenosis](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt27.jpeg?Expires=1728479088&Signature=d2OFJp9lhCumeh4fcP~6KzQ2l~nKIUvdhljXjxeqkaenWQSmNs1Q0d86-FVwVP6lpQok8Rl8QlYrHo5QF9RJf8pDFNTRz3NfdHfK7d097TYv6VLkU16HBpOmL9sW9XQZV1HIQUpugTWL9TlSK6DBuEZOSOevWUZ-6jm0lhc~1nThQ6ClVVtIX-kctkiLqcmOmmYpO0cWokAJm6V4BfxgZHGDn-bUs4-6Dy~0LGiJ1-SKBaNgZyRtr4ZmqtgAq97iY8jBH8LwWh2MdU-fKpIaaW6RtJhtPBF5CbNb8pPY1ktVAa~8Ve916XqKTd57xJdd-6idxb0rCWAs9hd2JBtTeg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

##### 8.2.3.3. Follow-up

Peri-operative and post-procedural medical management after carotid revascularization should include OMT. Post-operative hypertension is a risk factor for stroke and TIAs, wound bleeding, and intracranial haemorrhage.<sup><a href="javascript:;" reveal-id="ehae179-B743" data-open="ehae179-B743" class="link link-ref link-reveal xref-bibr">743</a></sup> Therefore, proper pharmacological BP control is important in optimizing outcomes.<sup><a href="javascript:;" reveal-id="ehae179-B744" data-open="ehae179-B744" class="link link-ref link-reveal xref-bibr">744</a></sup>

Fluctuations of hypertension and hypotension are not uncommon and should be treated promptly.<sup><a href="javascript:;" reveal-id="ehae179-B744" data-open="ehae179-B744" class="link link-ref link-reveal xref-bibr">744</a>,<a href="javascript:;" reveal-id="ehae179-B745" data-open="ehae179-B745" class="link link-ref link-reveal xref-bibr">745</a></sup>

An intensive lipid-lowering therapy (ILT) aiming at >50% LDL-C reduction and LDL-C <1.4 mmol/L (55 mg/dL) is also recommended.<sup><a href="javascript:;" reveal-id="ehae179-B19" data-open="ehae179-B19" class="link link-ref link-reveal xref-bibr">19</a></sup>

Antiplatelet therapy should be tailored according to type of intervention. In CEA, the reduction in peri-procedural and long-term ischaemic events under low-dose aspirin has been demonstrated.<sup><a href="javascript:;" reveal-id="ehae179-B746" data-open="ehae179-B746" class="link link-ref link-reveal xref-bibr">746</a>,<a href="javascript:;" reveal-id="ehae179-B747" data-open="ehae179-B747" class="link link-ref link-reveal xref-bibr">747</a></sup> After carotid stenting, DAPT (aspirin and clopidogrel) is recommended, while optimal duration is debated.<sup><a href="javascript:;" reveal-id="ehae179-B748" data-open="ehae179-B748" class="link link-ref link-reveal xref-bibr">748</a></sup> In the peri-operative period after CAS, DAPT should be prescribed and continued for at least 30 days post-procedure.<sup><a href="javascript:;" reveal-id="ehae179-B77" data-open="ehae179-B77" class="link link-ref link-reveal xref-bibr">77</a>,<a href="javascript:;" reveal-id="ehae179-B749" data-open="ehae179-B749" class="link link-ref link-reveal xref-bibr">749</a>,<a href="javascript:;" reveal-id="ehae179-B750" data-open="ehae179-B750" class="link link-ref link-reveal xref-bibr">750</a></sup> Ticagrelor, when included in DAPT following CAS/TCAR, presents a drawback due to its elevated bleeding risk compared with clopidogrel.<sup><a href="javascript:;" reveal-id="ehae179-B751 ehae179-B752 ehae179-B753" data-open="ehae179-B751 ehae179-B752 ehae179-B753" class="link link-ref link-reveal xref-bibr">751–753</a></sup>

Duplex ultrasound is the first-line technique to evaluate patients after CEA or CAS. CTA and MRA are alternative methods for determining restenosis.<sup><a href="javascript:;" reveal-id="ehae179-B749" data-open="ehae179-B749" class="link link-ref link-reveal xref-bibr">749</a>,<a href="javascript:;" reveal-id="ehae179-B754" data-open="ehae179-B754" class="link link-ref link-reveal xref-bibr">754</a></sup>

After CEA or CAS, DUS is recommended at baseline (<3 months) and annually thereafter until the patient is stable (i.e. until no restenosis is observed in two consecutive annual scans). Regular surveillance (e.g. every 2 years) can be performed based on the stenosis of the contralateral ICA, risk profile, and patient’s life expectancy.<sup><a href="javascript:;" reveal-id="ehae179-B749" data-open="ehae179-B749" class="link link-ref link-reveal xref-bibr">749</a>,<a href="javascript:;" reveal-id="ehae179-B754" data-open="ehae179-B754" class="link link-ref link-reveal xref-bibr">754</a></sup>

For patients combining multiple CVRFs after the procedure, DUS may be beneficial every 6 months until a stable clinical pattern is established, and annually thereafter.<sup><a href="javascript:;" reveal-id="ehae179-B749" data-open="ehae179-B749" class="link link-ref link-reveal xref-bibr">749</a>,<a href="javascript:;" reveal-id="ehae179-B754" data-open="ehae179-B754" class="link link-ref link-reveal xref-bibr">754</a></sup>

Early surveillance, especially within 1–3 months and particularly in cases where intraoperative completion imaging is absent (e.g. after CEA), aids in detecting technical errors and setting a baseline for future comparisons.

Follow-up enables the identification of ipsilateral carotid restenosis and contralateral disease progression, offering a chance for timely intervention to minimize the risk of stroke. Nevertheless, this concept is facing growing challenges due to a reduced and selective role for intervention in asymptomatic patients. A surveillance protocol holds significance when anticipated outcomes are expected to cost-effectively influence a medical or interventional treatment plan.<sup><a href="javascript:;" reveal-id="ehae179-B749" data-open="ehae179-B749" class="link link-ref link-reveal xref-bibr">749</a>,<a href="javascript:;" reveal-id="ehae179-B754" data-open="ehae179-B754" class="link link-ref link-reveal xref-bibr">754</a></sup>

Recommendation Table 28

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846200)

Recommendations for follow-up in patients with carotid artery stenosis

![Recommendations for follow-up in patients with carotid artery stenosis](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt28.jpeg?Expires=1728479088&Signature=uRolCVsyAHIyN1n5FW95ViY-He5ykGA325po9ZJue5teAQVkANJLsqTyHhv2v0ZaUnYhSEB7x5I9BlJU7UgMq6ooWOQUJa6M-NQcavTR6Y3ioqsNrfE9Pp-8n~k~QBs~RzHePhwwJ7u9DbMqJcSxyu-027EZd0lqMYgZKmJdFl0BBTr-BiVQZJScSpo6iWQTGIiZbUAa-3i67BVDO5AL-uyeKugHM7hYSXKr12znysIfkWTFqlbCs8wiDnD5iljYqYINQiNmS1~g1jATkrdsHNHKPeWj24d~jLeE3NLvq3i5paXM2QoKAdo5SX33U6AU9QW3yF-Q2iaJexvL7b~Lwg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 8.3. Other arterial locations

#### 8.3.1. Subclavian artery disease

##### 8.3.1.1. Clinical presentation and diagnosis

Atherosclerotic upper-limb artery disease (UEAD) is most frequently located in the subclavian artery.<sup><a href="javascript:;" reveal-id="ehae179-B755" data-open="ehae179-B755" class="link link-ref link-reveal xref-bibr">755</a>,<a href="javascript:;" reveal-id="ehae179-B756" data-open="ehae179-B756" class="link link-ref link-reveal xref-bibr">756</a></sup> Digital ischaemia is most frequently caused by non-atherosclerotic aetiologies, including thrombo-embolism, systemic sclerosis, idiopathic, thromboangiitis obliterans, iatrogenic, or cancer.<sup><a href="javascript:;" reveal-id="ehae179-B757" data-open="ehae179-B757" class="link link-ref link-reveal xref-bibr">757</a></sup> Isolated subclavian stenosis (SS) is often asymptomatic and may be suspected because of an absolute inter-arm SBP difference >10–15 mmHg.<sup><a href="javascript:;" reveal-id="ehae179-B758" data-open="ehae179-B758" class="link link-ref link-reveal xref-bibr">758</a></sup> In the Multi-Ethnic Study of Atherosclerosis (MESA), prevalence of asymptomatic SS was approximately 4.5% (male: 5.1%, female: 3.9%) in adults and more frequent in patients with PAD (11.4%).<sup><a href="javascript:;" reveal-id="ehae179-B759" data-open="ehae179-B759" class="link link-ref link-reveal xref-bibr">759</a></sup> In patients attending CV clinics, a >25 mmHg SBP difference doubles prevalence and independently predicts mortality.<sup><a href="javascript:;" reveal-id="ehae179-B32" data-open="ehae179-B32" class="link link-ref link-reveal xref-bibr">32</a>,<a href="javascript:;" reveal-id="ehae179-B758" data-open="ehae179-B758" class="link link-ref link-reveal xref-bibr">758</a></sup> As obstructive disease progresses, particularly affecting vertebral vessels, the risk of ischaemia or steal symptoms significantly rises. Visual disturbances, syncope, ataxia, vertigo, dysphasia, dysarthria, and facial sensory deficits during arm movements may indicate subclavian steal syndrome, correlating with inter-arm BP difference.<sup><a href="javascript:;" reveal-id="ehae179-B760" data-open="ehae179-B760" class="link link-ref link-reveal xref-bibr">760</a></sup> Brachiocephalic occlusive disease can lead to stroke or TIA in carotid and vertebral territories, manifesting as exercise-induced fatigue, pain, and arm claudication. Severe cases, especially with distal disease, may result in rest pain and digital ischaemia with necrosis.

Duplex ultrasound assessment of subclavian arteries enables the detection of SS via intrastenotic high-velocity flows (50% stenosis: peak systolic velocity \[PSV\] ≥230 cm/s, PSV ratio \[PSVr\] ≥2.2; 70% stenosis PSV ≥340 cm/s and PSVr ≥3.0) or monophasic post-stenotic waveforms.<sup><a href="javascript:;" reveal-id="ehae179-B761" data-open="ehae179-B761" class="link link-ref link-reveal xref-bibr">761</a></sup> The majority of patients (>90%) with at least 50% proximal SS have either intermittent or continuous flow reversal in the vertebral artery, though not all will be symptomatic.<sup><a href="javascript:;" reveal-id="ehae179-B760" data-open="ehae179-B760" class="link link-ref link-reveal xref-bibr">760</a>,<a href="javascript:;" reveal-id="ehae179-B762" data-open="ehae179-B762" class="link link-ref link-reveal xref-bibr">762</a></sup> When subclavian steal syndrome is suspected, flow reversal should be assessed in the ipsilateral extracranial vertebral artery by hyperaemia testing and if available transcranial Doppler.<sup><a href="javascript:;" reveal-id="ehae179-B762" data-open="ehae179-B762" class="link link-ref link-reveal xref-bibr">762</a></sup> Severe stenosis or occlusion of the right brachiocephalic trunk is associated with reduced flow velocities in the ipsilateral subclavian artery and the CCA. Abnormal or doubtful DUS should lead to anatomic imaging (CTA/MRA).<sup><a href="javascript:;" reveal-id="ehae179-B763" data-open="ehae179-B763" class="link link-ref link-reveal xref-bibr">763</a></sup> CTA is excellent for supra-aortic lesions and can provide extravascular information, especially when thoracic outlet syndrome is a differential diagnosis. MRA provides both functional and morphological information useful to distinguish antegrade from retrograde perfusion and to estimate stenosis severity.<sup><a href="javascript:;" reveal-id="ehae179-B764" data-open="ehae179-B764" class="link link-ref link-reveal xref-bibr">764</a></sup> DSA is performed if endovascular therapy is indicated. PET is useful for the diagnosis of arteritis but not for assessment of atherosclerotic lesions in clinical practice.

##### 8.3.1.2. Treatment strategy (medical and interventional)

Optimal medical treatment is recommended in all patients with symptomatic UEAD to reduce CV risk.<sup><a href="javascript:;" reveal-id="ehae179-B32" data-open="ehae179-B32" class="link link-ref link-reveal xref-bibr">32</a></sup> Revascularization is indicated in symptomatic patients with TIA/stroke, coronary subclavian steal syndrome, ipsilateral haemodialysis access dysfunction, or impaired HRQoL. Revascularization should be considered in asymptomatic patients with planned coronary artery bypass grafting (CABG) using the internal mammary artery and those with ipsilateral haemodialysis access, as well as asymptomatic patients with significant bilateral SS/occlusion for adequate BP surveillance. For revascularization, both endovascular and surgical procedures are available. There are no RCTs comparing endovascular vs. open repair but individual studies, including the Danish Vascular Registry, indicate similar long-term symptom resolution but higher general complication rates and hospital length of stay for open surgery.<sup><a href="javascript:;" reveal-id="ehae179-B765" data-open="ehae179-B765" class="link link-ref link-reveal xref-bibr">765</a></sup> The risk of severe complications, including vertebrobasilar stroke, is low with both approaches. The post-procedural stroke rate is reported at 1.3% for endovascular therapy<sup><a href="javascript:;" reveal-id="ehae179-B765" data-open="ehae179-B765" class="link link-ref link-reveal xref-bibr">765</a></sup> and 0.9%–2.4% after open surgery.<sup><a href="javascript:;" reveal-id="ehae179-B765 ehae179-B766 ehae179-B767" data-open="ehae179-B765 ehae179-B766 ehae179-B767" class="link link-ref link-reveal xref-bibr">765–767</a></sup>

Percutaneous angioplasty for subclavian arterial stenosis is often used with stenting. There is no conclusive evidence to determine whether stenting is more effective than balloon angioplasty.<sup><a href="javascript:;" reveal-id="ehae179-B768" data-open="ehae179-B768" class="link link-ref link-reveal xref-bibr">768</a></sup> Similar results were reported for endovascular therapy of the innominate artery.<sup><a href="javascript:;" reveal-id="ehae179-B769" data-open="ehae179-B769" class="link link-ref link-reveal xref-bibr">769</a></sup> In heavily calcified ostial lesions, balloon-expandable stents give more radial force than nitinol stents. An endovascular approach is often the default strategy. However, in selected patients with low operative risk, with subclavian artery occlusion or after endovascular therapy failure, surgical subclavian–carotid transposition is safe with excellent long-term patency results (5 year patency 96%).<sup><a href="javascript:;" reveal-id="ehae179-B766" data-open="ehae179-B766" class="link link-ref link-reveal xref-bibr">766</a></sup> Carotid–subclavian bypass surgery with a prosthetic graft showed long-term benefit with low operative mortality and morbidity, especially in patients with extensive disease or re-occlusion after stenting (5 year patency 97%).<sup><a href="javascript:;" reveal-id="ehae179-B770" data-open="ehae179-B770" class="link link-ref link-reveal xref-bibr">770</a></sup> Other options are extrathoracic extra-anatomic bypass procedures (axillo-axillary, carotid–axillary, or carotid–carotid bypass);<sup><a href="javascript:;" reveal-id="ehae179-B771" data-open="ehae179-B771" class="link link-ref link-reveal xref-bibr">771</a>,<a href="javascript:;" reveal-id="ehae179-B772" data-open="ehae179-B772" class="link link-ref link-reveal xref-bibr">772</a></sup> however, axillo-axillary bypasses may occlude at 1 year in 14% of cases.<sup><a href="javascript:;" reveal-id="ehae179-B773" data-open="ehae179-B773" class="link link-ref link-reveal xref-bibr">773</a></sup> The transthoracic approach is an option in patients with multivessel disease involving the aortic arch and several supra-aortic vessels.<sup><a href="javascript:;" reveal-id="ehae179-B767" data-open="ehae179-B767" class="link link-ref link-reveal xref-bibr">767</a></sup>

While critical hand ischaemia owing to below-the-elbow atherosclerotic occlusive disease is relatively uncommon, interventions are associated with a high rate of success, major amputations are rare, and many can be treated non-operatively.<sup><a href="javascript:;" reveal-id="ehae179-B756" data-open="ehae179-B756" class="link link-ref link-reveal xref-bibr">756</a></sup> In appropriately selected patients, both endovascular and open interventions have a high rate of success.<sup><a href="javascript:;" reveal-id="ehae179-B755" data-open="ehae179-B755" class="link link-ref link-reveal xref-bibr">755</a>,<a href="javascript:;" reveal-id="ehae179-B756" data-open="ehae179-B756" class="link link-ref link-reveal xref-bibr">756</a></sup>

In symptomatic patients with contraindications for endovascular therapy or open surgery, prostanoid infusion or thoracic sympathectomy may be considered.<sup><a href="javascript:;" reveal-id="ehae179-B774" data-open="ehae179-B774" class="link link-ref link-reveal xref-bibr">774</a></sup>

##### 8.3.1.3. Follow-up

Patients with UEAD should be followed up to ensure optimal CV prevention. Tighter follow-up is required in symptomatic patients to re-assess indication for revascularization as a large proportion of symptoms resolve spontaneously.<sup><a href="javascript:;" reveal-id="ehae179-B775" data-open="ehae179-B775" class="link link-ref link-reveal xref-bibr">775</a></sup> After revascularization, patients should be followed up to allow early detection and treatment of impending late procedural failure.

Recommendation Table 29

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846213)

Recommendations for the management of subclavian artery stenosis (see also Evidence Table 9)

![Recommendations for the management of subclavian artery stenosis (see also Evidence Table 9)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt29.jpeg?Expires=1728479088&Signature=mUXPGWh3Vu9es926zOQzc6nArM5oBqJ8FyHCtkFlcAf43eIAjVporRq--qxULMk4uCxVxsccFbcbheCo9jl-tPfefG7QMqFsHXeEB~I2hDkWrOUpQsf~hT3voVt30oyzxEnY82esS6ED4gAUIvbVA4PrSGe-hBdrp3x0CXsuqTZTzMVhuxiT47F4f66fc320UC4YyDvPUfBMlq7Eg08d-JI3O94FbBhYSaRkrGDDt8z8OGA9FdH65frjcrogb5Qsyu8sQyuHuKLCcHsYteyGBA~UKAG17r3h9QRax4ioy2o0THnzsE~NIF6oUdD1u--RjVrGHHRtSA4EjYzoMKeVEA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 8.3.2. Renal artery disease

##### 8.3.2.1. Clinical presentation and diagnosis

###### Epidemiology

In >90% of cases, RAS is caused by atherosclerosis and typically involves the ostial renal arterial segment (_[Table 13](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B782" data-open="ehae179-B782" class="link link-ref link-reveal xref-bibr">782</a></sup> Above 65 years of age, overall prevalence of ≥60% RAS is 6.8%, with a higher prevalence in men (9.1%) than in women (5.5%).<sup><a href="javascript:;" reveal-id="ehae179-B783" data-open="ehae179-B783" class="link link-ref link-reveal xref-bibr">783</a></sup> In patients with PAD, RAS prevalence ranges between 7% and 42%, influenced by diagnostic criteria.<sup><a href="javascript:;" reveal-id="ehae179-B784" data-open="ehae179-B784" class="link link-ref link-reveal xref-bibr">784</a></sup>

Table 13

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846218)

Clinical signs suggestive of renal artery disease

<table role="presentation" aria-labelledby="
                        label-61731" aria-describedby="
                        caption-61731"><tbody><tr><td>Hypertension onset before 30 years of age</td></tr><tr><td>Severe hypertension after the age of 55 years, when associated with CKD or heart failure</td></tr><tr><td>Hypertension and abdominal bruit</td></tr><tr><td>Rapid and persistent worsening of previously controlled hypertension</td></tr><tr><td>Resistant hypertension<ul class="bullet"><li><p class="chapter-para">Three antihypertensive drugs including a diuretic agent</p><p class="chapter-para">or</p></li><li><p class="chapter-para">≥4 antihypertensive drugs</p><p class="chapter-para">and</p></li><li><p class="chapter-para">Other secondary form unlikely</p></li></ul></td></tr><tr><td>Hypertensive crisis (i.e. acute renal failure, acute heart failure, hypertensive encephalopathy, or grade 3–4 retinopathy)</td></tr><tr><td>New azotaemia or worsening of renal function after treatment with RAAS blockers</td></tr><tr><td>Unexplained atrophic kidney or discrepancy in kidney size, or unexplained renal failure</td></tr><tr><td>Flash pulmonary oedema</td></tr></tbody></table>

CKD, chronic kidney disease; RAAS, renin–angiotensin–aldosterone system.

© ESC 2024

###### Clinical presentation

Clinical presentation comprises renovascular hypertension, renal function impairment and eventually, flash pulmonary oedema (_[Table 13](javascript:;)_). RAS reduces the filtration capacity of the affected kidney, which activates the renin_–_angiotensin_–_aldosterone pathway, potentially resulting in renovascular hypertension.<sup><a href="javascript:;" reveal-id="ehae179-B782" data-open="ehae179-B782" class="link link-ref link-reveal xref-bibr">782</a>,<a href="javascript:;" reveal-id="ehae179-B785" data-open="ehae179-B785" class="link link-ref link-reveal xref-bibr">785</a></sup> In unilateral RAS, the functioning contralateral kidney may increase sodium excretion to prevent sodium retention and volume overload. In high-grade bilateral RAS or in unilateral RAS without a functioning second kidney, the risk of cardiorenal deterioration is higher than in unilateral disease.<sup><a href="javascript:;" reveal-id="ehae179-B786" data-open="ehae179-B786" class="link link-ref link-reveal xref-bibr">786</a></sup>

###### Diagnosis of renal artery disease

First diagnostic steps include laboratory tests to examine renal function, analysis of office and out-of-office BP recordings (ambulatory BP monitoring or home BP monitoring, as recommended by \[upcoming\] ESC/European Society of Hypertension \[ESH\] Guidelines for arterial hypertension), and non-invasive haemodynamic assessment of renal arteries by DUS.<sup><a href="javascript:;" reveal-id="ehae179-B787" data-open="ehae179-B787" class="link link-ref link-reveal xref-bibr">787</a></sup>

Renal artery PSV >200 cm/s measured by DUS allows the diagnosis of a >50% RAS (sensitivity 95%, specificity 90%).<sup><a href="javascript:;" reveal-id="ehae179-B788" data-open="ehae179-B788" class="link link-ref link-reveal xref-bibr">788</a></sup> A renal-aortic peak flow velocity ratio (RAR = renal artery PSV/aortic PSV) >3.5 has 84%–91% sensitivity and 95%–97% specificity for the detection of ≥60% RAS.<sup><a href="javascript:;" reveal-id="ehae179-B789" data-open="ehae179-B789" class="link link-ref link-reveal xref-bibr">789</a></sup> A side-to-side difference of the intrarenal resistance index ≥0.5 between both kidneys may serve as an additional haemodynamic criterion for haemodynamically relevant RAS.<sup><a href="javascript:;" reveal-id="ehae179-B787" data-open="ehae179-B787" class="link link-ref link-reveal xref-bibr">787</a>,<a href="javascript:;" reveal-id="ehae179-B790" data-open="ehae179-B790" class="link link-ref link-reveal xref-bibr">790</a></sup> Other DUS criteria (acceleration time, acceleration index) have lower diagnostic accuracy.<sup><a href="javascript:;" reveal-id="ehae179-B791" data-open="ehae179-B791" class="link link-ref link-reveal xref-bibr">791</a></sup>

Sensitivity and specificity of contrast-enhanced MRA in the diagnosis of RAS is 88% and 100%, respectively;<sup><a href="javascript:;" reveal-id="ehae179-B789" data-open="ehae179-B789" class="link link-ref link-reveal xref-bibr">789</a></sup> however, MRA overestimates the degree of RAS by 26%–32%.<sup><a href="javascript:;" reveal-id="ehae179-B789" data-open="ehae179-B789" class="link link-ref link-reveal xref-bibr">789</a></sup> The advantages of MRA are the possibility of assessing renal parenchymal blood flow and freedom from radiation and iodinated contrast agents.

Spiral multidetector CTA allows renal artery diameter measurements and provides information on vessel wall calcification and mural plaques. RAS diagnosis by CTA presents 64%–100% sensitivity and 92%–98% specificity.<sup><a href="javascript:;" reveal-id="ehae179-B789" data-open="ehae179-B789" class="link link-ref link-reveal xref-bibr">789</a></sup> CTA drawbacks include radiation exposure, the need for contrast media in patients with impaired renal function, and limited haemodynamic assessment of RAS.

Catheter angiography is the gold standard for diagnosing RAS, enabling additional haemodynamic measures (_[Figure 19](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B792" data-open="ehae179-B792" class="link link-ref link-reveal xref-bibr">792</a></sup> Considering the potential risks of invasive procedures, DUS and other non-invasive modalities (CTA or MRA) should precede catheter angiography and invasive haemodynamic measurements (_[Figure 19](javascript:;)_).

![Diagnostic and treatment algorithm for renal artery stenosis.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f19.jpeg?Expires=1728479088&Signature=mXjiTKmRqJvWqJMFmhpvWvOG25oN8cT-O93XOhMkqrsDRYMSInAJegTRL5cHGIQkvXj85eLihz8Go94BY3t7-57Rwhb02QTFMNr6JniGORfO7c9oij3Ffha70wnTc-~ZfCwA39Zehc28Bg3M6C~urFQrHVQTKzISMFMwXNel-w8KDXJfftisbkQ43YlZOA~k1eqIxNCBnIU5DyqN72WYPq4EyxdMuDufVNqPnZq0Kqd1nC4HAmvMb-AB509VdXqCuwK4BUzQzZEfFTs6kXQCyXCw-fWpJ8DXNcdHS0785GWEOiM-a~e3kkBZ6KIjcSzI8kL0y9ZZ7YBpB5OlTSwZRg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 19

Diagnostic and treatment algorithm for renal artery stenosis.

CTA, computed tomography angiography; MRA, magnetic resonance angiography; OMT, optimal medical treatment; Pd/Pa, distal coronary pressure to aortic pressure ratio; PSV, peak systolic velocity; RAR, renal-aortic peak flow velocity ratio; RAS, renal artery stenosis.

<sup>a</sup>see table below

<table role="presentation"><tbody><tr><td colspan="3"><sup>a</sup>Kidney viability in RAS</td></tr><tr><td></td><td>Signs of viability</td><td>Signs of non-viability</td></tr><tr><td>Renal size</td><td>&gt;8 cm</td><td>&lt;7 cm</td></tr><tr><td>Renal cortex</td><td>Distinct cortex (&gt;0.5 cm)</td><td>Loss of corticomedullar differentiation</td></tr><tr><td>Proteinuria</td><td>Albumin-creatinine ratio &lt;20 mg/mmol</td><td>Albumin-creatinine ratio &gt;30 mg/mmol</td></tr><tr><td>Renal resistance index</td><td>&lt;0.8</td><td>&gt;0.8</td></tr></tbody></table>

© ESC 2024

<sup>b</sup>Rapidly progressive, treatment-resistant arterial hypertension; rapidly declining renal function; flash pulmonary oedema; solitary kidney.

<sup>c</sup>Resting mean pressure gradient >10 mmHg; systolic hyperaemic pressure gradient >20 mmHg; renal PdPa ≤ 0.9 (or 0.8).

[Open in new tab](https://academic.oup.com/view-large/figure/479846227/ehae179f19.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f19.jpeg?Expires=1728479088&Signature=WuxnZn94RZaJwmfIzTR-2hOBruJMIfAffhBsIQB93tuVuIMuJ7kSX2MC5ue3AqVdryZjEB9d3wqobnSLcF193W6yFaprsDepqns42TDJERAdcZ3US-U4Jnf8dDyObqVHdDPE~8h2zrC-x0AbZwxuy997q6oMnDLEXyUDG26k8jUDt-iIPGsiDcGP-NNVyvx4kQTgELuOVAI8VQzC8hfH9uJroZV63YjDQk-m4UBsiSdVc3cDi2MZ2tWdx2wesDFHh~0lXwLThPBr8SjbZZdVdMUTdi4Gb-PLkOXFt1S-nH0fqb5o6h-glflD6GZWxl6sD2G1-tcUZADcLKllb-El8Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846227&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Renal scintigraphy, plasma renin measurements before and after ACEI provocation, and venous renin measurements are not considered for RAS evaluation.

###### Prognosis

Atherosclerotic RAS progresses with respect to the degree of stenosis, while total renal artery occlusions occur less frequently.<sup><a href="javascript:;" reveal-id="ehae179-B793" data-open="ehae179-B793" class="link link-ref link-reveal xref-bibr">793</a></sup> The presence of significant RAS is a strong predictor for mortality<sup><a href="javascript:;" reveal-id="ehae179-B794" data-open="ehae179-B794" class="link link-ref link-reveal xref-bibr">794</a></sup> and renovascular disease is an important risk factor for the development of end-stage renal disease (ESRD).<sup><a href="javascript:;" reveal-id="ehae179-B795" data-open="ehae179-B795" class="link link-ref link-reveal xref-bibr">795</a></sup> The risk of RAS-related ESRD is higher in men than in women and increases with age.<sup><a href="javascript:;" reveal-id="ehae179-B795" data-open="ehae179-B795" class="link link-ref link-reveal xref-bibr">795</a></sup>

##### 8.3.2.2. Treatment strategy (medical and interventional)

###### Medical therapy

Optimal medical treatment is recommended in RAS patients.<sup><a href="javascript:;" reveal-id="ehae179-B785" data-open="ehae179-B785" class="link link-ref link-reveal xref-bibr">785</a></sup> Data on antithrombotic therapy in patients with atherosclerotic RAS are scarce and retrospective.<sup><a href="javascript:;" reveal-id="ehae179-B796" data-open="ehae179-B796" class="link link-ref link-reveal xref-bibr">796</a></sup> However, the use of an antiplatelet agent is reasonable in atherosclerotic RAS.

No prospective study has specifically examined antithrombotic therapy post-RAS stenting, and information from existing RAS stenting trials is limited.<sup><a href="javascript:;" reveal-id="ehae179-B797" data-open="ehae179-B797" class="link link-ref link-reveal xref-bibr">797</a></sup> Following the antithrombotic treatment approach in non-coronary arterial beds, it is suggested to use DAPT for at least 1 month after RAS stent implantation.<sup><a href="javascript:;" reveal-id="ehae179-B666" data-open="ehae179-B666" class="link link-ref link-reveal xref-bibr">666</a></sup>

###### Revascularization

Revascularization in atherosclerotic RAS

Prospective RCTs comparing endovascular revascularization with OMT in atherosclerotic RAS favoured renal artery stenting over balloon angioplasty.<sup><a href="javascript:;" reveal-id="ehae179-B792" data-open="ehae179-B792" class="link link-ref link-reveal xref-bibr">792</a></sup>

However, renal artery stenting showed no superiority over OMT in reducing BP, CV events, renal events, or mortality in unilateral atherosclerotic RAS.<sup><a href="javascript:;" reveal-id="ehae179-B788" data-open="ehae179-B788" class="link link-ref link-reveal xref-bibr">788</a>,<a href="javascript:;" reveal-id="ehae179-B798" data-open="ehae179-B798" class="link link-ref link-reveal xref-bibr">798</a>,<a href="javascript:;" reveal-id="ehae179-B799" data-open="ehae179-B799" class="link link-ref link-reveal xref-bibr">799</a></sup> A trial suggested a potential benefit of renal artery angioplasty for BP in bilateral RAS, but subsequent RCTs did not confirm this.<sup><a href="javascript:;" reveal-id="ehae179-B800 ehae179-B801 ehae179-B802" data-open="ehae179-B800 ehae179-B801 ehae179-B802" class="link link-ref link-reveal xref-bibr">800–802</a></sup> Data on the benefit of renal artery stenting in sparing antihypertensive drugs are inconsistent.<sup><a href="javascript:;" reveal-id="ehae179-B324" data-open="ehae179-B324" class="link link-ref link-reveal xref-bibr">324</a>,<a href="javascript:;" reveal-id="ehae179-B800" data-open="ehae179-B800" class="link link-ref link-reveal xref-bibr">800</a>,<a href="javascript:;" reveal-id="ehae179-B801" data-open="ehae179-B801" class="link link-ref link-reveal xref-bibr">801</a>,<a href="javascript:;" reveal-id="ehae179-B803" data-open="ehae179-B803" class="link link-ref link-reveal xref-bibr">803</a>,<a href="javascript:;" reveal-id="ehae179-B804" data-open="ehae179-B804" class="link link-ref link-reveal xref-bibr">804</a></sup>

In specific circumstances or RAS aetiologies, revascularization should be considered (_[Figure 19](javascript:;)_). Open surgical renal artery revascularization appears comparable to endovascular treatment regarding BP and renal function.<sup><a href="javascript:;" reveal-id="ehae179-B805" data-open="ehae179-B805" class="link link-ref link-reveal xref-bibr">805</a>,<a href="javascript:;" reveal-id="ehae179-B806" data-open="ehae179-B806" class="link link-ref link-reveal xref-bibr">806</a></sup> Thus, open surgery can be an alternative approach in cases with a revascularization indication and complex anatomy or failed endovascular repair.

##### 8.3.2.3. Follow-up

Following the diagnosis of significant RAS and the implementation of OMT and/or renal artery revascularization, regular follow-up exams are crucial. Monitoring should encompass laboratory tests to assess renal function, analysis of office and out-of-office BP recordings (ambulatory or home BP monitoring per upcoming ESC/ESH Guidelines for arterial hypertension), and renal artery DUS. DUS, comprising renal PSV, RAR, side-to-side difference of the resistance index, and kidney size, is the preferred imaging modality during follow-up.<sup><a href="javascript:;" reveal-id="ehae179-B787" data-open="ehae179-B787" class="link link-ref link-reveal xref-bibr">787</a></sup>

In conservatively managed RAS patients, follow-up assessment should re-evaluate potential indications for renal artery revascularization (_[Figure 19](javascript:;)_).

After renal artery stenting, the initial follow-up is recommended at 1 month and subsequently every 12 months or when new signs or symptoms arise.<sup><a href="javascript:;" reveal-id="ehae179-B807" data-open="ehae179-B807" class="link link-ref link-reveal xref-bibr">807</a></sup> Re-intervention may be considered for in-stent restenosis ≥60% detected by DUS, recurrent signs and symptoms (diastolic BP >90 mmHg on >3 antihypertensive drugs, or a >20% increase in serum creatinine).<sup><a href="javascript:;" reveal-id="ehae179-B787" data-open="ehae179-B787" class="link link-ref link-reveal xref-bibr">787</a>,<a href="javascript:;" reveal-id="ehae179-B808" data-open="ehae179-B808" class="link link-ref link-reveal xref-bibr">808</a></sup>

Recommendation Table 30

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846244)

Recommendations for diagnostic strategies for renal artery disease

![Recommendations for diagnostic strategies for renal artery disease](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt30.jpeg?Expires=1728479088&Signature=f-iKGw8-aTndyrBXlnB6RkFiftyoUXm~6Eicj2KGeRqZRnuH6gzS0q87sWIpD~gUqDYrjm~d~JoOI-dnh22vn1fu4VYZtLCHcZIzSQOwZklNz5k5z0HDWpjO~NXk5aTxh8bkTji2fQ2Ak16x1RjeEQkVr0WfAncbAVXa5LYoJ4ZfdGYCjxkuQFwMV2ti6cFHlySRAr6chOi7F7yeW7Ety21bREQoLex6dHvqgVp6LVyQA6e0QvXXEAcq-9WHj4364WRYqBBWgl0YzcHw49nSHxWe8hCpg0JTC6x9zfnhqOvIp8n6a1K~~KvvTBFt9axi7fIVW0kz41XDtA82U7Ehtg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 31

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846245)

Recommendations for treatment strategies for renal artery disease (see also Evidence Table 10)

![Recommendations for treatment strategies for renal artery disease (see also Evidence Table 10)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt31.jpeg?Expires=1728479088&Signature=WlZ5ol73iXg2yOmGBnq0U4a7tNLLvNsJKCOP6OUpldsQ9wn2-n30REq0IbUMqKU39gOC0U-BGxifLgND~I5WPxiPrfhRvYOW57am2dEy8X3CCWRECTXQzmvQFcchfTdJU16BoERF3aDq8FboHQjA823JVeP1Bxhym72cMim511NYvIAyG4FNraLvmFtPKDMH7sMjWNeDBlcCGxFubaD4bNeFgYqW9wBaC4WvQCb4dwFOH8y5gbQI7CCUDFIR-6kyyIUM8GfWX4pV0TIARIZC-2IjbshFlDLl1BeiqEfayHQ6U~WQ8Jm2RC~jvZY5FiTBmoX9LbjCwjULrD4zS6Vm0A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 8.3.3. Visceral artery disease

##### 8.3.3.1. Acute mesenteric ischaemia

Acute mesenteric ischaemia can be caused by arterial embolism or thrombosis _in situ_, non-occlusive mesenteric ischaemia (usually due to superior mesenteric artery \[SMA\] vasoconstriction), and venous thrombosis. In recent decades, embolism decreased from 46% to 35%, while arterial thrombosis increased from 20% to 35%.<sup><a href="javascript:;" reveal-id="ehae179-B815 ehae179-B816 ehae179-B817" data-open="ehae179-B815 ehae179-B816 ehae179-B817" class="link link-ref link-reveal xref-bibr">815–817</a></sup> Acute thrombo-embolic occlusion most frequently affects the SMA. Due to extensive collaterals, it infrequently leads to intestinal infarction.

###### Clinical presentation and diagnosis

Clinical examination

Early diagnosis of AMI is based on high clinical suspicion. Embolic AMI typically manifests as sudden onset intense abdominal pain, accompanied by minimal physical findings, bowel emptying (vomiting, diarrhoea), and a common embolic source (primarily AF).<sup><a href="javascript:;" reveal-id="ehae179-B818 ehae179-B819 ehae179-B820" data-open="ehae179-B818 ehae179-B819 ehae179-B820" class="link link-ref link-reveal xref-bibr">818–820</a></sup> Emboli may also lodge in other locations, aiding diagnosis. Acute arterial thrombosis tends to occur in areas with pre-existing atherosclerotic disease, resulting in a less dramatic clinical presentation. Patients may have previous symptoms of chronic mesenteric ischaemia (CMI) or other atherosclerotic manifestations.<sup><a href="javascript:;" reveal-id="ehae179-B821" data-open="ehae179-B821" class="link link-ref link-reveal xref-bibr">821</a></sup>

Laboratory tests are unreliable for the diagnosis of AMI, although elevated levels of l-lactate, leucocytosis, and D-dimer (DD) may exist.<sup><a href="javascript:;" reveal-id="ehae179-B822 ehae179-B823 ehae179-B824 ehae179-B825" data-open="ehae179-B822 ehae179-B823 ehae179-B824 ehae179-B825" class="link link-ref link-reveal xref-bibr">822–825</a></sup>

Imaging

Computed tomography angiography is the gold standard for diagnosis,<sup><a href="javascript:;" reveal-id="ehae179-B826" data-open="ehae179-B826" class="link link-ref link-reveal xref-bibr">826</a>,<a href="javascript:;" reveal-id="ehae179-B827" data-open="ehae179-B827" class="link link-ref link-reveal xref-bibr">827</a></sup> allowing the detection of thrombi and/or emboli in the SMA trunk or its branches together with the recognition of intestinal ischaemic signs. A plain abdominal X-ray lacks specificity. A normal result does not rule out the diagnosis.<sup><a href="javascript:;" reveal-id="ehae179-B828" data-open="ehae179-B828" class="link link-ref link-reveal xref-bibr">828</a></sup>

###### Treatment strategy

Most patients require immediate revascularization to survive. There are no RCTs comparing surgical vs. endovascular intervention in AMI. Two meta-analyses found endovascular revascularization to be superior to surgical intervention in terms of in-hospital mortality and rates of bowel resection.<sup><a href="javascript:;" reveal-id="ehae179-B829" data-open="ehae179-B829" class="link link-ref link-reveal xref-bibr">829</a>,<a href="javascript:;" reveal-id="ehae179-B830" data-open="ehae179-B830" class="link link-ref link-reveal xref-bibr">830</a></sup> An open surgical approach is most appropriate in centres where endovascular interventions are less available and in patients with peritonitis.<sup><a href="javascript:;" reveal-id="ehae179-B831" data-open="ehae179-B831" class="link link-ref link-reveal xref-bibr">831</a></sup> Retrograde open mesenteric stenting (ROMS) is an alternative that offers shorter operative time; the SMA is punctured in the open abdomen, followed by stenting.<sup><a href="javascript:;" reveal-id="ehae179-B832" data-open="ehae179-B832" class="link link-ref link-reveal xref-bibr">832</a></sup>

###### Follow-up

Most patients treated for AMI require lifelong anticoagulant/antiplatelet therapy to prevent recurrence. Patients undergoing revascularization should have surveillance with CTA or DUS within 6 months,<sup><a href="javascript:;" reveal-id="ehae179-B833" data-open="ehae179-B833" class="link link-ref link-reveal xref-bibr">833</a></sup> as recurrent AMI after mesenteric revascularization accounts for 6%–8% of late deaths.<sup><a href="javascript:;" reveal-id="ehae179-B834" data-open="ehae179-B834" class="link link-ref link-reveal xref-bibr">834</a></sup> Current Society for Vascular Surgery (SVS) Guidelines recommend DUS at 1, 6, and 12 months after the intervention, and then annually thereafter.<sup><a href="javascript:;" reveal-id="ehae179-B754" data-open="ehae179-B754" class="link link-ref link-reveal xref-bibr">754</a></sup>

##### 8.3.3.2. Chronic mesenteric artery disease

Occlusive CMI is mostly caused by atherosclerosis and more frequently affects females (65%–72%).<sup><a href="javascript:;" reveal-id="ehae179-B835" data-open="ehae179-B835" class="link link-ref link-reveal xref-bibr">835</a>,<a href="javascript:;" reveal-id="ehae179-B836" data-open="ehae179-B836" class="link link-ref link-reveal xref-bibr">836</a></sup> Symptoms typically manifest when at least two mesenteric vessels are involved due to extensive collaterals. Prevalence of asymptomatic coeliac artery and/or SMA stenosis is 3% in patients under 65 years of age and 18% in those aged >65.<sup><a href="javascript:;" reveal-id="ehae179-B837" data-open="ehae179-B837" class="link link-ref link-reveal xref-bibr">837</a></sup> However, inadequate anastomoses can result in symptomatic ischaemia even with a single-vessel atherosclerotic occlusion.<sup><a href="javascript:;" reveal-id="ehae179-B838" data-open="ehae179-B838" class="link link-ref link-reveal xref-bibr">838</a>,<a href="javascript:;" reveal-id="ehae179-B839" data-open="ehae179-B839" class="link link-ref link-reveal xref-bibr">839</a></sup>

###### Clinical presentation and diagnosis

Clinical examination

Like AMI, early diagnosis of CMI relies on clinical suspicion. Classic symptoms include post-prandial abdominal pain, weight loss, and gastrointestinal disturbances like diarrhoea or constipation. Patients may develop food aversion to avoid pain, but their appetite remains unaffected, distinguishing them from individuals with malignancies. An abdominal examination might reveal a bruit.

Lactate, lactate dehydrogenase, and/or leucocyte count are unhelpful in CMI diagnosis.<sup><a href="javascript:;" reveal-id="ehae179-B840" data-open="ehae179-B840" class="link link-ref link-reveal xref-bibr">840</a>,<a href="javascript:;" reveal-id="ehae179-B841" data-open="ehae179-B841" class="link link-ref link-reveal xref-bibr">841</a></sup> Functional testing (tonometry, visible light spectroscopy) is applicable in patients with symptomatic mesenteric stenosis and single-vessel disease.<sup><a href="javascript:;" reveal-id="ehae179-B842" data-open="ehae179-B842" class="link link-ref link-reveal xref-bibr">842</a></sup>

Imaging

Duplex ultrasound is valuable due to its low costs, absence of the need for contrast agents, and no radiation. However, skilled investigators in specialized centres are required for the examination. Despite suggested diagnostic criteria, consensus is lacking.<sup><a href="javascript:;" reveal-id="ehae179-B843" data-open="ehae179-B843" class="link link-ref link-reveal xref-bibr">843</a>,<a href="javascript:;" reveal-id="ehae179-B844" data-open="ehae179-B844" class="link link-ref link-reveal xref-bibr">844</a></sup> Anatomical mapping for treatment planning typically involves CTA or MRA, <sup><a href="javascript:;" reveal-id="ehae179-B845" data-open="ehae179-B845" class="link link-ref link-reveal xref-bibr">845</a>,<a href="javascript:;" reveal-id="ehae179-B846" data-open="ehae179-B846" class="link link-ref link-reveal xref-bibr">846</a></sup> with DSA reserved only for therapeutic purposes (_[Figure 20](javascript:;)_).

![Algorithm of chronic mesenteric ischaemia management.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f20.jpeg?Expires=1728479088&Signature=BW1nbagQUcoUS2EiGwffZU~vPHYj9Vvhu4c-iK4X5-6H9VMMaZ1zyHf9wf1EhWOEL4mRTZCaNpMH4IIN7i-p2adoxyd3hl3Nv7cWzaMfqzup6VkQAU3JdPXDIqXGiXuXoZgB2RgG1AiW-cbdFHxEu7q58yk9GsxGE7UKA3RYI6Iud1bywrvDyACUjULiO8YH3XVpHTf6YwpasENc~uRggKJ9zOwvrkbWqoxbo5COuyf9R14nRBr3zq9rfMcQWSBQ7hobYHDurAmrs-H-UdnAGYb9W3PmmiGnZ~kOp4cEAoZY~7MYM7yA3uGOqGIx5~tgvxxZUZWYBfOi6F9lketzpg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 20

Algorithm of chronic mesenteric ischaemia management.

CA, coeliac artery; CMI, chronic mesenteric ischaemia; CTA, computed tomography angiography; MALS, median arcuate ligament syndrome; NOMI, non-occlusive mesenteric ischaemia; SMA, superior mesenteric artery.

[Open in new tab](https://academic.oup.com/view-large/figure/479846267/ehae179f20.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f20.jpeg?Expires=1728479088&Signature=YCbiOFxjr-x0MVuYSJSCEQBfuQS~luUeBWyi5t8xsCi~KyfjcMZPwa3FKwYsLoieWWs1HwCH0XLqxUTQNFbgPTMzifuWDsPywEN4eCSaWQ6k98l7hHsYVU-BfWf8S~oqDolIuCF8O2z514jgqkhc30-5PCF5I3i8KCyhKy6LtwsnFZigFtw6bbSkAUjlPD56N1p-g51-r8BiYHs9uuJyMAw0VSPxJ-cqdK72tsvWxJxxgmErVe-ECDPvR96P4X4d3mpIvd8mSG9RI0CjfYMMgCCOWAsVIGrgTfQoAA5BSYUoraOG4oaHJ0tDXjhg8LofV~FuT9NrhAJywZpYlvQQEA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846267&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

###### Treatment strategy

Optimal medical treatment is the basis of CMI management. Prophylactic revascularization is not recommended for asymptomatic CMI. In symptomatic cases, a meta-analysis favoured endovascular over open surgery due to fewer complications and a trend towards lower 30 day mortality.<sup><a href="javascript:;" reveal-id="ehae179-B835" data-open="ehae179-B835" class="link link-ref link-reveal xref-bibr">835</a></sup> However, open surgery showed superior long-term results, with fewer symptom recurrences and higher 1 and 5 year primary patency rates in two additional meta-analyses.<sup><a href="javascript:;" reveal-id="ehae179-B847" data-open="ehae179-B847" class="link link-ref link-reveal xref-bibr">847</a>,<a href="javascript:;" reveal-id="ehae179-B848" data-open="ehae179-B848" class="link link-ref link-reveal xref-bibr">848</a></sup> Despite the growing use of endovascular therapy, open surgery remains indicated after failed endovascular therapy without the option for repeat intervention, and in cases with extensive occlusions, calcifications, or technical challenges.

###### Follow-up

Following CMI revascularization, lifelong medical treatment, including lifestyle changes and OMT for atherosclerosis, is recommended. SVS guidelines propose mesenteric DUS surveillance for recurrent stenosis. A potential follow-up schedule involves controls within 1 month post-procedure, biannually for the first 2 years, and annually thereafter.<sup><a href="javascript:;" reveal-id="ehae179-B849" data-open="ehae179-B849" class="link link-ref link-reveal xref-bibr">849</a></sup>

Recommendation Table 32

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846272)

Recommendations in patients with visceral artery stenosis

![Recommendations in patients with visceral artery stenosis](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt32.jpeg?Expires=1728479088&Signature=W8CK0hzePcSnsJd~cpvC-Ddmy7UCUx9Ll8cMYHRyQ2i7OnqEBrE9C3GVERAo5eQzXQcslQRyrr3UJhu4rtHz2qQOJw7Rq~VwvZ60PZsOJbWDKbTeRZNSlSkGjOAD3LjlcxZEbxnXEwOIqXivc9oWvF3Pfhn3FL7wgyUlNSJA01b31etsc7PwVPDvgFsAgYy80f6JoUTUvrtbwTQ5eecRpQiktL3FACpi-UFfCg6oVe2UV5c-53DpZ6u2tAC9laAkPSaqdE7o-UnVO3TJaIoGdfVeNnQm7i~02T1eiD6uOfVwzjy1q6BZwJd1fKIFeiNDI44SsZkntmiANM20gEZfLQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

## 9\. Aorta

### 9.1. Atheromatous disease of the aorta

#### 9.1.1. General concepts

Atheromatous disease of the aorta has an estimated incidence of 40%–51.3%, being complicated in 7.6% of cases.<sup><a href="javascript:;" reveal-id="ehae179-B850 ehae179-B851 ehae179-B852 ehae179-B853" data-open="ehae179-B850 ehae179-B851 ehae179-B852 ehae179-B853" class="link link-ref link-reveal xref-bibr">850–853</a></sup> Earlier stages of atherosclerosis, presenting as plaque inflammation, can be present in 48% of asymptomatic individuals.<sup><a href="javascript:;" reveal-id="ehae179-B850" data-open="ehae179-B850" class="link link-ref link-reveal xref-bibr">850</a></sup> Atherosclerotic plaque classification is based on plaque thickness and the presence of ulceration or mobile components (_[Table 14](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B159" data-open="ehae179-B159" class="link link-ref link-reveal xref-bibr">159</a>,<a href="javascript:;" reveal-id="ehae179-B171" data-open="ehae179-B171" class="link link-ref link-reveal xref-bibr">171</a>,<a href="javascript:;" reveal-id="ehae179-B854" data-open="ehae179-B854" class="link link-ref link-reveal xref-bibr">854</a></sup> This classification is crucial because severe or complex atherosclerotic plaques in the aortic arch or ascending aorta are strongly linked to cerebrovascular events (odds ratio \[OR\] 4–9.1 for plaques ≥4 mm).<sup><a href="javascript:;" reveal-id="ehae179-B855 ehae179-B856 ehae179-B857 ehae179-B858 ehae179-B859 ehae179-B860" data-open="ehae179-B855 ehae179-B856 ehae179-B857 ehae179-B858 ehae179-B859 ehae179-B860" class="link link-ref link-reveal xref-bibr">855–860</a></sup> Additionally, the annual incidence of stroke recurrence remains high (up to 16%) despite antiplatelet or anticoagulant therapy.<sup><a href="javascript:;" reveal-id="ehae179-B855" data-open="ehae179-B855" class="link link-ref link-reveal xref-bibr">855</a>,<a href="javascript:;" reveal-id="ehae179-B861" data-open="ehae179-B861" class="link link-ref link-reveal xref-bibr">861</a></sup>

Table 14

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846277)

Grading of atherosclerotic aortic plaques

| Grade | Severity (atheroma thickness) | Description |
| --- | --- | --- |
| 1 | Normal | Intimal thickness <2 mm |
| 2 | Mild | Intimal thickening of 2 to <3 mm |
| 3 | Moderate | Atheroma ≥3 to <4 mm (no mobile/ulcerated components) |
| 4 | Severe | Atheroma ≥4 mm (no mobile/ulcerated components) |
| 5 | Complex | Grade 2, 3, or 4 atheroma plus mobile/ulcerated components |

#### 9.1.2. Treatment

##### 9.1.2.1. Primary prevention

Asymptomatic non-severe/non-complex aortic plaques (_[Table 14](javascript:;)_) should not mandate antiplatelet therapy. Nonetheless, in severe/complex plaques, statins should be indicated to decrease plaque progression or CV events,<sup><a href="javascript:;" reveal-id="ehae179-B862" data-open="ehae179-B862" class="link link-ref link-reveal xref-bibr">862</a></sup> and SAPT with clopidogrel or low-dose aspirin should be considered after risk/benefit evaluation.<sup><a href="javascript:;" reveal-id="ehae179-B493" data-open="ehae179-B493" class="link link-ref link-reveal xref-bibr">493</a>,<a href="javascript:;" reveal-id="ehae179-B666" data-open="ehae179-B666" class="link link-ref link-reveal xref-bibr">666</a>,<a href="javascript:;" reveal-id="ehae179-B861" data-open="ehae179-B861" class="link link-ref link-reveal xref-bibr">861</a>,<a href="javascript:;" reveal-id="ehae179-B863" data-open="ehae179-B863" class="link link-ref link-reveal xref-bibr">863</a></sup> However, in this scenario, anticoagulation<sup><a href="javascript:;" reveal-id="ehae179-B861" data-open="ehae179-B861" class="link link-ref link-reveal xref-bibr">861</a></sup> or DAPT (low-dose aspirin and clopidogrel) are not indicated.<sup><a href="javascript:;" reveal-id="ehae179-B666" data-open="ehae179-B666" class="link link-ref link-reveal xref-bibr">666</a>,<a href="javascript:;" reveal-id="ehae179-B863" data-open="ehae179-B863" class="link link-ref link-reveal xref-bibr">863</a></sup> Floating aortic thrombi and complex mobile plaques are rare, with limited large-scale trials on their management. Guidance relies on case reports, observational studies, and expert opinions, yet there is evidence favouring anticoagulation, particularly for symptomatic cases.<sup><a href="javascript:;" reveal-id="ehae179-B864" data-open="ehae179-B864" class="link link-ref link-reveal xref-bibr">864</a></sup>

##### 9.1.2.2. Secondary prevention

Secondary prevention with antiplatelet therapy after an embolic event is recommended to prevent recurrences.<sup><a href="javascript:;" reveal-id="ehae179-B666" data-open="ehae179-B666" class="link link-ref link-reveal xref-bibr">666</a>,<a href="javascript:;" reveal-id="ehae179-B865" data-open="ehae179-B865" class="link link-ref link-reveal xref-bibr">865</a>,<a href="javascript:;" reveal-id="ehae179-B866" data-open="ehae179-B866" class="link link-ref link-reveal xref-bibr">866</a></sup> While the value of DAPT vs. SAPT remains uncertain, recent studies indicate that prolonged DAPT raises bleeding risk without added antithrombotic benefits.<sup><a href="javascript:;" reveal-id="ehae179-B667" data-open="ehae179-B667" class="link link-ref link-reveal xref-bibr">667</a>,<a href="javascript:;" reveal-id="ehae179-B863" data-open="ehae179-B863" class="link link-ref link-reveal xref-bibr">863</a>,<a href="javascript:;" reveal-id="ehae179-B867" data-open="ehae179-B867" class="link link-ref link-reveal xref-bibr">867</a></sup> Treatment duration is unclear and must strike a balance between early benefit (notably within 7 days post-emboli) and steady bleeding risk. Statins (LDL target below 1.4 mmol/L \[55 mg/dL\]) prove effective in preventing strokes regardless of the aetiology.<sup><a href="javascript:;" reveal-id="ehae179-B862" data-open="ehae179-B862" class="link link-ref link-reveal xref-bibr">862</a>,<a href="javascript:;" reveal-id="ehae179-B865" data-open="ehae179-B865" class="link link-ref link-reveal xref-bibr">865</a>,<a href="javascript:;" reveal-id="ehae179-B868" data-open="ehae179-B868" class="link link-ref link-reveal xref-bibr">868</a></sup> Additionally, a healthy lifestyle is crucial for improving CV health and reducing complications.

Recommendation Table 33

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846283)

Recommendations for primary and secondary prevention in aortic atheromatous plaques

![Recommendations for primary and secondary prevention in aortic atheromatous plaques](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt33.jpeg?Expires=1728479088&Signature=3KOeu3SDc4Fh0XE1KqwITUxZ9HO9lA2lqkzQ5VhQ0QM4ec51wY43z5C8mpsu-DLq16ytJH8UK5ROOGrg5UIo8u0bBRnMmd32-3pL0XPg89M5nIefDCw~27csRe7fanneyM~ZVaEbNB1aXinomR0kxi5NX2rhVosQaLd1rU~UMIBxr8kOvoklZy5ccF8c9sV5T8Q8XsP6AjQcTwOuJsxrcXD-tjnRmHNY-Urz~igbLbtWpoJ3SIpp8X0gKXDN7XlsQsEPIZcjW3FdZl0AccUXFzXsCeeDYFkwJppLKdJaW3tBSA9fC~LHFcrtI2mQagPt7ZLJRB1rglosO4V04KK2Mw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 9.2. Aortic aneurysms

#### 9.2.1. General concepts

##### 9.2.1.1. Definitions

Aortic dilatation, the second most frequent aortic disease after atherosclerosis, is defined as an aortic diameter >2 standard deviations of the predicted mean diameter depending on age, sex, and body size (z-score >2). However, in clinical practice, aortic root dilatation can be suspected in male adults when aortic diameter is >40 mm and in females at >36 mm,<sup><a href="javascript:;" reveal-id="ehae179-B138" data-open="ehae179-B138" class="link link-ref link-reveal xref-bibr">138</a>,<a href="javascript:;" reveal-id="ehae179-B149" data-open="ehae179-B149" class="link link-ref link-reveal xref-bibr">149</a>,<a href="javascript:;" reveal-id="ehae179-B869" data-open="ehae179-B869" class="link link-ref link-reveal xref-bibr">869</a></sup> or with an indexed diameter/BSA (aortic size index \[ASI\]) >22 mm/m<sup>2</sup>. In extreme BSA and age values, use of z-scores is recommended (see _Section [5.4](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#ehae179-s4.4)_ for their calculation).

Arterial aneurysm is defined as a diameter >1.5 times (>50%) larger than the predicted one. This definition, as well as the use of z-scores, introduces the need for normal values and correction for age, sex, and body size. However, correcting for BSA can lead to underestimation in overweight patients,<sup><a href="javascript:;" reveal-id="ehae179-B870" data-open="ehae179-B870" class="link link-ref link-reveal xref-bibr">870</a></sup> therefore a correction for height (aortic height index \[AHI\]) is becoming more popular.<sup><a href="javascript:;" reveal-id="ehae179-B153" data-open="ehae179-B153" class="link link-ref link-reveal xref-bibr">153</a></sup> In terms of clinical risk, both ASI and AHI have been shown to improve risk stratification for AAE.<sup><a href="javascript:;" reveal-id="ehae179-B153" data-open="ehae179-B153" class="link link-ref link-reveal xref-bibr">153</a>,<a href="javascript:;" reveal-id="ehae179-B871" data-open="ehae179-B871" class="link link-ref link-reveal xref-bibr">871</a></sup> Since in many cases of aortic dilatation the surgical indication is established before achieving this aneurysmal diameter, we strongly recommend the use of _significant aortic dilation_ specifying the diameter or the indexed diameter value rather than the term ‘aneurysm’.

Thoracic aortic aneurysms (TAAs) are more prevalent in men than in women (ratio 4:1);<sup><a href="javascript:;" reveal-id="ehae179-B872" data-open="ehae179-B872" class="link link-ref link-reveal xref-bibr">872</a></sup> however, the growth rate is greater in women (0.96 ± 1.00 mm per year) than in men (0.45 ± 0.58 mm per year), and thus the risk of AAE.<sup><a href="javascript:;" reveal-id="ehae179-B873" data-open="ehae179-B873" class="link link-ref link-reveal xref-bibr">873</a></sup>

Aneurysms can be fusiform or saccular based on morphology. Saccular aneurysms relate to infection, penetrating atherosclerotic ulcer (PAU), trauma, or inflammatory diseases, while fusiform aneurysms connect with degenerative and connective tissue conditions. Although evidence about their natural course is limited, saccular aneurysms are considered more malignant in terms of AAE. Based on location, aortic aneurysms are classified into TAA and abdominal aortic aneurysm (AAA) (_[Figure 21](javascript:;)_). They differ in treating specialists, causes, age at onset, risk factors, and complications. However, this binary classification is artificial due to the prevalence of thoracoabdominal aortic aneurysms (TAAA) and tandem lesions (20%–30% of AAA patients also have TAA),<sup><a href="javascript:;" reveal-id="ehae179-B874" data-open="ehae179-B874" class="link link-ref link-reveal xref-bibr">874</a>,<a href="javascript:;" reveal-id="ehae179-B875" data-open="ehae179-B875" class="link link-ref link-reveal xref-bibr">875</a></sup> emphasizing the importance of comprehensive aortic and vascular assessments at diagnosis. When detecting an aortic aneurysm at any site, it is advisable to conduct a thorough evaluation of the entire aorta initially and during subsequent follow-ups. Specifically, when diagnosing a TAA, it is crucial to assess the aortic valve, particularly in cases of BAV. Data on peripheral aneurysms in TAA, particularly in femoro-popliteal segments, is less clear compared with AAA. However, cerebral aneurysms, notably prevalent in women and those with HTAD, warrant thorough screening, particularly in symptomatic cases.<sup><a href="javascript:;" reveal-id="ehae179-B876 ehae179-B877 ehae179-B878" data-open="ehae179-B876 ehae179-B877 ehae179-B878" class="link link-ref link-reveal xref-bibr">876–878</a></sup>

![Thoracic and abdominal aortic aneurysms: aetiology, screening and diagnostic methods.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f21.jpeg?Expires=1728479088&Signature=AkHRIh~wLaLZimoSeqmckZm8ZJmQWxhk4XNtRvxTML6r6eaTwXTBgm6rANjMTIs8qK7oHFO1qyhuyWU~Px8KKMXk3qevPe7NcS5TxST3QRKXlx4KlM1eRSBfBnLHBofYHMEqhVQJb0Bte3C9OyvPoa4kDXXCah5fOp6vUXO7Xl14w0Y5XWKMFNg3vLwVW3rc6qPm03UBx0JdPBW0lqNyD6nhTVRG~MJgLkCAKJ8dMDWFouuETI5ygnRk8PK7F4JgYKv-TBwf-GgZ4XqKxh662GaAxl-uD277nSemOWGM4QLhLUW2Ghgxz9GugKKbAOjawowpiMwdGsmEK6vgFpDZLg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 21

Thoracic and abdominal aortic aneurysms: aetiology, screening and diagnostic methods.

AAA, abdominal aortic aneurysm; BAV, bicuspid aortic valve; CCT, cardiovascular computed tomography; CEUS, contrast-enhanced Doppler ultrasound; CMR, cardiovascular magnetic resonance; DUS, Doppler ultrasound; HTAD, heritable thoracic aortic disease; TAA, thoracic aortic aneurysm; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography.

[Open in new tab](https://academic.oup.com/view-large/figure/479846291/ehae179f21.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f21.jpeg?Expires=1728479088&Signature=fcRVHUoyYcNOCTZ2NuzFZiq72d7PztPXKNs5BeuObZBuXyAxjLvIvzTODyqlKRM2oLIhAA~wO1UDs95UIuLqcCvVfANznZe6k7y-MfK7Ldk2JQUK52CLACoktsZEiyC5bfov7ZzHiT3M9TAdEE~3S-pvDfxr4ZCrDRX-u~eWzmAHuBCWH~3-q02j0otUm3~EGcA7hNEOJHM~UE0j~2d1BzsRD4Q-awVTSqUrV7oyRuLsdqmGrjU8ohnu8~5OifrytUYSpPpg2oqpGqgPsnxaJL5-NOc0L3HF1VXAAQxWnAWKXScdhf2-XtuKA4R9mjv2-lGYpaco1EJ8ZZ2LxoTNUw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846291&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Recommendation Table 34

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846292)

Recommendations for initial evaluation of thoracic aortic aneurysm and abdominal aortic aneurysm

![Recommendations for initial evaluation of thoracic aortic aneurysm and abdominal aortic aneurysm](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt34.jpeg?Expires=1728479088&Signature=fnQ39fW6KWKmvN7DJw2gqJ2PJHXofd4G3xOZVRrdWqD5qnW4hJGQNbsjE~FzmEDqJIXnHUE9GjmeOu26aSwv6QieROZ-nBOzElsfqJ2UFZOeA-PUkuDEbU9egnuu6-RzNLdfR4iZZ2Z6tfQ14KX-D~AN-SNXIvT8UNToJ5zV4Ye6-a907n40qX-1FJnfhNR5QPQ7Aw67qBbUY4qG7sXjJatGJ34CoqumbS92ooTouzUjeQY8FFGAbjDGkzI5XYD~YcetY1QmXIiE81fkItgLyYABFPxFSjILJ0z7NfERISzNVdyqwXKqA5-Jkw2r8M6Q9~9pxN-bzIDlKmNeGf9K-Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 9.2.2. Thoracic aortic aneurysms

##### 9.2.2.1. Aetiology, risk factors, and natural history

Thoracic aortic aneurysms occur in 5–10/100 000 person-years,<sup><a href="javascript:;" reveal-id="ehae179-B884" data-open="ehae179-B884" class="link link-ref link-reveal xref-bibr">884</a></sup> with an approximate predominance of root and/or ascending aorta of ∼60%, arch of ∼10%, and descending aorta of ∼30%.<sup><a href="javascript:;" reveal-id="ehae179-B885" data-open="ehae179-B885" class="link link-ref link-reveal xref-bibr">885</a>,<a href="javascript:;" reveal-id="ehae179-B886" data-open="ehae179-B886" class="link link-ref link-reveal xref-bibr">886</a></sup>

Hypertension is the main risk factor (80%); however, genetics may be involved in 20% of cases.<sup><a href="javascript:;" reveal-id="ehae179-B887" data-open="ehae179-B887" class="link link-ref link-reveal xref-bibr">887</a></sup> The decision to refer patients for genetic evaluation should consider age, family history, and presence of syndromic features,<sup><a href="javascript:;" reveal-id="ehae179-B25" data-open="ehae179-B25" class="link link-ref link-reveal xref-bibr">25</a>,<a href="javascript:;" reveal-id="ehae179-B888" data-open="ehae179-B888" class="link link-ref link-reveal xref-bibr">888</a></sup> as reported in more detail in _Section [10.1](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#ehae179-s9.1)_.

##### 9.2.2.2. Ascending thoracic aorta and arch aneurysms

1.  **Aortic root aneurysms** (including sinuses of Valsalva: annulo-aortic ectasia). They can be idiopathic, associated with HTAD (syndromic/non-syndromic), or found in 20%–30% of BAV patients (see _Section [10](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#ehae179-s9)_).<sup><a href="javascript:;" reveal-id="ehae179-B879" data-open="ehae179-B879" class="link link-ref link-reveal xref-bibr">879</a>,<a href="javascript:;" reveal-id="ehae179-B880" data-open="ehae179-B880" class="link link-ref link-reveal xref-bibr">880</a></sup> Patients are usually younger (30–50 years of age), with aortic regurgitation, and with a 1:1 sex ratio.
    
2.  **Supra-coronary aortic aneurysms** (above sinuses of Valsalva). Caused by atherosclerosis in relation to hypertension affecting older patients (59–69 years) and males (ratio 3:1),<sup><a href="javascript:;" reveal-id="ehae179-B880" data-open="ehae179-B880" class="link link-ref link-reveal xref-bibr">880</a></sup> or related to medial degeneration (isolated or associated with aortic valve disease, including BAV) (see _Section [10](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#ehae179-s9)_). Primary bacterial infection or syphilis are uncommon. Arteritis is rare, but Takayasu’s and giant cell arteritis can lead to aneurysm formation.
    
3.  **Aortic arch aneurysms.** Often accompanying adjacent ascending or descending aorta aneurysms, aortic arch aneurysms present surgical challenges due to potential neurological and CV risks. They are typically linked to atherosclerosis, with cystic medial degeneration primarily affecting ascending aorta-related arch aneurysms. Deceleration injuries or coarctation may extend into the aortic arch.<sup><a href="javascript:;" reveal-id="ehae179-B889" data-open="ehae179-B889" class="link link-ref link-reveal xref-bibr">889</a></sup>
    

Thoracic aortic aneurysm patients are usually asymptomatic, diagnosed incidentally during unrelated imaging or screenings. Symptoms such as chest pain, aortic regurgitation, and compression-related issues may occur.<sup><a href="javascript:;" reveal-id="ehae179-B890" data-open="ehae179-B890" class="link link-ref link-reveal xref-bibr">890</a></sup> Patients with aortic root involvement (as seen in HTAD) are more prone to suffer from AAE.<sup><a href="javascript:;" reveal-id="ehae179-B891" data-open="ehae179-B891" class="link link-ref link-reveal xref-bibr">891</a>,<a href="javascript:;" reveal-id="ehae179-B892" data-open="ehae179-B892" class="link link-ref link-reveal xref-bibr">892</a></sup>

Thoracic aortic aneurysm growth rate is variable, associated with aetiology, location, and baseline aortic diameter.<sup><a href="javascript:;" reveal-id="ehae179-B893 ehae179-B894 ehae179-B895" data-open="ehae179-B893 ehae179-B894 ehae179-B895" class="link link-ref link-reveal xref-bibr">893–895</a></sup> Degenerative TAAs grow faster in women than men and are associated with a three-fold higher risk of AAE.<sup><a href="javascript:;" reveal-id="ehae179-B24" data-open="ehae179-B24" class="link link-ref link-reveal xref-bibr">24</a>,<a href="javascript:;" reveal-id="ehae179-B873" data-open="ehae179-B873" class="link link-ref link-reveal xref-bibr">873</a>,<a href="javascript:;" reveal-id="ehae179-B896" data-open="ehae179-B896" class="link link-ref link-reveal xref-bibr">896</a></sup> When the aorta reaches 57.5 mm in size, reported yearly rates of rupture, dissection, and death are 3.6%, 3.7%, and 10.8%, respectively.<sup><a href="javascript:;" reveal-id="ehae179-B897 ehae179-B898 ehae179-B899" data-open="ehae179-B897 ehae179-B898 ehae179-B899" class="link link-ref link-reveal xref-bibr">897–899</a></sup>

##### 9.2.2.3. Descending thoracic aorta and thoracoabdominal aorta aneurysms

They can involve different parts of the DTA and may extend to the AA: TAAA. TAAAs are divided into five groups<sup><a href="javascript:;" reveal-id="ehae179-B900" data-open="ehae179-B900" class="link link-ref link-reveal xref-bibr">900</a></sup> according to the modified TAAA classification scheme (_[Figure 22](javascript:;)_), which is crucial for risk stratification. By classifying aneurysm extent, surgeons can anticipate procedure complexity, select suitable techniques, and reduce risks during surgical planning.

![Classification of thoracoabdominal900 and abdominal aortic aneurysms.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f22.jpeg?Expires=1728479088&Signature=Mc7RHSCYOjc3ac~8iVKGMF0WTQrj9G25CSXGdnKAiLz43PifAHPgeJIjOHbmrEuzcQf0vjzukgutztY~rufwZShQa10BhCLAIn4yZnpB24WJpgS0JhWm4dbqikhqYTk-0hS6TrwJG6tpukOeFx6uYQEu6pcxnbJLRuNi9j89S~hEpShyZa~c1RaYaVKuzfy4DiKcIdUTyrkQMQBwKGrt9SN5AP4pIg-EDN1VDgEkuy~~jrnGiBXZFq3nY6ukqYGHQgIaULHzO6tw9JM6U2RNtVH3Ic2A8BksVWR84qyc2fbiaVrD-Bpg0QULTBynz4I4v-S275ei255FD3IE-erfFA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 22

Classification of thoracoabdominal<sup><a href="javascript:;" reveal-id="ehae179-B900" data-open="ehae179-B900" class="link link-ref link-reveal xref-bibr">900</a></sup> and abdominal aortic aneurysms.

AAA, abdominal aortic aneurysm; IMA, inferior mesenteric artery; SMA, superior mesenteric artery.

[Open in new tab](https://academic.oup.com/view-large/figure/479846303/ehae179f22.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f22.jpeg?Expires=1728479088&Signature=LZjmkXEjIb4se~-TSXiRTlaD-vISiyMzeN341zFQG7wygasCadLQgYTVpjDvV7nBAccOwz6oRxCkmoHa6Epp1b5OFRHqVEaaVaB8bOT8IcL9jGf78keV-oOzjO8seWd8pesRRUrTPLetUXlchdOscnLbz9FDVgjfxgyQi~LGB~2MFrvTG6beAgcBfjC2R83cVmVtvcT3gdbTz8zIMJyPERoZM3ynnSsI7bobhCHmkRV3qeOF5sezYnER4YN5um3yzzzQbna2cMt8FcAYHkn4ZJ~vQu~obCAiFh2fDH1dOlPfJnY80J1K4EvwOQNZRe4ShQiYbAB~UYuc3vIk9RXpRA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846303&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Most DTA aneurysms and TAAA are degenerative with calcification, although other causes include trauma, infection, inflammation, or genetic factors<sup><a href="javascript:;" reveal-id="ehae179-B901" data-open="ehae179-B901" class="link link-ref link-reveal xref-bibr">901</a>,<a href="javascript:;" reveal-id="ehae179-B902" data-open="ehae179-B902" class="link link-ref link-reveal xref-bibr">902</a></sup> (_[Figure 21](javascript:;)_). Patients with HTAD rarely develop thoracoabdominal aortic aneurysms without dissection. Mean age at diagnosis is 59–69, with a male predominance of 2–4:1. Aneurysm growth rate is 1.9–3.4 mm per year,<sup><a href="javascript:;" reveal-id="ehae179-B902" data-open="ehae179-B902" class="link link-ref link-reveal xref-bibr">902</a>,<a href="javascript:;" reveal-id="ehae179-B903" data-open="ehae179-B903" class="link link-ref link-reveal xref-bibr">903</a></sup> but tends to increase notably with diameters over 50 mm or post-proximal aorta surgery in patients with MFS. In this population, debate continues as to whether this reflects a more vulnerable aorta associated to the genetic disease or haemodynamic changes post-surgery.

For untreated DTA aneurysm patients, 5 year survival is about 54%, with aortic rupture as the leading cause of death.<sup><a href="javascript:;" reveal-id="ehae179-B904" data-open="ehae179-B904" class="link link-ref link-reveal xref-bibr">904</a></sup> Rupture risk factors include HTAD, a diameter over 50 mm, hypertension, smoking, chronic obstructive pulmonary disease (COPD), symptoms, chronic aortic dissection, and age. A significant rise in AAE risk occurs at a 60 mm diameter. Although dissection can occur in smaller aortas, the individual risk is low.<sup><a href="javascript:;" reveal-id="ehae179-B899" data-open="ehae179-B899" class="link link-ref link-reveal xref-bibr">899</a></sup> High-risk features for rupture are represented in _[Figure 23](javascript:;)_.

![Risk factors for thoracic and abdominal aneurysm rupture.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f23.jpeg?Expires=1728479088&Signature=Nm00E9pIk0ZUNlaej7ylxIxTz0q7Rz8wUAICnsLmdLhEFKGVj1M3IFCnuU03r25Zvoz8QiqPJtw4D35CZFDLtC~cpV9rIpeXoqegD0yheEpqf~YAWeavHhmvH727WIGYn92JlrCb34vH-u2Ed8tgjOCkPj1b-jyOemOuPb58d-gW7aUU8sDlh7LGpFzhAxFJUZuEO5Kbj~XuRdTdFDH54EF-4ywtKG3PFQHFLXPO4Z8pLOKx0VYTZBqXt9JAqgeeRwavKa9lf-Bq~U4BJ-k1rmMAw7IzsjEUaitg~nD4fISCRZ~Zr0-t0OmYdvXx5fqL0i~eNvyPVo2ULOHxHOHBMg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 23

Risk factors for thoracic and abdominal aneurysm rupture.

AAA, abdominal aortic aneurysm; COPD, chronic obstructive pulmonary disease; DTAA, descending thoracic aorta aneurysm; PAU, penetrating atherosclerotic ulcer; TAAA, thoracoabdominal aortic aneurysm.<sup><a href="javascript:;" reveal-id="ehae179-B905 ehae179-B906 ehae179-B907 ehae179-B908" data-open="ehae179-B905 ehae179-B906 ehae179-B907 ehae179-B908" class="link link-ref link-reveal xref-bibr">905–908</a></sup>

[Open in new tab](https://academic.oup.com/view-large/figure/479846306/ehae179f23.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f23.jpeg?Expires=1728479088&Signature=t950d6y~sF1UFIo9a~BgKAdjO52XQiBM2iBxBP9hhJcBaUXAweBDCRzWFPwZJBpiJSGJyaFyAzey1d4uCLXpTMbF4St0Av7Rwcg97Mw9xCCMJPY55tLoM85siqgvH0iG1CGPMyeYpRm7SrXkXHJQN-ni6YxHg4ApedLxkYx1qci8Q~658~VlCrNiJVEQ7xAO0oiSfJAKl5juiT~awXZZA6G80tp5XYT6s8UE-VDhvMYZ7i-H8KAj6gBQYxK8GMxrwaGPrtqhB64koCzsER-y1B5rAxvKJtgZmgxu8vPSQwpoleKF-ic6ItbO24HP3QesXfuAQ9JezsTWmjsjtdUO8w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846306&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

##### 9.2.2.4. Surveillance

Patients with TAA who do not meet surgical criteria require chronic follow-up that includes clinical evaluation and imaging techniques. The best imaging modality depends on aneurysm location: TTE, CCT, or CMR when affecting the aortic root and the ascending aorta; CMR and CCT when involving the distal ascending aorta, the aortic arch, or the DTA.<sup><a href="javascript:;" reveal-id="ehae179-B159" data-open="ehae179-B159" class="link link-ref link-reveal xref-bibr">159</a>,<a href="javascript:;" reveal-id="ehae179-B171" data-open="ehae179-B171" class="link link-ref link-reveal xref-bibr">171</a></sup> Follow-up should be conducted with the same imaging technique and in the same centre.<sup><a href="javascript:;" reveal-id="ehae179-B909" data-open="ehae179-B909" class="link link-ref link-reveal xref-bibr">909</a></sup> If a TAA is only moderate in size and remains relatively stable over time, CMR rather than CCT is reasonable to minimize radiation exposure.<sup><a href="javascript:;" reveal-id="ehae179-B172" data-open="ehae179-B172" class="link link-ref link-reveal xref-bibr">172</a>,<a href="javascript:;" reveal-id="ehae179-B910" data-open="ehae179-B910" class="link link-ref link-reveal xref-bibr">910</a></sup> Follow-up for aortic aneurysms associated with HTAD is described in _Section [10.1.3.2](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#ehae179-s9.1.3.2)_.

_[Figure 24](javascript:;)_ proposes a follow-up algorithm for patients with TAA. In cases of aortic root or proximal ascending aorta dilatation, after initial diagnosis by TTE the basal diameter and extension must be confirmed by CMR or CCT. If there is agreement between techniques, TTE can be used for follow-up; however, if there is a difference of ≥3 mm, surveillance must be performed by CMR or CCT. After the initial diagnosis, imaging is required at 6–12 months, depending on aetiology and baseline diameter (_[Figure 24](javascript:;)_); see _Sections [5.4.2](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#ehae179-s4.4.2)_ and _[9.2.1](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#ehae179-s8.2.1)_ about indexed values of aortic dimensions, to ensure stability.<sup><a href="javascript:;" reveal-id="ehae179-B159" data-open="ehae179-B159" class="link link-ref link-reveal xref-bibr">159</a>,<a href="javascript:;" reveal-id="ehae179-B911" data-open="ehae179-B911" class="link link-ref link-reveal xref-bibr">911</a></sup> Subsequently, imaging can be performed annually if there is no expansion/extension or customized according to the underlying condition. If the aorta shows rapid expansion (≥3 mm per year) or approaches the surgery/endovascular repair threshold, a closer evaluation is recommended every 6 months. In contrast, stability in aortic diameters over years could lengthen these intervals (especially in non-genetic aneurysms and those <45 mm). In cases of dilatation of aortic arch or DTA, diameters obtained by TTE are deemed less precise and need confirmation by CMR or CCT. In those types of aneurysms, follow-up frequency will depend on the baseline diameter and aetiology and will follow the same criteria established in the algorithm in _[Figure 24](javascript:;)_ for the 40–49 mm range. However, for the 50–55 mm range, the aorta should be re-imaged every 6 months until the threshold for intervention is reached (see _Sections [9.2.5.3](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#ehae179-s8.2.5.3)_ and _[9.2.5.4](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#ehae179-s8.2.5.4)_).

![Surveillance of patients with non-heritable thoracic aortic disease and abdominal aortic aneurysms.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f24.jpeg?Expires=1728479088&Signature=Nt0j4NbiwfzUHkhldD28mgeCyZmQ-Z6H5QeMczAcm7265cLWtCJcyao32JiqrSyTjJEHxTyKDF7u3WXeXV3dsCF2SOlEUdtnhuT9OxTwdRVUfEpgbsrsNPMDPd3VlL-spkpG9poW~qAMNnmLGS~RtSCCDZKSrAjrdmdNc8RWezdBqAW-nROG9sOfmJLIdUtiXkn9Q8IU4ThcqJc-fTCmqzR7rVLbhKq1A-Gem8zwTji46rdnwNFHvKEAe~u~OL~R2zUB6n4ef8dm91rGB~ppLxv8ZPy4daQR8t62dzeGkgCkihuMHuUsmL96DOUuxwOZS2wcsiq0S-6xWkTxnHfa9g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 24

Surveillance of patients with **non-heritable** thoracic aortic disease and abdominal aortic aneurysms.

AAA, abdominal aortic aneurysm, BAV, bicuspid aortic valve; CCT, cardiovascular computed tomography; HTAD, heritable thoracic aortic disease; CMR, cardiovascular magnetic resonance; TAV, tricuspid aortic valve; TTE, transthoracic echocardiography. <sup>a</sup>36–44 mm in women. <sup>b</sup>For TAV and BAV: age <50 years; height <1.69 m; ascending length >11 cm; uncontrolled hypertension; and, for BAV: coarctation; family history of acute aortic events.

[Open in new tab](https://academic.oup.com/view-large/figure/479846310/ehae179f24.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f24.jpeg?Expires=1728479088&Signature=1YSsQl8nw0WU8MJbEollsWOUwRI4gfjGKPLtsNxv~pEIca7BOLfIFdcgyelmi-AO5CmPmkQp~GbHTon9uNsMRgKGcS3t8szjt65WiksYhtGTUOKRNXgMbU6p~QKdYNp~MoqGnlEmsLcqGJGc4LrM2pAjy42xVlFO0J73wpW9Q7xmo0PVG3mHOdDEuDO05p-34xn37zaeaWlB~DjMohN~UTuTpyGTGtsSB7SCCX0iq4XLEvLJDg209TUgwyqipaEQls0PnxchC8iaoM6KOX2P3El0ylJ7zflwxVgKrEAlYDOlL-EqV1Khr6klnfGw7VckGj7dyeetFfgAsqlKbgvlYQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846310&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Recommendation Table 35

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846311)

Recommendation for the surveillance of patients with thoracic aortic aneurysms (non-heritable thoracic aortic disease)

![Recommendation for the surveillance of patients with thoracic aortic aneurysms (non-heritable thoracic aortic disease)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt35.jpeg?Expires=1728479088&Signature=pEFh~dpz1K~kxQrQIqthWxjkjWYJ3EkNP-tcFIaq6AQoKmuu5ij0A1Sk~G9J9uLSJV-rzROURH~7h9KCFn2VTjo1QLgKQ6KG1WSEn~mN8dJ8hvP4pXc8Cxb0YRv58nkKhzMIGoRVVpSbHEcuuUzb4iJYjv1RTKn6Aiq1BGoDAHPSdjZXXezeGpjc~ixJLV9mNFfR7MYmkBPh3alREdKZd6M0rFWvnrsRGAlFydU48sEeT1UpujZMXOYhyGZNOjO4IDmYMg-byQlh2JsnZ7~K9QusyT7hd3engPf4YnkEJgpx2gBRaf6wJRfrtoE5Vdysav1y41cHaVQuPNCgwRL4cw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 9.2.3. Abdominal aortic aneurysms

##### 9.2.3.1. General concepts

An AAA is defined as a focal dilation at least 1.5 times its normal diameter, generally ≥30 mm. Most AAAs are fusiform, and many are lined with laminated thrombi.<sup><a href="javascript:;" reveal-id="ehae179-B916" data-open="ehae179-B916" class="link link-ref link-reveal xref-bibr">916</a></sup> Their prevalence increases with age, with a 4:1 male/female ratio.<sup><a href="javascript:;" reveal-id="ehae179-B872" data-open="ehae179-B872" class="link link-ref link-reveal xref-bibr">872</a></sup> They are commonly classified based on their relation to renal arteries (_[Figure 22](javascript:;)_) because of the complexity of surgical treatment. AAA extends to the common iliac arteries in 25% of cases and in up to 20% of patients is associated with peripheral femoral and/or popliteal artery aneurysm.<sup><a href="javascript:;" reveal-id="ehae179-B876 ehae179-B877 ehae179-B878" data-open="ehae179-B876 ehae179-B877 ehae179-B878" class="link link-ref link-reveal xref-bibr">876–878</a></sup>

##### 9.2.3.2. Aetiology, risk factors, and natural history

Smoking, age, male sex, and familial history of aneurysmal disease are major risk factors,<sup><a href="javascript:;" reveal-id="ehae179-B917 ehae179-B918 ehae179-B919 ehae179-B920 ehae179-B921" data-open="ehae179-B917 ehae179-B918 ehae179-B919 ehae179-B920 ehae179-B921" class="link link-ref link-reveal xref-bibr">917–921</a></sup> whereas diabetes is associated with a decreased risk<sup><a href="javascript:;" reveal-id="ehae179-B922" data-open="ehae179-B922" class="link link-ref link-reveal xref-bibr">922</a>,<a href="javascript:;" reveal-id="ehae179-B923" data-open="ehae179-B923" class="link link-ref link-reveal xref-bibr">923</a></sup> and slower growth rate<sup><a href="javascript:;" reveal-id="ehae179-B924" data-open="ehae179-B924" class="link link-ref link-reveal xref-bibr">924</a></sup> (_[Figure 21](javascript:;)_, see also _Section [5](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#ehae179-s4)_). Other aetiologies include inflammation (5%–10% of all AAA),<sup><a href="javascript:;" reveal-id="ehae179-B925" data-open="ehae179-B925" class="link link-ref link-reveal xref-bibr">925</a></sup> genetic disorders, and infection. The mean growth rate is around 3 mm per year (1–6 mm)<sup><a href="javascript:;" reveal-id="ehae179-B906" data-open="ehae179-B906" class="link link-ref link-reveal xref-bibr">906</a>,<a href="javascript:;" reveal-id="ehae179-B926" data-open="ehae179-B926" class="link link-ref link-reveal xref-bibr">926</a></sup> and depends on sac diameter, presence of genetic disorders, continuous smoking, metabolism (presence of inflammation), and aortic wall calcification.<sup><a href="javascript:;" reveal-id="ehae179-B927 ehae179-B928 ehae179-B929" data-open="ehae179-B927 ehae179-B928 ehae179-B929" class="link link-ref link-reveal xref-bibr">927–929</a></sup> Risk of rupture rises exponentially depending on diameter, being higher in women.<sup><a href="javascript:;" reveal-id="ehae179-B930" data-open="ehae179-B930" class="link link-ref link-reveal xref-bibr">930</a>,<a href="javascript:;" reveal-id="ehae179-B931" data-open="ehae179-B931" class="link link-ref link-reveal xref-bibr">931</a></sup>

AAAs are asymptomatic in two-thirds of cases and if they become symptomatic, rupture is the main manifestation. They often represent incidental imaging findings, as the sensitivity of clinical examination—especially palpation of an abdominal mass—is generally poor. Symptoms may include acute abdominal or back pain, and in some cases, hypovolaemic shock. However, contained rupture may present with atypical low flank or abdominal pain (see _[Figure 23](javascript:;)_ for high-risk factors and radiological signs or AAA rupture).<sup><a href="javascript:;" reveal-id="ehae179-B932 ehae179-B933 ehae179-B934 ehae179-B935" data-open="ehae179-B932 ehae179-B933 ehae179-B934 ehae179-B935" class="link link-ref link-reveal xref-bibr">932–935</a></sup> Independently of risk of rupture, patients with AAA have impaired survival: the 5 year mortality rate is higher (×4 in women, ×2 in men) despite AAA repair, likely due to the presence of cardiovascular disease in other areas.<sup><a href="javascript:;" reveal-id="ehae179-B936" data-open="ehae179-B936" class="link link-ref link-reveal xref-bibr">936</a></sup>

##### 9.2.3.3. Surveillance

Those with an aortic diameter <25 mm present low risk of developing large AAA in 10 years, whereas a diameter of 25–29 mm deserves reassessment after 4 years.<sup><a href="javascript:;" reveal-id="ehae179-B937" data-open="ehae179-B937" class="link link-ref link-reveal xref-bibr">937</a>,<a href="javascript:;" reveal-id="ehae179-B938" data-open="ehae179-B938" class="link link-ref link-reveal xref-bibr">938</a></sup> DUS is the standard imaging technique for surveillance; however, CCT provides superior visualization of the AA and its branches, especially for pre-operative planning. CMR is reasonable in selected patients (young and female) when a long follow-up is considered, to avoid radiation.

A meta-analysis advises follow-up intervals for AAAs based on size: 3 years for 30–39 mm, 1 year for 40–44 mm, and 6 months for 45–54 mm in men, with <1% rupture risk.<sup><a href="javascript:;" reveal-id="ehae179-B938" data-open="ehae179-B938" class="link link-ref link-reveal xref-bibr">938</a></sup> Women have similar growth rates but a four-fold higher rupture risk.<sup><a href="javascript:;" reveal-id="ehae179-B938" data-open="ehae179-B938" class="link link-ref link-reveal xref-bibr">938</a></sup> A proposed follow-up algorithm is displayed in _[Figure 24](javascript:;)_. Consider shorter intervals for rapid growth (≥10 mm per year or ≥5 mm per 6 months), in which case repair may be considered.

Recommendation Table 36

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846321)

Recommendations for surveillance of patients with abdominal aortic aneurysm

![Recommendations for surveillance of patients with abdominal aortic aneurysm](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt36.jpeg?Expires=1728479088&Signature=ihKeEEQmBAx7jmQm7POsLLMfF-9Afgb8whf6ZOLUgE7FeU8EuynW00CZtBkBOR4XVGYmTLDxzqW4RWuHVFDuAUyINnxwope0uVyss-vEYugLV3o2OoFyuShXjdLM70la31sctZYF0A3pjt4FPctiYkRtYu51~8jL~GBYw2k45Bxfdb1so2Nz3fjgYFTu520Zq6mk~TARvnexOm7vhB8HXIG4stp86mYNVBBPoJhXRu2JgR6JnqoYSCJQdqIC~7FDTqzOZLt0qRgI20R9MzXJGpicr9nd2Ye07~sWg8PAVpp5eAeEuEHTVVLqz9-VCPnXIXhVt9f1LXTvFhW66TlA6A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 9.2.4. Optimal medical treatment of aortic aneurysms

In patients with aortic aneurysms, the role of antithrombotic therapy is uncertain. In complicated aortic atherosclerotic plaques, concomitant CAD is common (OR 2.99) and SAPT should be considered (see Section [9.1](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#ehae179-s8.1)). In patients with AAA, results of observational studies are conflicting in relation to aneurysm growth. Low-dose aspirin is not associated with a higher risk of AAA rupture but could worsen prognosis in cases of rupture.<sup><a href="javascript:;" reveal-id="ehae179-B944" data-open="ehae179-B944" class="link link-ref link-reveal xref-bibr">944</a></sup> In an RCT of patients with AAA (35–44 mm), ticagrelor did not reduce growth rate.<sup><a href="javascript:;" reveal-id="ehae179-B945" data-open="ehae179-B945" class="link link-ref link-reveal xref-bibr">945</a></sup>

Optimal medical treatment for aortic aneurysms aims to lower CV morbidity, slow growth rate, delay surgery, reduce peri-operative risk, and prevent AAE. Aneurysm patients face elevated CV risk due to common CVRFs, and the 10 year CV event mortality risk (heart attacks or strokes) is 15 times higher than AAE risk, even after repair.<sup><a href="javascript:;" reveal-id="ehae179-B882" data-open="ehae179-B882" class="link link-ref link-reveal xref-bibr">882</a>,<a href="javascript:;" reveal-id="ehae179-B883" data-open="ehae179-B883" class="link link-ref link-reveal xref-bibr">883</a></sup> According to the SMART risk score algorithm, optimal implementation of risk management guidelines would reduce the 10 year risk of MACE from 43% to 14% in patients with AAA.<sup><a href="javascript:;" reveal-id="ehae179-B936" data-open="ehae179-B936" class="link link-ref link-reveal xref-bibr">936</a></sup> Thus, lifestyle modification, exercise, smoking cessation, and treatment of risk factors are crucial (see _Section [7](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#ehae179-s6)_).

Risk factors and possible drug treatment to reduce AAA growth and/or the risk of rupture have been thoroughly discussed in a recent review paper.<sup><a href="javascript:;" reveal-id="ehae179-B946" data-open="ehae179-B946" class="link link-ref link-reveal xref-bibr">946</a></sup> Their meta-analysis suggested a possible effect of ACEIs (but not ARBs) on the risk of rupture, whereas another meta-analysis<sup><a href="javascript:;" reveal-id="ehae179-B947" data-open="ehae179-B947" class="link link-ref link-reveal xref-bibr">947</a></sup> did not indicate an effect of ACEIs on AAA growth. A reduction of AAA growth by statins is indicated in a recent meta-analysis.<sup><a href="javascript:;" reveal-id="ehae179-B352" data-open="ehae179-B352" class="link link-ref link-reveal xref-bibr">352</a></sup> Furthermore, reduced AAA growth by the antidiabetic drug metformin has been suggested in several meta-analyses<sup><a href="javascript:;" reveal-id="ehae179-B352" data-open="ehae179-B352" class="link link-ref link-reveal xref-bibr">352</a>,<a href="javascript:;" reveal-id="ehae179-B948" data-open="ehae179-B948" class="link link-ref link-reveal xref-bibr">948</a>,<a href="javascript:;" reveal-id="ehae179-B949" data-open="ehae179-B949" class="link link-ref link-reveal xref-bibr">949</a></sup> and there are several ongoing RCTs to explore this. For BP, follow general hypertension guidelines. Aim for BP below 140/90 mmHg, with a target of 120/80 mmHg, if tolerated.<sup><a href="javascript:;" reveal-id="ehae179-B300" data-open="ehae179-B300" class="link link-ref link-reveal xref-bibr">300</a>,<a href="javascript:;" reveal-id="ehae179-B302" data-open="ehae179-B302" class="link link-ref link-reveal xref-bibr">302</a>,<a href="javascript:;" reveal-id="ehae179-B305" data-open="ehae179-B305" class="link link-ref link-reveal xref-bibr">305</a></sup> Data on the specific positive effects of beta-blockers and ARBs in TAA and AAA are limited (mostly derived from MFS populations). However, it is reasonable to use BBs and/or ARBs as first-line antihypertensive drugs in TAA and AAA.

Consider moderate/high-intensity statins in TAA patients but skip for those with low CV risk and non-atherosclerotic (HTAD). In AAA, consider statins to reduce aneurysm risks, including growth, rupture, and peri-operative mortality.<sup><a href="javascript:;" reveal-id="ehae179-B330" data-open="ehae179-B330" class="link link-ref link-reveal xref-bibr">330</a>,<a href="javascript:;" reveal-id="ehae179-B347" data-open="ehae179-B347" class="link link-ref link-reveal xref-bibr">347</a>,<a href="javascript:;" reveal-id="ehae179-B348" data-open="ehae179-B348" class="link link-ref link-reveal xref-bibr">348</a></sup> Low-dose aspirin is debated but may be reasonable given elevated CV risk factors in TAA and AAA patients.<sup><a href="javascript:;" reveal-id="ehae179-B666" data-open="ehae179-B666" class="link link-ref link-reveal xref-bibr">666</a>,<a href="javascript:;" reveal-id="ehae179-B950" data-open="ehae179-B950" class="link link-ref link-reveal xref-bibr">950</a></sup> Additionally, apply all CVD secondary prevention measures to these patients (see _Section [7](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#ehae179-s6)_).

Some evidence suggests that fluoroquinolones could be associated with an increased risk for aneurysm progression and dissection,<sup><a href="javascript:;" reveal-id="ehae179-B951 ehae179-B952 ehae179-B953 ehae179-B954 ehae179-B955 ehae179-B956" data-open="ehae179-B951 ehae179-B952 ehae179-B953 ehae179-B954 ehae179-B955 ehae179-B956" class="link link-ref link-reveal xref-bibr">951–956</a></sup> but conflicting analyses do not support this association. The cautious use of fluoroquinolones should not be discouraged when there is a clinical indication, even considering concerns regarding aortic aneurysm and dissection (AA/AD). Note that AA/AD risk (both thoracic and abdominal) may increase due to infection itself, regardless of the antibiotic chosen. Infectious disease specialists discourage routine fluoroquinolone use as a first-line antibiotic if equally effective alternatives exist. Hence, do not withhold this therapy in aortic disease cases when clinically necessary. All medical and lifestyle recommendations are summarized in _[Figure 7](javascript:;)_.

Recommendation Table 37

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846328)

Recommendations for medical treatment in patients with thoracic aorta or abdominal aortic aneurysms

![Recommendations for medical treatment in patients with thoracic aorta or abdominal aortic aneurysms](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt37.jpeg?Expires=1728479088&Signature=DzKdW5YJl9TzwSG3C1-KttQEC-4oj5onk6pXxz2aEYy3v0225s8Cp2UJCrTjMSf-rbnxMnjaAfTg4JKnFjFylS1nBUwu7FDYBjLn8rluom6obhuZXocl870xONFgVZt3LywpOLVa~y7-VAMHro8vYjc~cBVntuoUHQojZgB5n6ZXxmyNRgNcdfq00xv04Kwl8pWvtiXvZBBzAlBWGm2V423vzB4OJbI6xT41EpVtSpN57vPqp56EAfnmrwcRYZoJ1x7jBl7~nZ4FtqXrB0jb-82KklGhBRS4edyHw~A9FO2bCE8HraMrBjyMRM2Hez-hRyV2cOBMpoYz4oZEz~H0kw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 9.2.5. Surgical management of aortic aneurysms

##### 9.2.5.1. Surgical treatment of aortic root and ascending aorta

In isolated dilatation of the ascending tubular (supra-coronary) aorta, a supra-commissural tubular graft is inserted with the distal anastomosis just before the aortic arch. For aneurysms extending proximally below the sinotubular junction (STJ) with involvement of aortic sinuses, the surgical approach depends on the aortic annulus and valve condition. If the aortic valve cusps are pliable, experienced centres may recommend aortic valve-sparing techniques,<sup><a href="javascript:;" reveal-id="ehae179-B961 ehae179-B962 ehae179-B963 ehae179-B964 ehae179-B965" data-open="ehae179-B961 ehae179-B962 ehae179-B963 ehae179-B964 ehae179-B965" class="link link-ref link-reveal xref-bibr">961–965</a></sup> such as David’s procedure (reimplantation) or the Yacoub technique (remodelling).<sup><a href="javascript:;" reveal-id="ehae179-B890" data-open="ehae179-B890" class="link link-ref link-reveal xref-bibr">890</a>,<a href="javascript:;" reveal-id="ehae179-B966 ehae179-B967 ehae179-B968" data-open="ehae179-B966 ehae179-B967 ehae179-B968" class="link link-ref link-reveal xref-bibr">966–968</a></sup> Otherwise, composite replacement of the aortic root and valve with the Bentall procedure is indicated.

Pre-operative evaluation<sup><a href="javascript:;" reveal-id="ehae179-B890" data-open="ehae179-B890" class="link link-ref link-reveal xref-bibr">890</a></sup> and initial follow-up of patients is defined in _[Figure 25](javascript:;)_. Patients with a bioprosthetic valve should be monitored by TTE annually. However, in patients with mechanical prosthesis or native aortic valve, clinical evaluation and TTE should be performed as soon as possible if new heart symptoms develop.<sup><a href="javascript:;" reveal-id="ehae179-B969" data-open="ehae179-B969" class="link link-ref link-reveal xref-bibr">969</a></sup> SAPT with low-dose aspirin (75–100 mg per day) should be considered for the first 3 months after conservative aortic valve surgery if there are no indications for OAC. Lifelong OAC with a VKA is recommended for all patients with a Bentall mechanical prosthesis.<sup><a href="javascript:;" reveal-id="ehae179-B970" data-open="ehae179-B970" class="link link-ref link-reveal xref-bibr">970</a>,<a href="javascript:;" reveal-id="ehae179-B971" data-open="ehae179-B971" class="link link-ref link-reveal xref-bibr">971</a></sup> However, in patients with no baseline indications for OAC, low-dose aspirin (75–100 mg/day) or OAC using a VKA should be considered for the first 3 months after Bentall surgery with a bioprosthesis.<sup><a href="javascript:;" reveal-id="ehae179-B972" data-open="ehae179-B972" class="link link-ref link-reveal xref-bibr">972</a>,<a href="javascript:;" reveal-id="ehae179-B973" data-open="ehae179-B973" class="link link-ref link-reveal xref-bibr">973</a></sup>

![Peri-operative algorithm for the management of patients with surgically treated aortic root and ascending aortic aneurysm.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f25.jpeg?Expires=1728479088&Signature=Ds9tnjPnJvRPkKAp7fHSz2ajhWHTq79Pc7PQwd49kNQPTH1ULmPfTGcaiirRjxVp4Vjfd1sAgZnIFFoo8toOAdo29094-jdCZI~gOmyH5UOcxXlj1QFkVrrTkmQQWwgUCLdl20ZWrutBjxqclrRFY~4aGYGdY8SWo1rY5hTOaeXLzJk8Tc-4deoDhddnM-9eLCqiopepk0VDzl7veOuVeM6PQiDUrCNxfNTfEYzCyiMchYMuswSKEJOkkHiZLKUFyJcKQ~S27m1lrCVGogKuTjzH6QXioj4frFHLrPMci1ia8CkCLigbdqGGQC5BlDYlEWY95bRpKh1~~W3~TCAjpg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 25

Peri-operative algorithm for the management of patients with surgically treated aortic root and ascending aortic aneurysm.

AR, aortic regurgitation; CCT, cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; STJ, sinotubular junction; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography.

[Open in new tab](https://academic.oup.com/view-large/figure/479846333/ehae179f25.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f25.jpeg?Expires=1728479088&Signature=RTf4sPdWsg29yFXIao6GY3w54XUB56sD8FKzhM6yeBSJSZVX5MSkC3OdhgShnL-4XfMg2USd7qeYd0-0jusSma9SLZJBsmxg9~8nTJYCPsl20HseqIvCUfZrTOMBsm5gg~cfk7Ngtmx0vqKkJ~s~g8DU8f8gnAhRi3v6Xv6xMEvjfjrlZ8VDsEc~9xzdw332QSqKmFEfWVK44oDoyEQbyAhhPMTmWBHDbM-5faNggSPVD3~15Vl9oepuT1KIzS7JCMV2U~rp8m4OWBOzFUzRJTT2at~A~VIWrhQ0ChMMmf2bNpSMVmDmjx62cw6VZbJsepoLLfzDXL78p0QippfIyw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846333&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Although many risk factors associated with AAE have been described (such as elongation, angulation, and unfavourable biomechanics), aortic diameter is still the main determinant of aortic complications and death.<sup><a href="javascript:;" reveal-id="ehae179-B974 ehae179-B975 ehae179-B976" data-open="ehae179-B974 ehae179-B975 ehae179-B976" class="link link-ref link-reveal xref-bibr">974–976</a></sup> AAE rates decreased with prophylactic aortic surgery over a decade,<sup><a href="javascript:;" reveal-id="ehae179-B977" data-open="ehae179-B977" class="link link-ref link-reveal xref-bibr">977</a></sup> and additionally, surgical risk for ascending aortic/aortic root surgery dropped significantly.<sup><a href="javascript:;" reveal-id="ehae179-B978 ehae179-B979 ehae179-B980" data-open="ehae179-B978 ehae179-B979 ehae179-B980" class="link link-ref link-reveal xref-bibr">978–980</a></sup> Now, experienced cardiac surgery centres report <1% mortality with elective surgery.<sup><a href="javascript:;" reveal-id="ehae179-B980" data-open="ehae179-B980" class="link link-ref link-reveal xref-bibr">980</a>,<a href="javascript:;" reveal-id="ehae179-B981" data-open="ehae179-B981" class="link link-ref link-reveal xref-bibr">981</a></sup>

Most acute type A aortic dissections (acute TAAD) occur at diameters below 55 mm. However, the risk exceeds 1% between 50 and 54 mm,<sup><a href="javascript:;" reveal-id="ehae179-B982" data-open="ehae179-B982" class="link link-ref link-reveal xref-bibr">982</a></sup> with a critical point at 52–53 mm.<sup><a href="javascript:;" reveal-id="ehae179-B153" data-open="ehae179-B153" class="link link-ref link-reveal xref-bibr">153</a>,<a href="javascript:;" reveal-id="ehae179-B981" data-open="ehae179-B981" class="link link-ref link-reveal xref-bibr">981</a>,<a href="javascript:;" reveal-id="ehae179-B983" data-open="ehae179-B983" class="link link-ref link-reveal xref-bibr">983</a></sup> Pre-dissection aortic diameter at the tubular level is 25%–30% smaller than post-dissection. Over 60% of non-MFS, non-BAV acute TAAD patients have a non-dilated ascending aorta before dissection.<sup><a href="javascript:;" reveal-id="ehae179-B984" data-open="ehae179-B984" class="link link-ref link-reveal xref-bibr">984</a>,<a href="javascript:;" reveal-id="ehae179-B985" data-open="ehae179-B985" class="link link-ref link-reveal xref-bibr">985</a></sup> Additionally, the ‘root phenotype’ has been reported to be more malignant than those with ascending phenotype, with higher velocity of progression and AAE risk.<sup><a href="javascript:;" reveal-id="ehae179-B154" data-open="ehae179-B154" class="link link-ref link-reveal xref-bibr">154</a>,<a href="javascript:;" reveal-id="ehae179-B891" data-open="ehae179-B891" class="link link-ref link-reveal xref-bibr">891</a>,<a href="javascript:;" reveal-id="ehae179-B892" data-open="ehae179-B892" class="link link-ref link-reveal xref-bibr">892</a>,<a href="javascript:;" reveal-id="ehae179-B986" data-open="ehae179-B986" class="link link-ref link-reveal xref-bibr">986</a></sup>

Novel parameters, like ascending aortic length (AAL) and the ascending-arch angle, correlate with acute TAAD risk.<sup><a href="javascript:;" reveal-id="ehae179-B155" data-open="ehae179-B155" class="link link-ref link-reveal xref-bibr">155</a>,<a href="javascript:;" reveal-id="ehae179-B976" data-open="ehae179-B976" class="link link-ref link-reveal xref-bibr">976</a></sup> AAL ≥13 cm links to nearly five-fold higher yearly AAE rates compared with AAL <9 cm, with a threshold of >11 cm as a risk indicator.<sup><a href="javascript:;" reveal-id="ehae179-B155" data-open="ehae179-B155" class="link link-ref link-reveal xref-bibr">155</a></sup> Indexing aortic diameters to anthropometric parameters has been suggested and a proportional increase in the risk of AAE has been retrospectively demonstrated for increasing diameter indexed to BSA,<sup><a href="javascript:;" reveal-id="ehae179-B904" data-open="ehae179-B904" class="link link-ref link-reveal xref-bibr">904</a></sup> diameter indexed to patient height,<sup><a href="javascript:;" reveal-id="ehae179-B153" data-open="ehae179-B153" class="link link-ref link-reveal xref-bibr">153</a></sup> or cross-sectional area indexed to patient height.<sup><a href="javascript:;" reveal-id="ehae179-B154" data-open="ehae179-B154" class="link link-ref link-reveal xref-bibr">154</a></sup> However, these diameter-based indexing methods share the same limitations in risk prediction as the absolute diameter in the general population,<sup><a href="javascript:;" reveal-id="ehae179-B984" data-open="ehae179-B984" class="link link-ref link-reveal xref-bibr">984</a>,<a href="javascript:;" reveal-id="ehae179-B985" data-open="ehae179-B985" class="link link-ref link-reveal xref-bibr">985</a></sup> whereas they can be advantageous in patients with small body size.<sup><a href="javascript:;" reveal-id="ehae179-B153" data-open="ehae179-B153" class="link link-ref link-reveal xref-bibr">153</a>,<a href="javascript:;" reveal-id="ehae179-B154" data-open="ehae179-B154" class="link link-ref link-reveal xref-bibr">154</a></sup> These additional risk factors (beyond the diameter) are summarized in _[Figure 23](javascript:;)_.

Recommendation Table 38

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846337)

Recommendations for surgery in aortic root and ascending aorta dilatation associated with tricuspid aortic valve (see also Evidence Table 11)

![Recommendations for surgery in aortic root and ascending aorta dilatation associated with tricuspid aortic valve (see also Evidence Table 11)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt38.jpeg?Expires=1728479088&Signature=l-4UX-hHkezgGY-6iSw1xpjukNtAUV87TR4h-zIemaR0BPU2WdkCFdTFhRRoHTtVKNXBqUkYt3WJcndpE3BsLnYyYPAZhkRfucd7wu4p8DXcMA9cPvlch0j59p9yGid8qW2tJkgsMqO-5w8Eq-2U3MLbwzUiapgY8FklZdPw8lohsLGhLkdoh7Lom0PQq9RYbIaqNK~A8STFrXtsvQj4JuoFDi5Av-Idm5ZDTnEvVj1MUTGsSlIfomFZtJLkkv9xnpFz73kZMGR0qKANpGaqhovIXkHrvzzmuNZ0aVzwOn3IhWO~FMlceGp5mqXrLkD6Z7GnXndE3hVrV1gk16xBNw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

##### 9.2.5.2. Surgical treatment of aortic arch aneurysms

Surgery for arch aneurysms is challenging, primarily due to risks like hypothermic circulatory arrest and the need for brain protection, resulting in higher mortality and stroke rates. Isolated aortic arch surgery is appropriate for asymptomatic degenerative aortic arch aneurysms ≥55 mm in diameter or symptoms or signs of local compression. Hemi-arch or total arch replacement are frequently required in patients who have an indication for surgery on an adjacent aneurysm of the ascending aorta. In specific cases, supra-aortic vessel transposition via off-pump debranching followed by TEVAR of the arch can be an alternative to traditional surgery, particularly when avoiding hypothermic circulatory arrest is a concern.<sup><a href="javascript:;" reveal-id="ehae179-B992 ehae179-B993 ehae179-B994 ehae179-B995 ehae179-B996" data-open="ehae179-B992 ehae179-B993 ehae179-B994 ehae179-B995 ehae179-B996" class="link link-ref link-reveal xref-bibr">992–996</a></sup> When the disease involves the proximal descending aorta or future need for treatment of the descending aorta is anticipated, the frozen elephant trunk (FET) technique is a good option.<sup><a href="javascript:;" reveal-id="ehae179-B997" data-open="ehae179-B997" class="link link-ref link-reveal xref-bibr">997</a></sup> Assessment of patency and morphology of the circle of Willis is recommended when treatment involves the aortic arch.<sup><a href="javascript:;" reveal-id="ehae179-B998" data-open="ehae179-B998" class="link link-ref link-reveal xref-bibr">998</a>,<a href="javascript:;" reveal-id="ehae179-B999" data-open="ehae179-B999" class="link link-ref link-reveal xref-bibr">999</a></sup>

Recommendation Table 39

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846340)

Recommendations for surgery in aortic arch aneurysms

![Recommendations for surgery in aortic arch aneurysms](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt39.jpeg?Expires=1728479088&Signature=4myjoDC53WBau4I-xYqNKCbYR1rQ0ZXhkfwH0QUAoxwTB8frAMouFlxX1L-MYgjD90kKsriJsLxxbu4vIanrXRsOGWFUOyk8XlnyyNGb2Klo3cFjA0X~8iQEH62SgzkAUAwy2uahtwz7ygpeJpnruVe12QXzxnuaz1Ds9Epe9pwN6fAL-Z078BbHsucES7YDH8TCiJ8PNtncOC9UJNPc0-kUWk7kV3x7MIe55e26IAfDexkDhDJ4FeSM9-F77LVz-aA7lwKenh5Btkc9wV-OmNdyWUqGUD40mm7yVTw6B3zYf~d5alI617jHIJHnOMdE9LsSG8rm-eZHJ6EQ3-4V4g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

##### 9.2.5.3. Surgical treatment of the thoracic descending aorta

###### General considerations

At 60 mm diameter, a DTA aneurysm has a 10% annual rupture risk, justifying intervention at ≥55 mm.<sup><a href="javascript:;" reveal-id="ehae179-B902" data-open="ehae179-B902" class="link link-ref link-reveal xref-bibr">902</a>,<a href="javascript:;" reveal-id="ehae179-B1002" data-open="ehae179-B1002" class="link link-ref link-reveal xref-bibr">1002</a></sup> Intervention at a diameter <55 mm may not bring any further survival benefit except for women,<sup><a href="javascript:;" reveal-id="ehae179-B904" data-open="ehae179-B904" class="link link-ref link-reveal xref-bibr">904</a>,<a href="javascript:;" reveal-id="ehae179-B1003" data-open="ehae179-B1003" class="link link-ref link-reveal xref-bibr">1003</a></sup> patients with connective tissue disorders,<sup><a href="javascript:;" reveal-id="ehae179-B904" data-open="ehae179-B904" class="link link-ref link-reveal xref-bibr">904</a></sup> or rapid growth (≥10 mm per year or ≥5 mm every 6 months),<sup><a href="javascript:;" reveal-id="ehae179-B1004" data-open="ehae179-B1004" class="link link-ref link-reveal xref-bibr">1004</a></sup> (for high-risk factors see _[Figure 23](javascript:;)_). This threshold may be increased in high surgical risk patients.<sup><a href="javascript:;" reveal-id="ehae179-B1005" data-open="ehae179-B1005" class="link link-ref link-reveal xref-bibr">1005</a></sup> It is advisable to centralize complex procedures in centres with expertise in aortic diseases and a multidisciplinary team for effective patient management.

###### Open repair

Thoracic endovascular aortic aneurysm repair is recommended as first-choice intervention for DTA aneurysms,<sup><a href="javascript:;" reveal-id="ehae179-B1006 ehae179-B1007 ehae179-B1008 ehae179-B1009 ehae179-B1010" data-open="ehae179-B1006 ehae179-B1007 ehae179-B1008 ehae179-B1009 ehae179-B1010" class="link link-ref link-reveal xref-bibr">1006–1010</a></sup> thus open repair is limited to patients with unsuitable anatomy for TEVAR<sup><a href="javascript:;" reveal-id="ehae179-B1011" data-open="ehae179-B1011" class="link link-ref link-reveal xref-bibr">1011</a></sup> or connective tissue disorders.<sup><a href="javascript:;" reveal-id="ehae179-B1012" data-open="ehae179-B1012" class="link link-ref link-reveal xref-bibr">1012</a></sup> The early mortality benefit of TEVAR seems to decrease after 1 year, and thereafter long-term survival (10 years) seems better with open repair.<sup><a href="javascript:;" reveal-id="ehae179-B1013" data-open="ehae179-B1013" class="link link-ref link-reveal xref-bibr">1013</a></sup> Therefore, open repair is advisable for young, healthy patients with unsuitable TEVAR anatomy and prolonged life expectancy, particularly when symptoms from aneurysm rupture or compression arise.

However, open repair involves significant post-operative risks, necessitating thorough pre-operative evaluations for cardiac, pulmonary, renal function, carotid, and peripheral arterial diseases. Risks include stroke, mesenteric and renal ischaemia due to clamping duration,<sup><a href="javascript:;" reveal-id="ehae179-B1014" data-open="ehae179-B1014" class="link link-ref link-reveal xref-bibr">1014</a>,<a href="javascript:;" reveal-id="ehae179-B1015" data-open="ehae179-B1015" class="link link-ref link-reveal xref-bibr">1015</a></sup> and paraplegia tied to the extent of aneurysmal disease.<sup><a href="javascript:;" reveal-id="ehae179-B1016" data-open="ehae179-B1016" class="link link-ref link-reveal xref-bibr">1016</a>,<a href="javascript:;" reveal-id="ehae179-B1017" data-open="ehae179-B1017" class="link link-ref link-reveal xref-bibr">1017</a></sup> Outside experienced centres, outcomes have shown minimal improvement in recent years, with mortality rates around 10% and spinal cord ischaemia rates at 11%–15%.<sup><a href="javascript:;" reveal-id="ehae179-B1016" data-open="ehae179-B1016" class="link link-ref link-reveal xref-bibr">1016</a>,<a href="javascript:;" reveal-id="ehae179-B1018" data-open="ehae179-B1018" class="link link-ref link-reveal xref-bibr">1018</a></sup>

###### Endovascular repair

Comparative studies favour TEVAR over open repair, showing lower mortality (6%) and morbidity.<sup><a href="javascript:;" reveal-id="ehae179-B1006" data-open="ehae179-B1006" class="link link-ref link-reveal xref-bibr">1006</a>,<a href="javascript:;" reveal-id="ehae179-B1019" data-open="ehae179-B1019" class="link link-ref link-reveal xref-bibr">1019</a>,<a href="javascript:;" reveal-id="ehae179-B1020" data-open="ehae179-B1020" class="link link-ref link-reveal xref-bibr">1020</a></sup> However, TEVAR’s survival advantage is balanced by an increased risk of follow-up re-intervention. It reduces spinal cord injury risk (3%).<sup><a href="javascript:;" reveal-id="ehae179-B1021 ehae179-B1022 ehae179-B1023 ehae179-B1024" data-open="ehae179-B1021 ehae179-B1022 ehae179-B1023 ehae179-B1024" class="link link-ref link-reveal xref-bibr">1021–1024</a></sup> Left subclavian artery (LSA) coverage during TEVAR for proximal sealing is required in up to 50% of cases.<sup><a href="javascript:;" reveal-id="ehae179-B1025" data-open="ehae179-B1025" class="link link-ref link-reveal xref-bibr">1025</a></sup> This is associated with an increased risk of cerebrovascular events, spinal cord ischaemia (SCI), and upper-limb ischaemia,<sup><a href="javascript:;" reveal-id="ehae179-B1026" data-open="ehae179-B1026" class="link link-ref link-reveal xref-bibr">1026</a>,<a href="javascript:;" reveal-id="ehae179-B1027" data-open="ehae179-B1027" class="link link-ref link-reveal xref-bibr">1027</a></sup> justifying previous surgical or concomitant endovascular (with branched or fenestrated grafts) revascularization of the LSA in an elective setting.<sup><a href="javascript:;" reveal-id="ehae179-B1026" data-open="ehae179-B1026" class="link link-ref link-reveal xref-bibr">1026</a>,<a href="javascript:;" reveal-id="ehae179-B1028" data-open="ehae179-B1028" class="link link-ref link-reveal xref-bibr">1028</a>,<a href="javascript:;" reveal-id="ehae179-B1029" data-open="ehae179-B1029" class="link link-ref link-reveal xref-bibr">1029</a></sup> In cases of inadequate distal zone sealing, safe coverage of the coeliac artery has been proposed when sufficient collateral circulation exists,<sup><a href="javascript:;" reveal-id="ehae179-B1030" data-open="ehae179-B1030" class="link link-ref link-reveal xref-bibr">1030</a>,<a href="javascript:;" reveal-id="ehae179-B1031" data-open="ehae179-B1031" class="link link-ref link-reveal xref-bibr">1031</a></sup> but results are controversial.<sup><a href="javascript:;" reveal-id="ehae179-B1032" data-open="ehae179-B1032" class="link link-ref link-reveal xref-bibr">1032</a></sup>

##### 9.2.5.4. Surgical treatment of thoracoabdominal aorta aneurysms

###### General considerations

Since AAEs increase when TAAA diameter exceeds 60 mm,<sup><a href="javascript:;" reveal-id="ehae179-B902" data-open="ehae179-B902" class="link link-ref link-reveal xref-bibr">902</a>,<a href="javascript:;" reveal-id="ehae179-B1002" data-open="ehae179-B1002" class="link link-ref link-reveal xref-bibr">1002</a>,<a href="javascript:;" reveal-id="ehae179-B1033" data-open="ehae179-B1033" class="link link-ref link-reveal xref-bibr">1033</a></sup> and there are more technical surgical challenges in TAAA repair (compared with DTA aneurysm or AAA), TAAA repair, in low-moderate surgical risk patients, is proposed if the aortic diameter is ≥60 mm. However, surgical repair should be considered at diameters ≥55 mm if patients present with high-risk features (_[Figure 24](javascript:;)_) or are at very low risk and under the care of experienced surgeons in a multidisciplinary aorta team.<sup><a href="javascript:;" reveal-id="ehae179-B1004" data-open="ehae179-B1004" class="link link-ref link-reveal xref-bibr">1004</a>,<a href="javascript:;" reveal-id="ehae179-B1033" data-open="ehae179-B1033" class="link link-ref link-reveal xref-bibr">1033</a>,<a href="javascript:;" reveal-id="ehae179-B1034" data-open="ehae179-B1034" class="link link-ref link-reveal xref-bibr">1034</a></sup> HTAD, distal location, chronic dissection, and BAV<sup><a href="javascript:;" reveal-id="ehae179-B903" data-open="ehae179-B903" class="link link-ref link-reveal xref-bibr">903</a></sup> are associated with rapid growth rate and will require closer follow-up.

###### Open repair

Open TAAA repair is a complex aortic procedure. Post-operative mortality risk increases with left ventricular (LV) dysfunction, renal insufficiency, and advanced age.<sup><a href="javascript:;" reveal-id="ehae179-B1035 ehae179-B1036 ehae179-B1037" data-open="ehae179-B1035 ehae179-B1036 ehae179-B1037" class="link link-ref link-reveal xref-bibr">1035–1037</a></sup> Since organs and tissues distal to the aortic clamp will suffer from prolonged ischaemia, extracorporeal circulation is mandatory to reduce complications,<sup><a href="javascript:;" reveal-id="ehae179-B1011" data-open="ehae179-B1011" class="link link-ref link-reveal xref-bibr">1011</a>,<a href="javascript:;" reveal-id="ehae179-B1038" data-open="ehae179-B1038" class="link link-ref link-reveal xref-bibr">1038</a></sup> especially SCI (2.5%–15%).<sup><a href="javascript:;" reveal-id="ehae179-B1011" data-open="ehae179-B1011" class="link link-ref link-reveal xref-bibr">1011</a>,<a href="javascript:;" reveal-id="ehae179-B1039 ehae179-B1040 ehae179-B1041 ehae179-B1042 ehae179-B1043 ehae179-B1044" data-open="ehae179-B1039 ehae179-B1040 ehae179-B1041 ehae179-B1042 ehae179-B1043 ehae179-B1044" class="link link-ref link-reveal xref-bibr">1039–1044</a></sup> The mortality rate after open TAAA repair varies between 6% and 8% in high-volume centres<sup><a href="javascript:;" reveal-id="ehae179-B1006" data-open="ehae179-B1006" class="link link-ref link-reveal xref-bibr">1006</a>,<a href="javascript:;" reveal-id="ehae179-B1011" data-open="ehae179-B1011" class="link link-ref link-reveal xref-bibr">1011</a>,<a href="javascript:;" reveal-id="ehae179-B1039" data-open="ehae179-B1039" class="link link-ref link-reveal xref-bibr">1039</a></sup> vs. 30% in less experienced centres,<sup><a href="javascript:;" reveal-id="ehae179-B1045" data-open="ehae179-B1045" class="link link-ref link-reveal xref-bibr">1045</a>,<a href="javascript:;" reveal-id="ehae179-B1046" data-open="ehae179-B1046" class="link link-ref link-reveal xref-bibr">1046</a></sup> raising the recommendation to perform these complex procedures only in specialized institutions.

###### Endovascular repair

Endovascular repair is a promising alternative for treating challenging aortic anatomy like juxta-renal AAA (_[Figure 22](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B1047" data-open="ehae179-B1047" class="link link-ref link-reveal xref-bibr">1047</a>,<a href="javascript:;" reveal-id="ehae179-B1048" data-open="ehae179-B1048" class="link link-ref link-reveal xref-bibr">1048</a></sup> The use of fenestrated and branched endografts has shown excellent results, allowing perfusion of visceral vessels.<sup><a href="javascript:;" reveal-id="ehae179-B1049 ehae179-B1050 ehae179-B1051 ehae179-B1052 ehae179-B1053" data-open="ehae179-B1049 ehae179-B1050 ehae179-B1051 ehae179-B1052 ehae179-B1053" class="link link-ref link-reveal xref-bibr">1049–1053</a></sup> While direct comparison studies with open TAAA repair are lacking,<sup><a href="javascript:;" reveal-id="ehae179-B1054" data-open="ehae179-B1054" class="link link-ref link-reveal xref-bibr">1054</a></sup> the increasing adoption of endovascular procedures is notable, especially for high-risk patients, with low post-operative mortality rates (<10%).<sup><a href="javascript:;" reveal-id="ehae179-B1051" data-open="ehae179-B1051" class="link link-ref link-reveal xref-bibr">1051</a>,<a href="javascript:;" reveal-id="ehae179-B1052" data-open="ehae179-B1052" class="link link-ref link-reveal xref-bibr">1052</a>,<a href="javascript:;" reveal-id="ehae179-B1055 ehae179-B1056 ehae179-B1057 ehae179-B1058" data-open="ehae179-B1055 ehae179-B1056 ehae179-B1057 ehae179-B1058" class="link link-ref link-reveal xref-bibr">1055–1058</a></sup> A recent meta-analysis confirms these excellent outcomes, endorsing endovascular repair for TAAA.<sup><a href="javascript:;" reveal-id="ehae179-B1059" data-open="ehae179-B1059" class="link link-ref link-reveal xref-bibr">1059</a></sup> The incidence of post-operative SCI (around 5%) is similar between endovascular and open repair.<sup><a href="javascript:;" reveal-id="ehae179-B1052" data-open="ehae179-B1052" class="link link-ref link-reveal xref-bibr">1052</a>,<a href="javascript:;" reveal-id="ehae179-B1057" data-open="ehae179-B1057" class="link link-ref link-reveal xref-bibr">1057</a>,<a href="javascript:;" reveal-id="ehae179-B1060" data-open="ehae179-B1060" class="link link-ref link-reveal xref-bibr">1060</a>,<a href="javascript:;" reveal-id="ehae179-B1061" data-open="ehae179-B1061" class="link link-ref link-reveal xref-bibr">1061</a></sup> Thus, at mid-term follow-up, endovascular repair is durable with acceptable secondary re-intervention rates, which remain one of the major limitations.<sup><a href="javascript:;" reveal-id="ehae179-B1052" data-open="ehae179-B1052" class="link link-ref link-reveal xref-bibr">1052</a>,<a href="javascript:;" reveal-id="ehae179-B1057" data-open="ehae179-B1057" class="link link-ref link-reveal xref-bibr">1057</a>,<a href="javascript:;" reveal-id="ehae179-B1058" data-open="ehae179-B1058" class="link link-ref link-reveal xref-bibr">1058</a>,<a href="javascript:;" reveal-id="ehae179-B1060" data-open="ehae179-B1060" class="link link-ref link-reveal xref-bibr">1060</a>,<a href="javascript:;" reveal-id="ehae179-B1061" data-open="ehae179-B1061" class="link link-ref link-reveal xref-bibr">1061</a></sup> Factors favouring endovascular vs. open repair in TAAA are presented in _[Table 15](javascript:;)_.

Table 15

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846356)

Overview of factors favouring open vs. endovascular repair in thoracoabdominal aortic aneurysm

| Characteristic | Favours open repair | Favours endovascular repair |
| --- | --- | --- |
| Biological age and life expectancy | 
-   Younger age
    
-   Considerable life expectancy with acceptable quality of life
    

 | 

-   Older age
    
-   Limited life expectancy
    

 |
| Anatomical considerations | 

-   If aortic and branch anatomy preclude endovascular approach
    
-   Poor vascular access
    

 | 

-   Suitable proximal and distal landing zones
    
-   Favourable visceral and renal configuration
    
-   Vascular access obtainable
    

 |
| Pathological | 

-   Chronic dissection
    

 | 

-   Acute dissection
    

 |
| Background/causal factor | 

-   Hereditary aortic disease
    

 | 

-   Degenerative aortic disease
    

 |
| Cardiopulmonary condition | 

-   Good cardiopulmonary reserve
    

 | 

-   Poor cardiopulmonary reserve
    

 |
| Fitness | 

-   No significant comorbidities
    
-   Successful rehabilitation likely
    

 | 

-   Severe organ impairment (renal, kidney, pulmonary)
    
-   Obesity
    
-   Limited mobility, unlikely to rehabilitate successfully
    

 |
| Urgency | 

-   Elective repair
    
-   Emergency repair without a viable endovascular solution
    

 | 

-   Elective repair
    
-   Emergency repair with time for custom-made graft or suitable for standard grafts
    

 |

Adapted from Ouzounian _et al._ with permission.<sup><a href="javascript:;" reveal-id="ehae179-B1062" data-open="ehae179-B1062" class="link link-ref link-reveal xref-bibr">1062</a></sup>

© ESC 2024

Recommendation Table 40

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846357)

Recommendations for the management of patients presenting with descending thoracic aortic and thoracoabdominal aortic aneurysms

![Recommendations for the management of patients presenting with descending thoracic aortic and thoracoabdominal aortic aneurysms](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt40.jpeg?Expires=1728479088&Signature=GKbt~v0orqEyoQ~P3NCsaOsO6YEy9CktE3nzT0tqWFkOM6ZJJ1QJakr-TGV0SvL~NwBu~OIwsqeRKV7B28aqI2qkBsAojQ0i1~yOmtZwxK~ciT8fJR8VhGH7NT3j9cV1GXKdDGMJLEkzuIY7cgtmGdFcUDHtK88GroaYxIq7i6SglaATjOHwCswSPGGJzIOHANOH4F3nOKlrz96BZBM~wys26FX-YuF-mGG9MsStUUKFVDH1nvJKeoyOvcNdHNKYQsO4MNWvyDuAiVxSTjEnyk7GEkZpcAOVpGSEVRMM-RK3HKfLiRjA7aKmDam9sw19YOf8S4EIeUkbui756aXIgA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

##### 9.2.5.5. Surgical treatment of abdominal aorta aneurysms

###### General considerations

Rupture remains the most feared AAA complication, and is associated with the maximum diameter,<sup><a href="javascript:;" reveal-id="ehae179-B1063" data-open="ehae179-B1063" class="link link-ref link-reveal xref-bibr">1063</a></sup> as well as other risk factors (_[Figure 23](javascript:;)_). Different studies<sup><a href="javascript:;" reveal-id="ehae179-B1064 ehae179-B1065 ehae179-B1066 ehae179-B1067 ehae179-B1068 ehae179-B1069 ehae179-B1070 ehae179-B1071" data-open="ehae179-B1064 ehae179-B1065 ehae179-B1066 ehae179-B1067 ehae179-B1068 ehae179-B1069 ehae179-B1070 ehae179-B1071" class="link link-ref link-reveal xref-bibr">1064–1071</a></sup> (including the United Kingdom Small Aneurysm Trial \[UKSAT\] and American Aneurysm Detection and Management \[ADAM\] trial) reported no benefits from open or endovascular interventions (despite lower peri-operative complication rates) in asymptomatic AAA patients with a maximal diameter <55 mm in men and <50 mm in women. Evidence that women are more likely to rupture under surveillance and at a smaller aortic diameter justified a lower (50 mm) threshold. Another interesting method to quantify the risk of rupture based on body size, which seems a better predictor in women, has been proposed.<sup><a href="javascript:;" reveal-id="ehae179-B1072" data-open="ehae179-B1072" class="link link-ref link-reveal xref-bibr">1072</a></sup> However, in the absence of recent studies, thresholds for intervention have not changed in recent years. Considering the complexity of patient management, it is advisable to centralize complex procedures in centres with a high level of expertise in aortic diseases and a multidisciplinary team.

###### Pre-operative cardiovascular evaluation and choice of treatment

Coronary artery disease is the leading cause of early mortality after AAA repair,<sup><a href="javascript:;" reveal-id="ehae179-B937" data-open="ehae179-B937" class="link link-ref link-reveal xref-bibr">937</a>,<a href="javascript:;" reveal-id="ehae179-B1073" data-open="ehae179-B1073" class="link link-ref link-reveal xref-bibr">1073</a></sup> and is associated with a 5%–10% rate of peri-operative CV complications such as death, MI, or stroke.<sup><a href="javascript:;" reveal-id="ehae179-B1074" data-open="ehae179-B1074" class="link link-ref link-reveal xref-bibr">1074</a>,<a href="javascript:;" reveal-id="ehae179-B1075" data-open="ehae179-B1075" class="link link-ref link-reveal xref-bibr">1075</a></sup> Since endovascular repair is associated with lower mortality (<1%) and CV complications,<sup><a href="javascript:;" reveal-id="ehae179-B1076 ehae179-B1077 ehae179-B1078 ehae179-B1079" data-open="ehae179-B1076 ehae179-B1077 ehae179-B1078 ehae179-B1079" class="link link-ref link-reveal xref-bibr">1076–1079</a></sup> the need for pre-operative cardiac work-up will depend on procedure risk, symptoms, and patient-specific CVRFs (see _Sections [4](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#ehae179-s3)_ and _[12](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#ehae179-s11)_, and the _2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery_).<sup><a href="javascript:;" reveal-id="ehae179-B1080" data-open="ehae179-B1080" class="link link-ref link-reveal xref-bibr">1080</a></sup> Coronary revascularization before elective aortic surgery in patients with stable cardiac symptoms cannot be recommended, since there is evidence that this strategy does not improve outcomes or reduce the 30 day MI rate.<sup><a href="javascript:;" reveal-id="ehae179-B1080" data-open="ehae179-B1080" class="link link-ref link-reveal xref-bibr">1080</a>,<a href="javascript:;" reveal-id="ehae179-B1081" data-open="ehae179-B1081" class="link link-ref link-reveal xref-bibr">1081</a></sup>

A complete vascular evaluation (that includes not only the AA but also the entire aorta: ascending, arch, and descending aorta) is mandatory to determine the best strategy in AAA management, CCT being, by consensus, the optimal pre-operative imaging modality.<sup><a href="javascript:;" reveal-id="ehae179-B1082" data-open="ehae179-B1082" class="link link-ref link-reveal xref-bibr">1082</a>,<a href="javascript:;" reveal-id="ehae179-B1083" data-open="ehae179-B1083" class="link link-ref link-reveal xref-bibr">1083</a></sup> When CCT is contraindicated, consider CMR, though calcification assessment is challenging. Pre-operative planning should determine EVAR feasibility by sizing the aorto-iliac system, yet adherence to device-specific instructions remains uncertain.<sup><a href="javascript:;" reveal-id="ehae179-B1084 ehae179-B1085 ehae179-B1086 ehae179-B1087 ehae179-B1088 ehae179-B1089 ehae179-B1090" data-open="ehae179-B1084 ehae179-B1085 ehae179-B1086 ehae179-B1087 ehae179-B1088 ehae179-B1089 ehae179-B1090" class="link link-ref link-reveal xref-bibr">1084–1090</a></sup> DUS assessment of the femoro-popliteal segment is advocated since femoro-popliteal aneurysms are commonly associated with AAA.<sup><a href="javascript:;" reveal-id="ehae179-B1091" data-open="ehae179-B1091" class="link link-ref link-reveal xref-bibr">1091</a>,<a href="javascript:;" reveal-id="ehae179-B1092" data-open="ehae179-B1092" class="link link-ref link-reveal xref-bibr">1092</a></sup> Additionally, the technique of choice should be discussed between the treating physician and the patient based on the patient’s life expectancy and preferences, operator and hospital volumes, and surveillance compliance.<sup><a href="javascript:;" reveal-id="ehae179-B910" data-open="ehae179-B910" class="link link-ref link-reveal xref-bibr">910</a>,<a href="javascript:;" reveal-id="ehae179-B1093 ehae179-B1094 ehae179-B1095 ehae179-B1096 ehae179-B1097" data-open="ehae179-B1093 ehae179-B1094 ehae179-B1095 ehae179-B1096 ehae179-B1097" class="link link-ref link-reveal xref-bibr">1093–1097</a></sup> Elective AAA repair is not recommended in frail patients or those with life expectancy <2 years.<sup><a href="javascript:;" reveal-id="ehae179-B1098" data-open="ehae179-B1098" class="link link-ref link-reveal xref-bibr">1098</a>,<a href="javascript:;" reveal-id="ehae179-B1099" data-open="ehae179-B1099" class="link link-ref link-reveal xref-bibr">1099</a></sup> The individual decision-making process in AAA patients is displayed in _[Figure 26](javascript:;)_.

![Algorithm for individual decision-making process in the treatment of patients with abdominal aortic aneurysm.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f26.jpeg?Expires=1728479088&Signature=JlHRcD6d~kEBb3Al-O-QEhJbiHoHENDfVAd2IGjIPD9T54QueTKCGjCMfLEwez0W-klhO1gdpEOE2berzwaKgs7qHfCMUWWApte7qhTFO656AHlDYFNbFO2zUEId2jub3kYwR2PXrht~ruRPvHGEJQZl-AyfTYHRtJl0ECa2zmapEoXmDSkS3q8BR1fcLqhh49O5VMvYHKmDT5fu0xJkgbbAe8zpr67X5uJAo3z7lFR9OE1oB~ncY1W6T4LXRDOk6vqdM~HFEa0RDlVlAB9jviYOAqWv3VlIjAJlevrlahA6H4AN7RjuyCHi6GWyBNhKt1Y0QrQqivjirtk5qSGM9w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 26

Algorithm for individual decision-making process in the treatment of patients with abdominal aortic aneurysm.

(_A_) Illustration of open repair (graft). (_B_) Illustration of endovascular treatment (EVAR). AAA, abdominal aortic aneurysm; EVAR, endovascular aortic aneurysm repair.

[Open in new tab](https://academic.oup.com/view-large/figure/479846364/ehae179f26.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f26.jpeg?Expires=1728479088&Signature=bMlSfNqPi~3oVAdUKOsR0kba6kH09uh0Wi9GT7D-e-kltFIntcChZnyW-hGZMirrU-6quSgu~LnlIcNJ20QbNfVTr1myuv5drdEXKZ-YKNwhvJBwr4xtT~EVpQmArcuozwaHIona3hSmHqa9JDwx-sfRm35bq4J9ob1e624PsucLhnsThnGHtmqmDA2yGnlDGyjvluYf3SFeBW8cFhceoEu2CuGH0LTWkb4M2DgHzmW4GOsPC4-XxXvP-lz3NDBvIe~EviMnzkXai4Mk~mXh15a2rwC74V3IrziprPwXK-bBjvklVppBGMWt8FkNaA7oIJ6oKHHJdV1Py3WHrYs1xw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846364&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Different studies have demonstrated a significant short-term survival benefit for EVAR, but with similar long-term outcomes compared with open repair (up to 15 years)<sup><a href="javascript:;" reveal-id="ehae179-B1100 ehae179-B1101 ehae179-B1102 ehae179-B1103" data-open="ehae179-B1100 ehae179-B1101 ehae179-B1102 ehae179-B1103" class="link link-ref link-reveal xref-bibr">1100–1103</a></sup> also reported in females.<sup><a href="javascript:;" reveal-id="ehae179-B1104" data-open="ehae179-B1104" class="link link-ref link-reveal xref-bibr">1104</a></sup> However, loss of early benefit is associated with an increased rate of late complications occurring after 8 years, especially late ruptures.<sup><a href="javascript:;" reveal-id="ehae179-B1079" data-open="ehae179-B1079" class="link link-ref link-reveal xref-bibr">1079</a></sup> These trials used earlier-generation EVAR devices, so the durability of the latest-generation devices remains uncertain. Recent data, however, suggest a reduced risk of late complications and fewer re-interventions.<sup><a href="javascript:;" reveal-id="ehae179-B1105 ehae179-B1106 ehae179-B1107 ehae179-B1108" data-open="ehae179-B1105 ehae179-B1106 ehae179-B1107 ehae179-B1108" class="link link-ref link-reveal xref-bibr">1105–1108</a></sup>

###### Open abdominal aorta aneurysm repair

Open AAA repair through mid-line laparotomy (with <30 min clamping time) with a Dacron graft has been the preferred choice for years, despite notable CV morbidity<sup><a href="javascript:;" reveal-id="ehae179-B1078" data-open="ehae179-B1078" class="link link-ref link-reveal xref-bibr">1078</a>,<a href="javascript:;" reveal-id="ehae179-B1100" data-open="ehae179-B1100" class="link link-ref link-reveal xref-bibr">1100</a>,<a href="javascript:;" reveal-id="ehae179-B1109 ehae179-B1110 ehae179-B1111 ehae179-B1112 ehae179-B1113" data-open="ehae179-B1109 ehae179-B1110 ehae179-B1111 ehae179-B1112 ehae179-B1113" class="link link-ref link-reveal xref-bibr">1109–1113</a></sup> and a 2%–5% mortality rate.<sup><a href="javascript:;" reveal-id="ehae179-B1110" data-open="ehae179-B1110" class="link link-ref link-reveal xref-bibr">1110</a>,<a href="javascript:;" reveal-id="ehae179-B1111" data-open="ehae179-B1111" class="link link-ref link-reveal xref-bibr">1111</a>,<a href="javascript:;" reveal-id="ehae179-B1113" data-open="ehae179-B1113" class="link link-ref link-reveal xref-bibr">1113</a>,<a href="javascript:;" reveal-id="ehae179-B1114" data-open="ehae179-B1114" class="link link-ref link-reveal xref-bibr">1114</a></sup> In ruptured AAA, open repair results are worse than those of elective surgery, with an unchanged complication rate of around 48%.<sup><a href="javascript:;" reveal-id="ehae179-B1115" data-open="ehae179-B1115" class="link link-ref link-reveal xref-bibr">1115</a></sup> Thus, endovascular repair is recommended to reduce peri-operative morbidity and mortality.<sup><a href="javascript:;" reveal-id="ehae179-B1116 ehae179-B1117 ehae179-B1118" data-open="ehae179-B1116 ehae179-B1117 ehae179-B1118" class="link link-ref link-reveal xref-bibr">1116–1118</a></sup>

Open AAA repair raises incisional hernia risk, particularly in obese patients, suggesting prophylactic mesh use in high-risk cases.<sup><a href="javascript:;" reveal-id="ehae179-B1119 ehae179-B1120 ehae179-B1121" data-open="ehae179-B1119 ehae179-B1120 ehae179-B1121" class="link link-ref link-reveal xref-bibr">1119–1121</a></sup>

###### Endovascular abdominal aorta aneurysm repair

Endovascular abdominal aorta aneurysm repair reduces peri-operative mortality to <1%, although it implies higher risk of re-intervention in the long term.<sup><a href="javascript:;" reveal-id="ehae179-B1122 ehae179-B1123 ehae179-B1124" data-open="ehae179-B1122 ehae179-B1123 ehae179-B1124" class="link link-ref link-reveal xref-bibr">1122–1124</a></sup> Current devices offer features like active fixation, repositioning ability, low-profile design, and polymer-filled rings for improved sealing.<sup><a href="javascript:;" reveal-id="ehae179-B1106" data-open="ehae179-B1106" class="link link-ref link-reveal xref-bibr">1106</a>,<a href="javascript:;" reveal-id="ehae179-B1125 ehae179-B1126 ehae179-B1127 ehae179-B1128" data-open="ehae179-B1125 ehae179-B1126 ehae179-B1127 ehae179-B1128" class="link link-ref link-reveal xref-bibr">1125–1128</a></sup> New devices demonstrate similar long-term outcomes with reduced re-intervention risk,<sup><a href="javascript:;" reveal-id="ehae179-B1090" data-open="ehae179-B1090" class="link link-ref link-reveal xref-bibr">1090</a></sup> expanding treatment possibilities to 60%–70% of infrarenal AAA cases.<sup><a href="javascript:;" reveal-id="ehae179-B1129" data-open="ehae179-B1129" class="link link-ref link-reveal xref-bibr">1129</a>,<a href="javascript:;" reveal-id="ehae179-B1130" data-open="ehae179-B1130" class="link link-ref link-reveal xref-bibr">1130</a></sup>

In cases of juxta- or para-renal AAA (_[Figure 22](javascript:;)_), both open and endovascular treatment can be proposed in high-volume centres, with similar short- and long-term results. The choice between open surgical repair and endovascular repair depends on various factors, including the patient’s anatomy, overall health, and the extent of the aneurysm (see _[Table 15](javascript:;)_). In cases of complex endovascular treatment, a fenestrated or branch stent endograft should be considered.<sup><a href="javascript:;" reveal-id="ehae179-B1096" data-open="ehae179-B1096" class="link link-ref link-reveal xref-bibr">1096</a>,<a href="javascript:;" reveal-id="ehae179-B1131" data-open="ehae179-B1131" class="link link-ref link-reveal xref-bibr">1131</a></sup>

A percutaneous femoral approach is suitable since it provides quicker access, reduced invasiveness, and allows local anaesthesia. Some evidence supports the use of ultrasound-guided percutaneous access for EVAR due to a lower rate of access-related complications and a shorter operation time.<sup><a href="javascript:;" reveal-id="ehae179-B1132 ehae179-B1133 ehae179-B1134 ehae179-B1135" data-open="ehae179-B1132 ehae179-B1133 ehae179-B1134 ehae179-B1135" class="link link-ref link-reveal xref-bibr">1132–1135</a></sup>

As patients treated by EVAR are more prone to late complications (endoleaks, migration, or rupture) and re-interventions, lifelong surveillance is currently mandatory.<sup><a href="javascript:;" reveal-id="ehae179-B1096" data-open="ehae179-B1096" class="link link-ref link-reveal xref-bibr">1096</a>,<a href="javascript:;" reveal-id="ehae179-B1136 ehae179-B1137 ehae179-B1138 ehae179-B1139 ehae179-B1140" data-open="ehae179-B1136 ehae179-B1137 ehae179-B1138 ehae179-B1139 ehae179-B1140" class="link link-ref link-reveal xref-bibr">1136–1140</a></sup>

Recommendation Table 41

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846374)

Recommendations for the management of patients presenting with abdominal aortic aneurysm

![Recommendations for the management of patients presenting with abdominal aortic aneurysm](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt41.jpeg?Expires=1728479088&Signature=yBTbYHE05kzPJMFTFMpAFNjOKhfn4mBLtl42qKTZyLiqQ26rpB4oh4ySOmEZzQELs8xHuD3ca2dotY~He7QSjKZWAGtGgpcJ477G7MhDSKl27-A3ZqbhiUeYE9ShaJASLK0RO-vZy-s3xTFOqilkdM3WceHCr-HjUYJtlggue2rZj2AMhUo7bju2iMOZXIioTXGL-TIXzEO9OBx9x9G1MHcWms-tJr9VVFZ-3wUJx3Muxql9fFOk2003s2l2fGAxbBwfwCymlXzcdA36ei9gxXb4y-eR6ZDn3OiEzidVIDzBxb9wlLyngjmotPkZnLEGN9ZbIzQdNk0UN1wty4NuKA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 9.2.6. Endoleaks

Endoleaks are defined as the persistence of blood flow outside the graft but inside the aneurysm sac, preventing complete thrombosis (_[Figure 27](javascript:;)_). They are the most common complication, with an incidence up to one-third of either early or late procedures (those appearing after 1 year).<sup><a href="javascript:;" reveal-id="ehae179-B1145" data-open="ehae179-B1145" class="link link-ref link-reveal xref-bibr">1145</a></sup> Chronic anticoagulation constitutes a risk factor for re-intervention, late conversion surgery, or mortality.<sup><a href="javascript:;" reveal-id="ehae179-B1146" data-open="ehae179-B1146" class="link link-ref link-reveal xref-bibr">1146</a></sup> Endoleaks exposing the aneurysm sac to systemic pressure and expansion will require re-intervention to prevent rupture.

![Algorithm for follow-up after thoracic endovascular aortic aneurysm repair, and management of endoleaks and their classification.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f27.jpeg?Expires=1728479088&Signature=IsN7MzlAAUq8aeQ~4e1j32eexvtfG6C1DYzoCPxsC1k9VesEgSuKMSAYGM8wdkU9wQXqpyIctSu4y1Jg7pc-K~DgS45vW3HicW-gyxY8Gnes809ixpQiEsX93~HxyiFtefNCmNnRR5NgyH3NwpqvJtuXY9V3GqiEChvP-cY5iETKeeyoDewX5BrWc7dkiirMCM04THwct3MIKq1F47wfUYzmxtM8T8z3UvPE59aKiT-KV5YyvyeumyDgascA49XU7~H0zhjBhvNf340t5dyjgjJbU5SIKZ-PmHJZml-8Ctp2BHY3QejotgrPjx~03FY-KR3yBb5YWw2YlmNyV0kFfQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 27

Algorithm for follow-up after thoracic endovascular aortic aneurysm repair, and management of endoleaks and their classification.

CEUS, contrast-enhanced ultrasound; CCT, cardiovascular computed tomography; DUS, duplex ultrasound; TEVAR, thoracic endovascular aortic aneurysm repair; EVAR: Endovascular aortic repair. <sup>a</sup>In cases of TEVAR, CCT is the preferred imaging technique since DUS/CEUS does not permit the correct evaluation of the thoracic aorta. In cases of renal failure, non-contrast CCT is a good alternative to monitor aneurysm sac growing and is associated to DUS/CEUS for EVAR monitoring. Endoleaks are classified into five types: Type Ia, proximal attachment site endoleak; Type Ib, distal attachment site endoleak; Type II, backfilling of the aneurysm sac through branch vessels of the aorta; Type III, graft defect or component misalignment; Type IV, leakage through the graft wall attributable to endograft porosity; and Type V; caused by ‘endotension’, possibly resulting from aortic pressure transmitted through the graft/thrombus to the aneurysm sac. Adapted from Rokosh _et al._ with permission.<sup><a href="javascript:;" reveal-id="ehae179-B1147" data-open="ehae179-B1147" class="link link-ref link-reveal xref-bibr">1147</a></sup>

[Open in new tab](https://academic.oup.com/view-large/figure/479846377/ehae179f27.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f27.jpeg?Expires=1728479088&Signature=Uod23Kip4TCiVP3tcwaZXuHX4Y2rT2n~kDvo5j9Mq1zQtGlJ44bOUMdY81nzMubvNkCWucovoyU6utUl16zSapjr9cHMsC04qp0bycl7Dz4468IHddsmWNkK6M0J2EJ-18HeWQapKI54KclNgViANEGDASKO6~RsYNRgHiQiLfhN38sSymt7PreXVABRBZaeOZrpjmtQ7tNnQmG8ViZdn8NVQNtQjGYmtLcpkPr7h8LhobNxfZ6yQ4cnuuB-tCSe~HJwnAcnvE1E~JxllD8LJyJ8GbU2Ut3ExTbfBL2E7Y85igpkxY~CFfe4xAPDnChpMMSA7hdBlSOszfnYxUg1ZQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846377&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Five types of endoleaks have been described, as detailed in _[Figure 27](javascript:;)_. Type I and type III require correction with a new (endovascular) procedure. Type II is present in about 25% of patients but may seal spontaneously in approximately 50% of cases. Risk factors for type II endoleaks include patent collaterals, presence of accessory arteries, and anticoagulation. In cases of significant sac expansion (≥10 mm), re-intervention should be considered, preferably by vessel or sac embolization. Type IV, attributed to device porosity, is rare with modern devices and no intervention is needed. Type V induces sac expansion without any visible endoleak. Treatment may be considered for significant sac growth (≥10 mm) and consists of stent graft relining or definitive endograft explant and open surgical repair.

Cardiovascular computed tomography with(out) contrast, and DUS and/or CEUS, are the main imaging modalities for TEVAR/EVAR follow-up. Imaging within the first 30 days is recommended to assess treatment success and/or complications. For TEVAR, contrast-enhanced CCT is the preferred imaging technique for follow-up and should be performed regularly (shorter or longer intervals are based on the expansion rate). In renally impaired patients, combined follow-up using DUS and non-contrast enhanced CCT is a suitable alternative (see follow-up algorithm, _[Figure 27](javascript:;)_). For EVAR, CCT and DUS/CEUS are recommended at 1 month following repair. Thereafter, surveillance should be based on the risk of late complications and includes DUS and/or CEUS (_[Figure 27](javascript:;)_).

Recommendation Table 42

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846380)

Recommendations for the management of patients presenting with endoleaks

![Recommendations for the management of patients presenting with endoleaks](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt42.jpeg?Expires=1728479088&Signature=Miv5g26Xv9q8qPAicI425dEnw1QOl-kakSeI0trqGFFLEqmVuGPBYI~9mTr4PgAYuY4mNqGxumRnbInfYZbYm~l4B8xHvLNT4D2c4BG~JFtmsDGsB1wkF8nNW5ls~zSSRhLYxil1tyaIzioRdVlgWi5AhlcLpOQB5wtw6AxmcpRfhcbUKdn9nQaV4TuDD6wtKxw8u-l10E~TX4a1v-ZMApebShkNZqQ~P6IUZm9aXM4E~LwUN~vwo~wB4praxfslAG8k455qQVOatfVJ6dGlkXFS9JeN4uijNyhtK5dviauH0cHP5t6M5XoS1I-wNiFVO0y~kXp82UwEkL0oDZsdyQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 9.2.7. Long-term follow-up after aortic repair

Long-term success in the management of aortic aneurysms depends also on strict post-treatment surveillance, for both secondary prevention of the aortic disease and early identification of post-repair complications.

In endovascularly treated patients, surveillance aims to detect endoleaks, aneurysmal sac dilatation, and graft structural failure or migration.<sup><a href="javascript:;" reveal-id="ehae179-B1150" data-open="ehae179-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup> Surgical treatments, while carrying higher operative risks, often yield more durable results with rarer late complications mostly related to laparotomy.<sup><a href="javascript:;" reveal-id="ehae179-B1151" data-open="ehae179-B1151" class="link link-ref link-reveal xref-bibr">1151</a></sup>

After intervention on the thoracic aorta, TTE, TOE, CCT, and CMR are used for follow-up, CCT being the most used and available method for both endovascular and surgical treatments.<sup><a href="javascript:;" reveal-id="ehae179-B1150 ehae179-B1151 ehae179-B1152" data-open="ehae179-B1150 ehae179-B1151 ehae179-B1152" class="link link-ref link-reveal xref-bibr">1150–1152</a></sup> After intervention on the AA, CCT, CMR, and DUS/CEUS are used. DUS/CEUS can detect the most common drawbacks of EVAR, except for graft structural issues. For chronic and periodic monitoring, the use of CMR, especially in young women, should be considered (to reduce radiation exposure). However, the choice between these modalities should consider patient factors, potential artefacts, and local imaging expertise and availability. Both for the thoracic and abdominal aorta, due to the lack of studies systematically comparing different surveillance time intervals, recommendations are mostly based on consensus or evidence from single-centre observational studies.<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B1153" data-open="ehae179-B1153" class="link link-ref link-reveal xref-bibr">1153</a></sup>

##### 9.2.7.1. Follow-up after thoracic aortic aneurysm treatment

Complications after ascending aorta graft replacement, though rare, include pseudo-aneurysms and graft infections. Pseudo-aneurysms, occurring in roughly 5% of cases, are most common within the first 2 post-operative years, linked to aortic dissection surgery, HTAD, and synthetic glues.<sup><a href="javascript:;" reveal-id="ehae179-B1154" data-open="ehae179-B1154" class="link link-ref link-reveal xref-bibr">1154</a></sup> CMR studies systematically following peri-anastomotic haematomas have reported higher rates (15%).<sup><a href="javascript:;" reveal-id="ehae179-B1155" data-open="ehae179-B1155" class="link link-ref link-reveal xref-bibr">1155</a></sup> Graft infections can occur in 0.5%–6% of surgical patients with high morbidity and mortality rates, requiring rapid diagnosis. Treatment typically involves surgery and antibiotics, tailored to factors like overall health, infection severity, and underlying conditions.<sup><a href="javascript:;" reveal-id="ehae179-B1156" data-open="ehae179-B1156" class="link link-ref link-reveal xref-bibr">1156</a></sup> Residual aortic disease progression depends on the underlying condition, such as HTAD, and requires individualized surveillance.

After TEVAR for DTA aneurysm, late complications are higher than with surgery (up to 38%), leading to re-operation in 24% of cases.<sup><a href="javascript:;" reveal-id="ehae179-B1150" data-open="ehae179-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup> However, over 80% of TEVAR complications arise within the initial post-operative years.<sup><a href="javascript:;" reveal-id="ehae179-B1157" data-open="ehae179-B1157" class="link link-ref link-reveal xref-bibr">1157</a></sup> Notably, FET results in fewer stent graft-related complications: 2% stent-induced intimal tear, 3% endoleak, and 7% need for additional TEVAR.<sup><a href="javascript:;" reveal-id="ehae179-B1158" data-open="ehae179-B1158" class="link link-ref link-reveal xref-bibr">1158</a></sup>

After surgical treatment of TAAs, the protocol is a first CCT scan at discharge or 1 month, then another in the first post-operative year (at 6, 9, or 12 months), followed by a 2 year scan, and if no issues arise, scans every 5 years thereafter (_[Figure 25](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B1062" data-open="ehae179-B1062" class="link link-ref link-reveal xref-bibr">1062</a>,<a href="javascript:;" reveal-id="ehae179-B1159" data-open="ehae179-B1159" class="link link-ref link-reveal xref-bibr">1159</a></sup> Stricter lifelong surveillance is recommended after TEVAR: after first imaging at 1 month, yearly controls are recommended for at least the first 5 post-operative years, then less frequently if no complications are detected (_[Figure 27](javascript:;)_).

Cardiovascular risk profile modification, cardiac rehabilitation, and lifestyle adjustments are an integral part of post-aneurysm repair follow-up (_[Figure 7](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B24" data-open="ehae179-B24" class="link link-ref link-reveal xref-bibr">24</a></sup>

##### 9.2.7.2. Follow-up after abdominal aortic aneurysm treatment

Evidence for follow-up after AAA is more robust than after TAA repair.<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B1096" data-open="ehae179-B1096" class="link link-ref link-reveal xref-bibr">1096</a></sup> Post-surgery, anastomotic or para-anastomotic complications are rare (2%–4%).<sup><a href="javascript:;" reveal-id="ehae179-B1160" data-open="ehae179-B1160" class="link link-ref link-reveal xref-bibr">1160</a></sup> In contrast, EVAR has higher complication rates (16%–30%), necessitating lifelong surveillance.<sup><a href="javascript:;" reveal-id="ehae179-B1079" data-open="ehae179-B1079" class="link link-ref link-reveal xref-bibr">1079</a>,<a href="javascript:;" reveal-id="ehae179-B1150" data-open="ehae179-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup> EVAR’s survival advantage over surgery diminishes after 8 years, with higher aneurysm-related mortality risk for EVAR.<sup><a href="javascript:;" reveal-id="ehae179-B1079" data-open="ehae179-B1079" class="link link-ref link-reveal xref-bibr">1079</a></sup> However, most failures are detectable early, and complications seldom occur later in patients with normal early controls.<sup><a href="javascript:;" reveal-id="ehae179-B1161" data-open="ehae179-B1161" class="link link-ref link-reveal xref-bibr">1161</a>,<a href="javascript:;" reveal-id="ehae179-B1162" data-open="ehae179-B1162" class="link link-ref link-reveal xref-bibr">1162</a></sup> CCT effectively detects early EVAR abnormalities,<sup><a href="javascript:;" reveal-id="ehae179-B1163" data-open="ehae179-B1163" class="link link-ref link-reveal xref-bibr">1163</a></sup> but DUS/CEUS surveillance proves accurate, reducing the need for radiation and nephrotoxic agents, and lowering costs (_[Figure 27](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B1164 ehae179-B1165 ehae179-B1166 ehae179-B1167" data-open="ehae179-B1164 ehae179-B1165 ehae179-B1166 ehae179-B1167" class="link link-ref link-reveal xref-bibr">1164–1167</a></sup>

Interestingly, a meta-analysis found low compliance of patients to post-operative surveillance without differences in all-cause mortality, aneurysm-related mortality, and re-intervention between compliant and non-compliant patients.<sup><a href="javascript:;" reveal-id="ehae179-B1168" data-open="ehae179-B1168" class="link link-ref link-reveal xref-bibr">1168</a></sup> Altogether, the above-mentioned evidence supports stratified methods of surveillance,<sup><a href="javascript:;" reveal-id="ehae179-B1096" data-open="ehae179-B1096" class="link link-ref link-reveal xref-bibr">1096</a></sup> with identification of high-risk situations (e.g. older patients, inadequate sealing, type II endoleaks, no early post-procedural shrinkage of the aneurysmal sac) for which more frequent evaluation should be planned.<sup><a href="javascript:;" reveal-id="ehae179-B1161" data-open="ehae179-B1161" class="link link-ref link-reveal xref-bibr">1161</a>,<a href="javascript:;" reveal-id="ehae179-B1169" data-open="ehae179-B1169" class="link link-ref link-reveal xref-bibr">1169</a>,<a href="javascript:;" reveal-id="ehae179-B1170" data-open="ehae179-B1170" class="link link-ref link-reveal xref-bibr">1170</a></sup>

Follow-up of OMT is highly important in AAA patients (_[Figure 7](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B24" data-open="ehae179-B24" class="link link-ref link-reveal xref-bibr">24</a></sup> Statin use after AAA repair (surgical or EVAR) is associated with decreased short- and long-term mortality.<sup><a href="javascript:;" reveal-id="ehae179-B1171" data-open="ehae179-B1171" class="link link-ref link-reveal xref-bibr">1171</a></sup> In addition, surveillance for aneurysm development in other arterial locations is recommended.

Recommendation Table 43

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846394)

Recommendations for follow-up after treatment of aortic aneurysms (see also Evidence Table 12)

![Recommendations for follow-up after treatment of aortic aneurysms (see also Evidence Table 12)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt43.jpeg?Expires=1728479088&Signature=iaDmMW7ejxnVzBhJN8PlJVzeUrcI7TPPz05KSGrLhNpTOZKIiR1y3Wl20fkRHxxvJ9EABbJPtkeBDuTIyIXqW9mHLudQqyJtDKn11BBFlnYIyWr~XfmNcmk5ggO-HOPl38oBAhIBgu9TqUJnhcghv4hVzfpZiVRG-CgPpfiw5xovLBOeNpy9jW7T1Ldym6IF7z6Hp3vLqwcho3-L9ZY9-R67deAwXb0cCMLBTJ4hNgx6emxtdJf5F9-xDaZwa2uJKT3iQVhGnptrOWUUOCvxA70tgnH8c6C3-DfjGaO3CfKWRMIj7b~QfO6m8xg74o7Tzzd65XFJ7JWcf9VAnwar1A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 9.3. Acute thoracic aortic syndromes

#### 9.3.1. General concepts

Acute aortic syndromes are life-threatening emergencies, including classic AAD, IMH, PAU, aortic pseudo-aneurysm, and traumatic aortic injuries (TAI). They involve aortic wall damage and share a dynamic, overlapping pathophysiology, clinical presentation, and diagnostic and therapeutic approaches.<sup><a href="javascript:;" reveal-id="ehae179-B24" data-open="ehae179-B24" class="link link-ref link-reveal xref-bibr">24</a>,<a href="javascript:;" reveal-id="ehae179-B172" data-open="ehae179-B172" class="link link-ref link-reveal xref-bibr">172</a>,<a href="javascript:;" reveal-id="ehae179-B174" data-open="ehae179-B174" class="link link-ref link-reveal xref-bibr">174</a>,<a href="javascript:;" reveal-id="ehae179-B910" data-open="ehae179-B910" class="link link-ref link-reveal xref-bibr">910</a></sup> AAS may also be iatrogenic following open or endovascular/percutaneous procedures, or cardiac surgery.<sup><a href="javascript:;" reveal-id="ehae179-B1172" data-open="ehae179-B1172" class="link link-ref link-reveal xref-bibr">1172</a></sup>

To guide AAS management, several anatomical classifications have been developed, the Stanford and the DeBakey systems being the most widely used. The Stanford system classifies AAS according to whether the ascending aorta is involved (type A or DeBakey type I and type II) or not (type B or DeBakey type IIIa and type IIIb) regardless of the site of origin of the intimal tear.<sup><a href="javascript:;" reveal-id="ehae179-B172" data-open="ehae179-B172" class="link link-ref link-reveal xref-bibr">172</a>,<a href="javascript:;" reveal-id="ehae179-B174" data-open="ehae179-B174" class="link link-ref link-reveal xref-bibr">174</a>,<a href="javascript:;" reveal-id="ehae179-B910" data-open="ehae179-B910" class="link link-ref link-reveal xref-bibr">910</a>,<a href="javascript:;" reveal-id="ehae179-B1173" data-open="ehae179-B1173" class="link link-ref link-reveal xref-bibr">1173</a></sup> This classification considers not only anatomical and treatment aspects, but also prognostic implications, since patients with DeBakey type II AAS will probably be left without structural aortic wall lesions after surgery (_[Figure 28](javascript:;)_).

![Anatomical and temporal classification of acute aortic syndrome.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f28.jpeg?Expires=1728479088&Signature=Yb589d2up1OTrvC4CJ33pPmCYRyDvH2nSq3Ykg7~43pIGPSpono7j1CV8RkjLgKwQj3DUnggqtje4c-NZhlO0-RjqlFLl4K0m5rfYFpKfQkEhk4xIpI16b-1b2OMkm5B~9D3UdnO-147QotIcy9DlYaTeNGM49tGyLwcT6wzGdZXySVsKlW-MhvtNuPgRFVqaoHmJ0R~Ree0OwDt5zvC21R0-cO1OkQ9lKr9OwuCIyK2W17MllxAFAtzOzvfjecY9pCBoizbP1RAsgR~c~~koDUmoVo71EEtPB0vw0h0Vjf7MWvbec39LZUpLUEyN8Tp0zybkjxSQQuV6gKK1xrZHA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 28

Anatomical and temporal classification of acute aortic syndrome.

AAS, acute aortic syndrome.

[Open in new tab](https://academic.oup.com/view-large/figure/479846399/ehae179f28.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f28.jpeg?Expires=1728479088&Signature=j-nolszo18pzZo1dRsHxvtzSIAhuneAa2uY13eS18-SH7etIipAv2iZkqTteLr0kcvthhGdYncBSRURTFFu~Lvdn9GgQcOTXBQ5e-ZYygtFho7xdNPf7wg8uk7ZKhIisx3kU~4Z89fUV-34yQsZ7VQ0YLjNAtX57EU7a9a879xKg51tSvQvXbBfkWWzu4brEf90GV-Gw-DSF-9TAZmd9AKHej-chCd70722PCWrDU7EGoeqi4Yw~MA43YntdFdWQWaUcq8aWKkKBjMXT5L7Lnx18-12ekRtW5ZxEjPAaw-v7Z3D3NWMV5LDQsy6YgjEzffNBlmmBk53Ec6trQ-5Vlw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846399&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Furthermore, if time elapsed from symptom onset to diagnosis is considered, AAS can be divided into hyperacute (<24 h), acute (1–14 days), subacute (15–90 days), and chronic (>90 days) (_[Figure 28](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B1174 ehae179-B1175 ehae179-B1176" data-open="ehae179-B1174 ehae179-B1175 ehae179-B1176" class="link link-ref link-reveal xref-bibr">1174–1176</a></sup>

A new classification considers the intimal tear’s entry site and dissection extension (_[Figure 29](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B136" data-open="ehae179-B136" class="link link-ref link-reveal xref-bibr">136</a></sup> Subscript P describes the proximal involved aorta, and subscript D indicates the distal zone. This classification guides treatment decisions for sealing the entry tear. AADs limited to the aortic arch or originating as retrograde dissections from the descending aorta that extend into the arch and stop before the ascending aorta are termed as **_non-A non-B AD_**.<sup><a href="javascript:;" reveal-id="ehae179-B1177 ehae179-B1178 ehae179-B1179" data-open="ehae179-B1177 ehae179-B1178 ehae179-B1179" class="link link-ref link-reveal xref-bibr">1177–1179</a></sup>

![Aortic dissection classification system based on the 2020 Society for Vascular Surgery/Society of Thoracic Surgeons Reporting Standards and the European update of the Stanford classification—Type Entry Malperfusion classification.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f29.jpeg?Expires=1728479088&Signature=p1wgp0nXo3nGP-5XyiOAUTZm69v5ZmdUfYu23a3mvgOpYwV7eEeK79iQwZCLfzK0zXDphRDNIpPkKlfkvm8OIE9rdge-UVkxx8DJAm99UeGcP~68D8XF5KBIZxiJ7LxQQDZK9ipX~G8cuXESfc66MWO5zTocgnjwDWJEJb-ti5Mx~E8nxwkO9LoB9~esN5t8grGW3JW8x5U9qwxst4nYcsZlb6RC6iUiED9BErX~gsk1AwbgUcIW9KcCyW9RkEDCcQz6FD6AqqclDzBn2DD2mXZJSVQu7CleXbyWCIHF~PLQL3c38L~Ya3NIpYokTsMIJU-4eKyQ8EwT4ih5Ut04lw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 29

Aortic dissection classification system based on the 2020 Society for Vascular Surgery/Society of Thoracic Surgeons Reporting Standards and the European update of the Stanford classification—Type Entry Malperfusion classification.

A, type A aortic dissection; B, type B aortic dissection; non-A, non-B, aortic dissection limited to the aortic arch or retrograde dissection extending into the arch (but not in the ascending aorta). Upper panel: Classification of AAD considering the intimal tear’s entry site and dissection extension. Subscript P describes the proximal involved aorta, and subscript D indicates the distal zone. Lower panel: The TEM classification is the European update of the Stanford classification combining information about the Type of dissection (T), the Entry site (E), and the presence of Malperfusion (M). Also refer to [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179_supplementary_data.pdf?Expires=1728479088&Signature=jsMN1psOaEf3KpW8UiQOwnEDCNM0eDJ9FhgPq~GNXqLItMAEdFx6foOGTBTeCpJhrfS5f9C1WsT6JBJ-OF2VSZCY4hMS9gJl7FbAOywEXjZ7FkQ8D8eMHICtPb1wzBA3uZZtBKMZczJqU~L965QcGSWu4bY5onpcoRMSzjgnNpdPf9L4pLKg-a0ahzhjNRwGHt5NoJ7ErFgx3duCbchEi0MsV0cDIkqzsUCeNEtwo8kpBYcJAps4DqCXaYZS5CPCAIpG4RbHZce70W~XP9IUuUZszMeWmEvwL5IF-0Kt0kkQwtSCyF6kopinSbFrVRYLZmYxxNRPbjwJpR0g1P88ZQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Section 1.6](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179_supplementary_data.pdf?Expires=1728479088&Signature=jsMN1psOaEf3KpW8UiQOwnEDCNM0eDJ9FhgPq~GNXqLItMAEdFx6foOGTBTeCpJhrfS5f9C1WsT6JBJ-OF2VSZCY4hMS9gJl7FbAOywEXjZ7FkQ8D8eMHICtPb1wzBA3uZZtBKMZczJqU~L965QcGSWu4bY5onpcoRMSzjgnNpdPf9L4pLKg-a0ahzhjNRwGHt5NoJ7ErFgx3duCbchEi0MsV0cDIkqzsUCeNEtwo8kpBYcJAps4DqCXaYZS5CPCAIpG4RbHZce70W~XP9IUuUZszMeWmEvwL5IF-0Kt0kkQwtSCyF6kopinSbFrVRYLZmYxxNRPbjwJpR0g1P88ZQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_. Society for Vascular Surgery/Society of Thoracic Surgeons (SVS/STS). Reproduced with permission from.<sup><a href="javascript:;" reveal-id="ehae179-B136" data-open="ehae179-B136" class="link link-ref link-reveal xref-bibr">136</a>,<a href="javascript:;" reveal-id="ehae179-B1180" data-open="ehae179-B1180" class="link link-ref link-reveal xref-bibr">1180</a></sup>

[Open in new tab](https://academic.oup.com/view-large/figure/479846402/ehae179f29.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f29.jpeg?Expires=1728479088&Signature=lh3d975gGYhOntVCFMxJv1oqAq9z8J9VuCD1s5eZswuggjuLxMBODVbHlocnEyNgiCE~DTa8hiHVagvqppGeOBgiEyNrJvaqMBhJLs-aY4OCKwlgXGOhj8I8p6p9lPhbmmbN6cC2PSmpRuTw9giuQ67B2T5-Ek09JyL661Q7MhPdAYdc6vdjNV--iWblnMH5RoyHlgiXdXGgv8OF7ducNAq-p42OFU6zNOHZ0WcJG1gXj0fVRuqGhFGjtus~NdInwlhIl~oKAhr-mpGsnQbiUa28DI2hjypgo8xlfWuPmIG6~Cg7j9192GqKZufvIw~b3HONSvTkmPu1A0f1uHMVZg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846402&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Recently, a European update of the Stanford classification—Type Entry Malperfusion (TEM) classification—has been proposed.<sup><a href="javascript:;" reveal-id="ehae179-B1180" data-open="ehae179-B1180" class="link link-ref link-reveal xref-bibr">1180</a></sup> This combines information about the type of dissection, its extent, and the presence of complications (malperfusion), thus providing greater prognostic insights (_[Figure 29](javascript:;)_). This classification is recommended by the European Association for Cardio-Thoracic Surgery. The TEM and other classifications are described in the [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179_supplementary_data.pdf?Expires=1728479088&Signature=jsMN1psOaEf3KpW8UiQOwnEDCNM0eDJ9FhgPq~GNXqLItMAEdFx6foOGTBTeCpJhrfS5f9C1WsT6JBJ-OF2VSZCY4hMS9gJl7FbAOywEXjZ7FkQ8D8eMHICtPb1wzBA3uZZtBKMZczJqU~L965QcGSWu4bY5onpcoRMSzjgnNpdPf9L4pLKg-a0ahzhjNRwGHt5NoJ7ErFgx3duCbchEi0MsV0cDIkqzsUCeNEtwo8kpBYcJAps4DqCXaYZS5CPCAIpG4RbHZce70W~XP9IUuUZszMeWmEvwL5IF-0Kt0kkQwtSCyF6kopinSbFrVRYLZmYxxNRPbjwJpR0g1P88ZQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Section 1.6](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179_supplementary_data.pdf?Expires=1728479088&Signature=jsMN1psOaEf3KpW8UiQOwnEDCNM0eDJ9FhgPq~GNXqLItMAEdFx6foOGTBTeCpJhrfS5f9C1WsT6JBJ-OF2VSZCY4hMS9gJl7FbAOywEXjZ7FkQ8D8eMHICtPb1wzBA3uZZtBKMZczJqU~L965QcGSWu4bY5onpcoRMSzjgnNpdPf9L4pLKg-a0ahzhjNRwGHt5NoJ7ErFgx3duCbchEi0MsV0cDIkqzsUCeNEtwo8kpBYcJAps4DqCXaYZS5CPCAIpG4RbHZce70W~XP9IUuUZszMeWmEvwL5IF-0Kt0kkQwtSCyF6kopinSbFrVRYLZmYxxNRPbjwJpR0g1P88ZQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_.

##### 9.3.1.1. Epidemiology and risk factors

Classic AAD (comprising 80%–90% of AAS; incidence of 2.6–3.5 cases per 100 000 person-years)<sup><a href="javascript:;" reveal-id="ehae179-B24" data-open="ehae179-B24" class="link link-ref link-reveal xref-bibr">24</a>,<a href="javascript:;" reveal-id="ehae179-B1181" data-open="ehae179-B1181" class="link link-ref link-reveal xref-bibr">1181</a></sup> is characterized by the presence of an intimal flap separating the true from the false lumen (FL).<sup><a href="javascript:;" reveal-id="ehae179-B24" data-open="ehae179-B24" class="link link-ref link-reveal xref-bibr">24</a>,<a href="javascript:;" reveal-id="ehae179-B172" data-open="ehae179-B172" class="link link-ref link-reveal xref-bibr">172</a>,<a href="javascript:;" reveal-id="ehae179-B910" data-open="ehae179-B910" class="link link-ref link-reveal xref-bibr">910</a></sup>

Acute aortic dissection occurs mostly in males (∼65%) and in the seventh decade of life (∼63 years).<sup><a href="javascript:;" reveal-id="ehae179-B1175" data-open="ehae179-B1175" class="link link-ref link-reveal xref-bibr">1175</a>,<a href="javascript:;" reveal-id="ehae179-B1182" data-open="ehae179-B1182" class="link link-ref link-reveal xref-bibr">1182</a></sup> Multiple risk factors often coexist directly linked to factors like wall stress (with systemic hypertension being the most common) and/or aortic media abnormalities, including syndromic and non-syndromic genetic diseases. HTAD, BAV, prior aortic surgery, and larger aortic dimensions are more frequent among young patients (<40 years).<sup><a href="javascript:;" reveal-id="ehae179-B24" data-open="ehae179-B24" class="link link-ref link-reveal xref-bibr">24</a>,<a href="javascript:;" reveal-id="ehae179-B1182" data-open="ehae179-B1182" class="link link-ref link-reveal xref-bibr">1182</a>,<a href="javascript:;" reveal-id="ehae179-B1183" data-open="ehae179-B1183" class="link link-ref link-reveal xref-bibr">1183</a></sup> Systemic hypertension and cocaine abuse are more common among African-American than among white patients.<sup><a href="javascript:;" reveal-id="ehae179-B1184" data-open="ehae179-B1184" class="link link-ref link-reveal xref-bibr">1184</a>,<a href="javascript:;" reveal-id="ehae179-B1185" data-open="ehae179-B1185" class="link link-ref link-reveal xref-bibr">1185</a></sup> Of note, the incidence of iatrogenic AD during cardiac catheterization is very low (around 0.01%–0.02%) and during cardiac surgery is 0.06%–0.23%, with favourable in-hospital and long-term prognosis.<sup><a href="javascript:;" reveal-id="ehae179-B1186" data-open="ehae179-B1186" class="link link-ref link-reveal xref-bibr">1186</a>,<a href="javascript:;" reveal-id="ehae179-B1187" data-open="ehae179-B1187" class="link link-ref link-reveal xref-bibr">1187</a></sup>

###### Sex differences

A specific female sex phenotype appears to be evident in acute TAAD. At admission, acute TAAD female patients are usually older but have lower body mass index (BMI), BSA, and creatinine plasma levels. They present less frequently with active smoking, BAV, and previous cardiac surgery,<sup><a href="javascript:;" reveal-id="ehae179-B1188" data-open="ehae179-B1188" class="link link-ref link-reveal xref-bibr">1188</a></sup> but diabetes mellitus is more common in women than in men. In-hospital surgical mortality does not differ between sexes, although 10 year survival appears to be higher in men. Among only medically treated acute TAAD patients, prohibitive high in-hospital mortality has been equally registered for both sexes (men 58.6% vs. women 53.8%).<sup><a href="javascript:;" reveal-id="ehae179-B1188" data-open="ehae179-B1188" class="link link-ref link-reveal xref-bibr">1188</a></sup> However, further studies are needed to explore AAD sex differences to design appropriate diagnostic and therapeutic interventions and preventive strategies.<sup><a href="javascript:;" reveal-id="ehae179-B1189" data-open="ehae179-B1189" class="link link-ref link-reveal xref-bibr">1189</a></sup>

Pregnancy increases the risk of AAS, more often in the last trimester (50%) or post-partum (33%).<sup><a href="javascript:;" reveal-id="ehae179-B1190" data-open="ehae179-B1190" class="link link-ref link-reveal xref-bibr">1190</a></sup>

###### Chronobiology

Acute aortic dissection presents chronobiological patterns, with a higher incidence in morning hours (peak between 8 am and 9 am) and winter (peak in January in the Northern Hemisphere).<sup><a href="javascript:;" reveal-id="ehae179-B24" data-open="ehae179-B24" class="link link-ref link-reveal xref-bibr">24</a>,<a href="javascript:;" reveal-id="ehae179-B1175" data-open="ehae179-B1175" class="link link-ref link-reveal xref-bibr">1175</a></sup>

###### Outcomes

For acute TAAD, in-hospital mortality has decreased from 31% to 22% due to better surgical outcomes; for acute type B aortic dissection (acute TBAD), in-hospital mortality has remained stable over the years (14%).<sup><a href="javascript:;" reveal-id="ehae179-B1175" data-open="ehae179-B1175" class="link link-ref link-reveal xref-bibr">1175</a>,<a href="javascript:;" reveal-id="ehae179-B1182" data-open="ehae179-B1182" class="link link-ref link-reveal xref-bibr">1182</a></sup> Including deaths before admission, 30 day mortality for AAD ranges from 23% to 55.8% in Western Europe.<sup><a href="javascript:;" reveal-id="ehae179-B1181" data-open="ehae179-B1181" class="link link-ref link-reveal xref-bibr">1181</a></sup>

Non-A, non-B dissection patients tend to be younger (median age 59 years) and have a lower mortality than acute TAAD patients.<sup><a href="javascript:;" reveal-id="ehae179-B1180" data-open="ehae179-B1180" class="link link-ref link-reveal xref-bibr">1180</a>,<a href="javascript:;" reveal-id="ehae179-B1191" data-open="ehae179-B1191" class="link link-ref link-reveal xref-bibr">1191</a></sup> The 30 day mortality in patients medically treated is around 14%,<sup><a href="javascript:;" reveal-id="ehae179-B1179" data-open="ehae179-B1179" class="link link-ref link-reveal xref-bibr">1179</a></sup> and 4.4% for those successfully treated surgically.<sup><a href="javascript:;" reveal-id="ehae179-B1177" data-open="ehae179-B1177" class="link link-ref link-reveal xref-bibr">1177</a></sup>

##### 9.3.1.2. Clinical presentation

Acute TAAD typically presents with sudden, severe chest/back pain, often described as ‘sharp’, alongside a history of arterial hypertension. However, around 6.4% of patients do not experience pain.<sup><a href="javascript:;" reveal-id="ehae179-B1182" data-open="ehae179-B1182" class="link link-ref link-reveal xref-bibr">1182</a>,<a href="javascript:;" reveal-id="ehae179-B1192" data-open="ehae179-B1192" class="link link-ref link-reveal xref-bibr">1192</a>,<a href="javascript:;" reveal-id="ehae179-B1193" data-open="ehae179-B1193" class="link link-ref link-reveal xref-bibr">1193</a></sup> Hypotension and shock are frequent. Unique clinical features specific to acute TAAD include pericardial effusion, aortic regurgitation, and coronary artery involvement leading to ACS (particularly the right coronary artery).<sup><a href="javascript:;" reveal-id="ehae179-B1194" data-open="ehae179-B1194" class="link link-ref link-reveal xref-bibr">1194</a></sup> Stroke may occur when supra-aortic branches are involved. Additional complications encompass paraplegia (resulting from spinal ischaemia), acute kidney injury, intestinal ischaemia, or limb ischaemia. Isolated abdominal aortic dissection occurs in about 1.3% of acute TBAD cases when the intimal flap originates below or at the renal arteries.<sup><a href="javascript:;" reveal-id="ehae179-B1195" data-open="ehae179-B1195" class="link link-ref link-reveal xref-bibr">1195</a></sup>

A complete clinical evaluation is mandatory, consisting of a central neurological evaluation, heart and lung auscultation (aortic diastolic murmur, pericardial rubbing, etc.), abdominal palpation (tenderness, etc.), and assessment of peripheral pulsations as well as mobility and sensibility in upper and lower limbs. SBP differences (pulse deficit) should be sought.

##### 9.3.1.3. Diagnostic work-up

Early diagnosis is still a major pitfall in managing AAD patients, therefore, a diagnostic multiparametric algorithm is proposed (_[Figure 30](javascript:;)_). It combines the aortic dissection detection-risk score (ADD-RS) with D-dimer (DD) and has been validated with an excellent capacity to rule out AAS.<sup><a href="javascript:;" reveal-id="ehae179-B1196 ehae179-B1197 ehae179-B1198 ehae179-B1199 ehae179-B1200" data-open="ehae179-B1196 ehae179-B1197 ehae179-B1198 ehae179-B1199 ehae179-B1200" class="link link-ref link-reveal xref-bibr">1196–1200</a></sup>

![Multiparametric diagnostic work-up of acute aortic syndrome.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f30.jpeg?Expires=1728479088&Signature=GxXlrECHXAdDpmalwtn5cYJDhgv~PTKz3RqWmPlZ2PG6FiTODsbUnVMZOiNeYLWHWv0lZOJAZO2jgowQkuOH~M-WqRofHoJr5MyPsGl3nM6x6euYV0A5PAlt-lA8f3m6VIqPbD6xR~JAJpH5FqqBT1lvfXygNP7adk~Z151HalF-1q3OVLyZqe97NsTPRWEbmU1AcjIRwZRN-etBpvflSJaMBLQ55lv7JpyN~N64ha3HBaqOyWc2zb6HLHXzQRUOKxmxN8QRYbe01G6Rks~EToce4EQA1gG1DG19F9s9tT8h-kR3JLDGDby3Q7~YDt4dVwVV-nu6RENG8g2rIKEqpA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 30

Multiparametric diagnostic work-up of acute aortic syndrome.

AAS, acute aortic syndrome; ADD-RS, aortic dissection detection-risk score; CCT, cardiovascular computed tomography; ECG, electrocardiogram; POCUS, point-of-care ultrasound; STEMI, ST elevation myocardial infarction; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography; +, findings compatible with AAS. <sup>a</sup>In haemodynamically unstable patients: consider TTE and/or TOE as first-line imaging technique depending on local expertise and availability.

[Open in new tab](https://academic.oup.com/view-large/figure/479846420/ehae179f30.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f30.jpeg?Expires=1728479088&Signature=3DUZ0dqxu8Nf-h65q5cYVd6-AEklsFJwuxy2wPSitT-dD-HKS878NE6f~~sdEeHY-vJCYVGPIyQlOXPktjiR0LSBDVrwZQej5dRtq0rIsglVL3YPmPp5-e54wzYC6sI7p925WSDrX0zaw8IT0uAQbYgZXeCfu4Vs~VhlNZc6ajtklVoqtFEQ5frytUDmzG4hq-NN-NiCCYKS7rPUWNCMHmPMxTUVQ~JY9R4I4Dnp3i6lqgIMVxWEzfxkHfC1lqqDM5uknqtYKDlOaFqt6CziMV~Gck6wzzC9ri7aHvV1umedQWFS4BYCvjvhwxpUgtG1mt~lBVh-Gjd790hcIUiXlA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846420&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

In patients presenting with chest pain, a routine chest radiography and ECG are recommended to exclude other aetiologies; however, the absence of these findings should not delay further investigations.<sup><a href="javascript:;" reveal-id="ehae179-B163" data-open="ehae179-B163" class="link link-ref link-reveal xref-bibr">163</a></sup> Laboratory tests should be obtained, but awaiting results should not delay imaging if there is a high probability of AAD. The most common finding is an increase in DD level, which is the case in several other conditions such as pulmonary embolism or infections. When DD levels are below 500 ng/mL, AAD is unlikely.<sup><a href="javascript:;" reveal-id="ehae179-B172" data-open="ehae179-B172" class="link link-ref link-reveal xref-bibr">172</a>,<a href="javascript:;" reveal-id="ehae179-B1201" data-open="ehae179-B1201" class="link link-ref link-reveal xref-bibr">1201</a></sup>

A focused TTE at the emergency department, if available, is recommended<sup><a href="javascript:;" reveal-id="ehae179-B1202" data-open="ehae179-B1202" class="link link-ref link-reveal xref-bibr">1202</a>,<a href="javascript:;" reveal-id="ehae179-B1203" data-open="ehae179-B1203" class="link link-ref link-reveal xref-bibr">1203</a></sup> to assess pericardial effusion, wall motion abnormalities, aortic regurgitation, and aortic diameters. Sometimes a dissection flap can be visualized, especially when using contrast.<sup><a href="javascript:;" reveal-id="ehae179-B165" data-open="ehae179-B165" class="link link-ref link-reveal xref-bibr">165</a></sup>

When AAD is suspected, ECG-gated CCT from neck to pelvis is the preferred imaging technique, with 100% sensitivity and 98% specificity, and should be performed as soon as possible to confirm diagnosis, localize entry tear, extension (type A vs. type B), and malperfusion.<sup><a href="javascript:;" reveal-id="ehae179-B170" data-open="ehae179-B170" class="link link-ref link-reveal xref-bibr">170</a>,<a href="javascript:;" reveal-id="ehae179-B172" data-open="ehae179-B172" class="link link-ref link-reveal xref-bibr">172</a>,<a href="javascript:;" reveal-id="ehae179-B1182" data-open="ehae179-B1182" class="link link-ref link-reveal xref-bibr">1182</a>,<a href="javascript:;" reveal-id="ehae179-B1204" data-open="ehae179-B1204" class="link link-ref link-reveal xref-bibr">1204</a></sup> When ACS or pulmonary embolism are still in the differential diagnosis, a triple rule-out ECG-gated CCT scan protocol can be performed be performed to avoid motion artefacts mimicking acute TAAD.<sup><a href="javascript:;" reveal-id="ehae179-B170" data-open="ehae179-B170" class="link link-ref link-reveal xref-bibr">170</a>,<a href="javascript:;" reveal-id="ehae179-B1205" data-open="ehae179-B1205" class="link link-ref link-reveal xref-bibr">1205</a>,<a href="javascript:;" reveal-id="ehae179-B1206" data-open="ehae179-B1206" class="link link-ref link-reveal xref-bibr">1206</a></sup> However, this strategy is associated with higher contrast and radiation doses, might be less accurate for AAS, and does not reduce the need for additional imaging tests.<sup><a href="javascript:;" reveal-id="ehae179-B170" data-open="ehae179-B170" class="link link-ref link-reveal xref-bibr">170</a>,<a href="javascript:;" reveal-id="ehae179-B1207" data-open="ehae179-B1207" class="link link-ref link-reveal xref-bibr">1207</a></sup> If CCT is not available or in haemodynamically unstable patients, TOE can confirm diagnosis. TOE is especially useful pre-, intra, and post-operatively to monitor changes in the anatomical AAD configuration or surgical complications. CMR could be a valuable alternative for CCT, however, it is less available, requires a longer examination time, relies on patient collaboration, and consequently, is less frequently used in the acute setting. CCT, CMR, and TOE all provide good diagnostic accuracy<sup><a href="javascript:;" reveal-id="ehae179-B172" data-open="ehae179-B172" class="link link-ref link-reveal xref-bibr">172</a>,<a href="javascript:;" reveal-id="ehae179-B1204" data-open="ehae179-B1204" class="link link-ref link-reveal xref-bibr">1204</a></sup> (See [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179_supplementary_data.pdf?Expires=1728479088&Signature=jsMN1psOaEf3KpW8UiQOwnEDCNM0eDJ9FhgPq~GNXqLItMAEdFx6foOGTBTeCpJhrfS5f9C1WsT6JBJ-OF2VSZCY4hMS9gJl7FbAOywEXjZ7FkQ8D8eMHICtPb1wzBA3uZZtBKMZczJqU~L965QcGSWu4bY5onpcoRMSzjgnNpdPf9L4pLKg-a0ahzhjNRwGHt5NoJ7ErFgx3duCbchEi0MsV0cDIkqzsUCeNEtwo8kpBYcJAps4DqCXaYZS5CPCAIpG4RbHZce70W~XP9IUuUZszMeWmEvwL5IF-0Kt0kkQwtSCyF6kopinSbFrVRYLZmYxxNRPbjwJpR0g1P88ZQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S4](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179_supplementary_data.pdf?Expires=1728479088&Signature=jsMN1psOaEf3KpW8UiQOwnEDCNM0eDJ9FhgPq~GNXqLItMAEdFx6foOGTBTeCpJhrfS5f9C1WsT6JBJ-OF2VSZCY4hMS9gJl7FbAOywEXjZ7FkQ8D8eMHICtPb1wzBA3uZZtBKMZczJqU~L965QcGSWu4bY5onpcoRMSzjgnNpdPf9L4pLKg-a0ahzhjNRwGHt5NoJ7ErFgx3duCbchEi0MsV0cDIkqzsUCeNEtwo8kpBYcJAps4DqCXaYZS5CPCAIpG4RbHZce70W~XP9IUuUZszMeWmEvwL5IF-0Kt0kkQwtSCyF6kopinSbFrVRYLZmYxxNRPbjwJpR0g1P88ZQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA))._

Recommendation Table 44

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846424)

Recommendations for diagnostic work-up of acute aortic syndromes

![Recommendations for diagnostic work-up of acute aortic syndromes](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt44.jpeg?Expires=1728479088&Signature=QRSXZ2G9dhzpXag4xxfOuowNVYN0B4ZUeEChlwVnrdMvCpId3AzluCG0TzfU8cOokCXMhXgNeDAgSqr7QoTsn6lDpCSYJHTI~rMNhVcnT-ngPzpcGu1glc1AHl3F5x3LZrJCjzjTQdNHuLFazzyaDtjabJQ1ywU2L3dRKDrh9xa-UqowEjaP1Kvpk4TsM7hPhPBALK2tpXcWbOgjIOImm33xqaDKxbWqHLf754b~qeJF1OF0UKfebWD7oVVNVuJ6Twh2ap62oFQWWQC4PXjkEwKfbq30sfWm40pVIpiQ0oDjKbDCyj4W-wQbg0AhRVCYbj2L6lByyRx~6RvD-eteQg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

##### 9.3.1.4. Therapeutic intervention in acute aortic dissection

###### Initial treatment

Acute aortic syndrome care should be centralized in experienced centres and managed by aorta teams.<sup><a href="javascript:;" reveal-id="ehae179-B1211" data-open="ehae179-B1211" class="link link-ref link-reveal xref-bibr">1211</a></sup> The cornerstone in AAS is initial reduction of the pulse pressure by lowering SBP below 120 mmHg and heart rhythm ≤60 beats per minute (b.p.m.). The aim is to decrease aortic wall stress to avoid further extension of dissection with possible rupture or malperfusion.<sup><a href="javascript:;" reveal-id="ehae179-B174" data-open="ehae179-B174" class="link link-ref link-reveal xref-bibr">174</a>,<a href="javascript:;" reveal-id="ehae179-B1212 ehae179-B1213 ehae179-B1214 ehae179-B1215 ehae179-B1216" data-open="ehae179-B1212 ehae179-B1213 ehae179-B1214 ehae179-B1215 ehae179-B1216" class="link link-ref link-reveal xref-bibr">1212–1216</a></sup> Intravenous beta blockade (labetalol as a first choice due to its alpha- and beta-blocking properties) is generally accepted as the best option. Also, esmolol, an ultra-short-acting beta-blocker, can be titrated quickly and easily, making it particularly useful in the acute setting. If contraindicated, i.v. non-dihydropyridine CCBs could be used for heart rate control. If the BP target is not reached after initiating beta-blockers, i.v. vasodilators such as nitrates or dihydropyridine CCBs (e.g. nicardipine) can be administered concomitantly with rate-controlling agents first to avoid reflex tachycardia. In cases of malperfusion, higher BP could be tolerated to optimize perfusion to the threatened region. Early placement of an arterial line to monitor BP invasively is mandatory and admission to an intensive care unit is advisable (including ECG and urine output monitoring).<sup><a href="javascript:;" reveal-id="ehae179-B1205" data-open="ehae179-B1205" class="link link-ref link-reveal xref-bibr">1205</a>,<a href="javascript:;" reveal-id="ehae179-B1217" data-open="ehae179-B1217" class="link link-ref link-reveal xref-bibr">1217</a>,<a href="javascript:;" reveal-id="ehae179-B1218" data-open="ehae179-B1218" class="link link-ref link-reveal xref-bibr">1218</a></sup> Antihypertensive treatment can be gradually switched to oral therapy once BP and heart rate targets are reached and the patient has normal gastrointestinal transit. Adequate pain control is necessary to help reach these haemodynamic goals. Intravenous morphine can be cautiously titrated to induce pain relief (_[Figure 31](javascript:;)_).

![Medical management of acute aortic syndrome.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f31.jpeg?Expires=1728479088&Signature=DrGt3Gso8lx0nzFoaLKE3KhejvUPDIPsAWJyPXrHUUC7vOqAPnrM-G-fx-jZdcEGvi0WPjpeGVzTgitkZFfIzLjC4Dv0KsY0jUgk7vM63l0EECKkQa94zV3sikTyNns5ymPaHumWvleUd4pNU5Ov6F1C~Z1GCf-azM45EnLsNCLbKOfN-sJTr1RGM2BeTlgVIH8kw7mvewnvZgj19Ye9qsLZp5G3agYix42WoLfI9v~VYvEfYw1LhE00n-GgxGQRJB1XUUWKP~Hl0xXu0axSdZx0qTsWbmdOelrDkClY80V1TX22SAHlIKheQD19j3DjbyhfeVfrLvSKJdYGdGGIzA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 31

Medical management of acute aortic syndrome.

BP, blood pressure; b.p.m: beats per minute.

[Open in new tab](https://academic.oup.com/view-large/figure/479846428/ehae179f31.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f31.jpeg?Expires=1728479088&Signature=Q34Jk9BdT2fvX9ZfHix1bPKKKSS51RAEwCjnZiv36O0AbgszACZOAcOlXRgRFgWy8wJD7-HFNEWmLIeuebIYrmdiO8OBDyR9TXAGwSq19YOYh2CXclVfwOCOHhSnL9zpJWQ1q9KI9so4MmHD0ioo6W8GLq753I40S1EzVx2OG3Blwi36iPVzfZ1X5REOH2OwPnroVlH6N84MLUbumIIvkGeWkSWvQ1gVJPNo3EwJ0C~Qr1p-hyXAODgwm2vanjkW53FlyLF1ccszllZtELs2mGeWKK6c8uDL9bITiKaPRJG1eq8ny6FlJSCVGZW0bmUZH0KwcKMdX62xbSfLp8LXkw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846428&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

In-hospital mortality, reaching 60%, correlates with AAS type, location, patient comorbidities, and treatment. Risk rises with complications like pericardial tamponade, coronary involvement, or malperfusion. _[Figure 32](javascript:;)_ describes the main signs and symptoms of complications and the mortality rate associated with them.<sup><a href="javascript:;" reveal-id="ehae179-B1219 ehae179-B1220 ehae179-B1221 ehae179-B1222 ehae179-B1223" data-open="ehae179-B1219 ehae179-B1220 ehae179-B1221 ehae179-B1222 ehae179-B1223" class="link link-ref link-reveal xref-bibr">1219–1223</a></sup>

![Complications in acute aortic syndromes, clinical evidence associated with malperfusion syndrome, and in-hospital mortality associated with these complications.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f32.jpeg?Expires=1728479088&Signature=i4MYVmQrMDPYWYGA-DDub5cYDzMvuugOQk91dtEYUElUgrbW-Df48dgkW-ON-9-qH3snIyroqfOJbbkS7x7xDqHKSeKdsc0w9zqRZ0uqWoCKsa4Hzx1hEv-eOUWscqjP-1ZdcEWj1IcqkXhb3HUo~V5h2Ngcpp2Y4LJGe6KgUtUOD0xVtPPTfHhsTXrNSZ5jLothN-SKa8hxQaqtmfyyvtlA9NNkXHGm2hL78zoTBdTXX6hVuePSBc2OVnLuGZ6s8sAxkucioP6uI0EQb7ZmNoh1xqT7UN1NM6A0LVqySV46wxEJtjdTYt-KISOEmF9jzLqI9rhzkyknj7PBkUvnLQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 32

Complications in acute aortic syndromes, clinical evidence associated with malperfusion syndrome, and in-hospital mortality associated with these complications.

[Open in new tab](https://academic.oup.com/view-large/figure/479846430/ehae179f32.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f32.jpeg?Expires=1728479088&Signature=dG82YVPNKzZLPUBOqRMzJNlxx1BNybwZcC52bDeKfpJRR3TgfGPPHDSYxXQtHGCnLUR-5RTEYI9NlfLzTIe4woekJQ~ZNiXcs-KQiF~jwUdVjbm7U26DnUZWexyKYp9S2qpmq9JzX~zBfcFR~3dPErMT7QYeQTwtxO-RMoAXO~mFYxjzmLtVAw3JeBS6boh2sq-yKGHLe2OaGszcS9MpxMLHplZ7X5iOrBKd-23wdI0POGtpRr09QlxDsl5P-Et6y4LkDkyLg~rA0wtmRblbBEzLPkAtAvpLJ~XOrcI4AwW~7GQRyvxhd6z~DHjR56irZe3uXXI8Fv26xTnRJBQelA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846430&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Recommendation Table 45

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846431)

Recommendation for medical treatment in acute aortic syndromes

![Recommendation for medical treatment in acute aortic syndromes](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt45.jpeg?Expires=1728479088&Signature=LAwJJITplcqp8T4wDQyn60QuUeksg0PxNZqi0RlkRc60Yk759NKOt7k~Qn6~ninr4StHW99Ppd3R709gOkQ~IeqoirALqNd9hm0IJat~P~o-fholP5-~nT30skrIzcMlOjv-7sDIgcntkh3AWL0Y1xx0cI51sQubYy6nCTcqxC0bse~8w9~WqQu-4QcJqO9m-BHPNowntiOh9PgXMgkxETlogTOY1XELaeU3js1TCJFQOEdLhr2Q02Sh7h8WjjJEPe646K-pU8uPYoZrXsl9jRCpdjiogyMCcME6PcBbfH40etp5BETbBprOQXNRIYeyELVVzkZ98d-Sf2SAA~-2nQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Interventional treatment in acute TAAD and acute TBAD is described in the next sections and summarized in _[Figure 33](javascript:;)_.

![Interventional treatment algorithm in acute aortic dissection.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f33.jpeg?Expires=1728479088&Signature=gWF2YDby0IN0wJM56wFgrQKvhtDQohdsZTwmpzghSE7cnolAFbnlMqdT3e0arW56UxRyvuWUhbTOS0HeOgEK-ds-BjlTCEi73nlIOdNlHX6ObEUxISBMIGGRPZ0Ad2j6hOphx2nmJnjQBRnDpXOzmaRs4Qm55HobbHg38tSyyRtZ3ffQZuId~KBCQxLFUB1cqzj0ciPem86UGYtSVVieVyN7KyRfdBD2vrRtoBHEPz7pRHDGyDdNWDo-hRCwTzSQGiffuzW5llbxKmAn7h~qw61cpq6oviNnjjsWHcgznqBnjPffU1bDBhyTQIOWO~hjBk8VDrl8AYkUOubcKZRdSQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 33

Interventional treatment algorithm in acute aortic dissection.

AAD, acute aortic dissection; Ao, aorta; CCT, cardiovascular computed tomography; OMT, optimal medical treatment; TEVAR, thoracic endovascular aortic repair. <sup>a</sup>On serial imaging in the acute phase during the hospital stay. <sup>b</sup>Ongoing hypertension despite more than three classes of antihypertensive drugs. <sup>c</sup>Defined as the presence of adequate proximal and distal landing zones for the prosthesis and adequate iliac/femoral vessels for vascular access. <sup>d</sup>Between 14 and 90 days after dissection onset.<sup><a href="javascript:;" reveal-id="ehae179-B172" data-open="ehae179-B172" class="link link-ref link-reveal xref-bibr">172</a>,<a href="javascript:;" reveal-id="ehae179-B1226 ehae179-B1227 ehae179-B1228 ehae179-B1229 ehae179-B1230 ehae179-B1231" data-open="ehae179-B1226 ehae179-B1227 ehae179-B1228 ehae179-B1229 ehae179-B1230 ehae179-B1231" class="link link-ref link-reveal xref-bibr">1226–1231</a></sup>

[Open in new tab](https://academic.oup.com/view-large/figure/479846433/ehae179f33.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f33.jpeg?Expires=1728479088&Signature=KA4jowOMWM-0GZFLYZ4AaUOQcIfx42ZEJodrPRaCQCF7ZS-NKKSRehg4sn1574s91kLUoA-vRUjKehYUGQTsuB--HGuLlQ5E3yN41GTeX8UiRzN4938bZnCDcGMGx6XyrEqCkLe0aXTLqROZZxoLZK~Ed~05OVHK5Dm6kifHmaZawuPXOLs4ham-5a2FoGVPUCyiZ~A7tCaAoU1cHl~Bozdpmp-TBOkrLq5wAPKoGPhuO2QbRx7wf41F0fNLzEefE-9oBQ8jru7vGfRdMd0FbQ9Ol0R7MyP3aCAiA2z6tctcEhXw8iZqDE94PcwzaCprT3WFZ4czhpFaZ48~nQ0JHg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846433&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

###### Type A aortic dissection interventional treatment

Immediate surgical repair is recommended for acute TAAD, however, a high mortality rate (∼50% and 1%–2% per hour) within the first 48 h is described if managed medically only.<sup><a href="javascript:;" reveal-id="ehae179-B1232" data-open="ehae179-B1232" class="link link-ref link-reveal xref-bibr">1232</a></sup> Despite advances in surgical and anaesthetic techniques, there is still a high risk of peri-operative mortality (17%–25%) and neurological complications (18%).<sup><a href="javascript:;" reveal-id="ehae179-B1233" data-open="ehae179-B1233" class="link link-ref link-reveal xref-bibr">1233</a></sup> In recent reports from the International Registry of Acute Aortic Dissection (IRAD), medically managed patients had a 23.7% mortality rate (0.5% per hour) compared with 4.4% (0.09% per hour) for those undergoing surgery.<sup><a href="javascript:;" reveal-id="ehae179-B1234" data-open="ehae179-B1234" class="link link-ref link-reveal xref-bibr">1234</a></sup> Analyses of pre- and post-July 2007 IRAD data showed no difference in 48 h mortality for medically treated patients, but surgical mortality decreased (from 5.5% to 3.9%).<sup><a href="javascript:;" reveal-id="ehae179-B1234" data-open="ehae179-B1234" class="link link-ref link-reveal xref-bibr">1234</a></sup> As surgical techniques have improved, data have shown improved post-operative survival rates.<sup><a href="javascript:;" reveal-id="ehae179-B1235" data-open="ehae179-B1235" class="link link-ref link-reveal xref-bibr">1235</a></sup> The use of the GERAADA (German Registry of Acute Aortic Dissection Type A) score<sup><a href="javascript:;" reveal-id="ehae179-B1236" data-open="ehae179-B1236" class="link link-ref link-reveal xref-bibr">1236</a></sup> should be considered in patients undergoing surgery to determine 30 day mortality ([https://www.dgthg.de/de/GERAADA\_Score](https://www.dgthg.de/de/GERAADA_Score)).

Surgical intervention surpasses conservative therapy in long-term follow-up,<sup><a href="javascript:;" reveal-id="ehae179-B1237" data-open="ehae179-B1237" class="link link-ref link-reveal xref-bibr">1237</a></sup> even for challenging cases. Thus, all acute TAAD patients should receive surgical treatment; however, cardiogenic shock secondary to pericardial tamponade, malperfusion of coronary arteries, mesenteric circulation, lower extremities, kidneys, or brain, and/or coma are major predictors for post-operative mortality (_[Figure 32](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B1234" data-open="ehae179-B1234" class="link link-ref link-reveal xref-bibr">1234</a>,<a href="javascript:;" reveal-id="ehae179-B1238" data-open="ehae179-B1238" class="link link-ref link-reveal xref-bibr">1238</a></sup> Among octogenarians, in-hospital mortality was lower after surgery than with conservative treatment (37.9% vs. 55.2%), but with a non-significant difference due to small sample size.<sup><a href="javascript:;" reveal-id="ehae179-B1239" data-open="ehae179-B1239" class="link link-ref link-reveal xref-bibr">1239</a></sup> While some have reported excellent surgical and quality of life (QoL) outcomes in elderly patients,<sup><a href="javascript:;" reveal-id="ehae179-B1239" data-open="ehae179-B1239" class="link link-ref link-reveal xref-bibr">1239</a></sup> others found a higher rate of post-operative neurological complications.<sup><a href="javascript:;" reveal-id="ehae179-B1240" data-open="ehae179-B1240" class="link link-ref link-reveal xref-bibr">1240</a></sup> Based on the current evidence, age per se should not be considered an exclusion criterion for surgery.

For optimal repair of acute TAAD regarding long-term outcomes, including risk of late death and late re-operation, the following points need to be addressed. First, in most cases of aortic regurgitation associated with acute TAAD, the aortic valve is essentially normal and can be preserved.<sup><a href="javascript:;" reveal-id="ehae179-B1241 ehae179-B1242 ehae179-B1243" data-open="ehae179-B1241 ehae179-B1242 ehae179-B1243" class="link link-ref link-reveal xref-bibr">1241–1243</a></sup> Alternatively, valve replacement can be performed in cases of pre-existent structural valve disease. The decision whether to replace the aortic root is based on the presence of tears in the sinuses, extensive dissection of sinuses/coronary ostia, or significant dilatation of the root. The risk of late dilatation of the aortic sinuses when spared should be considered.<sup><a href="javascript:;" reveal-id="ehae179-B1242" data-open="ehae179-B1242" class="link link-ref link-reveal xref-bibr">1242</a>,<a href="javascript:;" reveal-id="ehae179-B1244" data-open="ehae179-B1244" class="link link-ref link-reveal xref-bibr">1244</a></sup> Additionally, the distal extent of aortic repair is a topic of debate. Ascending aortic replacement or hemi-arch replacement alone is technically easier and effectively closes the entry site but leaves a large part of the diseased aorta untreated. In acute TAAD with visceral or renal malperfusion, the primary entry tear is often in the descending aorta. Consider extended therapies like FET repair for these patients, offering a complete repair with a low chance of late re-intervention despite increased technical complexity.<sup><a href="javascript:;" reveal-id="ehae179-B1245 ehae179-B1246 ehae179-B1247" data-open="ehae179-B1245 ehae179-B1246 ehae179-B1247" class="link link-ref link-reveal xref-bibr">1245–1247</a></sup>

For potential cardiac arrest from pericardial tamponade, consider an emergency pericardial puncture as a temporary life-saving measure before transferring to the operating room.<sup><a href="javascript:;" reveal-id="ehae179-B1248" data-open="ehae179-B1248" class="link link-ref link-reveal xref-bibr">1248</a>,<a href="javascript:;" reveal-id="ehae179-B1249" data-open="ehae179-B1249" class="link link-ref link-reveal xref-bibr">1249</a></sup>

Recommendation Table 46

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846439)

Recommendations for intervention in type A acute aortic dissection

![Recommendations for intervention in type A acute aortic dissection](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt46.jpeg?Expires=1728479088&Signature=tOktw-tl7OxV9ejl6vTwIvoqtvngZ6245DrncpdcNJAqPYCMFGXLOR~vNoyMMtw0I-7~oXkihabHuvsKfTxdfYshXbHoriday0sc2qidAgztbFhaaLOlnhL3uPBFWCa-ysnkJp4BsXy4RMGlv2aFbdtDAqyo3COhrBEUV6iB-PKeynoKZVbuIpcbm0ObidIdJ4j0gM6M2HhOaN8~avV5ay7bFBXYq3stmRv2vDL~EZWicP127EJ0pFvbc3X2NwvyqxhPHZf1wHcWfYGhTT903LlO87I3gmq5QqfXZ7vq2IDKekmEruKWUsRGg1x1LMKtLHI4UX0tdI6x9IQKpfB2bw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

The frozen elephant trunk technique

The FET technique addresses complex aortic and aortic arch issues in a single operation,<sup><a href="javascript:;" reveal-id="ehae179-B1260 ehae179-B1261 ehae179-B1262 ehae179-B1263" data-open="ehae179-B1260 ehae179-B1261 ehae179-B1262 ehae179-B1263" class="link link-ref link-reveal xref-bibr">1260–1263</a></sup> creating a secure landing zone for future interventions. Recent advances involve ‘proximalization’—placing the FET in the aortic arch’s zone 0 or 1, treating proximal arch aortic issues, and enhancing the landing zone for downstream procedures—which surpasses the standard elephant trunk technique.<sup><a href="javascript:;" reveal-id="ehae179-B1264" data-open="ehae179-B1264" class="link link-ref link-reveal xref-bibr">1264</a>,<a href="javascript:;" reveal-id="ehae179-B1265" data-open="ehae179-B1265" class="link link-ref link-reveal xref-bibr">1265</a></sup>

Recommendation Table 47

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846442)

Recommendations for aortic repair strategies in type A acute aortic dissection

![Recommendations for aortic repair strategies in type A acute aortic dissection](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt47.jpeg?Expires=1728479088&Signature=fUcNHnULzHxjXuHMYOknZXjojsmGt3LgqC8YRcn4yJV41tI7UEBsvJrur3osWmLFzprd7IiB6cdBnQwCTtfLzjmHP9EpV-8hzpxrlOti6z~PV4JYnsAB62zroCCOX6W08XasuL1zxj7~lReswdGBuHKFZmpl6LGJVoUxefLa43Y4kPD-igp-7WgD60d7UA2wd1X-xXP071NHSf-84x-Ov1LSgvPNIvw05DZcwTbmSAG-s~fidFSXXx6W7rNUDuK9adNCrGuPRDrvX2qr-sIp3hFUi~gik-KyVfABEpScj0-jrBEcKyBaIzECNtAFqrc8Zua3Oz9ESBvMVidPoiYlvw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Malperfusion in type A aortic dissection

In acute TAAD with malperfusion, operative mortality correlates with the number of affected organs. Around 30% of patients develop malperfusion syndrome due to elevated pressure in the FL caused by substantial proximal inflow and insufficient distal outflow, leading to visceral organ and limb ischaemia.<sup><a href="javascript:;" reveal-id="ehae179-B1175" data-open="ehae179-B1175" class="link link-ref link-reveal xref-bibr">1175</a></sup> The intimal flap may extend into peripheral arteries, causing a static ‘stenosis-like’ blockage. Malperfusion typically combines dynamic and static obstructions, necessitating surgical and hybrid interventions for affected patients (_[Figure 34](javascript:;)_).

![Mechanisms and clinical management of aortic branch obstruction in acute aortic dissection.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f34.jpeg?Expires=1728479088&Signature=PemRTEezqVWlkj2joZY5rEK1-w7zOvNiykXy6VH0tqZmxHAB8BSvTPYMSupVQrpuyuW2ypPrfgDpSG-eKog-jR6jwjL-g2vAZrCFf8nCeU02kmYzTwynKUVGv3p1aByhQzSkLblHIAPsBKAPpECvKlbcckjzMOY2MXzb~arTYleaUQ74sXJauFFpsKPHhOq39XDtsJfhJArNSwO0Q66QIZ8pCmR0WHCzySaN8AVRZpLS9w5w6JUihFZyasvIl4LZU49JvSf4yn-cZCQjMltsVeSmmlR9CEK4QxJ2Z2gxwqkdk~pBFM6xQCHNfz~M26ahYUPH3ItTAqNDUmVMk83ulA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 34

Mechanisms and clinical management of aortic branch obstruction in acute aortic dissection.

CPR, cardiopulmonary resuscitation; F, false lumen; FET, frozen elephant trunk; OR, operating room; T, true lumen; TOE, transoesophageal echocardiography; TEVAR/EVAR, thoracic endovascular aortic aneurysm repair. <sup>a</sup>Develops only in retrograde type A dissection.

[Open in new tab](https://academic.oup.com/view-large/figure/479846445/ehae179f34.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f34.jpeg?Expires=1728479088&Signature=yQIXuyMLugjD4HBsgR26HJeGP0FqpeU-MoWLkOmVCH5hOh6mGbgfKkUMxxug2xRf0-rQAdS-3D43gt0PAWc-zI76uZ8xl4E8Z77OOBtk7kbyLo219o-CgWOB7FmGsbtMhQ0Wzx-2Fm8Y6jlvnsj~fVs-3aK2IJyps4CYMWEc5i~Gz52WtMN2kNMydfNg6T4Rk3DWZ3CBzlwwuOpmy10ce0CBoNLHaWFVOkLOnrd5UgQO4EsNis7Mvuv0ctn8WEUUPBaC4xRWVkKKQntYGQzuDvurmMLQblT0o3Wu0uPpyiw9KfPFcH7pHbCzaX1UhGqIyYbrfGx83v9ZxbCJ5Q91tg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846445&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Mesenteric malperfusion, a life-threatening complication with a mortality rate of 65%–95%, leads to diverse treatment approaches. Some centres prefer early direct reperfusion before aortic surgery, while others favour conventional central aortic repair.<sup><a href="javascript:;" reveal-id="ehae179-B1275" data-open="ehae179-B1275" class="link link-ref link-reveal xref-bibr">1275</a></sup> The IRAD registry highlights the superiority of a surgical and hybrid approach over medical or endovascular therapy alone. Central aortic repair effectively restores perfusion, showing promising results for renal malperfusion, extremity malperfusion, uncomplicated mesenteric malperfusion, or combinations.

Cerebral malperfusion, equally grave, triggers treatment debates necessitating a multidisciplinary strategy. Evidence supports surgical intervention, reducing mortality rates to 25%–27%, compared with 76% with medical management alone.<sup><a href="javascript:;" reveal-id="ehae179-B1255" data-open="ehae179-B1255" class="link link-ref link-reveal xref-bibr">1255</a>,<a href="javascript:;" reveal-id="ehae179-B1276" data-open="ehae179-B1276" class="link link-ref link-reveal xref-bibr">1276</a></sup> Close monitoring and rapid intervention are essential to achieve optimal outcomes and minimize the risk of permanent neurological damage. A recommended algorithm for malperfusion management is displayed in _[Figure 34](javascript:;)_.

Recommendation Table 48

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846448)

Recommendations for the management of malperfusion in the setting of acute aortic dissection

![Recommendations for the management of malperfusion in the setting of acute aortic dissection](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt48.jpeg?Expires=1728479088&Signature=ZWmtg8RQaQNYoGecZ0rC0Zwq84lihwTZxCTYqMxlQvJPsfnAWwy1viL6yrUFghqxAjYnnxprjx9HYFx1aT5wgVWsGAk1YI9t33a8HjofV9K6~2cbG02ruBbqh7cuWvlDkej2JEw5jsdFGSFLsk2f-nnfMoSFGgEtzwyVfisPhPLTpR92UrmFFrgqU~~KNmDl~HtlYjGJSJ4uAA8NvWm4b4HdpoZuy-~eYHkR76cCB6IC82MhaU0aCgGPxcj-PWQ1b6mAla6QnXdaxPOO0dunTBnWFVoZFgjCst6ajUKBb44mC7N8~9eRNmbHR58Ub~8sLcSuZe~fmgENd9JfN~DSDA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Endovascular treatment in type A aortic dissection

Endovascular therapy alone has been attempted in highly selected cases and the concept of a single endovascular valve-carrying conduit was suggested recently but has not yet been validated.<sup><a href="javascript:;" reveal-id="ehae179-B1281" data-open="ehae179-B1281" class="link link-ref link-reveal xref-bibr">1281</a>,<a href="javascript:;" reveal-id="ehae179-B1282" data-open="ehae179-B1282" class="link link-ref link-reveal xref-bibr">1282</a></sup>

Treatment in non-A non-B aortic dissection

Conservative management leads to high mortality (malperfusion, aortic rupture); thus, surgery or endovascular therapy is favoured within 14 days of symptom onset. For complicated non-A non-B aortic dissection with an arch tear, consider FET repair, though if feasible, stent-graft implantation for primary tear coverage is an alternative.<sup><a href="javascript:;" reveal-id="ehae179-B1179" data-open="ehae179-B1179" class="link link-ref link-reveal xref-bibr">1179</a>,<a href="javascript:;" reveal-id="ehae179-B1283" data-open="ehae179-B1283" class="link link-ref link-reveal xref-bibr">1283</a></sup>

###### Acute type B aortic dissection interventional treatment

Acute TBAD presents without complications (uncomplicated) in around 50% of cases.<sup><a href="javascript:;" reveal-id="ehae179-B1250" data-open="ehae179-B1250" class="link link-ref link-reveal xref-bibr">1250</a></sup> Complicated acute TBAD includes aortic rupture, malperfusion-related issues, rapid aortic expansion, paraplegia/paraparesis, aortic haematoma, refractory pain, and hypertension despite optimal therapy, which associates with an approximately 50% mortality risk with conservative treatment.<sup><a href="javascript:;" reveal-id="ehae179-B1193" data-open="ehae179-B1193" class="link link-ref link-reveal xref-bibr">1193</a>,<a href="javascript:;" reveal-id="ehae179-B1250" data-open="ehae179-B1250" class="link link-ref link-reveal xref-bibr">1250</a>,<a href="javascript:;" reveal-id="ehae179-B1284" data-open="ehae179-B1284" class="link link-ref link-reveal xref-bibr">1284</a>,<a href="javascript:;" reveal-id="ehae179-B1285" data-open="ehae179-B1285" class="link link-ref link-reveal xref-bibr">1285</a></sup>

Open surgery used to be the sole option for complicated acute TBAD but carried a mortality rate of 25%–50%. Consequently, medical management, now considered the standard for uncomplicated cases, significantly reduces mortality. Goals include lowering SBP and heart rate with BBs (see _Section [9.3.1.4.1](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#ehae179-s8.3.1.4.1)_). However, adherence is the main limitation of chronic medical treatment, with a rate below 50%.<sup><a href="javascript:;" reveal-id="ehae179-B1286" data-open="ehae179-B1286" class="link link-ref link-reveal xref-bibr">1286</a>,<a href="javascript:;" reveal-id="ehae179-B1287" data-open="ehae179-B1287" class="link link-ref link-reveal xref-bibr">1287</a></sup> Compliance increases with previous aortic surgery, severity of hypertension, and understanding of the disease process. Thus, surveillance and disease awareness are imperative for these patients.

Endovascular therapy for complicated acute TBAD is now the first-line treatment, provided there is favourable anatomy, due to positive short- and long-term outcomes.<sup><a href="javascript:;" reveal-id="ehae179-B1288 ehae179-B1289 ehae179-B1290 ehae179-B1291 ehae179-B1292 ehae179-B1293 ehae179-B1294" data-open="ehae179-B1288 ehae179-B1289 ehae179-B1290 ehae179-B1291 ehae179-B1292 ehae179-B1293 ehae179-B1294" class="link link-ref link-reveal xref-bibr">1288–1294</a></sup> Open surgery is reserved for unsuitable cases, and fenestration could be considered as an ultima ratio. In selected instances, correcting side branch compression before proximal sealing may be considered.<sup><a href="javascript:;" reveal-id="ehae179-B136" data-open="ehae179-B136" class="link link-ref link-reveal xref-bibr">136</a></sup>

In recent years, the ADSORB (Acute Dissection Stentgraft OR Best Medical Treatment) and INSTEAD-XL (Investigation of Stent Grafts in Aortic Dissection with extended length of follow-up) trials<sup><a href="javascript:;" reveal-id="ehae179-B1219" data-open="ehae179-B1219" class="link link-ref link-reveal xref-bibr">1219</a>,<a href="javascript:;" reveal-id="ehae179-B1226" data-open="ehae179-B1226" class="link link-ref link-reveal xref-bibr">1226</a>,<a href="javascript:;" reveal-id="ehae179-B1295" data-open="ehae179-B1295" class="link link-ref link-reveal xref-bibr">1295</a></sup> have reported that early intervention for uncomplicated acute and subacute TBAD is beneficial compared with medical management, and there is important debate on whether to treat patients with uncomplicated acute TBAD to improve their life expectancy.<sup><a href="javascript:;" reveal-id="ehae179-B1296 ehae179-B1297 ehae179-B1298" data-open="ehae179-B1296 ehae179-B1297 ehae179-B1298" class="link link-ref link-reveal xref-bibr">1296–1298</a></sup> Intervention is considered early within 90 days after onset of symptoms and may be safer when performed in the subacute phase (>14 days after onset of symptoms), but data are scarce.<sup><a href="javascript:;" reveal-id="ehae179-B1298 ehae179-B1299 ehae179-B1300" data-open="ehae179-B1298 ehae179-B1299 ehae179-B1300" class="link link-ref link-reveal xref-bibr">1298–1300</a></sup> The Society of Thoracic Surgeons/American Association for Thoracic Surgery (STS/AATS) 2022 guidelines<sup><a href="javascript:;" reveal-id="ehae179-B1294" data-open="ehae179-B1294" class="link link-ref link-reveal xref-bibr">1294</a></sup> state that prophylactic TEVAR may be considered also in patients with suitable anatomy and high-risk features (_[Figure 33](javascript:;)_) to reduce late aortic-related adverse events. However, this matter is not entirely settled, and the Improving outcomes in vascular disease—aortic dissection (IMPROVE-AD trial) is currently underway. This trial aims to evaluate clinical outcomes in patients with subacute (from 48 h to 6 weeks) uncomplicated type B aortic dissection (uTBAD), comparing upfront TEVAR plus medical therapy against medical therapy with surveillance for deterioration.

Aortic characteristics change over time, and endovascular treatment in the chronic phase offers limited potential for aortic remodelling. Identifying specific characteristics at the time of acute TBAD diagnosis that predict a complicated course has been attempted. Independent predictors of TBAD outcomes include a primary entry tear >10 mm located at the inner aortic curvature,<sup><a href="javascript:;" reveal-id="ehae179-B1301" data-open="ehae179-B1301" class="link link-ref link-reveal xref-bibr">1301</a></sup> initial aortic diameter >40 mm,<sup><a href="javascript:;" reveal-id="ehae179-B1301" data-open="ehae179-B1301" class="link link-ref link-reveal xref-bibr">1301</a>,<a href="javascript:;" reveal-id="ehae179-B1302" data-open="ehae179-B1302" class="link link-ref link-reveal xref-bibr">1302</a></sup> initial FL diameter >20 mm,<sup><a href="javascript:;" reveal-id="ehae179-B1301" data-open="ehae179-B1301" class="link link-ref link-reveal xref-bibr">1301</a></sup> number/size of fenestrations between the true lumen and FL,<sup><a href="javascript:;" reveal-id="ehae179-B1303" data-open="ehae179-B1303" class="link link-ref link-reveal xref-bibr">1303</a></sup> stent graft-induced new entry tear,<sup><a href="javascript:;" reveal-id="ehae179-B1304" data-open="ehae179-B1304" class="link link-ref link-reveal xref-bibr">1304</a>,<a href="javascript:;" reveal-id="ehae179-B1305" data-open="ehae179-B1305" class="link link-ref link-reveal xref-bibr">1305</a></sup> and partial FL thrombosis.<sup><a href="javascript:;" reveal-id="ehae179-B1306" data-open="ehae179-B1306" class="link link-ref link-reveal xref-bibr">1306</a>,<a href="javascript:;" reveal-id="ehae179-B1307" data-open="ehae179-B1307" class="link link-ref link-reveal xref-bibr">1307</a></sup> These parameters are summarized in a new system for the categorization of AD, DISSECT (**D**uration from onset of symptoms, **I**ntimal tear location, **S**ize of the aorta based on maximum trans-aortic diameter, **S**egmental Extent, **C**linical complications related to the dissection, **T**hrombosis of the FL),<sup><a href="javascript:;" reveal-id="ehae179-B1308" data-open="ehae179-B1308" class="link link-ref link-reveal xref-bibr">1308</a></sup> which serves as a guide to support a therapeutic decision (_[Figure 33](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B1308" data-open="ehae179-B1308" class="link link-ref link-reveal xref-bibr">1308</a></sup> A recent meta-analysis found TEVAR to be superior to best medical therapy in uncomplicated acute TBAD. Early outcomes were similar, but TEVAR was associated with fewer long-term events and better aortic remodelling.<sup><a href="javascript:;" reveal-id="ehae179-B1297" data-open="ehae179-B1297" class="link link-ref link-reveal xref-bibr">1297</a>,<a href="javascript:;" reveal-id="ehae179-B1298" data-open="ehae179-B1298" class="link link-ref link-reveal xref-bibr">1298</a>,<a href="javascript:;" reveal-id="ehae179-B1309" data-open="ehae179-B1309" class="link link-ref link-reveal xref-bibr">1309</a></sup> Thus, in stable TBAD with suitable anatomy and high-risk features, pre-emptive TEVAR to improve the late outcome should be considered.

Accurate endograft sizing is vital for TEVAR success, as errors may lead to complications. Disease-specific factors, such as acute thoracic aortic syndromes, pose challenges due to fluctuations in aorta diameter from haemorrhagic shock and resuscitation. Sizing decisions must account for these changes. Measuring the thoracic aorta based on admission CCT may be imprecise, even with proper centreline measurements. Real-time imaging, especially IVUS, enhances accuracy, particularly in hypovolaemic cases. However, further research is required to clarify the role of intraoperative imaging methods (e.g. IVUS, TOE, 3D CCT) in endograft sizing and long-term outcomes for optimal patient care.<sup><a href="javascript:;" reveal-id="ehae179-B194" data-open="ehae179-B194" class="link link-ref link-reveal xref-bibr">194</a></sup>

Recommendation Table 49

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846460)

Recommendations for the management of patients presenting with acute type B aortic dissection

![Recommendations for the management of patients presenting with acute type B aortic dissection](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt49.jpeg?Expires=1728479088&Signature=qyhrCeioHfDYnsxELeniTDtvuOMOTVeasYZtSmno0WPPJDKXnNL7Mu9A34lbluJDVa6aodQU4Ca-wVY73BTP8KLGFX3Q9kzRHI0cSTyRfXzDbS7Lk2oQe77KB4wBgSAr5ISqP6gCrepLG7dcK9zjzaL1hd7ArqTRexyLnMCzvqRfchwUNKyHrXmSkcKIbw9b1uiJVlPH4Q2wScEnAsEXIzHRu02nntj6iZftB3vUDL7yu12kic5YHDA-uK~SRPda1t5xfmkZSuWuO0t3tO0jb8b3wxuucg~hY~kS~e7xZrnMTjJCnCluWlSanIwYGGCXu0ETzejz9jpH4fQ8cgZkLA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

###### Chronic type B aortic dissection interventional treatment

Type B aortic dissection is considered as chronic 3 months after the onset of symptoms, but it also includes residual type B dissection after repair of TAAD. Aortic complications, especially aneurysmal degeneration, will occur in up to 50% of these patients.<sup><a href="javascript:;" reveal-id="ehae179-B1302" data-open="ehae179-B1302" class="link link-ref link-reveal xref-bibr">1302</a>,<a href="javascript:;" reveal-id="ehae179-B1313" data-open="ehae179-B1313" class="link link-ref link-reveal xref-bibr">1313</a></sup> Therefore, in chronic TBAD, indications for treatment include the onset of new aortic symptoms such as rapid expansion, malperfusion, or rupture.<sup><a href="javascript:;" reveal-id="ehae179-B1314" data-open="ehae179-B1314" class="link link-ref link-reveal xref-bibr">1314</a></sup> In asymptomatic patients, aneurysmal dilatation is the most important risk factor for rupture, reaching 20% when the diameter exceeds 55 mm.<sup><a href="javascript:;" reveal-id="ehae179-B1302" data-open="ehae179-B1302" class="link link-ref link-reveal xref-bibr">1302</a>,<a href="javascript:;" reveal-id="ehae179-B1315" data-open="ehae179-B1315" class="link link-ref link-reveal xref-bibr">1315</a></sup> Risk of rupture increases with diameter; it has been reported a risk of 15.3% and 18.8% between 50–55 mm and 54–56 mm, respectively, thus suggesting 50–55 mm as a threshold for elective surgery.<sup><a href="javascript:;" reveal-id="ehae179-B1316" data-open="ehae179-B1316" class="link link-ref link-reveal xref-bibr">1316</a></sup> However, smaller diameters should be considered in patients with HTAD. According to several studies, mortality in the chronic phase is high (40%–70%) and it is mainly related to patients’ comorbidities, such as heart disease and stroke.

Open repair

Despite the lack of data comparing open repair vs. TEVAR in chronic TBAD, open surgery remains the first-line treatment in low-risk patients or those with HTAD. The STS/AATS guidelines<sup><a href="javascript:;" reveal-id="ehae179-B1294" data-open="ehae179-B1294" class="link link-ref link-reveal xref-bibr">1294</a></sup> state that open repair should be considered in chronic TBAD patients with indication for intervention, unless comorbidities are prohibitive or anatomy is not suitable for TEVAR. The surgical technique for chronic TBAD is like those for degenerative aneurysms, but repair is more complex due to the dissection flap.<sup><a href="javascript:;" reveal-id="ehae179-B1317" data-open="ehae179-B1317" class="link link-ref link-reveal xref-bibr">1317</a></sup> Surgical mortality rates between 6% and 11% and SCI rates between 3% and 11% have been reported.<sup><a href="javascript:;" reveal-id="ehae179-B1317 ehae179-B1318 ehae179-B1319 ehae179-B1320 ehae179-B1321" data-open="ehae179-B1317 ehae179-B1318 ehae179-B1319 ehae179-B1320 ehae179-B1321" class="link link-ref link-reveal xref-bibr">1317–1321</a></sup> Patients treated in low-volume centres present higher mortality rates (up to 20%), which reinforces the recommendation for centralization in experienced centres.

Endovascular repair

Thoracic endovascular aortic aneurysm repair (TEVAR) is the preferred treatment for eligible chronic TBAD patients, offering low early mortality (<5%), with stroke and SCI rates below 3%. It is also suitable for high-risk patients who are not candidates for open repair. The primary goal is to close the entry tear, induce FL thrombosis, and promote aortic remodelling to mitigate growth and rupture risk.<sup><a href="javascript:;" reveal-id="ehae179-B1322" data-open="ehae179-B1322" class="link link-ref link-reveal xref-bibr">1322</a>,<a href="javascript:;" reveal-id="ehae179-B1323" data-open="ehae179-B1323" class="link link-ref link-reveal xref-bibr">1323</a></sup> A systematic review showed 90% immediate technical success and 86% complete FL thrombosis. However, FL thrombosis usually occurs above the coeliac trunk, necessitating lifelong distal FL surveillance.<sup><a href="javascript:;" reveal-id="ehae179-B1324" data-open="ehae179-B1324" class="link link-ref link-reveal xref-bibr">1324</a></sup> Coverage of the LSA is often necessary and should be associated with revascularization. In a recent meta-analysis<sup><a href="javascript:;" reveal-id="ehae179-B1325" data-open="ehae179-B1325" class="link link-ref link-reveal xref-bibr">1325</a></sup> comparing TEVAR to open repair in chronic TBAD, TEVAR showed lower early mortality, stroke rates, SCI, and respiratory complications but a higher re-intervention rate. Long-term survival rates were similar, but open repair offered greater durability.<sup><a href="javascript:;" reveal-id="ehae179-B1326" data-open="ehae179-B1326" class="link link-ref link-reveal xref-bibr">1326</a></sup>

Adequate distal sealing poses a challenge due to the dissection extending to the iliac artery, with additional re-entries, allowing retrograde flow into the thoracic aneurysm. In chronic TBAD patients with AA enlargement, insufficient distal landing, or large re-entry tears, TEVAR alone is discouraged. Instead, a comprehensive repair involving the visceral aorta, infra-renal aorta, and iliac artery is needed. Recent studies have shown favourable results using custom or improvized fenestrated/branched endografts with careful patient selection.<sup><a href="javascript:;" reveal-id="ehae179-B1062" data-open="ehae179-B1062" class="link link-ref link-reveal xref-bibr">1062</a>,<a href="javascript:;" reveal-id="ehae179-B1327 ehae179-B1328 ehae179-B1329" data-open="ehae179-B1327 ehae179-B1328 ehae179-B1329" class="link link-ref link-reveal xref-bibr">1327–1329</a></sup> A multidisciplinary team-based approach in experienced centres is necessary for good outcomes.<sup><a href="javascript:;" reveal-id="ehae179-B1330" data-open="ehae179-B1330" class="link link-ref link-reveal xref-bibr">1330</a></sup>

Recommendation Table 50

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846468)

Recommendations for the management of patients presenting with chronic type B aortic dissection

![Recommendations for the management of patients presenting with chronic type B aortic dissection](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt50.jpeg?Expires=1728479088&Signature=eqzLu5~O5mTP-EwUN6F4-WqBdDCBeLML3PQa-gsGQ8pKpZmRozNgtZ3V-zN0JDPzpjtKF-0nzPeYo1BQW9CkCGw9scMf2FtHibNXq0yBzPfe1K1LGoqmuJ01pu-ZQgtXsa9DbZU9V-aWYUQB5y09xiRMULYR~Vw7jQV6gMLngAfunD1IlWj9NBmyxdmyfgH2hk305BygunIS42-upeGYV-jlUoCAuklTNPDxy~9W2P6EPvzRbWtiE0wNaVlzrDBF5X2QxJLka7SGzYZfUvqD-jNNlsskyjkxePZVKKR-2kqcrvh5hMBT4Iuhn~WlVmDUT~SsL1ybSuaX4UqmmFWApg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

###### Management during pregnancy

Management of AD during pregnancy requires a multidisciplinary team and specialized centres. Initial care should consider general medical recommendations (as previously described), using drugs with the lowest teratogenic impact.

In cases of type A dissection, if the foetus is viable, caesarean delivery will be performed before aortic repair. If the foetus is not viable, surgery will be done with the foetus in place.<sup><a href="javascript:;" reveal-id="ehae179-B1335" data-open="ehae179-B1335" class="link link-ref link-reveal xref-bibr">1335</a>,<a href="javascript:;" reveal-id="ehae179-B1336" data-open="ehae179-B1336" class="link link-ref link-reveal xref-bibr">1336</a></sup> In uncomplicated type B dissections, strict control of the pregnant patient and foetus with conservative medical management is recommended.<sup><a href="javascript:;" reveal-id="ehae179-B1224" data-open="ehae179-B1224" class="link link-ref link-reveal xref-bibr">1224</a>,<a href="javascript:;" reveal-id="ehae179-B1335" data-open="ehae179-B1335" class="link link-ref link-reveal xref-bibr">1335</a></sup> Although limited to selected cases, successful TEVAR has been described in complicated TBAD.<sup><a href="javascript:;" reveal-id="ehae179-B1227" data-open="ehae179-B1227" class="link link-ref link-reveal xref-bibr">1227</a></sup> More information is detailed in the _2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy_.<sup><a href="javascript:;" reveal-id="ehae179-B1337" data-open="ehae179-B1337" class="link link-ref link-reveal xref-bibr">1337</a></sup>

#### 9.3.2. Intramural haematoma

Intramural haematoma, constituting 5%–25% of AAS cases, involves vasa vasorum haemorrhage within the aortic media, with or without intimal disruption (ID).<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B172" data-open="ehae179-B172" class="link link-ref link-reveal xref-bibr">172</a>,<a href="javascript:;" reveal-id="ehae179-B1338" data-open="ehae179-B1338" class="link link-ref link-reveal xref-bibr">1338</a></sup> Most cases (60%–70%) involve the DTA (ascending aorta ∼30%, aortic arch ∼10%).<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B172" data-open="ehae179-B172" class="link link-ref link-reveal xref-bibr">172</a>,<a href="javascript:;" reveal-id="ehae179-B1192" data-open="ehae179-B1192" class="link link-ref link-reveal xref-bibr">1192</a></sup> Although it usually occurs at an older age than AAD, risk factors and symptoms are similar;<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B172" data-open="ehae179-B172" class="link link-ref link-reveal xref-bibr">172</a>,<a href="javascript:;" reveal-id="ehae179-B1192" data-open="ehae179-B1192" class="link link-ref link-reveal xref-bibr">1192</a>,<a href="javascript:;" reveal-id="ehae179-B1338" data-open="ehae179-B1338" class="link link-ref link-reveal xref-bibr">1338</a></sup> however, aortic regurgitation, malperfusion syndrome, and pulse deficits are less frequent in type A IMH than in TAAD.<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B172" data-open="ehae179-B172" class="link link-ref link-reveal xref-bibr">172</a></sup>

##### 9.3.2.1. Diagnostic work-up

Diagnostic IMH work-up should be similar to that proposed for AAS (_[Figure 30](javascript:;)_), but with different morphological features in the imaging techniques.

CCT and CMR (followed by TOE) are the leading techniques for diagnosis.<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B159" data-open="ehae179-B159" class="link link-ref link-reveal xref-bibr">159</a>,<a href="javascript:;" reveal-id="ehae179-B171 ehae179-B172 ehae179-B173" data-open="ehae179-B171 ehae179-B172 ehae179-B173" class="link link-ref link-reveal xref-bibr">171–173</a></sup> Unenhanced followed by contrast-enhanced CCT represents the most used tool in the acute setting (hyperintense signal of aortic wall before contrast administration).<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B171" data-open="ehae179-B171" class="link link-ref link-reveal xref-bibr">171</a>,<a href="javascript:;" reveal-id="ehae179-B172" data-open="ehae179-B172" class="link link-ref link-reveal xref-bibr">172</a></sup> The IMH diagnostic hallmark consists of crescentic or circular aortic wall thickening in the absence of an intimal flap or aortic wall enhancement following contrast administration.<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B171" data-open="ehae179-B171" class="link link-ref link-reveal xref-bibr">171</a>,<a href="javascript:;" reveal-id="ehae179-B172" data-open="ehae179-B172" class="link link-ref link-reveal xref-bibr">172</a></sup> CMR is an excellent imaging technique to detect small IMHs and for the differentiation of IMH (hyperenhanced images in T1-weighted images) from atherosclerotic thickening of the aorta, thrombus, or thrombosed dissection.<sup><a href="javascript:;" reveal-id="ehae179-B172" data-open="ehae179-B172" class="link link-ref link-reveal xref-bibr">172</a></sup> TTE yields low sensitivity (<40% for IMH cut-off limit of 5 mm).<sup><a href="javascript:;" reveal-id="ehae179-B171" data-open="ehae179-B171" class="link link-ref link-reveal xref-bibr">171</a></sup>

##### 9.3.2.2. Clinical outcomes

Intramural haematoma may evolve into AAD (12% of patients), saccular (8%) or fusiform aneurysm (22%), and/or ID (54%).<sup><a href="javascript:;" reveal-id="ehae179-B1192" data-open="ehae179-B1192" class="link link-ref link-reveal xref-bibr">1192</a>,<a href="javascript:;" reveal-id="ehae179-B1339 ehae179-B1340 ehae179-B1341 ehae179-B1342" data-open="ehae179-B1339 ehae179-B1340 ehae179-B1341 ehae179-B1342" class="link link-ref link-reveal xref-bibr">1339–1342</a></sup> Partial or total regression is reported in 34% of patients.<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B1192" data-open="ehae179-B1192" class="link link-ref link-reveal xref-bibr">1192</a>,<a href="javascript:;" reveal-id="ehae179-B1343" data-open="ehae179-B1343" class="link link-ref link-reveal xref-bibr">1343</a></sup> Outcomes are comparable to those in AAD. In-hospital mortality for type A IMH is 26.6% (surgical 24.1% and medical 40.0%). In this regard, higher mortality for IMH involving the aortic valvular complex has been observed.<sup><a href="javascript:;" reveal-id="ehae179-B1175" data-open="ehae179-B1175" class="link link-ref link-reveal xref-bibr">1175</a></sup> In-hospital mortality for type B IMH is 4.4% but worsens once surgery is indicated (surgical 20.0% vs. medical 3.8%).<sup><a href="javascript:;" reveal-id="ehae179-B1175" data-open="ehae179-B1175" class="link link-ref link-reveal xref-bibr">1175</a>,<a href="javascript:;" reveal-id="ehae179-B1344" data-open="ehae179-B1344" class="link link-ref link-reveal xref-bibr">1344</a></sup>

##### 9.3.2.3. Geographical variations

Reports from South Korea and Japan reveal notable disparities with Western nations in IMH incidence (28.9% vs. 5.7% of overall AAD as reported by IRAD), treatment strategies, and outcomes. In Eastern regions, the majority (80.8%) of type A IMH patients received medical treatment, resulting in significantly improved clinical outcomes (in-hospital mortality 6.6% \[5.9% for medical and 9.4% for surgical\]).<sup><a href="javascript:;" reveal-id="ehae179-B1345" data-open="ehae179-B1345" class="link link-ref link-reveal xref-bibr">1345</a></sup> These results may be partially explained by the detection of early-stage IMH (mild, uncomplicated cases) at primary centres.<sup><a href="javascript:;" reveal-id="ehae179-B1345 ehae179-B1346 ehae179-B1347" data-open="ehae179-B1345 ehae179-B1346 ehae179-B1347" class="link link-ref link-reveal xref-bibr">1345–1347</a></sup>

##### 9.3.2.4. Management

Current IMH therapeutic interventions are similar to AAD, with the first step consisting mainly of pain and BP control regardless of the anatomopathological features (_[Figure 31](javascript:;)_).

###### Type A intramural haematoma

As in AAD, type A IMH involves the ascending aorta. Surgery (emergency or urgent depending on clinical status) is recommended. In selected patients with increased operative risk (i.e. multiple comorbidities) and uncomplicated type A IMH without high-risk imaging features (_[Table 16](javascript:;)_) a ‘wait-and-see strategy’ in a reference/experienced centre may be reasonable.<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B172" data-open="ehae179-B172" class="link link-ref link-reveal xref-bibr">172</a>,<a href="javascript:;" reveal-id="ehae179-B1348" data-open="ehae179-B1348" class="link link-ref link-reveal xref-bibr">1348</a>,<a href="javascript:;" reveal-id="ehae179-B1349" data-open="ehae179-B1349" class="link link-ref link-reveal xref-bibr">1349</a></sup>

Table 16

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846485)

High-risk features of intramural haematoma type A and B

<table role="presentation" aria-labelledby="
                        label-97282" aria-describedby="
                        caption-97282"><tbody><tr><td>Ascending aorta involvement</td></tr><tr><td>Difficult BP control</td></tr><tr><td>Persistent/recurrent pain despite aggressive BP control</td></tr><tr><td>Maximum aortic diameter:<ul class="bullet"><li><p class="chapter-para">Type A: &gt;45–50 mm</p></li><li><p class="chapter-para">Type B: &gt;47–50 mm</p></li></ul></td></tr><tr><td>Progression to aortic dissection</td></tr><tr><td>Focal intimal disruption with ulcer-like projection</td></tr><tr><td>Haematoma thickness &gt;10 mm (type A) or &gt;13 mm (type B)</td></tr><tr><td>Enlarging haematoma thickness</td></tr><tr><td>Enlarging aortic diameter</td></tr><tr><td>Pericardial effusion at admission (type A)</td></tr><tr><td>Recurrent pleural effusion</td></tr><tr><td>Detection of organ malperfusion</td></tr></tbody></table>

BP, blood pressure.

Adapted with permission from.<sup><a href="javascript:;" reveal-id="ehae179-B172" data-open="ehae179-B172" class="link link-ref link-reveal xref-bibr">172</a></sup>

© ESC 2024

###### Type B intramural haematoma

In type B IMH, the disease is in the descending aorta, distal to the left subclavian artery. For uncomplicated type B IMH, initial management involves medical treatment and thorough clinical and imaging monitoring.<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B172" data-open="ehae179-B172" class="link link-ref link-reveal xref-bibr">172</a></sup> If uncomplicated type B IMH presents high-risk imaging characteristics (see _[Table 16](javascript:;)_), the multidisciplinary team should consider endovascular repair as an option. In contrast, complicated type B IMH warrants consideration of TEVAR.<sup><a href="javascript:;" reveal-id="ehae179-B1350" data-open="ehae179-B1350" class="link link-ref link-reveal xref-bibr">1350</a>,<a href="javascript:;" reveal-id="ehae179-B1351" data-open="ehae179-B1351" class="link link-ref link-reveal xref-bibr">1351</a></sup> However, in unfavourable anatomy, open surgery remains an alternative.

ID has been described in 54% of type B IMH cases.<sup><a href="javascript:;" reveal-id="ehae179-B1192" data-open="ehae179-B1192" class="link link-ref link-reveal xref-bibr">1192</a>,<a href="javascript:;" reveal-id="ehae179-B1339 ehae179-B1340 ehae179-B1341 ehae179-B1342" data-open="ehae179-B1339 ehae179-B1340 ehae179-B1341 ehae179-B1342" class="link link-ref link-reveal xref-bibr">1339–1342</a></sup> Approximately 28% of them are tiny intimal disruptions (≤3 mm) that are not related to AAEs. However, 14% of them evolve into focal intimal disruptions (FID) (>3 mm), with prognostic implications; thus, all patients with ID require close follow-up with imaging techniques. In the acute phase, FID has a poor prognosis owing to the high risk of aortic rupture and should be treated early and invasively, especially large FID (≥10 mm length and ≥5 mm depth).<sup><a href="javascript:;" reveal-id="ehae179-B1342" data-open="ehae179-B1342" class="link link-ref link-reveal xref-bibr">1342</a>,<a href="javascript:;" reveal-id="ehae179-B1352" data-open="ehae179-B1352" class="link link-ref link-reveal xref-bibr">1352</a></sup> However, in the chronic phase, most FIDs evolve with slow aortic dilatation and without complications, and they can be managed with medical treatment and close imaging surveillance.<sup><a href="javascript:;" reveal-id="ehae179-B1352" data-open="ehae179-B1352" class="link link-ref link-reveal xref-bibr">1352</a></sup>

Recommendation Table 51

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846489)

Recommendations for the management of intramural haematoma

![Recommendations for the management of intramural haematoma](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt51.jpeg?Expires=1728479088&Signature=LsF96JpIe68qkTBRM2AqimeZLmBghUi00jFWG5LsWGtoCS5nBbzO5pzBePM8k3l2jhEZIn860iMGSRiG2lHyb4RqtgyX6AkxE~WXRf6ijt8aRP6W7bKaKLSCgwAdJb2muhuNgP4XDJfyY2xy6ILkvuowut2v1OBLnCf~UzY9EsgYlDXdM1sYhJsLTIJdU9cbwa0VTgVrzsNyW49jDPIffEIrB6xmlUMP1OcB7DT2W4Jve6I39TbAvHt8Z8IJwURS04f3Yq3Sy2z1tU7tPEn55XgaFq3CdoTpsiz8zBgFN8C-E76ZWYsfI0VKGp7YgnRSI3HW-ya5uJc5LQvyJrIxTA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 9.3.3. Penetrating atherosclerotic ulcer

Penetrating atherosclerotic ulcer (2%–7% of all AAS cases) is characterized by localized ulceration of an aortic atherosclerotic plaque penetrating through the internal elastic lamina into the media, frequently associated with IMH and diffuse atherosclerosis.<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B172" data-open="ehae179-B172" class="link link-ref link-reveal xref-bibr">172</a>,<a href="javascript:;" reveal-id="ehae179-B174" data-open="ehae179-B174" class="link link-ref link-reveal xref-bibr">174</a>,<a href="javascript:;" reveal-id="ehae179-B910" data-open="ehae179-B910" class="link link-ref link-reveal xref-bibr">910</a>,<a href="javascript:;" reveal-id="ehae179-B1338" data-open="ehae179-B1338" class="link link-ref link-reveal xref-bibr">1338</a>,<a href="javascript:;" reveal-id="ehae179-B1343" data-open="ehae179-B1343" class="link link-ref link-reveal xref-bibr">1343</a></sup>

Often, multiple PAUs are present, ranging from 5 to 25 mm in diameter and 4 to 30 mm in depth.<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B172" data-open="ehae179-B172" class="link link-ref link-reveal xref-bibr">172</a>,<a href="javascript:;" reveal-id="ehae179-B174" data-open="ehae179-B174" class="link link-ref link-reveal xref-bibr">174</a>,<a href="javascript:;" reveal-id="ehae179-B1338" data-open="ehae179-B1338" class="link link-ref link-reveal xref-bibr">1338</a></sup> They occur mostly in the middle and lower DTA, with the aortic arch and AA less involved. The ascending aorta is rarely affected,<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B172" data-open="ehae179-B172" class="link link-ref link-reveal xref-bibr">172</a>,<a href="javascript:;" reveal-id="ehae179-B910" data-open="ehae179-B910" class="link link-ref link-reveal xref-bibr">910</a>,<a href="javascript:;" reveal-id="ehae179-B1192" data-open="ehae179-B1192" class="link link-ref link-reveal xref-bibr">1192</a></sup> but when this occurs, especially complicated with IMH, the risk of rupture is 33%–75% and progression to dissection is associated with a high mortality rate.

Most patients are older males, smokers, aged >65, with multiple comorbidities like systemic hypertension, CAD, COPD, renal insufficiency, and concurrent abdominal aneurysm.<sup><a href="javascript:;" reveal-id="ehae179-B24" data-open="ehae179-B24" class="link link-ref link-reveal xref-bibr">24</a>,<a href="javascript:;" reveal-id="ehae179-B172" data-open="ehae179-B172" class="link link-ref link-reveal xref-bibr">172</a>,<a href="javascript:;" reveal-id="ehae179-B910" data-open="ehae179-B910" class="link link-ref link-reveal xref-bibr">910</a>,<a href="javascript:;" reveal-id="ehae179-B1357" data-open="ehae179-B1357" class="link link-ref link-reveal xref-bibr">1357</a></sup>

Symptoms are like those in AAD and may manifest in older age after a long asymptomatic phase (often PAU is diagnosed as an incidental finding during an imaging examination).<sup><a href="javascript:;" reveal-id="ehae179-B24" data-open="ehae179-B24" class="link link-ref link-reveal xref-bibr">24</a>,<a href="javascript:;" reveal-id="ehae179-B172" data-open="ehae179-B172" class="link link-ref link-reveal xref-bibr">172</a>,<a href="javascript:;" reveal-id="ehae179-B910" data-open="ehae179-B910" class="link link-ref link-reveal xref-bibr">910</a>,<a href="javascript:;" reveal-id="ehae179-B1357" data-open="ehae179-B1357" class="link link-ref link-reveal xref-bibr">1357</a></sup> It should be highlighted that symptom onset may indicate PAU expansion (tunica adventitia involvement); thus, urgent imaging (CCT or CMR) and appropriate therapeutic intervention are needed to prevent aortic rupture.<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B171" data-open="ehae179-B171" class="link link-ref link-reveal xref-bibr">171</a>,<a href="javascript:;" reveal-id="ehae179-B172" data-open="ehae179-B172" class="link link-ref link-reveal xref-bibr">172</a>,<a href="javascript:;" reveal-id="ehae179-B174" data-open="ehae179-B174" class="link link-ref link-reveal xref-bibr">174</a></sup>

##### 9.3.3.1. Diagnosis

Diagnostic work-up is described in _[Figure 30](javascript:;)_. CCT represents the technique of choice for diagnosis. TOE and CMR represent possible valid alternatives considering availability and local expertise.<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B159" data-open="ehae179-B159" class="link link-ref link-reveal xref-bibr">159</a>,<a href="javascript:;" reveal-id="ehae179-B171 ehae179-B172 ehae179-B173" data-open="ehae179-B171 ehae179-B172 ehae179-B173" class="link link-ref link-reveal xref-bibr">171–173</a></sup> Of note, <sup>18</sup>FDG-PET-CT is a promising technique since it can detect increased glucose uptake in PAUs as a marker of increased metabolic activity and inflammation, which has been associated with major adverse events.<sup><a href="javascript:;" reveal-id="ehae179-B1358" data-open="ehae179-B1358" class="link link-ref link-reveal xref-bibr">1358</a>,<a href="javascript:;" reveal-id="ehae179-B1359" data-open="ehae179-B1359" class="link link-ref link-reveal xref-bibr">1359</a></sup> This information may be used to guide treatment decisions, such as the selection of patients who may benefit from endovascular or surgical intervention.<sup><a href="javascript:;" reveal-id="ehae179-B1360" data-open="ehae179-B1360" class="link link-ref link-reveal xref-bibr">1360</a></sup>

##### 9.3.3.2. Treatment

Medical treatment as described for AD is recommended (_[Figure 31](javascript:;)_). Management of incidental cases is not clearly defined.<sup><a href="javascript:;" reveal-id="ehae179-B174" data-open="ehae179-B174" class="link link-ref link-reveal xref-bibr">174</a></sup> Small series suggest that isolated, asymptomatic, small PAUs may be safely managed conservatively with regular surveillance.<sup><a href="javascript:;" reveal-id="ehae179-B1361" data-open="ehae179-B1361" class="link link-ref link-reveal xref-bibr">1361</a>,<a href="javascript:;" reveal-id="ehae179-B1362" data-open="ehae179-B1362" class="link link-ref link-reveal xref-bibr">1362</a></sup>

Surgery is recommended in type A PAU with the option of a ‘wait-and-see strategy’ in highly selected high-risk patients with no high-risk features (_[Figure 35](javascript:;)_). However, in uncomplicated type B PAU, medical treatment along with careful clinical and imaging surveillance is recommended.<sup><a href="javascript:;" reveal-id="ehae179-B174" data-open="ehae179-B174" class="link link-ref link-reveal xref-bibr">174</a>,<a href="javascript:;" reveal-id="ehae179-B1350" data-open="ehae179-B1350" class="link link-ref link-reveal xref-bibr">1350</a></sup> When intervention is needed, endovascular treatment (early and 3 year aortic mortality 7.2% and 10.4%, respectively)<sup><a href="javascript:;" reveal-id="ehae179-B1350" data-open="ehae179-B1350" class="link link-ref link-reveal xref-bibr">1350</a></sup> should be preferred to open surgery (early and 3 year aortic mortality of 15.9% and 25.0%, respectively).<sup><a href="javascript:;" reveal-id="ehae179-B174" data-open="ehae179-B174" class="link link-ref link-reveal xref-bibr">174</a>,<a href="javascript:;" reveal-id="ehae179-B1350" data-open="ehae179-B1350" class="link link-ref link-reveal xref-bibr">1350</a></sup> In cases of uncomplicated PAU with high-risk imaging features<sup><a href="javascript:;" reveal-id="ehae179-B1363 ehae179-B1364 ehae179-B1365" data-open="ehae179-B1363 ehae179-B1364 ehae179-B1365" class="link link-ref link-reveal xref-bibr">1363–1365</a></sup> (_[Figure 35](javascript:;)_), endovascular treatment should also be considered. The natural history of PAU of the abdominal aorta (AA) with associated IMH is less known. In a review of PAU of the AA, endovascular stenting was the preferred treatment of choice (62%), followed by open surgical repair (35%) and conservative therapy (3%).<sup><a href="javascript:;" reveal-id="ehae179-B1366" data-open="ehae179-B1366" class="link link-ref link-reveal xref-bibr">1366</a></sup>

![High-risk features in penetrating atherosclerotic ulcer and management of patients with type B penetrating atherosclerotic ulcer.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f35.jpeg?Expires=1728479088&Signature=wHQ~St2VAuCifGda015xQut~C5qgHJ9m~-LLKR3hKNffkWY~ejqwRb3mC~zoWi59p3B-X2rCZMkOA5DiA-l8OJg3T7lkS4CD7ZLBhGkXpV6bZnPm9DXFP8bnyXCsWkhFXKpNEeIvkLHnFgNvh7j8SPCoUwzXj5beIyLHcGVhItVet2DEKhbUZt8~Q5PGcwoddyY55LXH~-2hzLeV9pA12ORLxCRx0F7j8xKbnugW9JdVr580LX2MpL~NH2A9dmqu-r14-3MLXNfjdp37jit01ThRJBLfbbcB-SqNXo0SrW1YIqIZfg0DMir6bBocoUmyNo2-RYX2CvnjXitBnk6VuA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 35

High-risk features in penetrating atherosclerotic ulcer and management of patients with type B penetrating atherosclerotic ulcer.

IMH, intramural haematoma; PAU, penetrating atherosclerotic ulcer; TEVAR, thoracic endovascular aortic repair. (_A_) Maximum PAU width. (_B_) Maximum PAU depth; (_C_) Maximal aortic diameter at the site of the PAU.<sup><a href="javascript:;" reveal-id="ehae179-B910" data-open="ehae179-B910" class="link link-ref link-reveal xref-bibr">910</a></sup>

[Open in new tab](https://academic.oup.com/view-large/figure/479846500/ehae179f35.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f35.jpeg?Expires=1728479088&Signature=ffBf2EJ2a9vpMIeITdhsTrhiTTBP09l6R-U15fDOTlBiN-wJ-ZRSM2rjZq0Eddi-pQLoGr8sPIk2CEoCUr-F7GYEOGVWt-zakHLlZmgRo-RsSPlO99Riecjb32ZAoA8NqDx29qWrJ6Fi6wO~oKUNXXdHPHeU3Ia16Nmtxfk6K82oP5kaRMII-UFvPQJESeO3jw77dH9Dzj0jvU5e7AxqhjIlHKn85dhD3AAVSMZ8YrA9nhZdYGg9xJT9kTYK~a4VgB90Eax4soANpqASWRZ7X9ClUR2pN-qa4YySLdKfNlFcb7~-Zsxq1EUR5Vkv6Df60Umhnwz5NrkDbOzZqVT06w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846500&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Recommendation Table 52

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846501)

Recommendations for the management of penetrating atherosclerotic ulcer

![Recommendations for the management of penetrating atherosclerotic ulcer](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt52.jpeg?Expires=1728479088&Signature=VgOo3nwWv5dVI1WB5whksBFLWYUlml8cFC6VPNz8a6mMD0G5BQQsEgfdbIvXaltH-ZLb4GCsb-gilICeDlwzQOkllqNA1v8W6~CrOqFYm1-f-ZRh5bFM6Prh4PNvtStFPU9UK7Kfa~h57eOhRU3axRO3f8iM7YzS4w~tBqqAcNReX4Bi4Fmsx6HVz7JACWr8EZXuA90mJUQvN17~VDoUeePjFDslpXwNzN4jlAxZXE2O0kRayRx97UjxEvooqx2aDmkJEZpRkxU6LGCyicRL3dMdupBU1atROI6q3tbJhvGud8Jydn4X8qF9uPHtFpmv38S0n-ObXhsEDeeBav3QLg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 9.3.4. Aortic pseudo-aneurysm

Aortic pseudo-aneurysms, or false aneurysms, result from aortic wall disruption, typically caused by factors like trauma,<sup><a href="javascript:;" reveal-id="ehae179-B1368" data-open="ehae179-B1368" class="link link-ref link-reveal xref-bibr">1368</a></sup> surgery, or infections. They are often symptomless, detected incidentally during post-aortic procedure imaging. Symptoms may include chest pain, compression, and if untreated, they can lead to fatal rupture or other severe complications.<sup><a href="javascript:;" reveal-id="ehae179-B1369" data-open="ehae179-B1369" class="link link-ref link-reveal xref-bibr">1369</a>,<a href="javascript:;" reveal-id="ehae179-B1370" data-open="ehae179-B1370" class="link link-ref link-reveal xref-bibr">1370</a></sup>

Pseudo-aneurysm repair seems always indicated regardless of size or position to prevent progression and rupture. Nevertheless, in some circumstances and under close follow-up, patients could be monitored by CCT, CMR, or TOE and intervention could be postponed unless size expansion, symptoms, or compression of surrounding structures occur.<sup><a href="javascript:;" reveal-id="ehae179-B1371" data-open="ehae179-B1371" class="link link-ref link-reveal xref-bibr">1371</a></sup> Pseudo-aneurysms could be treated by open surgery or endovascular treatment (occluders, stent grafts, or coils). There is no randomized study comparing open surgery vs. TEVAR; however, treatment of choice is commonly based on anatomical features, clinical presentation, and the patient’s comorbidities and decided by a multidisciplinary team in specialized centres.<sup><a href="javascript:;" reveal-id="ehae179-B1045" data-open="ehae179-B1045" class="link link-ref link-reveal xref-bibr">1045</a>,<a href="javascript:;" reveal-id="ehae179-B1371" data-open="ehae179-B1371" class="link link-ref link-reveal xref-bibr">1371</a></sup>

#### 9.3.5. Traumatic aortic injury

Traumatic aortic injury (TAI), commonly from high-speed motor accidents or falls, involves partial or complete aorta transection. It results from rapid deceleration causing torsion and shearing forces, often affecting relatively immobile aorta segments like the aortic isthmus (90%), aortic root (5%), or diaphragmatic hiatus (5%).<sup><a href="javascript:;" reveal-id="ehae179-B24" data-open="ehae179-B24" class="link link-ref link-reveal xref-bibr">24</a>,<a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B172" data-open="ehae179-B172" class="link link-ref link-reveal xref-bibr">172</a></sup>

Traumatic aortic injury is classified based on the degree of lesion in the aortic wall (_[Figure 36](javascript:;)_): grade I (intimal tear), grade II (IMH), grade III (pseudo-aneurysm), and grade IV (aortic rupture). In the Crash Injury Study, 130/613 deaths (21%) were associated with TAI (mortality associated with aortic rupture 91%; at-scene survival 9%).<sup><a href="javascript:;" reveal-id="ehae179-B1372" data-open="ehae179-B1372" class="link link-ref link-reveal xref-bibr">1372</a></sup>

![Classification and treatment of traumatic aortic injuries.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f36.jpeg?Expires=1728479088&Signature=fkd0PRnDIdTG5~bweFTPcyoVsFP96vsI88AhJfMT6Dq6fJCeKMQtsZf3bmi~HC-IhtCJsS21dfp1rjsh8L0v91AEOPcDGFeGI9JVdiAa3wenqFqRhKdwaa0WfMYh9pTki-bcS8ww~7wg3CpHhKqZnWC~IFEUTO-Wqad8iVQuRp8tJV7ewhQ0AUEwKymXRvTlTZSFQEK1TOPqWlScSAOYmUEkVW75WekEZnqEUiNiTh34LHegLlNwJZDy~ZoB0j4u926Y7Xft3kUrwZDUynBmQKVkH~mJOAEkyA-fa81HLoDl3sPcoRBJhPufslFS-uPilSqTO16Ps90Btjc07v0gcw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 36

Classification and treatment of traumatic aortic injuries.

Med, medical; OR, open surgery repair; TEVAR, thoracic endovascular aortic repair; Tx, treatment.

[Open in new tab](https://academic.oup.com/view-large/figure/479846508/ehae179f36.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f36.jpeg?Expires=1728479088&Signature=3-p9JEXE3LoK4NfEkNZwISbwaQZTNdpvz6Z14ggIBLEU31jrSnTaOfgrJLvDaZeBDLa-qO6Gk-eTDIzyFpDay7DHO5la6BlH0TozIAvTrt5px28hhYAsVgmZqlF5-aaMpjd-HBfX70rPwc60dzuxwwheREopt0QcrFrG~c5Xyd4n2xzqKxqwO94vdK4P~sTbOjVMa2mpvxoN8opxti56TwnKz1C2fjbL65xc~~AKjtmi6sGxq-8amdKlfByHIwAVno-kQibIYOV0bB3C7MdVL2GI6uj6KjHZIffWMHG3H3nE5Ys194tqVXi4DVCYd0OsSbQw1WwKJCxiOw5REeGSIg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846508&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

##### 9.3.5.1. Diagnosis and therapeutic interventions

Due to non-specific symptoms and signs (often obscured by concomitant multiple organ injury) a timely diagnosis relies on a high level of clinical suspicion.<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B172" data-open="ehae179-B172" class="link link-ref link-reveal xref-bibr">172</a></sup> CCT (accuracy close to 100%) represents the technique of choice, acting as a ‘one-stop shop’ to rapidly assess the entire skeletal system and internal organs.<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B171" data-open="ehae179-B171" class="link link-ref link-reveal xref-bibr">171</a>,<a href="javascript:;" reveal-id="ehae179-B172" data-open="ehae179-B172" class="link link-ref link-reveal xref-bibr">172</a></sup> TOE may be an alternative, although limited by availability, local expertise, and potentially a patient’s multiple traumas.<sup><a href="javascript:;" reveal-id="ehae179-B24" data-open="ehae179-B24" class="link link-ref link-reveal xref-bibr">24</a>,<a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B172" data-open="ehae179-B172" class="link link-ref link-reveal xref-bibr">172</a></sup> Therapeutic interventions are dependent on the extent of aorta lesion and patient clinical status as assessed by a multidisciplinary team. Generally, aggressive fluid administration should be avoided because it may exacerbate bleeding, coagulopathy, and hypertension. To reduce risk of rupture, mean BP should not exceed 80 mmHg.<sup><a href="javascript:;" reveal-id="ehae179-B172" data-open="ehae179-B172" class="link link-ref link-reveal xref-bibr">172</a></sup> Minimal aortic injury (grades 1 and 2) may be managed medically along with strict clinical and imaging surveillance; moderate aortic injury (grade 3) with semi-elective repair (within 24–72 h) to allow patient stabilization (though in some patients urgent repair is needed);<sup><a href="javascript:;" reveal-id="ehae179-B24" data-open="ehae179-B24" class="link link-ref link-reveal xref-bibr">24</a>,<a href="javascript:;" reveal-id="ehae179-B1373" data-open="ehae179-B1373" class="link link-ref link-reveal xref-bibr">1373</a></sup> and severe aortic injury (grade 4) with immediate repair.<sup><a href="javascript:;" reveal-id="ehae179-B1374" data-open="ehae179-B1374" class="link link-ref link-reveal xref-bibr">1374</a></sup> If there is progression of the IMH (grade 2), semi-elective repair (within 24–72 h) may be considered. TEVAR is preferred (if feasible) to open surgery (in-hospital mortality 7.9% vs. 20% and 1 year mortality 8.7% vs. 17%). In semi-elective repair, if the LSA needs to be covered, prior LSA revascularization before TEVAR is suggested to reduce the risk of paraplegia <sup><a href="javascript:;" reveal-id="ehae179-B172" data-open="ehae179-B172" class="link link-ref link-reveal xref-bibr">172</a>,<a href="javascript:;" reveal-id="ehae179-B1373" data-open="ehae179-B1373" class="link link-ref link-reveal xref-bibr">1373</a>,<a href="javascript:;" reveal-id="ehae179-B1374" data-open="ehae179-B1374" class="link link-ref link-reveal xref-bibr">1374</a></sup>

##### 9.3.5.2. Long-term surveillance in traumatic aortic injury

In addition to clinical assessment, CCT is the imaging choice for follow-up.<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B171" data-open="ehae179-B171" class="link link-ref link-reveal xref-bibr">171</a>,<a href="javascript:;" reveal-id="ehae179-B172" data-open="ehae179-B172" class="link link-ref link-reveal xref-bibr">172</a></sup> Cumulative exposure to radiation and iodinated contrast medium remains the major limitation in young patients, especially in women. A combination of a chest X-ray and CMR (if no graft artefacts) would be a valid alternative.<sup><a href="javascript:;" reveal-id="ehae179-B24" data-open="ehae179-B24" class="link link-ref link-reveal xref-bibr">24</a>,<a href="javascript:;" reveal-id="ehae179-B171" data-open="ehae179-B171" class="link link-ref link-reveal xref-bibr">171</a>,<a href="javascript:;" reveal-id="ehae179-B172" data-open="ehae179-B172" class="link link-ref link-reveal xref-bibr">172</a></sup>

Recommendation Table 53

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846513)

Recommendations for traumatic aortic injury

![Recommendations for traumatic aortic injury](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt53.jpeg?Expires=1728479088&Signature=bu3YBKwoVyiYyNAVLyyp5KWPufwvN3OCV0BEGpooVMxt2cCmMuXFTBjuRL5FgHBXAlHwMRaSsIs-BgmiZRykt7mtlVy3nv8GeX9EcLyek4oj2zp25kv9iBDvqMB22IBYpwWhCnm1L69bkTamQCW7axb17CS~YlDH4XZbD~-YqLBKOtUx4r2Fp4Vxs2qQ8rzzd5yeTw6OX70guuxrd3nALrFWufXI4pTiBDBRiDXXPVM-4FvZCjgE5B9zU93DAF6QCJXUh7eB7SjNp48ZQ8zkxckqB04DW8jKDK9WglPyBPNexrNOo1qJF3aWWezaREUyXDG4hQV1eU9ROyRKbMskGw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 9.3.6. Iatrogenic aortic injuries

Iatrogenic aortic lesions are those associated with invasive procedures (cardiac surgery, most commonly dissection type A, or coronary angiography, with a similar proportion of type A and B dissections) (see _Section [9.3.2.1](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false#ehae179-s8.3.2.1)_). Incidence is low and ADs are the most common lesions. Main risk factors are advanced age, presence of CVRFs, atherosclerosis, aortic aneurysms, or PAD (_[Figure 37](javascript:;)_). Patients with iatrogenic AAS are often painless with correspondingly less chest or back pain.<sup><a href="javascript:;" reveal-id="ehae179-B1375" data-open="ehae179-B1375" class="link link-ref link-reveal xref-bibr">1375</a></sup>

![Aetiology, risk factors, and classification of iatrogenic aortic injuries.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f37.jpeg?Expires=1728479088&Signature=bGN6DrnMR2czHp5t7RTdaFliao66~NrsEYmYSabaT~Y9gjcQqrQBzGKzrXJb1qSKTaKfga436nGLZbeG7gANwx87NghzXIb730ezeTPxZuCs3pYQ9O38I69IGHzbJTiWI0-Si4acP3Q00eqc~vgMVdf6o3ycsZR1TXDiyhs37SH5GQx~5F3nwUd7kuEus~mvPlDQay7Q0HUz5lW6h1pxQcfDf3-ge8fRCMemZlQ2hHqKRkYD8~~tQuQ~GBADWOzKWbgudV7FQgEEOBNcR7R6aBz0Dnfz4P3sAHacFW4kplbwVGfilO-GPPlmXht6hqDHuMYKQfTeYJGj6EDj53Xkag__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 37

Aetiology, risk factors, and classification of iatrogenic aortic injuries.

PAD, peripheral arterial disease. Dunning classification of iatrogenic aortic dissection:<sup><a href="javascript:;" reveal-id="ehae179-B1377" data-open="ehae179-B1377" class="link link-ref link-reveal xref-bibr">1377</a></sup>: type 1, dissection limited to the sinuses of Valsalva; type 2, dissection of the ascending aorta outside the sinuses but < 40 mm from the aortic annulus. type 3, dissection > 40 mm from the annulus.

[Open in new tab](https://academic.oup.com/view-large/figure/479846516/ehae179f37.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f37.jpeg?Expires=1728479088&Signature=A9ss0RFhQVGd4VN8vdv4o90GZVUamTf8NHmvjDufiykh2y6-stvAMqAo8n9MHeYm4FimJ3M06Ip6i1jgDPjSZVFlJ06YFYDujd23zJnXyK4nOXT29wMENtd~UiQANc8wodmjJqtaFDm8FUM50Q4Qz16~hggH0NbIPPgA7wNl4CQISYz8BtnfQ8WK~eDM42y9igh2JfYh3N08XwHqJqLYAxVy0hmvH8ZeCYKLRl89biGv6hw-QGZLwmGfhVTJ2L5FxSUiBlZFyd5GrjkZ1LyE0AFULTiimQmeUGiGz0iZum9BmHQNblIS947HWT-Jw70r6h6GRqNc7cSjlFdT-g5t~w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846516&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

While historically associated with high mortality,<sup><a href="javascript:;" reveal-id="ehae179-B1375" data-open="ehae179-B1375" class="link link-ref link-reveal xref-bibr">1375</a></sup> recent registries like the German GERAADA indicate a mortality rate similar to that for spontaneous dissections.<sup><a href="javascript:;" reveal-id="ehae179-B1186" data-open="ehae179-B1186" class="link link-ref link-reveal xref-bibr">1186</a></sup>

Clinical management is based on the underlying lesion (AAD, IMH) and location; however, conservative management has been described with good results in type A iatrogenic dissection if the coronary flow is preserved and the dissection is small.<sup><a href="javascript:;" reveal-id="ehae179-B1376" data-open="ehae179-B1376" class="link link-ref link-reveal xref-bibr">1376</a></sup> Iatrogenic lesion classification is depicted in _[Figure 37](javascript:;)_.<sup><a href="javascript:;" reveal-id="ehae179-B1377" data-open="ehae179-B1377" class="link link-ref link-reveal xref-bibr">1377</a></sup> Although scarce, data support a conservative approach based on evolution in type 1 and 2 lesions (Dunning classification), and surgery in type 3.<sup><a href="javascript:;" reveal-id="ehae179-B1377" data-open="ehae179-B1377" class="link link-ref link-reveal xref-bibr">1377</a></sup> In cases of coronary involvement, stent implantation sealing the flap may be proposed.<sup><a href="javascript:;" reveal-id="ehae179-B1376" data-open="ehae179-B1376" class="link link-ref link-reveal xref-bibr">1376</a>,<a href="javascript:;" reveal-id="ehae179-B1377" data-open="ehae179-B1377" class="link link-ref link-reveal xref-bibr">1377</a></sup>

#### 9.3.7. Long-term follow-up of acute aortic syndrome

Imaging modalities and time intervals for surveillance vary according to lesion location (ascending/descending aorta), type of treatment (medical, endovascular, surgical), and underlying disease (HTAD).<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B1062" data-open="ehae179-B1062" class="link link-ref link-reveal xref-bibr">1062</a>,<a href="javascript:;" reveal-id="ehae179-B1153" data-open="ehae179-B1153" class="link link-ref link-reveal xref-bibr">1153</a></sup> Compared with the chronic disease setting, follow-up of AAS patients is characterized by a higher risk of complications and need for re-operation.<sup><a href="javascript:;" reveal-id="ehae179-B1378" data-open="ehae179-B1378" class="link link-ref link-reveal xref-bibr">1378</a></sup> Patients receiving TEVAR for AAS involving the descending aorta are more prone (27%–49%) to requiring a second intervention than patients undergoing surgical repair.<sup><a href="javascript:;" reveal-id="ehae179-B1379" data-open="ehae179-B1379" class="link link-ref link-reveal xref-bibr">1379</a>,<a href="javascript:;" reveal-id="ehae179-B1380" data-open="ehae179-B1380" class="link link-ref link-reveal xref-bibr">1380</a></sup> However, need for re-intervention at follow-up (after initial treatment of AAD) seems to have a significant impact on survival for TAAD<sup><a href="javascript:;" reveal-id="ehae179-B1381" data-open="ehae179-B1381" class="link link-ref link-reveal xref-bibr">1381</a></sup> but not for TBAD.<sup><a href="javascript:;" reveal-id="ehae179-B1380" data-open="ehae179-B1380" class="link link-ref link-reveal xref-bibr">1380</a></sup>

##### 9.3.7.1. Follow-up after invasive treatment

Following surgery for AAS, imaging surveillance will focus on persistence/obliteration of the FL, anastomotic dehiscence, progressive dilatation of residual native aorta (with or without residual dissection), or graft infection. CCT is the most used modality, but in patients requiring frequent examinations CMR can be considered to reduce radiation.

Compared with outcomes of open surgery for aortic aneurysms, time to re-intervention in patients developing complications is significantly shorter,<sup><a href="javascript:;" reveal-id="ehae179-B1159" data-open="ehae179-B1159" class="link link-ref link-reveal xref-bibr">1159</a></sup> also due to the faster average growth of the dissected aorta (about 1 mm per year).<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a></sup> Considering the reported incidence rates (around 10%) of complications requiring re-operation, it is reasonable to follow patients every 6 months in the first year (including an early—within 1 month—echocardiography to follow native or prosthetic aortic valve function), then yearly up to the third post-operative year and then every 2–3 years if there are no complications (_[Figure 38](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B1153" data-open="ehae179-B1153" class="link link-ref link-reveal xref-bibr">1153</a>,<a href="javascript:;" reveal-id="ehae179-B1159" data-open="ehae179-B1159" class="link link-ref link-reveal xref-bibr">1159</a></sup>

![Algorithm for follow-up after acute aortic syndrome.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f38.jpeg?Expires=1728479088&Signature=pry0T0exXgnCqv9U2iZuhSeG2lm0yjrzwwLj~P9i4QD84yVfBvUNVk1PpqIxnFGthNRtX7ox0NmCjrqiVER9lrkZF6Oz3pXc2T67E-mM341TMMkNSVSc0C78WLjTjxJ3GHDsaSm3ESc1vbzCSDhRCifU8mp7waZK6JJfZfnSGDVOQq7808CMzDrUxLb8L13hDOkJC3UNGbJ1VB8IAgQCa37alJbPQYzzHCkBEB6OfWFEJT-NVWcFi2RV6fsDWsNzQ-GFj5d5hHaVc~P4VEeCnmozFrMZnaJb80xTKmUypYanr5~0etobgUuLM4p7Xe5rP7Y6547QqCLo7WXT~xgU8w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 38

Algorithm for follow-up after acute aortic syndrome.

AAS, acute aortic syndrome; AD, aortic dissection; CMR, cardiovascular magnetic resonance; CCT, cardiovascular computed tomography IMH, intramural haematoma; PAU, penetrating atherosclerotic ulcer.

[Open in new tab](https://academic.oup.com/view-large/figure/479846524/ehae179f38.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f38.jpeg?Expires=1728479088&Signature=DzBLavxz2sfr3VjK3tGxOMz3GXrVsD0YD4rKX8BHnIHuJAczp8WuynmI~oOhyHFu4Nngzpza12VOwZLOt4wcsMPjoJKM~g~EhnkLZvYOCnsXlypuS4Aypwlbos2MPPaqN718ivxzJieBnyYeQHsSZ5cYFWymLXdFgigfboGFwP2PbCya5t67vIZ1hmjZwHvB5A~9dnTS4Vzl3COZsXMJEGzoPs2FsdFrxp5U-WLRAIONLPMzjAqXcW11W0vrQQck6ZMUnkq-s8meiZKlz2D4SdfdKLHFu4dum49uTwbRxLo-LR6-L-hbexq79IkPEYyWSeudm9F6woWZu32H9U6H-Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846524&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

TEVAR implies a higher risk for late re-interventions,<sup><a href="javascript:;" reveal-id="ehae179-B1159" data-open="ehae179-B1159" class="link link-ref link-reveal xref-bibr">1159</a>,<a href="javascript:;" reveal-id="ehae179-B1378" data-open="ehae179-B1378" class="link link-ref link-reveal xref-bibr">1378</a></sup> and a sequence of imaging intervals at 1, 6, 12, 24, 36, 48, and 60 months is recommended if no abnormality is detected (shorter intervals should be considered in high-risk patients). Thereafter, controls can be performed every 2–3 years. Compared with the time points after surgery, an adjunctive early control at 1 month is necessary to exclude asymptomatic retrograde type A dissection induced by TEVAR (70% of cases occurring within 30 post-operative days).<sup><a href="javascript:;" reveal-id="ehae179-B1382" data-open="ehae179-B1382" class="link link-ref link-reveal xref-bibr">1382</a></sup>

Besides imaging surveillance, clinical follow-up is aimed at achieving strict BP control, limiting the burden of CVRFs, and providing patients with counselling for lifestyle modifications and prescriptions for sport activity.<sup><a href="javascript:;" reveal-id="ehae179-B24" data-open="ehae179-B24" class="link link-ref link-reveal xref-bibr">24</a></sup> There is evidence that statin treatment may improve survival in AAS patients under medical treatment, whereas BBs may improve survival in surgically treated patients.<sup><a href="javascript:;" reveal-id="ehae179-B1333" data-open="ehae179-B1333" class="link link-ref link-reveal xref-bibr">1333</a></sup>

##### 9.3.7.2. Follow-up under medical treatment (chronic type B aortic dissection, intramural haematoma, penetrating atherosclerotic ulcer)

Around 70% of TBAD patients survive the hyperacute phase. If there is no malperfusion, uncontrolled hypertension, or impending rupture, initiate anti-impulse therapy alongside surveillance.

Chronic aortic dilatation, reaching 55 mm, is the leading cause (about 40%) of intervention, while acute complications necessitating immediate treatment are rare.<sup><a href="javascript:;" reveal-id="ehae179-B1301" data-open="ehae179-B1301" class="link link-ref link-reveal xref-bibr">1301</a>,<a href="javascript:;" reveal-id="ehae179-B1383" data-open="ehae179-B1383" class="link link-ref link-reveal xref-bibr">1383</a></sup> Imaging controls should be performed at least at 1, 6, and 12 months after discharge and yearly thereafter; however, one additional earlier scan, e.g. within 3 months, may reveal important changes occurring in the subacute phase, when the dissected aorta remains successfully amenable to early TEVAR.<sup><a href="javascript:;" reveal-id="ehae179-B1383" data-open="ehae179-B1383" class="link link-ref link-reveal xref-bibr">1383</a></sup> During surveillance, late complications may be predicted by imaging features, including the number and location of the entry tear(s), and dimensions of the FL, total (true + false) lumen, or entry tear.<sup><a href="javascript:;" reveal-id="ehae179-B1383" data-open="ehae179-B1383" class="link link-ref link-reveal xref-bibr">1383</a></sup> This might help in risk stratification to modulate the stringency of surveillance in the individual patient (_[Figure 33](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B1213" data-open="ehae179-B1213" class="link link-ref link-reveal xref-bibr">1213</a></sup>

Type B IMH and PAU are usually conservatively treated with antihypertensive therapy and watchful monitoring. Most of the medically treated IMHs have a favourable course, whereas PAUs are less predictable in terms of risk of acute TBAD or rupture.<sup><a href="javascript:;" reveal-id="ehae179-B1350" data-open="ehae179-B1350" class="link link-ref link-reveal xref-bibr">1350</a></sup> Therefore, for IMH the same surveillance criteria as for medically treated uncomplicated TBAD can be employed; for PAU more frequent controls are advisable, i.e. one every 6 months instead of every year. Selectively, in asymptomatic patients with 2 year growth-rate stabilization and no high-risk features, intervals between controls can be longer (every 1–2 years) (_[Figures 35](javascript:;)_ and _[38](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B1384" data-open="ehae179-B1384" class="link link-ref link-reveal xref-bibr">1384</a></sup>

Recommendation Table 54

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846531)

Recommendations for follow-up after treatment of acute aortic syndrome

![Recommendations for follow-up after treatment of acute aortic syndrome](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt54.jpeg?Expires=1728479088&Signature=b1DArPSXCfclpqaPwaAgyzjgjV2hA2CJN6kv9T7lSMvyW25XOE8ir~kmmDyUPUy641MeZswxgtGr6-IJ3~i6s~HwA6rD3xjygzBk3PY-Oq0wcjQyJkOSxChj2AZok3pOtjtE0ie6boC6uDbSVZr1UstbeG3DcKf4MGUyWv4zt7GMs7sD5auws3tSP-oVBEmPYBVatWAtR7jIUES9mCY7XfpMMrnLl0tsg5lLzJl3eHRQez1hAyT1JIEXczoXJJ-0jCZ30IbP5FFQgobzROW50mpOC8c8ZGhFwdEbv15w~zWhXFopDYn-0DUfmCe87vViN1jQczLjLXnSqp6KCI1Q3w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

## 10\. Genetic and congenital diseases of the aorta

### 10.1. Genetic and chromosomal diseases

This section discusses genetic and congenital aortic diseases. Aortic root and ascending aortic disease is commonly linked to congenital or hereditary factors, while descending aortic problems, especially in the AA, often result from atherosclerosis.<sup><a href="javascript:;" reveal-id="ehae179-B1385" data-open="ehae179-B1385" class="link link-ref link-reveal xref-bibr">1385</a></sup> Unless noted otherwise, recommendations provided herein are intended for adults.

Genetic diseases affecting the thoracic aorta are grouped under the broader term of HTAD. HTAD comprises a clinically and genetically heterogeneous group of disorders sharing the common denominator of aneurysm or dissection of the thoracic aorta. Familial forms (thoracic aortic disease \[TAD\] affecting ≥2 individuals in one family) or confirmed genetic entities (familial or sporadic) as well as syndromes conferring a risk for TAD fall under the definition of HTAD.<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a></sup> Due to the rarity of these conditions, robust evidence for many scenarios, such as intervention thresholds, surgical methods, open surgery vs. endovascular approaches, and pregnancy planning, is lacking. Thus, a multidisciplinary and individualized approach is advisable.<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B1386" data-open="ehae179-B1386" class="link link-ref link-reveal xref-bibr">1386</a>,<a href="javascript:;" reveal-id="ehae179-B1387" data-open="ehae179-B1387" class="link link-ref link-reveal xref-bibr">1387</a></sup>

Recommendation Table 55

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846536)

Recommendations for the management of patients with heritable thoracic aortic disease

![Recommendations for the management of patients with heritable thoracic aortic disease](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt55.jpeg?Expires=1728479088&Signature=wg2PJXSdFWkvei4BSXaan~Vc2v6NqzCFv-Tn-pOUtRdrISNRus-kHEITFpRb08oF2qrYdoPXqO-L6~57~bfv4YJBb595jIIDngKqv99jXU7uQuNlL6Qkltt06usUbdlXqV0sK2Xs8IKfy9OTVSKat-D2xXlpj5LW0QcU6sGXpODcdZUIvTKD-yuoy11Z6rUPO1f~n298hArDDUit2Y5zy8nJBlp6YI0chWufzITgDpuk5WbYdPyc6WtQzJBUUxSEMetsqkYakPdbDuQq~BeLWZQW9gDqQ~MDgIACZbI0y3Ut7mWjEvXxLLYjhiu-pRAV0KOHr5Ym98E2oTBaVZ5cqg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Clinically, HTADs can manifest as either syndromic or non-syndromic entities. The genes identified to date may underly both entities and predominantly show autosomal dominant inheritance patterns. While TAD is the primary feature in HTAD, extra-aortic features (skeletal/ocular) may be key to diagnosing certain syndromic cases. In some cases, the presence of extra-aortic manifestations may aid in risk stratification and hence in defining optimal management.<sup><a href="javascript:;" reveal-id="ehae179-B1388 ehae179-B1389 ehae179-B1390" data-open="ehae179-B1388 ehae179-B1389 ehae179-B1390" class="link link-ref link-reveal xref-bibr">1388–1390</a></sup> The main clinical and genetic data on syndromic and non-syndromic HTADs are summarized in the [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179_supplementary_data.pdf?Expires=1728479088&Signature=jsMN1psOaEf3KpW8UiQOwnEDCNM0eDJ9FhgPq~GNXqLItMAEdFx6foOGTBTeCpJhrfS5f9C1WsT6JBJ-OF2VSZCY4hMS9gJl7FbAOywEXjZ7FkQ8D8eMHICtPb1wzBA3uZZtBKMZczJqU~L965QcGSWu4bY5onpcoRMSzjgnNpdPf9L4pLKg-a0ahzhjNRwGHt5NoJ7ErFgx3duCbchEi0MsV0cDIkqzsUCeNEtwo8kpBYcJAps4DqCXaYZS5CPCAIpG4RbHZce70W~XP9IUuUZszMeWmEvwL5IF-0Kt0kkQwtSCyF6kopinSbFrVRYLZmYxxNRPbjwJpR0g1P88ZQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S5](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179_supplementary_data.pdf?Expires=1728479088&Signature=jsMN1psOaEf3KpW8UiQOwnEDCNM0eDJ9FhgPq~GNXqLItMAEdFx6foOGTBTeCpJhrfS5f9C1WsT6JBJ-OF2VSZCY4hMS9gJl7FbAOywEXjZ7FkQ8D8eMHICtPb1wzBA3uZZtBKMZczJqU~L965QcGSWu4bY5onpcoRMSzjgnNpdPf9L4pLKg-a0ahzhjNRwGHt5NoJ7ErFgx3duCbchEi0MsV0cDIkqzsUCeNEtwo8kpBYcJAps4DqCXaYZS5CPCAIpG4RbHZce70W~XP9IUuUZszMeWmEvwL5IF-0Kt0kkQwtSCyF6kopinSbFrVRYLZmYxxNRPbjwJpR0g1P88ZQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)._

Numerous underlying gene defects have been discovered in both syndromic and non-syndromic cases, leading to the constitution of three major molecular groups: genes encoding components of: (i) the extracellular matrix; (ii) the transforming growth factor-beta (TGF-ß) signalling pathway; and (iii) the smooth muscle cell contractile apparatus. Clinical and CV outcomes vary between these groups and will help pave the way to precision medicine in HTAD.<sup><a href="javascript:;" reveal-id="ehae179-B1391" data-open="ehae179-B1391" class="link link-ref link-reveal xref-bibr">1391</a></sup> Extensive clinical and imaging studies in HTAD revealed arterial vasculature involvement beyond the thoracic aorta. Patients may develop aneurysms and/or dissections beyond the aorta in diseases such as MFS, Loeys–Dietz or vascular Ehlers–Danlos syndrome (vEDS),<sup><a href="javascript:;" reveal-id="ehae179-B1390" data-open="ehae179-B1390" class="link link-ref link-reveal xref-bibr">1390</a>,<a href="javascript:;" reveal-id="ehae179-B1392" data-open="ehae179-B1392" class="link link-ref link-reveal xref-bibr">1392</a>,<a href="javascript:;" reveal-id="ehae179-B1393" data-open="ehae179-B1393" class="link link-ref link-reveal xref-bibr">1393</a></sup> or can be prone to occlusive vascular disease in the setting of alpha-actin gene (_ACTA2_) variants.<sup><a href="javascript:;" reveal-id="ehae179-B1394" data-open="ehae179-B1394" class="link link-ref link-reveal xref-bibr">1394</a></sup> Large clinical variability is observed within families carrying an identical variant and instances of incomplete penetrance (a ‘skipped generation’) are observed. All HTAD entities display cystic medial degeneration, hindering precise diagnosis using pathology.

Both genetic testing and imaging (mainly by TTE, but also consider CMR or CCT if the aortic root/ascending aorta are not properly visualized) in patients and family members are important in the diagnosis of HTAD. In those patients in whom no genetic cause is identified, but in whom there is a high suspicion of an underlying genetic defect, genetic re-evaluation needs to be considered after 3–5 years. Genetic testing should always be accompanied with appropriate counselling. Furthermore, appropriate assessment of HRQoL and psychological support should be offered to patients and families.<sup><a href="javascript:;" reveal-id="ehae179-B1395" data-open="ehae179-B1395" class="link link-ref link-reveal xref-bibr">1395</a></sup> Indications for genetic testing and aortic screening in HTAD are illustrated in the algorithm in _[Figure 39](javascript:;)_.

![Algorithm for genetic and imaging screening in patients with thoracic aortic disease.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f39.jpeg?Expires=1728479088&Signature=rP04CIL1nQ-yId12bWXI3NeFBz5Wi-ywo6hhkKp4tB4QJ0bpMqv-6w6BACglPYDDBEney5wrilMuRs-NbGjhNi8V3kao~kVQewIbd~9QgRDs5mmKc0B0SVZR7zLnhqaodpmSlYExGdz2aiFjynRX9PMlbAVpccbCZ57WeaRIgL3N2JWOfgcC4hrK~wgS5xGmmZfJoAOqF0K-Y4SHf7VpGJa-g30LWj8rypBH3rFJk4APefZDWrl18Zmk5h5oSYdPDL8IjbLZR0kvreKe2JXQRYc7QSJqltprMs4TXILM4TsGn9O8ZLcv7~ttyCdnihAo0FvsNOzCc8y35gvYb1TQow__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 39

Algorithm for genetic and imaging screening in patients with thoracic aortic disease.

CCT, cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; FDR, first-degree relative; HTAD, heritable thoracic aortic disease; HTN, arterial hypertension; TAD, thoracic aortic disease; TTE, transthoracic echocardiography; VUS, variant of uncertain significance. <sup>a</sup>mainly by TTE, but also consider CMR or CCT if the aortic root/ascending aorta are not properly visualized.

[Open in new tab](https://academic.oup.com/view-large/figure/479846540/ehae179f39.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f39.jpeg?Expires=1728479088&Signature=kt7TAkr9WFZvTLJxcWip~~mGZFhRY6Un3ESUgGbIMo-xvZQC2TjkZEaXtxb1f3bB4DJWuotpY4uqzpdQxrzGhP7F~ri4VK0FkBmVh9tBKckDn2uytZttBMMuROHhm5FkStEJJzJ312VZkDmAW6MW6ci7fmU~E8gpeZvNG9Z1wOngp4zFFC0xbhrvWXnuYmu6rNw7EnTE3fTiYduAfmXL09ALVgm7Vcp4-8KKS97jdN1ntpyhyf1d8caXtlGy9RLvv0myYLwYBCDZ~kIt8seKZF9PgqZAaL61kL8mppHCoTjc9HfgpsEcKc8cWrUgzSEAgq8U6EZGmSwhCb483wwMYw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846540&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Although isolated AAA is less frequently associated with a genetic basis, patients with high-risk features (syndromic features, early onset of disease, absence of CVRFs, and/or family history of TAD or AAA) should be evaluated in centres with experience in HTAD to evaluate the need for genetic testing and specific surveillance, including active clinical screening in family members.

Recommendation Table 56

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846542)

Recommendations for genetic testing and aortic screening in aortic disease

![Recommendations for genetic testing and aortic screening in aortic disease](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt56.jpeg?Expires=1728479088&Signature=Se4482Nhr-Tfrc6VJv3SRmUfOsiWrewTExjjrOBYLEsjHww1-3HzS-u2-I8ncozpX4DxdmQ5rpg2lAgZ~NHlZRRigR2M4MIOerq9AcEMEWRkLEqt4wdU7fGpnqnQ1d88hZmWuxnECTJsAgf-crLeiHrR5y9NS284G0sGVcOncE~xch2P33LBV8cpF9CmFIRmbWGE2-wTYbpeAN5hMcG6s92eQQ0lzZAn8DHYz27fBR~LmYuLlhJ-VaLHw3ivJTAPOzO7Z2HAT2X51XiferiADPbd2U0cYy4plXcrcQ0DDk6lqTG7o3xPENV72NuWvn~W0OJubCOQHW-8KEYFavrYtQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 10.1.1. Turner syndrome

##### 10.1.1.1. Diagnosis, clinical presentation, and natural history

Turner syndrome (TS), resulting from partial or complete monosomy of the X-chromosome, affects 1 in 2500 live-born females.

About 50% of patients experience CV issues like ascending aortic dilatation, BAV, aortic coarctation, elongated aortic arch, and partial abnormal pulmonary venous return.<sup><a href="javascript:;" reveal-id="ehae179-B1417 ehae179-B1418 ehae179-B1419" data-open="ehae179-B1417 ehae179-B1418 ehae179-B1419" class="link link-ref link-reveal xref-bibr">1417–1419</a></sup> All women present with generalized arteriopathy and TS itself is an independent risk factor for thoracic aortic dilatation. AD risk (type A in 85% and type B in 15%) is elevated in this population,<sup><a href="javascript:;" reveal-id="ehae179-B1420 ehae179-B1421 ehae179-B1422" data-open="ehae179-B1420 ehae179-B1421 ehae179-B1422" class="link link-ref link-reveal xref-bibr">1420–1422</a></sup> although recent studies indicate that this risk may be lower with proper treatment guidelines.<sup><a href="javascript:;" reveal-id="ehae179-B1423 ehae179-B1424 ehae179-B1425 ehae179-B1426" data-open="ehae179-B1423 ehae179-B1424 ehae179-B1425 ehae179-B1426" class="link link-ref link-reveal xref-bibr">1423–1426</a></sup> Risk factors include aortic dilatation, BAV, coarctation, and arterial hypertension. Defining aortic dilatation in TS requires adjustment for anthropometric parameters and aortic growth data for dissection risk estimation.<sup><a href="javascript:;" reveal-id="ehae179-B1427" data-open="ehae179-B1427" class="link link-ref link-reveal xref-bibr">1427</a></sup> Z-scores used in the general population are equivalent to Turner-specific z-scores.<sup><a href="javascript:;" reveal-id="ehae179-B1428" data-open="ehae179-B1428" class="link link-ref link-reveal xref-bibr">1428</a></sup>

Imaging surveillance

In newly diagnosed TS, TTE and CMR are recommended at baseline for the evaluation of congenital heart defects and aortic anatomy/diameters. For women aged 15 years and older with TS, adjusting for their smaller body size is essential when assessing aortic dimensions. Utilize metrics like the ascending aortic size index (ASI), aortic height index (AHI), or aortic z-scores to gauge aortic dilation and dissection risk. Further follow-up is dictated by baseline aortic diameters, age, and risk factors (_[Figure 40](javascript:;)_).

![Algorithm for surveillance in women (≥15 years) with Turner syndrome.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f40.jpeg?Expires=1728479088&Signature=uyFv0gxQ691myVzTlKPWesHA5gjmHcNMyrI3SOBOHMKKREoMkTGKUxGpppRX193oe-TQigZdr01vWQ8-I63HTSDTjqyUu7mFEDiWLtWU3MwTpIpZz2Cc59hqnTw2EwGsjT53-57YTKm9-v9za4dATsdcALMhHD6OldAWCFNldNXUx~Om3Z2Q3oNE6zsqlg4lvqXW-KLv6iZbX98~nZcxnPy8kdo5Lahdas5VCJenbAOigK3CcAv7NI~nn44xYdmr-~WTiMmunAV0Es3atKTvWPi0xmLrXBOXsYSOqt-c9zJcU1h9A76PwqRCRCLuddwdxeP6ctmUQRda2v7SjZOEXA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 40

Algorithm for surveillance in women (≥15 years) with Turner syndrome.

AHI, aortic height index (ratio of aortic diameter \[mm\] to height \[m\]); ASI, aortic size index (ratio of aortic diameter \[mm\] to BSA \[m<sup>2</sup>\]); BAV, bicuspid aortic valve; BSA, body surface area; CCT, Cardiovascular Computed Tomography; CMR, cardiovascular magnetic resonance; CoA, coarctation of the aorta; HTN, arterial hypertension; TTE, transthoracic echocardiography. <sup>a</sup>HTN: arterial hypertension, not under control despite more than three classes of antihypertensive drugs. <sup>b</sup>CMR (preferably) or CCT if inadequate visualization of the ascending aorta.

[Open in new tab](https://academic.oup.com/view-large/figure/479846549/ehae179f40.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f40.jpeg?Expires=1728479088&Signature=Q8lLxnNeDZhVBOKJji5ciG~6eJu9JZQn2EFFNgU-wWtYu~6laiznqfDARxcOlHfiA11DCHSLjKIrsW8FQpnM-Aq2cxJPfzn6gUUQ0ayDcXDSBwmv5bniwZ5g8IJnOiTrirnPff9BTAPHC4a3OVI3g3uNAkKUxVOgiGrgnfdVi-sn5i~LC-fR6lIP4kRqwiyMNaixU~bs4HivpUw4xUZbwfuO2R-TBcpVO4jGJH5Lr2BL-48TjKEORX8qXTSHVRGxyy~pWbNR4wL6xAGUojjUdXLRy0vqYkTTAwtfRdtDU-4vb1RTISZf5WosKDkxFz-DJBhISvY63U3t5v1wrQzbzQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846549&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Recommendation Table 57

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846550)

Recommendations for imaging in women with Turner syndrome

![Recommendations for imaging in women with Turner syndrome](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt57.jpeg?Expires=1728479088&Signature=IWgDvADUa7PEbssLzXYNgf3tPxxaobHnlOnicl~4Nrr8uujmxJ~~qFMx~L2d5da6jkjDgAusrn-tQadf~fu~aAdkILxzWMZ4PYgAedwKdGltnRD8zwxI69QwrRddH5frkKZnJX-gEauQggtAo8IXyWWDY5V4ZYZwbsxYoTZ2zxiUNCCOkW510ZHl3Bp6uWr1AvIl3TDK8mVSaBSOEahhJ9w9JADTdaBdS7-2aFhC2sTj0BNh~jhWoKBtEza-yLZFmwKwBq7XGiTsNbjrgXUfK0NG4OM6X0SO6Svdb~wH1wwz0oOTMwPwtJj9ZiAx8FiN3BPRB91vHB84jpKNcR50Qw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

##### 10.1.1.2. Medical treatment

In the absence of clinical trials, a pragmatic approach in a shared-decision model is adopted regarding TS medical treatment. Adoption of the strategy for inhibition of aortic growth with BBs and/or ARBs as in MFS may be considered. Hypertension should be treated according to general guidelines.<sup><a href="javascript:;" reveal-id="ehae179-B300" data-open="ehae179-B300" class="link link-ref link-reveal xref-bibr">300</a></sup>

Hormonal treatment with growth hormone (in childhood), sex (oestrogen and/or progesterone), and thyroid hormones needs to be discussed in a multidisciplinary team with the paediatrician and endocrinologist.<sup><a href="javascript:;" reveal-id="ehae179-B1430 ehae179-B1431 ehae179-B1432 ehae179-B1433 ehae179-B1434" data-open="ehae179-B1430 ehae179-B1431 ehae179-B1432 ehae179-B1433 ehae179-B1434" class="link link-ref link-reveal xref-bibr">1430–1434</a></sup>

##### 10.1.1.3. Surgery of aortic aneurysms

Aortic aneurysm surgery in TS should be informed, individualized, and consider factors beyond aortic diameter (indexed). These include BAV, coarctation, uncontrolled hypertension (despite more than three classes of antihypertensive drugs), rapid aortic growth (≥3 mm per year) and planned pregnancy.

Recommendation Table 58

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846556)

Recommendations for aortic surgery in women with Turner syndrome

![Recommendations for aortic surgery in women with Turner syndrome](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt58.jpeg?Expires=1728479088&Signature=cZyAaj6Cw0ZFp-NWG~KIU-jDYREm2l8iR8d3-DNKOesK5nxTai9fdcq5AJUB-PfxtVrKr52dsdES98-5CP-yXyHV2lsgSyS4-dJWQHtL3N62-01EvJbKU9wIMyPY5K9sQ8VXJvKFqFQxVIYKp7gueAYsv6Nbq-URf9rYf2ELTNwb66f00ZbDH3Sd3R5d2G1Il8krvtoeLgwLPS1N9MwFlZ6UugxMrcTACSZrgSQereZbqmT7OPWDLc8KF3dxghGBR39kvXwQX~lxnSQWqRc2aX-rcMid2EwVbZ9IiRIQ5rsoQ8E7L7V-5gqlDWMPkX5jrttUjO3CrtOKFo---91QWA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

##### 10.1.1.4. Pregnancy and physical exercise

Turner syndrome often involves fertility challenges, but assisted reproductive therapy has increased pregnancy rates. However, pregnancy in TS can elevate the risk of AD, particularly with additional risk factors (_[Figure 40](javascript:;)_). Recent studies suggest improved pregnancy outcomes due to better guideline adherence.<sup><a href="javascript:;" reveal-id="ehae179-B1435" data-open="ehae179-B1435" class="link link-ref link-reveal xref-bibr">1435</a>,<a href="javascript:;" reveal-id="ehae179-B1436" data-open="ehae179-B1436" class="link link-ref link-reveal xref-bibr">1436</a></sup> Prophylactic aortic root surgery in women with TS contemplating pregnancy is recommended when the ASI reaches 25 mm/m<sup>2</sup>.<sup><a href="javascript:;" reveal-id="ehae179-B1337" data-open="ehae179-B1337" class="link link-ref link-reveal xref-bibr">1337</a></sup> These decisions should be made by an expert team in a shared-decision process.

Physical exercise has a beneficial impact on CVD risk and HRQoL in TS.<sup><a href="javascript:;" reveal-id="ehae179-B1437" data-open="ehae179-B1437" class="link link-ref link-reveal xref-bibr">1437</a></sup> Structural congenital heart defects and aortic diameters (ASI, AHI and z-score) (_[Figure 40](javascript:;)_) need to be considered in the recommendations on the level of sports practice.<sup><a href="javascript:;" reveal-id="ehae179-B1418" data-open="ehae179-B1418" class="link link-ref link-reveal xref-bibr">1418</a></sup>

#### 10.1.2. Vascular Ehlers–Danlos syndrome

##### 10.1.2.1. Diagnosis, clinical presentation, and natural history

Vascular Ehlers–Danlos syndrome is a rare (prevalence of 1/50 000 to 1/200 000) autosomal dominant disease caused by pathogenic variants in the _COL3A1_ gene, which encodes the pro-alpha1 chains of type III procollagen. The most common _COL3A1_ variants provoke a disruption in the assembly of type III collagen fibrils, causing an important loss of mechanical strength of arteries and other hollow organs, especially the bowel and uterus.<sup><a href="javascript:;" reveal-id="ehae179-B1438" data-open="ehae179-B1438" class="link link-ref link-reveal xref-bibr">1438</a></sup> Identification of a causal _COL3A1_ variant is a requirement for the diagnosis of vEDS.<sup><a href="javascript:;" reveal-id="ehae179-B1439" data-open="ehae179-B1439" class="link link-ref link-reveal xref-bibr">1439</a></sup>

vEDS is the most severe form of Ehlers–Danlos syndrome because of its clinical life-threatening vascular complications, making early identification and a thorough family inquiry particularly crucial.

Clinical complications may start during adolescence and repeat at unpredictable time intervals. The most common complications involve medium-sized arteries: dissections, aneurysms, arterial ruptures, and arteriovenous fistulas. AD (both type A and B) occurs in up to 10% of patients.<sup><a href="javascript:;" reveal-id="ehae179-B1440" data-open="ehae179-B1440" class="link link-ref link-reveal xref-bibr">1440</a></sup>

Prognosis depends on the type of _COL3A1_ variant, with null variants (no gene product or absence of function) showing a better outcome.<sup><a href="javascript:;" reveal-id="ehae179-B1441" data-open="ehae179-B1441" class="link link-ref link-reveal xref-bibr">1441</a></sup> The rate of recurrence of organic complications in patients with vEDS is 1.6 events per 5 year period. Life expectancy is reduced to an average of 51 years.<sup><a href="javascript:;" reveal-id="ehae179-B1442" data-open="ehae179-B1442" class="link link-ref link-reveal xref-bibr">1442</a></sup>

##### 10.1.2.2. Surveillance and imaging

Management of vEDS is complex and requires a multidisciplinary approach. Recommendations include: lifestyle modification to minimize injury and risk of vessel/organ rupture, identification of a care team, individualized emergency care plans, maintaining BP in the normal range, aggressive hypertension treatment, and annual surveillance of the vascular tree by DUS, CCT (low radiation alternatives), or CMR (if feasible).<sup><a href="javascript:;" reveal-id="ehae179-B1439" data-open="ehae179-B1439" class="link link-ref link-reveal xref-bibr">1439</a></sup> A recent survey among European expert centres indicated that arterial monitoring is standard clinical practice and that frequency of follow-up should be adapted individually.<sup><a href="javascript:;" reveal-id="ehae179-B1443" data-open="ehae179-B1443" class="link link-ref link-reveal xref-bibr">1443</a></sup> The prognosis improves when patients are properly managed.<sup><a href="javascript:;" reveal-id="ehae179-B1441" data-open="ehae179-B1441" class="link link-ref link-reveal xref-bibr">1441</a></sup>

##### 10.1.2.3. Medical treatment

Medical management is based on optimal BP control. Celiprolol, a BB with vasodilatory properties, has been shown to reduce vascular morbidity in two retrospective studies<sup><a href="javascript:;" reveal-id="ehae179-B1441" data-open="ehae179-B1441" class="link link-ref link-reveal xref-bibr">1441</a>,<a href="javascript:;" reveal-id="ehae179-B1444" data-open="ehae179-B1444" class="link link-ref link-reveal xref-bibr">1444</a></sup> and one randomized, open-label trial.<sup><a href="javascript:;" reveal-id="ehae179-B1445" data-open="ehae179-B1445" class="link link-ref link-reveal xref-bibr">1445</a></sup> There is no consensus about the age at which to start treatment, but starting after 10 years of age is considered reasonable by many experts.

Recommendation Table 59

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846570)

Recommendations for medical treatment in patients with vascular Ehlers–Danlos syndrome (see also Evidence Table 13)

![Recommendations for medical treatment in patients with vascular Ehlers–Danlos syndrome (see also Evidence Table 13)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt59.jpeg?Expires=1728479088&Signature=pEuK3cmZ7Fi2OIKkN1QNNLNrl6Uj0243v1veZ4cAWDpnCuJjzRVO1pAf9f3x4HNilvat~gdBz4XYAm22RmE7zB1s-5~fvucyvxyE9KasYxthPtHWODKjC77BfDuf2PYCPcmi~OvmtWzK2GD2BOgRHqO8gjkNGV1efZwIGPBtn4~PwAHwp8JRK~1YCoKKUnK8PsTIlZ8a5zchr39cPGuzGm4lf6ckqLip7AXhLiT2ExIX~ezfqpHkgay51OSnykytFxe-ai1OsGMI7F6X9h8TD7zASf5PK2EYOOFepuKD6G3mf5mJ2gk1iUf-AtWBH5xlOaaLLFSlguoErOoSPos7KQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

##### 10.1.2.4. Surgical treatment

Acute, unexplained pain requires urgent imaging to exclude arterial rupture. Acute arterial complications usually require hospitalization and a conservative approach in most cases. Interventional vascular or intestinal procedures are limited to vital risk. Procedures requiring organ inflation should be avoided or performed with extreme caution. There are no clear recommendations regarding aortic/arterial diameters at which to intervene in patients with vEDS. Thus, decisions need to be made on a case-by-case basis.

##### 10.1.2.5. Pregnancy

Pregnancy in vEDS incurs a risk of (fatal) arterial and uterine complications. Pregnancy does not appear to affect overall mortality compared with nulliparous vEDS women.<sup><a href="javascript:;" reveal-id="ehae179-B1446" data-open="ehae179-B1446" class="link link-ref link-reveal xref-bibr">1446</a></sup> However, patients need to be engaged in a shared-decision process, informed by vascular status and underlying variant type.

#### 10.1.3. Marfan syndrome

##### 10.1.3.1. Diagnosis, clinical presentation, and natural history

Marfan syndrome, the most common syndromic HTAD condition (prevalence of 1/5000–1/10 000), arises from pathogenic fibrillin-1 gene (_FBN1_) variants. Beyond the CV system, multiple organ systems are often affected, including the eyes and skeleton. Diagnosis relies on recognizing clinical features in line with the revised Ghent nosology, which includes genetic testing.<sup><a href="javascript:;" reveal-id="ehae179-B1447" data-open="ehae179-B1447" class="link link-ref link-reveal xref-bibr">1447</a></sup>

Aortic aneurysm and dissection involving the aortic root are a hallmark of the disease. Less commonly, the descending thoracic and abdominal aorta may be involved. With increasing survival and age in MFS, the prevalence of TBAD seems to be increasing, exceeding type A dissection rates in recent reports.<sup><a href="javascript:;" reveal-id="ehae179-B1448" data-open="ehae179-B1448" class="link link-ref link-reveal xref-bibr">1448</a>,<a href="javascript:;" reveal-id="ehae179-B1449" data-open="ehae179-B1449" class="link link-ref link-reveal xref-bibr">1449</a></sup> TBAD will often occur at diameters below surgical thresholds. Previous aortic root replacement, mitral valve surgery, and a longer life span are associated with TBAD. Additional CV features include mitral valve prolapse, extra-aortic arterial involvement, myocardial dysfunction, and arrhythmias.<sup><a href="javascript:;" reveal-id="ehae179-B1393" data-open="ehae179-B1393" class="link link-ref link-reveal xref-bibr">1393</a>,<a href="javascript:;" reveal-id="ehae179-B1450 ehae179-B1451 ehae179-B1452" data-open="ehae179-B1450 ehae179-B1451 ehae179-B1452" class="link link-ref link-reveal xref-bibr">1450–1452</a></sup> Thanks to improved diagnosis in earlier stages, proper management including surveillance, medical treatment, and timely prophylactic aortic surgery, life expectancy in MFS patients is now approaching that of the general population.<sup><a href="javascript:;" reveal-id="ehae179-B1416" data-open="ehae179-B1416" class="link link-ref link-reveal xref-bibr">1416</a>,<a href="javascript:;" reveal-id="ehae179-B1453" data-open="ehae179-B1453" class="link link-ref link-reveal xref-bibr">1453</a></sup>

The major determinant of TAAD is the aortic root diameter, with increased risk of rupture when it exceeds 50 mm.<sup><a href="javascript:;" reveal-id="ehae179-B1454" data-open="ehae179-B1454" class="link link-ref link-reveal xref-bibr">1454</a></sup> Other risk factors include family history of AAS at low diameter, aortic root growth rate (annualized growth rate ≥3 mm or more in adults), pregnancy, and hypertension (hypertension persisting notwithstanding three or more antihypertensive medications prescribed by a physician with experience in hypertension treatment). Increasing evidence for variant-based differences in aortic risk is emerging and may be considered.<sup><a href="javascript:;" reveal-id="ehae179-B1413" data-open="ehae179-B1413" class="link link-ref link-reveal xref-bibr">1413</a>,<a href="javascript:;" reveal-id="ehae179-B1416" data-open="ehae179-B1416" class="link link-ref link-reveal xref-bibr">1416</a></sup>

##### 10.1.3.2. Imaging surveillance

Transthoracic echocardiography is the appropriate imaging modality for initial evaluation and follow-up of the aortic root in most patients and allows evaluation of the distal segments of the aorta in many. Also, TTE is useful for assessing mitral and aortic valve regurgitation, mitral valve prolapse with/out annular disjunction, and LV dysfunction. In some cases (especially when pectus abnormalities are present) TTE windows may be suboptimal, and CMR (preferably)/CCT may be preferred. Periodical evaluation of the global aorta and peripheral arteries with CMR/CCT and DUS (every 3–5 years based on the patient’s evolution) is indicated since they also present a higher incidence of peripheral aneurysms,<sup><a href="javascript:;" reveal-id="ehae179-B1455" data-open="ehae179-B1455" class="link link-ref link-reveal xref-bibr">1455</a></sup> which are associated with more aggressive forms of the disease.<sup><a href="javascript:;" reveal-id="ehae179-B1393" data-open="ehae179-B1393" class="link link-ref link-reveal xref-bibr">1393</a></sup> CMR is preferred over CCT to avoid radiation exposure; however, its use should be adapted to local availability/expertise. Additionally, CMR allows evaluation of biomechanical and haemodynamic parameters that can be useful in risk stratification.<sup><a href="javascript:;" reveal-id="ehae179-B181" data-open="ehae179-B181" class="link link-ref link-reveal xref-bibr">181</a>,<a href="javascript:;" reveal-id="ehae179-B1456" data-open="ehae179-B1456" class="link link-ref link-reveal xref-bibr">1456</a>,<a href="javascript:;" reveal-id="ehae179-B1457" data-open="ehae179-B1457" class="link link-ref link-reveal xref-bibr">1457</a></sup> Given its superior spatial resolution, CCT may be recommended for pre-operative planning and in cases of measurement inconsistency. Imaging of intracerebral vessels is indicated in cases of symptoms and/or clinical manifestations of aneurysms/rupture. Recommendations for imaging surveillance are illustrated in _[Figure 41](javascript:;)_ and should be adjusted to the individual patient, taking the history and presence of abnormalities during preceding studies into account.

![Algorithm for imaging surveillance in patients with syndromic and non-syndromic heritable thoracic aortic disease.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f41.jpeg?Expires=1728479088&Signature=B5AOJxh8Uek8tta4EQI7ydVGjrJsR3FBtcADEcGgKRaFybIikgl7YfeMsQHNyfFHv4zsRF992ET0egJhvDt3s2UQJCJhPJrR-3tVlwgTU8cu8YtDVFTSCo6HzFNA9KL8MYE5rBULs0jikhEJyXrmtRsC0j1Gq4d-tUvyW~-5EbylERwJUlhyfVHvAmgggKeOQx3Ok8iFewnWIimyTgkxxX~cReGZtPQQkkiJ8Owwaxppx2qpMp9lj87SMi17KqFPHLUIvrDfUF~8omhLYnFDjEPG26AqAflXJbYTWlwrFgMRAs1yfZEF6YYfwX3XxraxSLcu8aHEtF7fcnqjQwmmtw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 41

Algorithm for imaging surveillance in patients with syndromic and non-syndromic heritable thoracic aortic disease.

CCT, cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; DUS, duplex ultrasound; HTAD, heritable thoracic aortic disease; SMC, smoth muscle cell; TTE, transthoracic echocardiography. <sup>a</sup>Pre-surgical CCT. <sup>b</sup>See respective tables of recommendations for aortic surgery in Marfan ([Table 62](javascript:;)) and Loeys-Dietz syndrome ([Table 66](javascript:;)).

[Open in new tab](https://academic.oup.com/view-large/figure/479846582/ehae179f41.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f41.jpeg?Expires=1728479088&Signature=fo-FqUqKUJODk3GPOeZ7uFa7CAb-ZtxjWR7ha8hKmHrz2fM~Ok46dfOhyvH4g8Tu8cYMaK~Ewb~~2nsKAB6NaK9p74nf4Cj5aEqGTqSPUUGIp3F80WtyhMCvQMsHEK7Z-x99D1Al8~Dx3hZcqToK7x0c1iBto1xjxe1eAM9~qlzF6F3cZpLOLNcdM6jVFUMoTJpJ3c0xa9ezUQTQVgt0Kv9ui-Jz7TOxoGLdJ5BT7pa2ZCxbV3XBjuE2FjcVcpm6kaTOM0W5vfq8sNEhcfeSThMn8ftyJFMguuc5IUgu3SNbYwd-u7cBsfzxhaVGRuY3sYBAHEe-HsQez4QAg~KUoA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846582&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Recommendation Table 60

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846583)

Recommendations for vascular imaging in Marfan syndrome

![Recommendations for vascular imaging in Marfan syndrome](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt60.jpeg?Expires=1728479088&Signature=ArmzvHGBJBgOwwTLUT7twNPgUCbWsuD95CgH4pF2OHIuNDVYnez~7TW6UwS9Irne4ThnLS-flPlZ~fS~AXsBnsu0ulMj6zLYsYjNCPZgEJR~1WadMgQx71MMBF06SIjmlbsIMlqpkL3z9z9aNkaXAas2bjR3TohStO4dAsoYNLJ1vdljxM4FhGPugImw9sDU0~E9Ix-Uq5NBefqYRUSXWIVXHjhdWu4xwjg6pPOjMdJmLUXzHhAcXaiPS2JSl8O7ijSsebo7n9yvL0xiRVSS8D~IBCNkN~gPIac4syE0KLgO-wj-0OlmuXUJA-1o7OwLRVpLcv8~Yf6mPrnqbO8sZA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

##### 10.1.3.3. Medical treatment

Medical treatment is described in Recommendation Table 61. Some caution may be warranted with the use of CCBs: these have shown an increased aortic risk in a mouse model and in retrospective case control studies,<sup><a href="javascript:;" reveal-id="ehae179-B1460" data-open="ehae179-B1460" class="link link-ref link-reveal xref-bibr">1460</a></sup> and alternatives are preferred for hypertension treatment.

Recommendation Table 61

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846586)

Recommendations for medical treatment in Marfan syndrome (see also Evidence Table 14)

![Recommendations for medical treatment in Marfan syndrome (see also Evidence Table 14)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt61.jpeg?Expires=1728479088&Signature=yovq2YrtYYm~iaLhbRP1P1X4tljhtQaJeUKaDIi6A8WA5YDCFJ1ssVFW7SafWZq4NbyTBcl~9~fUeniazjhXh8PtlLfUUaL4gOAln~YKY0KmlCieEuCOH4LJngXFvluhJEsgmwYM9JDzdQitylA59CymbRpMR78jAHWXMI7rc~WDCFIAg5I18ltpuDTpEi79aDdm-ZGk1ARzT~1KDozxGHIcmNDbRp603NeF826BoviqTUUG5gQmr6NeBP28oXP5BJNDjPlqHqaDQ0qS9LjY6eLGlIVPPuYHJx3tN1o0BB5FhNoB3T5rpjLXNJbUiFjaCGNZiM9agj1lH6P0FtAOIw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

##### 10.1.3.4. Aortic surgery

Open surgery is preferred over endovascular procedures in patients with MFS. Endovascular procedures may be considered in selected cases in emergency settings and/or in centres with a high level of expertise.<sup><a href="javascript:;" reveal-id="ehae179-B1465" data-open="ehae179-B1465" class="link link-ref link-reveal xref-bibr">1465</a></sup> The thresholds for aortic root surgery need to take additional risk factors, as well as the expertise of the team, into account.<sup><a href="javascript:;" reveal-id="ehae179-B1466" data-open="ehae179-B1466" class="link link-ref link-reveal xref-bibr">1466</a></sup>

Recommendation Table 62

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846589)

Recommendations for aortic surgery in Marfan syndrome

![Recommendations for aortic surgery in Marfan syndrome](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt62.jpeg?Expires=1728479088&Signature=YAnGh7e7HpJ44fhGyZ8I9XZVnLMJBzgIVNOVSkvO29fF0OAxRnUBrNZrJMjydOtiLU3Qv~tn7qUlJS7c44uPxFr6117pvk5txJgo5R1bro1lRYMotBq9Qdva52TaxhvBna2IJzer8rbA9xMv9XDplrq9G~mDkOlAaaYQxWBC-y42i1L0asIBuL9JzOZHpbzaKcSqNCtySnQR8yHXsFSTP~zFBIRLhSqsnBNr1DDTMGQu5ozW2~N-A9ENsm9dJ51zEGu-XajrSB~MzE~Zue68at4564NsaAkwM9ENUnWCLtfGiWM0LxByuhHIJPI2nhLpQPBVmzx9E67CDnQXsCrNHw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

##### 10.1.3.5. Pregnancy and physical exercise

In pregnant MFS women, the risk of AD increases up to eight times relative to the general population.<sup><a href="javascript:;" reveal-id="ehae179-B1470" data-open="ehae179-B1470" class="link link-ref link-reveal xref-bibr">1470</a></sup> The risk for TAAD is determined by the aortic diameter, but type B dissections tend to occur even more commonly and may occur without prior dilatation.<sup><a href="javascript:;" reveal-id="ehae179-B1470" data-open="ehae179-B1470" class="link link-ref link-reveal xref-bibr">1470</a>,<a href="javascript:;" reveal-id="ehae179-B1471" data-open="ehae179-B1471" class="link link-ref link-reveal xref-bibr">1471</a></sup> Patients should be aware of the persisting risk of TBAD after aortic root replacement.<sup><a href="javascript:;" reveal-id="ehae179-B1471" data-open="ehae179-B1471" class="link link-ref link-reveal xref-bibr">1471</a></sup> Women unaware of the diagnosis are at the highest risk of dissection.<sup><a href="javascript:;" reveal-id="ehae179-B1470 ehae179-B1471 ehae179-B1472" data-open="ehae179-B1470 ehae179-B1471 ehae179-B1472" class="link link-ref link-reveal xref-bibr">1470–1472</a></sup>

The Registry Of Pregnancy And Cardiac disease (ROPAC) indicates that women managed according to guidelines are at low risk of pregnancy-related complications and major effects of BBs on foetal growth were not shown, although this needs to be carefully monitored.<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B1337" data-open="ehae179-B1337" class="link link-ref link-reveal xref-bibr">1337</a>,<a href="javascript:;" reveal-id="ehae179-B1435" data-open="ehae179-B1435" class="link link-ref link-reveal xref-bibr">1435</a>,<a href="javascript:;" reveal-id="ehae179-B1471" data-open="ehae179-B1471" class="link link-ref link-reveal xref-bibr">1471</a>,<a href="javascript:;" reveal-id="ehae179-B1472" data-open="ehae179-B1472" class="link link-ref link-reveal xref-bibr">1472</a></sup>

Recommendation Table 63

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846593)

Recommendations for pregnancy in women with Marfan syndrome

![Recommendations for pregnancy in women with Marfan syndrome](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt63.jpeg?Expires=1728479088&Signature=OSGk7biKbvj3kYbzlnnZoD0alYtixSQTmD~kDJtEQS3xgTtywW1IE-lQdRCQGScRnIGDyxEDd9ygXuxsEuTapGqDHlcy6qJpibr9naIiOlkKRHXrF9GZOWOFE9oUOXX~f3lnIxZlNJ0u3-27kJILTcEchNP60EHF204J~qctcAeMjl4ginfn7SmVnqiHti2pDMXpKVs~VQDCizMTkRYFSsyEQHQzbWxY~UwYsxXvX4VNsvty5fXhgoO4YWL4bN-DLxqrEytQhT2gz29MG5u0zF5Uu8XVcGXI3tsoN567oNKfxSg5i7dYyj57av4JnMN72a2rm6MdbwK2P6WLvqFcLg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Exercise is potentially associated with an increased risk of aortic dilatation and AAD. It is recommended to individualize physical activity in MFS based on aortic diameter, family history of dissection or sudden death, and pre-existing fitness status.<sup><a href="javascript:;" reveal-id="ehae179-B71" data-open="ehae179-B71" class="link link-ref link-reveal xref-bibr">71</a></sup> Although competitive sports are contraindicated, moderate aerobic exercise is recommended with a level of intensity based on aortic diameters.<sup><a href="javascript:;" reveal-id="ehae179-B71" data-open="ehae179-B71" class="link link-ref link-reveal xref-bibr">71</a></sup>

Two studies<sup><a href="javascript:;" reveal-id="ehae179-B1481" data-open="ehae179-B1481" class="link link-ref link-reveal xref-bibr">1481</a>,<a href="javascript:;" reveal-id="ehae179-B1482" data-open="ehae179-B1482" class="link link-ref link-reveal xref-bibr">1482</a></sup> showed that mild-moderate dynamic exercise improved aortic wall structure and function and reduced aortic growth rate in MFS mouse models. Recent data in MFS children and young adults indicate that adhering to daily physical exercise (10 000 steps a day) had a beneficial effect on aortic root growth.<sup><a href="javascript:;" reveal-id="ehae179-B1483" data-open="ehae179-B1483" class="link link-ref link-reveal xref-bibr">1483</a></sup> Although a limited number of clinical studies have evaluated physical activity rehabilitation programmes, two studies<sup><a href="javascript:;" reveal-id="ehae179-B1484" data-open="ehae179-B1484" class="link link-ref link-reveal xref-bibr">1484</a>,<a href="javascript:;" reveal-id="ehae179-B1485" data-open="ehae179-B1485" class="link link-ref link-reveal xref-bibr">1485</a></sup> evidenced that physical activity, up to a moderate specific intensity, may be recommended. Thus, although physical activity poses a dilemma, individualized adapted programmes are most likely successful in encouraging exercise in MFS.

Recommendation Table 64

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846596)

Recommendations for physical exercise in patients with Marfan syndrome

![Recommendations for physical exercise in patients with Marfan syndrome](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt64.jpeg?Expires=1728479088&Signature=t6lSmBBKNCzrtyBMhV-NczujyvOPSXa745RWGU-z4S2Ud7YPk54bhP7cfPz~xtlGA~yJltXg8hwNwF6WNLZz-fmDlpfLnfBTkfpovDRCQutFz0tK2VfV34B4u6EqR2Cvb2pjh2CR6Dqxd4ecR7GA-tedN2T4AGbX-jyT9f36k2rwKgzxUQSPu~i0ief0OmCwkLctB6drASG3n5rAoFAda22eU1~GXsfR4n2g19e5-sVJ1ErjZ2HYlAnH2p0yoF5~yBW5a4IVv~9G3~~yjvCTZ-QjjD~rfJXyFJ5Aepf3kMMJJpx3xcHrUjhk~5du~qS9fgkSZTk85EQFjWY7WgLwBA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 10.1.4. Other syndromic and non-syndromic heritable thoracic aortic diseases and/or arterial disorders

Main clinical and genetic data of known syndromic and non-syndromic HTAD entities are summarized in the [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179_supplementary_data.pdf?Expires=1728479088&Signature=jsMN1psOaEf3KpW8UiQOwnEDCNM0eDJ9FhgPq~GNXqLItMAEdFx6foOGTBTeCpJhrfS5f9C1WsT6JBJ-OF2VSZCY4hMS9gJl7FbAOywEXjZ7FkQ8D8eMHICtPb1wzBA3uZZtBKMZczJqU~L965QcGSWu4bY5onpcoRMSzjgnNpdPf9L4pLKg-a0ahzhjNRwGHt5NoJ7ErFgx3duCbchEi0MsV0cDIkqzsUCeNEtwo8kpBYcJAps4DqCXaYZS5CPCAIpG4RbHZce70W~XP9IUuUZszMeWmEvwL5IF-0Kt0kkQwtSCyF6kopinSbFrVRYLZmYxxNRPbjwJpR0g1P88ZQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S5](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179_supplementary_data.pdf?Expires=1728479088&Signature=jsMN1psOaEf3KpW8UiQOwnEDCNM0eDJ9FhgPq~GNXqLItMAEdFx6foOGTBTeCpJhrfS5f9C1WsT6JBJ-OF2VSZCY4hMS9gJl7FbAOywEXjZ7FkQ8D8eMHICtPb1wzBA3uZZtBKMZczJqU~L965QcGSWu4bY5onpcoRMSzjgnNpdPf9L4pLKg-a0ahzhjNRwGHt5NoJ7ErFgx3duCbchEi0MsV0cDIkqzsUCeNEtwo8kpBYcJAps4DqCXaYZS5CPCAIpG4RbHZce70W~XP9IUuUZszMeWmEvwL5IF-0Kt0kkQwtSCyF6kopinSbFrVRYLZmYxxNRPbjwJpR0g1P88ZQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_. The two most prevalent diseases for each entity include Loeys–Dietz syndrome and _ACTA2_\-related HTAD, respectively. Given the rarity of these entities, specific recommendations regarding surveillance and treatment are lacking and largely adopted from the recommendations for MFS. Some disease-specific recommendations are mentioned below.

##### 10.1.4.1. Loeys–Dietz syndrome

###### Diagnosis, clinical presentation, and natural evolution

The spectrum of clinical presentations in Loeys–Dietz syndrome is very wide. Some patients fulfil criteria for MFS,<sup><a href="javascript:;" reveal-id="ehae179-B1447" data-open="ehae179-B1447" class="link link-ref link-reveal xref-bibr">1447</a></sup> while some features such as bifid uvula and hypertelorism are very specific to the disease. Clinical manifestations are listed in the [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179_supplementary_data.pdf?Expires=1728479088&Signature=jsMN1psOaEf3KpW8UiQOwnEDCNM0eDJ9FhgPq~GNXqLItMAEdFx6foOGTBTeCpJhrfS5f9C1WsT6JBJ-OF2VSZCY4hMS9gJl7FbAOywEXjZ7FkQ8D8eMHICtPb1wzBA3uZZtBKMZczJqU~L965QcGSWu4bY5onpcoRMSzjgnNpdPf9L4pLKg-a0ahzhjNRwGHt5NoJ7ErFgx3duCbchEi0MsV0cDIkqzsUCeNEtwo8kpBYcJAps4DqCXaYZS5CPCAIpG4RbHZce70W~XP9IUuUZszMeWmEvwL5IF-0Kt0kkQwtSCyF6kopinSbFrVRYLZmYxxNRPbjwJpR0g1P88ZQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S5](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179_supplementary_data.pdf?Expires=1728479088&Signature=jsMN1psOaEf3KpW8UiQOwnEDCNM0eDJ9FhgPq~GNXqLItMAEdFx6foOGTBTeCpJhrfS5f9C1WsT6JBJ-OF2VSZCY4hMS9gJl7FbAOywEXjZ7FkQ8D8eMHICtPb1wzBA3uZZtBKMZczJqU~L965QcGSWu4bY5onpcoRMSzjgnNpdPf9L4pLKg-a0ahzhjNRwGHt5NoJ7ErFgx3duCbchEi0MsV0cDIkqzsUCeNEtwo8kpBYcJAps4DqCXaYZS5CPCAIpG4RbHZce70W~XP9IUuUZszMeWmEvwL5IF-0Kt0kkQwtSCyF6kopinSbFrVRYLZmYxxNRPbjwJpR0g1P88ZQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_. There is a tendency for AD and rupture at lower vessel dimensions than is typically seen in other similar conditions.<sup><a href="javascript:;" reveal-id="ehae179-B1390" data-open="ehae179-B1390" class="link link-ref link-reveal xref-bibr">1390</a>,<a href="javascript:;" reveal-id="ehae179-B1487" data-open="ehae179-B1487" class="link link-ref link-reveal xref-bibr">1487</a></sup> Pathogenic variants in six genes _(TGFBR1_ and _TGFBR2, TGFB2_ and _TGFB3, SMAD2_ and _SMAD3)_, all encoding components of the TGF-ß signalling pathway, cause Loeys–Dietz syndrome. Differences in clinical manifestations and aortic outcome according to the underlying gene and the extent of extra-aortic features have been reported and need to be considered in surveillance and defining thresholds for surgery.<sup><a href="javascript:;" reveal-id="ehae179-B1388" data-open="ehae179-B1388" class="link link-ref link-reveal xref-bibr">1388</a>,<a href="javascript:;" reveal-id="ehae179-B1390" data-open="ehae179-B1390" class="link link-ref link-reveal xref-bibr">1390</a>,<a href="javascript:;" reveal-id="ehae179-B1391" data-open="ehae179-B1391" class="link link-ref link-reveal xref-bibr">1391</a></sup>

Surveillance in Loeys–Dietz syndrome is described in Recommendation Table 65 and _[Figure 41](javascript:;)_. Although the indication for surgery must be considered according to the underlying genetic defect and the presence of risk factors (Recommendation Table 66 and _[Figure 42](javascript:;)_), a 45 mm aortic diameter threshold should be considered (≥40 mm in cases of associated high-risk features).

![Suggested thresholds for prophylactic aortic root/ascending replacement in Loeys–Dietz syndrome.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f42.jpeg?Expires=1728479088&Signature=HLhhYtRZfLcuoJPq63ITK3hfc9I4MTdTe-fEEZCvNcBn~SQwdFtVTmk63XC5BMkG2DX9BmUDprWOweISKR22yDI06RgdZdEL3ptXDlF~QQksr8CTso5T5Gg6ZZgF905ZYo2Hqxw8wE5XkZKg5XJeViaM6yUIq~hmyi0rplFgPwVqYIFW2Y9Yjd~8uM~p6BY66P2-o0b6tU7AEJvpoZulsdkfdS7ZL0tyRLnk8DUrCV7CX-3bzEYsoE3bC88hTjHTZoXPxWnmxKxIuIReZhNzrhHGEEQiAnqdcM3IhAD8TtBKu7ImKPIXyHqLmPl~pst8M-r6RXhN7cxpvIM7gb3ggA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 42

Suggested thresholds for prophylactic aortic root/ascending replacement in Loeys–Dietz syndrome.

From a<sup><a href="javascript:;" reveal-id="ehae179-B1388" data-open="ehae179-B1388" class="link link-ref link-reveal xref-bibr">1388</a></sup>, b<sup><a href="javascript:;" reveal-id="ehae179-B1391" data-open="ehae179-B1391" class="link link-ref link-reveal xref-bibr">1391</a></sup>, c<sup><a href="javascript:;" reveal-id="ehae179-B1492" data-open="ehae179-B1492" class="link link-ref link-reveal xref-bibr">1492</a></sup>, d<sup><a href="javascript:;" reveal-id="ehae179-B1491" data-open="ehae179-B1491" class="link link-ref link-reveal xref-bibr">1491</a></sup>, e<sup><a href="javascript:;" reveal-id="ehae179-B1490" data-open="ehae179-B1490" class="link link-ref link-reveal xref-bibr">1490</a></sup>, f<sup><a href="javascript:;" reveal-id="ehae179-B1489" data-open="ehae179-B1489" class="link link-ref link-reveal xref-bibr">1489</a></sup>, g<sup><a href="javascript:;" reveal-id="ehae179-B1493" data-open="ehae179-B1493" class="link link-ref link-reveal xref-bibr">1493</a></sup>, h<sup><a href="javascript:;" reveal-id="ehae179-B1494" data-open="ehae179-B1494" class="link link-ref link-reveal xref-bibr">1494</a></sup>, i<sup><a href="javascript:;" reveal-id="ehae179-B1495" data-open="ehae179-B1495" class="link link-ref link-reveal xref-bibr">1495</a></sup>.

[Open in new tab](https://academic.oup.com/view-large/figure/479846603/ehae179f42.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f42.jpeg?Expires=1728479088&Signature=NJuejaDTkDk~0eLS90kKrKqtTRz-fpRULKiFrQIxe0fEN7KuEXQ~ghkshicRcWyXi3ZoHL4ZEDu~AvKRxrvsHmHmRYHTaQLf9EjebT3OT2zjrwzw33DxM-BQxVNrfaNIiijgDvdr6MdiFco-7AJqJwTWBmJ2-8El5Dr3VXKa~xeUI3Yii~K1Q2RPPjzFHKQTTeCXJG5QXDOaSq~Ih~noPaQo84offj0Ll5Cw4MvjJrGdsMGy~-S4-w9tqXrABBUcnTL78xVAqV20y8GGzP50K0qG8m67nmxnuKBsaqxOXFEpNKoKEPtU6CTQRdLKHAel7VoUqfGw2xQasFwtaw1V3Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846603&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Recommendation Table 65

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846604)

Recommendations for imaging follow-up in Loeys–Dietz syndrome

![Recommendations for imaging follow-up in Loeys–Dietz syndrome](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt65.jpeg?Expires=1728479088&Signature=jn4pmTm7oA1F2JJd-olG4ZA9fYyLQ4K57CVqOmdhMeE~L~MBxlcIK23ojoQbqQjcEPlqsc8yBnh7C0E4EZYzw3xbdK35LhvPRLSXtj-WbvYU0WXApVAchf-q8N6GNKmil3bEFKtpgO4d6GYzHBpyjllU6JknYTZOItOieF-tY7oqajkDvq3ciZUBrA9hhIu2nfwtzx~M-YhRXOPaGrA53mMrEMmDZcnq7CNho1vf6p2q~VCHYYNVz8joext-wHCIg9w9H6e0JuiZzYc8uCr7DNsob2LlaNSB~6aOd3Gql0r6Q0-ul5TgqfoUKKTQaFhcALlp8cpqH8sSD7oada7uiA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 66

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846605)

Recommendations for aortic root surgery in Loeys–Dietz syndrome

![Recommendations for aortic root surgery in Loeys–Dietz syndrome](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt66.jpeg?Expires=1728479088&Signature=LAezqbHe-hWRomTN6-s2cXrMR7ELgJ7qwzEaFKrh4nNg7v9pca~qtyG-AUv9cQhff4G9xVnB5Gzv9n1MhR291jme3nbBRfctkaW65MrwxYRm9laGyJvbXgkt1stZPb9EeVrBnq7~z2rWmtMPnkIEKU7XE-iv6P1Ugor9ZsvYKPOat8QwaIB8uBIMRij0Vi2c3NJ9RBoAlXL-xASq8kai6pwR-PpmEkj-OUDP~pu762uEJwhbnzb52P-qPazF81cqx~FFcXjHWwaU0KfQXlhB-Yp5IveCexSzDp57y9~tBNjghYZKDLto8L524rjcTxnAnXp97XBkCrnlleIxmpR0vQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

##### 10.1.4.2. _ACTA2_\-related heritable thoracic aortic disease

Pathogenic variants in the _ACTA2_ gene, encoding for smooth muscle-specific alpha-actin (a critical component of the vascular smooth muscle cell contractile apparatus), lead to aortic aneurysms and dissections in non-syndromic patients.<sup><a href="javascript:;" reveal-id="ehae179-B1496" data-open="ehae179-B1496" class="link link-ref link-reveal xref-bibr">1496</a></sup> Patients primarily present with type A or B aortic dissection, and with aneurysms that involve the root and/or ascending aorta. A subset of pathogenic variants predisposes to occlusive vascular diseases.<sup><a href="javascript:;" reveal-id="ehae179-B1497" data-open="ehae179-B1497" class="link link-ref link-reveal xref-bibr">1497</a></sup> Surveillance is summarized in Recommendation Table 67 and _[Figure 41](javascript:;)_. TAAD may occur at aortic diameters <45 mm, and consideration of surgery at diameters <45 mm should be informed by the presence of additional clinical and genetic risk factors.<sup><a href="javascript:;" reveal-id="ehae179-B1410" data-open="ehae179-B1410" class="link link-ref link-reveal xref-bibr">1410</a></sup> Genetic and imaging cascade screening of first-degree family members is an essential element of care, as treatable disease may otherwise be missed in family members—with fatal consequences.

Recommendation Table 67

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846608)

Recommendations for imaging and surgery in _ACTA2_\-related heritable thoracic aortic disease (see also Evidence Table 11)

![Recommendations for imaging and surgery in ACTA2-related heritable thoracic aortic disease (see also Evidence Table 11)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt67.jpeg?Expires=1728479088&Signature=t9-QmXr5RJK0KSxEgRwtCrM36toxgTfLLhqE2LtqgoDynpKXYf3GO2L0zfay3mAUqrgVpVSw1tBRCMBWJJ5nScO0X2G8KajJSKWrhlfjQpFMzwQH2SzfxSRGxg~vIEFAozZPpWBD42uAqLUcMXtciWDCiblAkLGie1yYPpEvdPOizIoCevOehiBZnb-Yer-1ir754oQa9XmemrS6V0MLYnj47ZgD~~cGYqSHfO-Zetg4S2QHupqijDpfy5671tZBUqLniP-CADjPAdvjD-KZ9MpniLTWUNIGlteFFPP5td24Suk7kkEYKss9aHHS99Wn~uN9WDan3F2FUfBFC~ZsIQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 10.2. Aortic disease associated with bicuspid aortic valves

Bicuspid aortic valves, the most common congenital heart defect (0.5%–2% of live births), besides being a risk factor for aortic valve disease, is associated with a peculiar form of aortopathy, characterized by morphological and clinical heterogeneity (bicuspid valvulo-aortopathy). Its inheritance is high, with autosomal dominant transmission of BAV in a minority of cases, but no single-gene model clearly explaining BAV inheritance.<sup><a href="javascript:;" reveal-id="ehae179-B1500 ehae179-B1501 ehae179-B1502" data-open="ehae179-B1500 ehae179-B1501 ehae179-B1502" class="link link-ref link-reveal xref-bibr">1500–1502</a></sup> Several genes, generally implicated in embryogenesis and cell differentiation, have been associated with BAV/BAV-related aortopathy, but each of them explained <5% of cases.<sup><a href="javascript:;" reveal-id="ehae179-B1503 ehae179-B1504 ehae179-B1505 ehae179-B1506 ehae179-B1507" data-open="ehae179-B1503 ehae179-B1504 ehae179-B1505 ehae179-B1506 ehae179-B1507" class="link link-ref link-reveal xref-bibr">1503–1507</a></sup> Therefore, genetic testing is not indicated for isolated BAV disease, but reserved for patients with syndromic features, family history of aortic disease, or aneurysms/dissections of medium-sized arteries other than the thoracic aorta, and may be considered in patients with the root phenotype.<sup><a href="javascript:;" reveal-id="ehae179-B1389" data-open="ehae179-B1389" class="link link-ref link-reveal xref-bibr">1389</a>,<a href="javascript:;" reveal-id="ehae179-B1508" data-open="ehae179-B1508" class="link link-ref link-reveal xref-bibr">1508</a>,<a href="javascript:;" reveal-id="ehae179-B1509" data-open="ehae179-B1509" class="link link-ref link-reveal xref-bibr">1509</a></sup>

We recommend adopting a new international consensus nomenclature and classification, established by a panel of experts, to replace the previous various concurrent nomenclatures used<sup><a href="javascript:;" reveal-id="ehae179-B1510" data-open="ehae179-B1510" class="link link-ref link-reveal xref-bibr">1510</a></sup> (_[Figure 43](javascript:;)_). Aneurysm prevalence reaches 40% in clinical series and 0.85 per 100 patient-years in population studies. AAEs are rare, but 8- to 10-fold more frequent than in the general population.<sup><a href="javascript:;" reveal-id="ehae179-B1001" data-open="ehae179-B1001" class="link link-ref link-reveal xref-bibr">1001</a>,<a href="javascript:;" reveal-id="ehae179-B1511" data-open="ehae179-B1511" class="link link-ref link-reveal xref-bibr">1511</a></sup> The longest available follow-up of BAV subjects was recently reported,<sup><a href="javascript:;" reveal-id="ehae179-B1512" data-open="ehae179-B1512" class="link link-ref link-reveal xref-bibr">1512</a></sup> showing a total lifetime morbidity burden as high as 86%, a predominant part of which was driven by valve-related complications (aortic stenosis, endocarditis, HF).

![Bicuspid aortic valve, valvulo-aortopathy nomenclature.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f43.jpeg?Expires=1728479088&Signature=nE1K~IY4vU2GVyB2Vym1O4hnA5e6k4rgcDMuSNWXjBHPqDh-F1xkoPl7jjwrWwittQ3Zr0w~X2RvPJJuk4SP4sf4lqR3GYF95YFry8wnldoF5w2Uo01Rsr9fpsqHTLYqoQZVDEuGgPXgGLYMmzrzpX2eCvb8PuuGG2r4Qa4mIPCNRSAWhdmk4AQTf3R9yA3JcE6Bo2rYYKv20S3bZ1c5I9wt5mYAXt2BPk1UIjWtRT21Io89i1-WmCqrQ-9Fei5UMj9UhfuSI1eKTLBc5WRrG47~m3YmaLtv1qSAp-vHIUf~DRBjLQ4IP6UmuYLkppfUjLYdvGngdeu44iNpTVItvg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 43

Bicuspid aortic valve, valvulo-aortopathy nomenclature.

Modified from Michelena _et al_.<sup><a href="javascript:;" reveal-id="ehae179-B1510" data-open="ehae179-B1510" class="link link-ref link-reveal xref-bibr">1510</a></sup> A, anterior; BAV, bicuspid aortic valve; L, lateral; P, posterior. Although preferential associations exist, each of the three valve types—‘fused BAV’, ‘2-sinus BAV’, and ‘partial-fusion BAV’—can be variably associated with dilatation predominantly located at the sinuses of Valsalva (‘root phenotype’, 15%–20%) or at the tubular (supra-coronary) tract (‘ascending phenotype’, 70%–75%). A minor proportion of patients present with equal dilatation of the sinusal and tubular segments or ascending dilatation extending into the proximal arch (‘extended phenotype’, 5%–10%).

[Open in new tab](https://academic.oup.com/view-large/figure/479846612/ehae179f43.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f43.jpeg?Expires=1728479088&Signature=DzmgZyGEy5FZ7pFGbxU76TObKF2keue03-YTw2Jco~xHnbdcLNIgSEDJBtNJOA13rIl8Closo91OZIynHMRi-YLX3aySdUZkIedv8~UXzjbT1TIUMcqINA8RF13wTvZZqtnt7j~hV2ZCh4kFfD7P81zfAS7iV72u-rzp9prnqFau8ypuDWIm-F0ZRuAVIPOTDmgyC2t0eTkNw5ZJ6R6orxnIfLIrsvQaAQGh5fPGzQ0LaNAsflcF9iJnolePNxo7oP0BIFbJNDHr~--12ERkH~QQRBcDnkXFIU7CrgcTov0iXbI5qZOS1SxDW6TF6Odmtc39gP4qr5fMSo1FAc~2lg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846612&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

When a BAV is first detected, a complete study of the thoracic aorta is necessary; vice versa, in every patient with ascending aortic dilatation, valve morphology should be ascertained.<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B969" data-open="ehae179-B969" class="link link-ref link-reveal xref-bibr">969</a></sup> When TTE detects BAV-associated aortic dilatation, CCT or CMR is recommended to confirm measurements, exclude coarctation, and record baseline diameters at different levels for subsequent periodic assessments.<sup><a href="javascript:;" reveal-id="ehae179-B137" data-open="ehae179-B137" class="link link-ref link-reveal xref-bibr">137</a>,<a href="javascript:;" reveal-id="ehae179-B1001" data-open="ehae179-B1001" class="link link-ref link-reveal xref-bibr">1001</a></sup> Surveillance by TTE becomes necessary when the maximum diameter exceeds 40 mm. In mixed tricuspid aortic valve (TAV) and BAV series, AAEs occurred in 2/10 000 patient-years with a diameter >40 mm (vs. 0.1–0.3/10 000 patient-years in the general population)<sup><a href="javascript:;" reveal-id="ehae179-B894" data-open="ehae179-B894" class="link link-ref link-reveal xref-bibr">894</a></sup> (_[Figure 43](javascript:;)_). Considering average aortic diameter growth of 0.2–0.6 mm per year,<sup><a href="javascript:;" reveal-id="ehae179-B893" data-open="ehae179-B893" class="link link-ref link-reveal xref-bibr">893</a>,<a href="javascript:;" reveal-id="ehae179-B1513" data-open="ehae179-B1513" class="link link-ref link-reveal xref-bibr">1513</a></sup> once fast progression is excluded, follow-up can be scheduled every 2–3 years (according to risk profile). In 5%–15% of cases, BAV patients have at least one FDR with either BAV or ascending aortic dilatation; root phenotype and aortic regurgitation in the proband predict ascending dilatation in FDRs.<sup><a href="javascript:;" reveal-id="ehae179-B1514" data-open="ehae179-B1514" class="link link-ref link-reveal xref-bibr">1514</a></sup> FDR screening is considered cost-effective, but the age at which relatives should undergo TTE remains to be determined.<sup><a href="javascript:;" reveal-id="ehae179-B1515" data-open="ehae179-B1515" class="link link-ref link-reveal xref-bibr">1515</a>,<a href="javascript:;" reveal-id="ehae179-B1516" data-open="ehae179-B1516" class="link link-ref link-reveal xref-bibr">1516</a></sup>

A diameter exceeding 55 mm at any level mandates surgery.<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B969" data-open="ehae179-B969" class="link link-ref link-reveal xref-bibr">969</a>,<a href="javascript:;" reveal-id="ehae179-B1001" data-open="ehae179-B1001" class="link link-ref link-reveal xref-bibr">1001</a></sup> However, the historically known relation between diameter and acute complications has been recently reappraised. Both in large mixed<sup><a href="javascript:;" reveal-id="ehae179-B153" data-open="ehae179-B153" class="link link-ref link-reveal xref-bibr">153</a></sup> and purely BAV series,<sup><a href="javascript:;" reveal-id="ehae179-B981" data-open="ehae179-B981" class="link link-ref link-reveal xref-bibr">981</a></sup> an ascending diameter of about 52 mm already marked an AAE risk increase from ∼1% to 4%–5%. Additionally, early post-operative mortality for elective surgery of the proximal aorta ranges today between 0.25% and 2%.<sup><a href="javascript:;" reveal-id="ehae179-B980" data-open="ehae179-B980" class="link link-ref link-reveal xref-bibr">980</a>,<a href="javascript:;" reveal-id="ehae179-B981" data-open="ehae179-B981" class="link link-ref link-reveal xref-bibr">981</a></sup> Therefore, aortic surgery in low surgical risk (<3%) patients with an ascending diameter >52 mm implies a lower risk than observed in the natural history of the disease. For aortic root dilatation in BAV patients, the ‘hinge point’ was at 50 mm;<sup><a href="javascript:;" reveal-id="ehae179-B981" data-open="ehae179-B981" class="link link-ref link-reveal xref-bibr">981</a></sup> this phenotype is associated with faster growth rate,<sup><a href="javascript:;" reveal-id="ehae179-B893" data-open="ehae179-B893" class="link link-ref link-reveal xref-bibr">893</a></sup> higher risk of events following isolated aortic valve replacement,<sup><a href="javascript:;" reveal-id="ehae179-B1517" data-open="ehae179-B1517" class="link link-ref link-reveal xref-bibr">1517</a></sup> worse survival if not operated,<sup><a href="javascript:;" reveal-id="ehae179-B1518" data-open="ehae179-B1518" class="link link-ref link-reveal xref-bibr">1518</a></sup> and higher risk of acute TAAD.<sup><a href="javascript:;" reveal-id="ehae179-B976" data-open="ehae179-B976" class="link link-ref link-reveal xref-bibr">976</a>,<a href="javascript:;" reveal-id="ehae179-B1519" data-open="ehae179-B1519" class="link link-ref link-reveal xref-bibr">1519</a></sup>

Surgery should be considered when the diameter is ≥50 mm in selected ascending phenotype patients (_[Figures 23](javascript:;), [24](javascript:;)_ and _[43](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B1001" data-open="ehae179-B1001" class="link link-ref link-reveal xref-bibr">1001</a></sup> Among those factors, family history of AAEs, poorly controlled hypertension, aortic coarctation, and rapid (≥3 mm per year) diameter growth should be noted. Surgery at >50 mm may also be considered in a shared decision with the patient, taking lifestyle and psychological factors into consideration,<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae179-B1001" data-open="ehae179-B1001" class="link link-ref link-reveal xref-bibr">1001</a></sup> since 50 mm should correspond to an approximately 10-fold increase in the risk of AAEs.<sup><a href="javascript:;" reveal-id="ehae179-B894" data-open="ehae179-B894" class="link link-ref link-reveal xref-bibr">894</a></sup> In a study of patients with aortic diameter ≥40 mm, those with diameters of 50 mm faced a 1% risk of AAEs within 5 years, compared with 0.1% for those with 40 mm diameters, explaining the 10-fold difference; however, this study did not exclusively involve BAV patients.<sup><a href="javascript:;" reveal-id="ehae179-B894" data-open="ehae179-B894" class="link link-ref link-reveal xref-bibr">894</a></sup> Another recent study<sup><a href="javascript:;" reveal-id="ehae179-B1520" data-open="ehae179-B1520" class="link link-ref link-reveal xref-bibr">1520</a></sup> specifically focused on BAV patients found a 0.4% incidence of AAEs per patient-year for diameters above 50 mm, in contrast to the general BAV population’s 0.03% incidence.<sup><a href="javascript:;" reveal-id="ehae179-B1521" data-open="ehae179-B1521" class="link link-ref link-reveal xref-bibr">1521</a></sup> Previous guidelines also suggested aortic repair for a cross-sectional area-to-height ratio (CSA/h) >10 cm<sup>2</sup>/m;<sup><a href="javascript:;" reveal-id="ehae179-B70" data-open="ehae179-B70" class="link link-ref link-reveal xref-bibr">70</a></sup> nevertheless, more recently, it has been suggested that the CSA/h threshold for the ascending tract in BAV should be 13 cm<sup>2</sup>/m.<sup><a href="javascript:;" reveal-id="ehae179-B981" data-open="ehae179-B981" class="link link-ref link-reveal xref-bibr">981</a></sup> For the average height of male and female Europeans (1.8 m and 1.67 m, respectively), a CSA/h of 10 cm<sup>2</sup>/m would correspond to a diameter of 48 mm or 46 mm, respectively, whereas 13 cm<sup>2</sup>/m means 54 mm or 53 mm. It is reasonable to refer to the 13 cm<sup>2</sup>/m CSA/h cut-off for ascending aortic repair, especially in individuals ≤1.69 m in height (since 13 cm<sup>2</sup>/m corresponds to ≤52 mm diameter). Recently, besides dilatation, aortic elongation is also considered a risk factor,<sup><a href="javascript:;" reveal-id="ehae179-B974" data-open="ehae179-B974" class="link link-ref link-reveal xref-bibr">974</a></sup> and a curvilinear length >11.5 cm at the vessel’s centreline increases the yearly risk of AAEs.<sup><a href="javascript:;" reveal-id="ehae179-B155" data-open="ehae179-B155" class="link link-ref link-reveal xref-bibr">155</a></sup> Age is another factor to consider: at 50 years, a 40 mm ascending aorta corresponds to the upper normal limit for patients with large body size,<sup><a href="javascript:;" reveal-id="ehae179-B149" data-open="ehae179-B149" class="link link-ref link-reveal xref-bibr">149</a></sup> and therefore the same diameter at a higher age could imply a lower risk of AAEs.

Recommendation Table 68

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846616)

Recommendations for bicuspid aortic valve-associated aortopathy management

![Recommendations for bicuspid aortic valve-associated aortopathy management](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt68.jpeg?Expires=1728479088&Signature=5MKO5X5nl~hWVoVwmxGWnpGIlV-K9EN0JFamrk~XylMoMkp8z82BKCzG9LjPhQEUmEIh5PgB3hs8Q-Pt4WZMuu6EXT-zUK7PYvXFjd1y6c5CU0KBpfn~3NKgpIYfvmJCRP3XXsN1pmj9Y760xKN5Pv5NiyEntGmN6zh47cg~PyOz~26CcPUgTwucq612Cc292RjyFI5~N07ICV36M2LIoB9CE1nixLKZyGfohFBwfGS~DZ6m1OKYJU35lS2DjHcs~Sc2EpsExr1-GbECV7Dsqx1CutzpIVNdgAZa8sOXGO-ARinTjCYDXyIWHuyVXtk3uvh0BuLWGDBBpfsKC7432A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 10.3. Coarctation of the aorta and aortic arch variants

#### 10.3.1. Coarctation of the aorta

This topic is extensively discussed in the _ESC 2020 Guidelines for the management of adult congenital heart disease_.<sup><a href="javascript:;" reveal-id="ehae179-B1468" data-open="ehae179-B1468" class="link link-ref link-reveal xref-bibr">1468</a></sup> Coarctation of the aorta (CoA) manifests as a discrete stenosis or a hypoplastic segment typically located at the insertion of the ductus arteriosus. More distal locations are known as mid-aortic syndrome and require dedicated management.<sup><a href="javascript:;" reveal-id="ehae179-B1524" data-open="ehae179-B1524" class="link link-ref link-reveal xref-bibr">1524</a></sup> Associated lesions include BAV (up to 50%–85%), intracerebral aneurysms (10%), and ascending aortic aneurysms.<sup><a href="javascript:;" reveal-id="ehae179-B1525" data-open="ehae179-B1525" class="link link-ref link-reveal xref-bibr">1525</a>,<a href="javascript:;" reveal-id="ehae179-B1526" data-open="ehae179-B1526" class="link link-ref link-reveal xref-bibr">1526</a></sup> CoA may be associated with syndromes such as TS. Research indicates that up to 12.6% of females diagnosed with CoA also have TS, and coarctation is observed in 7%–18% of patients with TS.<sup><a href="javascript:;" reveal-id="ehae179-B1417" data-open="ehae179-B1417" class="link link-ref link-reveal xref-bibr">1417</a>,<a href="javascript:;" reveal-id="ehae179-B1468" data-open="ehae179-B1468" class="link link-ref link-reveal xref-bibr">1468</a>,<a href="javascript:;" reveal-id="ehae179-B1527" data-open="ehae179-B1527" class="link link-ref link-reveal xref-bibr">1527</a></sup>

##### 10.3.1.1. Diagnostic work-up

Mild cases of CoA may only become evident in adulthood. Symptoms reflect pre-stenotic hypertension (e.g. headache, nosebleeds) and post-stenotic hypoperfusion (e.g. abdominal angina and claudication). The natural course is largely driven by hypertension-related complications, including HF, intracranial haemorrhage, premature coronary/cerebral artery disease, and aortic rupture/dissection.<sup><a href="javascript:;" reveal-id="ehae179-B1528" data-open="ehae179-B1528" class="link link-ref link-reveal xref-bibr">1528</a></sup> Presently, there is no evidence supporting screening for intracerebral aneurysms in asymptomatic patients.

A systolic non-invasive gradient between upper and lower extremities, an abnormal ABI, or an invasive peak-to-peak gradient ≥20 mmHg indicates significant CoA. In the presence of collaterals or decreased LV function, gradients or ABI may underestimate severity. A diastolic tail in the DTA or abdominal diastolic antegrade flow by TTE is suggestive of significant narrowing. Criteria to consider significant CoA are listed in _[Figure 44](javascript:;)_. TTE is also useful to detect LV hypertrophy, which is a marker of disease. CMR and CCT are the preferred imaging techniques, depicting the narrowing as well as the surrounding anatomy, necessary for interventional decision-making.

![Criteria for significant coarctation/re-coarctation of the aorta and management algorithm.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f44.jpeg?Expires=1728479088&Signature=EdI61-~6q7Z4uYwz4NFeEGs6P-dpxiVT2f7Ra7ADgrhe3Ddi13YlSb9BRqFNn-0x04St-vHsbSLG~YonhJw2pCkmAE85hghjMLxPEdoGck-xsTR3d22xPEeDwbdHE6VHdDrc-ol2wr1nnahlEAnOokvvne1lmK1N2sqTWDCsX3Qj4spmwZ~mZJ95eoCw52zVM2iLtF5YgwsGOw86~4Jgw6BXGixrvF-vz7HVzX2XfYOLl1MLgr47kYUqGOJo6GoaKheTcMlIY6scsLkIvmwMzlSBUPolPQOvpuulJ4WfsHBIcNeeHwRGeUVfld-QUVFfWfLnzBS0qVFiTJmsKMHtfw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 44

Criteria for significant coarctation/re-coarctation of the aorta and management algorithm.

BP, blood pressure; CCT, cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; CoA, coarctation of the aorta; DUS, duplex ultrasound; HTN, hypertension; TTE, transthoracic echocardiography. <sup>a</sup>Diagnosis of hypertension may require confirmation with ambulatory BP measurement and should also be considered in cases of exercise-induced hypertension and/or left ventricular hypertrophy on TTE.

[Open in new tab](https://academic.oup.com/view-large/figure/479846623/ehae179f44.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f44.jpeg?Expires=1728479088&Signature=zLiaPHXhX~ri8E-Mz~tNPYccjSmb556BuVcAxAtXEC-3RPW9oJTNUkfWAYNRUOMze-oMt5TThqYXuPKf~EdYVeBEB60dFhAbiperRg9XlyLOKqjVqYwrdLD1S82H5RA5TVhiIbZ4fbMwbWISGrMZsywHNTVr25PvMEQ0ORwd4oF9bLW94EcHJyZ1v~sD2u5xYKbW57nHcrJ5flPUKx3PASJZaOmRIQx6y0qR4DQQk9HwbxU4ZpZrm1OY2p-YTHFXkvFhP7ANrICW8kVqx8cVbiNvVwKW~EdnPKTMP2Nm8cpEw8nJmBy8II5fLo9BLfrnJe-nhp43EBYrOLPnuqsPZA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846623&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

##### 10.3.1.2. Treatment and follow-up

In native CoA and re-coarctation (_[Figure 44](javascript:;)_) covered stenting is the first-choice treatment. Interposition of a tube graft is the preferred surgical therapy if stenting is less suitable.<sup><a href="javascript:;" reveal-id="ehae179-B1529" data-open="ehae179-B1529" class="link link-ref link-reveal xref-bibr">1529</a></sup> Hypertension remains an important complication, even after successful treatment, and is more common when the initial repair is performed in adulthood.<sup><a href="javascript:;" reveal-id="ehae179-B1528" data-open="ehae179-B1528" class="link link-ref link-reveal xref-bibr">1528</a></sup> Right arm 24 h ambulatory BP measurement or exercise tests better detect hypertension.<sup><a href="javascript:;" reveal-id="ehae179-B1530" data-open="ehae179-B1530" class="link link-ref link-reveal xref-bibr">1530</a>,<a href="javascript:;" reveal-id="ehae179-B1531" data-open="ehae179-B1531" class="link link-ref link-reveal xref-bibr">1531</a></sup>

All CoA patients require lifelong follow-up.<sup><a href="javascript:;" reveal-id="ehae179-B1532" data-open="ehae179-B1532" class="link link-ref link-reveal xref-bibr">1532</a></sup> Imaging of the aorta with CMR/CCT every 3–5 years, adjusted to previous imaging findings and type of intervention, is required to document post-repair or post-interventional complications (such as re-coarctation). Patch repairs are at particular risk of repair-site para-anastomotic aneurysms or pseudo-aneurysms, the latter possibly occurring following interposition grafts as well.<sup><a href="javascript:;" reveal-id="ehae179-B1533" data-open="ehae179-B1533" class="link link-ref link-reveal xref-bibr">1533</a></sup>

Recommendation Table 69

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846627)

Recommendations for evaluation and medical treatment of patients with coarctation of the aorta

![Recommendations for evaluation and medical treatment of patients with coarctation of the aorta](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt69.jpeg?Expires=1728479088&Signature=HknwdXKDKq9~tRMHl-HULR~FOKmCU3kXHWJmgfQlE64wRlnkPas5Xb1Wmtv0i29wQ5dGJA4gOwSgrbwfY3bS6TAbpd7vcwqy5MnIkcXwN9gwfaEwroJXaDORco1v0msbzNioU~VwPR0gncsj14TK-y0niAmAOLEsqMz5PgafqoMtXrZgWsFEune1Ca1etyTbwRQtRCyMIP-iYO8DhRrXtJOVnqfKa~shPDLwxbRlKZDkoy8mnKznjJnz9YuXPddaQw~gD0cdaBxLKmSSwGLY5pR~TgygWdQM6q8Zu3318YqYZK-v7n90NC~w3m7goRrfQPIeCk2EczspI0WFDDCGvw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 10.3.2. Aortic arch anatomic variants

A type I arch, where the three great vessels directly arise from the aorta, is the most common form, occurring in about 70% of the population. The type II (bovine) arch is the most frequent variant: type II-A (9% of the population) has the left common carotid artery arising from the innominate artery, and type II-B (13% of the population) has both the innominate and left common carotid arteries originating from a common point on the aortic arch.<sup><a href="javascript:;" reveal-id="ehae179-B1538" data-open="ehae179-B1538" class="link link-ref link-reveal xref-bibr">1538</a>,<a href="javascript:;" reveal-id="ehae179-B1539" data-open="ehae179-B1539" class="link link-ref link-reveal xref-bibr">1539</a></sup> Limited data suggest that a bovine arch is associated with a higher risk of aortic dilation and aortic events/complications.<sup><a href="javascript:;" reveal-id="ehae179-B1540" data-open="ehae179-B1540" class="link link-ref link-reveal xref-bibr">1540</a>,<a href="javascript:;" reveal-id="ehae179-B1541" data-open="ehae179-B1541" class="link link-ref link-reveal xref-bibr">1541</a></sup> These variations are important to report as they can impact specific medical procedures and diagnostic interpretations.

#### 10.3.3. Aberrant subclavian artery and Kommerell’s diverticulum

The most common variant is the aberrant right subclavian artery, where the right subclavian artery arises as the last branch of the aortic arch, usually after the left subclavian artery, and often passes behind the oesophagus through the mediastinum, potentially causing dysphagia lusoria, respiratory symptoms, or recurrent laryngeal nerve palsy. The less common variant, the aberrant left subclavian artery, is typically associated with congenital heart defects, such as a right aortic arch. However, in adulthood, both variations are often incidental findings.<sup><a href="javascript:;" reveal-id="ehae179-B1542" data-open="ehae179-B1542" class="link link-ref link-reveal xref-bibr">1542</a></sup>

Kommerell’s diverticulum is a remnant of the fourth dorsal aortic arch due to incomplete regression, found in 20%–60% of those with an aberrant subclavian artery.<sup><a href="javascript:;" reveal-id="ehae179-B1543" data-open="ehae179-B1543" class="link link-ref link-reveal xref-bibr">1543</a></sup> Surgical intervention is advised for a diverticulum orifice >30 mm or combined diverticulum and adjacent descending aorta diameter >50 mm, or both.<sup><a href="javascript:;" reveal-id="ehae179-B1544" data-open="ehae179-B1544" class="link link-ref link-reveal xref-bibr">1544</a></sup> Successful repair has been described using open, endovascular, or hybrid approaches depending on anatomy, comorbidities, and expertise.<sup><a href="javascript:;" reveal-id="ehae179-B1543" data-open="ehae179-B1543" class="link link-ref link-reveal xref-bibr">1543</a></sup>

## 11\. Polyvascular peripheral arterial disease and peripheral arterial disease in patients with cardiac diseases

### 11.1. Polyvascular disease

Polyvascular disease is defined as the simultaneous presence of clinically relevant obstructive atherosclerotic lesions in at least two major arterial territories.

#### 11.1.1. Epidemiology and prognosis

Approximately 1 in 4–6 patients with atherosclerosis have PVD (_[Figure 45](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae179-B620" data-open="ehae179-B620" class="link link-ref link-reveal xref-bibr">620</a>,<a href="javascript:;" reveal-id="ehae179-B1545" data-open="ehae179-B1545" class="link link-ref link-reveal xref-bibr">1545</a></sup> According to the REACH registry, patients with PAD were most likely both to have PVD at baseline and to develop PVD over the observational period.<sup><a href="javascript:;" reveal-id="ehae179-B1546" data-open="ehae179-B1546" class="link link-ref link-reveal xref-bibr">1546</a>,<a href="javascript:;" reveal-id="ehae179-B1547" data-open="ehae179-B1547" class="link link-ref link-reveal xref-bibr">1547</a></sup>

![Reported rate ranges of other localizations of atherosclerosis in patients with a specific arterial disease.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179f45.jpeg?Expires=1728479088&Signature=QywLh4q-OYl8GBpwSQCvQeplMRm8RpUhBG9PQSAi0BcoL-7Gv~dpRprZtaygca7qJLaaKqdUJqL62GgpIVKjMZUti08tWTgLEqeNVipASYvQ1vW5c3uPs34mRCPE64ptbljqKl5PBuMSD8iX-HLbbH1LsehHKYCcgNviw8b0RlvG8oTehvsK8h3wGltaXtYiGHMhZ3HQxhEcNNultp8PMMuitDMAn6GdSXVghuhvn6YHW4E1jQfKKGIoZCUatLa-0phTix6jjm8ELJ~9GXdubKKFJ06qqoLN5hvx53gv67f2gpZqS2QwpfJ351-FL6mQxYamdfqmx~i73TNsytl3jw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 45

Reported rate ranges of other localizations of atherosclerosis in patients with a specific arterial disease.

The graph reports the rates of concomitant arterial diseases in patients presenting an arterial disease in one territory (e.g. in patients with CAD, 5%–9% of cases have concomitant carotid stenosis >70%). Adapted from 2017 ESC Guidelines on PAD.<sup><a href="javascript:;" reveal-id="ehae179-B77" data-open="ehae179-B77" class="link link-ref link-reveal xref-bibr">77</a>,<a href="javascript:;" reveal-id="ehae179-B493" data-open="ehae179-B493" class="link link-ref link-reveal xref-bibr">493</a>,<a href="javascript:;" reveal-id="ehae179-B784" data-open="ehae179-B784" class="link link-ref link-reveal xref-bibr">784</a>,<a href="javascript:;" reveal-id="ehae179-B1549" data-open="ehae179-B1549" class="link link-ref link-reveal xref-bibr">1549</a>,<a href="javascript:;" reveal-id="ehae179-B1551 ehae179-B1552 ehae179-B1553 ehae179-B1554 ehae179-B1555 ehae179-B1556" data-open="ehae179-B1551 ehae179-B1552 ehae179-B1553 ehae179-B1554 ehae179-B1555 ehae179-B1556" class="link link-ref link-reveal xref-bibr">1551–1556</a></sup> ABI, ankle–brachial index; CAD, coronary artery disease; PAD, peripheral arterial disease; RAS, renal artery stenosis.

[Open in new tab](https://academic.oup.com/view-large/figure/479846638/ehae179f45.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179f45.jpeg?Expires=1728479088&Signature=aRC5IoU8i3i9B148EyLJucl~4msVPlGi1KE9HepsOC2g09t78ZYa-C5EolZnc0QiPH6JHMYl2h8L994827mxu-Rl9VUdVsnHZ-msMT9mc8XsB34PiEDSzVFmTg0rFcmaly6CycwOhWoNLXJYFH9Vy9YCDBch2sCWSSnZBljTdyFWnuGgpK3wyVt63JGA8rnDKQsfiqeTq5Kcd15ps~I~A6m9ajXOLJYX1XNgV1FEdvENq7TDlqjf1d-iy0yhKUkBp6hUGvKnHCEu3e6qyOff18nIq9ou1hQRqgiZerIEkUqUOFkQ65pLp7hF4XNve3JbmL7QD5REuBZmSgn5QJMLbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479846638&ar=7738955&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

PVD independently increases major CV event risk, roughly doubling it compared with single arterial bed symptoms.<sup><a href="javascript:;" reveal-id="ehae179-B1547 ehae179-B1548 ehae179-B1549" data-open="ehae179-B1547 ehae179-B1548 ehae179-B1549" class="link link-ref link-reveal xref-bibr">1547–1549</a></sup> Event rates rise with the number of affected arterial beds.<sup><a href="javascript:;" reveal-id="ehae179-B1546" data-open="ehae179-B1546" class="link link-ref link-reveal xref-bibr">1546</a>,<a href="javascript:;" reveal-id="ehae179-B1550" data-open="ehae179-B1550" class="link link-ref link-reveal xref-bibr">1550</a></sup>

#### 11.1.2. Screening for atherosclerosis in other arterial territories

Screening for PVD in atherosclerotic patients relies on medical history, clinical exam, and ABI measurement. If suspected, start with non-invasive DUS, followed by CTA/MRA if needed.<sup><a href="javascript:;" reveal-id="ehae179-B1557" data-open="ehae179-B1557" class="link link-ref link-reveal xref-bibr">1557</a></sup> Assessing concurrent atherosclerosis in other vascular regions is detailed in _[Table 17](javascript:;)_.

Table 17

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846642)

Need for assessment of associated atherosclerotic disease in additional vascular territories in symptomatic patients with coronary artery disease, peripheral arterial disease, or carotid stenosis

|  | Leading disease |
| --- | --- |
| Assessment in other vascular territories | CAD | PAD | Carotid stenosis |
| --- | --- | --- | --- |
| **CAD** |  | May be helpful to optimize medical treatment<sup><a href="javascript:;" reveal-id="ehae179-B431" data-open="ehae179-B431" class="link link-ref link-reveal xref-bibr">431</a></sup> and to be considered in patients scheduled for open vascular surgery with poor functional capacity or significant risk factors or symptoms. <sup><a href="javascript:;" reveal-id="ehae179-B1080" data-open="ehae179-B1080" class="link link-ref link-reveal xref-bibr">1080</a></sup> | Consider in patients scheduled for carotid endarterectomy and suspected CAD.<sup><a href="javascript:;" reveal-id="ehae179-B1558" data-open="ehae179-B1558" class="link link-ref link-reveal xref-bibr">1558</a></sup> |
| **PAD** | Potential benefits in identifying high-risk patients and guiding treatment decisions.<sup><a href="javascript:;" reveal-id="ehae179-B429" data-open="ehae179-B429" class="link link-ref link-reveal xref-bibr">429</a>,<a href="javascript:;" reveal-id="ehae179-B1559 ehae179-B1560 ehae179-B1561" data-open="ehae179-B1559 ehae179-B1560 ehae179-B1561" class="link link-ref link-reveal xref-bibr">1559–1561</a></sup> |  |  |
| **Carotid stenosis** | Useful in patients undergoing elective CABG.<sup><a href="javascript:;" reveal-id="ehae179-B1555" data-open="ehae179-B1555" class="link link-ref link-reveal xref-bibr">1555</a>,<a href="javascript:;" reveal-id="ehae179-B1562" data-open="ehae179-B1562" class="link link-ref link-reveal xref-bibr">1562</a></sup> |  |  |

CABG, coronary artery bypass grafting; CAD, coronary artery disease; PAD, peripheral arterial disease.

© ESC 2024

##### 11.1.2.1. Screening for coronary artery disease in patients with symptomatic peripheral arterial disease

The morbidity and mortality of patients with PAD is high due to CV complications. Given high CAD event rates in patients with PAD, CAD screening may be helpful to optimize medical treatment and is not intended to increase the rate of coronary interventions.<sup><a href="javascript:;" reveal-id="ehae179-B431" data-open="ehae179-B431" class="link link-ref link-reveal xref-bibr">431</a></sup> Evaluation can be performed by stress testing or CCT; however, there is no evidence that systematic screening for CAD in stable PAD improves outcomes. Coronary angiography is less suitable due to invasiveness. In patients requiring lower-limb revascularization, CAD management should be based on the _2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery_.<sup><a href="javascript:;" reveal-id="ehae179-B1080" data-open="ehae179-B1080" class="link link-ref link-reveal xref-bibr">1080</a></sup>

##### 11.1.2.2. Screening for peripheral arterial disease in patients with coronary artery disease

In high-risk CAD patients with three-vessel disease or recent ACS, systematic screening for multisite atherosclerotic disease through ABI and DUS of carotids, lower-extremity, and renal arteries did not improve outcomes.<sup><a href="javascript:;" reveal-id="ehae179-B1563" data-open="ehae179-B1563" class="link link-ref link-reveal xref-bibr">1563</a></sup> However, a subgroup analysis of the COMPASS trial suggests potential benefits when adding vascular-dose rivaroxaban to aspirin in stable patients with CAD and PAD, raising the question of whether identifying PAD in stable CAD patients could be advantageous.<sup><a href="javascript:;" reveal-id="ehae179-B429" data-open="ehae179-B429" class="link link-ref link-reveal xref-bibr">429</a>,<a href="javascript:;" reveal-id="ehae179-B1559" data-open="ehae179-B1559" class="link link-ref link-reveal xref-bibr">1559</a></sup> In patients undergoing CABG, the presence of concomitant PAD is associated with a three-fold risk of subsequent CV events after CABG.<sup><a href="javascript:;" reveal-id="ehae179-B1560" data-open="ehae179-B1560" class="link link-ref link-reveal xref-bibr">1560</a>,<a href="javascript:;" reveal-id="ehae179-B1561" data-open="ehae179-B1561" class="link link-ref link-reveal xref-bibr">1561</a></sup> The GSV should be spared whenever possible, since the success of peripheral arterial revascularization in complex lesions is strongly associated with the availability of sufficient autologous venous segments.<sup><a href="javascript:;" reveal-id="ehae179-B567" data-open="ehae179-B567" class="link link-ref link-reveal xref-bibr">567</a>,<a href="javascript:;" reveal-id="ehae179-B1564" data-open="ehae179-B1564" class="link link-ref link-reveal xref-bibr">1564</a></sup>

##### 11.1.2.3. Screening for coronary artery disease in patients with carotid stenosis

Due to the high prevalence of CAD among patients scheduled for elective CEA,<sup><a href="javascript:;" reveal-id="ehae179-B1565" data-open="ehae179-B1565" class="link link-ref link-reveal xref-bibr">1565</a>,<a href="javascript:;" reveal-id="ehae179-B1566" data-open="ehae179-B1566" class="link link-ref link-reveal xref-bibr">1566</a></sup> pre-operative CAD screening, including coronary angiography, may be considered in suspected patients.<sup><a href="javascript:;" reveal-id="ehae179-B1558" data-open="ehae179-B1558" class="link link-ref link-reveal xref-bibr">1558</a></sup> CAD requires prioritization of revascularization according to the patient’s clinical status and the severity of carotid disease and CAD. Coronary revascularization should generally be performed first; the exception is recently symptomatic patients with unstable neurological symptoms in whom carotid revascularization should be prioritized.<sup><a href="javascript:;" reveal-id="ehae179-B680" data-open="ehae179-B680" class="link link-ref link-reveal xref-bibr">680</a></sup>

##### 11.1.2.4. Screening for carotid stenosis in patients with coronary artery disease

Carotid artery stenosis screening may be useful in patients undergoing elective CABG. Ischaemic stroke after CABG is multifactorial,<sup><a href="javascript:;" reveal-id="ehae179-B1567" data-open="ehae179-B1567" class="link link-ref link-reveal xref-bibr">1567</a></sup> but also depends on the degree of carotid disease.<sup><a href="javascript:;" reveal-id="ehae179-B1556" data-open="ehae179-B1556" class="link link-ref link-reveal xref-bibr">1556</a></sup> Two studies suggest that limiting DUS to patients with at least one risk factor (age >65 years, history of cerebrovascular disease, presence of a carotid bruit, multivessel CAD or PAD) identifies most patients with significant (≥70%) CS.<sup><a href="javascript:;" reveal-id="ehae179-B1555" data-open="ehae179-B1555" class="link link-ref link-reveal xref-bibr">1555</a>,<a href="javascript:;" reveal-id="ehae179-B1562" data-open="ehae179-B1562" class="link link-ref link-reveal xref-bibr">1562</a></sup> Nevertheless, addition of CEA to CABG is unlikely to provide significant stroke reduction. In a study in patients with CAD with >80% CS undergoing staged or synchronous carotid procedures (two-thirds were neurologically asymptomatic and 73% had unilateral asymptomatic carotid stenosis), in-hospital stroke rates and 30 day mortality were similar in patients treated with CABG + CEA and in those treated with isolated CABG.<sup><a href="javascript:;" reveal-id="ehae179-B1568" data-open="ehae179-B1568" class="link link-ref link-reveal xref-bibr">1568</a></sup> Another study suggests that selective use of DUS should be considered before CABG in patients with a history of neurological events or PAD.<sup><a href="javascript:;" reveal-id="ehae179-B1569" data-open="ehae179-B1569" class="link link-ref link-reveal xref-bibr">1569</a></sup>

#### 11.1.3. Management of patients with polyvascular disease

Polyvascular disease requires proactive management of all modifiable risk factors through lifestyle changes and drug therapy. Scientific evidence suggests the benefit of intensified antithrombotic therapy, with no increase in risk of bleeding.<sup><a href="javascript:;" reveal-id="ehae179-B1570" data-open="ehae179-B1570" class="link link-ref link-reveal xref-bibr">1570</a></sup> ILT offers comparable benefits for PVD patients and those with single arterial territory disease. However, the benefits of ILT in patients with PVD are not dependent on baseline LDL-C.<sup><a href="javascript:;" reveal-id="ehae179-B1571" data-open="ehae179-B1571" class="link link-ref link-reveal xref-bibr">1571</a></sup>

Revascularization should be reserved for symptomatic arterial territories, using the least invasive strategy in a multidisciplinary vascular team approach.

### 11.2. Peripheral arterial disease and heart failure

Left ventricular (LV) dysfunction is observed in 20%–30% of PAD patients,<sup><a href="javascript:;" reveal-id="ehae179-B1572" data-open="ehae179-B1572" class="link link-ref link-reveal xref-bibr">1572</a>,<a href="javascript:;" reveal-id="ehae179-B1573" data-open="ehae179-B1573" class="link link-ref link-reveal xref-bibr">1573</a></sup> mostly associated with CAD.<sup><a href="javascript:;" reveal-id="ehae179-B1574" data-open="ehae179-B1574" class="link link-ref link-reveal xref-bibr">1574</a></sup> High aortic stiffness can increase LV afterload and impair coronary blood flow, resulting in hypertension, LV hypertrophy, LV diastolic dysfunction, and HF.<sup><a href="javascript:;" reveal-id="ehae179-B1575" data-open="ehae179-B1575" class="link link-ref link-reveal xref-bibr">1575</a>,<a href="javascript:;" reveal-id="ehae179-B1576" data-open="ehae179-B1576" class="link link-ref link-reveal xref-bibr">1576</a></sup> Skeletal muscle involvement and deconditioning due to PAD may aggravate HF severity.<sup><a href="javascript:;" reveal-id="ehae179-B1577" data-open="ehae179-B1577" class="link link-ref link-reveal xref-bibr">1577</a>,<a href="javascript:;" reveal-id="ehae179-B1578" data-open="ehae179-B1578" class="link link-ref link-reveal xref-bibr">1578</a></sup>

Peripheral arterial disease and HF are independently associated with poor outcomes and those with concomitant HF have a 30% higher risk of MACE and 40% higher risk of all-cause mortality.<sup><a href="javascript:;" reveal-id="ehae179-B1574" data-open="ehae179-B1574" class="link link-ref link-reveal xref-bibr">1574</a></sup> Evaluation of LV function in patients with PAD may be useful for better CV risk stratification and comprehensive management of their CV disease.<sup><a href="javascript:;" reveal-id="ehae179-B1579" data-open="ehae179-B1579" class="link link-ref link-reveal xref-bibr">1579</a></sup> This is of particular importance when an intermediate- or high-risk vascular intervention is planned. Expectedly, the presence of PAD in patients with HF is also associated with poor outcomes.<sup><a href="javascript:;" reveal-id="ehae179-B1580 ehae179-B1581 ehae179-B1582 ehae179-B1583 ehae179-B1584" data-open="ehae179-B1580 ehae179-B1581 ehae179-B1582 ehae179-B1583 ehae179-B1584" class="link link-ref link-reveal xref-bibr">1580–1584</a></sup> These patients represent a high-risk group in which intense risk-factor modification strategies and optimization of HF therapy are warranted.

### 11.3. Peripheral arterial disease and AF

The prevalence of AF among patients with PAD is around 12%.<sup><a href="javascript:;" reveal-id="ehae179-B1585 ehae179-B1586 ehae179-B1587 ehae179-B1588 ehae179-B1589 ehae179-B1590" data-open="ehae179-B1585 ehae179-B1586 ehae179-B1587 ehae179-B1588 ehae179-B1589 ehae179-B1590" class="link link-ref link-reveal xref-bibr">1585–1590</a></sup> A meta-analysis revealed that in patients with AF and PAD, risk of all-cause mortality, CV mortality, and MACE is 40%, over 60%, and over 70% higher, respectively compared with patients with AF without PAD.<sup><a href="javascript:;" reveal-id="ehae179-B1591" data-open="ehae179-B1591" class="link link-ref link-reveal xref-bibr">1591</a></sup> PAD is included in the CHA<sub>2</sub>DS<sub>2</sub>\-VASc (congestive heart failure, hypertension, age ≥75 \[doubled\], diabetes, stroke \[doubled\], vascular disease, age 65 to 74 and sex category \[female\]) risk score, which underlies the prognostic importance of PAD in patients with AF.<sup><a href="javascript:;" reveal-id="ehae179-B1592" data-open="ehae179-B1592" class="link link-ref link-reveal xref-bibr">1592</a></sup>

### 11.4. Peripheral arterial disease and aortic stenosis

Peripheral arterial disease frequently accompanies symptomatic aortic stenosis, especially among patients not eligible for surgical aortic valve replacement (20%–30%).<sup><a href="javascript:;" reveal-id="ehae179-B198" data-open="ehae179-B198" class="link link-ref link-reveal xref-bibr">198</a>,<a href="javascript:;" reveal-id="ehae179-B1593 ehae179-B1594 ehae179-B1595" data-open="ehae179-B1593 ehae179-B1594 ehae179-B1595" class="link link-ref link-reveal xref-bibr">1593–1595</a></sup> In these patients, pre-procedural CCT/CTA or CMR<sup><a href="javascript:;" reveal-id="ehae179-B1596" data-open="ehae179-B1596" class="link link-ref link-reveal xref-bibr">1596</a></sup> of the aorta and major peripheral arteries is mandatory to evaluate the access site for transcatheter aortic valve implantation (TAVI) and plan a closure strategy for the access site. Patients with PAD have increased risk of all-cause mortality and vascular complications after TAVI,<sup><a href="javascript:;" reveal-id="ehae179-B198" data-open="ehae179-B198" class="link link-ref link-reveal xref-bibr">198</a></sup> thus, screening for PAD in these patients may be helpful.

Recommendation Table 70

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846661)

Recommendations for screening and management of polyvascular disease and peripheral arterial disease with cardiac diseases (see also Evidence Table 15)

![Recommendations for screening and management of polyvascular disease and peripheral arterial disease with cardiac diseases (see also Evidence Table 15)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179ilt70.jpeg?Expires=1728479088&Signature=d1z-WMzwkOahAgaPT4FQ1KW2XLgREvvd1F2loN3Uio86h8MlcYCxjxz7HLTPBSSjQ0Fkz0Ko~cnihiqEwLzHz1g-Kvo4FdtFgibrHhr3Msli6h4j0J23JWWVF2aO7-dNsMcI0jTlVfbq0kVRy4fLnJVpsZVxuXXpELEi-lGD~wYfxsxIepd-BypnfELERWZCGBn9uY0jrfKJQNg4o-405z7guFSISGIEjVqMUOM1IZ97NJUi7efIyyAQAsEyJRqVhGaUr6qWke807Gr4VNzW0-zuqAEdB8So0Wodi2EQouBJwpsCzjr8WzImtwlceS6R6c0Yp6YfgHpULFPTQ-~DJQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

## 12\. Key messages

Peripheral arterial and aortic diseases are highly prevalent, often asymptomatic, and linked to increased morbidity and mortality. Early diagnosis is crucial for better outcomes and management requires a multidisciplinary team. CVRF control is crucial to prevent progression and complications. Despite the benefit of medical therapy, lifestyle changes, healthy diet, abstinence from smoking, exercise/rehabilitation, and education are essential for effective management. Patient empowerment is essential to improve adherence and close/regular monitoring is essential to improve prognosis. Use of web- or app-based calculators for estimation of CV risk in the secondary prevention of ASCVD may aid patient motivation for lifestyle changes and adherence to medication.

**Peripheral arteries**

Atherosclerotic lower-extremity PAD is a chronic disease needing lifelong follow-up.

Assessment of walking impairment, functional status, and amputation risk is crucial in PAD management.

Ankle–brachial index should be the initial diagnostic test for screening and diagnosing PAD, and serves as a surrogate marker for CV and all-cause mortality. DUS is the first-line imaging method to confirm PAD lesions.

Supervised exercise training or, if not available, HBET, improves walking and functional performances, and reduces CV risk. Exercise training remains underused and increased awareness is warranted.

In asymptomatic PAD patient revascularization is not recommended. In symptomatic PAD patient need for interventional treatment, following a period of optimal medical treatment and exercise, should be discussed in a multidisciplinary setting.

Chronic limb-threatening ischaemia increases the risk of CV events, needs early diagnosis, rapid referral to a multidisciplinary vascular team, and revascularization for limb salvage.

Acute limb ischaemia warrants rapid clinical assessment by a vascular team and urgent revascularization.

Duplex ultrasound is the first-line diagnostic modality for carotid stenosis. Routine revascularization is not recommended if asymptomatic. In symptomatic patients multidisciplinary assessment is recommended.

Atherosclerotic UEAD is most frequently located in the subclavian artery and may be suspected because of an absolute inter-arm SBP difference >10–15 mmHg. DUS is first-line imaging and routine revascularization is not recommended.

The key to early diagnosis of acute and chronic mesenteric ischaemia is a high level of clinical suspicion—laboratory tests are unreliable for the diagnosis. Acute SMA occlusion requires immediate revascularization.

**Aorta**

Aortic aneurysms are managed based on size, location, and growth rate. Small aneurysms are monitored regularly (Guidelines provide disease-specific follow-up algorithms), while larger ones may require surgical/endovascular repair to prevent rupture.

In aortic root aneurysms, aortic replacement may be considered at >52 mm in low-risk patients and at experienced centres.

Aortic diameter is the primary risk factor for aortic events. However, evidence supports diameter indexation (especially in extreme BSA populations) and the use of aortic length (>11 cm), the AHI (>32.1 mm/m), growth rate (≥3 mm per year for ascending aorta and arch or >5 mm per 6 months in the thoracoabdominall aorta), and age/sex for risk assessment.

Multidisciplinary collaboration, hybrid operating rooms, and advanced stent technology have increased the adoption of hybrid approaches and endovascular therapies for different thoracoabdominal aortic diseases.

Acute aortic syndrome management involves medical treatment in critical care units and selective surgical intervention based on location and complications. The main problem in these conditions continues to be a delay in diagnosing patients or transferring them to an aortic centre. Improved diagnostic algorithms and reduced surgical complications have lowered mortality rates. Surgical/endovascular treatment in the subacute phase is advised for high-risk patients with type B aortic syndrome.

Suspected genetic aortic conditions require evaluation at experienced centres to assess both the patient and their FDRs for genetic studies. Genetic aortic conditions should be considered based on family history, syndromic features, age <60 years, and no CVRFs (Guidelines offer a screening algorithm for thoracic aorta disease). A comprehensive evaluation of the entire aorta and other vascular territories is recommended in HTAD. Recent advances in genetics are enabling personalized and patient-centred assessment. This includes using different aortic diameter thresholds to indicate surgery and implementing diverse surveillance algorithms.

## 13\. Gaps in evidence

There are several areas where robust evidence is still lacking and which deserve to be addressed in future clinical research.

1.  Epidemiology and risk factors in PAAD:
    
    -   Improve PAAD risk definition.
        
    -   Provide contemporary data on PAAD prevalence in Europe.
        
    -   Inflammation biomarkers, metabolomics, and proteomics may have prognostic value in PAAD.
        
2.  Evaluation of peripheral arteries and aorta:
    
    -   Follow-up algorithms can assist PAAD patient management but have limitations and evidence on cost-effectiveness is needed.
        
    -   The best methodology for aortic measurements remains to be elucidated.
        
3.  Screening for carotid, peripheral arterial, and aortic diseases:
    
    -   Screening in specific populations: research is needed to understand the nuances of screening in particular populations and whether modifications to current guidelines are necessary.
        
    -   Patient outcomes and benefits of screening: impact of screening on patient outcome should be assessed.
        
4.  OMT and PAAD:
    
    -   Research needed on QoL and workability.
        
    -   Research needed for optimal preventive strategies.
        
    -   Exercise therapy and rehabilitation for PAAD should be more accessible and employed.
        
    -   Anti-inflammatory therapy should be investigated.
        
    -   Antithrombotic therapies in specific risk groups of PAAD and patients undergoing revascularization should be addressed.
        
5.  Aortic aneurysms:
    
    -   Discovering novel individualized risk stratification parameters beyond well-established markers.
        
    -   Assessing the safety of fluoroquinolone use in patients with aortic aneurysm.
        
6.  Acute aortic syndromes:
    
    -   Assess the management of pregnancy-related AAS.
        
    -   Identify diagnostic biomarkers other than D-dimer.
        
    -   Management in uncomplicated TBAD and IMH should be assessed.
        
7.  Genetic aortic diseases:
    
    -   Need to refine risk estimation in AD, particularly in HTAD, especially the risk of type B aortic dissection.
        
    -   There is insufficient evidence to support the efficacy of any medication in reducing the risk of AD.
        
8.  Sex differences in PAAD:
    
    -   Investigate sex and age differences.
        
    -   Assess the optimal parameter or indexed parameter to guide intervention decisions in women with aortic and PAD diseases.
        

## 14\. Sex differences

Sex differences have been evaluated and discussed in the specific sections.

## 15\. ‘What to do’ and ‘What not to do’ messages from the guidelines

_[Table 18](javascript:;)_ ‘What to do’ and 'What not to do’. ‘What to do and What not to do’ lists all Class I and Class III recommendations from the text.

Table 18

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae179/7738955?login=false
                                /view-large/479846689)

‘What to do’ and ‘What not to do’

![‘What to do’ and ‘What not to do’](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179t18.jpeg?Expires=1728479088&Signature=gj1BxWd4FKRPCMuTDT9jZY5CwPrPgZPR23vCk8JNwNYPuOruLAEHeJmiRLLbhqKagtP0-PmnJqfsNIXSFsyTx8H9u4YREEPiO6bmOug~PM11C4KogF-PjOxSMZ7Enk2eKa~nvm1DbA-VW62HQhcCBBxJdwJCOjzoZsw2nUbsh7KxPY2tERHw8hvn8tZCwlmo~FkXzAf-~aKlfFVc9I04~ER6QYxxkzESX7C-BRG-1ophjAj~fTRINe3EMeW8lQQniV17yVeHC31pox4ury0TaUBQJhtZpH8onPRm3Fm8vYJKgiPMmdh2JZbbipkOZWqKou5CgWzmLe8X2di4IklDhQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

## 16\. Evidence tables

[Evidence tables](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/2024_esc_guidelines_paad_evidencetables.pdf?Expires=1728479088&Signature=RWemGThDgJYX8NC0dklBdA8mbXs3VvcIxrjS6em0u03n~mTBpOqYQJC33ZJQYHcuSoCzruAEU5hMuzhw1daCYdx6ltQyUeWHz48ZfnWVEiNwmuNehHMEwizdhZlx1mFAooaMl7DMlHZuKZpgP1VI6qfy6ZPLCyHs0DuhhtAdS~lwoVo7vr~Hxq98vfdqICGnpuO16dD6x6E7DcfEK5vU83Y0~f0LBXnvxJK3r8eOZsNVSwKd9MD7M-43Cl00qjfWvSUy7WUL0F6dG7MEMvgBx6j0hfHg7VYbwOzcOLr~tC48ppCeZjgu~fRdd32EWj1L~Yib~f0EwA4EM9eWLW4Tzg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) are available on the _European Heart Journal_ website.

## 17\. Data availability statement

No new data were generated or analysed in support of this research.

## 18\. Author information

**Author/task force Member Affiliations: Gisela Teixido-Tura**, Cardiovascular Imaging section and Aortic diseases Unit (VASCERN), Department of Cardiology, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Vall d′Hebron Institut de Recerca (VHIR), Barcelona, Spain, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Instituto de Salud Carlos III, Madrid, Spain; **Stefano Lanzi**, Department of Angiology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland; **Vinko Boc**, Department of Vascular Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia; **Eduardo Bossone**, Department of Public Health, University of Naples “Federico II”, Naples, Italy, Department of Translational Medical Sciences, University of Naples “Federico II”, Naples, Italy; **Marianne Brodmann**, Division of Angiology, Medical University Graz, Graz, Austria; **Alessandra Bura-Rivière**, Vascular Medicine Department, Toulouse University Hospital, Toulouse, France, Faculty of Medicine, University Toulouse 3, Toulouse, France; **Julie De Backer**, Cardiology and Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium; **Sebastien Deglise**, Department of Vascular Surgery, University Hospital Lausanne (CHUV), Lausanne, Switzerland; **Alessandro Della Corte**, Department of Translational Medical Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy, Unit of Cardiac Surgery, Monaldi Hospital, Naples, Italy; **Christian Heiss**, Department of Clinical and Experimental Medicine, University of Surrey, Guildford, United Kingdom, Vascular Medicine Department, Surrey and Sussex Healthcare NHS Trust, Redhill, United Kingdom; **Marta Kałużna-Oleksy**, 1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland; **Donata Kurpas**, Division of Research Methodology, Department of Nursing, Faculty of Nursing and Midwifery, Wroclaw Medical University, Poland; **Carmel M. McEniery**, Medicine, University of Cambridge, Cambridge, United Kingdom; **Tristan Mirault**, Vascular Medicine Department, Université Paris Cité, Paris, France, Vascular Medicine Department, Assistance Publique Hôpitaux de Paris-APHP, Hôpital Européen Georges-Pompidou, Paris, PARCC U970 team 5 Innate and Adaptative Immunity in Vascular Diseases, INSERM, Paris, France; **Agnes A. Pasquet**, Department of Cardiovascular Diseases, Cliniques Universitaires Saint Luc, Brussels, Belgium, IREC/CARD, UCLouvain, Brussels, Belgium; **Alex Pitcher**, The Heart Centre, Oxford University NHS Foundation Trust, Oxford, United Kingdom; **Hannah A.I. Schaubroeck**, Department of Intensive Care Medicine, Ghent University Hospital, Ghent, Belgium; **Oliver Schlager,** Division of Angiology, Department of Medicine II, Medical University of Vienna, Vienna, Austria; **Per Anton Sirnes**, Cardiology Practice, Kardiokonsult, Son, Norway, Cardiology section, Volvat Medical Centre, Moss, Norway; **Muriel G. Sprynger**, Cardiology, University Hospital of Liège, Liège, Belgium; **Eugenio Stabile**, Division of Cardiology, Health Science Department, Università della Basilicata, Potenza, Italy; **Françoise Steinbach** (France), ESC Patient Forum, Sophia Antipolis, France; **Matthias Thielmann**, Department of Thoracic and Cardiovascular Surgery, West-German Heart and Vascular Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; **Roland R.J. van Kimmenade**, Department of Cardiology, Radboud University Medical Center, Nijmegen, Netherlands; and **Maarit Venermo**, Department of Vascular Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

### 19\. Appendix

**ESC Scientific Document Group**

Includes Document Reviewers and ESC National Cardiac Societies.

**Document Reviewers:**

Alessia Gimelli (CPG Review Co-ordinator) (Italy), Jean-Baptiste Ricco (CPG Review Co-ordinator) (France), Elena Arbelo (Spain), Christian-Alexander Behrendt (Germany), Michael Böhm (Germany), Michael A. Borger (Germany), Margarita Brida (Croatia), Sergio Buccheri (Sweden), Gill Louise Buchanan (United Kingdom), Christina Christersson (Sweden), Gert J. de Borst (Netherlands), Marco De Carlo (Italy), Roman Gottardi (Austria), Lydia Hanna (United Kingdom), Lynne Hinterbuchner (Austria), Borja Ibanez (Spain), Ignatios Ikonomidis (Greece), Stefan James (Sweden), Thomas Kahan (Sweden), Klaus Kallenbach<sup>2</sup> (Luxemburg), Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), Juraj Madaric<sup>1</sup> (Slovakia), Blandine Maurel (France), John William McEvoy (Ireland), Gil Meltzer (Israel), Borislava Mihaylova (United Kingdom), Richard Mindham (United Kingdom), Ioana Mozos (Romania), Jens Cosedis Nielsen (Denmark), Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), Barbara Rantner (Germany), Bianca Rocca (Italy), Xavier Rossello (Spain), Jean Paul Schmid (Switzerland), Daniel Staub (Switzerland), Sabine Steiner (Germany), Isabella Sudano (Switzerland), Martin Teraa (Netherlands), Ilonca Vaartjes (Netherlands), Rafael Vidal-Perez (Spain), Christiaan Vrints (Belgium), and Katja Zeppenfeld (Netherlands).

**ESC National Cardiac Societies** actively involved in the review process of the _2024 ESC Guidelines for the management of peripheral arterial and aortic diseases_:

**Algeria**: Algerian Society of Cardiology, Mohammed El Amine Bouzid; **Armenia**: Armenian Cardiologists Association, Arsen A. Tsaturyan; **Austria**: Austrian Society of Cardiology, Georg Delle Karth; **Azerbaijan**: Azerbaijan Society of Cardiology, Fuad Samadov; **Belgium**: Belgian Society of Cardiology, Antoine Bondue; **Bosnia and Herzegovina**: Association of Cardiologists of Bosnia and Herzegovina, Alden Begić; **Bulgaria**: Bulgarian Society of Cardiology, Ivo Petrov; **Croatia**: Croatian Cardiac Society, Majda Vrkic Kirhmajer; **Cyprus**: Cyprus Society of Cardiology, Georgios P. Georghiou; **Czechia**: Czech Society of Cardiology, Pavel Procházka; **Denmark**: Danish Society of Cardiology, Torsten B. Rasmussen; **Egypt**: Egyptian Society of Cardiology, Yasser A. Sadek; **Estonia**: Estonian Society of Cardiology, Jaagup Truusalu; **Finland**: Finnish Cardiac Society, Petri Saari; **France**: French Society of Cardiology, Guillaume Jondeau; **Germany**: German Cardiac Society, Christiane Tiefenbacher; **Greece**: Hellenic Society of Cardiology, Kimon Stamatelopoulos; **Hungary**: Hungarian Society of Cardiology, Endre Kolossváry; **Iceland**: Icelandic Society of Cardiology, Elín Hanna Laxdal; **Ireland**: Irish Cardiac Society, Monica Monaghan; **Israel**: Israel Heart Society, Jonathan Koslowsky; **Italy**: Italian Federation of Cardiology, Ciro Indolfi; **Kazakhstan**: Association of Cardiologists of Kazakhstan, Nursultan Kospanov; **Kosovo (Republic of)**: Kosovo Society of Cardiology, Pranvera Ibrahimi; **Kyrgyzstan**: Kyrgyz Society of Cardiology, Olga Lunegova; **Latvia**: Latvian Society of Cardiology, Ainars Rudzitis; **Lithuania**: Lithuanian Society of Cardiology, Andrius Berūkštis; **Luxembourg**: Luxembourg Society of Cardiology, Katja Lottermoser; **Malta**: Maltese Cardiac Society, Maryanne Caruana; **Morocco**: Moroccan Society of Cardiology, Raissuni Zainab; **North Macedonia**: National Society of Cardiology of North Macedonia, Marijan Bosevski; **Norway**: Norwegian Society of Cardiology, Stein Samstad; **Portugal**: Portuguese Society of Cardiology, Ana Teresa Timoteo; **Romania**: Romanian Society of Cardiology, Ovidiu Dragomir Chioncel; **San Marino**: San Marino Society of Cardiology, Pier Camillo Pavesi; **Slovakia**: Slovak Society of Cardiology, Maria Rasiova; **Slovenia**: Slovenian Society of Cardiology, Borut Jug; **Spain**: Spanish Society of Cardiology, Ariana González Gomez; **Sweden**: Swedish Society of Cardiology, Stefan James; **Switzerland**: Swiss Society of Cardiology, Marc Righini; **Tunisia**: Tunisian Society of Cardiology and Cardio-Vascular Surgery, Amine Tarmiz; **Turkey**: Turkish Society of Cardiology, Eralp Tutar; and **Ukraine**: Ukrainian Association of Cardiology, Maksym Sokolov.

**ESC Clinical Practice Guidelines (CPG) Committee:** Eva Prescott (Chairperson) (Denmark), Stefan James (Co-Chairperson) (Sweden), Elena Arbelo (Spain), Colin Baigent (United Kingdom), Michael A. Borger (Germany), Sergio Buccheri (Sweden), Borja Ibanez (Spain), Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), John William McEvoy (Ireland), Borislava Mihaylova (United Kingdom), Richard Mindham (United Kingdom), Lis Neubeck (United Kingdom), Jens Cosedis Nielsen (Denmark), Agnes A. Pasquet (Belgium), Amina Rakisheva (Kazakhstan), Bianca Rocca (Italy), Xavier Rossello (Spain), Ilonca Vaartjes (Netherlands), Christiaan Vrints (Belgium), Adam Witkowski (Poland), and Katja Zeppenfeld (Netherlands).

##20. References
1	van Kuijk JP, Flu WJ, Welten GM, Hoeks SE, Chonchol M, Vidakovic R, et al.  Long-term prognosis of patients with peripheral arterial disease with or without polyvascular atherosclerotic disease. Eur Heart J 2010;31:992–9. https://doi.org/10.1093/eurheartj/ehp553
  2	Dolmaci OB, El Mathari S, Driessen AHG, Klautz RJM, Poelmann RE, Lindeman JHN, et al.  Are thoracic aortic aneurysm patients at increased risk for cardiovascular diseases? J Clin Med 2023;12:272. https://doi.org/10.3390/jcm12010272
Google ScholarCrossrefWorldCat 
3	Tully L, Gianos E, Vani A, Guo Y, Balakrishnan R, Schwartzbard A, et al.  Suboptimal risk factor control in patients undergoing elective coronary or peripheral percutaneous intervention. Am Heart J 2014;168:310–6.e3. https://doi.org/10.1016/j.ahj.2014.05.011
  4	Saratzis A, Jaspers NEM, Gwilym B, Thomas O, Tsui A, Lefroy R, et al.  Observational study of the medical management of patients with peripheral artery disease. Br J Surg 2019;106:1168–77. https://doi.org/10.1002/bjs.11214
  5	McDermott MM, Mandapat AL, Moates A, Albay M, Chiou E, Celic L, et al.  Knowledge and attitudes regarding cardiovascular disease risk and prevention in patients with coronary or peripheral arterial disease. Arch Intern Med 2003;163:2157–62. https://doi.org/10.1001/archinte.163.18.2157
  6	Grayson PC, Ponte C, Suppiah R, Robson JC, Gribbons KB, Judge A, et al.  2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis. Ann Rheum Dis 2022;81:1654–60. https://doi.org/10.1136/ard-2022-223482
  7	Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, et al.  2018 update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2020;79:19–30. https://doi.org/10.1136/annrheumdis-2019-215672
  8	Ponte C, Grayson PC, Robson JC, Suppiah R, Gribbons KB, Judge A, et al.  2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis. Ann Rheum Dis 2022;81:1647–53. https://doi.org/10.1136/ard-2022-223480
  9	Stone JR, Bruneval P, Angelini A, Bartoloni G, Basso C, Batoroeva L, et al.  Consensus statement on surgical pathology of the aorta from the Society for Cardiovascular Pathology and the Association for European Cardiovascular Pathology: I. Inflammatory diseases. Cardiovasc Pathol 2015;24:267–78. https://doi.org/10.1016/j.carpath.2015.05.001
  10	Diseases GBD, Injuries C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease study 2019. Lancet 2020;396:1204–22. https://doi.org/10.1016/S0140-6736(20)30925-9
  
11	Lin J, Chen Y, Jiang N, Li Z, Xu S. Burden of peripheral artery disease and its attributable risk factors in 204 countries and territories from 1990 to 2019. Front Cardiovasc Med 2022;9:868370. https://doi.org/10.3389/fcvm.2022.868370
  12	GBD 2019 Peripheral Artery Disease Collaborators. Global burden of peripheral artery disease and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease study 2019. Lancet Glob Health 2023;11:e1553–65. https://doi.org/10.1016/S2214-109X(23)00355-8
CrossrefPubMedWorldCat 
13	Liu W, Yang C, Chen, Lei F, Qin J-J, Liu H, et al.  Global death burden and attributable risk factors of peripheral artery disease by age, sex, SDI regions, and countries from 1990 to 2030: results from the Global Burden of Disease study 2019. Atherosclerosis 2022;347:17–27. https://doi.org/10.1016/j.atherosclerosis.2022.03.002
  14	Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al.  Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol 2020;76:2982–3021. https://doi.org/10.1016/j.jacc.2020.11.010
  15	Pu L, Wang L, Zhang R, Zhao T, Jiang Y, Han L. Projected global trends in ischemic stroke incidence, deaths and disability-adjusted life years from 2020 to 2030. Stroke 2023;54:1330–9. https://doi.org/10.1161/STROKEAHA.122.040073
  16	Summers KL, Kerut EK, Sheahan CM, Sheahan MG, III. Evaluating the prevalence of abdominal aortic aneurysms in the United States through a national screening database. J Vasc Surg 2021;73:61–8. https://doi.org10.1016/j.jvs.2020.03.046
  17	Behrendt CA, Thomalla G, Rimmele DL, Petersen EL, Twerenbold R, Debus ES, et al.  Editor’s choice—prevalence of peripheral arterial disease, abdominal aortic aneurysm, and risk factors in the Hamburg city health study: a cross sectional analysis. Eur J Vasc Endovasc Surg 2023;65:590–8. https://doi.org/10.1016/j.ejvs.2023.01.002
  18	Rossello X, Dorresteijn JA, Janssen A, Lambrinou E, Scherrenberg M, Bonnefoy-Cudraz E, et al.  Risk prediction tools in cardiovascular disease prevention: a report from the ESC Prevention of CVD programme led by the European Association of Preventive Cardiology (EAPC) in collaboration with the Acute Cardiovascular Care Association (ACCA) and the Association of Cardiovascular Nursing and Allied Professions (ACNAP). Eur Heart J Acute Cardiovasc Care 2020;9:522–32. https://doi.org/10.1177/2048872619858285
  19	Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al.  2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021;42:3227–337. https://doi.org/10.1093/eurheartj/ehab484
  20	Aday AW, Matsushita K. Epidemiology of peripheral artery disease and polyvascular disease. Circ Res 2021;128:1818–32. https://doi.org/10.1161/CIRCRESAHA.121.318535
  21	Pabon M, Cheng S, Altin SE, Sethi SS, Nelson MD, Moreau KL, et al.  Sex differences in peripheral artery disease. Circ Res 2022;130:496–511. https://doi.org/10.1161/CIRCRESAHA.121.320702
  22	Khawaja T, Janus SE, Tashtish N, Janko M, Baeza C, Gilkeson R, et al.  Prevalence of thoracic aortic aneurysm in patients referred for no/low-charge coronary artery calcium scoring: insights from the CLARIFY registry. Am J Prev Cardiol 2022;12:100378. https://doi.org/10.1016/j.ajpc.2022.100378
  23	Obel LM, Diederichsen AC, Steffensen FH, Frost L, Lambrechtsen J, Busk M, et al.  Population-based risk factors for ascending, arch, descending, and abdominal aortic dilations for 60-74-year-old individuals. J Am Coll Cardiol 2021;78:201–11. https://doi.org/10.1016/j.jacc.2021.04.094
  24	Bossone E, Eagle KA. Epidemiology and management of aortic disease: aortic aneurysms and acute aortic syndromes. Nat Rev Cardiol 2021;18:331–48. https://doi.org/10.1038/s41569-020-00472-6
  25	Verhagen JMA, Kempers M, Cozijnsen L, Bouma BJ, Duijnhouwer AL, Post JG, et al.  Expert consensus recommendations on the cardiogenetic care for patients with thoracic aortic disease and their first-degree relatives. Int J Cardiol 2018;258:243–8. https://doi.org/10.1016/j.ijcard.2018.01.145
  26	Burger PM, Pradhan AD, Dorresteijn JAN, Koudstaal S, Teraa M, de Borst GJ, et al.  C-reactive protein and risk of cardiovascular events and mortality in patients with various cardiovascular disease locations. Am J Cardiol 2023;197:13–23. https://doi.org/10.1016/j.amjcard.2023.03.025
  27	Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al.  Colchicine in patients with chronic coronary disease. N Engl J Med 2020;383:1838–47. https://doi.org/10.1056/NEJMoa2021372
  28	Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al.  Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 2019;381:2497–505. https://doi.org/10.1056/NEJMoa1912388
  29	Parkkila K, Kiviniemi A, Tulppo M, Perkiömäki J, Kesäniemi YA, Ukkola O. Carotid and femoral bruits as cardiovascular risk indicators in a middle-aged Finnish population: a 20-year prospective study. PLoS One 2022;17:e0278901. https://doi.org/10.1371/journal.pone.0278901
  30	Pickett CA, Jackson JL, Hemann BA, Atwood JE. Carotid bruits as a prognostic indicator of cardiovascular death and myocardial infarction: a meta-analysis. Lancet 2008;371:1587–94. https://doi.org/10.1016/s0140-6736(08)60691-1
  31	Charry D, Gouskova N, Meyer ML, Ring K, Nambi V, Heiss G, et al.  Arterial stiffness and contralateral differences in blood pressure: the Atherosclerosis Risk in Communities (ARIC) study. J Clin Hypertens (Greenwich) 2022;24:878–84. https://doi.org/10.1111/jch.14493
  32	Aboyans V, Criqui MH, McDermott MM, Allison MA, Denenberg JO, Shadman R, et al.  The vital prognosis of subclavian stenosis. J Am Coll Cardiol 2007;49:1540–5. https://doi.org/10.1016/j.jacc.2006.09.055
  33	Marcovina SM, Shapiro MD. Measurement of lipoprotein(a): a once in a lifetime opportunity. J Am Coll Cardiol 2022;79:629–31. https://doi.org/10.1016/j.jacc.2021.11.053
  34	Arndt H, Nordanstig J, Bertges DJ, Budtz-Lilly J, Venermo M, Espada CL, et al.  A Delphi consensus on patient reported outcomes for registries and trials including patients with intermittent claudication: recommendations and reporting standard. Eur J Vasc Endovasc Surg 2022;64:526–33. https://doi.org/10.1016/j.ejvs.2022.08.011
  35	Rymer JA, Narcisse D, Cosiano M, Tanaka J, McDermott MM, Treat-Jacobson DJ, et al.  Patient-reported outcome measures in symptomatic, non-limb-threatening peripheral artery disease: a state-of-the-art review. Circ Cardiovasc Interv 2022;15:e011320. https://doi.org/10.1161/circinterventions.121.011320
  36	Raja A, Spertus J, Yeh RW, Secemsky EA. Assessing health-related quality of life among patients with peripheral artery disease: a review of the literature and focus on patient-reported outcome measures. Vasc Med 2021;26:317–25. https://doi.org/10.1177/1358863x20977016
  37	Treat-Jacobson D, McDermott MM, Bronas UG, Campia U, Collins TC, Criqui MH, et al.  Optimal exercise programs for patients with peripheral artery disease: a scientific statement from the American Heart Association. Circulation 2019;139:e10–33. https://doi.org/10.1161/cir.0000000000000623
  38	Poku E, Duncan R, Keetharuth A, Essat M, Phillips P, Woods HB, et al.  Patient-reported outcome measures in patients with peripheral arterial disease: a systematic review of psychometric properties. Health Qual Life Outcomes 2016;14:161. https://doi.org/10.1186/s12955-016-0563-y
  39	Mays RJ, Casserly IP, Kohrt WM, Ho PM, Hiatt WR, Nehler MR, et al.  Assessment of functional status and quality of life in claudication. J Vasc Surg 2011;53:1410–21. https://doi.org/10.1016/j.jvs.2010.11.092
  40	Regensteiner JG, Hiatt WR, Coll JR, Criqui MH, Treat-Jacobson D, McDermott MM, et al.  The impact of peripheral arterial disease on health-related quality of life in the peripheral arterial disease awareness, risk, and treatment: new resources for survival (PARTNERS) program. Vasc Med 2008;13:15–24. https://doi.org/10.1177/1358863x07084911
  41	Harwood AE, King S, Totty J, Smith GE, Vanicek N, Chetter IC. A systematic review of muscle morphology and function in intermittent claudication. J Vasc Surg 2017;66:1241–57. https://doi.org/10.1016/j.jvs.2017.05.106
  42	Schieber MN, Hasenkamp RM, Pipinos II, Johanning JM, Stergiou N, DeSpiegelaere HK, et al.  Muscle strength and control characteristics are altered by peripheral artery disease. J Vasc Surg 2017;66:178–86.e12. https://doi.org/10.1016/j.jvs.2017.01.051
  43	Gohil RA, Mockford KA, Mazari F, Khan J, Vanicek N, Chetter IC, et al.  Balance impairment, physical ability, and its link with disease severity in patients with intermittent claudication. Ann Vasc Surg 2013;27:68–74. https://doi.org/10.1016/j.avsg.2012.05.005
  44	Mockford KA, Mazari FA, Jordan AR, Vanicek N, Chetter IC, Coughlin PA. Computerized dynamic posturography in the objective assessment of balance in patients with intermittent claudication. Ann Vasc Surg 2011;25:182–90. https://doi.org/10.1016/j.avsg.2010.07.021
  45	Gardner AW, Montgomery PS. Impaired balance and higher prevalence of falls in subjects with intermittent claudication. J Gerontol A Biol Sci Med Sci 2001;56:M454–8. https://doi.org/10.1093/gerona/56.7.m454
  46	McDermott MM, Ferrucci L, Liu K, Guralnik JM, Tian Lu, Liao Y, et al.  Leg symptom categories and rates of mobility decline in peripheral arterial disease. J Am Geriatr Soc 2010;58:1256–62. https://doi.org/10.1111/j.1532-5415.2010.02941.x
  47	McDermott MM, Liu K, Greenland P, Guralnik JM, Criqui MH, Chan C, et al.  Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. JAMA 2004;292:453–61. https://doi.org/10.1001/jama.292.4.453
  48	McDermott MM, Greenland P, Guralnik JM, Guralnik JM, Criqui MH, Chan C, et al.  Depressive symptoms and lower extremity functioning in men and women with peripheral arterial disease. J Gen Intern Med 2003;18:461–7. https://doi.org/10.1046/j.1525-1497.2003.20527.x
  49	Ramirez JL, Drudi LM, Grenon SM. Review of biologic and behavioral risk factors linking depression and peripheral artery disease. Vasc Med 2018;23:478–88. https://doi.org/10.1177/1358863X18773161
  50	Golledge J, Leicht AS, Yip L, Rowbotham SE, Pinchbeck J, Jenkins JS, et al.  Relationship between disease specific quality of life measures, physical performance, and activity in people with intermittent claudication caused by peripheral artery disease. Eur J Vasc Endovasc Surg 2020;59:957–64. https://doi.org/10.1016/j.ejvs.2020.02.006
  51	Gardner AW, Montgomery PS, Wang M, Xu C. Predictors of health-related quality of life in patients with symptomatic peripheral artery disease. J Vasc Surg 2018;68:1126–34. https://doi.org/10.1016/j.jvs.2017.12.074
  52	McDermott MM, Tian L, Liu K, Guralnik JM, Ferrucci L, Tan J, et al.  Prognostic value of functional performance for mortality in patients with peripheral artery disease. J Am Coll Cardiol 2008;51:1482–9. https://doi.org/10.1016/j.jacc.2007.12.034
  53	McDermott MM, Guralnik JM, Tian L, Ferrucci L, Liu K, Liao Y, et al.  Baseline functional performance predicts the rate of mobility loss in persons with peripheral arterial disease. J Am Coll Cardiol 2007;50:974–82. https://doi.org/10.1016/j.jacc.2007.05.030
  54	Sprengers RW, Teraa M, Moll FL, de Wit GA, van der Graaf Y, Verhaar MC. Quality of life in patients with no-option critical limb ischemia underlines the need for new effective treatment. J Vasc Surg 2010;52:843–9.e1. https://doi.org/10.1016/j.jvs.2010.04.057
  55	Rose GA. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull World Health Organ 1962;27:645–58 .
  
56	Leng GC, Fowkes FG. The Edinburgh claudication questionnaire: an improved version of the WHO/Rose questionnaire for use in epidemiological surveys. J Clin Epidemiol 1992;45:1101–9. https://doi.org/10.1016/0895-4356(92)90150-l
  
57	Birkett ST, Harwood AE, Caldow E, Ibeggazene S, Ingle L, Pymer S. A systematic review of exercise testing in patients with intermittent claudication: a focus on test standardisation and reporting quality in randomised controlled trials of exercise interventions. PLoS One 2021;16:e0249277. https://doi.org/10.1371/journal.pone.0249277
  58	Harwood AE, Pymer S, Ingle L, Doherty P, Chetter IC, Parmenter B. Exercise training for intermittent claudication: a narrative review and summary of guidelines for practitioners. BMJ Open Sport Exerc Med 2020;6:e000897. https://doi.org/10.1136/bmjsem-2020-000897
  59	Treat-Jacobson D, McDermott MM, Beckman JA, Burt MA, Creager MA, Ehrman JK, et al.  Implementation of supervised exercise therapy for patients with symptomatic peripheral artery disease: a science advisory from the American Heart Association. Circulation 2019;140:e700–10. https://doi.org/10.1161/cir.0000000000000727
  60	Hiatt WR, Rogers RK, Brass EP. The treadmill is a better functional test than the 6-minute walk test in therapeutic trials of patients with peripheral artery disease. Circulation 2014;130:69–78. https://doi.org/10.1161/circulationaha.113.007003
  61	Nicolaï SP, Viechtbauer W, Kruidenier LM, Candel MJJM, Prins MH, Teijink JAW. Reliability of treadmill testing in peripheral arterial disease: a meta-regression analysis. J Vasc Surg 2009;50:322–9. https://doi.org/10.1016/j.jvs.2009.01.042
  62	Mazzolai L, Belch J, Venermo M, Aboyans V, Brodmann M, Bura-Rivière A, et al.  Exercise therapy for chronic symptomatic peripheral artery disease. Eur Heart J 2024;45:1303–21. https://doi.org/10.1093/eurheartj/ehad734
  63	McDermott MM, Guralnik JM, Criqui MH, Liu K, Kibbe MR, Ferrucci L. Six-minute walk is a better outcome measure than treadmill walking tests in therapeutic trials of patients with peripheral artery disease. Circulation 2014;130:61–8. https://doi.org/10.1161/circulationaha.114.007002
  64	McDermott MM, Ades PA, Dyer A, Guralnik JM, Kibbe M, Criqui MH. Corridor-based functional performance measures correlate better with physical activity during daily life than treadmill measures in persons with peripheral arterial disease. J Vasc Surg 2008;48:1231–7.e1. https://doi.org/10.1016/j.jvs.2008.06.050
  65	ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111–7. https://doi.org/10.1164/ajrccm.166.1.at1102
CrossrefPubMedWorldCat 
66	Verdijk LB, van Loon L, Meijer K, Savelberg HH. One-repetition maximum strength test represents a valid means to assess leg strength in vivo in humans. J Sports Sci 2009;27:59–68. https://doi.org/10.1080/02640410802428089
  67	Ritti-Dias RM, Basyches M, Câmara L, Puech-Leao P, Battistella L, Wolosker N. Test-retest reliability of isokinetic strength and endurance tests in patients with intermittent claudication. Vasc Med 2010;15:275–8. https://doi.org/10.1177/1358863x10371415
  68	Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al.  A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol 1994;49:M85–94. https://doi.org/10.1093/geronj/49.2.m85
  69	Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med 1995;332:556–62. https://doi.org/10.1056/nejm199503023320902
  70	Isselbacher EM, Preventza O, Hamilton Black J III, Augoustides JG, Beck AW, Bolen MA, et al.  2022 ACC/AHA Guideline for the diagnosis and management of aortic disease: a report of the American Heart Association/American College of Cardiology Joint Committee on clinical practice guidelines. J Am Coll Cardiol 2022;80:e223–393. https://doi.org/10.1016/j.jacc.2022.08.004
  71	Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, et al.  2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J 2021;42:17–96. https://doi.org/10.1093/eurheartj/ehaa605
  72	de Heer F, Gökalp AL, Kluin J, Takkenberg JJM. Measuring what matters to the patient: health related quality of life after aortic valve and thoracic aortic surgery. Gen Thorac Cardiovasc Surg 2019;67:37–43. https://doi.org/10.1007/s11748-017-0830-9
  73	Chaddha A, Kline-Rogers E, Braverman AC, Erickson SR, Jackson EA, Franklin BA, et al.  Survivors of aortic dissection: activity, mental health, and sexual function. Clin Cardiol 2015;38:652–9. https://doi.org/10.1002/clc.22418
  74	Andonian C, Freilinger S, Achenbach S, Ewert P, Gundlach U, Kaemmerer H, et al.  Quality of life in patients with Marfan syndrome: a cross-sectional study of 102 adult patients. Cardiovasc Diagn Ther 2021;11:602–10. https://doi.org/10.21037/cdt-20-692
  75	Vanem TT, Rand-Hendriksen S, Brunborg C, Geiran OR, Røe C. Health-related quality of life in Marfan syndrome: a 10-year follow-up. Health Qual Life Outcomes 2020;18:376. https://doi.org/10.1186/s12955-020-01633-4
  76	Cervin A, Wanhainen A, Björck M. Popliteal aneurysms are common among men with screening detected abdominal aortic aneurysms, and prevalence correlates with the diameters of the common iliac arteries. Eur J Vasc Endovasc Surg 2020;59:67–72. https://doi.org/10.1016/j.ejvs.2019.07.042
  77	Aboyans V, Ricco JB, Bartelink MEL, Björck M, Brodmann M, Cohnert T, et al.  2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO), the task force for the diagnosis and treatment of peripheral arterial diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 2018;39:763–816. https://doi.org/10.1093/eurheartj/ehx095
  78	Ichihashi S, Desormais I, Hashimoto T, Magne J, Kichikawa K, Aboyans V. Accuracy and reliability of the ankle brachial index measurement using a multicuff oscillometric device versus the Doppler method. Eur J Vasc Endovasc Surg 2020;60:462–8. https://doi.org/10.1016/j.ejvs.2020.06.013
  79	Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, Diehm C, et al.  Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation 2012;126:2890–909. https://doi.org/10.1161/CIR.0b013e318276fbcb
  80	Høyer C, Strandberg J, Overvad Jordansen MK, Zacho HD. The ability of the toe-brachial index to predict the outcome of treadmill exercise testing in patients with a normal resting ankle-brachial index. Ann Vasc Surg 2020;64:263–9. https://doi.org/10.1016/j.avsg.2019.10.041
  81	Godet R, Bruneau A, Vielle B, Vincent F, Le Tourneau T, Carre F, et al.  Post-exercise ankle blood pressure and ankle to brachial index after heavy load bicycle exercise. Scand J Med Sci Sports 2018;28:2144–52. https://doi.org/10.1111/sms.13234
  82	van Langen H, van Gurp J, Rubbens L. Interobserver variability of ankle-brachial index measurements at rest and post exercise in patients with intermittent claudication. Vasc Med 2009;14:221–6. https://doi.org/10.1177/1358863x08101017
  83	Stein R, Hriljac I, Halperin JL, Gustavson SM, Teodorescu V, Olin JW, Limitation of the resting ankle-brachial index in symptomatic patients with peripheral arterial disease. Vasc Med 2006;11:29–33. https://doi.org/10.1191/1358863x06vm663oa
  84	Abraham P, Desvaux B, Saumet JL. Ankle-brachial index after maximum exercise in treadmill and cycle ergometers in athletes. Clin Physiol 1998;18:321–6. https://doi.org/10.1046/j.1365-2281.1998.00100.x
  85	Stoffers HE, Kester AD, Kaiser V, Rinkens PELM, Kitslaar PJEHM, Knottnerus JA, The diagnostic value of the measurement of the ankle-brachial systolic pressure index in primary health care. J Clin Epidemiol 1996;49:1401–5. https://doi.org/10.1016/s0895-4356(96)00275-2
  86	Ouriel K, McDonnell AE, Metz CE, Zarins CK. Critical evaluation of stress testing in the diagnosis of peripheral vascular disease. Surgery 1982;91:686–93 .
  
87	Laing S, Greenhalgh RM. The detection and progression of asymptomatic peripheral arterial disease. Br J Surg 2005;70:628–30. https://doi.org/10.1002/bjs.1800701017
Google ScholarCrossrefWorldCat 
88	Ankle Brachial Index Collaboration; Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, et al.  Ankle brachial index combined with Framingham risk score to predict cardiovascular events and mortality: a meta-analysis. JAMA 2008;300:197–208. https://doi.org/10.1001/jama.300.2.197
  
89	Criqui MH, McClelland RL, McDermott MM, McDermott MM, Allison MA, Blumenthal RS, et al.  The ankle-brachial index and incident cardiovascular events in the MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol 2010;56:1506–12. https://doi.org/10.1016/j.jacc.2010.04.060
  90	Herraiz-Adillo Á, Cavero-Redondo I, Álvarez-Bueno C, Pozuelo-Carrascosa DP, Solera-Martínez M. The accuracy of toe brachial index and ankle brachial index in the diagnosis of lower limb peripheral arterial disease: a systematic review and meta-analysis. Atherosclerosis 2020;315:81–92. https://doi.org/10.1016/j.atherosclerosis.2020.09.026
  91	Tehan PE, Santos D, Chuter VH. A systematic review of the sensitivity and specificity of the toe-brachial index for detecting peripheral artery disease. Vasc Med 2016;21:382–9. https://doi.org/10.1177/1358863x16645854
  92	Fukui M, Tanaka M, Hamaguchi M, Senmaru T, Sakabe K, Asano M, et al.  Toe-brachial index is associated more strongly with albuminuria or glomerular filtration rate than ankle-brachial index in patients with type 2 diabetes. Hypertens Res 2012;35:745–9. https://doi.org/10.1038/hr.2012.16
  93	Dachun X, Jue L, Liling Z, Xu Y, Hu D, Pagoto SL, et al.  Sensitivity and specificity of the ankle—brachial index to diagnose peripheral artery disease: a structured review. Vasc Med 2010;15:361–9. https://doi.org/10.1177/1358863x10378376
  94	Morimoto S, Nakajima F, Yurugi T, Morita T, Jo F, Nishikawa M, et al.  Risk factors of normal ankle-brachial index and low toe-brachial index in hemodialysis patients. Ther Apher Dial 2009;13:103–7. https://doi.org/10.1111/j.1744-9987.2009.00663.x
  95	Young MJ, Adams JE, Anderson GF, Boulton AJ, Cavanagh PR. Medial arterial calcification in the feet of diabetic patients and matched non-diabetic control subjects. Diabetologia 1993;36:615–21. https://doi.org/10.1007/bf00404070
  96	Carter SA, Lezack JD. Digital systolic pressures in the lower limb in arterial disease. Circulation 1971;43:905–14. https://doi.org/10.1161/01.cir.43.6.905
  97	Watanabe Y, Masaki H, Kojima K, Tanemoto K. Toe-brachial index in the second toe: substitutability to toe-brachial index in the great toe and ankle-brachial index. Ann Vasc Dis 2016;9:300–6. https://doi.org/10.3400/avd.oa.16-00078
  98	Pérez-Martin A, Meyer G, Demattei C, Böge G, Laroche J-P, Quéré I, et al.  Validation of a fully automatic photoplethysmographic device for toe blood pressure measurement. Eur J Vasc Endovasc Surg 2010;40:515–20. https://doi.org/10.1016/j.ejvs.2010.06.008
  99	Hoyer C, Sandermann J, Petersen LJ. The toe-brachial index in the diagnosis of peripheral arterial disease. J Vasc Surg 2013;58:231–8. https://doi.org/10.1016/j.jvs.2013.03.044
  100	Monti M, Calanca L, Alatri A, Mazzolai L. Accuracy of in-patients ankle-brachial index measurement by medical students. Vasa 2016;45:43–8. https://doi.org/10.1024/0301-1526/a000494
  101	Kaiser V, Kester AD, Stoffers HE, Kitslaar PJ, Knottnerus JA. The influence of experience on the reproducibility of the ankle-brachial systolic pressure ratio in peripheral arterial occlusive disease. Eur J Vasc Endovasc Surg 1999;18:25–9. https://doi.org/10.1053/ejvs.1999.0843
  102	Ray SA, Srodon PD, Taylor RS, Dormandy JA. Reliability of ankle:brachial pressure index measurement by junior doctors. Br J Surg 1994;81:188–90. https://doi.org/10.1002/bjs.1800810208
  103	Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al.  2016 AHA/ACC Guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation 2017;135:e726–79. https://doi.org/10.1161/CIR.0000000000000471
  
104	Stivalet O, Paisant A, Belabbas D, Omarjee L, Le Faucheur A, Landreau P, et al.  Exercise testing criteria to diagnose lower extremity peripheral artery disease assessed by computed-tomography angiography. PLoS One 2019;14:e0219082. https://doi.org/10.1371/journal.pone.0219082
  105	Abraham P, Picquet J, Vielle B, Sigaudo-Roussel D, Paisant-Thouveny F, Enon B, et al.  Transcutaneous oxygen pressure measurements on the buttocks during exercise to detect proximal arterial ischemia: comparison with arteriography. Circulation 2003;107:1896–900. https://doi.org/10.1161/01.Cir.0000060500.60646.E0
  106	Yamamoto K, Miyata T, Onozuka A, Koyama H, Ohtsu H, Nagawa H. Plantar flexion as an alternative to treadmill exercise for evaluating patients with intermittent claudication. Eur J Vasc Endovasc Surg 2007;33:325–9. https://doi.org/10.1016/j.ejvs.2006.10.012
  107	Maufus M, Sevestre-Pietri MA, Sessa C, Pignon B, Egelhofer H, Dupas S, et al.  Critical limb ischaemia and the response to bone marrow-derived cell therapy according to tcPO(2) measurement. Vasa 2017;46:23–8. https://doi.org/10.1024/0301-1526/a000590
  108	Leenstra B, Wijnand J, Verhoeven B, Koning O, Teraa M, Verhaar MC, et al.  Applicability of transcutaneous oxygen tension measurement in the assessment of chronic limb-threatening ischemia. Angiology 2020;71:208–16. https://doi.org/10.1177/0003319719866958
  109	Ott A. Inflammation and transcutaneous measurement of oxygen pressure in dermatology. Adv Exp Med Biol 1987;220:79–82. https://doi.org/10.1007/978-1-4613-1927-6_14
  
110	Woo Y, Suh YJ, Lee H, Jeong E, Park SC, Yun SS, et al.  TcPO2 value can predict wound healing time in clinical practice of CLTI patients. Ann Vasc Surg 2023;91:249–56. https://doi.org/10.1016/j.avsg.2022.11.020
  111	Wang Z, Hasan R, Firwana B, Elraiyah T, Tsapas A, Prokop L, et al.  A systematic review and meta-analysis of tests to predict wound healing in diabetic foot. J Vasc Surg 2016;63:29S–36S.e2. https://doi.org/10.1016/j.jvs.2015.10.004
  112	Yamada T, Ohta T, Ishibashi H, Sugimoto I, Iwata H, Takahashi M, et al.  Clinical reliability and utility of skin perfusion pressure measurement in ischemic limbs—comparison with other noninvasive diagnostic methods. J Vasc Surg 2008;47:318–23. https://doi.org/10.1016/j.jvs.2007.10.045
  113	Noori N, Haruno L, Schroeder I, Vrahas M, Little M, Moon C, et al.  Preoperative transcutaneous oxygen perfusion measurements in predicting atraumatic wound healing after major lower extremity amputation. Orthopedics 2022;45:174–80. https://doi.org/10.3928/01477447-20220128-05
  114	Nishio H, Minakata K, Kawaguchi A, Kumagai M, Ikeda T, Shimizu A, et al.  Transcutaneous oxygen pressure as a surrogate index of lower limb amputation. Int Angiol 2016;35:565–72.
  
115	Sarin S, Shami S, Shields DA, Scurr JH, Smith PD. Selection of amputation level: a review. Eur J Vasc Surg 1991;5:611–20. https://doi.org/10.1016/s0950-821x(05)80894-1
  116	Abraham P, Ramondou P, Hersant J, Sempore WY, Feuilloy M, Henni S. Investigation of arterial claudication with transcutaneous oxygen pressure at exercise: interests and limits. Trends Cardiovasc Med 2021;31:218–23. https://doi.org/10.1016/j.tcm.2020.03.003
  117	Abraham P, Gu Y, Guo L, Kroeger K, Ouedraogo N, Wennberg P, et al.  Clinical application of transcutaneous oxygen pressure measurements during exercise. Atherosclerosis 2018;276:117–23. https://doi.org/10.1016/j.atherosclerosis.2018.07.023
  118	Colas-Ribas C, Signolet I, Henni S, Feuillloy M, Gagnadoux F, Abraham P. High prevalence of known and unknown pulmonary diseases in patients with claudication during exercise oximetry: a retrospective analysis. Medicine (Baltimore) 2016;95:e4888. https://doi.org/10.1097/md.0000000000004888
  119	Frank U, Nikol S, Belch J, Boc V, Brodmann M, Carpentier PH, et al.  ESVM guideline on peripheral arterial disease. Vasa 2019;48:1–79. https://doi.org/10.1024/0301-1526/a000834
Google ScholarWorldCat 
120	Schlager O, Francesconi M, Haumer M, Dick P, Sabeti S, Amighi J, et al.  Duplex sonography versus angiography for assessment of femoropopliteal arterial disease in a ‘real-world’ setting. J Endovasc Ther 2007;14:452–9. https://doi.org/10.1177/152660280701400404
  121	Collins R, Burch J, Cranny G, Aguiar-Ibáñez R, Craig D, Wright K, et al.  Duplex ultrasonography, magnetic resonance angiography, and computed tomography angiography for diagnosis and assessment of symptomatic, lower limb peripheral arterial disease: systematic review. BMJ 2007;334:1257. https://doi.org/10.1136/bmj.39217.473275.55
  122	Sprynger M, Rigo F, Moonen M, Aboyans V, Edvardsen T, de Alcantara ML, et al.  Focus on echovascular imaging assessment of arterial disease: complement to the ESC Guidelines (PARTIM 1) in collaboration with the working group on aorta and peripheral vascular diseases. Eur Heart J Cardiovasc Imaging 2018;19:1195–221. https://doi.org/10.1093/ehjci/jey103
  123	Collins R, Cranny G, Burch J, Aguiar-Ibáñez R, Craig D, Wright K, et al.  A systematic review of duplex ultrasound, magnetic resonance angiography and computed tomography angiography for the diagnosis and assessment of symptomatic, lower limb peripheral arterial disease. Health Technol Assess 2007;11:iii–iv, xi-xiii, 1–184. https://doi.org/10.3310/hta11200
Google ScholarWorldCat 
124	Rodway AD, Cheal D, Allan C, Pazos-Casal F, Hanna L, Field BCT, et al.  Ankle Doppler for cuffless ankle brachial index estimation and peripheral artery disease diagnosis independent of diabetes. J Clin Med 2022;12:97. https://doi.org/10.3390/jcm12010097
  125	Katsanos K, Tepe G, Tsetis D, Fanelli F. Standards of practice for superficial femoral and popliteal artery angioplasty and stenting. Cardiovasc Intervent Radiol 2014;37:592–603. https://doi.org/10.1007/s00270-014-0876-3
  126	Coffi SB, Ubbink DT, Zwiers I, van Gurp JA, Legemate DA. Improved assessment of the hemodynamic significance of borderline iliac stenoses with use of hyperemic duplex scanning. J Vasc Surg 2002;36:575–80. https://doi.org/10.1067/mva.2002.126086
  127	Elsman BH, Legemate DA, de Vos HJ, Mali WP, Eikelboom BC. Hyperaemic colour duplex scanning for the detection of aortoiliac stenoses. a comparative study with intra-arterial pressure measurement. Eur J Vasc Endovasc Surg 1997;14:462–7. https://doi.org/10.1016/s1078-5884(97)80125-6
  128	Venermo M, Sprynger M, Desormais I, Björck M, Brodmann M, Cohnert T, et al.  Follow-up of patients after revascularisation for peripheral arterial diseases: a consensus document from the European Society of Cardiology working group on aorta and peripheral vascular diseases and the European Society for Vascular Surgery. Eur J Prev Cardiol 2019;26:1971–84. https://doi.org/10.1177/2047487319846999
  129	Golemati S, Cokkinos DD. Recent advances in vascular ultrasound imaging technology and their clinical implications. Ultrasonics 2022;119:106599. https://doi.org/10.1016/j.ultras.2021.106599
  130	Itoga NK, Minami HR, Chelvakumar M, Pearson K, Mell MM, Bendavid E, et al.  Cost-effectiveness analysis of asymptomatic peripheral artery disease screening with the ABI test. Vasc Med 2018;23:97–106. https://doi.org/10.1177/1358863X17745371
  131	Xu D, Zou L, Xing Y, Hou L, Wei Y, Zhang J, et al.  Diagnostic value of ankle-brachial index in peripheral arterial disease: a meta-analysis. Can J Cardiol 2013;29:492–8. https://doi.org/10.1016/j.cjca.2012.06.014
  132	Hashimoto T, Ichihashi S, Iwakoshi S, Kichikawa K. Combination of pulse volume recording (PVR) parameters and ankle-brachial index (ABI) improves diagnostic accuracy for peripheral arterial disease compared with ABI alone. Hypertens Res 2016;39:430–4. https://doi.org/10.1038/hr.2016.13
  133	Tehan PE, Bray A, Chuter VH. Non-invasive vascular assessment in the foot with diabetes: sensitivity and specificity of the ankle brachial index, toe brachial index and continuous wave Doppler for detecting peripheral arterial disease. J Diabetes Complications 2016;30:155–60. https://doi.org/10.1016/j.jdiacomp.2015.07.019
  134	Loukas M, Bilinsky E, Bilinsky S, Blaak C, Tubbs RS, Anderson RH. The anatomy of the aortic root. Clin Anat 2014;27:748–56. https://doi.org/10.1002/ca.22295
  135	Dagenais F. Anatomy of the thoracic aorta and of its branches. Thorac Surg Clin 2011;21:219–27, viii. https://doi.org/10.1016/j.thorsurg.2010.12.004
  136	Lombardi JV, Hughes GC, Appoo JJ, Bavaria JE, Beck AW, Cambria RP, et al.  Society for Vascular Surgery (SVS) and Society of Thoracic Surgeons (STS) reporting standards for type B aortic dissections. Ann Thorac Surg 2020;109:959–81. https://doi.org/10.1016/j.athoracsur.2019.10.005
  137	Rodríguez-Palomares JF, Teixidó-Tura G, Galuppo V, Cuéllar H, Laynez A, Gutiérrez L, et al.  Multimodality assessment of ascending aortic diameters: comparison of different measurement methods. J Am Soc Echocardiogr 2016;29:819–26.e4. https://doi.org/10.1016/j.echo.2016.04.006
  138	Saura D, Dulgheru R, Caballero L, Bernard A, Kou S, Gonjilashvili N, et al.  Two-dimensional transthoracic echocardiographic normal reference ranges for proximal aorta dimensions: results from the EACVI NORRE study. Eur Heart J Cardiovasc Imaging 2017;18:167–79. https://doi.org/10.1093/ehjci/jew053
  139	Bons LR, Duijnhouwer AL, Boccalini S, van den Hoven AT, van der Vlugt MJ, Chelu RG, et al.  Intermodality variation of aortic dimensions: how, where and when to measure the ascending aorta. Int J Cardiol 2019;276:230–5. https://doi.org/10.1016/j.ijcard.2018.08.067
  140	Amsallem M, Ou P, Milleron O, Henry-Feugeas M-C, Detaint D, Arnoult F, et al.  Comparative assessment of ascending aortic aneurysms in Marfan patients using ECG-gated computerized tomographic angiography versus trans-thoracic echocardiography. Int J Cardiol 2015;184:22–7. https://doi.org/10.1016/j.ijcard.2015.01.086
  141	Matthews EO, Pinchbeck J, Elmore K, Jones RE, Moxon JV, Golledge J. The reproducibility of measuring maximum abdominal aortic aneurysm diameter from ultrasound images. Ultrasound J 2021;13:13. https://doi.org/10.1186/s13089-021-00211-z
  142	Bonnafy T, Lacroix P, Desormais I, Labrunie A, Marin B, Leclerc A, et al.  Reliability of the measurement of the abdominal aortic diameter by novice operators using a pocket-sized ultrasound system. Arch Cardiovasc Dis 2013;106:644–50. https://doi.org/10.1016/j.acvd.2013.08.004
  143	Fitzgerald BT, Kwon A, Scalia GM. The new dimension in aortic measurements—use of the inner edge measurement for the thoracic aorta in Australian patients. Heart Lung Circ 2015;24:1104–10. https://doi.org/10.1016/j.hlc.2015.05.001
  144	Burman ED, Keegan J, Kilner PJ. Aortic root measurement by cardiovascular magnetic resonance: specification of planes and lines of measurement and corresponding normal values. Circ Cardiovasc Imaging 2008;1:104–13. https://doi.org/10.1161/circimaging.108.768911
  145	Muraru D, Maffessanti F, Kocabay G, Peluso D, Bianco LD, Piasentini E, et al.  Ascending aorta diameters measured by echocardiography using both leading edge-to-leading edge and inner edge-to-inner edge conventions in healthy volunteers. Eur Heart J Cardiovasc Imaging 2014;15:415–22. https://doi.org/10.1093/ehjci/jet173
  146	Vis JC, Rodríguez-Palomares JF, Teixidó-Tura G, Galian-Gay L, Granato C, Guala A, et al.  Implications of asymmetry and valvular morphotype on echocardiographic measurements of the aortic root in bicuspid aortic valve. J Am Soc Echocardiogr 2019;32:105–12. https://doi.org/10.1016/j.echo.2018.08.004
  147	Ghulam Ali S, Fusini L, Dalla Cia A, Tamborini G, Gripari P, Muratori M, et al.  Technological advancements in echocardiographic assessment of thoracic aortic dilatation: head to head comparison among multidetector computed tomography, 2-dimensional, and 3-dimensional echocardiography measurements. J Thorac Imaging 2018;33:232–9. https://doi.org/10.1097/rti.0000000000000330
  148	Mendoza DD, Kochar M, Devereux RB, Basson CT, Min JK, Holmes K, et al.  Impact of image analysis methodology on diagnostic and surgical classification of patients with thoracic aortic aneurysms. Ann Thorac Surg 2011;92:904–12. https://doi.org/10.1016/j.athoracsur.2011.03.130
  149	Campens L, Demulier L, De Groote K, Vandekerckhove K, De Wolf D, Roman MJ, et al.  Reference values for echocardiographic assessment of the diameter of the aortic root and ascending aorta spanning all age categories. Am J Cardiol 2014;114:914–20. https://doi.org/10.1016/j.amjcard.2014.06.024
  150	Pedersen OM, Aslaksen A, Vik-Mo H. Ultrasound measurement of the luminal diameter of the abdominal aorta and iliac arteries in patients without vascular disease. J Vasc Surg 1993;17:596–601. https://doi.org/10.1067/mva.1993.39525
  151	Kim H, Kwon TW, Choi E, Jeong S, Kim H-K, Han Y, et al.  Aortoiliac diameter and length in a healthy cohort. PLoS One 2022;17:e0268077. https://doi.org/10.1371/journal.pone.0268077
  152	Evangelista A, Flachskampf FA, Erbel R, Antonini-Canterin F, Vlachopoulos C, Rocchi G, et al.  Echocardiography in aortic diseases: EAE recommendations for clinical practice. Eur J Echocardiogr 2010;11:645–58. https://doi.org/10.1093/ejechocard/jeq056
  153	Zafar MA, Li Y, Rizzo JA, Charilaou P, Saeyeldin A, Velasquez CA, et al.  Height alone, rather than body surface area, suffices for risk estimation in ascending aortic aneurysm. J Thorac Cardiovasc Surg 2018;155:1938–50. https://doi.org/10.1016/j.jtcvs.2017.10.140
  154	Masri A, Kalahasti V, Svensson LG, Roselli EE, Johnston D, Hammer D, et al.  Aortic cross-sectional area/height ratio and outcomes in patients with a trileaflet aortic valve and a dilated aorta. Circulation 2016;134:1724–37. https://doi.org/10.1161/circulationaha.116.022995
  155	Wu J, Zafar MA, Li Y, Saeyeldin A, Huang Y, Zhao R, et al.  Ascending aortic length and risk of aortic adverse events: the neglected dimension. J Am Coll Cardiol 2019;74:1883–94. https://doi.org/10.1016/j.jacc.2019.07.078
  156	Pham MHC, Ballegaard C, de Knegt MC, Sigvardsen PE, Sørgaard MH, Fuchs A, et al.  Normal values of aortic dimensions assessed by multidetector computed tomography in the Copenhagen general population study. Eur Heart J Cardiovasc Imaging 2019;20:939–48. https://doi.org/10.1093/ehjci/jez012
  157	Davis AE, Lewandowski AJ, Holloway CJ, Ntusi NAB, Banerjee R, Nethononda R, et al.  Observational study of regional aortic size referenced to body size: production of a cardiovascular magnetic resonance nomogram. J Cardiovasc Magn Reson 2014;16:9. https://doi.org/10.1186/1532-429x-16-9
  158	Braley KT, Tang X, Makil ES, Borroughs-Ray D, Collins RT. The impact of body weight on the diagnosis of aortic dilation—misdiagnosis in overweight and underweight groups. Echocardiography 2017;34:1029–34. https://doi.org/10.1111/echo.13565
  159	Evangelista A, Sitges M, Jondeau G, Nijveldt R, Pepi M, Cuellar H, et al.  Multimodality imaging in thoracic aortic diseases: a clinical consensus statement from the European Association of Cardiovascular Imaging and the European Society of Cardiology working group on aorta and peripheral vascular diseases. Eur Heart J Cardiovasc Imaging 2023;24:e65–85. https://doi.org/10.1093/ehjci/jead024
  160	Macdonald DB, Hurrell C, Costa AF, McInnes MDF, O’Malley ME, Barrett B, et al.  Canadian Association of Radiologists Guidance on contrast associated acute kidney injury. Can Assoc Radiol J 2022;73:499–514. https://doi.org/10.1177/08465371221083970
  161	Committee opinion no. 723: guidelines for diagnostic imaging during pregnancy and lactation. Obstet Gynecol 2017;130:e210–6. https://doi.org/10.1097/AOG.0000000000002355
CrossrefPubMedWorldCat 
162	von Kodolitsch Y, Nienaber CA, Dieckmann C, Schwartz AG, Hofmann T, Brekenfeld C, et al.  Chest radiography for the diagnosis of acute aortic syndrome. Am J Med 2004;116:73–7. https://doi.org/10.1016/j.amjmed.2003.08.030
  163	Nazerian P, Pivetta E, Veglia S, Cavigli E, Mueller C, de Matos Soeiro A, et al.  Integrated use of conventional chest radiography cannot rule out acute aortic syndromes in emergency department patients at low clinical probability. Acad Emerg Med 2019;26:1255–65. https://doi.org/10.1111/acem.13819
  164	Hartnell GG, Wakeley CJ, Tottle A, Papouchado M, Wilde RP. Limitations of chest radiography in discriminating between aortic dissection and myocardial infarction: implications for thrombolysis. J Thorac Imaging 1993;8:152–5. https://doi.org/10.1097/00005382-199321000-00008
  165	Evangelista A, Avegliano G, Aguilar R, Cuellar H, Igual A, Gonzalez-Alujas T, et al.  Impact of contrast-enhanced echocardiography on the diagnostic algorithm of acute aortic dissection. Eur Heart J 2010;31:472–9. https://doi.org/10.1093/eurheartj/ehp505
  166	Litmanovich D, Bankier AA, Cantin L, Raptopoulos V, Boiselle PM. CT and MRI in diseases of the aorta. AJR Am J Roentgenol 2009;193:928–40. https://doi.org/10.2214/ajr.08.2166
  167	Pennell DJ, Sechtem UP, Higgins CB, Manning W, Pohost G, Rademakers F, et al.  Clinical indications for cardiovascular magnetic resonance (CMR): consensus panel report. J Cardiovasc Magn Reson 2004;6:727–65. https://doi.org/10.1081/jcmr-200038581
  168	Yoshioka K, Tanaka R. MRI and MRA of aortic disease. Ann Vasc Dis 2010;3:196–201. https://doi.org/10.3400/avd.sasdi10003
  169	Fadel BM, Mohty D, Kazzi BE, Alamro B, Arshi F, Mustafa M, et al.  Ultrasound imaging of the abdominal aorta: a comprehensive review. J Am Soc Echocardiogr 2021;34:1119–36. https://doi.org/10.1016/j.echo.2021.06.012
  170	Bhave NM, Nienaber CA, Clough RE, Eagle KA. Multimodality imaging of thoracic aortic diseases in adults. JACC Cardiovasc Imaging 2018;11:902–19. https://doi.org/10.1016/j.jcmg.2018.03.009
  171	Goldstein SA, Evangelista A, Abbara S, Arai A, Asch FM, Badano LP, et al.  Multimodality imaging of diseases of the thoracic aorta in adults: from the American Society of Echocardiography and the European Association of Cardiovascular Imaging: endorsed by the Society of Cardiovascular Computed Tomography and Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 2015;28:119–82. https://doi.org/10.1016/j.echo.2014.11.015
  172	Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, et al.  2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The task force for the diagnosis and treatment of aortic diseases of the European Society of Cardiology (ESC). Eur Heart J 2014;35:2873–926. https://doi.org/10.1093/eurheartj/ehu281
  
173	Bossone E, Czerny M, Lerakis S, Rodríguez-Palomares J, Kukar N, Ranieri B, et al.  Imaging and biomarkers in acute aortic syndromes: diagnostic and prognostic implications. Curr Probl Cardiol 2021;46:100654. https://doi.org/10.1016/j.cpcardiol.2020.100654
  174	Bossone E, LaBounty TM, Eagle KA. Acute aortic syndromes: diagnosis and management, an update. Eur Heart J 2018;39:739–49d. https://doi.org/10.1093/eurheartj/ehx319
  175	Vardhanabhuti V, Nicol E, Morgan-Hughes G, Roobottom CA, Roditi G, Hamilton MCK, et al.  Recommendations for accurate CT diagnosis of suspected acute aortic syndrome (AAS)—on behalf of the British Society of Cardiovascular Imaging (BSCI)/British Society of Cardiovascular CT (BSCCT). Br J Radiol 2016;89:20150705. https://doi.org/10.1259/bjr.20150705
  176	Carstensen M, Keer D, Rempel J, Jeon P, Barrett B. Prevalence of risk factors for contrast-induced nephrotoxicity in outpatients undergoing intravenous contrast-enhanced computed tomography studies. Can Assoc Radiol J 2012;63:177–82. https://doi.org/10.1016/j.carj.2010.12.004
  177	Brenner DJ, Hall EJ. Computed tomography—an increasing source of radiation exposure. N Engl J Med 2007;357:2277–84. https://doi.org/10.1056/NEJMra072149
  178	Barra L, Kanji T, Malette J, Pagnoux C. Imaging modalities for the diagnosis and disease activity assessment of Takayasu’s arteritis: a systematic review and meta-analysis. Autoimmun Rev 2018;17:175–87. https://doi.org/10.1016/j.autrev.2017.11.021
  179	Dyverfeldt P, Bissell M, Barker AJ, Bolger AF, Carlhäll C-J, Ebbers T, et al.  4D flow cardiovascular magnetic resonance consensus statement. J Cardiovasc Magn Reson 2015;17:72. https://doi.org/10.1186/s12968-015-0174-5
  180	Rodriguez-Palomares JF. Genetics of bicuspid aortic valve: ready for clinical use? Heart 2022;108:1078–9. https://doi.org/10.1136/heartjnl-2021-320742
  181	Guala A, Teixido-Tura G, Dux-Santoy L, Granato C, Ruiz-Muñoz A, Valente F, et al.  Decreased rotational flow and circumferential wall shear stress as early markers of descending aorta dilation in Marfan syndrome: a 4D flow CMR study. J Cardiovasc Magn Reson 2019;21:63. https://doi.org/10.1186/s12968-019-0572-1
  182	Horowitz MJ, Kupsky DF, El-Said HG, Alshawabkeh L, Kligerman SJ, Hsiao A. 4D flow MRI quantification of congenital shunts: comparison to invasive catheterization. Radiol Cardiothorac Imaging 2021;3:e200446. https://doi.org/10.1148/ryct.2021200446
  183	Rizk J. 4D flow MRI applications in congenital heart disease. Eur Radiol 2021;31:1160–74. https://doi.org/10.1007/s00330-020-07210-z
  184	Gupta SK, Ya’qoub L, Wimmer AP, Fisher S, Saeed IM. Safety and clinical impact of MRI in patients with non-MRI-conditional cardiac devices. Radiol Cardiothorac Imaging 2020;2:e200086. https://doi.org/10.1148/ryct.2020200086
  185	Munawar DA, Chan JEZ, Emami M, Kadhim K, Khokhar K, O’Shea C, et al.  Magnetic resonance imaging in non-conditional pacemakers and implantable cardioverter-defibrillators: a systematic review and meta-analysis. Europace 2020;22:288–98. https://doi.org/10.1093/europace/euz343
  186	Nienaber CA. The role of imaging in acute aortic syndromes. Eur Heart J Cardiovasc Imaging 2013;14:15–23. https://doi.org/10.1093/ehjci/jes215
  187	van der Geest KSM, Treglia G, Glaudemans A, Brouwer E, Sandovici M, Jamar F, et al.  Diagnostic value of [18F]FDG-PET/CT for treatment monitoring in large vessel vasculitis: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2021;48:3886–902. https://doi.org/10.1007/s00259-021-05362-8
  188	Dejaco C, Ramiro S, Duftner C, Besson FL, Bley TA, Blockmans D, et al.  EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis 2018;77:636–43. https://doi.org/10.1136/annrheumdis-2017-212649
  189	Forsythe RO, Dweck MR, McBride OMB, Vesey AT, Semple SI, Shah ASV, et al.  (18)F-sodium fluoride uptake in abdominal aortic aneurysms: the SoFIA(3) study. J Am Coll Cardiol 2018;71:513–23. https://doi.org/10.1016/j.jacc.2017.11.053
  190	Roque A, Pizzi MN. (18)F-FDG PET/CT: not only a promise for complex scenarios-let’s talk about aortic grafts. J Nucl Cardiol 2022;29:2949–51. https://doi.org/10.1007/s12350-021-02888-0
  191	Roque A, Pizzi MN, Fernández-Hidalgo N, Permanyer E, Cuellar-Calabria H, Romero-Farina G, et al.  Morpho-metabolic post-surgical patterns of non-infected prosthetic heart valves by [18F]FDG PET/CTA: ‘normality’ is a possible diagnosis. Eur Heart J Cardiovasc Imaging 2020;21:24–33. https://doi.org/10.1093/ehjci/jez222
  192	Pizzi MN, Roque A, Cuéllar-Calabria H, Fernández-Hidalgo N, Ferreira-González I, González-Alujas MT, et al.  (18)F-FDG-PET/CTA of prosthetic cardiac valves and valve-tube grafts: infective versus inflammatory patterns. JACC Cardiovasc Imaging 2016;9:1224–7. https://doi.org/10.1016/j.jcmg.2016.05.013
  193	Pizzi MN, Roque A, Fernández-Hidalgo N, Cuéllar-Calabria H, Ferreira-González I, Gonzàlez-Alujas MT, et al.  Improving the diagnosis of infective endocarditis in prosthetic valves and intracardiac devices with 18F-fluordeoxyglucose positron emission tomography/computed tomography angiography: initial results at an infective endocarditis referral center. Circulation 2015;132:1113–26. https://doi.org/10.1161/circulationaha.115.015316
  194	Teraa M, Hazenberg CE, Houben IB, Trimarchi S, van Herwaarden JA. Important issues regarding planning and sizing for emergent TEVAR. J Cardiovasc Surg (Torino) 2020;61:708–12. https://doi.org/10.23736/S0021-9509.20.11571-4
  
195	Lindholt JS, Sogaard R. Population screening and intervention for vascular disease in Danish men (VIVA): a randomised controlled trial. Lancet 2017;390:2256–65. https://doi.org/10.1016/S0140-6736(17)32250-X
  196	Lin JS, Evans CV, Johnson E, Redmond N, Coppola EL, Smith N. Nontraditional risk factors in cardiovascular disease risk assessment: updated evidence report and systematic review for the US preventive services task force. JAMA 2018;320:281–97. https://doi.org/10.1001/jama.2018.4242
  197	Normahani P, Burgess L, Norrie J, Epstein DM, Kandiyil N, Saratzis A, et al.  Study protocol for a multicentre comparative diagnostic accuracy study of tools to establish the presence and severity of peripheral arterial disease in people with diabetes mellitus: the DM PAD study. BMJ Open 2022;12:e066950. https://doi.org/10.1136/bmjopen-2022-066950
  198	Ueshima D, Barioli A, Nai Fovino L, D'Amico G, Fabris T, Brener SJ, et al.  The impact of pre-existing peripheral artery disease on transcatheter aortic valve implantation outcomes: a systematic review and meta-analysis. Catheter Cardiovasc Interv 2020;95:993–1000. https://doi.org/10.1002/ccd.28335
  199	de Weerd M, Greving JP, Hedblad B, Lorenz MW, Mathiesen EB, O'Leary DH, et al.  Prevalence of asymptomatic carotid artery stenosis in the general population: an individual participant data meta-analysis. Stroke 2010;41:1294–7. https://doi.org/10.1161/STROKEAHA.110.581058
  200	Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, Caughey AB, et al.  Screening for asymptomatic carotid artery stenosis: US preventive services task force recommendation statement. JAMA 2021;325:476–81. https://doi.org/10.1001/jama.2020.26988
  
201	AbuRahma AF, Avgerinos ED, Chang RW, Darling RC, Duncan AA, Forbes TL, et al.  Society for Vascular Surgery clinical practice guidelines for management of extracranial cerebrovascular disease. J Vasc Surg 2022;75:4S–22S. https://doi.org/10.1016/j.jvs.2021.04.073
  202	Howard DPJ, Gaziano L, Rothwell PM. Risk of stroke in relation to degree of asymptomatic carotid stenosis: a population-based cohort study, systematic review, and meta-analysis. Lancet Neurol 2021;20:193–202. https://doi.org/10.1016/s1474-4422(20)30484-1
  203	Paraskevas KI, Spence JD, Mikhailidis DP, Antignani PL, Gloviczki P, Eckstein H-H, et al.  Why do guidelines recommend screening for abdominal aortic aneurysms, but not for asymptomatic carotid stenosis? A plea for a randomized controlled trial. Int J Cardiol 2023;371:406–12. https://doi.org/10.1016/j.ijcard.2022.09.045
  204	Kobo O, Saada M, von Birgelen C, Tonino PAL, Íñiguez-Romo A, Fröbert O, et al.  Impact of multisite artery disease on clinical outcomes after percutaneous coronary intervention: an analysis from the e-Ultimaster registry. Eur Heart J Qual Care Clin Outcomes 2023;9:417–26. https://doi.org/10.1093/ehjqcco/qcac043
  
205	Steffel J, Eikelboom JW, Anand SS, Shestakovska O, Yusuf S, Fox KAA. The COMPASS trial: net clinical benefit of low-dose rivaroxaban plus aspirin as compared with aspirin in patients with chronic vascular disease. Circulation 2020;142:40–8. https://doi.org/10.1161/CIRCULATIONAHA.120.046048
  206	Del Giorno R, Reveilhac M, Stauffer I, Berthoud M, Mazzolai L, Depairon M, et al.  A new score for improving cardiovascular risk prediction and prevention. Nutr Metab Cardiovasc Dis 2023;33:1546–55. https://doi.org/10.1016/j.numecd.2023.04.019
  207	Mehta A, Rigdon J, Tattersall MC, German CA, Barringer TA, Joshi PH, et al.  Association of carotid artery plaque with cardiovascular events and incident coronary artery calcium in individuals with absent coronary calcification: the MESA. Circ Cardiovasc Imaging 2021;14:e011701. https://doi.org/10.1161/circimaging.120.011701
  208	Gepner AD, Young R, Delaney JA, Budoff MJ, Polak JF, Blaha MJ, et al.  Comparison of carotid plaque score and coronary artery calcium score for predicting cardiovascular disease events: the multi-ethnic study of atherosclerosis. J Am Heart Assoc 2017;6:e005179. https://doi.org/10.1161/jaha.116.005179
  209	Laclaustra M, Casasnovas JA, Fernández-Ortiz A, Fuster V, León-Latre M, Jiménez-Borreguero LJ, et al.  Femoral and carotid subclinical atherosclerosis association with risk factors and coronary calcium: the AWHS study. J Am Coll Cardiol 2016;67:1263–74. https://doi.org/10.1016/j.jacc.2015.12.056
  210	Jacobowitz GR, Rockman CB, Gagne PJ, Adelman MA, Lamparello PJ, Landis R, et al.  A model for predicting occult carotid artery stenosis: screening is justified in a selected population. J Vasc Surg 2003;38:705–9. https://doi.org/10.1016/s0741-5214(03)00730-4
  211	Rockman CB, Jacobowitz GR, Gagne PJ, Adelman MA, Lamparello PJ, Landis R, et al.  Focused screening for occult carotid artery disease: patients with known heart disease are at high risk. J Vasc Surg 2004;39:44–50. https://doi.org/10.1016/j.jvs.2003.07.008
  212	Yuo TH, Sidaoui J, Marone LK, Makaroun MS, Chaer RA. Revascularization of asymptomatic carotid stenosis is not appropriate in patients on dialysis. J Vasc Surg 2015;61:670–4. https://doi.org/10.1016/j.jvs.2014.10.002
  213	Ramos MJ, González-Fajardo JA, Vaquero-Puerta C, Vallina-Victorero M, Vicente-Santiago M, Vaquero-Lorenzo F, et al.  Asymptomatic carotid stenosis in patients with intermittent claudication: epidemiological study. J Cardiovasc Surg (Torino) 2011;52:761–8 .
  
214	Aboyans V, Lacroix P, Guilloux J, Rollé F, Le Guyader A, Cautrès M, et al.  A predictive model for screening cerebrovascular disease in patient undergoing coronary artery bypass grafting. Interact Cardiovasc Thorac Surg 2005;4:90–5. https://doi.org/10.1510/icvts.2004.092262
  215	Cornily JC, Le Saux D, Vinsonneau U, Bezon E, Le Ven F, Le Gal G, et al.  Assessment of carotid artery stenosis before coronary artery bypass surgery. Is it always necessary? Arch Cardiovasc Dis 2011;104:77–83. https://doi.org/10.1016/j.acvd.2010.11.008
  216	Johansson EP, Wester P. Carotid bruits as predictor for carotid stenoses detected by ultrasonography: an observational study. BMC Neurol 2008;8:23. https://doi.org/10.1186/1471-2377-8-23
  217	Carmody BJ, Arora S, Avena R, Curry KM, Simpkins J, Cosby K, et al.  Accelerated carotid artery disease after high-dose head and neck radiotherapy: is there a role for routine carotid duplex surveillance? J Vasc Surg 1999;30:1045–51. https://doi.org/10.1016/s0741-5214(99)70042-x
  218	Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, et al.  Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health 2019;7:e1020–30. https://doi.org/10.1016/s2214-109x(19)30255-4
  219	Campia U, Gerhard-Herman M, Piazza G, Goldhaber SZ. Peripheral artery disease: past, present, and future. Am J Med 2019;132:1133–41. https://doi.org/10.1016/j.amjmed.2019.04.043
  220	Søgaard R, Lindholt JS. Cost-effectiveness of population-based vascular disease screening and intervention in men from the Viborg Vascular (VIVA) trial. Br J Surg 2018;105:1283–93. https://doi.org/10.1002/bjs.10872
  221	Lindholt JS, Juul S, Fasting H, Henneberg EW. Screening for abdominal aortic aneurysms: single centre randomised controlled trial. BMJ 2005;330:750. https://doi.org/10.1136/bmj.38369.620162.82
  222	Norman PE, Jamrozik K, Lawrence-Brown MM, Le MT, Spencer CA, Tuohy RJ, et al.  Population based randomised controlled trial on impact of screening on mortality from abdominal aortic aneurysm. BMJ 2004;329:1259. https://doi.org/10.1136/bmj.38272.478438.55
  223	Ashton HA, Buxton MJ, Day NE, Kim LG, Marteau TM, Scott RA, et al.  The multicentre aneurysm screening study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. Lancet 2002;360:1531–9. https://doi.org/10.1016/s0140-6736(02)11522-4
  
224	Scott RA, Wilson NM, Ashton HA, Kay DN. Influence of screening on the incidence of ruptured abdominal aortic aneurysm: 5-year results of a randomized controlled study. Br J Surg 1995;82:1066–70. https://doi.org/10.1002/bjs.1800820821
  225	Duncan A, Maslen C, Gibson C, Hartshorne T, Farooqi A, Saratzis A, et al.  Ultrasound screening for abdominal aortic aneurysm in high-risk women. Br J Surg 2021;108:1192–8. https://doi.org/10.1093/bjs/znab220
  226	Lindholt JS, Sogaard R, Rasmussen LM, Mejldal A, Lambrechtsen J, Steffensen FH, et al.  Five-year outcomes of the Danish cardiovascular screening (DANCAVAS) trial. N Engl J Med 2022;387:1385–94. https://doi.org/10.1056/NEJMoa2208681
  227	Howard DP, Banerjee A, Fairhead JF, Handa A, Silver LE, Rothwell PM. Population-based study of incidence of acute abdominal aortic aneurysms with projected impact of screening strategy. J Am Heart Assoc 2015;4:e001926. https://doi.org/10.1161/JAHA.115.001926
  228	Howard DP, Banerjee A, Fairhead JF, Handa A, Silver LE, Rothwell PM. Age-specific incidence, risk factors and outcome of acute abdominal aortic aneurysms in a defined population. Br J Surg 2015;102:907–15. https://doi.org/10.1002/bjs.9838
  229	Sprynger M, Willems M, Van Damme H, Drieghe B, Wautrecht JC, Moonen M. Screening program of abdominal aortic aneurysm. Angiology 2019;70:407–13. https://doi.org/10.1177/0003319718824940
  230	Larsson E, Granath F, Swedenborg J, Hultgren R. A population-based case-control study of the familial risk of abdominal aortic aneurysm. J Vasc Surg 2009;49:47–50; discussion 51. https://doi.org/10.1016/j.jvs.2008.08.012
  231	Linné A, Forsberg J, Lindström D, Ideskog E, Hultgren R. Age at detection of abdominal aortic aneurysms in siblings of patients with abdominal aortic aneurysms. J Vasc Surg 2016;63:883–7. https://doi.org/10.1016/j.jvs.2015.10.057
  232	Aboyans V, Bataille V, Bliscaux P, Ederhy S, Filliol D, Honton B, et al.  Effectiveness of screening for abdominal aortic aneurysm during echocardiography. Am J Cardiol 2014;114:1100–4. https://doi.org/10.1016/j.amjcard.2014.07.024
  233	Hicks CW, Al-Qunaibet A, Ding N, Kwak L, Folsom AR, Tanaka H, et al.  Symptomatic and asymptomatic peripheral artery disease and the risk of abdominal aortic aneurysm: the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis 2021;333:32–8. https://doi.org/10.1016/j.atherosclerosis.2021.08.016
  234	Benson RA, Poole R, Murray S, Moxey P, Loftus IM. Screening results from a large United Kingdom abdominal aortic aneurysm screening center in the context of optimizing United Kingdom National Abdominal Aortic Aneurysm Screening Programme protocols. J Vasc Surg 2016;63:301–4. https://doi.org/10.1016/j.jvs.2015.08.091
  235	Sciria CT, Osorio B, Wang J, Lu DY, Amin N, Vohra A, et al.  Sex-based disparities in outcomes with abdominal aortic aneurysms. Am J Cardiol 2021;155:135–48. https://doi.org/10.1016/j.amjcard.2021.06.023
  236	Carter JL, Morris DR, Sherliker P, Clack R, Lam KBH, Halliday A, et al.  Sex-specific associations of vascular risk factors with abdominal aortic aneurysm: findings from 1.5 million women and 0.8 million men in the United States and United Kingdom. J Am Heart Assoc 2020;9:e014748. https://doi.org/10.1161/JAHA.119.014748
  237	Wanhainen A, Lundkvist J, Bergqvist D, Bjorck M. Cost-effectiveness of screening women for abdominal aortic aneurysm. J Vasc Surg 2006;43:908–14; discussion 914. https://doi.org/10.1016/j.jvs.2005.12.064
  238	Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr 2010;92:1189–96. https://doi.org/10.3945/ajcn.2010.29673
  239	Mente A, Dehghan M, Rangarajan S, O’Donnell M, Hu W, Dagenais G, et al.  Diet, cardiovascular disease, and mortality in 80 countries. Eur Heart J 2023;44:2560–79. https://doi.org/10.1093/eurheartj/ehad269
  240	Wan D, Dehghan M, de Souza RJ, Ramasundarahettige C, Eikelboom JW, Bosch J, et al.  Dietary intake and cardiovascular outcomes in patients with chronic vascular disease: insights from the COMPASS trial cohort. Eur J Prev Cardiol 2023;30:709–18. https://doi.org/10.1093/eurjpc/zwad062
  241	Adegbola A, Behrendt CA, Zyriax BC, Windler E, Kreutzburg T. The impact of nutrition on the development and progression of peripheral artery disease: a systematic review. Clin Nutr 2022;41:49–70. https://doi.org/10.1016/j.clnu.2021.11.005
  242	Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al.  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111–88. https://doi.org/10.1093/eurheartj/ehz455
  243	Amarenco P, Kim JS, Labreuche J, Charles H, Giroud M, Lee B-C, et al.  Benefit of targeting a LDL (low-density lipoprotein) cholesterol <70 mg/dL during 5 years after ischemic stroke. Stroke 2020;51:1231–9. https://doi.org/10.1161/strokeaha.119.028718
  244	Aung PP, Maxwell HG, Jepson RG, Price JF, Leng GC. Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev 2007;4:CD000123. https://doi.org/10.1002/14651858.CD000123.pub2
Google ScholarWorldCat 
245	Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 2007;45:645–54; discussion 653–644. https://doi.org/10.1016/j.jvs.2006.12.054
CrossrefPubMedWorldCat 
246	Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–78. https://doi.org/10.1016/S0140-6736(05)67394-1
  
247	Bonaca MP, Gutierrez JA, Cannon C, Giugliano R, Blazing M, Park J-G, et al.  Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. Lancet Diabetes Endocrinol 2018;6:934–43. https://doi.org/10.1016/s2213-8587(18)30290-0
  248	Yu E, Malik VS, Hu FB. Cardiovascular disease prevention by diet modification: JACC health promotion series. J Am Coll Cardiol 2018;72:914–26. https://doi.org/10.1016/j.jacc.2018.02.085
  249	López-Laguna N, Martínez-González MA, Toledo E, Babio N, Sorlí JV, Ros E, et al.  Risk of peripheral artery disease according to a healthy lifestyle score: the PREDIMED study. Atherosclerosis 2018;275:133–40. https://doi.org/10.1016/j.atherosclerosis.2018.05.049
  250	Kaluza J, Stackelberg O, Harris HR, Akesson A, Björck M, Wolk A. Mediterranean diet is associated with reduced risk of abdominal aortic aneurysm in smokers: results of two prospective cohort studies. Eur J Vasc Endovasc Surg 2021;62:284–93. https://doi.org/10.1016/j.ejvs.2021.04.017
  251	Liu L, Yang Y. Nutritional management mode of early cardiac rehabilitation in patients with Stanford type A aortic dissection. Comput Math Methods Med 2022;2022:2124636. https://doi.org/10.1155/2022/2124636
  
252	Lauret GJ, Fokkenrood HJ, Bendermacher BL, Scheltinga MR, Teijink JA. Physical activity monitoring in patients with intermittent claudication. Eur J Vasc Endovasc Surg 2014;47:656–63. https://doi.org/10.1016/j.ejvs.2014.03.001
  253	Gardner AW, Addison O, Katzel LI, Montgomery PS, Prior SJ, Serra MC, et al.  Association between physical activity and mortality in patients with claudication. Med Sci Sports Exerc 2021;53:732–9. https://doi.org/10.1249/mss.0000000000002526
  254	Gardner AW, Montgomery PS, Parker DE. Physical activity is a predictor of all-cause mortality in patients with intermittent claudication. J Vasc Surg 2008;47:117–22. https://doi.org/10.1016/j.jvs.2007.09.033
  255	Gardner AW, Montgomery PS, Wang M, Shen B, Zhang S, Pomilla WA. Association between meeting physical activity time-intensity guidelines with ambulation, quality of life, and inflammation in claudication. J Cardiopulm Rehabil Prev 2022;42:E82–9. https://doi.org/10.1097/hcr.0000000000000686
  256	Thijssen CGE, Bons LR, Gökalp AL, Van Kimmenade RRJ, Mokhles MM, Pelliccia A, et al.  Exercise and sports participation in patients with thoracic aortic disease: a review. Expert Rev Cardiovasc Ther 2019;17:251–66. https://doi.org/10.1080/14779072.2019.1585807
  257	Delsart P, Maldonado-Kauffmann P, Bic M, Boudghene-Stambouli F, Sobocinski J, Juthier F, et al.  Post aortic dissection: gap between activity recommendation and real life patients aerobic capacities. Int J Cardiol 2016;219:271–6. https://doi.org/10.1016/j.ijcard.2016.06.026
  258	Chaddha A, Eagle KA, Braverman AC, Kline-Rogers E, Hirsch AT, Brook R, et al.  Exercise and physical activity for the post-aortic dissection patient: the clinician’s conundrum. Clin Cardiol 2015;38:647–51. https://doi.org/10.1002/clc.22481
  259	Chaddha A, Kline-Rogers E, Woznicki EM, Brook R, Housholder-Hughes S, Braverman AC, et al.  Cardiology patient page. Activity recommendations for postaortic dissection patients. Circulation 2014;130:e140–2. https://doi.org/10.1161/circulationaha.113.005819
  260	Katsiki N, Papadopoulou SK, Fachantidou AI, Mikhailidis DP. Smoking and vascular risk: are all forms of smoking harmful to all types of vascular disease? Public Health 2013;127:435–41. https://doi.org/10.1016/j.puhe.2012.12.021
  261	Wu CW, Chuang HY, Watanabe K, Wu P-S, Pan H-C, Wang C-L, et al.  Association between secondhand smoke and peripheral arterial disease: a meta-analysis of cross-sectional studies. Int Arch Occup Environ Health 2022;95:1091–101. https://doi.org/10.1007/s00420-022-01837-9
  262	Sode BF, Nordestgaard BG, Gronbaek M, Dahl M. Tobacco smoking and aortic aneurysm: two population-based studies. Int J Cardiol 2013;167:2271–7. https://doi.org/10.1016/j.ijcard.2012.06.003
  263	Altobelli E, Rapacchietta L, Profeta VF, Fagnano R. Risk factors for abdominal aortic aneurysm in population-based studies: a systematic review and meta-analysis. Int J Environ Res Public Health 2018;15:2805. https://doi.org/10.3390/ijerph15122805
  264	Lederle FA, Nelson DB, Joseph AM. Smokers’ relative risk for aortic aneurysm compared with other smoking-related diseases: a systematic review. J Vasc Surg 2003;38:329–34. https://doi.org/10.1016/s0741-5214(03)00136-8
  265	Teo KK, Ounpuu S, Hawken S, Pandey MR, Valentin V, Hunt D, et al.  Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 2006;368:647–58. https://doi.org/10.1016/S0140-6736(06)69249-0
  266	Mahtta D, Ramsey D, Krittanawong C, Al Rifai M, Khurram N, Samad Z, et al.  Recreational substance use among patients with premature atherosclerotic cardiovascular disease. Heart 2021;107:650–6. https://doi.org/10.1136/heartjnl-2020-318119
  267	Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142:233–9. https://doi.org/10.7326/0003-4819-142-4-200502150-00005
  268	Suissa K, Lariviere J, Eisenberg MJ, Eberg M, Gore GC, Grad R, et al.  Efficacy and safety of smoking cessation interventions in patients with cardiovascular disease: a network meta-analysis of randomized controlled trials. Circ Cardiovasc Qual Outcomes 2017;10:e002458. https://doi.org/10.1161/CIRCOUTCOMES.115.002458
  269	Livingstone-Banks J, Fanshawe TR, Thomas KH, Theodoulou A, Hajizadeh A, Hartman L, et al.  Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2023;5:CD006103. https://doi.org/10.1002/14651858.CD006103.pub8
  
270	Rose JJ, Krishnan-Sarin S, Exil VJ, Hamburg NM, Fetterman JL, Ichinose F, et al.  Cardiopulmonary impact of electronic cigarettes and vaping products: a scientific statement from the American Heart Association. Circulation 2023;148:703–28. https://doi.org/10.1161/CIR.0000000000001160
  271	Lindson N, Butler AR, McRobbie H, Bullen C, Hajek P, Begh R, et al.  Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev 2024;1:CD010216. https://doi.org/10.1002/14651858.CD010216.pub8
  
272	Travis N, Knoll M, Cadham CJ, Cook S, Warner KE, Fleischer NL, et al.  Health effects of electronic cigarettes: an umbrella review and methodological considerations. Int J Environ Res Public Health 2022;19:9054. https://doi.org/10.3390/ijerph19159054
  273	Abbott AJ, Reibel YG, Arnett MC, Marka N, Drake MA. Oral and systemic health implications of electronic cigarette usage as compared to conventional tobacco cigarettes: a review of the literature. J Dent Hyg 2023;97:21–35.
  
274	Hamann SL, Kungskulniti N, Charoenca N, Kasemsup V, Ruangkanchanasetr S, Jongkhajornpong P. Electronic cigarette harms: aggregate evidence shows damage to biological systems. Int J Environ Res Public Health 2023;20:6808. https://doi.org/10.3390/ijerph20196808
  275	Kavousi M, Pisinger C, Barthelemy JC, De Smedt D, Koskinas K, Marques-Vidal P, et al.  Electronic cigarettes and health with special focus on cardiovascular effects: position paper of the European Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol 2021;28:1552–66. https://doi.org/10.1177/2047487320941993
  276	Goldman RE, Parker DR, Eaton CB, Borkan JM, Gramling R, Cover RT, et al.  Patients’ perceptions of cholesterol, cardiovascular disease risk, and risk communication strategies. Ann Fam Med 2006;4:205–12. https://doi.org/10.1370/afm.534
  277	Howarth M, Lister C. Social prescribing in cardiology: rediscovering the nature within us. Br J Card Nurs 2019;14:1–9. https://doi.org/10.12968/bjca.2019.0036
Google ScholarCrossrefWorldCat 
278	Nichols LO, Martindale-Adams J, Burns R, Graney MJ, Zuber J. Translation of a dementia caregiver support program in a health care system—REACH VA. Arch Intern Med 2011;171:353–9. https://doi.org/10.1001/archinternmed.2010.548
  279	Martire LM, Schulz R, Keefe FJ, Rudy TE, Starz TW. Couple-oriented education and support intervention for osteoarthritis: effects on spouses’ support and responses to patient pain. Fam Syst Health 2008;26:185–95. https://doi.org/10.1037/1091-7527.26.2.185
  280	Morris SM, King C, Turner M, Payne S. Family carers providing support to a person dying in the home setting: a narrative literature review. Palliat Med 2015;29:487–95. https://doi.org/10.1177/0269216314565706
  281	Ventura AD, Burney S, Brooker J, Fletcher J, Ricciardelli L. Home-based palliative care: a systematic literature review of the self-reported unmet needs of patients and carers. Palliat Med 2014;28:391–402. https://doi.org/10.1177/0269216313511141
  282	Reynolds CF, III, Jeste DV, Sachdev PS, Blazer DG. Mental health care for older adults: recent advances and new directions in clinical practice and research. World Psychiatry 2022;21:336–63. https://doi.org/10.1002/wps.20996
  283	Katch H. The role of self-efficacy in cardiovascular disease self-management: a review of effective programs. Patient Intelligence 2010;2:33–4. doi: https://doi.org/10.2147/PI.S12624]
Google ScholarWorldCat 
284	Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau C-S, et al.  The REduction of Atherothrombosis for Continued Health (REACH) registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events–study design. Am Heart J 2006;151:786.e1–10. https://doi.org/10.1016/j.ahj.2005.11.004
  285	Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y. Second manifestations of ARTerial disease (SMART) study: rationale and design. Eur J Epidemiol 1999;15:773–81. https://doi.org/10.1023/a:1007621514757
  286	Dorresteijn JA, Visseren FL, Wassink AM, Gondrie MJA, Steyerberg EW, Ridker PM, et al.  Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score. Heart 2013;99:866–72. https://doi.org/10.1136/heartjnl-2013-303640
  287	Kaasenbrood L, Bhatt DL, Dorresteijn JAN, Wilson PWF, D'Agostino RB, Massaro JM, et al.  Estimated life expectancy without recurrent cardiovascular events in patients with vascular disease: the SMART-REACH model. J Am Heart Assoc 2018;7:e009217. https://doi.org/10.1161/JAHA.118.009217
  288	Hageman SHJ, McKay AJ, Ueda P, Gunn LH, Jernberg T, Hagström E, et al.  Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm. Eur Heart J 2022;43:1715–27. https://doi.org/10.1093/eurheartj/ehac056
  289	van Trier TJ, Snaterse M, Boekholdt SM, Scholte Op Reimer WJM, Hageman SHJ, Visseren FLJ, et al.  Validation of systematic coronary risk evaluation 2 (SCORE2) and SCORE2-older persons in the EPIC Norfolk prospective population cohort. Eur J Prev Cardiol 2024;31:182–9. https://doi.org/10.1093/eurjpc/zwad318
  290	Wan D, Li V, Banfield L, Azab S, de Souza RJ, Anand SS, et al.  Diet and nutrition in peripheral artery disease: a systematic review. Can J Cardiol 2022;38:672–80. https://doi.org/10.1016/j.cjca.2022.01.021
  291	Sesso HD, Rist PM, Aragaki AK, Rautiainen S, Johnson LG, Friedenberg G, et al.  Multivitamins in the prevention of cancer and cardiovascular disease: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial. Am J Clin Nutr 2022;115:1501–10. https://doi.org/10.1093/ajcn/nqac056
  292	Bondonno NP, Murray K, Cassidy A, Bondonno CP, Lewis JR, Croft KD, et al.  Higher habitual flavonoid intakes are associated with a lower risk of peripheral artery disease hospitalizations. Am J Clin Nutr 2021;113:187–99. https://doi.org/10.1093/ajcn/nqaa300
  293	Bapir M, Untracht GR, Cooke D, McVey JH, Skene SS, Campagnolo P, et al.  Cocoa flavanol consumption improves lower extremity endothelial function in healthy individuals and people with type 2 diabetes. Food Funct 2022;13:10439–48. https://doi.org/10.1039/d2fo02017c
  294	Fassora M, Calanca L, Jaques C, Mazzolai L, Kayser B, Lanzi S. Intensity-dependent effects of exercise therapy on walking performance and aerobic fitness in symptomatic patients with lower-extremity peripheral artery disease: a systematic review and meta-analysis. Vasc Med 2022;27:158–70. https://doi.org/10.1177/1358863x211034577
  295	O’Connor EA, Evans CV, Rushkin MC, Redmond N, Lin JS. Behavioral counseling to promote a healthy diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors: updated evidence report and systematic review for the US preventive services task force. JAMA 2020;324:2076–94. https://doi.org/10.1001/jama.2020.17108
  296	Hartmann-Boyce J, McRobbie H, Lindson N, Bullen C, Begh R, Theodoulou A, et al.  Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev 2021;4:CD010216. https://doi.org/10.1002/14651858.CD010216.pub5
  
297	Krabbe B, Espinola-Klein C, Malyar N, Brodmann M, Mazzolai L, Belch JJF, et al.  Health effects of e-cigarettes and their use for smoking cessation from a vascular perspective. Vasa 2023;52:81–5. https://doi.org/10.1024/0301-1526/a001056
  298	Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee I-M, et al.  American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc 2011;43:1334–59. https://doi.org/10.1249/MSS.0b013e318213fefb
  299	Twine CP, Kakkos SK, Aboyans V, Baumgartner I, Behrendt C-A, Bellmunt-Montoya S, et al.  Editor’s choice—European Society for Vascular Surgery (ESVS) 2023 clinical practice guidelines on antithrombotic therapy for vascular diseases. Eur J Vasc Endovasc Surg 2023;65:627–89. https://doi.org/10.1016/j.ejvs.2023.03.042
  300	McEvoy JW, Touyz RM, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, et al.  2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J 2024. https://doi.org/10.1093/eurheartj/ehae178
Google ScholarWorldCat 
301	Blood Pressure Lowering Treatment Trialists’ Collaboration. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet 2021;398:1053–64. https://doi.org/10.1016/S0140-6736(21)01921-8
CrossrefPubMedWorldCat 
302	Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al.  Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;387:957–67. https://doi.org/10.1016/s0140-6736(15)01225-8
  303	Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, et al.  Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA 2016;315:2673–82. https://doi.org/10.1001/jama.2016.7050
  304	Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al.  Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med 2021;385:1268–79. https://doi.org/10.1056/NEJMoa2111437
  305	Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens 2014;32:2285–95. https://doi.org/10.1097/hjh.0000000000000378
  306	Wright JT, Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al.  A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103–16. https://doi.org/10.1056/NEJMoa1511939
  
307	Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145–53. https://doi.org/10.1056/nejm200001203420301
  
308	Bavry AA, Anderson RD, Gong Y, Denardo SJ, Cooper-DeHoff RM, Handberg EM, et al.  Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy. Hypertension 2010;55:48–53. https://doi.org/10.1161/hypertensionaha.109.142240
  309	Fudim M, Hopley CW, Huang Z, Kavanagh S, Rockhold FW, Baumgartner I, et al.  Association of hypertension and arterial blood pressure on limb and cardiovascular outcomes in symptomatic peripheral artery disease: the EUCLID trial. Circ Cardiovasc Qual Outcomes 2020;13:e006512. https://doi.org/10.1161/circoutcomes.120.006512
  310	Thomas Manapurathe D, Krishna SM, Dewdney B, Moxon JV, Biros E, Golledge J, Effect of blood pressure lowering medications on leg ischemia in peripheral artery disease patients: a meta-analysis of randomised controlled trials. PLoS One 2017;12:e0178713. https://doi.org/10.1371/journal.pone.0178713
  311	Lu Y, Ballew SH, Tanaka H, Szklo M, Heiss G, Coresh J, et al.  2017 ACC/AHA blood pressure classification and incident peripheral artery disease: the Atherosclerosis Risk in Communities (ARIC) study. Eur J Prev Cardiol 2020;27:51–9. https://doi.org/10.1177/2047487319865378
  312	Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al.  Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547–59. https://doi.org/10.1056/NEJMoa0801317
  
313	Ostergren J, Sleight P, Dagenais G, Danisa K, Bosch J, Qilong Y, et al.  Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004;25:17–24. https://doi.org/10.1016/j.ehj.2003.10.033
  314	Paravastu SC, Mendonca DA, Da Silva A. Beta blockers for peripheral arterial disease. Cochrane Database Syst Rev 2013;9:CD005508. https://doi.org/10.1002/14651858.CD005508.pub3
Google ScholarWorldCat 
315	Kray JE, Dombrovskiy VY, Vogel TR. Use of angiotensin-converting enzyme inhibitors and freedom from amputation after lower extremity revascularization. Vasc Health Risk Manag 2017;13:269–74. https://doi.org/10.2147/vhrm.S137698
  316	Høgh A, Lindholt JS, Nielsen H, Jensen LP, Johnsen SP. Use of angiotensin-converting enzyme inhibitors and cardiovascular outcomes following primary vascular surgery: a nationwide propensity score matched follow-up study. Vasc Endovascular Surg 2012;46:515–23. https://doi.org/10.1177/1538574412455229
  317	Armstrong EJ, Chen DC, Singh GD, Amsterdam EA, Laird JR. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia. Vasc Med 2015;20:237–44. https://doi.org/10.1177/1358863x15574321
  318	Aronow WS, Ahn C. Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease. Am J Cardiol 2001;87:1284–6. https://doi.org/10.1016/s0002-9149(01)01521-1
  319	Soga Y, Iida O, Takahara M, Hirano K, Suzuki K, Kawasaki D. Beta-blocker treatment does not worsen critical limb ischemia in patients receiving endovascular therapy. J Atheroscler Thromb 2015;22:481–9. https://doi.org/10.5551/jat.27359
  320	Carey RM, Wright JT, Jr, Taler SJ, Whelton PK. Guideline-driven management of hypertension: an evidence-based update. Circ Res 2021;128:827–46. https://doi.org/10.1161/circresaha.121.318083
  321	Evans KL, Tuttle KR, Folt DA, Dawson T, Haller ST, Brewster PS, et al.  Use of renin-angiotensin inhibitors in people with renal artery stenosis. Clin J Am Soc Nephrol 2014;9:1199–206. https://doi.org/10.2215/cjn.11611113
  322	Hackam DG, Duong-Hua ML, Mamdani M, Li Ping, Tobe SW, Spence JD, et al.  Angiotensin inhibition in renovascular disease: a population-based cohort study. Am Heart J 2008;156:549–55. https://doi.org/10.1016/j.ahj.2008.05.013
  323	Solomon SD, Rice MM, Jablonski KA, Jose P, Domanski M, Sabatine M, et al.  Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation 2006;114:26–31. https://doi.org/10.1161/circulationaha.105.592733
  324	Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, Reid DM, et al.  Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 2014;370:13–22. https://doi.org/10.1056/NEJMoa1310753
  325	Mayr NP, Hapfelmeier A, Martin K, Kurz A, van der Starre P, Babik B, et al.  Comparison of sedation and general anaesthesia for transcatheter aortic valve implantation on cerebral oxygen saturation and neurocognitive outcomedagger. Br J Anaesth 2016;116:90–9. https://doi.org/10.1093/bja/aev294
  326	Singh K, Bønaa KH, Jacobsen BK, Bjørk L, Solberg S. Prevalence of and risk factors for abdominal aortic aneurysms in a population-based study: the Tromsø study. Am J Epidemiol 2001;154:236–44. https://doi.org/10.1093/aje/154.3.236
  327	Vogel TR, Dombrovskiy VY, Galiñanes EL, Kruse RL. Preoperative statins and limb salvage after lower extremity revascularization in the Medicare population. Circ Cardiovasc Interv 2013;6:694–700. https://doi.org/10.1161/circinterventions.113.000274
  328	Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC, Goto S, et al.  Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J 2014;35:2864–72. https://doi.org/10.1093/eurheartj/ehu080
  329	Pastori D, Farcomeni A, Milanese A, Del Sole F, Menichelli D, Hiatt WR, et al.  Statins and major adverse limb events in patients with peripheral artery disease: a systematic review and meta-analysis. Thromb Haemost 2020;120:866–75. https://doi.org/10.1055/s-0040-1709711
  
330	Su Z, Guo J, Gu Y. Pharmacotherapy in clinical trials for abdominal aortic aneurysms: a systematic review and meta-analysis. Clin Appl Thromb Hemost 2022;28:10760296221120423. https://doi.org/10.1177/10760296221120423
Google ScholarWorldCat 
331	Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al.  Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387–97. https://doi.org/10.1056/NEJMoa1410489
  332	Kaasenbrood L, Boekholdt SM, van der Graaf Y, Ray KK, Peters RJG, Kastelein JJP, et al.  Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a secondary prevention population. Circulation 2016;134:1419–29. https://doi.org/10.1161/CIRCULATIONAHA.116.021314
  333	Clavijo LC, Caro J, Choi J, Caro JA, Tun H, Rowe V, et al.  The addition of evolocumab to maximal tolerated statin therapy improves walking performance in patients with peripheral arterial disease and intermittent claudication (Evol-PAD study). Cardiovasc Revasc Med 2023;55:1–5. https://doi.org/10.1016/j.carrev.2023.04.020
  334	Cholesterol Treatment Trialists Collaboration; Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, et al.  Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015;385:1397–405. https://doi.org/10.1016/S0140-6736(14)61368-4
  
335	Murphy SA, Cannon CP, Blazing MA, Giugliano RP, White JA, Lokhnygina Y, et al.  Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome: the IMPROVE-IT trial. J Am Coll Cardiol 2016;67:353–61. https://doi.org/10.1016/j.jacc.2015.10.077
  336	Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al.  Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713–22. https://doi.org/10.1056/NEJMoa1615664
  337	Westin GG, Armstrong EJ, Bang H, Yeo K-K, Anderson D, Dawson DL, et al.  Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia. J Am Coll Cardiol 2014;63:682–90. https://doi.org/10.1016/j.jacc.2013.09.073
  338	Belch JJF, Brodmann M, Baumgartner I, Binder CJ, Casula M, Heiss C, et al.  Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease. Vasa 2021;50:401–11. https://doi.org/10.1024/0301-1526/a000969
  339	Momsen AH, Jensen MB, Norager CB, Madsen MR, Vestersgaard-Andersen T, Lindholt JS. Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies. Eur J Vasc Endovasc Surg 2009;38:463–74. https://doi.org/10.1016/j.ejvs.2009.06.002
  340	Flint AC, Conell C, Ren X, Kamel H, Chan SL, Rao VA, et al.  Statin adherence is associated with reduced recurrent stroke risk in patients with or without atrial fibrillation. Stroke 2017;48:1788–94. https://doi.org/10.1161/strokeaha.117.017343
  341	Merwick Á, Albers GW, Arsava EM, Ay H, Calvet D, Coutts SB, et al.  Reduction in early stroke risk in carotid stenosis with transient ischemic attack associated with statin treatment. Stroke 2013;44:2814–20. https://doi.org/10.1161/strokeaha.113.001576
  342	Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009;8:453–63. https://doi.org/10.1016/s1474-4422(09)70058-4
  343	Amarenco P, Bogousslavsky J, Callahan A, III, Goldstein LB, Hennerici M, Rudolph AE, et al.  High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549–59. https://doi.org/10.1056/NEJMoa061894
  
344	Hackam DG, Wu F, Li P, Austin PC, Tobe SW, Mamdani MM, et al.  Statins and renovascular disease in the elderly: a population-based cohort study. Eur Heart J 2011;32:598–610. https://doi.org/10.1093/eurheartj/ehq452
  345	Peng M, Dong H, Jiang X, Che W, Zou Y, Zhang Y, et al.  A randomized unblinded trial to compare effects of intensive versus conventional lipid-lowering therapy in patients undergoing renal artery stenting. J Cardiol 2019;74:443–50. https://doi.org/10.1016/j.jjcc.2019.04.010
  346	Vashist A, Heller EN, Brown EJ, Jr, Alhaddad IA. Renal artery stenosis: a cardiovascular perspective. Am Heart J 2002;143:559–64. https://doi.org/10.1067/mhj.2002.120769
  347	Pan Z, Cui H, Wu N, Zhang H. Effect of statin therapy on abdominal aortic aneurysm growth rate and mortality: a systematic review and meta-analysis. Ann Vasc Surg 2020;67:503–10. https://doi.org/10.1016/j.avsg.2020.03.036
  348	Salata K, Syed M, Hussain MA, de Mestral C, Greco E, Mamdani M, et al.  Statins reduce abdominal aortic aneurysm growth, rupture, and perioperative mortality: a systematic review and meta-analysis. J Am Heart Assoc 2018;7:e008657. https://doi.org/10.1161/jaha.118.008657
  349	Takagi H, Yamamoto H, Iwata K, Goto S, Umemoto T. Effects of statin therapy on abdominal aortic aneurysm growth: a meta-analysis and meta-regression of observational comparative studies. Eur J Vasc Endovasc Surg 2012;44:287–92. https://doi.org/10.1016/j.ejvs.2012.06.021
  350	Stein LH, Berger J, Tranquilli M, Elefteraides JA. Effect of statin drugs on thoracic aortic aneurysms. Am J Cardiol 2013;112:1240–5. https://doi.org/10.1016/j.amjcard.2013.05.081
  351	Jovin IS, Duggal M, Ebisu K, Paek H, Oprea AD, Tranquilli M, et al.  Comparison of the effect on long-term outcomes in patients with thoracic aortic aneurysms of taking versus not taking a statin drug. Am J Cardiol 2012;109:1050–4. https://doi.org/10.1016/j.amjcard.2011.11.038
  352	Skovbo Kristensen JS, Krasniqi L, Obel LM, Kavaliunaite E, Liisberg M, Lindholt JS. Exploring drug repurposing for treatment of abdominal aortic aneurysms: a systematic review and meta-analysis. Eur J Vasc Endovasc Surg 2024;67:570–82. https://doi.org/10.1016/j.ejvs.2023.11.037
  353	Rahman MN, Khan JA, Mazari FA, Mockford K, McCollum PT, Chetter IC. A randomized placebo controlled trial of the effect of preoperative statin use on matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in areas of low and peak wall stress in patients undergoing elective open repair of abdominal aortic aneurysm. Ann Vasc Surg 2011;25:32–8. https://doi.org/10.1016/j.avsg.2010.06.006
  354	Periard D, Guessous I, Mazzolai L, Haesler E, Monney P, Hayoz D. Reduction of small infrarenal abdominal aortic aneurysm expansion rate by statins. Vasa 2012;41:35–42. https://doi.org/10.1024/0301-1526/a000161
  355	Angeloni E, Vitaterna A, Pirelli M, Refice S. Effects of statin therapy on ascending aorta aneurysms growth: a propensity-matched analysis. Int J Cardiol 2015;191:52–5. https://doi.org/10.1016/j.ijcard.2015.05.001
  356	Rowbotham SE, Krishna SM, Moran CS, Golledge J. Fenofibrate and telmisartan in the management of abdominal aortic aneurysm. Curr Drug Targets 2018;19:1241–6. https://doi.org/10.2174/1389450119666171227224655
  357	Pinchbeck JL, Moxon JV, Rowbotham SE, Bourke M, Lazzaroni S, Morton SK, et al.  Randomized placebo-controlled trial assessing the effect of 24-week fenofibrate therapy on circulating markers of abdominal aortic aneurysm: outcomes from the FAME-2 trial. J Am Heart Assoc 2018;7:e009866. https://doi.org/10.1161/JAHA.118.009866
  358	Lamb YN. Inclisiran: first approval. Drugs 2021;81:389–95. https://doi.org/10.1007/s40265-021-01473-6
  359	Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al.  Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med 2019;380:1022–32. https://doi.org/10.1056/NEJMoa1803917
  360	Ballantyne CM, Banach M, Mancini GBJ, Lepor NE, Hanselman JC, Zhao X, et al.  Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis 2018;277:195–203. https://doi.org/10.1016/j.atherosclerosis.2018.06.002
  361	Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al.  Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med 2023;388:1353–64. https://doi.org/10.1056/NEJMoa2215024
  362	Balling M, Afzal S, Davey Smith G, Varbo A, Langsted A, Kamstrup PR, et al.  Elevated LDL triglycerides and atherosclerotic risk. J Am Coll Cardiol 2023;81:136–52. https://doi.org/10.1016/j.jacc.2022.10.019
  363	Gao JW, Hao QY, Gao M, Zhang K, Li X-Z, Wang J-F, et al.  Triglyceride-glucose index in the development of peripheral artery disease: findings from the Atherosclerosis Risk in Communities (ARIC) study. Cardiovasc Diabetol 2021;20:126. https://doi.org/10.1186/s12933-021-01319-1
  364	Britton KA, Mukamal KJ, Ix JH, Siscovick DS, Newman AB, de Boer IH, et al.  Insulin resistance and incident peripheral artery disease in the cardiovascular health study. Vasc Med 2012;17:85–93. https://doi.org/10.1177/1358863X11436195
  365	Pande RL, Perlstein TS, Beckman JA, Creager MA. Association of insulin resistance and inflammation with peripheral arterial disease: the National Health and Nutrition Examination Survey, 1999 to 2004. Circulation 2008;118:33–41. https://doi.org/10.1161/CIRCULATIONAHA.107.721878
  366	Wang D, Liu B, Tao W, Hao Z, Liu M. Fibrates for secondary prevention of cardiovascular disease and stroke. Cochrane Database Syst Rev 2015;10:CD009580. https://doi.org/10.1002/14651858.CD009580.pub2
Google ScholarWorldCat 
367	Meade T, Zuhrie R, Cook C, Cooper J. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ 2002;325:1139. https://doi.org/10.1136/bmj.325.7373.1139
  368	Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al.  Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019;380:11–22. https://doi.org/10.1056/NEJMoa1812792
  369	Bhatt DS, Steg PG, Miller M, Brinton E, Jacobson T, Tardif J-C, et al.  Abstract 10627: benefits of icosapent ethyl in patients with prior peripheral artery disease: REDUCE-IT PAD. Circulation 2021;144:A10627. https://doi.org/10.1161/circ.144.suppl_1.10627
Google ScholarWorldCat 
370	Kobayashi Y, Fujikawa T, Haruna A, Kawano R, Ozawa M, Haze T, et al.  Omega-3 fatty acids reduce remnant-like lipoprotein cholesterol and improve the ankle-brachial index of hemodialysis patients with dyslipidemia: a pilot study. Medicina (Kaunas) 2024;60:75. https://doi.org/10.3390/medicina60010075
Google ScholarCrossrefWorldCat 
371	Dopheide JF, Veit J, Ramadani H, Adam L, Papac L, Vonbank A, et al.  Adherence to statin therapy favours survival of patients with symptomatic peripheral artery disease. Eur Heart J Cardiovasc Pharmacother 2021;7:263–70. https://doi.org/10.1093/ehjcvp/pvz081
  372	Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, et al.  Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation 2018;137:338–50. https://doi.org/10.1161/circulationaha.117.032235
  373	Oyama K, Giugliano RP, Tang M, Bonaca MP, Saver JL, Murphy SA, et al.  Effect of evolocumab on acute arterial events across all vascular territories: results from the FOURIER trial. Eur Heart J 2021;42:4821–9. https://doi.org/10.1093/eurheartj/ehab604
  374	Marx N, Federici M, Schutt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al.  2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 2023;44:4043–140. https://doi.org/10.1093/eurheartj/ehad192
  375	Lazzarini PA, Cramb SM, Golledge J, Morton JI, Magliano DJ, Van Netten JJ. Global trends in the incidence of hospital admissions for diabetes-related foot disease and amputations: a review of national rates in the 21st century. Diabetologia 2023;66:267–87. https://doi.org/10.1007/s00125-022-05845-9
  376	Armstrong PA. Visceral duplex scanning: evaluation before and after artery intervention for chronic mesenteric ischemia. Perspect Vasc Surg Endovasc Ther 2007;19:386–92; discussion 393–384. https://doi.org/10.1177/1531003507311802
  377	Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res 2015;116:1509–26. https://doi.org/10.1161/CIRCRESAHA.116.303849
  378	McGurnaghan SJ, McKeigue PM, Read SH, Franzen S, Svensson A-M, Colombo M, et al.  Development and validation of a cardiovascular risk prediction model in type 1 diabetes. Diabetologia 2021;64:2001–11. https://doi.org/10.1007/s00125-021-05478-4
  379	Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med 2017;376:2367–75. https://doi.org/10.1056/NEJMra1615439
  380	Malyar NM, Freisinger E, Meyborg M, Lüders F, Gebauer K, Reinecke H, et al.  Amputations and mortality in in-hospital treated patients with peripheral artery disease and diabetic foot syndrome. J Diabetes Complications 2016;30:1117–22. https://doi.org/10.1016/j.jdiacomp.2016.03.033
  381	Verma S, Al-Omran M, Leiter LA, Mazer CD, Rasmussen S, Saevereid HA, et al.  Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease. Diabetes Obes Metab 2022;24:1288–99. https://doi.org/10.1111/dom.14700
  382	Verma S, Mazer CD, Al-Omran M, Inzucchi SE, Fitchett D, Hehnke U, et al.  Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME. Circulation 2018;137:405–7. https://doi.org/10.1161/circulationaha.117.032031
  383	American Diabetes Association. Standards of care in diabetes–2023 abridged for primary care providers. Clin Diabetes 2022;41:4–31. https://doi.org/10.2337/cd23-as01
PubMedWorldCat 
384	Sattar N, McGuire DK. Prevention of CV outcomes in antihyperglycaemic drug-naive patients with type 2 diabetes with, or at elevated risk of, ASCVD: to start or not to start with metformin. Eur Heart J 2021;42:2574–6. https://doi.org/10.1093/eurheartj/ehaa879
  385	Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, et al.  Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (canagliflozin cardiovascular assessment study). Circulation 2018;137:323–34. https://doi.org/10.1161/CIRCULATIONAHA.117.032038
  386	Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al.  Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644–57. https://doi.org/10.1056/NEJMoa1611925
  387	Goldenberg RM, Cheng AYY, Fitzpatrick T, Gilbert JD, Verma S, Hopyan JJ. Benefits of GLP-1 (glucagon-like peptide 1) receptor agonists for stroke reduction in type 2 diabetes: a call to action for neurologists. Stroke 2022;53:1813–22. https://doi.org/10.1161/STROKEAHA.121.038151
  388	Malhotra K, Katsanos AH, Lambadiari V, Goyal N, Palaiodimou L, Kosmidou M, et al.  GLP-1 receptor agonists in diabetes for stroke prevention: a systematic review and meta-analysis. J Neurol 2020;267:2117–22. https://doi.org/10.1007/s00415-020-09813-4
  389	Tsai WH, Chuang SM, Liu SC, Lee C-C, Chien M-N, Leung C-H, et al.  Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis. Sci Rep 2021;11:15364. https://doi.org/10.1038/s41598-021-94945-4
  390	Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854–65 .
CrossrefPubMedWorldCat 
391	Kooy A, de Jager J, Lehert P, Bets D, Wulffelé MG, Donker AJM, et al.  Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 2009;169:616–25. https://doi.org/10.1001/archinternmed.2009.20
  392	Tan S, Goudot G, Arnoux A, Tran Y, Maissoro H, Poenou G, et al.  Occurrence of major local lower limb events in type 2 diabetic patients with lower extremity arterial disease: impact of metformin. Ann Vasc Surg 2023;90:153–61. https://doi.org/10.1016/j.avsg.2022.09.064
  393	Ferrannini G, Gerstein H, Colhoun HM, Dagenais GR, Diaz R, Dyal L, et al.  Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. Eur Heart J 2021;42:2565–73. https://doi.org/10.1093/eurheartj/ehaa777
  394	Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, et al.  Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol 2017;5:431–7. https://doi.org/10.1016/S2213-8587(17)30104-3
  395	Group AC, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560–72. https://doi.org/10.1056/NEJMoa0802987
  
396	UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–53. https://doi.org/10.1016/S0140-6736(98)07019-6
CrossrefPubMedWorldCat 
397	Diabetes Control and Complications Trial Research Group; Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–86. https://doi.org/10.1056/NEJM199309303291401
  
398	McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, et al.  Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol 2021;6:148–58. https://doi.org/10.1001/jamacardio.2020.4511
  399	Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al.  Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 2021;384:117–28. https://doi.org/10.1056/NEJMoa2030183
  400	Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al.  Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med 2021;384:129–39. https://doi.org/10.1056/NEJMoa2030186
  401	Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al.  Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347–57. https://doi.org/10.1056/NEJMoa1812389
  402	Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al.  Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–28. https://doi.org/10.1056/NEJMoa1504720
  403	Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al.  Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 2021;9:653–62. https://doi.org/10.1016/S2213-8587(21)00203-5
  404	Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al.  Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med 2021;385:896–907. https://doi.org/10.1056/NEJMoa2108269
  405	Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al.  Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019;394:121–30. https://doi.org/10.1016/S0140-6736(19)31149-3
  406	Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al.  Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311–22. https://doi.org/10.1056/NEJMoa1603827
  407	Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al.  Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834–44. https://doi.org/10.1056/NEJMoa1607141
  408	International Hypoglycaemia Study Group. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol 2019;7:385–96. https://doi.org/10.1016/S2213-8587(18)30315-2
CrossrefPubMedWorldCat 
409	Zoungas S, Chalmers J, Ninomiya T, Li Q, Cooper ME, Colagiuri S, et al.  Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia 2012;55:636–43. https://doi.org/10.1007/s00125-011-2404-1
  410	Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, et al.  Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010;375:481–9. https://doi.org/10.1016/S0140-6736(09)61969-3
  411	Control G, Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, et al.  Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52:2288–98. https://doi.org/10.1007/s00125-009-1470-0
  
412	Caturano A, Galiero R, Pafundi PC, Cesaro A, Vetrano E, Palmiero G, et al.  Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence. Diabetes Res Clin Pract 2021;178:108959. https://doi.org/10.1016/j.diabres.2021.108959
  413	Soehnlein O, Libby P. Targeting inflammation in atherosclerosis—from experimental insights to the clinic. Nat Rev Drug Discov 2021;20:589–610. https://doi.org/10.1038/s41573-021-00198-1
  414	Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al.  Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377:1119–31. https://doi.org/10.1056/NEJMoa1707914
  415	Samuel M, Tardif JC, Bouabdallaoui N, Khairy P, Dubé M-P, Blondeau L, et al.  Colchicine for secondary prevention of cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials. Can J Cardiol 2021;37:776–85. https://doi.org/10.1016/j.cjca.2020.10.006
  416	Antonopoulos AS, Papanikolaou E, Vogiatzi G, Oikonomou E, Tousoulis D. Anti-inflammatory agents in peripheral arterial disease. Curr Opin Pharmacol 2018;39:1–8. https://doi.org/10.1016/j.coph.2017.11.001
  417	Mills JL, Sr, Conte MS, Armstrong DG, Pomposelli FB, Schanzer A, Sidawy AN, et al.  The Society for Vascular Surgery lower extremity threatened limb classification system: risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg 2014;59:220–34.e1–2. https://doi.org/10.1016/j.jvs.2013.08.003
  418	Fowkes FG, Aboyans V, Fowkes FJ, McDermott MM, Sampson UKA, Criqui MH, Peripheral artery disease: epidemiology and global perspectives. Nat Rev Cardiol 2017;14:156–70. https://doi.org/10.1038/nrcardio.2016.179
  419	Diehm C, Allenberg JR, Pittrow D, Mahn M, Tepohl G, Haberl RL, et al.  Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation 2009;120:2053–61. https://doi.org/10.1161/circulationaha.109.865600
  420	McDermott MM, Greenland P, Liu K, Guralnik JM, Criqui MH, Dolan NC, et al.  Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA 2001;286:1599–606. https://doi.org/10.1001/jama.286.13.1599
  421	Sigvant B, Wiberg-Hedman K, Bergqvist D, Rolandsson O, Andersson B, Persson E, et al.  A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. J Vasc Surg 2007;45:1185–91. https://doi.org/10.1016/j.jvs.2007.02.004
  422	Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FGR, et al.  Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007;33:S1–75. https://doi.org/10.1016/j.ejvs.2006.09.024
  423	Buso G, Aboyans V, Mazzolai L. Lower extremity artery disease in patients with type 2 diabetes. Eur J Prev Cardiol 2019;26:114–24. https://doi.org/10.1177/2047487319880044
  424	Porras CP, Bots ML, Teraa M, van Doorn S, Vernooij RWM. Differences in symptom presentation in women and men with confirmed lower limb peripheral artery disease: a systematic review and meta-analysis. Eur J Vasc Endovasc Surg 2022;63:602–12. https://doi.org/10.1016/j.ejvs.2021.12.039
  425	Fereydooni A, Gorecka J, Dardik A. Using the epidemiology of critical limb ischemia to estimate the number of patients amenable to endovascular therapy. Vasc Med 2020;25:78–87. https://doi.org/10.1177/1358863X19878271
  426	Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, et al.  Global vascular guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg 2019;58:S1–109.e33. https://doi.org/10.1016/j.ejvs.2019.05.006
  427	Sigvant B, Lundin F, Wahlberg E. The risk of disease progression in peripheral arterial disease is higher than expected: a meta-analysis of mortality and disease progression in peripheral arterial disease. Eur J Vasc Endovasc Surg 2016;51:395–403. https://doi.org/10.1016/j.ejvs.2015.10.022
  428	Hageman SHJ, de Borst GJ, Dorresteijn JAN, Bots ML, Westerink J, Asselbergs FW, et al.  Cardiovascular risk factors and the risk of major adverse limb events in patients with symptomatic cardiovascular disease. Heart 2020;106:1686–92. https://doi.org/10.1136/heartjnl-2019-316088
  429	Anand SS, Caron F, Eikelboom JW, Bosch J, Dyal L, Aboyans V, et al.  Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial. J Am Coll Cardiol 2018;71:2306–15. https://doi.org/10.1016/j.jacc.2018.03.008
  430	Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al.  Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017;377:1319–30. https://doi.org/10.1056/NEJMoa1709118
  431	Agnelli G, Belch JJF, Baumgartner I, Giovas P, Hoffmann U. Morbidity and mortality associated with atherosclerotic peripheral artery disease: a systematic review. Atherosclerosis 2020;293:94–100. https://doi.org/10.1016/j.atherosclerosis.2019.09.012
  432	Wijnand JGJ, van Koeverden ID, Teraa M, Spreen MI, Mali WPTM, van Overhagen H, et al.  Validation of randomized controlled trial-derived models for the prediction of postintervention outcomes in chronic limb-threatening ischemia. J Vasc Surg 2020;71:869–79. https://doi.org/10.1016/j.jvs.2019.06.195
  433	Jaramillo EA, Smith EJT, Matthay ZA, Sanders KM, Hiramoto JS, Gasper WJ, et al.  Racial and ethnic disparities in major adverse limb events persist for chronic limb threatening ischemia despite presenting limb threat severity after peripheral vascular intervention. J Vasc Surg 2023;77:848–57.e2. https://doi.org/10.1016/j.jvs.2022.10.043
  434	Brizuela Sanz JA, Gonzalez Fajardo JA, Taylor JH, Río Solá L, Muñoz Moreno MF, Vaquero Puerta C, et al.  Design of a new risk score in critical limb ischaemia: the ERICVA model. Eur J Vasc Endovasc Surg 2016;51:90–9. https://doi.org/10.1016/j.ejvs.2015.09.025
  435	Kreutzburg T, Peters F, Kuchenbecker J, Marschall U, Lee R, Kriston L, et al.  Editor’s choice—the GermanVasc score: a pragmatic risk score predicts five year amputation free survival in patients with peripheral arterial occlusive disease. Eur J Vasc Endovasc Surg 2021;61:248–56. https://doi.org/10.1016/j.ejvs.2020.11.013
  436	Niazi K, Khan TH, Easley KA. Diagnostic utility of the two methods of ankle brachial index in the detection of peripheral arterial disease of lower extremities. Catheter Cardiovasc Interv 2006;68:788–92. https://doi.org/10.1002/ccd.20906
  437	Crawford F, Welch K, Andras A, Chappell FM. Ankle brachial index for the diagnosis of lower limb peripheral arterial disease. Cochrane Database Syst Rev 2016;9:CD010680. https://doi.org/10.1002/14651858.CD010680.pub2
  
438	Aday AW, Kinlay S, Gerhard-Herman MD. Comparison of different exercise ankle pressure indices in the diagnosis of peripheral artery disease. Vasc Med 2018;23:541–8. https://doi.org/10.1177/1358863X18781723
  439	Tehan PE, Barwick AL, Sebastian M, Chuter VH. Diagnostic accuracy of the postexercise ankle-brachial index for detecting peripheral artery disease in suspected claudicants with and without diabetes. Vasc Med 2018;23:116–25. https://doi.org/10.1177/1358863X17751259
  440	Manu CA, Freedman B, Rashid H, Winkley K, Edmonds ME. Peripheral arterial disease located in the feet of patients with diabetes and foot ulceration demands a new approach to the assessment of ischemia. Int J Low Extrem Wounds 2022;21:397–404. https://doi.org/10.1177/1534734620947979
  441	Salaun P, Desormais I, Lapébie FX, Rivière AB, Aboyans V, Lacroix P, et al.  Comparison of ankle pressure, systolic toe pressure, and transcutaneous oxygen pressure to predict major amputation after 1 year in the copart cohort. Angiology 2019;70:229–36. https://doi.org/10.1177/0003319718793566
  442	Fowkes FG, Murray GD, Butcher I, Folsom AR, Hirsch AT, Couper DJ, et al.  Development and validation of an ankle brachial index risk model for the prediction of cardiovascular events. Eur J Prev Cardiol 2014;21:310–20. https://doi.org/10.1177/2047487313516564
  443	Wang FM, Yang C, Ballew SH, Kalbaugh CA, Meyer ML, Tanaka H, et al.  Ankle-brachial index and subsequent risk of incident and recurrent cardiovascular events in older adults: the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis 2021;336:39–47. https://doi.org/10.1016/j.atherosclerosis.2021.09.028
  444	Cull DL, Manos G, Hartley MC, Taylor SM, Langan EM, Eidt JF, et al.  An early validation of the Society for Vascular Surgery lower extremity threatened limb classification system. J Vasc Surg 2014;60:1535–42. https://doi.org/10.1016/j.jvs.2014.08.107
  445	Liette MD, Crisologo PA, Masadeh S, Yang SH, Bergmann CB, Caldwell CC, et al.  A prospective analysis of the SVS WIfI classification system to stratify immediate and 1-year patient outcomes. J Foot Ankle Surg 2023;62:661–5. https://doi.org/10.1053/j.jfas.2023.02.003
  446	van Reijen NS, Ponchant K, Ubbink DT, Koelemay MJW. Editor’s choice—the prognostic value of the WIfI classification in patients with chronic limb threatening ischaemia: a systematic review and meta-analysis. Eur J Vasc Endovasc Surg 2019;58:362–71. https://doi.org/10.1016/j.ejvs.2019.03.040
  447	Eiberg JP, Gronvall Rasmussen JB, Hansen MA, Schroeder TV. Duplex ultrasound scanning of peripheral arterial disease of the lower limb. Eur J Vasc Endovasc Surg 2010;40:507–12. https://doi.org/10.1016/j.ejvs.2010.06.002
  448	Met R, Bipat S, Legemate DA, Reekers JA, Koelemay MJ. Diagnostic performance of computed tomography angiography in peripheral arterial disease: a systematic review and meta-analysis. JAMA 2009;301:415–24. https://doi.org/10.1001/jama.301.4.415
  449	Itoga NK, Kim T, Sailer AM, Fleischmann D, Mell MW. Lower extremity computed tomography angiography can help predict technical success of endovascular revascularization in the superficial femoral and popliteal artery. J Vasc Surg 2017;66:835–43.e1. https://doi.org/10.1016/j.jvs.2017.02.031
  450	Selvin E, Hirsch AT. Contemporary risk factor control and walking dysfunction in individuals with peripheral arterial disease: NHANES 1999–2004. Atherosclerosis 2008;201:425–33. https://doi.org/10.1016/j.atherosclerosis.2008.02.002
  451	Pande RL, Perlstein TS, Beckman JA, Creager MA. Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. Circulation 2011;124:17–23. https://doi.org/10.1161/circulationaha.110.003954
  452	Krishnamurthy V, Munir K, Rectenwald JE, Mansour A, Hans S, Eliason JL, et al.  Contemporary outcomes with percutaneous vascular interventions for peripheral critical limb ischemia in those with and without poly-vascular disease. Vasc Med 2014;19:491–9. https://doi.org/10.1177/1358863x14552013
  453	Penin-Grandes S, Lopez-Ortiz S, Maroto-Izquierdo S, Menéndez H, Pinto-Fraga J, Martín-Hernández J, et al.  Winners do what they fear: exercise and peripheral arterial disease–an umbrella review. Eur J Prev Cardiol 2024;31:380–388. https://doi.org/10.1093/eurjpc/zwad261
  454	Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA 1995;274:975–80.
  455	Parmenter BJ, Raymond J, Dinnen P, Singh MA. A systematic review of randomized controlled trials: walking versus alternative exercise prescription as treatment for intermittent claudication. Atherosclerosis 2011;218:1–12. https://doi.org/10.1016/j.atherosclerosis.2011.04.024
  456	Fakhry F, van de Luijtgaarden KM, Bax L, den Hoed PT, Hunink MGGM, Rouwet EV, et al.  Supervised walking therapy in patients with intermittent claudication. J Vasc Surg 2012;56:1132–42. https://doi.org/10.1016/j.jvs.2012.04.046
  457	Parmenter BJ, Dieberg G, Smart NA. Exercise training for management of peripheral arterial disease: a systematic review and meta-analysis. Sports Med 2015;45:231–44. https://doi.org/10.1007/s40279-014-0261-z
  458	Lane R, Harwood A, Watson L, Leng GC. Exercise for intermittent claudication. Cochrane Database Syst Rev 2017;12:CD000990. https://doi.org/10.1002/14651858.CD000990.pub4
  
459	Parmenter BJ, Mavros Y, Ritti Dias R, King S, Fiatarone Singh M. Resistance training as a treatment for older persons with peripheral artery disease: a systematic review and meta-analysis. Br J Sports Med 2020;54:452–61. https://doi.org/10.1136/bjsports-2018-100205
  
460	Perks J, Zaccardi F, Paterson C, Houghton JSM, Nickinson ATO, Pepper CJ, et al.  Effect of high-pain versus low-pain structured exercise on walking ability in people with intermittent claudication: meta-analysis. Br J Surg 2022;109:686–94. https://doi.org/10.1093/bjs/znac134
  461	Guidon M, McGee H. Exercise-based interventions and health-related quality of life in intermittent claudication: a 20-year (1989–2008) review. Eur J Cardiovasc Prev Rehabil 2010;17:140–54. https://doi.org/10.1097/HJR.0b013e3283377f08
  462	Parmenter BJ, Dieberg G, Phipps G, Smart NA. Exercise training for health-related quality of life in peripheral artery disease: a systematic review and meta-analysis. Vasc Med 2015;20:30–40. https://doi.org/10.1177/1358863x14559092
  463	Gommans LN, Fokkenrood HJ, van Dalen HC, Scheltinga MRM, Teijink JAW, Peters RJG. Safety of supervised exercise therapy in patients with intermittent claudication. J Vasc Surg 2015;61:512–8.e2. https://doi.org/10.1016/j.jvs.2014.08.070
  464	Harwood AE, Pymer S, Ibeggazene S, Ingle L, Caldow E, Birkett ST. Provision of exercise services in patients with peripheral artery disease in the United Kingdom. Vascular 2022;30:874–81. https://doi.org/10.1177/17085381211035259
  465	Lanzi S, Belch J, Brodmann M, Madaric J, Bura-Riviere A, Visonà A, et al.  Supervised exercise training in patients with lower extremity peripheral artery disease. Vasa 2022;51:267–74. https://doi.org/10.1024/0301-1526/a001024
  466	Gommans LN, Saarloos R, Scheltinga MR, Houterman S, de Bie RA, Fokkenrood HJP, et al.  Editor’s choice—the effect of supervision on walking distance in patients with intermittent claudication: a meta-analysis. Eur J Vasc Endovasc Surg 2014;48:169–84. https://doi.org/10.1016/j.ejvs.2014.04.019
  467	Vemulapalli S, Dolor RJ, Hasselblad V, Schmit K, Banks A, Heidenfelder B, et al.  Supervised vs unsupervised exercise for intermittent claudication: a systematic review and meta-analysis. Am Heart J 2015;169:924–37.e3. https://doi.org/10.1016/j.ahj.2015.03.009
  468	Hageman D, Fokkenrood HJ, Gommans LN, van den Houten MM, Teijink JA. Supervised exercise therapy versus home-based exercise therapy versus walking advice for intermittent claudication. Cochrane Database Syst Rev 2018;4:CD005263. https://doi.org/10.1002/14651858.CD005263.pub4
  
469	Pymer S, Ibeggazene S, Palmer J, Tew GA, Ingle L, Smith GE, et al.  An updated systematic review and meta-analysis of home-based exercise programs for individuals with intermittent claudication. J Vasc Surg 2021;74:2076–85.e20. https://doi.org/10.1016/j.jvs.2021.03.063
  470	Waddell A, Seed S, Broom DR, McGregor G, Birkett ST, Harwood AE. Safety of home-based exercise for people with intermittent claudication: a systematic review. Vasc Med 2022;27:186–92. https://doi.org/10.1177/1358863x211060388
  471	Golledge J, Singh TP, Alahakoon C, Pinchbeck J, Yip L, Moxon JV, et al.  Meta-analysis of clinical trials examining the benefit of structured home exercise in patients with peripheral artery disease. Br J Surg 2019;106:319–31. https://doi.org/10.1002/bjs.11101
  472	Bulmer AC, Coombes JS. Optimising exercise training in peripheral arterial disease. Sports Med 2004;34:983–1003. https://doi.org/10.2165/00007256-200434140-00004
  473	Ehrman JK, Gardner AW, Salisbury D, Lui K, Treat-Jacobson D. Supervised exercise therapy for symptomatic peripheral artery disease: a review of current experience and practice-based recommendations. J Cardiopulm Rehabil Prev 2023;43:15–21. https://doi.org/10.1097/hcr.0000000000000723
  474	McDermott MM, Spring B, Tian L, Treat-Jacobson D, Ferrucci L, Lloyd-Jones D, et al.  Effect of low-intensity vs high-intensity home-based walking exercise on walk distance in patients with peripheral artery disease: the LITE randomized clinical trial. JAMA 2021;325:1266–76. https://doi.org/10.1001/jama.2021.2536
  475	Jansen SC, Abaraogu UO, Lauret GJ, Fakhry F, Fokkenrood HJP, Teijink JAW. Modes of exercise training for intermittent claudication. Cochrane Database Syst Rev 2020;8:CD009638. https://doi.org/10.1002/14651858.CD009638.pub3
  
476	Gardner AW, Parker DE, Montgomery PS, Blevins SM. Diabetic women are poor responders to exercise rehabilitation in the treatment of claudication. J Vasc Surg 2014;59:1036–43. https://doi.org/10.1016/j.jvs.2013.10.058
  477	Gommans LN, Scheltinga MR, van Sambeek MR, Maas AHEM, Bendermacher BLW, Teijink JAW. Gender differences following supervised exercise therapy in patients with intermittent claudication. J Vasc Surg 2015;62:681–8. https://doi.org/10.1016/j.jvs.2015.03.076
  478	Dipnarine K, Barak S, Martinez CA, Carmeli E, Stopka CB. Pain-free treadmill exercise for patients with intermittent claudication: are there gender differences? Vascular 2016;24:304–14. https://doi.org/10.1177/1708538115592800
  479	Gardner AW, Parker DE, Montgomery PS. Sex-specific predictors of improved walking with step-monitored, home-based exercise in peripheral artery disease. Vasc Med 2015;20:424–31. https://doi.org/10.1177/1358863x15596237
  480	Ney B, Lanzi S, Calanca L, Mazzolai L. Multimodal supervised exercise training is effective in improving long term walking performance in patients with symptomatic lower extremity peripheral artery disease. J Clin Med 2021;10:2057.https://doi.org/10.3390/jcm10102057
  481	Lanzi S, Pousaz A, Calanca L, Mazzolai L. Sex-based differences in supervised exercise therapy outcomes for symptomatic peripheral artery disease. Vasc Med 2023;28:147–9. https://doi.org/10.1177/1358863x221149454
  482	Fakhry F, Spronk S, van der Laan L, Wever JJ, Teijink JAW, Hoffmann WH, et al.  Endovascular revascularization and supervised exercise for peripheral artery disease and intermittent claudication: a randomized clinical trial. JAMA 2015;314:1936–44. https://doi.org/10.1001/jama.2015.14851
  483	Pandey A, Banerjee S, Ngo C, Mody P, Marso SP, Brilakis ES, et al.  Comparative efficacy of endovascular revascularization versus supervised exercise training in patients with intermittent claudication: meta-analysis of randomized controlled trials. JACC Cardiovasc Interv 2017;10:712–24. https://doi.org/10.1016/j.jcin.2017.01.027
  484	Dorn A, Dorweiler B, Ahmad W, Mylonas S, Becker I, Majd P. Low and high ankle-brachial index are both associated with mortality in German nursing home residents–the five-year follow-up of the ‘allo-study’ Cohort. J Clin Med 2023;12:4411. https://doi.org/10.3390/jcm12134411
  485	Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, et al.  Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010;303:841–8. https://doi.org/10.1001/jama.2010.221
  486	Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al.  The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008;337:a1840. https://doi.org/10.1136/bmj.a1840
  487	Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, et al.  Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 2018;379:1529–39. https://doi.org/10.1056/NEJMoa1804988
  
488	Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71–86. https://doi.org/10.1136/bmj.324.7329.71
CrossrefPubMedWorldCat 
489	De Carlo M, Di Minno G, Sayre T, Fazeli MS, Siliman G, Cimminiello C. Efficacy and safety of antiplatelet therapies in symptomatic peripheral artery disease: a systematic review and network meta-analysis. Curr Vasc Pharmacol 2021;19:542–55. https://doi.org/10.2174/1570161118666200820141131
  490	Willems LH, Maas D, Kramers K, Reijnen MMPJ, Riksen NP, Ten Cate H, et al.  Antithrombotic therapy for symptomatic peripheral arterial disease: a systematic review and network meta-analysis. Drugs 2022;82:1287–302. https://doi.org/10.1007/s40265-022-01756-6
  491	Katsanos K, Spiliopoulos S, Saha P, Diamantopoulos A, Karunanithy N, Krokidis M, et al.  Comparative efficacy and safety of different antiplatelet agents for prevention of major cardiovascular events and leg amputations in patients with peripheral arterial disease: a systematic review and network meta-analysis. PLoS One 2015;10:e0135692. https://doi.org/10.1371/journal.pone.0135692
  492	Basili S, Raparelli V, Vestri A, Di Tanna GL, Violi F. Comparison of efficacy of antiplatelet treatments for patients with claudication. A meta-analysis. Thromb Haemost 2010;103:766–73. https://doi.org/10.1160/th09-09-0635
  493	CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348:1329–39. https://doi.org/10.1016/s0140-6736(96)09457-3
CrossrefPubMedWorldCat 
494	Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 2009;301:1909–19. https://doi.org/10.1001/jama.2009.623
  495	Hiatt WR, Fowkes FG, Heizer G, Berger JS, Baumgartner I, Held P, et al.  Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med 2017;376:32–40. https://doi.org/10.1056/NEJMoa1611688
  496	Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al.  Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706–17. https://doi.org/10.1056/NEJMoa060989
  497	Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, et al.  Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007;49:1982–8. https://doi.org/10.1016/j.jacc.2007.03.025
  498	Kaplovitch E, Eikelboom JW, Dyal L, Aboyans V, Abola MT, Verhamme P, et al.  Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: a subanalysis of the COMPASS randomized clinical trial. JAMA Cardiol 2021;6:21–9. https://doi.org/10.1001/jamacardio.2020.4390
  
499	Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, et al.  Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018;391:219–29. https://doi.org/10.1016/s0140-6736(17)32409-1
  500	Strobl FF, Brechtel K, Schmehl J, Zeller T, Reiser MF, Claussen CD, et al.  Twelve-month results of a randomized trial comparing mono with dual antiplatelet therapy in endovascularly treated patients with peripheral artery disease. J Endovasc Ther 2013;20:699–706. https://doi.org/10.1583/13-4275mr.1
  501	Tsai SY, Li YS, Lee CH, Cha S-W, Wang Y-C, Su T-W, et al.  Mono or dual antiplatelet therapy for treating patients with peripheral artery disease after lower extremity revascularization: a systematic review and meta-analysis. Pharmaceuticals (Basel) 2022;15:596. https://doi.org/10.3390/ph15050596
  502	Thott O, Granath F, Malmstedt J, Wahlgren CM. Editor’s choice—dual antiplatelet therapy improves outcome in diabetic patients undergoing endovascular femoropopliteal stenting for critical limb ischaemia. Eur J Vasc Endovasc Surg 2017;53:403–10. https://doi.org/10.1016/j.ejvs.2016.12.014
  503	Cho S, Lee YJ, Ko YG, Kang TS, Lim S-H, Hong S-J, et al.  Optimal strategy for antiplatelet therapy after endovascular revascularization for lower extremity peripheral artery disease. JACC Cardiovasc Interv 2019;12:2359–70. https://doi.org/10.1016/j.jcin.2019.08.006
  504	Ipema J, Welling RHA, Bakker OJ, Bokkers RPH, de Vries J-PPM, Ünlü Ç. Short-term clinical outcomes of single versus dual antiplatelet therapy after infrainguinal endovascular treatment for peripheral arterial disease. J Clin Med 2020;9:3515. https://doi.org/10.3390/jcm9113515
  505	Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, et al.  Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med 2020;382:1994–2004. https://doi.org/10.1056/NEJMoa2000052
  506	Hiatt WR, Bonaca MP, Patel MR, Nehler MR, Debus ES, Anand SS, et al.  Rivaroxaban and aspirin in peripheral artery disease lower extremity revascularization: impact of concomitant clopidogrel on efficacy and safety. Circulation 2020;142:2219–30. https://doi.org/10.1161/circulationaha.120.050465
  507	Duff S, Mafilios MS, Bhounsule P, Hasegawa JT. The burden of critical limb ischemia: a review of recent literature. Vasc Health Risk Manag 2019;15:187–208. https://doi.org/10.2147/VHRM.S209241
  508	Sarac TP, Huber TS, Back MR, Ozaki CK, Carlton LM, Flynn TC, et al.  Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure. J Vasc Surg 1998;28:446–57. https://doi.org/10.1016/s0741-5214(98)70130-2
  509	Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (the Dutch bypass oral anticoagulants or aspirin study): a randomised trial. Lancet 2000;355:346–51. https://doi.org/10.1016/S0140-6736(99)07199-8
CrossrefPubMedWorldCat 
510	Belch JJ, Dormandy J, Biasi GM, Cairols M, Diehm C, Eikelboom B, et al.  Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg 2010;52:825–33.e2. https://doi.org/10.1016/j.jvs.2010.04.027
  511	Brumberg RS, Back MR, Armstrong PA, Cuthbertson D, Shames ML, Johnson BL, et al.  The relative importance of graft surveillance and warfarin therapy in infrainguinal prosthetic bypass failure. J Vasc Surg 2007;46:1160–6. https://doi.org/10.1016/j.jvs.2007.07.046
  512	Van Gelder IC, Kotecha D, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, et al.  2024 ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2024. https://doi.org/10.1093/eurheartj/ehae176
Google ScholarWorldCat 
513	Spiliopoulos S, Pastromas G, Katsanos K, Kitrou P, Karnabatidis D, Siablis D. Platelet responsiveness to clopidogrel treatment after peripheral endovascular procedures: the PRECLOP study: clinical impact and optimal cutoff value of on-treatment high platelet reactivity. J Am Coll Cardiol 2013;61:2428–34. https://doi.org/10.1016/j.jacc.2013.03.036
  514	Busch L, Stern M, Dannenberg L, Mourikis P, Gröne M, Özaslan G, et al.  Impact of high on-treatment platelet reactivity after angioplasty in patients with peripheral arterial disease. Platelets 2021;32:391–7. https://doi.org/10.1080/09537104.2020.1742314
  515	Cosmi B, Conti E, Coccheri S. Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication. Cochrane Database Syst Rev 2014;5:CD001999. https://doi.org/10.1002/14651858.CD001999.pub2
Google ScholarWorldCat 
516	Bagger JP, Helligsoe P, Randsbaek F, Kimose HH, Jensen BS. Effect of verapamil in intermittent claudication. A randomized, double-blind, placebo-controlled, cross-over study after individual dose-response assessment. Circulation 1997;95:411–4. https://doi.org/10.1161/01.cir.95.2.411
  517	Gargiulo G, Giugliano G, Brevetti L, Sannino A, Schiattarella GG, Serino F, et al.  Use of statins in lower extremity artery disease: a review. BMC Surg 2012;12:S15. https://doi.org/10.1186/1471-2482-12-s1-s15
  518	McDermott MM, Guralnik JM, Greenland P, Pearce WH, Criqui MH, Liu K, et al.  Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation 2003;107:757–61. https://doi.org/10.1161/01.cir.0000050380.64025.07
  519	Robertson L, Andras A. Prostanoids for intermittent claudication. Cochrane Database Syst Rev 2013;4:CD000986. https://doi.org/10.1002/14651858.CD000986.pub3
Google ScholarWorldCat 
520	Stevens JW, Simpson E, Harnan S, Squires H, Meng Y, Thomas S, et al.  Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg 2012;99:1630–8. https://doi.org/10.1002/bjs.8895
  521	Bedenis R, Stewart M, Cleanthis M, Robless P, Mikhailidis DP, Stansby G. Cilostazol for intermittent claudication. Cochrane Database Syst Rev 2014;10:CD003748. https://doi.org/10.1002/14651858.CD003748.pub4
Google ScholarWorldCat 
522	Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (cilostazol: a study in long-term effects). J Vasc Surg 2008;47:330–6. https://doi.org/10.1016/j.jvs.2007.10.009
  523	Iida O, Yokoi H, Soga Y, Inoue N, Suzuki K, Yokoi Y, et al.  Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the sufficient treatment of peripheral intervention by cilostazol study. Circulation 2013;127:2307–15. https://doi.org/10.1161/circulationaha.112.000711
  524	de Backer TL, Vander Stichele R, Lehert P, Van Bortel L. Naftidrofuryl for intermittent claudication. Cochrane Database Syst Rev 2012;12:Cd001368. https://doi.org/10.1002/14651858.CD001368.pub4
  
525	Boccalon H, Lehert P, Mosnier M. Effect of naftidrofuryl on physiological walking distance in patients with intermittent claudication. Ann Cardiol Angeiol 2001;50:175–82. https://doi.org/10.1016/s0003-3928(01)00016-6
Google ScholarCrossrefWorldCat 
526	Broderick C, Forster R, Abdel-Hadi M, Salhiyyah K. Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev 2020;10:Cd005262. https://doi.org/10.1002/14651858.CD005262.pub4
  
527	Nicolaï SP, Kruidenier LM, Bendermacher BL, Prins MH, Stokmans RA, Broos PPHL, et al.  Ginkgo biloba for intermittent claudication. Cochrane Database Syst Rev 2013;6:Cd006888. https://doi.org/10.1002/14651858.CD006888.pub3
Google ScholarWorldCat 
528	Premaratne S, Newman J, Hobbs S, Garnham A, Wall M. Meta-analysis of direct surgical versus endovascular revascularization for aortoiliac occlusive disease. J Vasc Surg 2020;72:726–37. https://doi.org/10.1016/j.jvs.2019.12.035
  529	Aboyans V, Björck M, Brodmann M, Collet J-P, Czerny M, De Carlo M, et al.  Questions and answers on diagnosis and management of patients with peripheral arterial diseases: a companion document of the 2017 ESC Guidelines for the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Endorsed by: the European Stroke Organisation (ESO), The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 2018;39:e35–41. https://doi.org/10.1093/eurheartj/ehx499
  530	McQuade K, Gable D, Pearl G, Theune B, Black S. Four-year randomized prospective comparison of percutaneous ePTFE/nitinol self-expanding stent graft versus prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease. J Vasc Surg 2010;52:584–91.e7. https://doi.org/10.1016/j.jvs.2010.03.071
  531	Bosiers M, Deloose K, Callaert J, Moreels N, Keirse K, Verbist J, et al.  Results of the Protégé EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions. J Vasc Surg 2011;54:1042–50. https://doi.org/10.1016/j.jvs.2011.03.272
  532	Farhan S, Enzmann FK, Bjorkman P, Kamran H, Zhang Z, Sartori S, et al.  Revascularization strategies for patients with femoropopliteal peripheral artery disease. J Am Coll Cardiol 2023;81:358–70. https://doi.org/10.1016/j.jacc.2022.10.036
  533	Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2018;7:e011245. https://doi.org/10.1161/jaha.118.011245
  534	Ouriel K, Adelman MA, Rosenfield K, Scheinert D, Brodmann M, Peña C, et al.  Safety of paclitaxel-coated balloon angioplasty for femoropopliteal peripheral artery disease. JACC Cardiovasc Interv 2019;12:2515–24. https://doi.org/10.1016/j.jcin.2019.08.025
  535	Freisinger E, Koeppe J, Gerss J, Goerlich D, Malyar NM, Marschall U, et al.  Mortality after use of paclitaxel-based devices in peripheral arteries: a real-world safety analysis. Eur Heart J 2020;41:3732–9. https://doi.org/10.1093/eurheartj/ehz698
  536	Lyden SP, Brodmann M, Parikh SA, Krishnan P, Schroeder H, Werner M, et al.  Four-year patient-level pooled mortality analysis of the ILLUMENATE US pivotal and EU randomized controlled trials. J Vasc Surg 2022;75:600–7. https://doi.org/10.1016/j.jvs.2021.07.244
  537	Secemsky EA, Song Y, Schermerhorn M, Yeh RW. Update from the longitudinal assessment of safety of femoropopliteal endovascular treatment with paclitaxel-coated devices among medicare beneficiaries: the SAFE-PAD study. Circ Cardiovasc Interv 2022;15:e012074. https://doi.org/10.1161/circinterventions.122.012074
  538	Nordanstig J, James S, Andersson M, Andersson M, Danielsson P, Gillgren P, et al.  Mortality with paclitaxel-coated devices in peripheral artery disease. N Engl J Med 2020;383:2538–46. https://doi.org/10.1056/NEJMoa2005206
  539	Fashandi AZ, Mehaffey JH, Hawkins RB, Kron IL, Upchurch GR, Robinson WP. Major adverse limb events and major adverse cardiac events after contemporary lower extremity bypass and infrainguinal endovascular intervention in patients with claudication. J Vasc Surg 2018;68:1817–23. https://doi.org/10.1016/j.jvs.2018.06.193
  540	Koelemay MJW, van Reijen NS, van Dieren S, Frans FA, Vermeulen EJG, Buscher HCJL, et al.  Editor's choice—randomised clinical trial of supervised exercise therapy vs. endovascular revascularisation for intermittent claudication caused by iliac artery obstruction: the SUPER study. Eur J Vasc Endovasc Surg 2022;63:421–9. https://doi.org/10.1016/j.ejvs.2021.09.042
  541	Dormandy J, Mahir M, Ascady G, Balsano F, De Leeuw P, Blombery P, et al.  Fate of the patient with chronic leg ischaemia. A review article. J Cardiovasc Surg (Torino) 1989;30:50–7.
  
542	Jelnes R, Gaardsting O, Hougaard Jensen K, Baekgaard N, Tonnesen KH, Schroeder T. Fate in intermittent claudication: outcome and risk factors. BMJ 1986;293:1137–40. https://doi.org/10.1136/bmj.293.6555.1137
  543	Leng GC, Lee AJ, Fowkes FG, Whiteman M, Dunbar J, Housley E, et al.  Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol 1996;25:1172–81. https://doi.org/10.1093/ije/25.6.1172
  544	Bloor K. Natural history of arteriosclerosis of the lower extremities: Hunterian lecture delivered at the Royal College of Surgeons of England on 22nd April 1960. Ann R Coll Surg Engl 1961;28:36–52.
  
545	Goode SD, Cleveland TJ, Gaines PA, Collaborators S. Randomized clinical trial of stents versus angioplasty for the treatment of iliac artery occlusions (STAG trial). Br J Surg 2013;100:1148–53. https://doi.org/10.1002/bjs.9197
  546	Hajibandeh S, Hajibandeh S, Antoniou SA, Torella F, Antoniou GA. Covered vs uncovered stents for aortoiliac and femoropopliteal arterial disease: a systematic review and meta-analysis. J Endovasc Ther 2016;23:442–52. https://doi.org/10.1177/1526602816643834
  547	Krankenberg H, Zeller T, Ingwersen M, Schmalstieg J, Gissler HM, Nikol S, et al.  Self-expanding versus balloon-expandable stents for iliac artery occlusive disease: the randomized ICE trial. JACC Cardiovasc Interv 2017;10:1694–704. https://doi.org/10.1016/j.jcin.2017.05.015
  548	Bosch JL, Hunink MG. Meta-analysis of the results of percutaneous transluminal angioplasty and stent placement for aortoiliac occlusive disease. Radiology 1997;204:87–96. https://doi.org/10.1148/radiology.204.1.9205227
  549	Committee TS, Jaff MR, White CJ, Hiatt WR, Fowkes GR, Dormandy J, et al.  An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: a supplement to the inter-society consensus for the management of peripheral arterial disease (TASC II). J Endovasc Ther 2015;22:663–77. https://doi.org/10.1177/1526602815592206
  
550	Boc V, Kozak M, Erzen B, Božič Mijovski M, Boc A, Blinc A. Prognostic factors for restenosis of superficial femoral artery after endovascular treatment. J Clin Med 2023;12:6343. https://doi.org/10.3390/jcm12196343
  551	Alves-Cabratosa L, Comas-Cufi M, Ponjoan A, Garcia-Gil M, Martí-Lluch R, Blanch J, et al.  Levels of ankle-brachial index and the risk of diabetes mellitus complications. BMJ Open Diabetes Res Care 2020;8:e000977. https://doi.org/10.1136/bmjdrc-2019-000977
  552	Heiss C, Olinic DM, Belch JJF, Brodmann M, Mazzolai L, Stanek A, et al.  Management of chronic peripheral artery disease patients with indication for endovascular revascularization. Vasa 2022;51:121–37. https://doi.org/10.1024/0301-1526/a000998
  553	Hajibandeh S, Hajibandeh S, Shah S, Child E, Antoniou GA, Torella F. Prognostic significance of ankle brachial pressure index: a systematic review and meta-analysis. Vascular 2017;25:208–24. https://doi.org/10.1177/1708538116658392
  554	Meza-Torres B, Cunningham SG, Heiss C, Joy M, Feher M, Leese GP, et al.  Adherence to general diabetes and foot care processes, with prompt referral, are associated with amputation-free survival in people with type 2 diabetes and foot ulcers: a Scottish national registry analysis. J Diabetes Res 2022;2022:7414258. https://doi.org/10.1155/2022/7414258
  555	Shishehbor MH, White CJ, Gray BH, Menard MT, Lookstein R, Rosenfield K, et al.  Critical limb ischemia: an expert statement. J Am Coll Cardiol 2016;68:2002–15. https://doi.org/10.1016/j.jacc.2016.04.071
  556	Misra S, Shishehbor MH, Takahashi EA, Aronow HD, Brewster LP, Bunte MC, et al.  Perfusion assessment in critical limb ischemia: principles for understanding and the development of evidence and evaluation of devices: a scientific statement from the American Heart Association. Circulation 2019;140:e657–72. https://doi.org/10.1161/cir.0000000000000708
  557	Sukul D, Grey SF, Henke PK, Gurm HS, Grossman PM. Heterogeneity of ankle-brachial indices in patients undergoing revascularization for critical limb ischemia. JACC Cardiovasc Interv 2017;10:2307–16. https://doi.org/10.1016/j.jcin.2017.08.026
  558	Shishehbor MH, Hammad TA, Zeller T, Baumgartner I, Scheinert D, Rocha-Singh KJ. An analysis of IN.PACT DEEP randomized trial on the limitations of the societal guidelines–recommended hemodynamic parameters to diagnose critical limb ischemia. J Vasc Surg 2016;63:1311–7. https://doi.org/10.1016/j.jvs.2015.11.042
  559	Randhawa MS, Reed GW, Grafmiller K, Gornik HL, Shishehbor MH. Prevalence of tibial artery and pedal arch patency by angiography in patients with critical limb ischemia and noncompressible ankle brachial index. Circ Cardiovasc Interv 2017;10:e004605. https://doi.org/10.1161/CIRCINTERVENTIONS.116.004605
  560	Mustapha JA, Saab FA, Martinsen BJ, Pena CS, Zeller T, Driver VR, et al.  Digital subtraction angiography prior to an amputation for critical limb ischemia (CLI): an expert recommendation statement from the CLI global society to optimize limb salvage. J Endovasc Ther 2020;27:540–6. https://doi.org/10.1177/1526602820928590
  561	Menke J, Larsen J. Meta-analysis: accuracy of contrast-enhanced magnetic resonance angiography for assessing steno-occlusions in peripheral arterial disease. Ann Intern Med 2010;153:325–34. https://doi.org/10.7326/0003-4819-153-5-201009070-00007
  562	Reinecke H, Unrath M, Freisinger E, Bunzemeier H, Meyborg M, Luders F, et al.  Peripheral arterial disease and critical limb ischaemia: still poor outcomes and lack of guideline adherence. Eur Heart J 2015;36:932–8. https://doi.org/10.1093/eurheartj/ehv006
  563	Hess CN, Wang TY, Weleski Fu J, Gundrum J, Allen LaPointe NM, Rogers RK, et al.  Long-term outcomes and associations with major adverse limb events after peripheral artery revascularization. J Am Coll Cardiol 2020;75:498–508. https://doi.org/10.1016/j.jacc.2019.11.050
  564	Bradbury AW, Adam DJ, Bell J, Forbes JF, Fowkes FGR, Gillespie I, et al.  Bypass versus angioplasty in severe ischaemia of the leg (BASIL) trial: a survival prediction model to facilitate clinical decision making. J Vasc Surg 2010;51:52s–68s. https://doi.org/10.1016/j.jvs.2010.01.077
  565	Meltzer AJ, Graham A, Connolly PH, Meltzer EC, Karwowski JK, Bush HL, et al.  The comprehensive risk assessment for bypass (CRAB) facilitates efficient perioperative risk assessment for patients with critical limb ischemia. J Vasc Surg 2013;57:1186–95. https://doi.org/10.1016/j.jvs.2012.09.083
  566	van Netten JJ, Fortington LV, Hinchliffe RJ, Hijmans JM. Early post-operative mortality after major lower limb amputation: a systematic review of population and regional based studies. Eur J Vasc Endovasc Surg 2016;51:248–57. https://doi.org/10.1016/j.ejvs.2015.10.001
  567	Farber A, Menard MT, Conte MS, Kaufman JA, Powell RJ, Choudhry NK, et al.  Surgery or endovascular therapy for chronic limb-threatening ischemia. N Engl J Med 2022;387:2305–16. https://doi.org/10.1056/NEJMoa2207899
  568	Meza-Torres B, Carinci F, Heiss C, Joy M, de Lusignan S. Health service organisation impact on lower extremity amputations in people with type 2 diabetes with foot ulcers: systematic review and meta-analysis. Acta Diabetol 2021;58:735–47. https://doi.org/10.1007/s00592-020-01662-x
  569	Peters EJ, Lipsky BA, Berendt AR, Embil JM, Lavery LA, Senneville E, et al.  A systematic review of the effectiveness of interventions in the management of infection in the diabetic foot. Diabetes Metab Res Rev 2012;28:142–62. https://doi.org/10.1002/dmrr.2247
  570	Peters EJG, Lipsky BA, Senneville É, Abbas ZG, Aragón-Sánchez J, Diggle M, et al.  Interventions in the management of infection in the foot in diabetes: a systematic review. Diabetes Metab Res Rev 2020;36:e3282. https://doi.org/10.1002/dmrr.3282
  571	Dumville JC, Lipsky BA, Hoey C, Cruciani M, Fiscon M, Xia J. Topical antimicrobial agents for treating foot ulcers in people with diabetes. Cochrane Database Syst Rev 2017;6:CD011038. https://doi.org/10.1002/14651858.CD011038.pub2
  
572	Luo Y, Li L, Zhao P, Yang C, Zhang J. Effectiveness of silver dressings in the treatment of diabetic foot ulcers: a systematic review and meta-analysis. J Wound Care 2022;31:979–86. https://doi.org/10.12968/jowc.2022.31.11.979
  573	Shu H, Xia Z, Qin X, Wang X, Lu W, Luo Q, et al.  The clinical efficacy of collagen dressing on chronic wounds: a meta-analysis of 11 randomized controlled trials. Front Surg 2022;9:978407. https://doi.org/10.3389/fsurg.2022.978407
  574	Zhang F, Chen Z, Su F, Zhang T. Comparison of topical honey and povidone iodine-based dressings for wound healing: a systematic review and meta-analysis. J Wound Care 2021;30:S28–s36. https://doi.org/10.12968/jowc.2021.30.Sup4.S28
  575	Yin XL, Hu L, Li T, Zou Y, Li HL. A meta-analysis on the efficacy of vacuum sealing drainage combined with autologous platelet-rich plasma in the treatment of grade 2 and grade 3 diabetic foot ulcers. Int Wound J 2022;20:1033–41. https://doi.org/10.1111/iwj.13956
  576	Lim K, Lim X, Hong Q, Yong E, Chandrasekar S, Tan GWL, et al.  Use of home negative pressure wound therapy in peripheral artery disease and diabetic limb salvage. Int Wound J 2020;17:531–9. https://doi.org/10.1111/iwj.13307
  577	Uddin A, Russell D, Game F, Santos D, Siddle HJ. The effectiveness of systemic antibiotics for osteomyelitis of the foot in adults with diabetes mellitus: a systematic review protocol. J Foot Ankle Res 2022;15:48. https://doi.org/10.1186/s13047-022-00554-3
  578	O'Meara S, Nelson EA, Golder S, Dalton JE, Craig D, Iglesias C. Systematic review of methods to diagnose infection in foot ulcers in diabetes. Diabet Med 2006;23:341–7. https://doi.org/10.1111/j.1464-5491.2006.01830.x
  579	Nelson A, Wright-Hughes A, Backhouse MR, Lipsky BA, Nixon J, Bhogal MS, et al.  CODIFI (concordance in diabetic foot ulcer infection): a cross-sectional study of wound swab versus tissue sampling in infected diabetic foot ulcers in England. BMJ Open 2018;8:e019437. https://doi.org/10.1136/bmjopen-2017-019437
  580	Gardner SE, Frantz RA. Wound bioburden and infection-related complications in diabetic foot ulcers. Biol Res Nurs 2008;10:44–53. https://doi.org/10.1177/1099800408319056
  581	Selva Olid A, Solà I, Barajas-Nava LA, Gianneo OD, Bonfill Cosp X, Lipsky BA. Systemic antibiotics for treating diabetic foot infections. Cochrane Database Syst Rev 2015;9:CD009061. https://doi.org/10.1002/14651858.CD009061.pub2
Google ScholarWorldCat 
582	Patton D, Avsar P, Sayeh A, Budri A, O’Connor T, Walsh S, et al.  A meta-review of the impact of compression therapy on venous leg ulcer healing. Int Wound J 2023;20:430–47. https://doi.org/10.1111/iwj.13891
  583	Lazzarini PA, Armstrong DG, Crews RT, Gooday C, Jarl G, Kirketerp-Moller K, et al.  Effectiveness of offloading interventions for people with diabetes-related foot ulcers: a systematic review and meta-analysis. Diabetes Metab Res Rev 2024;40:e3650. https://doi.org/10.1002/dmrr.3650
  584	Elraiyah T, Prutsky G, Domecq JP, Tsapas A, Nabhan M, Frykberg RG, et al.  A systematic review and meta-analysis of off-loading methods for diabetic foot ulcers. J Vasc Surg 2016;63:59S–68S.e2. https://doi.org/10.1016/j.jvs.2015.10.006
  585	Lumsden AB, Davies MG, Peden EK. Medical and endovascular management of critical limb ischemia. J Endovasc Ther 2009;16:Ii31–62. https://doi.org/10.1583/08-2657.1
  586	Manzi M, Palena L, Cester G. Endovascular techniques for limb salvage in diabetics with crural and pedal disease. J Cardiovasc Surg 2011;52:485–92.
Google ScholarWorldCat 
587	Dominguez A, III, Bahadorani J, Reeves R, Mahmud E, Patel M. Endovascular therapy for critical limb ischemia. Expert Rev Cardiovasc Ther 2015;13:429–44. https://doi.org/10.1586/14779072.2015.1019472
  588	Abu Dabrh AM, Steffen MW, Undavalli C, Asi N, Wang Z, Elamin MB, et al.  The natural history of untreated severe or critical limb ischemia. J Vasc Surg 2015;62:1642–51.e3. https://doi.org/10.1016/j.jvs.2015.07.065
  589	Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, et al.  Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet 2005;366:1925–34. https://doi.org/10.1016/s0140-6736(05)67704-5
  
590	Bradbury AW, Moakes CA, Popplewell M, Meecham L, Bate GR, Kelly L, et al.  A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial. Lancet 2023;401:1798–809. https://doi.org/10.1016/S0140-6736(23)00462-2
  591	Popplewell MA, Davies H, Jarrett H, Bate G, Grant M, Patel S, et al.  Bypass versus angio plasty in severe ischaemia of the leg—2 (BASIL-2) trial: study protocol for a randomised controlled trial. Trials 2016;17:11. https://doi.org/10.1186/s13063-015-1114-2
  592	Patel K, Liu Y, Etaee F, Patel C, Monteleone P, Patel M, et al.  Differences between patients with intermittent claudication and critical limb ischemia undergoing endovascular intervention: insights from the excellence in peripheral artery disease registry. Circ Cardiovasc Interv 2021;14:e010635. https://doi.org/10.1161/CIRCINTERVENTIONS.121.010635
  593	Almasri J, Adusumalli J, Asi N, Lakis S, Alsawas M, Prokop LJ, et al.  A systematic review and meta-analysis of revascularization outcomes of infrainguinal chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg 2019;58:S110–s119. https://doi.org/10.1016/j.ejvs.2019.04.013
  594	Söder HK, Manninen HI, Jaakkola P, Matsi PJ, Räsänen HT, Kaukanen E, et al.  Prospective trial of infrapopliteal artery balloon angioplasty for critical limb ischemia: angiographic and clinical results. J Vasc Interv Radiol 2000;11:1021–31. https://doi.org/10.1016/s1051-0443(07)61332-3
  595	Balmer H, Mahler F, Do DD, Triller J, Baumgartner I. Balloon angioplasty in chronic critical limb ischemia: factors affecting clinical and angiographic outcome. J Endovasc Ther 2002;9:403–10. https://doi.org/10.1177/152660280200900403
  596	Kudo T, Chandra FA, Kwun WH, Haas BT, Ahn SS. Changing pattern of surgical revascularization for critical limb ischemia over 12 years: endovascular vs. open bypass surgery. J Vasc Surg 2006;44:304–13. https://doi.org/10.1016/j.jvs.2006.03.040
  597	Kim KG, Meshkin DH, Tirrell AR, Bekeny JC, Tefera EA, Fan KL, et al.  A systematic review and meta-analysis of endovascular angiosomal revascularization in the setting of collateral vessels. J Vasc Surg 2021;74:1406–16.e3. https://doi.org/10.1016/j.jvs.2021.04.026
  598	Shishehbor MH, Powell RJ, Montero-Baker MF, Dua A, Martínez-Trabal JL, Bunte MC, et al.  Transcatheter arterialization of deep veins in chronic limb-threatening ischemia. N Engl J Med 2023;388:1171–80. https://doi.org/10.1056/NEJMoa2212754
  599	Salem M, Hosny MS, Francia F, Sallam M, Saratzis A, Saha P, et al.  Management of extensive aorto-iliac disease: a systematic review and meta-analysis of 9319 patients. Cardiovasc Intervent Radiol 2021;44:1518–35. https://doi.org/10.1007/s00270-021-02785-6
  600	Bekken JA, Vroegindeweij D, Vos JA, de Vries J-PPM, Lardenoije JWHP, Petri B-J, et al.  Editor’s choice—two year results of the randomised DISCOVER trial comparing covered versus bare metal stents in the common iliac artery. Eur J Vasc Endovasc Surg 2023;65:359–68. https://doi.org/10.1016/j.ejvs.2022.11.008
  601	Jongkind V, Akkersdijk GJ, Yeung KK, Wisselink W. A systematic review of endovascular treatment of extensive aortoiliac occlusive disease. J Vasc Surg 2010;52:1376–83. https://doi.org/10.1016/j.jvs.2010.04.080
  602	Ye W, Liu CW, Ricco JB, Mani K, Zeng R, Jiang J. Early and late outcomes of percutaneous treatment of TransAtlantic inter-society consensus class C and D aorto-iliac lesions. J Vasc Surg 2011;53:1728–37. https://doi.org/10.1016/j.jvs.2011.02.005
  603	Bosiers M, Deloose K, Callaert J, Maene L, Beelen R, Keirse K, et al.  BRAVISSIMO: 12-month results from a large scale prospective trial. J Cardiovasc Surg 2013;54:235–53.
Google ScholarWorldCat 
604	Danczyk RC, Mitchell EL, Petersen BD, Edwards J, Liem TK, Landry GJ, et al.  Outcomes of open operation for aortoiliac occlusive disease after failed endovascular therapy. Arch Surg 2012;147:841–5. https://doi.org/10.1001/archsurg.2012.1649
  605	Fereydooni A, Zhou B, Xu Y, Deng Y, Dardik A, Ochoa Chaar CI. Rapid increase in hybrid surgery for the treatment of peripheral artery disease in the vascular quality initiative database. J Vasc Surg 2020;72:977–86.e1. https://doi.org/10.1016/j.jvs.2019.11.041
  606	Zeller T, Baumgartner I, Scheinert D, Brodmann M, Bosiers M, Micari A, et al.  Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. J Am Coll Cardiol 2014;64:1568–76. https://doi.org/10.1016/j.jacc.2014.06.1198
  607	Zeller T, Micari A, Scheinert D, Baumgartner I, Bosiers M, Vermassen FEG, et al.  The IN.PACT DEEP clinical drug-coated balloon trial: 5-year outcomes. JACC Cardiovasc Interv 2020;13:431–43. https://doi.org/10.1016/j.jcin.2019.10.059
  608	Brizzi V, Caradu C, Berard X, Sassoust G, Midy D, Ducasse E. Six-year multicenter experience of standard endovascular treatment of critical limb ischemia in the era of drug-eluting devices. J Cardiovasc Surg 2018;59:707–15. https://doi.org/10.23736/S0021-9509.16.09737-8
Google ScholarCrossrefWorldCat 
609	Jude EB, Oyibo SO, Chalmers N, Boulton AJ. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care 2001;24:1433–7. https://doi.org/10.2337/diacare.24.8.1433
  610	Ozkan U, Oguzkurt L, Tercan F. Atherosclerotic risk factors and segmental distribution in symptomatic peripheral artery disease. J Vasc Interv Radiol 2009;20:437–41. https://doi.org/10.1016/j.jvir.2009.01.010
  611	Todd KE, Jr, Ahanchi SS, Maurer CA, Kim JH, Chipman CR, Panneton JM. Atherectomy offers no benefits over balloon angioplasty in tibial interventions for critical limb ischemia. J Vasc Surg 2013;58:941–8. https://doi.org/10.1016/j.jvs.2013.04.024
  612	Teichgraber U, Lehmann T, Thieme M, Wahl K-U, Stelzner C, Bormann A, et al.  Drug-coated balloon angioplasty of infrapopliteal lesions in patients with critical limb ischaemia: 1-year results of the APOLLO trial. Cardiovasc Intervent Radiol 2019;42:1380–90. https://doi.org/10.1007/s00270-019-02279-6
  613	Yang X, Lu X, Ye K, Li X, Qin J, Jiang M. Systematic review and meta-analysis of balloon angioplasty versus primary stenting in the infrapopliteal disease. Vasc Endovascular Surg 2014;48:18–26. https://doi.org/10.1177/1538574413510626
  614	Zhang J, Xu X, Kong J, Xu R, Fan X, Chen J, et al.  Systematic review and meta-analysis of drug-eluting balloon and stent for infrapopliteal artery revascularization. Vasc Endovascular Surg 2017;51:72–83. https://doi.org/10.1177/1538574416689426
  615	Matsuoka EK, Hasebe T, Ishii R, Miyazaki N, Soejima K, Iwasaki K. Comparative performance analysis of interventional devices for the treatment of ischemic disease in below-the-knee lesions: a systematic review and meta-analysis. Cardiovasc Interv Ther 2022;37:145–57. https://doi.org/10.1007/s12928-021-00758-7
  616	Fong KY, Xin L, Ng J, Loh SEK, Ng JJ, Choong AMTL. A systematic review and meta-analysis of sirolimus-eluting stents for treatment of below-the-knee arterial disease. J Vasc Surg 2023;77:1264–73.e3. https://doi.org/10.1016/j.jvs.2022.09.022
  617	Ubbink DT, Vermeulen H. Spinal cord stimulation for non-reconstructable chronic critical leg ischaemia. Cochrane Database Syst Rev 2013;2:CD004001. https://doi.org/10.1002/14651858.CD004001.pub3
Google ScholarWorldCat 
618	Asimakidou E, Matis GK. Spinal cord stimulation in the treatment of peripheral vascular disease: a systematic review—revival of a promising therapeutic option? Br J Neurosurg 2022;36:555–63. https://doi.org/10.1080/02688697.2021.1884189
  619	Nicoloff AD, Taylor LM, Jr, Sexton GJ, Schuff RA, Edwards JM, Yeager RA, et al.  Relationship between site of initial symptoms and subsequent progression of disease in a prospective study of atherosclerosis progression in patients receiving long-term treatment for symptomatic peripheral arterial disease. J Vasc Surg 2002;35:38–46; discussion 46–37.
  
620	Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al.  International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180–9. https://doi.org/10.1001/jama.295.2.180
  621	Wilson YG, Davies AH, Currie IC, Morgan M, McGrath C, Baird RN, et al.  Vein graft stenosis: incidence and intervention. Eur J Vasc Endovasc Surg 1996;11:164–9. https://doi.org/10.1016/s1078-5884(96)80046-3
  622	Armstrong PA, Bandyk DF, Wilson JS, Shames ML, Johnson BL, Back MR. Optimizing infrainguinal arm vein bypass patency with duplex ultrasound surveillance and endovascular therapy. J Vasc Surg 2004;40:724–31; discussion 730–721. https://doi.org/10.1016/j.jvs.2004.07.037
  623	Pulli R, Dorigo W, Fargion A, Innocenti AA, Pratesi G, Marek J, et al.  Early and long-term comparison of endovascular treatment of iliac artery occlusions and stenosis. J Vasc Surg 2011;53:92–8. https://doi.org/10.1016/j.jvs.2010.08.034
  624	Lo RC, Darling J, Bensley RP, Giles KA, Dahlberg SE, Hamdan AD, et al.  Outcomes following infrapopliteal angioplasty for critical limb ischemia. J Vasc Surg 2013;57:1455–64; discussion 1463–1454. https://doi.org/10.1016/j.jvs.2012.10.109
  625	Rodway AD, Hanna L, Harris J, Jarrett R, Allan C, Pazos Casal F, et al.  Prognostic and predictive value of ultrasound-based estimated ankle brachial pressure index at early follow-up after endovascular revascularization of chronic limb-threatening ischaemia: a prospective, single-centre, service evaluation. EClinicalMedicine 2024;68:102410. https://doi.org/10.1016/j.eclinm.2023.102410
  626	Poursina O, Elizondo-Adamchik H, Montero-Baker M, Pallister ZS, Mills JL, Chung J. Safety and efficacy of an endovascular-first approach to acute limb ischemia. J Vasc Surg 2021;73:1741–9. https://doi.org/10.1016/j.jvs.2020.10.002
  627	Hawkins KE, Valentine RJ, Duke JM, Wang Q, Reed AB. Ankle-brachial index use in peripheral vascular interventions for claudication. J Vasc Surg 2022;76:196–201. https://doi.org/10.1016/j.jvs.2022.02.049
  628	Armstrong EJ, Chen DC, Westin GG, Singh S, McCoach CE, Bang H, et al.  Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J Am Heart Assoc 2014;3:e000697. https://doi.org/10.1161/jaha.113.000697
  629	Araujo ST, Moreno DH, Cacione DG. Percutaneous thrombectomy or ultrasound-accelerated thrombolysis for initial management of acute limb ischaemia. Cochrane Database Syst Rev 2022;1:CD013486. https://doi.org/10.1002/14651858.CD013486.pub2
  
630	Kokkinidis DG, Arfaras-Melainis A, Giannopoulos S, Katsaros I, Jawaid O, Jonnalagadda AK, et al.  Statin therapy for reduction of cardiovascular and limb-related events in critical limb ischemia: a systematic review and meta-analysis. Vasc Med 2020;25:106–17. https://doi.org/10.1177/1358863x19894055
  631	Londero LS, Nørgaard B, Houlind K. Patient delay is the main cause of treatment delay in acute limb ischemia: an investigation of pre- and in-hospital time delay. World J Emerg Surg 2014;9:56. https://doi.org/10.1186/1749-7922-9-56
  632	Duval S, Keo HH, Oldenburg NC, Baumgartner I, Jaff MR, Peacock JM, et al.  The impact of prolonged lower limb ischemia on amputation, mortality, and functional status: the FRIENDS registry. Am Heart J 2014;168:577–87. https://doi.org/10.1016/j.ahj.2014.06.013
  633	Kulezic A, Macek M, Acosta S. Inadequacies of physical examination in patients with acute lower limb ischemia are associated with dreadful consequences. Ann Vasc Surg 2022;82:190–6. https://doi.org/10.1016/j.avsg.2021.10.067
  634	Blaisdell FW. The pathophysiology of skeletal muscle ischemia and the reperfusion syndrome: a review. Cardiovasc Surg 2002;10:620–30. https://doi.org/10.1016/s0967-2109(02)00070-4
  635	Jivegård L, Bergqvist D, Holm J. When is urgent revascularization unnecessary for acute lower limb ischaemia? Eur J Vasc Endovasc Surg 1995;9:448–53. https://doi.org/10.1016/s1078-5884(05)80014-0
  636	Crawford JD, Perrone KH, Jung E, Mitchell EL, Landry GJ, Moneta GL, et al.  Arterial duplex for diagnosis of peripheral arterial emboli. J Vasc Surg 2016;64:1351–6. https://doi.org/10.1016/j.jvs.2016.04.005
  637	Hemingway J, Emanuels D, Aarabi S, Quiroga E, Tran N, Starnes B, et al.  Safety of transfer, type of procedure, and factors predictive of limb salvage in a modern series of acute limb ischemia. J Vasc Surg 2019;69:1174–9. https://doi.org/10.1016/j.jvs.2018.08.174
  638	Currie IS, Wakelin SJ, Lee AJ, Chalmers RT. Plasma creatine kinase indicates major amputation or limb preservation in acute lower limb ischemia. J Vasc Surg 2007;45:733–9. https://doi.org/10.1016/j.jvs.2006.12.050
  639	Brow TD, Kakkar VV, Das SK. The significance of creatine kinase in cardiac patients with acute limb ischaemia. J Cardiovasc Surg 1999;40:637–44.
Google ScholarWorldCat 
640	Adiseshiah M, Round JM, Jones DA. Reperfusion injury in skeletal muscle: a prospective study in patients with acute limb ischaemia and claudicants treated by revascularization. Br J Surg 2005;79:1026–9. https://doi.org/10.1002/bjs.1800791013
Google ScholarCrossrefWorldCat 
641	Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al.  Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997;26:517–38. https://doi.org/10.1016/s0741-5214(97)70045-4
  642	Ontario Health. Mechanical thrombectomy for acute and subacute blocked arteries and veins in the lower limbs: a health technology assessment. Ont Health Technol Assess Ser 2023;23:1–244.
WorldCat 
643	Gong M, He X, Zhao B, Kong J, Gu J, Chen G, et al.  Endovascular revascularization strategies using catheter-based thrombectomy versus conventional catheter-directed thrombolysis for acute limb ischemia. Thromb J 2021;19:96. https://doi.org/10.1186/s12959-021-00349-9
  644	Doelare SAN, Koedam TWA, Ebben HP, Tournoij E, Hoksbergen AWJ, Yeung KK, et al.  Catheter directed thrombolysis for not immediately threatening acute limb ischaemia: systematic review and meta-analysis. Eur J Vasc Endovasc Surg 2023;65:537–45. https://doi.org/10.1016/j.ejvs.2022.12.030
  645	Veenstra EB, van der Laan MJ, Zeebregts CJ, de Heide E-J, Kater M, Bokkers RPH. A systematic review and meta-analysis of endovascular and surgical revascularization techniques in acute limb ischemia. J Vasc Surg 2020;71:654–68.e3. https://doi.org/10.1016/j.jvs.2019.05.031
  646	Kolte D, Kennedy KF, Shishehbor MH, Mamdani ST, Stangenberg L, Hyder ON, et al.  Endovascular versus surgical revascularization for acute limb ischemia: a propensity-score matched analysis. Circ Cardiovasc Interv 2020;13:e008150. https://doi.org/10.1161/CIRCINTERVENTIONS.119.008150
  647	Grip O, Wanhainen A, Michaelsson K, Lindhagen L, Bjorck M. Open or endovascular revascularization in the treatment of acute lower limb ischaemia. Br J Surg 2018;105:1598–606. https://doi.org/10.1002/bjs.10954
  648	Darwood R, Berridge DC, Kessel DO, Robertson I, Forster R. Surgery versus thrombolysis for initial management of acute limb ischaemia. Cochrane Database Syst Rev 2018;8:CD002784. https://doi.org/10.1002/14651858.CD002784.pub3
  
649	Schrijver AM, van Leersum M, Fioole B, Reijnen MMPJ, Hoksbergen AWJ, Vahl AC, et al.  Dutch randomized trial comparing standard catheter-directed thrombolysis and ultrasound-accelerated thrombolysis for arterial thromboembolic infrainguinal disease (DUET). J Endovasc Ther 2015;22:87–95. https://doi.org/10.1177/1526602814566578
  650	Juneja A, Garuthara M, Talathi S, Rao A, Landis G, Etkin Y. Predictors of poor outcomes after lower extremity revascularization for acute limb ischemia. Vascular 2024;32:632–9. https://doi.org/10.1177/17085381231154290
  651	Ouriel K, Veith FJ. Acute lower limb ischemia: determinants of outcome. Surgery 1998;124:336–41; discussion 341–332. https://doi.org/10.1016/S0039-6060(98)70139-4
  652	Sobel M, Verhaeghe R. Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133:815s–43s. https://doi.org/10.1378/chest.08-0686
  653	Hess CN, Debus ES, Nehler MR, Anand SS, Patel MR, Szarek M, et al.  Reduction in acute limb ischemia with rivaroxaban versus placebo in peripheral artery disease after lower extremity revascularization: insights from VOYAGER PAD. Circulation 2021;144:1831–41. https://doi.org/10.1161/circulationaha.121.055146
  654	Jivegård L, Holm J, Bergqvist D, Björck CG, Björkman H, Brunius U, et al.  Acute lower limb ischemia: failure of anticoagulant treatment to improve one-month results of arterial thromboembolectomy. A prospective randomized multi-center study. Surgery 1991;109:610–6.
  
655	Jivegård L, Holm J, Scherstén T. Arterial thromboembolectomy—should anticoagulants be administered? Acta Chir Scand 1986;152:493–7.
  
656	Campbell WB, Ridler BM, Szymanska TH. Two-year follow-up after acute thromboembolic limb ischaemia: the importance of anticoagulation. Eur J Vasc Endovasc Surg 2000;19:169–73. https://doi.org/10.1053/ejvs.1999.0999
  657	Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al.  Heart disease and stroke statistics–2018 update: a report from the American Heart Association. Circulation 2018;137:e67–492. https://doi.org/10.1161/cir.0000000000000558
  658	Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, et al.  Mannheim carotid intima-media thickness and plaque consensus (2004–2006–2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis 2012;34:290–6. https://doi.org/10.1159/000343145
  659	Johri AM, Nambi V, Naqvi TZ, Feinstein SB, Kim ESH, Park MM, et al.  Recommendations for the assessment of carotid arterial plaque by ultrasound for the characterization of atherosclerosis and evaluation of cardiovascular risk: from the American Society of Echocardiography. J Am Soc Echocardiogr 2020;33:917–33. https://doi.org/10.1016/j.echo.2020.04.021
  660	Barnett HJM, Taylor DW, Haynes RB, Sackett DL, Peerless SJ, Ferguson GG, et al.  Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991;325:445–53. https://doi.org/10.1056/nejm199108153250701
  
661	Gornik HL, Rundek T, Gardener H, Benenati JF, Dahiya N, Hamburg NM, et al.  Optimization of duplex velocity criteria for diagnosis of internal carotid artery (ICA) stenosis: a report of the Intersocietal Accreditation Commission (IAC) Vascular Testing Division Carotid Diagnostic Criteria Committee. Vasc Med 2021;26:515–25. https://doi.org/10.1177/1358863X211011253
  662	Grant EG, Benson CB, Moneta GL, Alexandrov AV, Baker JD, Bluth EI, et al.  Carotid artery stenosis: grayscale and Doppler ultrasound diagnosis—Society of Radiologists in ultrasound consensus conference. Ultrasound Q 2003;19:190–8. https://doi.org/10.1097/00013644-200312000-00005
  663	Rustempasic N, Gengo M. Assesment of carotid stenosis with CT angiography and color Doppler ultrasonography. Med Arch 2019;73:321–5. https://doi.org/10.5455/medarh.2019.73.321-325
  664	Clezar CN, Flumignan CD, Cassola N, Nakano LCU, Trevisani VFM, Flumignan RLG. Pharmacological interventions for asymptomatic carotid stenosis. Cochrane Database Syst Rev 2023;8:CD013573. https://doi.org/10.1002/14651858.CD013573.pub2
  
665	Côté R, Battista RN, Abrahamowicz M, Langlois Y, Bourque F, Mackey A. Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The asymptomatic cervical bruit study group. Ann Intern Med 1995;123:649–55. https://doi.org/10.7326/0003-4819-123-9-199511010-00002
  666	Aboyans V, Bauersachs R, Mazzolai L, Brodmann M, Palomares JFR, Debus S, et al.  Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. Eur Heart J 2021;42:4013–24. https://doi.org/10.1093/eurheartj/ehab390
  667	Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, et al.  Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med 2018;379:215–25. https://doi.org/10.1056/NEJMoa1800410
  668	Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, et al.  Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013;369:11–9. https://doi.org/10.1056/NEJMoa1215340
  669	Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 2007;6:961–9. https://doi.org/10.1016/S1474-4422(07)70250-8
  670	Murphy SJX, Naylor AR, Ricco JB, Sillesen H, Kakkos S, Halliday A, et al.  Optimal antiplatelet therapy in moderate to severe asymptomatic and symptomatic carotid stenosis: a comprehensive review of the literature. Eur J Vasc Endovasc Surg 2019;57:199–211. https://doi.org/10.1016/j.ejvs.2018.09.018
  671	King A, Shipley M, Markus H, Investigators A. The effect of medical treatments on stroke risk in asymptomatic carotid stenosis. Stroke 2013;44:542–6. https://doi.org/10.1161/STROKEAHA.112.673608
  672	Endarterectomy for asymptomatic carotid artery stenosis. Executive committee for the asymptomatic carotid atherosclerosis study. JAMA 1995;273:1421–8.
CrossrefPubMedWorldCat 
673	Halliday A, Mansfield A, Marro J, Peto C, Peto R, Potter J, et al.  Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet 2004;363:1491–502. https://doi.org/10.1016/s0140-6736(04)16146-1
  
674	Halliday A, Harrison M, Hayter E, Kong X, Mansfield A, Marro J, et al.  10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial. Lancet 2010;376:1074–84. https://doi.org/10.1016/s0140-6736(10)61197-x
  675	Rothwell PM, Goldstein LB. Carotid endarterectomy for asymptomatic carotid stenosis: asymptomatic carotid surgery trial. Stroke 2004;35:2425–7. https://doi.org/10.1161/01.STR.0000141706.50170.a7
  676	Hadar N, Raman G, Moorthy D, O’Donnell TF, Thaler DE, Feldmann E, et al.  Asymptomatic carotid artery stenosis treated with medical therapy alone: temporal trends and implications for risk assessment and the design of future studies. Cerebrovasc Dis 2014;38:163–73. https://doi.org/10.1159/000365206
  677	Reiff T, Eckstein HH, Mansmann U, Jansen O, Fraedrich G, Mudra H, et al.  Angioplasty in asymptomatic carotid artery stenosis vs. endarterectomy compared to best medical treatment: one-year interim results of SPACE-2. Int J Stroke 2020;15:638–49. https://doi.org/10.1177/1747493019833017
Google ScholarCrossrefWorldCat 
678	Naylor AR, Schroeder TV, Sillesen H. Clinical and imaging features associated with an increased risk of late stroke in patients with asymptomatic carotid disease. Eur J Vasc Endovasc Surg 2014;48:633–40. https://doi.org/10.1016/j.ejvs.2014.08.017
  679	Paraskevas KI, Brown MM, Lal BK, Myrcha P, Lyden SP, Schneider PA, et al.  Recent advances and controversial issues in the optimal management of asymptomatic carotid stenosis. J Vasc Surg 2024;79:695–703. https://doi.org/10.1016/j.jvs.2023.11.004
  680	Naylor R, Rantner B, Ancetti S, de Borst GJ, De Carlo M, Halliday A, et al.  Editor’s choice—European Society for Vascular Surgery (ESVS) 2023 clinical practice guidelines on the management of atherosclerotic carotid and vertebral artery disease. Eur J Vasc Endovasc Surg 2023;65:7–111. https://doi.org/10.1016/j.ejvs.2022.04.011
  681	Kashyap VS, Schneider PA, Foteh M, Motaganahalli R, Shah R, Eckstein H-H, et al.  Early outcomes in the ROADSTER 2 study of transcarotid artery revascularization in patients with significant carotid artery disease. Stroke 2020;51:2620–9. https://doi.org/10.1161/strokeaha.120.030550
  682	Nicolaides AN, Kakkos SK, Griffin M, Sabetai M, Dhanjil S, Tegos T, et al.  Severity of asymptomatic carotid stenosis and risk of ipsilateral hemispheric ischaemic events: results from the ACSRS study. Eur J Vasc Endovasc Surg 2005;30:275–84. https://doi.org/10.1016/j.ejvs.2005.04.031
  683	Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 2004;62:569–73. https://doi.org/10.1212/01.wnl.0000110311.09970.83
  684	Kakkos SK, Sabetai M, Tegos T, Stevens J, Thomas D, Griffin M, et al.  Silent embolic infarcts on computed tomography brain scans and risk of ipsilateral hemispheric events in patients with asymptomatic internal carotid artery stenosis. J Vasc Surg 2009;49:902–9. https://doi.org/10.1016/j.jvs.2008.10.059
  685	Kakkos SK, Nicolaides AN, Charalambous I, Thomas D, Giannopoulos A, Naylor AR, et al.  Predictors and clinical significance of progression or regression of asymptomatic carotid stenosis. J Vasc Surg 2014;59:956–67.e1. https://doi.org/10.1016/j.jvs.2013.10.073
  686	Markus HS, King A, Shipley M, Topakian R, Cullinane M, Reihill S, et al.  Asymptomatic embolisation for prediction of stroke in the Asymptomatic Carotid Emboli Study (ACES): a prospective observational study. Lancet Neurol 2010;9:663–71. https://doi.org/10.1016/s1474-4422(10)70120-4
  687	Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral ischemia. Stroke 1977;8:301–14. https://doi.org/10.1161/01.str.8.3.301
  688	King A, Serena J, Bornstein NM, Markus HS. Does impaired cerebrovascular reactivity predict stroke risk in asymptomatic carotid stenosis? A prospective substudy of the asymptomatic carotid emboli study. Stroke 2011;42:1550–5. https://doi.org/10.1161/strokeaha.110.609057
  689	Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, et al.  Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Lancet Neurol 2017;16:301–10. https://doi.org/10.1016/s1474-4422(17)30038-8
  690	Kakkos SK, Griffin MB, Nicolaides AN, Kyriacou E, Sabetai MM, Tegos T, et al.  The size of juxtaluminal hypoechoic area in ultrasound images of asymptomatic carotid plaques predicts the occurrence of stroke. J Vasc Surg 2013;57:609–18.e1; discussion 617–608. https://doi.org/10.1016/j.jvs.2012.09.045
  691	Gupta A, Kesavabhotla K, Baradaran H, Kamel H, Pandya A, Giambrone AE, et al.  Plaque echolucency and stroke risk in asymptomatic carotid stenosis: a systematic review and meta-analysis. Stroke 2015;46:91–7. https://doi.org/10.1161/strokeaha.114.006091
  692	Palacio S, Hart RG, Pearce LA, Anderson DC, Sharma M, Birnbaum LA, et al.  Effect of addition of clopidogrel to aspirin on stroke incidence: meta-analysis of randomized trials. Int J Stroke 2015;10:686–91. https://doi.org/10.1111/ijs.12050
  693	Gupta A, Baradaran H, Schweitzer AD, Kamel H, Pandya A, Delgado D, et al.  Carotid plaque MRI and stroke risk: a systematic review and meta-analysis. Stroke 2013;44:3071–7. https://doi.org/10.1161/strokeaha.113.002551
  694	Wong KS, Chen C, Fu J, Chang HM, Suwanwela NC, Huang YN, et al.  Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol 2010;9:489–97. https://doi.org/10.1016/s1474-4422(10)70060-0
  695	Karlöf E, Buckler A, Liljeqvist ML, Lengquist M, Kronqvist M, Toonsi MA, et al.  Carotid plaque phenotyping by correlating plaque morphology from computed tomography angiography with transcriptional profiling. Eur J Vasc Endovasc Surg 2021;62:716–26. https://doi.org/10.1016/j.ejvs.2021.07.011
  696	Silver FL, Mackey A, Clark WM, Brooks W, Timaran CH, Chiu D, et al.  Safety of stenting and endarterectomy by symptomatic status in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST). Stroke 2011;42:675–80. https://doi.org/10.1161/strokeaha.110.610212
  697	Baker WH, Howard VJ, Howard G, Toole JF. Effect of contralateral occlusion on long-term efficacy of endarterectomy in the asymptomatic carotid atherosclerosis study (ACAS). ACAS Investigators. Stroke 2000;31:2330–4. https://doi.org/10.1161/01.str.31.10.2330
  698	Kamtchum-Tatuene J, Noubiap JJ, Wilman AH, Saqqur M, Shuaib A, Jickling GC. Prevalence of high-risk plaques and risk of stroke in patients with asymptomatic carotid stenosis: a meta-analysis. JAMA Neurol 2020;77:1524–35. https://doi.org/10.1001/jamaneurol.2020.2658
  699	Saratzis A, Naylor R. 30 day outcomes after carotid interventions: an updated meta-analysis of randomised controlled trials in asymptomatic patients. Eur J Vasc Endovasc Surg 2022;63:157–8. https://doi.org/10.1016/j.ejvs.2021.10.029
  700	Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M, et al.  Ticagrelor added to aspirin in acute nonsevere ischemic stroke or transient ischemic attack of atherosclerotic origin. Stroke 2020;51:3504–13. https://doi.org/10.1161/strokeaha.120.032239
  701	Halliday A, Bulbulia R, Bonati LH, Chester J, Cradduck-Bamford A, Peto R, et al.  Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy. Lancet 2021;398:1065–73. https://doi.org/10.1016/s0140-6736(21)01910-3
  702	Rosenfield K, Matsumura JS, Chaturvedi S, Riles T, Ansel GM, Metzger DC, et al.  Randomized trial of stent versus surgery for asymptomatic carotid stenosis. N Engl J Med 2016;374:1011–20. https://doi.org/10.1056/NEJMoa1515706
  703	Brott TG, Howard G, Roubin GS, Meschia JF, Mackey A, Brooks W, et al.  Long-term results of stenting versus endarterectomy for carotid-artery stenosis. N Engl J Med 2016;374:1021–31. https://doi.org/10.1056/NEJMoa1505215
  704	Yadav JS, Wholey MH, Kuntz RE, Fayad P, Katzen BT, Mishkel GJ, et al.  Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med 2004;351:1493–501. https://doi.org/10.1056/NEJMoa040127
  705	Karpenko A, Bugurov S, Ignatenko P, Starodubtsev V, Popova I, Malinowski K, et al.  Randomized controlled trial of conventional versus micronet-covered stent in carotid artery revascularization. JACC Cardiovasc Interv 2021;14:2377–87. https://doi.org/10.1016/j.jcin.2021.08.005
  706	Karpenko A, Bugurov S, Ignatenko P, Starodubtsev V, Popova I, Malinowski K, et al.  Randomized controlled trial of conventional versus micronet-covered stent in carotid artery revascularization: 12-month outcomes. JACC Cardiovasc Interv 2023;16:878–80. https://doi.org/10.1016/j.jcin.2023.01.369
  707	Columbo JA, Martinez-Camblor P, Stone DH, Goodney PP, O’Malley AJ. Procedural safety comparison between transcarotid artery revascularization, carotid endarterectomy, and carotid stenting: perioperative and 1-year rates of stroke or death. J Am Heart Assoc 2022;11:e024964. https://doi.org/10.1161/jaha.121.024964
  708	de Borst GJ. Transcarotid artery revascularization. Br J Surg 2023;110:127–8. https://doi.org/10.1093/bjs/znac421
  709	Hawkins BM, Kennedy KF, Aronow HD, Nguyen LL, White CJ, Rosenfield K, et al.  Hospital variation in carotid stenting outcomes. JACC Cardiovasc Interv 2015;8:858–63. https://doi.org/10.1016/j.jcin.2015.01.026
  710	Paraskevas KI, Kalmykov EL, Naylor AR. Stroke/death rates following carotid artery stenting and carotid endarterectomy in contemporary administrative dataset registries: a systematic review. Eur J Vasc Endovasc Surg 2016;51:3–12. https://doi.org/10.1016/j.ejvs.2015.07.032
  711	Brott TG, Hobson RW, II, Howard G, Roubin GS, Clark WM, Brooks W, et al.  Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010;363:11–23. https://doi.org/10.1056/NEJMoa0912321
  712	Sacco RL, Diener HC, Yusuf S, Cotton D, Ôunpuu S, Lawton WA, et al.  Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008;359:1238–51. https://doi.org/10.1056/NEJMoa0805002
  713	Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol 2007;6:115–24. https://doi.org/10.1016/s1474-4422(06)70685-8
  
714	Markus HS, Droste DW, Kaps M, Larrue V, Lees KR, Siebler M, et al.  Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: the clopidogrel and aspirin for reduction of emboli in symptomatic carotid stenosis (CARESS) trial. Circulation 2005;111:2233–40. https://doi.org/10.1161/01.Cir.0000163561.90680.1c
  715	Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, et al.  Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med 2020;383:207–17. https://doi.org/10.1056/NEJMoa1916870
  716	Wang Y, Pan Y, Li H, Amarenco P, Denison H, Evans SR, et al.  Efficacy and safety of ticagrelor and aspirin in patients with moderate ischemic stroke: an exploratory analysis of the THALES randomized clinical trial. JAMA Neurol 2021;78:1091–8. https://doi.org/10.1001/jamaneurol.2021.2440
  717	Messas E, Goudot G, Halliday A, Sitruk J, Mirault T, Khider L, et al.  Management of carotid stenosis for primary and secondary prevention of stroke: state-of-the-art 2020: a critical review. Eur Heart J Suppl 2020;22:M35–42. https://doi.org/10.1093/eurheartj/suaa162
  718	Rothwell PM, Eliasziw M, Gutnikov SA, Fox AJ, Taylor DW, Mayberg MR, et al.  Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet 2003;361:107–16. https://doi.org/10.1016/s0140-6736(03)12228-3
  719	Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998;351:1379–87. https://doi.org/10.1016/S0140-6736(97)09292-1
CrossrefPubMedWorldCat 
720	Mayberg MR, Wilson SE, Yatsu F, Weiss DG, Messina L, Hershey LA, et al.  Carotid endarterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis. Veterans affairs cooperative studies program 309 trialist group. JAMA 1991;266:3289–94.
  721	Naylor AR, Sillesen H, Schroeder TV. Clinical and imaging features associated with an increased risk of early and late stroke in patients with symptomatic carotid disease. Eur J Vasc Endovasc Surg 2015;49:513–23. https://doi.org/10.1016/j.ejvs.2015.01.011
  722	Tsantilas P, Kuehnl A, König T, Breitkreuz T, Kallmayer M, Knappich C, et al.  Short time interval between neurologic event and carotid surgery is not associated with an increased procedural risk. Stroke 2016;47:2783–90. https://doi.org/10.1161/strokeaha.116.014058
  723	Loftus IM, Paraskevas KI, Johal A, Waton S, Heikkila K, Naylor AR, et al.  Editor’s choice—delays to surgery and procedural risks following carotid endarterectomy in the UK national vascular registry. Eur J Vasc Endovasc Surg 2016;52:438–43. https://doi.org/10.1016/j.ejvs.2016.05.031
  724	Strömberg S, Gelin J, Osterberg T, Bergström GML, Karlström L, Österberg K, et al.  Very urgent carotid endarterectomy confers increased procedural risk. Stroke 2012;43:1331–5. https://doi.org/10.1161/strokeaha.111.639344
  725	Bush CK, Kurimella D, Cross LJ, Conner KR, Martin-Schild D, He J, et al.  Endovascular treatment with stent-retriever devices for acute ischemic stroke: a meta-analysis of randomized controlled trials. PLoS One 2016;11:e0147287. https://doi.org/10.1371/journal.pone.0147287
  726	Savardekar AR, Narayan V, Patra DP, Spetzler RF, Sun H. Timing of carotid endarterectomy for symptomatic carotid stenosis: a snapshot of current trends and systematic review of literature on changing paradigm towards early surgery. Neurosurgery 2019;85:E214–25. https://doi.org/10.1093/neuros/nyy557
  727	Hill MD, Brooks W, Mackey A, Clark WM, Meschia JF, Morrish WF, et al.  Stroke after carotid stenting and endarterectomy in the carotid revascularization endarterectomy versus stenting trial (CREST). Circulation 2012;126:3054–61. https://doi.org/10.1161/circulationaha.112.120030
  728	Blackshear JL, Cutlip DE, Roubin GS, Hill MD, Leimgruber PP, Begg RJ, et al.  Myocardial infarction after carotid stenting and endarterectomy: results from the carotid revascularization endarterectomy versus stenting trial. Circulation 2011;123:2571–8. https://doi.org/10.1161/circulationaha.110.008250
  729	Howard G, Roubin GS, Jansen O, Hendrikse J, Halliday A, Fraedrich G, et al.  Association between age and risk of stroke or death from carotid endarterectomy and carotid stenting: a meta-analysis of pooled patient data from four randomised trials. Lancet 2016;387:1305–11. https://doi.org/10.1016/s0140-6736(15)01309-4
  730	Alamowitch S, Eliasziw M, Algra A, Meldrum H, Barnett HJ. Risk, causes, and prevention of ischaemic stroke in elderly patients with symptomatic internal-carotid-artery stenosis. Lancet 2001;357:1154–60. https://doi.org/10.1016/s0140-6736(00)04332-4
  731	Bonati LH, Lyrer P, Ederle J, Featherstone R, Brown MM. Percutaneous transluminal balloon angioplasty and stenting for carotid artery stenosis. Cochrane Database Syst Rev 2012;9:CD000515. https://doi.org/10.1002/14651858.CD000515.pub4
Google ScholarWorldCat 
732	Economopoulos KP, Sergentanis TN, Tsivgoulis G, Mariolis AD, Stefanadis C. Carotid artery stenting versus carotid endarterectomy: a comprehensive meta-analysis of short-term and long-term outcomes. Stroke 2011;42:687–92. https://doi.org/10.1161/strokeaha.110.606079
  733	Bonati LH, Dobson J, Featherstone RL, Ederle J, van der Worp HB, de Borst GJ, et al.  Long-term outcomes after stenting versus endarterectomy for treatment of symptomatic carotid stenosis: the International Carotid Stenting Study (ICSS) randomised trial. Lancet 2015;385:529–38. https://doi.org/10.1016/s0140-6736(14)61184-3
  734	Rothwell PM, Eliasziw M, Gutnikov SA, Warlow CP, Barnett HJ. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet 2004;363:915–24. https://doi.org/10.1016/s0140-6736(04)15785-1
  735	Rantner B, Kollerits B, Roubin GS, Ringleb PA, Jansen O, Howard G, et al.  Early endarterectomy carries a lower procedural risk than early stenting in patients with symptomatic stenosis of the internal carotid artery: results from 4 randomized controlled trials. Stroke 2017;48:1580–7. https://doi.org/10.1161/strokeaha.116.016233
  736	Schermerhorn ML, Fokkema M, Goodney P, Dillavou ED, Jim J, Kenwood CT, et al.  The impact of centers for medicare and medicaid services high-risk criteria on outcome after carotid endarterectomy and carotid artery stenting in the SVS vascular registry. J Vasc Surg 2013;57:1318–24. https://doi.org/10.1016/j.jvs.2012.10.107
  737	Schermerhorn ML, Liang P, Eldrup-Jorgensen J, Cronenwett JL, Nolan BW, Kashyap VS, et al.  Association of transcarotid artery revascularization vs transfemoral carotid artery stenting with stroke or death among patients with carotid artery stenosis. JAMA 2019;322:2313–22. https://doi.org/10.1001/jama.2019.18441
  738	Pineau S, Fajardo A, Saqib NU, Tanaka A, Motaganahalli RL, Keyhani A, et al.  Transcarotid revascularization timing and early postoperative outcomes in symptomatic patients. Vasc Endovascular Surg 2023;57:344–9. https://doi.org/10.1177/15385744221146678
  739	Kieffer E, Praquin B, Chiche L, Koskas F, Bahnini A. Distal vertebral artery reconstruction: long-term outcome. J Vasc Surg 2002;36:549–54. https://doi.org/10.1067/mva.2002.126092
  740	Berguer R, Flynn LM, Kline RA, Caplan L. Surgical reconstruction of the extracranial vertebral artery: management and outcome. J Vasc Surg 2000;31:9–18. https://doi.org/10.1016/s0741-5214(00)70063-2
  741	Markus HS, Harshfield EL, Compter A, Kuker W, Kappelle LJ, Clifton A, et al.  Stenting for symptomatic vertebral artery stenosis: a preplanned pooled individual patient data analysis. Lancet Neurol 2019;18:666–73. https://doi.org/10.1016/s1474-4422(19)30149-8
  742	Hanel RA, Brasiliense LB, Spetzler RF. Microsurgical revascularization of proximal vertebral artery: a single-center, single-operator analysis. Neurosurgery 2009;64:1043–51; discussion 1051. https://doi.org/10.1227/01.Neu.0000347099.17437.64
  743	Asiddao CB, Donegan JH, Whitesell RC, Kalbfleisch JH. Factors associated with perioperative complications during carotid endarterectomy. Anesth Analg 1982;61:631–7.
  744	Obeid T, Arhuidese I, Gaidry A, Qazi U, Abularrage C, Goodney P, et al.  Beta-blocker use is associated with lower stroke and death after carotid artery stenting. J Vasc Surg 2016;63:363–9. https://doi.org/10.1016/j.jvs.2015.08.108
  745	Abou-Chebl A, Reginelli J, Bajzer CT, Yadav JS. Intensive treatment of hypertension decreases the risk of hyperperfusion and intracerebral hemorrhage following carotid artery stenting. Catheter Cardiovasc Interv 2007;69:690–6. https://doi.org/10.1002/ccd.20693
  746	Lindblad B, Persson NH, Takolander R, Bergqvist D. Does low-dose acetylsalicylic acid prevent stroke after carotid surgery? A double-blind, placebo-controlled randomized trial. Stroke 1993;24:1125–8. https://doi.org/10.1161/01.str.24.8.1125
  747	Kretschmer G, Pratschner T, Prager M, Wenzi E, Polterauer P, Schemper M, et al.  Antiplatelet treatment prolongs survival after carotid bifurcation endarterectomy. Analysis of the clinical series followed by a controlled trial. Ann Surg 1990;211:317–22. https://doi.org/10.1097/00000658-199003000-00002
  748	Dalainas I, Nano G, Bianchi P, Stegher S, Malacrida G, Tealdi DG. Dual antiplatelet regime versus acetyl-acetic acid for carotid artery stenting. Cardiovasc Intervent Radiol 2006;29:519–21. https://doi.org/10.1007/s00270-005-5288-y
  749	AbuRahma AF, Avgerinos ED, Chang RW, Darling RC, Duncan AA, Forbes TL, et al.  The Society for Vascular Surgery implementation document for management of extracranial cerebrovascular disease. J Vasc Surg 2022;75:26s–98s. https://doi.org/10.1016/j.jvs.2021.04.074
  750	Naylor AR, Ricco JB, de Borst GJ, Debus S, de Haro J, Halliday A, et al.  Editor’s choice—management of atherosclerotic carotid and vertebral artery disease: 2017 clinical practice guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 2018;55:3–81. https://doi.org/10.1016/j.ejvs.2017.06.021
  751	Ghamraoui AK, Chang H, Maldonado TS, Ricotta JJ, II. Clopidogrel versus ticagrelor for antiplatelet therapy in transcarotid artery revascularization in the Society for Vascular Surgery vascular quality initiative. J Vasc Surg 2022;75:1652–60. https://doi.org/10.1016/j.jvs.2021.11.060
  752	Marcaccio CL, Patel PB, Liang P, Rastogi V, Stangenberg L, Jim J, et al.  Efficacy and safety of perioperative dual antiplatelet therapy with ticagrelor versus clopidogrel in carotid artery stenting. J Vasc Surg 2022;75:1293–303.e8. https://doi.org/10.1016/j.jvs.2021.09.045
  753	Ghamraoui AK, Ricotta JJ, II. Outcomes and strategy of tailored antiplatelet therapy with ticagrelor in patients undergoing transcarotid artery revascularization. J Vasc Surg 2021;73:132–41. https://doi.org/10.1016/j.jvs.2020.04.518
  754	Zierler RE, Jordan WD, Lal BK, Mussa F, Leers S, Fulton J, et al.  The Society for Vascular Surgery practice guidelines on follow-up after vascular surgery arterial procedures. J Vasc Surg 2018;68:256–84. https://doi.org/10.1016/j.jvs.2018.04.018
  755	Cheun TJ, Jayakumar L, Sheehan MK, Sideman MJK, Pounds LL, Davies MG. Outcomes of upper extremity interventions for chronic critical ischemia. J Vasc Surg 2019;69:120–8.e2. https://doi.org/10.1016/j.jvs.2018.04.056
  756	Awad El-Karim G, Kennedy SA, Ferraresi R, Addas JAK, Oreopoulos GD, Jaberi A, et al.  Percutaneous transluminal angioplasty for below-the-elbow critical hand ischemia: a systematic review. J Endovasc Ther 2022;29:468–77. https://doi.org/10.1177/15266028211050309
  757	Raimbeau A, Pistorius MA, Goueffic Y, Connault J, Plissonneau-Duquene P, Maurel B, et al.  Digital ischaemia aetiologies and mid-term follow-up: a cohort study of 323 patients. Medicine 2021;100:e25659. https://doi.org/10.1097/md.0000000000025659
  758	Clark CE, Taylor RS, Shore AC, Ukoumunne OC, Campbell JL. Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and meta-analysis. Lancet 2012;379:905–14. https://doi.org/10.1016/s0140-6736(11)61710-8
  759	Aboyans V, Kamineni A, Allison MA, McDermott MM, Crouse JR, Ni H, et al.  The epidemiology of subclavian stenosis and its association with markers of subclinical atherosclerosis: the multi-ethnic study of atherosclerosis (MESA). Atherosclerosis 2010;211:266–70. https://doi.org/10.1016/j.atherosclerosis.2010.01.013
  760	Labropoulos N, Nandivada P, Bekelis K. Prevalence and impact of the subclavian steal syndrome. Ann Surg 2010;252:166–70. https://doi.org/10.1097/SLA.0b013e3181e3375a
  761	Zhang J, Wang L, Chen Y, Wang S, Xing Y, Cui L. Color Doppler ultrasonography for the evaluation of subclavian artery stenosis. Front Neurol 2022;13:804039. https://doi.org/10.3389/fneur.2022.804039
  762	Harper C, Cardullo PA, Weyman AK, Patterson RB. Transcranial Doppler ultrasonography of the basilar artery in patients with retrograde vertebral artery flow. J Vasc Surg 2008;48:859–64. https://doi.org/10.1016/j.jvs.2008.05.057
  763	Chidambaram PK, Swaminathan RK, Ganesan P, Mayavan M. Segmental comparison of peripheral arteries by Doppler ultrasound and CT angiography. J Clin Diagn Res 2016;10:TC12–16. https://doi.org/10.7860/JCDR/2016/17191.7242
  
764	Tsao TF, Cheng KL, Shen CY, Wu M-C, Huang H-H, Su C-H, et al.  Diagnostic performance of combined contrast-enhanced magnetic resonance angiography and phase-contrast magnetic resonance imaging in suspected subclavian steal syndrome. Can Assoc Radiol J 2016;67:190–201. https://doi.org/10.1016/j.carj.2015.08.007
  765	Klitfod L, Jensen LP. Treatment of chronic upper limb ischaemia is safe and results are good. Dan Med J 2014;61:A4859.
  
766	Duran M, Grotemeyer D, Danch MA, Grabitz K, Schelzig H, Sagban TA. Subclavian carotid transposition: immediate and long-term outcomes of 126 surgical reconstructions. Ann Vasc Surg 2015;29:397–403. https://doi.org/10.1016/j.avsg.2014.09.030
  767	Daniel VT, Madenci AL, Nguyen LL, Eslami MH, Kalish JA, Farber A, et al.  Contemporary comparison of supra-aortic trunk surgical reconstructions for occlusive disease. J Vasc Surg 2014;59:1577–82, 1582.e1–2. https://doi.org/10.1016/j.jvs.2013.12.017
  768	Burihan E, Soma F, Iared W. Angioplasty versus stenting for subclavian artery stenosis. Cochrane Database Syst Rev 2011;10:CD008461. https://doi.org/10.1002/14651858.CD008461.pub2
Google ScholarWorldCat 
769	Hüttl K, Nemes B, Simonffy A, Entz L, Bérczi V. Angioplasty of the innominate artery in 89 patients: experience over 19 years. Cardiovasc Intervent Radiol 2002;25:109–14. https://doi.org/10.1007/s00270-001-0074-y
  
770	Modarai B, Ali T, Dourado R, Reidy JF, Taylor PR, Burnand KG. Comparison of extra-anatomic bypass grafting with angioplasty for atherosclerotic disease of the supra-aortic trunks. Br J Surg 2004;91:1453–7. https://doi.org/10.1002/bjs.4751
  771	Song L, Zhang J, Li J, Gu Y, Yu H, Chen B, et al.  Endovascular stenting vs. extrathoracic surgical bypass for symptomatic subclavian steal syndrome. J Endovasc Ther 2012;19:44–51. https://doi.org/10.1583/11-3692.1
  772	Owens LV, Tinsley EA, Jr, Criado E, Burnham SJ, Keagy BA. Extrathoracic reconstruction of arterial occlusive disease involving the supraaortic trunks. J Vasc Surg 1995;22:217–21; discussion 221–2. https://doi.org/10.1016/s0741-5214(95)70133-8
  773	Huijben M, Meershoek AJA, de Borst GJ, Toorop RJ. Long-term outcome of axillo-axillary bypass in patients with subclavian or innominate artery stenosis. Ann Vasc Surg 2021;73:321–8. https://doi.org/10.1016/j.avsg.2020.10.029
  774	Lee AD, Agarwal S, Sadhu D. A 7-year experience with thoracoscopic sympathectomy for critical upper limb ischemia. World J Surg 2006;30:1644–7. https://doi.org/10.1007/s00268-005-0559-y
  775	Schillinger M, Haumer M, Schillinger S, Mlekusch W, Ahmadi R, Minar E. Outcome of conservative versus interventional treatment of subclavian artery stenosis. J Endovasc Ther 2002;9:139–46. https://doi.org/10.1177/152660280200900201
  
776	Ahmed AT, Mohammed K, Chehab M, Brinjikji W, Hassan Murad M, Cloft H, et al.  Comparing percutaneous transluminal angioplasty and stent placement for treatment of subclavian arterial occlusive disease: a systematic review and meta-analysis. Cardiovasc Intervent Radiol 2016;39:652–67. https://doi.org/10.1007/s00270-015-1250-9
  777	Che W, Dong H, Jiang X, Peng M, Zou Y, Song L, et al.  Subclavian artery stenting for coronary-subclavian steal syndrome. Catheter Cardiovasc Interv 2017;89:601–8. https://doi.org/10.1002/ccd.26902
  778	Hamdan R, Guilleminot P, Leclercq T, Monin A. Coronary-subclavian steal syndrome causing myocardial infarction after arteriovenous fistula creation: a case report. ESC Heart Fail 2023;10:2084–9. https://doi.org/10.1002/ehf2.14341
  779	Che WQ, Dong H, Jiang XJ, Peng M, Zou Y, Qian H, et al.  Stenting for left subclavian artery stenosis in patients scheduled for left internal mammary artery-coronary artery bypass grafting. Catheter Cardiovasc Interv 2016;87:579–88. https://doi.org/10.1002/ccd.26477
  780	Muller AM, Bertram J, Bradaric C, Koppara T, Cassese S, Xhepa E, et al.  Frequency of subclavian artery stenosis in patients with mammarian artery coronary bypass and suspected coronary artery disease progression. Clin Res Cardiol 2023;112:1204–11. https://doi.org/10.1007/s00392-022-02113-z
  781	Angle JF, Matsumoto AH, McGraw JK, Spinosa DJ, Hagspiel KD, Leung DA, et al.  Percutaneous angioplasty and stenting of left subclavian artery stenosis in patients with left internal mammary-coronary bypass grafts: clinical experience and long-term follow-up. Vasc Endovascular Surg 2003;37:89–97. https://doi.org/10.1177/153857440303700202
  782	Safian RD, Textor SC. Renal-artery stenosis. N Engl J Med 2001;344:431–42. https://doi.org/10.1056/nejm200102083440607
  783	Hansen KJ, Edwards MS, Craven TE, Cherr GS, Jackson SA, Appel RG, et al.  Prevalence of renovascular disease in the elderly: a population-based study. J Vasc Surg 2002;36:443–51. https://doi.org/10.1067/mva.2002.127351
  784	Aboyans V, Desormais I, Magne J, Morange G, Mohty D, Lacroix P. Renal artery stenosis in patients with peripheral artery disease: prevalence, risk factors and long-term prognosis. Eur J Vasc Endovasc Surg 2017;53:380–5. https://doi.org/10.1016/j.ejvs.2016.10.029
  785	Safian RD. Renal artery stenosis. Prog Cardiovasc Dis 2021;65:60–70. https://doi.org/10.1016/j.pcad.2021.03.003
  786	Messerli FH, Bangalore S, Makani H, Rimoldi SF, Allemann Y, White CJ, et al.  Flash pulmonary oedema and bilateral renal artery stenosis: the pickering syndrome. Eur Heart J 2011;32:2231–5. https://doi.org/10.1093/eurheartj/ehr056
  787	Zeller T, Bonvini RF, Sixt S. Color-coded duplex ultrasound for diagnosis of renal artery stenosis and as follow-up examination after revascularization. Catheter Cardiovasc Interv 2008;71:995–9. https://doi.org/10.1002/ccd.21525
  788	Prince M, Tafur JD, White CJ. When and how should we revascularize patients with atherosclerotic renal artery stenosis? JACC Cardiovasc Interv 2019;12:505–17. https://doi.org/10.1016/j.jcin.2018.10.023
  789	AbuRahma AF, Yacoub M. Renal imaging: duplex ultrasound, computed tomography angiography, magnetic resonance angiography, and angiography. Semin Vasc Surg 2013;26:134–43. https://doi.org/10.1053/j.semvascsurg.2014.06.001
  790	Staub D, Canevascini R, Huegli RW, Aschwanden M, Thalhammer C, Imfeld S, et al.  Best duplex-sonographic criteria for the assessment of renal artery stenosis—correlation with intra-arterial pressure gradient. Ultraschall Med 2007;28:45–51. https://doi.org/10.1055/s-2007-962881
  791	Williams GJ, Macaskill P, Chan SF, Karplus TE, Yung W, Hodson EM, et al.  Comparative accuracy of renal duplex sonographic parameters in the diagnosis of renal artery stenosis: paired and unpaired analysis. AJR Am J Roentgenol 2007;188:798–811. https://doi.org/10.2214/ajr.06.0355
  792	Parikh SA, Shishehbor MH, Gray BH, White CJ, Jaff MR. SCAI expert consensus statement for renal artery stenting appropriate use. Catheter Cardiovasc Interv 2014;84:1163–71. https://doi.org/10.1002/ccd.25559
  793	Caps MT, Perissinotto C, Zierler RE, Polissar NL, Bergelin RO, Tullis MJ, et al.  Prospective study of atherosclerotic disease progression in the renal artery. Circulation 1998;98:2866–72. https://doi.org/10.1161/01.cir.98.25.2866
  794	Amighi J, Schlager O, Haumer M, Dick P, Mlekusch W, Loewe C, et al.  Renal artery stenosis predicts adverse cardiovascular and renal outcome in patients with peripheral artery disease. Eur J Clin Invest 2009;39:784–92. https://doi.org/10.1111/j.1365-2362.2009.02180.x
  795	Fatica RA, Port FK, Young EW. Incidence trends and mortality in end-stage renal disease attributed to renovascular disease in the United States. Am J Kidney Dis 2001;37:1184–90. https://doi.org/10.1053/ajkd.2001.24521
  796	Ritchie J, Green D, Alderson HV, Chrysochou C, Vassallo D, Sinha S, et al.  Associations of antiplatelet therapy and beta blockade with patient outcomes in atherosclerotic renovascular disease. J Am Soc Hypertens 2016;10:149–58.e3. https://doi.org/10.1016/j.jash.2015.12.002
  797	Raman G, Adam GP, Halladay CW, Langberg VN, Azodo IA, Balk EM. Comparative effectiveness of management strategies for renal artery stenosis: an updated systematic review. Ann Intern Med 2016;165:635–49. https://doi.org/10.7326/M16-1053
  798	Bhalla V, Textor SC, Beckman JA, Casanegra AI, Cooper CJ, Kim ESH, et al.  Revascularization for renovascular disease: a scientific statement from the American Heart Association. Hypertension 2022;79:e128–43. https://doi.org/10.1161/hyp.0000000000000217
  799	Piaggio D, Bracale U, Pecchia L, Di Taranto MD, Sodo M, Bracale UM. Endovascular treatment versus medical therapy for hypertensive patients with renal artery stenosis: an updated systematic review. Ann Vasc Surg 2019;61:445–54. https://doi.org/10.1016/j.avsg.2019.04.050
  800	Wheatley K, Ives N, Gray R, Kalra PA, Moss JG, Baigent C, et al.  Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 2009;361:1953–62. https://doi.org/10.1056/NEJMoa0905368
  
801	Bax L, Woittiez AJ, Kouwenberg HJ, Mali WP, Buskens E, Beek FJ, et al.  Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial. Ann Intern Med 2009;150:840–8, w150–1. https://doi.org/10.7326/0003-4819-150-12-200906160-00119
  802	Webster J, Marshall F, Abdalla M, Dominiczak A, Edwards R, Isles CG, et al.  Randomised comparison of percutaneous angioplasty vs continued medical therapy for hypertensive patients with atheromatous renal artery stenosis. Scottish and Newcastle Renal Artery Stenosis Collaborative Group. J Hum Hypertens 1998;12:329–35. https://doi.org/10.1038/sj.jhh.1000599
  803	van Jaarsveld BC, Krijnen P, Pieterman H, Derkx FHM, Deinum J, Postma CT, et al.  The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group. N Engl J Med 2000;342:1007–14. https://doi.org/10.1056/nejm200004063421403
  804	Plouin PF, Chatellier G, Darné B, Raynaud A. Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis: a randomized trial. Essai Multicentrique Medicaments vs Angioplastie (EMMA) Study Group. Hypertension 1998;31:823–9. https://doi.org/10.1161/01.hyp.31.3.823
  805	Abela R, Ivanova S, Lidder S, Morris R, Hamilton G. An analysis comparing open surgical and endovascular treatment of atherosclerotic renal artery stenosis. Eur J Vasc Endovasc Surg 2009;38:666–75. https://doi.org/10.1016/j.ejvs.2009.08.002
  806	Balzer KM, Pfeiffer T, Rossbach S, Voiculescu A, Mödder U, Godehardt E, et al.  Prospective randomized trial of operative vs interventional treatment for renal artery ostial occlusive disease (RAOOD). J Vasc Surg 2009;49:667–75; discussion 674–665. https://doi.org/10.1016/j.jvs.2008.10.006
  807	Mohler ER, III, Gornik HL, Gerhard-Herman M, Misra S, Olin JW, Zierler RE. ACCF/ACR/AIUM/ASE/ASN/ICAVL/SCAI/SCCT/SIR/SVM/SVS/SVU [corrected] 2012 appropriate use criteria for peripheral vascular ultrasound and physiological testing part I: arterial ultrasound and physiological testing: a report of the American College of Cardiology Foundation appropriate use criteria task force, American College of Radiology, American Institute of Ultrasound in Medicine, American Society of Echocardiography, American Society of Nephrology, Intersocietal Commission for the Accreditation of Vascular Laboratories, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Interventional Radiology, Society for Vascular Medicine, Society for Vascular Surgery, [corrected] and Society for Vascular Ultrasound. [corrected]. J Am Coll Cardiol 2012;60:242–76. https://doi.org/10.1016/j.jacc.2012.02.009
  808	Davies MG, Saad WA, Bismuth JX, Peden EK, Naoum JJ, Lumsden AB. Outcomes of endoluminal reintervention for restenosis after percutaneous renal angioplasty and stenting. J Vasc Surg 2009;49:946–52. https://doi.org/10.1016/j.jvs.2008.11.039
  809	Hicks CW, Clark TWI, Cooper CJ, de Bhailís ÁM, De Carlo M, Green D, et al.  Atherosclerotic renovascular disease: A KDIGO (kidney disease: improving global outcomes) controversies conference. Am J Kidney Dis 2022;79:289–301. https://doi.org/10.1053/j.ajkd.2021.06.025
  810	Johansen KL, Garimella PS, Hicks CW, Kalra PA, Kelly DM, Martens S, et al.  Central and peripheral arterial diseases in chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 2021;100:35–48. https://doi.org/10.1016/j.kint.2021.04.029
  811	Pappaccogli M, Robberechts T, Lengele JP, Van der Niepen P, Sarafidis P, Rabbia F, et al.  Endovascular versus medical management of atherosclerotic renovascular disease: update and emerging concepts. Hypertension 2023;80:1150–61. https://doi.org/10.1161/HYPERTENSIONAHA.122.17965
  812	Tian Y, Yuan B, Zhang N, Huang Z. Outcomes following the endovascular treatment of renal artery stenosis caused by fibromuscular dysplasia: a systematic review and meta-analysis. Ann Vasc Surg 2022;78:362–72. https://doi.org/10.1016/j.avsg.2021.06.042
  813	Persu A, Giavarini A, Touzé E, Januszewicz A, Sapoval M, Azizi M, et al.  European consensus on the diagnosis and management of fibromuscular dysplasia. J Hypertens 2014;32:1367–78. https://doi.org/10.1097/hjh.0000000000000213
  814	Zeller T, Krankenberg H, Erglis A, Blessing E, Fuss T, Scheinert D, et al.  A randomized, multi-center, prospective study comparing best medical treatment versus best medical treatment plus renal artery stenting in patients with hemodynamically relevant atherosclerotic renal artery stenosis (RADAR)—one-year results of a pre-maturely terminated study. Trials 2017;18:380. https://doi.org/10.1186/s13063-017-2126-x
  815	Tamme K, Reintam Blaser A, Laisaar KT, Mändul M, Kals J, Forbes A, et al.  Incidence and outcomes of acute mesenteric ischaemia: a systematic review and meta-analysis. BMJ Open 2022;12:e062846. https://doi.org/10.1136/bmjopen-2022-062846
  816	Acosta S. Epidemiology of mesenteric vascular disease: clinical implications. Semin Vasc Surg 2010;23:4–8. https://doi.org/10.1053/j.semvascsurg.2009.12.001
  817	Acosta S, Ogren M, Sternby NH, Bergqvist D, Björck M. Incidence of acute thrombo-embolic occlusion of the superior mesenteric artery—a population-based study. Eur J Vasc Endovasc Surg 2004;27:145–50. https://doi.org/10.1016/j.ejvs.2003.11.003
  818	Carver TW, Vora RS, Taneja A. Mesenteric ischemia. Crit Care Clin 2016;32:155–71. https://doi.org/10.1016/j.ccc.2015.11.001
  819	Klass AA. Embolectomy in acute mesenteric occlusion. Ann Surg 1951;134:913–7. https://doi.org/10.1097/00000658-195111000-00016
  820	Acosta S, Björck M. Acute thrombo-embolic occlusion of the superior mesenteric artery: a prospective study in a well defined population. Eur J Vasc Endovasc Surg 2003;26:179–83. https://doi.org/10.1053/ejvs.2002.1893
  821	Kärkkäinen JM, Acosta S. Acute mesenteric ischemia (part I)—incidence, etiologies, and how to improve early diagnosis. Best Pract Res Clin Gastroenterol 2017;31:15–25. https://doi.org/10.1016/j.bpg.2016.10.018
  822	Kärkkäinen JM. Acute mesenteric ischemia: a challenge for the acute care surgeon. Scand J Surg 2021;110:150–8. https://doi.org/10.1177/14574969211007590
  823	Powell A, Armstrong P. Plasma biomarkers for early diagnosis of acute intestinal ischemia. Semin Vasc Surg 2014;27:170–5. https://doi.org/10.1053/j.semvascsurg.2015.01.008
  824	Block T, Nilsson TK, Björck M, Acosta S. Diagnostic accuracy of plasma biomarkers for intestinal ischaemia. Scand J Clin Lab Invest 2008;68:242–8. https://doi.org/10.1080/00365510701646264
  825	Kougias P, Lau D, El Sayed HF, Zhou W, Huynh TT, Lin PH. Determinants of mortality and treatment outcome following surgical interventions for acute mesenteric ischemia. J Vasc Surg 2007;46:467–74. https://doi.org/10.1016/j.jvs.2007.04.045
  826	Lehtimäki TT, Kärkkäinen JM, Saari P, Manninen H, Paajanen H, Vanninen R. Detecting acute mesenteric ischemia in CT of the acute abdomen is dependent on clinical suspicion: review of 95 consecutive patients. Eur J Radiol 2015;84:2444–53. https://doi.org/10.1016/j.ejrad.2015.09.006
  827	Kirkpatrick ID, Kroeker MA, Greenberg HM. Biphasic CT with mesenteric CT angiography in the evaluation of acute mesenteric ischemia: initial experience. Radiology 2003;229:91–8. https://doi.org/10.1148/radiol.2291020991
  828	Oliva IB, Davarpanah AH, Rybicki FJ, Desjardins B, Flamm SD, Francois CJ, et al.  ACR appropriateness Criteria ® imaging of mesenteric ischemia. Abdom Imaging 2013;38:714–9. https://doi.org/10.1007/s00261-012-9975-2
  829	Salsano G, Salsano A, Sportelli E, Petrocelli F, Dahmane M, Spinella G, et al.  What is the best revascularization strategy for acute occlusive arterial mesenteric ischemia: systematic review and meta-analysis. Cardiovasc Intervent Radiol 2018;41:27–36. https://doi.org/10.1007/s00270-017-1749-3
  830	El Farargy M, Abdel Hadi A, Abou Eisha M, Bashaeb K, Antoniou GA. Systematic review and meta-analysis of endovascular treatment for acute mesenteric ischaemia. Vascular 2017;25:430–8. https://doi.org/10.1177/1708538116689353
  831	Kärkkäinen JM, Acosta S. Acute mesenteric ischemia (part II)—vascular and endovascular surgical approaches. Best Pract Res Clin Gastroenterol 2017;31:27–38. https://doi.org/10.1016/j.bpg.2016.11.003
  832	Wyers MC, Powell RJ, Nolan BW, Cronenwett JL. Retrograde mesenteric stenting during laparotomy for acute occlusive mesenteric ischemia. J Vasc Surg 2007;45:269–75. https://doi.org/10.1016/j.jvs.2006.10.047
  833	Tilsed JV, Casamassima A, Kurihara H, Mariani D, Martinez I, Pereira J, et al.  ESTES guidelines: acute mesenteric ischaemia. Eur J Trauma Emerg Surg 2016;42:253–70. https://doi.org/10.1007/s00068-016-0634-0
  834	Tallarita T, Oderich GS, Gloviczki P, Duncan AA, Kalra M, Cha S, et al.  Patient survival after open and endovascular mesenteric revascularization for chronic mesenteric ischemia. J Vasc Surg 2013;57:747–55; discussion 754–745. https://doi.org/10.1016/j.jvs.2012.09.047
  835	Alahdab F, Arwani R, Pasha AK, Razouki ZA, Prokop LJ, Huber TS, et al.  A systematic review and meta-analysis of endovascular versus open surgical revascularization for chronic mesenteric ischemia. J Vasc Surg 2018;67:1598–605. https://doi.org/10.1016/j.jvs.2017.12.046
  836	Mensink PB, Moons LM, Kuipers EJ. Chronic gastrointestinal ischaemia: shifting paradigms. Gut 2011;60:722–37. https://doi.org/10.1136/gut.2009.199695
  837	Roobottom CA, Dubbins PA. Significant disease of the celiac and superior mesenteric arteries in asymptomatic patients: predictive value of Doppler sonography. AJR Am J Roentgenol 1993;161:985–8. https://doi.org/10.2214/ajr.161.5.8273642
  838	Høyer C, Christensen MH, Sandermann J, Leusink R, Abrahamsen J. Chronic mesenteric ischaemia: the importance of the individual mesenteric artery. Clin Physiol Funct Imaging 2022;42:15–22. https://doi.org/10.1111/cpf.12730
  839	Mensink PB, van Petersen AS, Geelkerken RH, Otte JA, Huisman AB, Kolkman JJ, et al.  Clinical significance of splanchnic artery stenosis. Br J Surg 2006;93:1377–82. https://doi.org/10.1002/bjs.5481
  840	van Noord D, Mensink PB, de Knegt RJ, Ouwendijk M, Francke J, van Vuuren AJ, et al.  Serum markers and intestinal mucosal injury in chronic gastrointestinal ischemia. Dig Dis Sci 2011;56:506–12. https://doi.org/10.1007/s10620-010-1303-5
  841	Mensink PB, Hol L, Borghuis-Koertshuis N, Geelkerken RH, Huisman AB, Doelman CJA, et al.  Transient postprandial ischemia is associated with increased intestinal fatty acid binding protein in patients with chronic gastrointestinal ischemia. Eur J Gastroenterol Hepatol 2009;21:278–82. https://doi.org/10.1097/MEG.0b013e32832183a7
  842	van Noord D, Kolkman JJ. Functional testing in the diagnosis of chronic mesenteric ischemia. Best Pract Res Clin Gastroenterol 2017;31:59–68. https://doi.org/10.1016/j.bpg.2016.12.002
  843	van Petersen AS, Meerwaldt R, Kolkman JJ, Huisman AB, van der Palen J, van Bockel JH, et al.  The influence of respiration on criteria for transabdominal duplex examination of the splanchnic arteries in patients with suspected chronic splanchnic ischemia. J Vasc Surg 2013;57:1603–11, 1611.e1–10. https://doi.org/10.1016/j.jvs.2012.11.120
  844	Zwolak RM, Fillinger MF, Walsh DB, LaBombard FA, Musson A, Darling CE, et al.  Mesenteric and celiac duplex scanning: a validation study. J Vasc Surg 1998;27:1078–88; discussion 1088. https://doi.org/10.1016/s0741-5214(98)60010-0
  845	Schaefer PJ, Pfarr J, Trentmann J, Wulff A, Langer C, Siggelkow M, et al.  Comparison of noninvasive imaging modalities for stenosis grading in mesenteric arteries. Rofo 2013;185:628–34. https://doi.org/10.1055/s-0033-1335212
  
846	Cademartiri F, Palumbo A, Maffei E, Martini C, Malagò R, Belgrano M, et al.  Noninvasive evaluation of the celiac trunk and superior mesenteric artery with multislice CT in patients with chronic mesenteric ischaemia. Radiol Med 2008;113:1135–42. https://doi.org/10.1007/s11547-008-0330-1
  847	Pecoraro F, Rancic Z, Lachat M, Mayer D, Amann-Vesti B, Pfammatter T, et al.  Chronic mesenteric ischemia: critical review and guidelines for management. Ann Vasc Surg 2013;27:113–22. https://doi.org/10.1016/j.avsg.2012.05.012
  848	Gupta PK, Horan SM, Turaga KK, Miller WJ, Pipinos II. Chronic mesenteric ischemia: endovascular versus open revascularization. J Endovasc Ther 2010;17:540–9. https://doi.org/10.1583/09-2935.1
  849	Huber TS, Björck M, Chandra A, Clouse WD, Dalsing MC, Oderich GS, et al.  Chronic mesenteric ischemia: clinical practice guidelines from the society for vascular surgery. J Vasc Surg 2021;73:87s–115s. https://doi.org/10.1016/j.jvs.2020.10.029
  850	Fernández-Friera L, Fuster V, López-Melgar B, Oliva B, Sánchez-González J, Macías A, et al.  Vascular inflammation in subclinical atherosclerosis detected by hybrid PET/MRI. J Am Coll Cardiol 2019;73:1371–82. https://doi.org/10.1016/j.jacc.2018.12.075
  851	Meissner I, Whisnant JP, Khandheria BK, Spittell PC, O'Fallon WM, Pascoe RD, et al.  Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: the SPARC study. Stroke prevention: assessment of risk in a community. Mayo Clin Proc 1999;74:862–9. https://doi.org/10.4065/74.9.862
  852	Russo C, Jin Z, Rundek T, Homma S, Sacco RL, Di Tullio MR. Atherosclerotic disease of the proximal aorta and the risk of vascular events in a population-based cohort: the Aortic Plaques and Risk of Ischemic Stroke (APRIS) study. Stroke 2009;40:2313–8. https://doi.org/10.1161/strokeaha.109.548313
  853	Oyama N, Gona P, Salton CJ, Chuang ML, Jhaveri RR, Blease SJ, et al.  Differential impact of age, sex, and hypertension on aortic atherosclerosis: the Framingham heart study. Arterioscler Thromb Vasc Biol 2008;28:155–9. https://doi.org/10.1161/atvbaha.107.153544
  854	Montgomery DH, Ververis JJ, McGorisk G, Frohwein S, Martin RP, Taylor WR. Natural history of severe atheromatous disease of the thoracic aorta: a transesophageal echocardiographic study. J Am Coll Cardiol 1996;27:95–101. https://doi.org/10.1016/0735-1097(95)00431-9
  855	Amarenco P, Cohen A, Hommel M, Moulin T, Leys D, Bousser M-G. Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. N Engl J Med 1996;334:1216–21. https://doi.org/10.1056/nejm199605093341902
  
856	Fujimoto S, Yasaka M, Otsubo R, Oe H, Nagatsuka K, Minematsu K. Aortic arch atherosclerotic lesions and the recurrence of ischemic stroke. Stroke 2004;35:1426–9. https://doi.org/10.1161/01.STR.0000127788.32550.d4
  857	Koren MJ, Bryant B, Hilton TC. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med 1995;332:1237–8. author reply 1237-1238. https://doi.org/10.1056/NEJM199505043321815
  
858	Meissner I, Khandheria BK, Sheps SG, Schwartz GL, Wiebers DO, Whisnant JP, et al.  Atherosclerosis of the aorta: risk factor, risk marker, or innocent bystander? A prospective population-based transesophageal echocardiography study. J Am Coll Cardiol 2004;44:1018–24. https://doi.org/10.1016/j.jacc.2004.05.075
  859	Mitusch R, Doherty C, Wucherpfennig H, Memmesheimer C, Tepe C, Stierle U, et al.  Vascular events during follow-up in patients with aortic arch atherosclerosis. Stroke 1997;28:36–9. https://doi.org/10.1161/01.str.28.1.36
  860	Tunick PA, Rosenzweig BP, Katz ES, Freedberg RS, Perez JL, Kronzon I. High risk for vascular events in patients with protruding aortic atheromas: a prospective study. J Am Coll Cardiol 1994;23:1085–90. https://doi.org/10.1016/0735-1097(94)90595-9
  861	Di Tullio MR, Russo C, Jin Z, Sacco RL, Mohr JP, Homma S. Aortic arch plaques and risk of recurrent stroke and death. Circulation 2009;119:2376–82. https://doi.org/10.1161/circulationaha.108.811935
  862	Tunick PA, Nayar AC, Goodkin GM, Mirchandani S, Francescone S, Rosenzweig BP, et al.  Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque. Am J Cardiol 2002;90:1320–5. https://doi.org/10.1016/s0002-9149(02)02870-9
  863	Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al.  Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331–7. https://doi.org/10.1016/s0140-6736(04)16721-4
  864	Bowdish ME, Weaver FA, Liebman HA, Rowe VL, Hood DB. Anticoagulation is an effective treatment for aortic mural thrombi. J Vasc Surg 2002;36:713–9.
  865	Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, et al.  2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke 2021;52:e364–467. https://doi.org/10.1161/str.0000000000000375
  866	Amarenco P, Davis S, Jones EF, Cohen AA, Heiss W-D, Kaste M, et al.  Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. Stroke 2014;45:1248–57. https://doi.org/10.1161/strokeaha.113.004251
  867	Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, Pearce LA. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012;367:817–25. https://doi.org/10.1056/NEJMoa1204133
  
868	Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, Béjot Y, et al.  A comparison of two LDL cholesterol targets after ischemic stroke. N Engl J Med 2020;382:9. https://doi.org/10.1056/NEJMoa1910355
  869	Devereux RB, de Simone G, Arnett DK, Best LG, Boerwinkle E, Howard BV, et al.  Normal limits in relation to age, body size and gender of two-dimensional echocardiographic aortic root dimensions in persons ≥15 years of age. Am J Cardiol 2012;110:1189–94. https://doi.org/10.1016/j.amjcard.2012.05.063
  870	van Kimmenade RR, Kempers M, de Boer MJ, Loeys BL, Timmermans J. A clinical appraisal of different Z-score equations for aortic root assessment in the diagnostic evaluation of Marfan syndrome. Genet Med 2013;15:528–32. https://doi.org/10.1038/gim.2012.172
  871	Davies RR, Gallo A, Coady MA, Tellides G, Botta DM, Burke B, et al.  Novel measurement of relative aortic size predicts rupture of thoracic aortic aneurysms. Ann Thorac Surg 2006;81:169–77. https://doi.org/10.1016/j.athoracsur.2005.06.026
  872	Hannawa KK, Eliason JL, Upchurch GR, Jr. Gender differences in abdominal aortic aneurysms. Vascular 2009;17:30–9. https://doi.org/10.2310/6670.2008.00092
Google ScholarCrossrefWorldCat 
873	Boczar KE, Cheung K, Boodhwani M, Beauchesne L, Dennie C, Nagpal S, et al.  Sex differences in thoracic aortic aneurysm growth. Hypertension 2019;73:190–6. https://doi.org/10.1161/hypertensionaha.118.11851
  874	Hultgren R, Larsson E, Wahlgren CM, Swedenborg J. Female and elderly abdominal aortic aneurysm patients more commonly have concurrent thoracic aortic aneurysm. Ann Vasc Surg 2012;26:918–23. https://doi.org/10.1016/j.avsg.2012.01.023
  875	Chaer RA, Vasoncelos R, Marone LK, Al-Khoury G, Rhee RY, Cho JS, et al.  Synchronous and metachronous thoracic aneurysms in patients with abdominal aortic aneurysms. J Vasc Surg 2012;56:1261–5. https://doi.org/10.1016/j.jvs.2012.04.056
  876	Olsen PS, Schroeder T, Agerskov K, Agerskov K, Røder O, Sørensen S, et al.  Surgery for abdominal aortic aneurysms. A survey of 656 patients. J Cardiovasc Surg 1991;32:636–42.
Google ScholarWorldCat 
877	Tuveson V, Löfdahl HE, Hultgren R. Patients with abdominal aortic aneurysm have a high prevalence of popliteal artery aneurysms. Vasc Med 2016;21:369–75. https://doi.org/10.1177/1358863x16648404
  878	Brunkwall J, Hauksson H, Bengtsson H, Bergqvist D, Takolander R, Bergentz S-E. Solitary aneurysms of the iliac arterial system: an estimate of their frequency of occurrence. J Vasc Surg 1989;10:381–4. https://doi.org/10.1067/mva.1989.13733
  879	Bickerstaff LK, Pairolero PC, Hollier LH, Melton LJ, Van Peenen HJ, Cherry KJ, et al.  Thoracic aortic aneurysms: a population-based study. Surgery 1982;92:1103–8.
  
880	Coady MA, Rizzo JA, Goldstein LJ, Elefteriades JA. Natural history, pathogenesis, and etiology of thoracic aortic aneurysms and dissections. Cardiol Clin 1999;17:615–35; vii. https://doi.org/10.1016/s0733-8651(05)70105-3
  881	Diwan A, Sarkar R, Stanley JC, Zelenock GB, Wakefield TW. Incidence of femoral and popliteal artery aneurysms in patients with abdominal aortic aneurysms. J Vasc Surg 2000;31:863–9. https://doi.org/10.1067/mva.2000.105955
  882	Brown LC, Thompson SG, Greenhalgh RM, Powell JT. Incidence of cardiovascular events and death after open or endovascular repair of abdominal aortic aneurysm in the randomized EVAR trial 1. Br J Surg 2011;98:935–42. https://doi.org/10.1002/bjs.7485
  883	Hammo S, Grannas D, Wahlgren CM. High risk of early and late cardiovascular events after endovascular aortic aneurysm repair. Ann Vasc Surg 2022;86:320–7. https://doi.org/10.1016/j.avsg.2022.04.028
  884	Kuzmik GA, Sang AX, Elefteriades JA. Natural history of thoracic aortic aneurysms. J Vasc Surg 2012;56:565–71. https://doi.org/10.1016/j.jvs.2012.04.053
  885	Olsson C, Thelin S, Ståhle E, Ekbom A, Granath F. Thoracic aortic aneurysm and dissection: increasing prevalence and improved outcomes reported in a nationwide population-based study of more than 14,000 cases from 1987 to 2002. Circulation 2006;114:2611–8. https://doi.org/10.1161/circulationaha.106.630400
  886	Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE, et al.  2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation 2010;121:e266–369. https://doi.org/10.1161/CIR.0b013e3181d4739e
  887	Goldfinger JZ, Halperin JL, Marin ML, Stewart AS, Eagle KA, Fuster V. Thoracic aortic aneurysm and dissection. J Am Coll Cardiol 2014;64:1725–39. https://doi.org/10.1016/j.jacc.2014.08.025
  888	Caruana M, Baars MJ, Bashiardes E, Benke K, Björck E, Codreanu A, et al.  HTAD patient pathway: strategy for diagnostic work-up of patients and families with (suspected) heritable thoracic aortic diseases (HTAD). A statement from the HTAD working group of VASCERN. Eur J Med Genet 2023;66:104673. https://doi.org/10.1016/j.ejmg.2022.104673
  889	Patel HJ, Deeb GM. Ascending and arch aorta: pathology, natural history, and treatment. Circulation 2008;118:188–95. https://doi.org/10.1161/circulationaha.107.690933
  890	Boodhwani M, de Kerchove L, Glineur D, Poncelet A, Rubay J, Astarci P, et al.  Repair-oriented classification of aortic insufficiency: impact on surgical techniques and clinical outcomes. J Thorac Cardiovasc Surg 2009;137:286–94. https://doi.org/10.1016/j.jtcvs.2008.08.054
  891	Ganapathi AM, Ranney DN, Peterson MD, Lindsay ME, Patel HJ, Pyeritz RE, et al.  Location of aortic enlargement and risk of type A dissection at smaller diameters. J Am Coll Cardiol 2022;79:1890–7. https://doi.org/10.1016/j.jacc.2022.02.053
  892	Kalogerakos PD, Zafar MA, Li Y, Mukherjee SK, Ziganshin BA, Rizzo JA, et al.  Root dilatation is more malignant than ascending aortic dilation. J Am Heart Assoc 2021;10:e020645. https://doi.org/10.1161/jaha.120.020645
  893	Della Corte A, Bancone C, Buonocore M, Dialetto G, Covino FE, Manduca S, et al.  Pattern of ascending aortic dimensions predicts the growth rate of the aorta in patients with bicuspid aortic valve. JACC Cardiovasc Imaging 2013;6:1301–10. https://doi.org/10.1016/j.jcmg.2013.07.009
  894	Kim JB, Spotnitz M, Lindsay ME, MacGillivray TE, Isselbacher EM, Sundt TM. Risk of aortic dissection in the moderately dilated ascending aorta. J Am Coll Cardiol 2016;68:1209–19. https://doi.org/10.1016/j.jacc.2016.06.025
  895	Saeyeldin A, Zafar MA, Velasquez CA, Ip K, Gryaznov A, Brownstein AJ, et al.  Natural history of aortic root aneurysms in Marfan syndrome. Ann Cardiothorac Surg 2017;6:625–32. https://doi.org/10.21037/acs.2017.11.10
  896	Cheung K, Boodhwani M, Chan KL, Beauchesne L, Dick A, Coutinho T. Thoracic aortic aneurysm growth: role of sex and aneurysm etiology. J Am Heart Assoc 2017;6:e003792. https://doi.org/10.1161/jaha.116.003792
  897	Nataf P, Lansac E. Dilation of the thoracic aorta: medical and surgical management. Heart 2006;92:1345–52. https://doi.org/10.1136/hrt.2005.074781
  898	Yiu RS, Cheng SW. Natural history and risk factors for rupture of thoracic aortic arch aneurysms. J Vasc Surg 2016;63:1189–94. https://doi.org/10.1016/j.jvs.2015.12.043
  899	Coady MA, Rizzo JA, Hammond GL, Mandapati D, Darr U, Kopf GS, et al.  What is the appropriate size criterion for resection of thoracic aortic aneurysms? J Thorac Cardiovasc Surg 1997;113:476–91; discussion 489–491. https://doi.org/10.1016/s0022-5223(97)70360-x
  900	Safi HJ, Winnerkvist A, Miller CC, III, Iliopoulos DC, Reardon MJ, Espada R, et al.  Effect of extended cross-clamp time during thoracoabdominal aortic aneurysm repair. Ann Thorac Surg 1998;66:1204–8. https://doi.org/10.1016/s0003-4975(98)00781-4
  901	Isselbacher EM. Thoracic and abdominal aortic aneurysms. Circulation 2005;111:816–28. https://doi.org/10.1161/01.Cir.0000154569.08857.7a
  902	Zafar MA, Chen JF, Wu J, Li Y, Papanikolaou D, Abdelbaky M, et al.  Natural history of descending thoracic and thoracoabdominal aortic aneurysms. J Thorac Cardiovasc Surg 2021;161:498–511.e1. https://doi.org/10.1016/j.jtcvs.2019.10.125
  903	Oladokun D, Patterson BO, Sobocinski J, Karthikesalingam A, Loftus I, Thompson MM, et al.  Systematic review of the growth rates and influencing factors in thoracic aortic aneurysms. Eur J Vasc Endovasc Surg 2016;51:674–81. https://doi.org/10.1016/j.ejvs.2016.01.017
  904	Davies RR, Goldstein LJ, Coady MA, Tittle SL, Rizzo JA, Kopf GS, et al.  Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann Thorac Surg 2002;73:17–28; discussion 27–18. https://doi.org/10.1016/s0003-4975(01)03236-2
  905	Verloes A, Sakalihasan N, Koulischer L, Limet R. Aneurysms of the abdominal aorta: familial and genetic aspects in three hundred thirteen pedigrees. J Vasc Surg 1995;21:646–55. https://doi.org/10.1016/s0741-5214(95)70196-6
  906	Thompson SG, Brown LC, Sweeting MJ, Bown MJ, Kim LG, Glover MJ, et al.  Systematic review and meta-analysis of the growth and rupture rates of small abdominal aortic aneurysms: implications for surveillance intervals and their cost-effectiveness. Health Technol Assess 2013;17:1–118. https://doi.org/10.3310/hta17410
  907	Sakalihasan N, Defraigne JO, Kerstenne MA, Cheramy-Bien J-P, Smelser DT, Tromp G, et al.  Family members of patients with abdominal aortic aneurysms are at increased risk for aneurysms: analysis of 618 probands and their families from the Liege AAA family study. Ann Vasc Surg 2014;28:787–97. https://doi.org/10.1016/j.avsg.2013.11.005
  908	Brown LC, Powell JT. Risk factors for aneurysm rupture in patients kept under ultrasound surveillance. UK small aneurysm trial participants. Ann Surg 1999;230:289–96; discussion 296–287. https://doi.org/10.1097/00000658-199909000-00002
  909	Mani K, Wanhainen A. Accurate and reproducible diameter measurement is essential in surveillance and treatment of thoracic aortic aneurysms. Eur J Vasc Endovasc Surg 2014;47:27. https://doi.org/10.1016/j.ejvs.2013.10.004
  910	Isselbacher EM, Preventza O, Hamilton Black J, III, Augoustides JG, Beck AW, Bolen MA, et al.  2022 ACC/AHA guideline for the diagnosis and management of aortic disease: a report of the American Heart Association/American College of Cardiology joint committee on clinical practice guidelines. Circulation 2022;146:e334–482. https://doi.org/10.1161/cir.0000000000001106
  911	Booher AM, Eagle KA. Diagnosis and management issues in thoracic aortic aneurysm. Am Heart J 2011;162:38–46.e1. https://doi.org/10.1016/j.ahj.2011.04.010
  912	Wang TKM, Desai MY. Thoracic aortic aneurysm: optimal surveillance and treatment. Cleve Clin J Med 2020;87:557–68. https://doi.org/10.3949/ccjm.87a.19140-1
  913	Roberts DA. Magnetic resonance imaging of thoracic aortic aneurysm and dissection. Semin Roentgenol 2001;36:295–308. https://doi.org/10.1053/sroe.2001.26938
  914	Rajiah P. CT and MRI in the evaluation of thoracic aortic diseases. Int J Vasc Med 2013;2013:797189. https://doi.org/10.1155/2013/797189
  
915	Lin FY, Devereux RB, Roman MJ, Meng J, Jow VM, Jacobs A, et al.  Assessment of the thoracic aorta by multidetector computed tomography: age- and sex-specific reference values in adults without evident cardiovascular disease. J Cardiovasc Comput Tomogr 2008;2:298–308. https://doi.org/10.1016/j.jcct.2008.08.002
  916	McPhee JT, Hill JS, Eslami MH. The impact of gender on presentation, therapy, and mortality of abdominal aortic aneurysm in the United States, 2001–2004. J Vasc Surg 2007;45:891–9. https://doi.org/10.1016/j.jvs.2007.01.043
  917	Forsdahl SH, Singh K, Solberg S, Jacobsen BK. Risk factors for abdominal aortic aneurysms: a 7-year prospective study: the Tromsø study, 1994–2001. Circulation 2009;119:2202–8. https://doi.org/10.1161/circulationaha.108.817619
  918	Jahangir E, Lipworth L, Edwards TL, Kabagambe EK, Mumma MT, Mensah GA, et al.  Smoking, sex, risk factors and abdominal aortic aneurysms: a prospective study of 18 782 persons aged above 65 years in the southern community cohort study. J Epidemiol Community Health 2015;69:481–8. https://doi.org/10.1136/jech-2014-204920
  919	Strachan DP. Predictors of death from aortic aneurysm among middle-aged men: the Whitehall study. Br J Surg 2005;78:401–4. https://doi.org/10.1002/bjs.1800780407
Google ScholarCrossrefWorldCat 
920	Wanhainen A, Bergqvist D, Boman K, Nilsson TK, Rutegård J, Björck M. Risk factors associated with abdominal aortic aneurysm: a population-based study with historical and current data. J Vasc Surg 2005;41:390–6. https://doi.org/10.1016/j.jvs.2005.01.002
  921	Kent KC, Zwolak RM, Egorova NN, Riles TS, Manganaro A, Moskowitz AJ, et al.  Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals. J Vasc Surg 2010;52:539–48. https://doi.org/10.1016/j.jvs.2010.05.090
  922	Raffort J, Lareyre F, Clément M, Hassen-Khodja R, Chinetti G, Mallat Z. Diabetes and aortic aneurysm: current state of the art. Cardiovasc Res 2018;114:1702–13. https://doi.org/10.1093/cvr/cvy174
  923	Avdic T, Franzén S, Zarrouk M, Acosta S, Nilsson P, Gottsäter A, et al.  Reduced long-term risk of aortic aneurysm and aortic dissection among individuals with type 2 diabetes mellitus: a nationwide observational study. J Am Heart Assoc 2018;7:e007618. https://doi.org/10.1161/jaha.117.007618
  924	Nordness MJ, Baxter BT, Matsumura J, Terrin M, Zhang K, Ye F, et al.  The effect of diabetes on abdominal aortic aneurysm growth over 2 years. J Vasc Surg 2022;75:1211–22.e1. https://doi.org/10.1016/j.jvs.2021.10.019
  925	Yusuf K, Murat B, Unal A, Ulku K, Taylan K, Ozerdem O, et al.  Inflammatory abdominal aortic aneurysm: predictors of long-term outcome in a case-control study. Surgery 2007;141:83–9. https://doi.org/10.1016/j.surg.2006.04.007
  926	Oliver-Williams C, Sweeting MJ, Turton G, Parkin D, Cooper D, Rodd C, et al.  Lessons learned about prevalence and growth rates of abdominal aortic aneurysms from a 25-year ultrasound population screening programme. Br J Surg 2018;105:68–74. https://doi.org/10.1002/bjs.10715
  927	Golledge J, Tsao PS, Dalman RL, Norman PE. Circulating markers of abdominal aortic aneurysm presence and progression. Circulation 2008;118:2382–92. https://doi.org/10.1161/circulationaha.108.802074
  928	Vermeulen JJM, Meijer M, de Vries FBG, Reijnen MMPJ, Holewijn S, Thijssen DHJ, et al.  A systematic review summarizing local vascular characteristics of aneurysm wall to predict for progression and rupture risk of abdominal aortic aneurysms. J Vasc Surg 2023;77:288–98.e2. https://doi.org/10.1016/j.jvs.2022.07.008
  929	Brady AR, Thompson SG, Fowkes FG, Greenhalgh RM, Powell JT. Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation 2004;110:16–21. https://doi.org/10.1161/01.Cir.0000133279.07468.9f
  930	Malayala SV, Raza A, Vanaparthy R. Gender-based differences in abdominal aortic aneurysm rupture: a retrospective study. J Clin Med Res 2020;12:794–802. https://doi.org/10.14740/jocmr4376
  931	Skibba AA, Evans JR, Hopkins SP, Yoon HR, Katras T, Kalbfleisch JH, et al.  Reconsidering gender relative to risk of rupture in the contemporary management of abdominal aortic aneurysms. J Vasc Surg 2015;62:1429–36. https://doi.org/10.1016/j.jvs.2015.07.079
  932	Catalano O, Siani A. Ruptured abdominal aortic aneurysm: categorization of sonographic findings and report of 3 new signs. J Ultrasound Med 2005;24:1077–83. https://doi.org/10.7863/jum.2005.24.8.1077
  933	Schermerhorn ML, Bensley RP, Giles KA, Hurks R, O'Malley AJ, Cotterill P, et al.  Changes in abdominal aortic aneurysm rupture and short-term mortality, 1995-2008: a retrospective observational study. Ann Surg 2012;256:651–8. https://doi.org/10.1097/SLA.0b013e31826b4f91
  934	Rakita D, Newatia A, Hines JJ, Siegel DN, Friedman B. Spectrum of CT findings in rupture and impending rupture of abdominal aortic aneurysms. Radiographics 2007;27:497–507. https://doi.org/10.1148/rg.272065026
  935	Schwartz SA, Taljanovic MS, Smyth S, O'Brien MJ, Rogers LF. CT findings of rupture, impending rupture, and contained rupture of abdominal aortic aneurysms. AJR Am J Roentgenol 2007;188:W57–62. https://doi.org/10.2214/ajr.05.1554
  936	Tomee SM, Bulder RMA, Meijer CA, van Berkum I, Hinnen J-W, Schoones JW, et al.  Excess mortality for abdominal aortic aneurysms and the potential of strict implementation of cardiovascular risk management: a multifaceted study integrating meta-analysis, national registry, and PHAST and TEDY trial data. Eur J Vasc Endovasc Surg 2023;65:348–57. https://doi.org/10.1016/j.ejvs.2022.11.019
  937	Freiberg MS, Arnold AM, Newman AB, Edwards MS, Kraemer KL, Kuller LH. Abdominal aortic aneurysms, increasing infrarenal aortic diameter, and risk of total mortality and incident cardiovascular disease events: 10-year follow-up data from the cardiovascular health study. Circulation 2008;117:1010–7. https://doi.org/10.1161/circulationaha.107.720219
  938	Bown MJ, Sweeting MJ, Brown LC, Powell JT, Thompson SG. Surveillance intervals for small abdominal aortic aneurysms: a meta-analysis. JAMA 2013;309:806–13. https://doi.org/10.1001/jama.2013.950
  
939	Dugas A, Therasse E, Kauffmann C, Tang A, Elkouri S, Nozza A, et al.  Reproducibility of abdominal aortic aneurysm diameter measurement and growth evaluation on axial and multiplanar computed tomography reformations. Cardiovasc Intervent Radiol 2012;35:779–87. https://doi.org/10.1007/s00270-011-0259-y
  940	Kontopodis N, Metaxa E, Gionis M, Papaharilaou Y, Ioannou CV. Discrepancies in determination of abdominal aortic aneurysms maximum diameter and growth rate, using axial and orhtogonal computed tomography measurements. Eur J Radiol 2013;82:1398–403. https://doi.org/10.1016/j.ejrad.2013.04.031
  941	Foo FJ, Hammond CJ, Goldstone AR, Abuhamdiah M, Rashid ST, West RM, et al.  Agreement between computed tomography and ultrasound on abdominal aortic aneurysms and implications on clinical decisions. Eur J Vasc Endovasc Surg 2011;42:608–14. https://doi.org/10.1016/j.ejvs.2011.07.003
  942	Zhu C, Tian B, Leach JR, Liu Q, Lu J, Chen L, et al.  Non-contrast 3D black blood MRI for abdominal aortic aneurysm surveillance: comparison with CT angiography. Eur Radiol 2017;27:1787–94. https://doi.org/10.1007/s00330-016-4559-0
  943	Sakalihasan N, Michel JB, Katsargyris A, Kuivaniemi H, Defraigne J-O, Nchimi A, et al.  Abdominal aortic aneurysms. Nat Rev Dis Primers 2018;4:34. https://doi.org/10.1038/s41572-018-0030-7
  944	Wemmelund H, Jørgensen TM, Høgh A, Behr-Rasmussen C, Johnsen SP, Lindholt JS, et al.  Low-dose aspirin and rupture of abdominal aortic aneurysm. J Vasc Surg 2017;65:616–5.e4. https://doi.org/10.1016/j.jvs.2016.04.061
  945	Wanhainen A, Mani K, Kullberg J, Svensjö S, Bersztel A, Karlsson L, et al.  The effect of ticagrelor on growth of small abdominal aortic aneurysms–a randomized controlled trial. Cardiovasc Res 2020;116:450–6. https://doi.org/10.1093/cvr/cvz133
  
946	Golledge J, Thanigaimani S, Powell JT, Tsao PS. Pathogenesis and management of abdominal aortic aneurysm. Eur Heart J 2023;44:2682–97. https://doi.org/10.1093/eurheartj/ehad386
  947	Sweeting MJ, Thompson SG, Brown LC, Powell JT, Collaborators R. Meta-analysis of individual patient data to examine factors affecting growth and rupture of small abdominal aortic aneurysms. Br J Surg 2012;99:655–65. https://doi.org/10.1002/bjs.8707
  948	Golledge J, Moxon J, Pinchbeck J, Anderson G, Rowbotham S, Jenkins J, et al.  Association between metformin prescription and growth rates of abdominal aortic aneurysms. Br J Surg 2017;104:1486–93. https://doi.org/10.1002/bjs.10587
  949	Thanigaimani S, Singh TP, Unosson J, Phie J, Moxon J, Wanhainen A, et al.  Editor’s choice—association between metformin prescription and abdominal aortic aneurysm growth and clinical events: a systematic review and meta-analysis. Eur J Vasc Endovasc Surg 2021;62:747–56. https://doi.org/10.1016/j.ejvs.2021.06.013
  950	Wong KHF, Zlatanovic P, Bosanquet DC, Saratzis A, Kakkos SK, Aboyans V, et al.  Antithrombotic therapy for aortic aneurysms: a systematic review and meta-analysis. Eur J Vasc Endovasc Surg 2022;64:544–56. https://doi.org/10.1016/j.ejvs.2022.07.008
  951	Newton ER, Akerman AW, Strassle PD, Kibbe MR. Association of fluoroquinolone use with short-term risk of development of aortic aneurysm. JAMA Surg 2021;156:264–72. https://doi.org/10.1001/jamasurg.2020.6165
  952	Wee I, Chin B, Syn N, Lee KS, Ng JJ, Choong AMTL. The association between fluoroquinolones and aortic dissection and aortic aneurysms: a systematic review and meta-analysis. Sci Rep 2021;11:11073. https://doi.org/10.1038/s41598-021-90692-8
  953	Pasternak B, Inghammar M, Svanström H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ 2018;360:k678. https://doi.org/10.1136/bmj.k678
  
954	Garg M, Venugopalan V, Vouri SM, Diaby V, Iovine NM, Park H, et al.  Oral fluoroquinolones and risk of aortic aneurysm or dissection: a nationwide population-based propensity score-matched cohort study. Pharmacotherapy 2023;43:883–93. https://doi.org/10.1002/phar.2841
  955	Fatima K, Uzair SU, Salman A, Jawed A, Husain MA, Shah MG, et al.  Fluoroquinolones and the risk of aortic aneurysm or aortic dissection: an updated systematic review and meta-analysis including 53,651,283 patients. Minerva Cardiol Angiol 2023;71:485–93. https://doi.org/10.23736/S2724-5683.22.06124-5
  956	LeMaire SA, Zhang L, Luo W, Ren P, Azares AR, Wang Y, et al.  Effect of ciprofloxacin on susceptibility to aortic dissection and rupture in mice. JAMA Surg 2018;153:e181804. https://doi.org/10.1001/jamasurg.2018.1804
  957	Brown JP, Wing K, Leyrat C, Evans SJ, Mansfield KE, Wong AYS, et al.  Association between fluoroquinolone use and hospitalization with aortic aneurysm or aortic dissection. JAMA Cardiol 2023;8:865. https://doi.org/10.1001/jamacardio.2023.2418
  958	Gopalakrishnan C, Bykov K, Fischer MA, Connolly JG, Gagne JJ, Fralick M. Association of fluoroquinolones with the risk of aortic aneurysm or aortic dissection. JAMA Intern Med 2020;180:1596–605. https://doi.org/10.1001/jamainternmed.2020.4199
  959	Lee CC, Lee MT, Chen YS, Lee S-H, Chen Y-S, Chen S-C, et al.  Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone. JAMA Intern Med 2015;175:1839–47. https://doi.org/10.1001/jamainternmed.2015.5389
  960	Huh K, Kang M, Jung J. Lack of association between fluoroquinolone and aortic aneurysm or dissection. Eur Heart J 2023;44:4476–84. https://doi.org/10.1093/eurheartj/ehad627
  961	Klotz S, Stock S, Sievers HH, Diwoky M, Petersen M, Stierle U, et al.  Survival and reoperation pattern after 20 years of experience with aortic valve-sparing root replacement in patients with tricuspid and bicuspid valves. J Thorac Cardiovasc Surg 2018;155:1403–11.e1. https://doi.org/10.1016/j.jtcvs.2017.12.039
  962	Lee H, Cho YH, Sung K, Kim WS, Park K-H, Jeong DS, et al.  Clinical outcomes of root reimplantation and Bentall procedure: propensity score matching analysis. Ann Thorac Surg 2018;106:539–47. https://doi.org/10.1016/j.athoracsur.2018.02.057
  963	Mastrobuoni S, de Kerchove L, Navarra E, Watremez C, Vancraeynest D, Rubay J, et al.  Long-term experience with valve-sparing reimplantation technique for the treatment of aortic aneurysm and aortic regurgitation. J Thorac Cardiovasc Surg 2019;158:14–23. https://doi.org/10.1016/j.jtcvs.2018.10.155
  964	Leontyev S, Schamberger L, Davierwala PM, Von Aspern K, Etz C, Lehmann S, et al.  Early and late results after David vs Bentall procedure: a propensity matched analysis. Ann Thorac Surg 2020;110:120–6. https://doi.org/10.1016/j.athoracsur.2019.10.020
  965	Elbatarny M, Tam DY, Edelman JJ, Rocha RV, Chu MWA, Peterson MD, et al.  Valve-sparing root replacement versus composite valve grafting in aortic root dilation: a meta-analysis. Ann Thorac Surg 2020;110:296–306. https://doi.org/10.1016/j.athoracsur.2019.11.054
  966	Leyh RG, Fischer S, Kallenbach K, Kofidis T, Pethig K, Harringer W, et al.  High failure rate after valve-sparing aortic root replacement using the “remodeling technique” in acute type A aortic dissection. Circulation 2002;106:I229–33.
  967	Schäfers H, Fries R, Langer F, Nikoloudakis N, Graeter T, Grundmann U. Valve-preserving replacement of the ascending aorta: remodeling versus reimplantation. J Thorac Cardiovasc Surg 1998;116:990–6. https://doi.org/10.1016/s0022-5223(98)70051-0
  968	Rahnavardi M, Yan TD, Bannon PG, Wilson MK. Aortic valve-sparing operations in aortic root aneurysms: remodeling or reimplantation? Interact Cardiovasc Thorac Surg 2011;13:189–97. https://doi.org/10.1510/icvts.2011.267401
  969	Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al.  2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022;43:561–632. https://doi.org/10.1093/eurheartj/ehab395
  970	Mok CK, Boey J, Wang R, Chan TK, Cheung KL, Lee PK, et al.  Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial. Circulation 1985;72:1059–63. https://doi.org/10.1161/01.cir.72.5.1059
  971	Cannegieter SC, Rosendaal FR, Briët E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994;89:635–41. https://doi.org/10.1161/01.cir.89.2.635
  972	Brennan JM, Edwards FH, Zhao Y, O'Brien S, Booth ME, Dokholyan RS, et al.  Early anticoagulation of bioprosthetic aortic valves in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. J Am Coll Cardiol 2012;60:971–7. https://doi.org/10.1016/j.jacc.2012.05.029
  973	Rafiq S, Steinbrüchel DA, Lilleør NB, Møller CH, Lund JT, Thiis JJ, et al.  Antithrombotic therapy after bioprosthetic aortic valve implantation: warfarin versus aspirin, a randomized controlled trial. Thromb Res 2017;150:104–10. https://doi.org/10.1016/j.thromres.2016.11.021
Google ScholarCrossrefWorldCat 
974	Czerny M, Rylski B, Della Corte A, Krüger T. Decision-making to perform elective surgery for patients with proximal thoracic aortic pathology: a European perspective. J Thorac Cardiovasc Surg 2022;163:2025–30. https://doi.org/10.1016/j.jtcvs.2021.01.141
Google ScholarCrossrefWorldCat 
975	Vorp DA, Schiro BJ, Ehrlich MP, Juvonen TS, Ergin MA, Griffith BP. Effect of aneurysm on the tensile strength and biomechanical behavior of the ascending thoracic aorta. Ann Thorac Surg 2003;75:1210–4. https://doi.org/10.1016/s0003-4975(02)04711-2
Google ScholarCrossrefWorldCat 
976	Della Corte A, Lo Presti F, Saade W, Rubino AS, Palmieri L, Patanè F, et al.  Acute type A aortic dissection in bicuspid versus tricuspid aortic valve patients: focus on geometrical features of the aorta. Eur J Cardiothorac Surg 2023;63:ezac576. https://doi.org/10.1093/ejcts/ezac576
Google ScholarCrossrefWorldCat 
977	Mullan CW, Mori M, Bin Mahmood SU, Yousef S, Mangi AA, Elefteriades JA, et al.  Incidence and characteristics of hospitalization for proximal aortic surgery for acute syndromes and for aneurysms in the USA from 2005 to 2014. Eur J Cardiothorac Surg 2020;58:583–9. https://doi.org/10.1093/ejcts/ezaa067
Google ScholarCrossrefWorldCat 
978	Williams JB, Peterson ED, Zhao Y, O’Brien SM, Andersen ND, Miller DC, et al.  Contemporary results for proximal aortic replacement in North America. J Am Coll Cardiol 2012;60:1156–62. https://doi.org/10.1016/j.jacc.2012.06.023
Google ScholarCrossrefWorldCat 
979	Wallen T, Habertheuer A, Bavaria JE, Hughes GC, Badhwar V, Jacobs JP, et al.  Elective aortic root replacement in North America: analysis of STS adult cardiac surgery database. Ann Thorac Surg 2019;107:1307–12. https://doi.org/10.1016/j.athoracsur.2018.12.039
Google ScholarCrossrefWorldCat 
980	Mori M, Shioda K, Wang X, Mangi AA, Yun JJ, Darr U, et al.  Perioperative risk profiles and volume-outcome relationships in proximal thoracic aortic surgery. Ann Thorac Surg 2018;106:1095–104. https://doi.org/10.1016/j.athoracsur.2018.05.081
Google ScholarCrossrefWorldCat 
981	Wojnarski CM, Svensson LG, Roselli EE, Idrees JJ, Lowry AM, Ehrlinger J, et al.  Aortic dissection in patients with bicuspid aortic valve-associated aneurysms. Ann Thorac Surg 2015;100:1666–73; discussion 1673–74. https://doi.org/10.1016/j.athoracsur.2015.04.126
Google ScholarCrossrefWorldCat 
982	Wu J, Zafar MA, Liu Y, Chen JF, Li Y, Ziganshin BA, et al.  Fate of the unoperated ascending thoracic aortic aneurysm: three-decade experience from the Aortic Institute at Yale University. Eur Heart J 2023;44:4579–88. https://doi.org/10.1093/eurheartj/ehad148
Google ScholarCrossrefWorldCat 
983	Ziganshin BA, Zafar MA, Elefteriades JA. Descending threshold for ascending aortic aneurysmectomy: is it time for a “left-shift” in guidelines? J Thorac Cardiovasc Surg 2019;157:37–42. https://doi.org/10.1016/j.jtcvs.2018.07.114
Google ScholarCrossrefWorldCat 
984	Rylski B, Branchetti E, Bavaria JE, Vallabhajosyula P, Szeto WY, Milewski RK, et al.  Modeling of predissection aortic size in acute type A dissection: more than 90% fail to meet the guidelines for elective ascending replacement. J Thorac Cardiovasc Surg 2014;148:944–8.e1. https://doi.org/10.1016/j.jtcvs.2014.05.050
Google ScholarCrossrefWorldCat 
985	Mansour AM, Peterss S, Zafar MA, Rizzo JA, Fang H, Charilaou P, et al.  Prevention of aortic dissection suggests a diameter shift to a lower aortic size threshold for intervention. Cardiology 2018;139:139–46. https://doi.org/10.1159/000481930
Google ScholarCrossrefWorldCat 
986	Masri A, Kalahasti V, Alkharabsheh S, Svensson LG, Sabik JF, Roselli EE, et al.  Characteristics and long-term outcomes of contemporary patients with bicuspid aortic valves. J Thorac Cardiovasc Surg 2016;151:1650–9.e1. https://doi.org/10.1016/j.jtcvs.2015.12.019
Google ScholarCrossrefWorldCat 
987	Winkler A, Puiu P, Krombholz-Reindl P, Vötsch A, Steindl J, Neuner M, et al.  Impact of concomitant replacement of the ascending aorta in patients undergoing aortic valve replacement on operative morbidity and mortality. Eur J Cardiothorac Surg 2022;61:587–93. https://doi.org/10.1093/ejcts/ezab420
Google ScholarCrossrefWorldCat 
988	Peterss S, Charilaou P, Dumfarth J, Li Y, Bhandari R, Tranquilli M, et al.  Aortic valve disease with ascending aortic aneurysm: impact of concomitant root-sparing (supracoronary) aortic replacement in nonsyndromic patients. J Thorac Cardiovasc Surg 2016;152:791–8.e1. https://doi.org/10.1016/j.jtcvs.2016.05.020
Google ScholarCrossrefWorldCat 
989	Lim JY, Jung SH, Kim JB, Kim DK, Chung CH, Song H, et al.  Concomitant replacement of the dilated ascending aorta during aortic valve replacement; does it increase the perioperative morbidity and mortality risks? J Card Surg 2013;28:285–90. https://doi.org/10.1111/jocs.12111
Google ScholarCrossrefWorldCat 
990	Idrees JJ, Roselli EE, Lowry AM, Reside JM, Javadikasgari H, Johnson DJ, et al.  Outcomes after elective proximal aortic replacement: a matched comparison of isolated versus multicomponent operations. Ann Thorac Surg 2016;101:2185–92. https://doi.org/10.1016/j.athoracsur.2015.12.026
Google ScholarCrossrefWorldCat 
991	Idrees JJ, Roselli EE, Blackstone EH, Lowry AM, Soltesz EG, Johnston DR, et al.  Risk of adding prophylactic aorta replacement to a cardiac operation. J Thorac Cardiovasc Surg 2020;159:1669–78.e10. https://doi.org/10.1016/j.jtcvs.2019.05.001
Google ScholarCrossrefWorldCat 
992	Grabenwöger M, Alfonso F, Bachet J, Bonser R, Czerny M, Eggebrecht H, et al.  Thoracic Endovascular Aortic Repair (TEVAR) for the treatment of aortic diseases: a position statement from the European Association for Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2012;33:1558–63. https://doi.org/10.1093/eurheartj/ehs074
Google ScholarCrossrefWorldCat 
993	Eggebrecht H, Thompson M, Rousseau H, Czerny M, Lönn L, Mehta RH, et al.  Retrograde ascending aortic dissection during or after thoracic aortic stent graft placement: insight from the European registry on endovascular aortic repair complications. Circulation 2009;120:S276–281. https://doi.org/10.1161/circulationaha.108.835926
Google ScholarCrossrefWorldCat 
994	Zerwes S, Leissner G, Gosslau Y, Jakob R, Bruijnen H-K, Oertl F, et al.  Clinical outcomes in hybrid repair procedures for pathologies involving the aortic arch. Vascular 2015;23:9–16. https://doi.org/10.1177/1708538114525608
Google ScholarCrossrefWorldCat 
995	Czerny M, Weigang E, Sodeck G, Schmidli J, Antona C, Gelpi G, et al.  Targeting landing zone 0 by total arch rerouting and TEVAR: midterm results of a transcontinental registry. Ann Thorac Surg 2012;94:84–9. https://doi.org/10.1016/j.athoracsur.2012.03.024
Google ScholarCrossrefWorldCat 
996	Chiesa R, Melissano G, Tshomba Y, Civilini E, Marone EM, Bertoglio L, et al.  Ten years of endovascular aortic arch repair. J Endovasc Ther 2010;17:1–11. https://doi.org/10.1583/09-2884.1
Google ScholarCrossrefWorldCat 
997	Shrestha M, Bachet J, Bavaria J, Carrel TP, De Paulis R, Di Bartolomeo R, et al.  Current status and recommendations for use of the frozen elephant trunk technique: a position paper by the vascular domain of EACTS. Eur J Cardiothorac Surg 2015;47:759–69. https://doi.org/10.1093/ejcts/ezv085
Google ScholarCrossrefWorldCat 
998	Czerny M, Schmidli J, Adler S, van den Berg JC, Bertoglio L, Carrel T, et al.  Current options and recommendations for the treatment of thoracic aortic pathologies involving the aortic arch: an expert consensus document of the European Association for Cardio-Thoracic Surgery (EACTS) and the European Society for Vascular Surgery (ESVS). Eur J Cardiothorac Surg 2019;55:133–62. https://doi.org/10.1093/ejcts/ezy313
Google ScholarCrossrefWorldCat 
999	Abjigitova D, Veen KM, van Tussenbroek G, Mokhles MM, Bekkers JA, Takkenberg JJM, et al.  Cerebral protection in aortic arch surgery: systematic review and meta-analysis. Interact Cardiovasc Thorac Surg 2022;35:ivac270. https://doi.org/10.1093/icvts/ivac128
Google ScholarCrossrefWorldCat 
1000	Malaisrie SC, Duncan BF, Mehta CK, Badiwala MV, Rinewalt D, Kruse J, et al.  The addition of hemiarch replacement to aortic root surgery does not affect safety. J Thorac Cardiovasc Surg 2015;150:118–24.e2. https://doi.org/10.1016/j.jtcvs.2015.03.020
Google ScholarCrossrefWorldCat 
1001	Borger MA, Fedak PWM, Stephens EH, Gleason TG, Girdauskas E, Ikonomidis JS, et al.  The American Association for Thoracic Surgery consensus guidelines on bicuspid aortic valve-related aortopathy: full online-only version. J Thorac Cardiovasc Surg 2018;156:e41–74. https://doi.org/10.1016/j.jtcvs.2018.02.115
Google ScholarCrossrefWorldCat 
1002	Kim JB, Kim K, Lindsay ME, MacGillivray T, Isselbacher EM, Cambria RP, et al.  Risk of rupture or dissection in descending thoracic aortic aneurysm. Circulation 2015;132:1620–9. https://doi.org/10.1161/circulationaha.114.015177
Google ScholarCrossrefWorldCat 
1003	Chen JF, Zafar MA, Wu J, Li Y, Rizzo JA, Papanikolaou D, et al.  Increased virulence of descending thoracic and thoracoabdominal aortic aneurysms in women. Ann Thorac Surg 2021;112:45–52. https://doi.org/10.1016/j.athoracsur.2020.08.026
Google ScholarCrossrefWorldCat 
1004	Lobato AC, Puech-Leão P. Predictive factors for rupture of thoracoabdominal aortic aneurysm. J Vasc Surg 1998;27:446–53. https://doi.org/10.1016/s0741-5214(98)70319-2
Google ScholarCrossrefWorldCat 
1005	Harris DG, Olson SL, Panthofer AM, Matsumura JS, DiMusto PD. A frailty-based risk score predicts morbidity and mortality after elective endovascular repair of descending thoracic aortic aneurysms. Ann Vasc Surg 2020;67:90–9. https://doi.org/10.1016/j.avsg.2019.10.090
Google ScholarCrossrefWorldCat 
1006	Goodney PP, Travis L, Lucas FL, Fillinger MF, Goodman DC, Cronenwett JL, et al.  Survival after open versus endovascular thoracic aortic aneurysm repair in an observational study of the Medicare population. Circulation 2011;124:2661–9. https://doi.org/10.1161/circulationaha.111.033944
Google ScholarCrossrefWorldCat 
1007	Grausgruber W, Scharfen E. Problems of the fight against zoonoses in Austria. Wien Tierarztl Monatsschr 1968;55:625–36.
Google ScholarWorldCat 
1008	Chiu P, Goldstone AB, Schaffer JM, Lingala B, Miller DC, Mitchell RS, et al.  Endovascular versus open repair of intact descending thoracic aortic aneurysms. J Am Coll Cardiol 2019;73:643–51. https://doi.org/10.1016/j.jacc.2018.10.086
Google ScholarCrossrefWorldCat 
1009	Fairman RM, Criado F, Farber M, Kwolek C, Mehta M, White R, et al.  Pivotal results of the medtronic vascular talent thoracic stent graft system: the VALOR trial. J Vasc Surg 2008;48:546–54.e2. https://doi.org/10.1016/j.jvs.2008.03.061
Google ScholarCrossrefWorldCat 
1010	Matsumura JS, Cambria RP, Dake MD, Moore RD, Svensson LG, Snyder S. International controlled clinical trial of thoracic endovascular aneurysm repair with the Zenith TX2 endovascular graft: 1-year results. J Vasc Surg 2008;47:247–57; discussion 257. https://doi.org/10.1016/j.jvs.2007.10.032
Google ScholarCrossrefWorldCat 
1011	Coselli JS, Bozinovski J, LeMaire SA. Open surgical repair of 2286 thoracoabdominal aortic aneurysms. Ann Thorac Surg 2007;83:S862–4; discussion S890–862. https://doi.org/10.1016/j.athoracsur.2006.10.088
Google ScholarCrossrefWorldCat 
1012	Coselli JS, Green SY, Price MD, Hash JA, Ouyang Y, Volguina IV, et al.  Results of open surgical repair in patients with Marfan syndrome and distal aortic dissection. Ann Thorac Surg 2016;101:2193–201. https://doi.org/10.1016/j.athoracsur.2015.11.008
Google ScholarCrossrefWorldCat 
1013	Tong MZ, Eagleton MJ, Roselli EE, Blackstone EH, Xiang F, Ibrahim M, et al.  Outcomes of open versus endovascular repair of descending thoracic and thoracoabdominal aortic aneurysms. Ann Thorac Surg 2022;113:1144–52. https://doi.org/10.1016/j.athoracsur.2021.04.100
Google ScholarCrossrefWorldCat 
1014	Goldstein LJ, Davies RR, Rizzo JA, Davila JJ, Cooperberg MR, Shaw RK, et al.  Stroke in surgery of the thoracic aorta: incidence, impact, etiology, and prevention. J Thorac Cardiovasc Surg 2001;122:935–45. https://doi.org/10.1067/mtc.2001.117276
Google ScholarCrossrefWorldCat 
1015	Svensson LG, Crawford ES, Hess KR, Coselli JS, Safi HJ. Experience with 1509 patients undergoing thoracoabdominal aortic operations. J Vasc Surg 1993;17:357–68; discussion 368–70.
Google ScholarCrossrefWorldCat 
1016	Schermerhorn ML, Giles KA, Hamdan AD, Dalhberg SE, Hagberg R, Pomposelli F. Population-based outcomes of open descending thoracic aortic aneurysm repair. J Vasc Surg 2008;48:821–7. https://doi.org/10.1016/j.jvs.2008.05.022
Google ScholarCrossrefWorldCat 
1017	Yamauchi T, Takano H, Nishimura M, Matsumiya G, Sawa Y. Paraplegia and paraparesis after descending thoracic aortic aneurysm repair: a risk factor analysis. Ann Thorac Cardiovasc Surg 2006;12:179–83.
Google ScholarWorldCat 
1018	Patel VI, Mukhopadhyay S, Ergul E, Aranson N, Conrad MF, LaMuraglia GM, et al.  Impact of hospital volume and type on outcomes of open and endovascular repair of descending thoracic aneurysms in the United States Medicare population. J Vasc Surg 2013;58:346–54. https://doi.org/10.1016/j.jvs.2013.01.035
Google ScholarCrossrefWorldCat 
1019	Cheng D, Martin J, Shennib H, Dunning J, Muneretto C, Schueler S, et al.  Endovascular aortic repair versus open surgical repair for descending thoracic aortic disease a systematic review and meta-analysis of comparative studies. J Am Coll Cardiol 2010;55:986–1001. https://doi.org/10.1016/j.jacc.2009.11.047
Google ScholarCrossrefWorldCat 
1020	Harky A, Kai Chan JS, Ming Wong CH, Bashir M. Open versus endovascular repair of descending thoracic aortic aneurysm disease: a systematic review and meta-analysis. Ann Vasc Surg 2019;54:304–15.e5. https://doi.org/10.1016/j.avsg.2018.05.043
Google ScholarCrossrefWorldCat 
1021	Ranney DN, Cox ML, Yerokun BA, Benrashid E, McCann RL, Hughes GC. Long-term results of endovascular repair for descending thoracic aortic aneurysms. J Vasc Surg 2018;67:363–8. https://doi.org/10.1016/j.jvs.2017.06.094
Google ScholarCrossrefWorldCat 
1022	Biancari F, Mariscalco G, Mariani S, Saari P, Satta J, Juvonen T. Endovascular treatment of degenerative aneurysms involving only the descending thoracic aorta: systematic review and meta-analysis. J Endovasc Ther 2016;23:387–92. https://doi.org/10.1177/1526602815626560
Google ScholarCrossrefWorldCat 
1023	Mousa AY, Morcos R, Broce M, Bates MC, AbuRahma AF. New preoperative spinal cord ischemia risk stratification model for patients undergoing thoracic endovascular aortic repair. Vasc Endovascular Surg 2020;54:487–96. https://doi.org/10.1177/1538574420929135
Google ScholarCrossrefWorldCat 
1024	Walsh SR, Tang TY, Sadat U, Naik J, Gaunt ME, Boyle JR, et al.  Endovascular stenting versus open surgery for thoracic aortic disease: systematic review and meta-analysis of perioperative results. J Vasc Surg 2008;47:1094–8.e3. https://doi.org/10.1016/j.jvs.2007.09.062
Google ScholarCrossrefWorldCat 
1025	Kotelis D, Geisbüsch P, Hinz U, Hyhlik-Dürr A, von Tengg-Kobligk H, Allenberg JR, et al.  Short and midterm results after left subclavian artery coverage during endovascular repair of the thoracic aorta. J Vasc Surg 2009;50:1285–92. https://doi.org/10.1016/j.jvs.2009.07.106
Google ScholarCrossrefWorldCat 
1026	Cooper DG, Walsh SR, Sadat U, Noorani A, Hayes PD, Boyle JR, et al.  Neurological complications after left subclavian artery coverage during thoracic endovascular aortic repair: a systematic review and meta-analysis. J Vasc Surg 2009;49:1594–601. https://doi.org/10.1016/j.jvs.2008.12.075
Google ScholarCrossrefWorldCat 
1027	Buth J, Harris PL, Hobo R, van Eps R, Cuypers P, Duijm L, et al.  Neurologic complications associated with endovascular repair of thoracic aortic pathology: incidence and risk factors. a study from the European Collaborators on Stent/Graft Techniques for Aortic Aneurysm Repair (EUROSTAR) registry. J Vasc Surg 2007;46:1103–10; discussion 1110–1. https://doi.org/10.1016/j.jvs.2007.08.020
Google ScholarCrossrefWorldCat 
1028	Teixeira PG, Woo K, Beck AW, Scali ST, Weaver FA. Association of left subclavian artery coverage without revascularization and spinal cord ischemia in patients undergoing thoracic endovascular aortic repair: a Vascular Quality Initiative® analysis. Vascular 2017;25:587–97. https://doi.org/10.1177/1708538116681910
Google ScholarCrossrefWorldCat 
1029	Chen X, Wang J, Premaratne S, Zhao J, Zhang WW. Meta-analysis of the outcomes of revascularization after intentional coverage of the left subclavian artery for thoracic endovascular aortic repair. J Vasc Surg 2019;70:1330–40. https://doi.org/10.1016/j.jvs.2019.03.022
Google ScholarCrossrefWorldCat 
1030	Banno H, Ikeda S, Kawai Y, Meshii K, Takahashi N, Sugimoto M, et al.  Early and midterm outcomes of celiac artery coverage during thoracic endovascular aortic repair. J Vasc Surg 2020;72:1552–7. https://doi.org/10.1016/j.jvs.2020.02.025
Google ScholarCrossrefWorldCat 
1031	Argyriou C, Spiliopoulos S, Katsanos K, Papatheodorou N, Lazarides MK, Georgiadis GS. Safety and efficacy of intentional celiac artery coverage in endovascular management of thoracoabdominal aortic diseases: a systematic review and meta-analysis. J Endovasc Ther 2022;29:646–58. https://doi.org/10.1177/15266028211059451
Google ScholarCrossrefWorldCat 
1032	Hanna L, Lam K, Agbeko AE, Amoako JK, Ashrafian H, Sounderajah V, et al.  Coverage of the coeliac artery during thoracic endovascular aortic repair: a systematic review and meta-analysis. Eur J Vasc Endovasc Surg 2022;63:828–37. https://doi.org/10.1016/j.ejvs.2022.02.026
Google ScholarCrossrefWorldCat 
1033	Cambria RA, Gloviczki P, Stanson AW, Cherry KJ, Bower TC, Hallett JW, et al.  Outcome and expansion rate of 57 thoracoabdominal aortic aneurysms managed nonoperatively. Am J Surg 1995;170:213–7. https://doi.org/10.1016/s0002-9610(99)80289-x
Google ScholarCrossrefWorldCat 
1034	Elefteriades JA. Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks. Ann Thorac Surg 2002;74:S1877–80; discussion S1892–8. https://doi.org/10.1016/s0003-4975(02)04147-4
Google ScholarCrossrefWorldCat 
1035	Girardi LN, Ohmes LB, Lau C, Di Franco A, Gambardella I, Elsayed M, et al.  Open repair of descending thoracic and thoracoabdominal aortic aneurysms in patients with preoperative renal failure. Eur J Cardiothorac Surg 2017;51:971–7. https://doi.org/10.1093/ejcts/ezx007
Google ScholarCrossrefWorldCat 
1036	LeMaire SA, Miller CC, III, Conklin LD, Schmittling ZC, Köksoy C, Coselli JS, et al.  A new predictive model for adverse outcomes after elective thoracoabdominal aortic aneurysm repair. Ann Thorac Surg 2001;71:1233–8. https://doi.org/10.1016/s0003-4975(00)02678-3
Google ScholarCrossrefWorldCat 
1037	Suzuki S, Davis CA, III, Miller CC, III, Huynh TT, Estrera AL, Porat EE, et al.  Cardiac function predicts mortality following thoracoabdominal and descending thoracic aortic aneurysm repair. Eur J Cardiothorac Surg 2003;24:119–24; discussion 124. https://doi.org/10.1016/s1010-7940(03)00170-2
Google ScholarCrossrefWorldCat 
1038	Mohebali J, Carvalho S, Lancaster RT, Ergul EA, Conrad MF, Clouse WD, et al.  Use of extracorporeal bypass is associated with improved outcomes in open thoracic and thoracoabdominal aortic aneurysm repair. J Vasc Surg 2018;68:941–7. https://doi.org/10.1016/j.jvs.2017.12.072
Google ScholarCrossrefWorldCat 
1039	Coselli JS, LeMaire SA, Preventza O, de la Cruz KI, Cooley DA, Price MD, et al.  Outcomes of 3309 thoracoabdominal aortic aneurysm repairs. J Thorac Cardiovasc Surg 2016;151:1323–38. https://doi.org/10.1016/j.jtcvs.2015.12.050
Google ScholarCrossrefWorldCat 
1040	Drinkwater SL, Goebells A, Haydar A, Bourke P, Brown L, Hamady M, et al.  The incidence of spinal cord ischaemia following thoracic and thoracoabdominal aortic endovascular intervention. Eur J Vasc Endovasc Surg 2010;40:729–35. https://doi.org/10.1016/j.ejvs.2010.08.013
Google ScholarCrossrefWorldCat 
1041	Bicknell CD, Riga CV, Wolfe JH. Prevention of paraplegia during thoracoabdominal aortic aneurysm repair. Eur J Vasc Endovasc Surg 2009;37:654–60. https://doi.org/10.1016/j.ejvs.2009.02.008
Google ScholarCrossrefWorldCat 
1042	Von Aspern K, Luehr M, Mohr FW, Etz CD. Spinal cord protection in open- and endovascular thoracoabdominal aortic aneurysm repair: critical review of current concepts and future perspectives. J Cardiovasc Surg (Torino) 2015;56:745–9.
Google ScholarWorldCat 
1043	Hsu CC, Kwan GN, van Driel ML, Rophael JA. Distal aortic perfusion during thoracoabdominal aneurysm repair for prevention of paraplegia. Cochrane Database Syst Rev 2012;3:CD008197. https://doi.org/10.1002/14651858.CD008197.pub2
Google ScholarWorldCat 
1044	Bischoff MS, Di Luozzo G, Griepp EB, Griepp RB. Spinal cord preservation in thoracoabdominal aneurysm repair. Perspect Vasc Surg Endovasc Ther 2011;23:214–22. https://doi.org/10.1177/1531003511400622
Google ScholarCrossrefWorldCat 
1045	Cowan JA, Jr, Dimick JB, Henke PK, Huber TS, Stanley JC, Upchurch GR. Surgical treatment of intact thoracoabdominal aortic aneurysms in the United States: hospital and surgeon volume-related outcomes. J Vasc Surg 2003;37:1169–74. https://doi.org/10.1016/s0741-5214(03)00085-5
Google ScholarCrossrefWorldCat 
1046	Rigberg DA, McGory ML, Zingmond DS, Maggard MA, Agustin M, Lawrence PF, et al.  Thirty-day mortality statistics underestimate the risk of repair of thoracoabdominal aortic aneurysms: a statewide experience. J Vasc Surg 2006;43:217–22; discussion 223. https://doi.org/10.1016/j.jvs.2005.10.070
Google ScholarCrossrefWorldCat 
1047	Pomy BJ, Rosenfeld ES, Lala S, Lee KB, Sparks AD, Amdur RL, et al.  Fenestrated endovascular aneurysm repair affords fewer renal complications than open surgical repair for juxtarenal abdominal aortic aneurysms in patients with chronic renal insufficiency. Ann Vasc Surg 2021;75:349–57. https://doi.org/10.1016/j.avsg.2021.03.026
Google ScholarCrossrefWorldCat 
1048	Varkevisser RRB, O’Donnell TFX, Swerdlow NJ, Liang P, Li C, Ultee KHJ, et al.  Fenestrated endovascular aneurysm repair is associated with lower perioperative morbidity and mortality compared with open repair for complex abdominal aortic aneurysms. J Vasc Surg 2019;69:1670–8. https://doi.org/10.1016/j.jvs.2018.08.192
Google ScholarCrossrefWorldCat 
1049	Gallitto E, Faggioli G, Melissano G, Fargion A, Isernia G, Lenti M, et al.  Preoperative and postoperative predictors of clinical outcome of fenestrated and branched endovascular repair for complex abdominal and thoracoabdominal aortic aneurysms in an Italian multicenter registry. J Vasc Surg 2021;74:1795–806.e6. https://doi.org/10.1016/j.jvs.2021.04.072
Google ScholarCrossrefWorldCat 
1050	Silverberg D, Bar-Dayan A, Hater H, Khaitovich B, Halak M. Short-term outcomes of inner branches for endovascular repair of complex abdominal and thoracoabdominal aortic aneurysms. Vascular 2021;29:644–51. https://doi.org/10.1177/1708538120977279
Google ScholarCrossrefWorldCat 
1051	Hu Z, Li Y, Peng R, Liu J, Jia X, Liu X, et al.  Multibranched stent-grafts for the treatment of thoracoabdominal aortic aneurysms: a systematic review and meta-analysis. J Endovasc Ther 2016;23:626–33. https://doi.org/10.1177/1526602816647723
Google ScholarCrossrefWorldCat 
1052	Simonte G, Isernia G, Gatta E, Neri E, Parlani G, Candeloro L, et al.  Inner branched complex aortic repair outcomes from a national multicenter registry using the E-xtra design platform. J Vasc Surg 2023;77:338–46. https://doi.org/10.1016/j.jvs.2022.08.034
Google ScholarCrossrefWorldCat 
1053	Gallitto E, Faggioli G, Pini R, Logiacco A, Mascoli C, Fenelli C, et al.  Proximal aortic coverage and clinical results of the endovascular repair of juxta-/para-renal and type IV thoracoabdominal aneurysm with custom-made fenestrated endografts. Ann Vasc Surg 2021;73:397–406. https://doi.org/10.1016/j.avsg.2020.12.008
Google ScholarCrossrefWorldCat 
1054	Sultan S, Concannon J, Veerasingam D, Tawfick W, McHugh P, Jordan F, et al.  Endovascular versus conventional open surgical repair for thoracoabdominal aortic aneurysms. Cochrane Database Syst Rev 2022;4:CD012926. https://doi.org/10.1002/14651858.CD012926.pub2
Google ScholarWorldCat 
1055	Kölbel T, Spanos K, Jama K, Behrendt CA, Panuccio G, Eleshra A, et al.  Early outcomes of the t-Branch off-the-shelf multi-branched stent graft in 542 patients for elective and urgent aortic pathologies: a retrospective observational study. J Vasc Surg 2021;74:1817–24. https://doi.org/10.1016/j.jvs.2021.05.041
Google ScholarCrossrefWorldCat 
1056	Oderich GS, Ribeiro M, Hofer J, Wigham J, Cha S, Chini J, et al.  Prospective, nonrandomized study to evaluate endovascular repair of pararenal and thoracoabdominal aortic aneurysms using fenestrated-branched endografts based on supraceliac sealing zones. J Vasc Surg 2017;65:1249–59.e10. https://doi.org/10.1016/j.jvs.2016.09.038
Google ScholarCrossrefWorldCat 
1057	Oderich GS, Tenorio ER, Mendes BC, Lima GBB, Marcondes GB, Saqib N, et al.  Midterm outcomes of a prospective, nonrandomized study to evaluate endovascular repair of complex aortic aneurysms using fenestrated-branched endografts. Ann Surg 2021;274:491–9. https://doi.org/10.1097/sla.0000000000004982
Google ScholarCrossrefWorldCat 
1058	Konstantinou N, Antonopoulos CN, Jerkku T, Banafsche R, Kölbel T, Fiorucci B, et al.  Systematic review and meta-analysis of published studies on endovascular repair of thoracoabdominal aortic aneurysms with the t-Branch off-the-shelf multibranched endograft. J Vasc Surg 2020;72:716–25.e1. https://doi.org/10.1016/j.jvs.2020.01.049
Google ScholarCrossrefWorldCat 
1059	Ellahi A, Shaikh FN, Kashif H, Khan H, Ali E, Nasim B, et al.  Effectiveness of endovascular repair versus open surgery for the treatment of thoracoabdominal aneurysm: a systematic review and meta analysis. Ann Med Surg 2022;81:104477. https://doi.org/10.1016/j.amsu.2022.104477
Google ScholarCrossrefWorldCat 
1060	Hongku K, Sonesson B, Bjorses K, Holst J, Resch T, Dias NV, et al.  Mid-term Outcomes of Endovascular Repair of Ruptured Thoraco-abdominal Aortic Aneurysms with Off the Shelf Branched Stent Grafts. Eur J Vasc Endovasc Surg 2018;55:377–84. https://doi.org/10.1016/j.ejvs.2017.11.021
Google ScholarCrossrefWorldCat 
1061	Youssef M, Deglise S, Szopinski P, Jost-Philipp S, Jomha A, Vahl CF, et al.  A multicenter experience with a new fenestrated-branched device for endovascular repair of thoracoabdominal aortic aneurysms. J Endovasc Ther 2018;25:209–19. https://doi.org/10.1177/1526602817752147
Google ScholarCrossrefWorldCat 
1062	Ouzounian M, Tadros RO, Svensson LG, Lyden SP, Oderich GS, Coselli JS Thoracoabdominal aortic disease and repair: JACC focus seminar, part 3. J Am Coll Cardiol 2022;80:845–56. https://doi.org/10.1016/j.jacc.2021.05.056
Google ScholarCrossrefWorldCat 
1063	Hofmann Bowman MA, Eagle KA, Milewicz DM. Update on clinical trials of losartan with and without β-blockers to block aneurysm growth in patients with Marfan syndrome: a review. JAMA Cardiol 2019;4:702–7. https://doi.org/10.1001/jamacardio.2019.1176
Google ScholarCrossrefWorldCat 
1064	Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. The UK Small Aneurysm Trial Participants. Lancet 1998;352:1649–55.
CrossrefWorldCat 
1065	Powell JT, Brady AR, Brown LC, Fowkes FG, Greenhalgh RM, Ruckley CV, et al.  Long-term outcomes of immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med 2002;346:1445–52. https://doi.org/10.1056/NEJMoa013527
Google ScholarWorldCat 
1066	Lederle FA, Wilson SE, Johnson GR, Reinke DB, Littooy FN, Acher CW, et al.  Immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med 2002;346:1437–44. https://doi.org/10.1056/NEJMoa012573
Google ScholarCrossrefWorldCat 
1067	Shirasu T, Takagi H, Yasuhara J, Kuno T, Kent KC, Clouse WD. Smaller size is more suitable for pharmacotherapy among undersized abdominal aortic aneurysm: a systematic review and meta-analysis. Vasc Med 2022;27:261–8. https://doi.org/10.1177/1358863x211061603
Google ScholarCrossrefWorldCat 
1068	Ouriel K, Clair DG, Kent KC, Zarins CK. Endovascular repair compared with surveillance for patients with small abdominal aortic aneurysms. J Vasc Surg 2010;51:1081–7. https://doi.org/10.1016/j.jvs.2009.10.113
Google ScholarCrossrefWorldCat 
1069	Golledge J, Parr A, Boult M, Maddern G, Fitridge R. The outcome of endovascular repair of small abdominal aortic aneurysms. Ann Surg 2007;245:326–33. https://doi.org/10.1097/01.sla.0000253965.95368.52
Google ScholarCrossrefWorldCat 
1070	Filardo G, Powell JT, Martinez MA, Ballard DJ. Surgery for small asymptomatic abdominal aortic aneurysms. Cochrane Database Syst Rev 2015;2:CD001835. https://doi.org/10.1002/14651858.CD001835.pub4
Google ScholarWorldCat 
1071	Cao P, De Rango P, Verzini F, Parlani G, Romano L, Cieri E. Comparison of surveillance versus aortic endografting for small aneurysm repair (CAESAR): results from a randomised trial. Eur J Vasc Endovasc Surg 2011;41:13–25. https://doi.org/10.1016/j.ejvs.2010.08.026
Google ScholarCrossrefWorldCat 
1072	Lo RC, Lu B, Fokkema MT, Conrad M, Patel VI, Fillinger M, et al.  Relative importance of aneurysm diameter and body size for predicting abdominal aortic aneurysm rupture in men and women. J Vasc Surg 2014;59:1209–16. https://doi.org/10.1016/j.jvs.2013.10.104
Google ScholarCrossrefWorldCat 
1073	Bath MF, Gokani VJ, Sidloff DA, Jones LR, Choke E, Sayers RD, et al.  Systematic review of cardiovascular disease and cardiovascular death in patients with a small abdominal aortic aneurysm. Br J Surg 2015;102:866–72. https://doi.org/10.1002/bjs.9837
Google ScholarCrossrefWorldCat 
1074	Kristensen SD, Knuuti J. New ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management. Eur Heart J 2014;35:2344–5. https://doi.org/10.1093/eurheartj/ehu285
Google ScholarCrossrefWorldCat 
1075	Devereaux PJ, Chan MT, Alonso-Coello P, Walsh M, Berwanger O, Villar JC, et al.  Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA 2012;307:2295–304. https://doi.org/10.1001/jama.2012.5502
Google ScholarWorldCat 
1076	EVAR trial participants. Endovascular aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR trial 1): randomised controlled trial. Lancet 2005;365:2179–86. https://doi.org/10.1016/s0140-6736(05)66627-5
CrossrefWorldCat 
1077	Lederle FA, Freischlag JA, Kyriakides TC, Padberg FT, Jr, Matsumura JS, Kohler TR, et al.  Outcomes following endovascular vs open repair of abdominal aortic aneurysm: a randomized trial. JAMA 2009;302:1535–42. https://doi.org/10.1001/jama.2009.1426
Google ScholarCrossrefWorldCat 
1078	Becquemin JP, Pillet JC, Lescalie F, Sapoval M, Goueffic Y, Lermusiaux P, et al.  A randomized controlled trial of endovascular aneurysm repair versus open surgery for abdominal aortic aneurysms in low- to moderate-risk patients. J Vasc Surg 2011;53:1167–73.e1. https://doi.org/10.1016/j.jvs.2010.10.124
Google ScholarCrossrefWorldCat 
1079	Antoniou GA, Antoniou SA, Torella F. Editor’s choice—endovascular vs. open repair for abdominal aortic aneurysm: systematic review and meta-analysis of updated peri-operative and long term data of randomised controlled trials. Eur J Vasc Endovasc Surg 2020;59:385–97. https://doi.org/10.1016/j.ejvs.2019.11.030
Google ScholarCrossrefWorldCat 
1080	Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, et al.  2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J 2022;43:3826–924. https://doi.org/10.1093/eurheartj/ehac270
Google ScholarCrossrefWorldCat 
1081	McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski WC, Littooy F, et al.  Coronary-artery revascularization before elective major vascular surgery. N Engl J Med 2004;351:2795–804. https://doi.org/10.1056/NEJMoa041905
Google ScholarCrossrefWorldCat 
1082	Saida T, Mori K, Sato F, Shindo M, Takahashi H, Takahashi N, et al.  Prospective intraindividual comparison of unenhanced magnetic resonance imaging vs contrast-enhanced computed tomography for the planning of endovascular abdominal aortic aneurysm repair. J Vasc Surg 2012;55:679–87. https://doi.org/10.1016/j.jvs.2011.09.091
Google ScholarCrossrefWorldCat 
1083	Parker MV, O’Donnell SD, Chang AS, Johnson CA, Gillespie DL, Goff JM, et al.  What imaging studies are necessary for abdominal aortic endograft sizing? A prospective blinded study using conventional computed tomography, aortography, and three-dimensional computed tomography. J Vasc Surg 2005;41:199–205. https://doi.org/10.1016/j.jvs.2004.12.010
Google ScholarCrossrefWorldCat 
1084	Schanzer A, Greenberg RK, Hevelone N, Robinson WP, Eslami MH, Goldberg RJ, et al.  Predictors of abdominal aortic aneurysm sac enlargement after endovascular repair. Circulation 2011;123:2848–55. https://doi.org/10.1161/circulationaha.110.014902
Google ScholarCrossrefWorldCat 
1085	Protto S, Hahl T, Koskinen KJA, Järvenpää V, Uurto I, Väärämäki S, et al.  Endovascular repair of abdominal aortic aneurysms is a valid alternative to open repair also in patients treated outside of instructions for use criteria. Cardiovasc Intervent Radiol 2022;45:1765–73. https://doi.org/10.1007/s00270-022-03297-7
Google ScholarCrossrefWorldCat 
1086	Charbonneau P, Hongku K, Herman CR, Habib M, Girsowicz E, Doonan RJ, et al.  Long-term survival after endovascular and open repair in patients with anatomy outside instructions for use criteria for endovascular aneurysm repair. J Vasc Surg 2019;70:1823–30. https://doi.org/10.1016/j.jvs.2019.01.081
Google ScholarCrossrefWorldCat 
1087	O’Donnell TFX, McElroy IE, Boitano LT, Mohebali J, Lamuraglia GM, Kwolek CJ, et al.  Comparison of treatment options for aortic necks outside standard endovascular aneurysm repair instructions for use. J Vasc Surg 2021;74:1548–57. https://doi.org/10.1016/j.jvs.2021.04.052
Google ScholarCrossrefWorldCat 
1088	Antoniou GA, Juszczak MT, Nasr H, Narlawar R, Antoniou SA, Matsagkas M, et al.  Prognosis review and time-to-event data meta-analysis of endovascular aneurysm repair outside versus within instructions for use of aortic endograft devices. J Vasc Surg 2020;71:1415–31.e15. https://doi.org/10.1016/j.jvs.2019.08.247
Google ScholarCrossrefWorldCat 
1089	Chaikof EL, Blankensteijn JD, Harris PL, White GH, Zarins CK, Bernhard VM, et al.  Reporting standards for endovascular aortic aneurysm repair. J Vasc Surg 2002;35:1048–60. https://doi.org/10.1067/mva.2002.123763
Google ScholarCrossrefWorldCat 
1090	Falster MO, Garland SK, Jorm LR, Beiles CB, Freeman AJ, Sedrakyan A, et al.  Editor’s choice—comparison of outcomes for major contemporary endograft devices used for endovascular repair of intact abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2023;65:272–80. https://doi.org/10.1016/j.ejvs.2022.11.005
Google ScholarCrossrefWorldCat 
1091	van Laarhoven C, Jorritsma NKN, Balderston J, Brinjikji W, Björck M, van Herwaarden JA, et al.  Systematic review of the co-prevalence of arterial aneurysms within the vasculature. Eur J Vasc Endovasc Surg 2021;61:473–83. https://doi.org/10.1016/j.ejvs.2020.10.002
Google ScholarCrossrefWorldCat 
1092	Hohneck A, Keese M, Ruemenapf G, Amendt K, Muertz H, Janda K, et al.  Prevalence of abdominal aortic aneurysm and associated lower extremity artery aneurysm in men hospitalized for suspected or known cardiopulmonary disease. BMC Cardiovasc Disord 2019;19:284. https://doi.org/10.1186/s12872-019-1265-2
Google ScholarCrossrefWorldCat 
1093	D’Oria M, Scali S, Mao J, Szeberin Z, Thomson I, Beiles B, et al.  Association between hospital volume and failure to rescue after open or endovascular repair of intact abdominal aortic aneurysms in the vascunet and international consortium of vascular registries. Ann Surg 2021;274:e452–9. https://doi.org/10.1097/sla.0000000000005044
Google ScholarCrossrefWorldCat 
1094	Scali ST, Columbo JA, Suckow BD, D’Oria M, Neal D, Goodney PP, et al.  Center volume is associated with diminished failure to rescue and improved outcomes following elective open abdominal aortic aneurysm repair. J Vasc Surg 2022;76:400–8.e2. https://doi.org/10.1016/j.jvs.2021.12.076
Google ScholarCrossrefWorldCat 
1095	Eid MA, Barnes JA, Mehta K, Wanken Z, Columbo J, Kang R, et al.  Factors associated with preference of choice of aortic aneurysm repair in the PReference for Open Versus Endovascular repair of AAA (PROVE-AAA) study. J Vasc Surg 2022;76:1556–64. https://doi.org/10.1016/j.jvs.2022.06.018
Google ScholarCrossrefWorldCat 
1096	Wanhainen A, Verzini F, Van Herzeele I, Allaire E, Bown M, Cohnert T, et al.  Editor’s choice—European Society for Vascular Surgery (ESVS) 2019 clinical practice guidelines on the management of abdominal aorto-iliac artery aneurysms. Eur J Vasc Endovasc Surg 2019;57:8–93. https://doi.org/10.1016/j.ejvs.2018.09.020
Google ScholarCrossrefWorldCat 
1097	Reise JA, Sheldon H, Earnshaw J, Naylor AR, Dick F, Powell JT, et al.  Patient preference for surgical method of abdominal aortic aneurysm repair: postal survey. Eur J Vasc Endovasc Surg 2010;39:55–61. https://doi.org/10.1016/j.ejvs.2009.08.008
Google ScholarCrossrefWorldCat 
1098	EVAR trial participants. Endovascular aneurysm repair and outcome in patients unfit for open repair of abdominal aortic aneurysm (EVAR trial 2): randomised controlled trial. Lancet 2005;365:2187–92. https://doi.org/10.1016/s0140-6736(05)66628-7
CrossrefWorldCat 
1099	Greenhalgh RM, Brown LC, Powell JT, Thompson SG, Epstein D. Endovascular repair of aortic aneurysm in patients physically ineligible for open repair. N Engl J Med 2010;362:1872–80. https://doi.org/10.1056/NEJMoa0911056
Google ScholarWorldCat 
1100	Patel R, Sweeting MJ, Powell JT, Greenhalgh RM. Endovascular versus open repair of abdominal aortic aneurysm in 15-years’ follow-up of the UK endovascular aneurysm repair trial 1 (EVAR trial 1): a randomised controlled trial. Lancet 2016;388:2366–74. https://doi.org/10.1016/s0140-6736(16)31135-7
Google ScholarCrossrefWorldCat 
1101	Lederle FA, Kyriakides TC, Stroupe KT, Freischlag JA, Padberg FT, Matsumura JS, et al.  Open versus endovascular repair of abdominal aortic aneurysm. N Engl J Med 2019;380:2126–35. https://doi.org/10.1056/NEJMoa1715955
Google ScholarCrossrefWorldCat 
1102	Lederle FA, Freischlag JA, Kyriakides TC, Matsumura JS, Padberg FT, Kohler TR, et al.  Long-term comparison of endovascular and open repair of abdominal aortic aneurysm. N Engl J Med 2012;367:1988–97. https://doi.org/10.1056/NEJMoa1207481
Google ScholarCrossrefWorldCat 
1103	Schermerhorn ML, Buck DB, O’Malley AJ, Curran T, McCallum JC, Darling Jet al.  et al.  Long-term outcomes of abdominal aortic aneurysm in the Medicare population. N Engl J Med 2015;373:328–38. https://doi.org/10.1056/NEJMoa1405778
Google ScholarCrossrefWorldCat 
1104	Nana P, Dakis K, Brodis A, Spanos K, Kouvelos G, Eckstein H-H, et al.  A systematic review and meta-analysis on early mortality after abdominal aortic aneurysm repair in females in urgent and elective settings. J Vasc Surg 2022;75:1082–8.e6. https://doi.org/10.1016/j.jvs.2021.10.040
Google ScholarCrossrefWorldCat 
1105	Böckler D, Power AH, Bouwman LH, van Sterkenburg S, Bosiers M, Peeters P, et al.  Improvements in patient outcomes with next generation endovascular aortic repair devices in the ENGAGE global registry and the EVAR-1 clinical trial. J Cardiovasc Surg 2020;61:604–9. https://doi.org/10.23736/s0021-9509.19.11021-x
Google ScholarCrossrefWorldCat 
1106	Teijink JAW, Power AH, Böckler D, Peeters P, van Sterkenburg S, Bouwman LH, et al.  Editor’s choice—five year outcomes of the endurant stent graft for endovascular abdominal aortic aneurysm repair in the ENGAGE registry. Eur J Vasc Endovasc Surg 2019;58:175–81. https://doi.org/10.1016/j.ejvs.2019.01.008
Google ScholarCrossrefWorldCat 
1107	Oliveira-Pinto J, Oliveira NFG, Bastos-Gonçalves FM, Hoeks S, Rijn MJV, Raa ST, et al.  Long-term results after standard endovascular aneurysm repair with the endurant and excluder stent grafts. J Vasc Surg 2020;71:64–74. https://doi.org/10.1016/j.jvs.2019.03.039
Google ScholarCrossrefWorldCat 
1108	Deery SE, Shean KE, Pothof AB, O'Donnell TFX, Dalebout BA, Darling JD, et al.  Three-Year Results of the Endurant Stent Graft System Post Approval Study. Ann Vasc Surg 2018;50:202–8. https://doi.org/10.1016/j.avsg.2017.12.017
Google ScholarCrossrefWorldCat 
1109	Prinssen M, Verhoeven EL, Buth J, Cuypers PWM, van Sambeek MRHM, Balm R, et al.  A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms. N Engl J Med 2004;351:1607–18. https://doi.org/10.1056/NEJMoa042002
Google ScholarCrossrefWorldCat 
1110	Dakour-Aridi H, Paracha NZ, Locham S, Nejim B, Malas MB. Assessment of failure to rescue after abdominal aortic aneurysm repair using the National Surgical Quality Improvement Program procedure-targeted data set. J Vasc Surg 2018;68:1335–44.e1. https://doi.org/10.1016/j.jvs.2018.01.059
Google ScholarCrossrefWorldCat 
1111	Scali ST, Giles KA, Kubilis P, Beck AW, Crippen CJ, Hughes SJ, et al.  Impact of hospital volume on patient safety indicators and failure to rescue following open aortic aneurysm repair. J Vasc Surg 2020;71:1135–46.e4. https://doi.org/10.1016/j.jvs.2019.06.194
Google ScholarCrossrefWorldCat 
1112	Ma B, Wang YN, Chen KY, Zhang Y, Pan H, Yang K. Transperitoneal versus retroperitoneal approach for elective open abdominal aortic aneurysm repair. Cochrane Database Syst Rev 2016;2:CD010373. https://doi.org/10.1002/14651858.CD010373.pub2
Google ScholarWorldCat 
1113	Camazine M, Bath J, Singh P, Kruse RL, Vogel TR. Characteristics associated with failure to rescue after open abdominal aortic aneurysm repair. J Surg Res 2023;283:683–9. https://doi.org/10.1016/j.jss.2022.11.018
Google ScholarCrossrefWorldCat 
1114	Blair R, Harkin D, Johnston D, Lim A, McFetridge L, Mitchell H. Open surgery for abdominal aortic aneurysm: 980 consecutive patient outcomes from a high-volume centre in the United Kingdom. Vasc Endovascular Surg 2023;57:463–70. https://doi.org/10.1177/15385744221149585
Google ScholarCrossrefWorldCat 
1115	Hoornweg LL, Storm-Versloot MN, Ubbink DT, Koelemay MJW, Legemate DA, Balm R, et al.  Meta analysis on mortality of ruptured abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2008;35:558–70. https://doi.org/10.1016/j.ejvs.2007.11.019
Google ScholarCrossrefWorldCat 
1116	Kontopodis N, Galanakis N, Antoniou SA, Tsetis D, Ioannou CV, Veith FJ, et al.  Meta-analysis and meta-regression analysis of outcomes of endovascular and open repair for ruptured abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 2020;59:399–410. https://doi.org/10.1016/j.ejvs.2019.12.023
Google ScholarCrossrefWorldCat 
1117	Wang LJ, Locham S, Al-Nouri O, Eagleton MJ, Clouse WD, Malas MB. Endovascular repair of ruptured abdominal aortic aneurysm is superior to open repair: propensity-matched analysis in the vascular quality initiative. J Vasc Surg 2020;72:498–507. https://doi.org/10.1016/j.jvs.2019.11.063
Google ScholarCrossrefWorldCat 
1118	Tan TW, Eslami M, Rybin D, Doros G, Zhang WW, Farber A. Outcomes of endovascular and open surgical repair of ruptured abdominal aortic aneurysms in elderly patients. J Vasc Surg 2017;66:64–70. https://doi.org/10.1016/j.jvs.2016.10.119
Google ScholarCrossrefWorldCat 
1119	Dewulf M, Muysoms F, Vierendeels T, Huyghe M, Miserez M, Ruppert M, et al.  Prevention of incisional hernias by prophylactic mesh-augmented reinforcement of midline laparotomies for abdominal aortic aneurysm treatment: five-year follow-up of a randomized controlled trial. Ann Surg 2022;276:e217–22. https://doi.org/10.1097/sla.0000000000005545
Google ScholarCrossrefWorldCat 
1120	Honig S, Diener H, Kölbel T, Reinpold W, Zapf A, Bibiza-Freiwald E, et al.  Abdominal incision defect following AAA-surgery (AIDA): 2-year results of prophylactic onlay-mesh augmentation in a multicentre, double-blind, randomised controlled trial. Updates Surg 2022;74:1105–16. https://doi.org/10.1007/s13304-021-01125-0
Google ScholarCrossrefWorldCat 
1121	Indrakusuma R, Jalalzadeh H, van der Meij JE, Balm R, Koelemay MJW. Prophylactic mesh reinforcement versus sutured closure to prevent incisional hernias after open abdominal aortic aneurysm repair via midline laparotomy: a systematic review and meta-analysis. Eur J Vasc Endovasc Surg 2018;56:120–8. https://doi.org/10.1016/j.ejvs.2018.03.021
Google ScholarCrossrefWorldCat 
1122	van Keulen JW, de Vries JP, Dekker H, Gonçalves FB, Moll FL, Verhagen HJ, et al.  One-year multicenter results of 100 abdominal aortic aneurysm patients treated with the endurant stent graft. J Vasc Surg 2011;54:609–15. https://doi.org/10.1016/j.jvs.2011.02.053
Google ScholarCrossrefWorldCat 
1123	Piazza M, Squizzato F, Suominen V, Grego F, Trimarchi S, Antonello M, et al.  Early and long-term outcomes of endovascular aortic repair in young and low surgical risk patients in the global registry for endovascular aortic treatment. J Endovasc Ther 2022;29:248–57. https://doi.org/10.1177/15266028211045703
Google ScholarCrossrefWorldCat 
1124	Paravastu SC, Jayarajasingam R, Cottam R, Palfreyman SJ, Michaels JA, Thomas SM. Endovascular repair of abdominal aortic aneurysm. Cochrane Database Syst Rev 2014;1:CD004178. https://doi.org/10.1002/14651858.CD004178.pub2
Google ScholarWorldCat 
1125	Dosluoglu HH, Lall P, Blochle R, Harris LM, Dryjski ML. Ambulatory percutaneous endovascular abdominal aortic aneurysm repair. J Vasc Surg 2014;59:58–64. https://doi.org/10.1016/j.jvs.2013.06.076
Google ScholarCrossrefWorldCat 
1126	Geragotellis A, Cox K, Yip HCA, Jubouri M, Williams IM, Bailey DM, et al.  Renal outcomes of suprarenal vs. infrarenal endograft fixation in endovascular abdominal aortic aneurysm repair: a narrative review. Cardiovasc Diagn Ther 2022;12:531–44. https://doi.org/10.21037/cdt-22-196
Google ScholarCrossrefWorldCat 
1127	Verhoeven EL, Katsargyris A, Bachoo P, Larzon T, Fisher R, Ettles D, et al.  Real-world performance of the new C3 gore excluder stent-graft: 1-year results from the European C3 module of the global registry for endovascular aortic treatment (GREAT). Eur J Vasc Endovasc Surg 2014;48:131–7. https://doi.org/10.1016/j.ejvs.2014.04.009
Google ScholarCrossrefWorldCat 
1128	Torsello G, Scheinert D, Brunkwall JS, Chiesa R, Coppi G, Pratesi C. Safety and effectiveness of the INCRAFT AAA stent graft for endovascular repair of abdominal aortic aneurysms. J Vasc Surg 2015;61:1–8. https://doi.org/10.1016/j.jvs.2014.06.007
Google ScholarCrossrefWorldCat 
1129	Kontopodis N, Galanakis N, Tzartzalou I, Tavlas E, Georgakarakos E, Dimopoulos I, et al.  An update on the improvement of patient eligibility with the use of new generation endografts for the treatment of abdominal aortic aneurysms. Expert Rev Med Devices 2020;17:1231–8. https://doi.org/10.1080/17434440.2020.1841629
Google ScholarCrossrefWorldCat 
1130	Kontopodis N, Papadopoulos G, Galanakis N, Tsetis D, Ioannou CV. Improvement of patient eligibility with the use of new generation endografts for the treatment of abdominal aortic aneurysms. A comparison study among currently used endografts and literature review. Expert Rev Med Devices 2017;14:245–50. https://doi.org/10.1080/17434440.2017.1281738
Google ScholarCrossrefWorldCat 
1131	Zlatanovic P, Mascia D, Ancetti S, Yeung KK, Graumans MJ, Jongkind V, et al.  Short term and long term clinical outcomes of endovascular versus open repair for juxtarenal and pararenal abdominal aortic aneurysms using propensity score matching: results from juxta- and pararenal aortic aneurysm multicentre European study (JAMES). Eur J Vasc Endovasc Surg 2023;65:828–36. https://doi.org/10.1016/j.ejvs.2023.02.070
Google ScholarCrossrefWorldCat 
1132	Hajibandeh S, Hajibandeh S, Antoniou SA, Child E, Torella F, Antoniou GA. Percutaneous access for endovascular aortic aneurysm repair: a systematic review and meta-analysis. Vascular 2016;24:638–48. https://doi.org/10.1177/1708538116639201
Google ScholarCrossrefWorldCat 
1133	Antoniou GA, Antoniou SA. Editor’s choice—percutaneous access does not confer superior clinical outcomes over cutdown access for endovascular aneurysm repair: meta-analysis and trial sequential analysis of randomised controlled trials. Eur J Vasc Endovasc Surg 2021;61:383–94. https://doi.org/10.1016/j.ejvs.2020.11.008
Google ScholarCrossrefWorldCat 
1134	Cao Z, Wu W, Zhao K, Yang Yu, Jiang C, Zhu R. Safety and efficacy of totally percutaneous access compared with open femoral exposure for endovascular aneurysm repair: a meta-analysis. J Endovasc Ther 2017;24:246–53. https://doi.org/10.1177/1526602816689679
Google ScholarCrossrefWorldCat 
1135	Wang Q, Wu J, Ma Y, Zhu Y, Song X, Xie S, et al.  Totally percutaneous versus surgical cut-down femoral artery access for elective bifurcated abdominal endovascular aneurysm repair. Cochrane Database Syst Rev 2023;1:CD010185. https://doi.org/10.1002/14651858.CD010185.pub4
Google ScholarWorldCat 
1136	Antoniou GA, Georgiadis GS, Antoniou SA, Neequaye S, Brennan JA, Torella F, et al.  Late rupture of abdominal aortic aneurysm after previous endovascular repair: a systematic review and meta-analysis. J Endovasc Ther 2015;22:734–44. https://doi.org/10.1177/1526602815601405
Google ScholarCrossrefWorldCat 
1137	Fransen GA, Vallabhaneni SR, Sr, van Marrewijk CJ, Laheij RJF, Harris PL, Buth J. Rupture of infra-renal aortic aneurysm after endovascular repair: a series from EUROSTAR registry. Eur J Vasc Endovasc Surg 2003;26:487–93. https://doi.org/10.1016/s1078-5884(03)00350-2
Google ScholarCrossrefWorldCat 
1138	Marcaccio CL, Patel PB, de Guerre L, Wade JE, Rastogi V, Anjorin A, et al.  Disparities in 5-year outcomes and imaging surveillance following elective endovascular repair of abdominal aortic aneurysm by sex, race, and ethnicity. J Vasc Surg 2022;76:1205–15.e4. https://doi.org/10.1016/j.jvs.2022.03.886
Google ScholarCrossrefWorldCat 
1139	Schlösser FJ, Gusberg RJ, Dardik A, Lin PH, Verhagen HJM, Moll FL, et al.  Aneurysm rupture after EVAR: can the ultimate failure be predicted? Eur J Vasc Endovasc Surg 2009;37:15–22. https://doi.org/10.1016/j.ejvs.2008.10.011
Google ScholarCrossrefWorldCat 
1140	Stather PW, Sidloff D, Dattani N, Choke E, Bown MJ, Sayers RD. Systematic review and meta-analysis of the early and late outcomes of open and endovascular repair of abdominal aortic aneurysm. Br J Surg 2013;100:863–72. https://doi.org/10.1002/bjs.9101
Google ScholarCrossrefWorldCat 
1141	Swart M, McCarthy R. Shared decision making for elective abdominal aortic aneurysm surgery. Clin Med (Lond) 2019;19:473–7. https://doi.org/10.7861/clinmed.2019-0352
Google ScholarCrossrefWorldCat 
1142	Stubenrouch FE, Peters LJ, de Mik SML, Klemm PL, Peppelenbosch AG, Schreurs SCWM, et al.  Improving shared decision making in vascular surgery: a stepped wedge cluster randomised trial. Eur J Vasc Endovasc Surg 2022;64:73–81. https://doi.org/10.1016/j.ejvs.2022.04.016
Google ScholarCrossrefWorldCat 
1143	Machin M, Van Herzeele I, Ubbink D, Powell JT. Shared decision making in and management of intact abdominal aortic aneurysm: a scoping review of the literature. Eur J Vasc Endovasc Surg 2023;65:839–49. https://doi.org/10.1016/j.ejvs.2023.01.036
Google ScholarCrossrefWorldCat 
1144	Karthaus EG, Tong TML, Vahl A, Hamming JF. Saccular abdominal aortic aneurysms: patient characteristics, clinical presentation, treatment, and outcomes in the Netherlands. Ann Surg 2019;270:852–8. https://doi.org/10.1097/sla.0000000000003529
Google ScholarCrossrefWorldCat 
1145	O'Donnell TF, McElroy IE, Mohebali J, Boitano LT, Lamuraglia GM, Kwolek CJ, et al.  Late type 1A endoleaks: associated factors, prognosis and management strategies. Ann Vasc Surg 2022;80:273–82. https://doi.org/10.1016/j.avsg.2021.08.057
Google ScholarCrossrefWorldCat 
1146	De Rango P, Verzini F, Parlani G, Cieri E, Simonte G, Farchioni L, et al.  Safety of chronic anticoagulation therapy after endovascular abdominal aneurysm repair (EVAR). Eur J Vasc Endovasc Surg 2014;47:296–303. https://doi.org/10.1016/j.ejvs.2013.12.009
Google ScholarCrossrefWorldCat 
1147	Rokosh RS, Wu WW, Dalman RL, Chaikof EL. Society for Vascular Surgery implementation of clinical practice guidelines for patients with an abdominal aortic aneurysm. Endoleak management. J Vasc Surg 2021;74:1792–4. https://doi.org/10.1016/j.jvs.2021.04.042
Google ScholarCrossrefWorldCat 
1148	Jordan WD, Jr, Mehta M, Varnagy D, Moore WM, Arko FR, Joye J, et al.  Results of the ANCHOR prospective, multicenter registry of EndoAnchors for type Ia endoleaks and endograft migration in patients with challenging anatomy. J Vasc Surg 2014;60:885–92.e2. https://doi.org/10.1016/j.jvs.2014.04.063
Google ScholarCrossrefWorldCat 
1149	Sidloff DA, Stather PW, Choke E, Bown MJ, Sayers RD. Type II endoleak after endovascular aneurysm repair. Br J Surg 2013;100:1262–70. https://doi.org/10.1002/bjs.9181
Google ScholarCrossrefWorldCat 
1150	Daye D, Walker TG. Complications of endovascular aneurysm repair of the thoracic and abdominal aorta: evaluation and management. Cardiovasc Diagn Ther 2018;8:S138–56. https://doi.org/10.21037/cdt.2017.09.17
Google ScholarCrossrefWorldCat 
1151	Latson LA, Jr, DeAnda A, Jr, Ko JP. Imaging of the postsurgical thoracic aorta: a state-of-the-art review. J Thorac Imaging 2017;32:1–25. https://doi.org/10.1097/rti.0000000000000246
Google ScholarCrossrefWorldCat 
1152	Prescott-Focht JA, Martinez-Jimenez S, Hurwitz LM, Hoang JK, Christensen JD, Ghoshhajra BB, et al.  Ascending thoracic aorta: postoperative imaging evaluation. Radiographics 2013;33:73–85. https://doi.org/10.1148/rg.331125090
Google ScholarCrossrefWorldCat 
1153	Riambau V, Böckler D, Brunkwall J, Cao P, Chiesa R, Coppi G, et al.  Editor’s choice—management of descending thoracic aorta diseases: clinical practice guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 2017;53:4–52. https://doi.org/10.1016/j.ejvs.2016.06.005
Google ScholarCrossrefWorldCat 
1154	Quevedo HC, Santiago-Trinidad R, Castellanos J, Atianzar K, Anwar A, Abi Rafeh N. Systematic review of interventions to repair ascending aortic pseudoaneurysms. Ochsner J 2014;14:576–85.
Google ScholarWorldCat 
1155	Mesana TG, Caus T, Gaubert J, Collart F, Ayari R, Bartoli J-M, et al.  Late complications after prosthetic replacement of the ascending aorta: what did we learn from routine magnetic resonance imaging follow-up? Eur J Cardiothorac Surg 2000;18:313–20. https://doi.org/10.1016/s1010-7940(00)00512-1
Google ScholarCrossrefWorldCat 
1156	Bianco V, Kilic A, Gleason TG, Arnaoutakis GJ, Sultan I. Management of thoracic aortic graft infections. J Card Surg 2018;33:658–65. https://doi.org/10.1111/jocs.13792
Google ScholarCrossrefWorldCat 
1157	Liisberg M, Baudier F, Akgül C, Lindholt JS. Long-term thoracic endovascular repair follow-up from 1999 to 2019: a single-center experience. Ann Vasc Surg 2022;86:399–407. https://doi.org/10.1016/j.avsg.2022.04.013
Google ScholarCrossrefWorldCat 
1158	Nakhaei P, Bashir M, Jubouri M, Banar S, Ilkhani S, Borzeshi EZ, et al.  Aortic remodeling, distal stent-graft induced new entry and endoleak following frozen elephant trunk: a systematic review and meta-analysis. J Card Surg 2022;37:3848–62. https://doi.org/10.1111/jocs.16918
Google ScholarCrossrefWorldCat 
1159	Iribarne A, Keenan J, Benrashid E, Wang H, Meza JM, Ganapathi A, et al.  Imaging surveillance after proximal aortic operations: is it necessary? Ann Thorac Surg 2017;103:734–41. https://doi.org/10.1016/j.athoracsur.2016.06.085
Google ScholarCrossrefWorldCat 
1160	Hensley SE, Upchurch GR, Jr. Repair of abdominal aortic aneurysms: JACC focus seminar, part 1. J Am Coll Cardiol 2022;80:821–31. https://doi.org/10.1016/j.jacc.2022.04.066
Google ScholarCrossrefWorldCat 
1161	Bastos Gonçalves F, Baderkhan H, Verhagen HJ, Wanhainen A, Björck M, Stolker RJ, et al.  Early sac shrinkage predicts a low risk of late complications after endovascular aortic aneurysm repair. Br J Surg 2014;101:802–10. https://doi.org/10.1002/bjs.9516
Google ScholarCrossrefWorldCat 
1162	Troutman DA, Chaudry M, Dougherty MJ, Calligaro KD. Endovascular aortic aneurysm repair surveillance may not be necessary for the first 3 years after an initially normal duplex postoperative study. J Vasc Surg 2014;60:558–62. https://doi.org/10.1016/j.jvs.2014.03.278
Google ScholarCrossrefWorldCat 
1163	Jean-Baptiste E, Feugier P, Cruzel C, Sarlon-Bartoli G, Reix T, Steinmetz E, et al.  Computed tomography-aortography versus color-duplex ultrasound for surveillance of endovascular abdominal aortic aneurysm repair: a prospective multicenter diagnostic-accuracy study (the ESSEA trial). Circ Cardiovasc Imaging 2020;13:e009886. https://doi.org/10.1161/circimaging.119.009886
Google ScholarCrossrefWorldCat 
1164	Johnsen L, Hisdal J, Jonung T, Braaten A, Pedersen G. Contrast-enhanced ultrasound detects type II endoleaks during follow-up for endovascular aneurysm repair. J Vasc Surg 2020;72:1952–9. https://doi.org/10.1016/j.jvs.2020.02.020
Google ScholarCrossrefWorldCat 
1165	George J, Tadros RO, Rao A, Png CYM, Han DK, Ilonzo N, et al.  Duplex ultrasound can successfully identify endoleaks and renovisceral stent patency in patients undergoing complex endovascular aneurysm repair. Vasc Endovascular Surg 2021;55:234–8. https://doi.org/10.1177/1538574420980605
Google ScholarCrossrefWorldCat 
1166	Smith L, Thomas N, Arnold A, Bell R, Zayed H, Tyrrell M, et al.  Editor’s choice—a comparison of computed tomography angiography and colour duplex ultrasound surveillance post infrarenal endovascular aortic aneurysm repair: financial implications and impact of different international surveillance guidelines. Eur J Vasc Endovasc Surg 2021;62:193–201. https://doi.org/10.1016/j.ejvs.2021.04.005
Google ScholarCrossrefWorldCat 
1167	Iscan HZ, Unal EU, Akkaya B, Daglı M, Karahan M, Civelek I, et al.  Color Doppler ultrasound for surveillance following EVAR as the primary tool. J Card Surg 2021;36:111–7. https://doi.org/10.1111/jocs.15194
Google ScholarCrossrefWorldCat 
1168	Antoniou GA, Kontopodis N, Rogers SK, Golledge J, Forbes TL, Torella F, et al.  Editor’s choice—meta-analysis of compliance with endovascular aneurysm repair surveillance: the EVAR surveillance paradox. Eur J Vasc Endovasc Surg 2023;65:244–54. https://doi.org/10.1016/j.ejvs.2022.10.033
Google ScholarCrossrefWorldCat 
1169	Baderkhan H, Haller O, Wanhainen A, Björck M, Mani K. Follow-up after endovascular aortic aneurysm repair can be stratified based on first postoperative imaging. Br J Surg 2018;105:709–18. https://doi.org/10.1002/bjs.10766
Google ScholarCrossrefWorldCat 
1170	Png CY, Tadros RO, Faries PL, Torres MR, Kim SY, Lookstein R, et al.  The effect of age on post-EVAR outcomes. Ann Vasc Surg 2016;35:156–62. https://doi.org/10.1016/j.avsg.2016.01.022
Google ScholarCrossrefWorldCat 
1171	Xiong X, Wu Z, Qin X, Huang Q, Wang X, Qin J, et al.  Meta-analysis suggests statins reduce mortality after abdominal aortic aneurysm repair. J Vasc Surg 2022;75:356–62.e4. https://doi.org/10.1016/j.jvs.2021.06.033
Google ScholarCrossrefWorldCat 
1172	Schrimpf C, Teebken OE, Wilhelmi M. Thoracic endovascular aortic repair after iatrogenic aortic dissection and false lumen stent grafting. Ann Thorac Surg 2015;99:1447–9. https://doi.org/10.1016/j.athoracsur.2014.05.101
Google ScholarCrossrefWorldCat 
1173	Sampson UK, Norman PE, Fowkes FG, Aboyans V, Song Y, Harrell FE, Jr, et al.  Global and regional burden of aortic dissection and aneurysms: mortality trends in 21 world regions, 1990 to 2010. Glob Heart 2014;9:171–80.e110. https://doi.org/10.1016/j.gheart.2013.12.010
Google ScholarCrossrefWorldCat 
1174	Clough RE, Nienaber CA. Management of acute aortic syndrome. Nat Rev Cardiol 2015;12:103–14. https://doi.org/10.1038/nrcardio.2014.203
Google ScholarCrossrefWorldCat 
1175	Evangelista A, Isselbacher EM, Bossone E, Gleason TG, Eusanio MD, Sechtem U, et al.  Insights from the international registry of acute aortic dissection: a 20-year experience of collaborative clinical research. Circulation 2018;137:1846–60. https://doi.org/10.1161/circulationaha.117.031264
Google ScholarCrossrefWorldCat 
1176	Booher AM, Isselbacher EM, Nienaber CA, Trimarchi S, Evangelista A, Montgomery DG, et al.  The IRAD classification system for characterizing survival after aortic dissection. Am J Med 2013;126:730.e19–24. https://doi.org/10.1016/j.amjmed.2013.01.020
Google ScholarCrossrefWorldCat 
1177	Howard C, Ponnapalli A, Shaikh S, Idhrees M, Bashir M. Non-A non-B aortic dissection: a literature review. J Card Surg 2021;36:1806–13. https://doi.org/10.1111/jocs.15349
Google ScholarCrossrefWorldCat 
1178	Urbanski PP, Wagner M. Acute non-A-non-B aortic dissection: surgical or conservative approach? Eur J Cardiothorac Surg 2016;49:1249–54. https://doi.org/10.1093/ejcts/ezv301
Google ScholarCrossrefWorldCat 
1179	Carino D, Singh M, Molardi A, Agostinelli A, Goldoni M, Pacini D, et al.  Non-A non-B aortic dissection: a systematic review and meta-analysis. Eur J Cardiothorac Surg 2019;55:653–9. https://doi.org/10.1093/ejcts/ezy337
Google ScholarCrossrefWorldCat 
1180	Sievers HH, Rylski B, Czerny M, Baier ALM, Kreibich M, Siepe M, et al.  Aortic dissection reconsidered: type, entry site, malperfusion classification adding clarity and enabling outcome prediction. Interact Cardiovasc Thorac Surg 2020;30:451–7. https://doi.org/10.1093/icvts/ivz281
Google ScholarCrossrefWorldCat 
1181	Aboyans V, Boukhris M. Dissecting the epidemiology of aortic dissection. Eur Heart J Acute Cardiovasc Care 2021;10:710–1. https://doi.org/10.1093/ehjacc/zuab065
Google ScholarCrossrefWorldCat 
1182	Pape LA, Awais M, Woznicki EM, Suzuki T, Trimarchi S, Evangelista A, et al.  Presentation, diagnosis, and outcomes of acute aortic dissection: 17-year trends from the international registry of acute aortic dissection. J Am Coll Cardiol 2015;66:350–8. https://doi.org/10.1016/j.jacc.2015.05.029
Google ScholarCrossrefWorldCat 
1183	Januzzi JL, Isselbacher EM, Fattori R, Cooper JV, Smith DE, Fang J, et al.  Characterizing the young patient with aortic dissection: results from the international registry of aortic dissection (IRAD). J Am Coll Cardiol 2004;43:665–9. https://doi.org/10.1016/j.jacc.2003.08.054
Google ScholarCrossrefWorldCat 
1184	Dalen JE, Alpert JS, Goldberg RJ, Weinstein RS. The epidemic of the 20(th) century: coronary heart disease. Am J Med 2014;127:807–12. https://doi.org/10.1016/j.amjmed.2014.04.015
Google ScholarCrossrefWorldCat 
1185	Bossone E, Pyeritz RE, O'Gara P, Harris KM, Braverman AC, Pape L, et al.  Acute aortic dissection in blacks: insights from the international registry of acute aortic dissection. Am J Med 2013;126:909–15. https://doi.org/10.1016/j.amjmed.2013.04.020
Google ScholarCrossrefWorldCat 
1186	Rylski B, Hoffmann I, Beyersdorf F, Suedkamp M, Siepe M, Nitsch B, et al.  Iatrogenic acute aortic dissection type A: insight from the German registry for acute aortic dissection type A (GERAADA). Eur J Cardiothorac Surg 2013;44:353–9; discussion 359. https://doi.org/10.1093/ejcts/ezt055
Google ScholarCrossrefWorldCat 
1187	Núñez-Gil IJ, Bautista D, Cerrato E, Salinas P, Varbella F, Omedè P, et al.  Incidence, management, and immediate- and long-term outcomes after iatrogenic aortic dissection during diagnostic or interventional coronary procedures. Circulation 2015;131:2114–9. https://doi.org/10.1161/circulationaha.115.015334
Google ScholarCrossrefWorldCat 
1188	Carbone A, Ranieri B, Castaldo R, Franzese M, Rega S, Cittadini A, et al.  Sex differences in type A acute aortic dissection: a systematic review and meta-analysis. Eur J Prev Cardiol 2023;30:1074–89. https://doi.org/10.1093/eurjpc/zwad009
Google ScholarCrossrefWorldCat 
1189	Nienaber CA, Fattori R, Mehta RH, Richartz BM, Evangelista A, Petzsch M, et al.  Gender-related differences in acute aortic dissection. Circulation 2004;109:3014–21. https://doi.org/10.1161/01.Cir.0000130644.78677.2c
Google ScholarCrossrefWorldCat 
1190	Manalo-Estrella P, Barker AE. Histopathologic findings in human aortic media associated with pregnancy. Arch Pathol 1967;83:336–41.
Google ScholarWorldCat 
1191	Lempel JK, Frazier AA, Jeudy J, Kligerman SJ, Schultz R, Ninalowo HA, et al.  Aortic arch dissection: a controversy of classification. Radiology 2014;271:848–55. https://doi.org/10.1148/radiol.14131457
Google ScholarCrossrefWorldCat 
1192	Mussa FF, Horton JD, Moridzadeh R, Nicholson J, Trimarchi S, Eagle KA. Acute aortic dissection and intramural hematoma: a systematic review. JAMA 2016;316:754–63. https://doi.org/10.1001/jama.2016.10026
Google ScholarCrossrefWorldCat 
1193	Tsai TT, Trimarchi S, Nienaber CA. Acute aortic dissection: perspectives from the international registry of acute aortic dissection (IRAD). Eur J Vasc Endovasc Surg 2009;37:149–59. https://doi.org/10.1016/j.ejvs.2008.11.032
Google ScholarCrossrefWorldCat 
1194	Neri E, Toscano T, Papalia U, Frati G, Massetti M, Capannini G, et al.  Proximal aortic dissection with coronary malperfusion: presentation, management, and outcome. J Thorac Cardiovasc Surg 2001;121:552–60. https://doi.org/10.1067/mtc.2001.112534
Google ScholarCrossrefWorldCat 
1195	Trimarchi S, Tsai T, Eagle KA, Isselbacher EM, Froehlich J, et al.  Acute abdominal aortic dissection: insight from the International Registry of Acute Aortic Dissection (IRAD). J Vasc Surg 2007;46:913–9. https://doi.org/10.1016/j.jvs.2007.07.030
Google ScholarCrossrefWorldCat 
1196	Gorla R, Erbel R, Kahlert P, Tsagakis K, Jakob H, Mahabadi A-A, et al.  Accuracy of a diagnostic strategy combining aortic dissection detection risk score and D-dimer levels in patients with suspected acute aortic syndrome. Eur Heart J Acute Cardiovasc Care 2017;6:371–8. https://doi.org/10.1177/2048872615594497
Google ScholarCrossrefWorldCat 
1197	Strayer RJ, Shearer PL, Hermann LK. Screening, evaluation, and early management of acute aortic dissection in the ED. Curr Cardiol Rev 2012;8:152–7. https://doi.org/10.2174/157340312801784970
Google ScholarCrossrefWorldCat 
1198	Nazerian P, Mueller C, Soeiro AM, Leidel BA, Salvadeo SAT, Giachino F, et al.  Diagnostic accuracy of the aortic dissection detection risk score plus D-dimer for acute aortic syndromes: the ADvISED prospective multicenter study. Circulation 2018;137:250–8. https://doi.org/10.1161/circulationaha.117.029457
Google ScholarCrossrefWorldCat 
1199	Bima P, Pivetta E, Nazerian P, Toyofuku M, Gorla R, Bossone E, et al.  Systematic review of aortic dissection detection risk score plus d-dimer for diagnostic rule-out of suspected acute aortic syndromes. Acad Emerg Med 2020;27:1013–27. https://doi.org/10.1111/acem.13969
Google ScholarCrossrefWorldCat 
1200	Rogers AM, Hermann LK, Booher AM, Nienaber CA, Williams DM, Kazerooni EA, et al.  Sensitivity of the aortic dissection detection risk score, a novel guideline-based tool for identification of acute aortic dissection at initial presentation: results from the international registry of acute aortic dissection. Circulation 2011;123:2213–8. https://doi.org/10.1161/CIRCULATIONAHA.110.988568
Google ScholarCrossrefWorldCat 
1201	Suzuki T, Distante A, Zizza A, Trimarchi S, Villani M, Salerno Uriarte JA, et al.  Diagnosis of acute aortic dissection by D-dimer: the international registry of acute aortic dissection substudy on biomarkers (IRAD-bio) experience. Circulation 2009;119:2702–7. https://doi.org/10.1161/circulationaha.108.833004
Google ScholarCrossrefWorldCat 
1202	Baliga RR, Nienaber CA, Bossone E, Oh JK, Isselbacher EM, Sechtem U, et al.  The role of imaging in aortic dissection and related syndromes. JACC Cardiovasc Imaging 2014;7:406–24. https://doi.org/10.1016/j.jcmg.2013.10.015
Google ScholarCrossrefWorldCat 
1203	Nazerian P, Mueller C, Vanni S, Soeiro AM, Leidel BA, Cerini G, et al.  Integration of transthoracic focused cardiac ultrasound in the diagnostic algorithm for suspected acute aortic syndromes. Eur Heart J 2019;40:1952–60. https://doi.org/10.1093/eurheartj/ehz207
Google ScholarCrossrefWorldCat 
1204	Shiga T, Wajima Z, Apfel CC, Inoue T, Ohe Y. Diagnostic accuracy of transesophageal echocardiography, helical computed tomography, and magnetic resonance imaging for suspected thoracic aortic dissection: systematic review and meta-analysis. Arch Intern Med 2006;166:1350–6. https://doi.org/10.1001/archinte.166.13.1350
Google ScholarCrossrefWorldCat 
1205	Nienaber CA, Clough RE. Management of acute aortic dissection. Lancet 2015;385:800–11. https://doi.org/10.1016/s0140-6736(14)61005-9
Google ScholarCrossrefWorldCat 
1206	Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al.  2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J 2023;44:3720–826. https://doi.org/10.1093/eurheartj/ehad191
Google ScholarCrossrefWorldCat 
1207	Rogers IS, Banerji D, Siegel EL, Truong QA, Ghoshhajra BB, Irlbeck T, et al.  Usefulness of comprehensive cardiothoracic computed tomography in the evaluation of acute undifferentiated chest discomfort in the emergency department (CAPTURE). Am J Cardiol 2011;107:643–50. https://doi.org/10.1016/j.amjcard.2010.10.039
Google ScholarCrossrefWorldCat 
1208	Evangelista A, Maldonado G, Gruosso D, Gutiérrez L, Granato C, Villalva N, et al.  The current role of echocardiography in acute aortic syndrome. Echo Res Pract 2019;6:R53–r63. https://doi.org/10.1530/erp-18-0058
Google ScholarCrossrefWorldCat 
1209	Vignon P, Guéret P, Vedrinne JM, Lagrange P, Cornu E, Abrieu O, et al.  Role of transesophageal echocardiography in the diagnosis and management of traumatic aortic disruption. Circulation 1995;92:2959–68. https://doi.org/10.1161/01.cir.92.10.2959
Google ScholarCrossrefWorldCat 
1210	Moral S, Avegliano G, Cuéllar H, Ballesteros E, Rodríguez-Palomares J, Teixidó G, et al.  Usefulness of transesophageal echocardiography in the evaluation of celiac trunk and superior mesenteric artery involvement in acute aortic dissection. J Am Soc Echocardiogr 2021;34:327–35. https://doi.org/10.1016/j.echo.2020.12.019
Google ScholarCrossrefWorldCat 
1211	Nienaber CA, Clough RE, Sakalihasan N, Suzuki T, Gibbs R, Mussa F, et al.  Aortic dissection. Nat Rev Dis Primers 2016;2:16053. https://doi.org/10.1038/nrdp.2016.53
Google ScholarCrossrefWorldCat 
1212	Vilacosta I, San Román JA, di Bartolomeo R, Eagle K, Estrera AL, Ferrera C, et al.  Acute aortic syndrome revisited: JACC state-of-the-art review. J Am Coll Cardiol 2021;78:2106–25. https://doi.org/10.1016/j.jacc.2021.09.022
Google ScholarCrossrefWorldCat 
1213	Tadros RO, Tang GHL, Barnes HJ, Mousavi I, Kovacic JC, Faries P, et al.  Optimal treatment of uncomplicated type B aortic dissection: JACC review topic of the week. J Am Coll Cardiol 2019;74:1494–504. https://doi.org/10.1016/j.jacc.2019.07.063
Google ScholarCrossrefWorldCat 
1214	Kodama K, Nishigami K, Sakamoto T, Sawamura T, Hirayama T, Misumi H, et al.  Tight heart rate control reduces secondary adverse events in patients with type B acute aortic dissection. Circulation 2008;118:S167–70. https://doi.org/10.1161/circulationaha.107.755801
Google ScholarCrossrefWorldCat 
1215	Estrera AL, Miller CC, III, Safi HJ, Goodrick JS, Keyhani A, Porat EE, et al.  Outcomes of medical management of acute type B aortic dissection. Circulation 2006;114:I384–389. https://doi.org/10.1161/circulationaha.105.001479
Google ScholarCrossrefWorldCat 
1216	Nejim B, Mathlouthi A, Naazie I, Malas MB. The effect of intravenous and oral beta-blocker use in patients with type B thoracic aortic dissection. Ann Vasc Surg 2022;80:170–9. https://doi.org/10.1016/j.avsg.2021.07.056
Google ScholarCrossrefWorldCat 
1217	Hameed I, Cifu AS, Vallabhajosyula P. Management of thoracic aortic dissection. JAMA 2023;329:756–7. https://doi.org/10.1001/jama.2023.0265
Google ScholarCrossrefWorldCat 
1218	Fukui T. Management of acute aortic dissection and thoracic aortic rupture. J Intensive Care 2018;6:15. https://doi.org/10.1186/s40560-018-0287-7
Google ScholarCrossrefWorldCat 
1219	Suzuki T, Mehta RH, Ince H, Nagai R, Sakomura Y, Weber F, et al.  Clinical profiles and outcomes of acute type B aortic dissection in the current era: lessons from the international registry of aortic dissection (IRAD). Circulation 2003;108:Ii312–7. https://doi.org/10.1161/01.cir.0000087386.07204.09
Google ScholarCrossrefWorldCat 
1220	Mehta RH, Suzuki T, Hagan PG, Bossone E, Gilon D, Llovet A, et al.  Predicting death in patients with acute type a aortic dissection. Circulation 2002;105:200–6. https://doi.org/10.1161/hc0202.102246
Google ScholarCrossrefWorldCat 
1221	Mészáros I, Mórocz J, Szlávi J, Schmidt J, Tornóci L, Nagy L, et al.  Epidemiology and clinicopathology of aortic dissection. Chest 2000;117:1271–8. https://doi.org/10.1378/chest.117.5.1271
Google ScholarCrossrefWorldCat 
1222	Glower DD, Speier RH, White WD, Smith LR, Rankin JS, Wolfe WG. Management and long-term outcome of aortic dissection. Ann Surg 1991;214:31–41. https://doi.org/10.1097/00000658-199107000-00006
Google ScholarCrossrefWorldCat 
1223	Nallamothu BK, Mehta RH, Saint S, Llovet A, Bossone E, Cooper JV, et al.  Syncope in acute aortic dissection: diagnostic, prognostic, and clinical implications. Am J Med 2002;113:468–71. https://doi.org/10.1016/s0002-9343(02)01254-8
Google ScholarCrossrefWorldCat 
1224	Suzuki T, Isselbacher EM, Nienaber CA, Pyeritz RE, Eagle KA, Tsai TT, et al.  Type-selective benefits of medications in treatment of acute aortic dissection (from the international registry of acute aortic dissection [IRAD]). Am J Cardiol 2012;109:122–7. https://doi.org/10.1016/j.amjcard.2011.08.012
Google ScholarCrossrefWorldCat 
1225	Palmer J, Gelmann D, Engelbrecht-Wiggans E, Hollis G, Hart E, Ali A, et al.  Invasive arterial blood pressure monitoring may aid in the medical management of hypertensive patients with acute aortic disease. Am J Emerg Med 2022;59:85–93. https://doi.org/10.1016/j.ajem.2022.06.054
Google ScholarCrossrefWorldCat 
1226	Nienaber CA, Kische S, Rousseau H, Eggebrecht H, Rehders TC, Kundt G, et al.  Endovascular repair of type B aortic dissection: long-term results of the randomized investigation of stent grafts in aortic dissection trial. Circ Cardiovasc Interv 2013;6:407–16. https://doi.org/10.1161/circinterventions.113.000463
Google ScholarCrossrefWorldCat 
1227	Fattori R, Montgomery D, Lovato L, Kische S, Di Eusanio M, Ince H, et al.  Survival after endovascular therapy in patients with type B aortic dissection: a report from the international registry of acute aortic dissection (IRAD). JACC Cardiovasc Interv 2013;6:876–82. https://doi.org/10.1016/j.jcin.2013.05.003
Google ScholarCrossrefWorldCat 
1228	Durham CA, Cambria RP, Wang LJ, Ergul EA, Aranson NJ, Patel VI, et al.  The natural history of medically managed acute type B aortic dissection. J Vasc Surg 2015;61:1192–8. https://doi.org/10.1016/j.jvs.2014.12.038
Google ScholarCrossrefWorldCat 
1229	Lou X, Chen EP, Duwayri YM, Veeraswamy RK, Jordan WD, Zehner CA, et al.  The impact of thoracic endovascular aortic repair on long-term survival in type B aortic dissection. Ann Thorac Surg 2018;105:31–8. https://doi.org/10.1016/j.athoracsur.2017.06.016
Google ScholarCrossrefWorldCat 
1230	Lou X, Duwayri YM, Chen EP, Jordan WD, Forcillo J, Zehner CA, et al.  Predictors of failure of medical management in uncomplicated type B aortic dissection. Ann Thorac Surg 2019;107:493–8. https://doi.org/10.1016/j.athoracsur.2018.08.012
Google ScholarCrossrefWorldCat 
1231	Lou X, Duwayri YM, Jordan WD, Jr, Chen EP, Veeraswamy RK, Leshnower BG. The safety and efficacy of extended TEVAR in acute type B aortic dissection. Ann Thorac Surg 2020;110:799–806. https://doi.org/10.1016/j.athoracsur.2019.12.036
Google ScholarCrossrefWorldCat 
1232	Hirst AE, Jr, Johns VJ, Jr, Kime SW, Jr. Dissecting aneurysm of the aorta: a review of 505 cases. Medicine 1958;37:217–79. https://doi.org/10.1097/00005792-195809000-00003
Google ScholarCrossrefWorldCat 
1233	Chiappini B, Schepens M, Tan E, Amore AD, Morshuis W, Dossche K, et al.  Early and late outcomes of acute type A aortic dissection: analysis of risk factors in 487 consecutive patients. Eur Heart J 2005;26:180–6. https://doi.org/10.1093/eurheartj/ehi024
Google ScholarCrossrefWorldCat 
1234	Harris KM, Nienaber CA, Peterson MD, Woznicki EM, Braverman AC, Trimarchi S, et al.  Early mortality in type A acute aortic dissection: insights from the international registry of acute aortic dissection. JAMA Cardiol 2022;7:1009–15. https://doi.org/10.1001/jamacardio.2022.2718
Google ScholarCrossrefWorldCat 
1235	Zhu Y, Lingala B, Baiocchi M, Tao JJ, Toro Arana V, Khoo JW, et al.  Type A aortic dissection-experience over 5 decades: JACC historical breakthroughs in perspective. J Am Coll Cardiol 2020;76:1703–13. https://doi.org/10.1016/j.jacc.2020.07.061
Google ScholarCrossrefWorldCat 
1236	Czerny M, Siepe M, Beyersdorf F, Feisst M, Gabel M, Pilz M, et al.  Prediction of mortality rate in acute type A dissection: the German registry for acute type A aortic dissection score. Eur J Cardiothorac Surg 2020;58:700–6. https://doi.org/10.1093/ejcts/ezaa156
Google ScholarCrossrefWorldCat 
1237	Perko MJ, Nørgaard M, Herzog TM, Olsen PS, Schroeder TV, Pettersson G. Unoperated aortic aneurysm: a survey of 170 patients. Ann Thorac Surg 1995;59:1204–9. https://doi.org/10.1016/0003-4975(95)00132-5
Google ScholarCrossrefWorldCat 
1238	Wolfe SB, Sundt TM, III, Isselbacher EM, Cameron DE, Trimarchi S, Bekeredjian R, et al.  Survival after operative repair of acute type A aortic dissection varies according to the presence and type of preoperative malperfusion. J Thorac Cardiovasc Surg 2024;168:37–49.e6. https://doi.org/10.1016/j.jtcvs.2022.09.034
Google ScholarCrossrefWorldCat 
1239	Trimarchi S, Eagle KA, Nienaber CA, Rampoldi V, Jonker FHW, De Vincentiis C, et al.  Role of age in acute type A aortic dissection outcome: report from the international registry of acute aortic dissection (IRAD). J Thorac Cardiovasc Surg 2010;140:784–9. https://doi.org/10.1016/j.jtcvs.2009.11.014
Google ScholarCrossrefWorldCat 
1240	Shrestha M, Khaladj N, Haverich A, Hagl C. Is treatment of acute type A aortic dissection in septuagenarians justifiable? Asian Cardiovasc Thorac Ann 2008;16:33–6. https://doi.org/10.1177/021849230801600109
Google ScholarCrossrefWorldCat 
1241	Bonser RS, Ranasinghe AM, Loubani M, Evans JD, Thalji NMA, Bachet JE, et al.  Evidence, lack of evidence, controversy, and debate in the provision and performance of the surgery of acute type A aortic dissection. J Am Coll Cardiol 2011;58:2455–74. https://doi.org/10.1016/j.jacc.2011.06.067
Google ScholarCrossrefWorldCat 
1242	Subramanian S, Leontyev S, Borger MA, Trommer C, Misfeld M, Mohr FW. Valve-sparing root reconstruction does not compromise survival in acute type A aortic dissection. Ann Thorac Surg 2012;94:1230–4. https://doi.org/10.1016/j.athoracsur.2012.04.094
Google ScholarCrossrefWorldCat 
1243	Urbanski PP, Hijazi H, Dinstak W, Diegeler A. Valve-sparing aortic root repair in acute type A dissection: how many sinuses have to be repaired for curative surgery? Eur J Cardiothorac Surg 2013;44:439–43; discussion 443–4. https://doi.org/10.1093/ejcts/ezt042
Google ScholarCrossrefWorldCat 
1244	Shrestha M, Baraki H, Maeding I, Fitzner S, Sarikouch S, Khaladj N, et al.  Long-term results after aortic valve-sparing operation (David I). Eur J Cardiothorac Surg 2012;41:56–61; discussion 61–2. https://doi.org/10.1016/j.ejcts.2011.04.012
Google ScholarWorldCat 
1245	Tsagakis K, Pacini D, Di Bartolomeo R, Gorlitzer M, Weiss G, Grabenwoger M, et al.  Multicenter early experience with extended aortic repair in acute aortic dissection: is simultaneous descending stent grafting justified? J Thorac Cardiovasc Surg 2010;140:S116–20; discussion S142–S146. https://doi.org/10.1016/j.jtcvs.2010.07.066
Google ScholarCrossrefWorldCat 
1246	Tsagakis K, Pacini D, Grabenwöger M, Borger MA, Goebel N, Hemmer W, et al.  Results of frozen elephant trunk from the international E-vita Open registry. Ann Cardiothorac Surg 2020;9:178–88. https://doi.org/10.21037/acs-2020-fet-25
Google ScholarCrossrefWorldCat 
1247	Beckmann E, Martens A, Kaufeld T, Natanov R, Krueger H, Rudolph L, et al.  Frozen elephant trunk in acute aortic type a dissection: risk analysis of concomitant root replacement. Eur J Cardiothorac Surg 2022;62:ezac051. https://doi.org/10.1093/ejcts/ezac051
Google ScholarCrossrefWorldCat 
1248	Cruz I, Stuart B, Caldeira D, Morgado G, Gomes AC, Almeida AR, et al.  Controlled pericardiocentesis in patients with cardiac tamponade complicating aortic dissection: experience of a centre without cardiothoracic surgery. Eur Heart J Acute Cardiovasc Care 2015;4:124–8. https://doi.org/10.1177/2048872614549737
Google ScholarCrossrefWorldCat 
1249	Hayashi T, Tsukube T, Yamashita T, Haraguchi T, Matsukawa R, Kozawa S, et al.  Impact of controlled pericardial drainage on critical cardiac tamponade with acute type A aortic dissection. Circulation 2012;126:S97–101. https://doi.org/10.1161/CIRCULATIONAHA.111.082685
Google ScholarCrossrefWorldCat 
1250	Hagan PG, Nienaber CA, Isselbacher EM, Bruckman D, Karavite DJ, Russman PL, et al.  The international registry of acute aortic dissection (IRAD): new insights into an old disease. JAMA 2000;283:897–903. https://doi.org/10.1001/jama.283.7.897
Google ScholarCrossrefWorldCat 
1251	Saczkowski R, Malas T, Mesana T, de Kerchove L, El Khoury G, Boodhwani M. Aortic valve preservation and repair in acute type A aortic dissection. Eur J Cardiothorac Surg 2014;45:e220–226. https://doi.org/10.1093/ejcts/ezu099
Google ScholarCrossrefWorldCat 
1252	Hysi I, Juthier F, Fabre O, Fouquet O, Rousse N, Banfi C, et al.  Aortic root surgery improves long-term survival after acute type A aortic dissection. Int J Cardiol 2015;184:285–90. https://doi.org/10.1016/j.ijcard.2015.02.020
Google ScholarCrossrefWorldCat 
1253	Peterss S, Dumfarth J, Rizzo JA, Bonaros N, Fang H, Tranquilli M, et al.  Sparing the aortic root in acute aortic dissection type A: risk reduction and restored integrity of the untouched root. Eur J Cardiothorac Surg 2016;50:232–9. https://doi.org/10.1093/ejcts/ezw012
Google ScholarCrossrefWorldCat 
1254	Chen SK, Qiu ZH, Fang GH, Wu XJ, Chen LW. Reported outcomes after aortic valve resuspension for acute type A aortic dissection: a systematic review and meta-analysis. Interact Cardiovasc Thorac Surg 2019;29:331–8. https://doi.org/10.1093/icvts/ivz080
Google ScholarCrossrefWorldCat 
1255	Qiu J, Wu J, Xie E, Luo X, Chen JF, Gao W, et al.  Surgical management and outcomes of the aortic root in acute type A aortic dissection. Ann Thorac Surg 2020;110:136–43. https://doi.org/10.1016/j.athoracsur.2019.10.014
Google ScholarCrossrefWorldCat 
1256	Umana-Pizano JB, Nissen AP, Sandhu HK, Miller CC, Loghin A, Safi HJ, et al.  Acute type A dissection repair by high-volume vs low-volume surgeons at a high-volume aortic center. Ann Thorac Surg 2019;108:1330–6. https://doi.org/10.1016/j.athoracsur.2019.04.040
Google ScholarCrossrefWorldCat 
1257	Goldstone AB, Chiu P, Baiocchi M, Lingala B, Lee J, Rigdon J, et al.  Interfacility transfer of medicare beneficiaries with acute type A aortic dissection and regionalization of care in the United States. Circulation 2019;140:1239–50. https://doi.org/10.1161/circulationaha.118.038867
Google ScholarCrossrefWorldCat 
1258	Mosbahi S, Stak D, Gravestock I, Burgstaller JM, Steurer J, Eckstein F, et al.  A systemic review and meta-analysis: Bentall versus David procedure in acute type A aortic dissection. Eur J Cardiothorac Surg 2019;55:201–9. https://doi.org/10.1093/ejcts/ezy266
Google ScholarCrossrefWorldCat 
1259	Beckmann E, Martens A, Pertz J, Kaufeld T, Umminger J, Hanke JS, et al.  Valve-sparing David I procedure in acute aortic type A dissection: a 20-year experience with more than 100 patients. Eur J Cardiothorac Surg 2017;52:319–24. https://doi.org/10.1093/ejcts/ezx170
Google ScholarCrossrefWorldCat 
1260	Weiss G, Tsagakis K, Jakob H, Di Bartolomeo R, Pacini D, Barberio G, et al.  The frozen elephant trunk technique for the treatment of complicated type B aortic dissection with involvement of the aortic arch: multicentre early experience. Eur J Cardiothorac Surg 2015;47:106–14; discussion 114. https://doi.org/10.1093/ejcts/ezu067
Google ScholarCrossrefWorldCat 
1261	Iafrancesco M, Goebel N, Mascaro J, Franke UFW, Pacini D, Di Bartolomeo R, et al.  Aortic diameter remodelling after the frozen elephant trunk technique in aortic dissection: results from an international multicentre registry. Eur J Cardiothorac Surg 2017;52:310–8. https://doi.org/10.1093/ejcts/ezx131
Google ScholarCrossrefWorldCat 
1262	Tsagakis K, Wendt D, Dimitriou AM, Thielmann M, Shehada S-D, El Gabry M, et al.  The frozen elephant trunk treatment is the operation of choice for all kinds of arch disease. J Cardiovasc Surg (Torino) 2018;59:540–6. https://doi.org/10.23736/s0021-9509.18.10597-0
Google ScholarWorldCat 
1263	Widenka KJ, Kosiorowska M, Jakob H, Pacini D, Hemmer W, Grabenwoeger M, et al.  Early and midterm results of frozen elephant trunk operation with Evita open stent-graft in patients with Marfan syndrome: results of a multicentre study. BMC Cardiovasc Disord 2022;22:333. https://doi.org/10.1186/s12872-022-02777-5
Google ScholarCrossrefWorldCat 
1264	Jakob H, Shehada SE, Dohle D, Wendt D, El Gabry M, Schlosser T, et al.  New 3-zone hybrid graft: first-in-man experience in acute type I dissection. J Thorac Cardiovasc Surg 2022;163:568–74.e1. https://doi.org/10.1016/j.jtcvs.2020.04.113
Google ScholarCrossrefWorldCat 
1265	Tsagakis K, Osswald A, Weymann A, Demircioglu A, Schmack B, Wendt D, et al.  The frozen elephant trunk technique: impact of proximalization and the four-sites perfusion technique. Eur J Cardiothorac Surg 2021;61:195–203. https://doi.org/10.1093/ejcts/ezab295
Google ScholarCrossrefWorldCat 
1266	Rampoldi V, Trimarchi S, Eagle KA, Nienaber CA, Oh JK, Bossone E, et al.  Simple risk models to predict surgical mortality in acute type A aortic dissection: the international registry of acute aortic dissection score. Ann Thorac Surg 2007;83:55–61. https://doi.org/10.1016/j.athoracsur.2006.08.007
Google ScholarCrossrefWorldCat 
1267	Lawton JS, Liu J, Kulshrestha K, Moon MR, Damiano RJ, Maniar H, et al.  The impact of surgical strategy on survival after repair of type A aortic dissection. J Thorac Cardiovasc Surg 2015;150:294–301.e1. https://doi.org/10.1016/j.jtcvs.2015.03.023
Google ScholarCrossrefWorldCat 
1268	Malvindi PG, Modi A, Miskolczi S, Kaarne M, Velissaris T, Barlow C, et al.  Open and closed distal anastomosis for acute type A aortic dissection repair. Interact Cardiovasc Thorac Surg 2016;22:776–83. https://doi.org/10.1093/icvts/ivw044
Google ScholarCrossrefWorldCat 
1269	Geirsson A, Shioda K, Olsson C, Ahlsson A, Gunn J, Hansson EC, et al.  Differential outcomes of open and clamp-on distal anastomosis techniques in acute type A aortic dissection. J Thorac Cardiovasc Surg 2019;157:1750–8. https://doi.org/10.1016/j.jtcvs.2018.09.020
Google ScholarCrossrefWorldCat 
1270	Yan Y, Xu L, Zhang H, Xu Z-Y, Ding X-Y, Wang S-W, et al.  Proximal aortic repair versus extensive aortic repair in the treatment of acute type A aortic dissection: a meta-analysis. Eur J Cardiothorac Surg 2016;49:1392–401. https://doi.org/10.1093/ejcts/ezv351
Google ScholarCrossrefWorldCat 
1271	Poon SS, Theologou T, Harrington D, Kuduvalli M, Oo A, Field M. Hemiarch versus total aortic arch replacement in acute type A dissection: a systematic review and meta-analysis. Ann Cardiothorac Surg 2016;5:156–73. https://doi.org/10.21037/acs.2016.05.06
Google ScholarCrossrefWorldCat 
1272	Hsieh WC, Kan CD, Yu HC, Aboud A, Lindner J, Henry BM, et al.  Ascending aorta replacement vs. total aortic arch replacement in the treatment of acute type A dissection: a meta-analysis. Eur Rev Med Pharmacol Sci 2019;23:9590–611. https://doi.org/10.26355/eurrev_201911_19454
Google ScholarWorldCat 
1273	Preventza O, Cervera R, Cooley DA, Bakaeen FG, Mohamed AS, Cheong BYC, et al.  Acute type I aortic dissection: traditional versus hybrid repair with antegrade stent delivery to the descending thoracic aorta. J Thorac Cardiovasc Surg 2014;148:119–25. https://doi.org/10.1016/j.jtcvs.2013.07.055
Google ScholarCrossrefWorldCat 
1274	Roselli EE, Idrees JJ, Bakaeen FG, Tong MZ, Soltesz EG, Mick S, et al.  Evolution of simplified frozen elephant trunk repair for acute DeBakey type I dissection: midterm outcomes. Ann Thorac Surg 2018;105:749–55. https://doi.org/10.1016/j.athoracsur.2017.08.037
Google ScholarCrossrefWorldCat 
1275	Berretta P, Trimarchi S, Patel HJ, Gleason TG, Eagle KA, Di Eusanio M. Malperfusion syndromes in type A aortic dissection: what we have learned from IRAD. J Vis Surg 2018;4:65. https://doi.org/10.21037/jovs.2018.03.13
Google ScholarCrossrefWorldCat 
1276	Benedetto U, Mohamed H, Vitulli P, Petrou M. Axillary versus femoral arterial cannulation in type A acute aortic dissection: evidence from a meta-analysis of comparative studies and adjusted risk estimates. Eur J Cardiothorac Surg 2015;48:953–9. https://doi.org/10.1093/ejcts/ezv035
Google ScholarCrossrefWorldCat 
1277	Geirsson A, Szeto WY, Pochettino A, McGarvey ML, Keane MG, Woo YJ, et al.  Significance of malperfusion syndromes prior to contemporary surgical repair for acute type A dissection: outcomes and need for additional revascularizations. Eur J Cardiothorac Surg 2007;32:255–62. https://doi.org/10.1016/j.ejcts.2007.04.012
Google ScholarCrossrefWorldCat 
1278	Yang B, Norton EL, Rosati CM, Wu X, Kim KM, Khaja MS, et al.  Managing patients with acute type A aortic dissection and mesenteric malperfusion syndrome: a 20-year experience. J Thorac Cardiovasc Surg 2019;158:675–87.e4. https://doi.org/10.1016/j.jtcvs.2018.11.127
Google ScholarCrossrefWorldCat 
1279	Yang B, Rosati CM, Norton EL, Kim KM, Khaja MS, Dasika N, et al.  Endovascular fenestration/stenting first followed by delayed open aortic repair for acute type A aortic dissection with malperfusion syndrome. Circulation 2018;138:2091–103. https://doi.org/10.1161/circulationaha.118.036328
Google ScholarCrossrefWorldCat 
1280	Leshnower BG, Keeling WB, Duwayri YM, Jordan WD, Jr, Chen EP. The “thoracic endovascular aortic repair-first” strategy for acute type A dissection with mesenteric malperfusion: initial results compared with conventional algorithms. J Thorac Cardiovasc Surg 2019;158:1516–24. https://doi.org/10.1016/j.jtcvs.2019.01.116
Google ScholarCrossrefWorldCat 
1281	Rylski B, Szeto WY, Bavaria JE, Branchetti E, Moser W, Milewski RK. Development of a single endovascular device for aortic valve replacement and ascending aortic repair. J Card Surg 2014;29:371–6. https://doi.org/10.1111/jocs.12348
Google ScholarCrossrefWorldCat 
1282	Kreibich M, Rylski B, Kondov S, Morlock J, Scheumann J, Kari FA, et al.  Endovascular treatment of acute type A aortic dissection-the Endo Bentall approach. J Vis Surg 2018;4:69. https://doi.org/10.21037/jovs.2018.03.14
Google ScholarCrossrefWorldCat 
1283	Brown CR, Chen Z, Khurshan F, Kreibich M, Bavaria J, Groeneveld P, et al.  Outcomes after thoracic endovascular aortic repair in patients with chronic kidney disease in the Medicare population. J Thorac Cardiovasc Surg 2020;159:402–13. https://doi.org/10.1016/j.jtcvs.2019.01.118
Google ScholarCrossrefWorldCat 
1284	Trimarchi S, Nienaber CA, Rampoldi V, Myrmel T, Suzuki T, Bossone E, et al.  Role and results of surgery in acute type B aortic dissection: insights from the international registry of acute aortic dissection (IRAD). Circulation 2006;114:I357–64. https://doi.org/10.1161/circulationaha.105.000620
Google ScholarCrossrefWorldCat 
1285	Tolenaar JL, Froehlich W, Jonker FH, Upchurch GR, Rampoldi V, Tsai TT, et al.  Predicting in-hospital mortality in acute type B aortic dissection: evidence from international registry of acute aortic dissection. Circulation 2014;130:S45–50. https://doi.org/10.1161/circulationaha.113.007117
Google ScholarCrossrefWorldCat 
1286	Martin G, Patel N, Grant Y, Jenkins M, Gibbs R, Bicknell C. Antihypertensive medication adherence in chronic type B aortic dissection is an important consideration in the management debate. J Vasc Surg 2018;68:693–9.e2. https://doi.org/10.1016/j.jvs.2017.12.063
Google ScholarCrossrefWorldCat 
1287	Brooke BS, Griffin CL, Glotzbach JP, Horns JJ, Patel S, Kraiss LW, et al.  Predictors of adherence to anti-impulse therapy among patients treated for acute type-B aortic dissections. Ann Vasc Surg 2021;76:95–103. https://doi.org/10.1016/j.avsg.2021.04.011
Google ScholarCrossrefWorldCat 
1288	Zeeshan A, Woo EY, Bavaria JE, Fairman RM, Desai ND, Pochettino A, et al.  Thoracic endovascular aortic repair for acute complicated type B aortic dissection: superiority relative to conventional open surgical and medical therapy. J Thorac Cardiovasc Surg 2010;140:S109–115; discussion S142–S146. https://doi.org/10.1016/j.jtcvs.2010.06.024
Google ScholarCrossrefWorldCat 
1289	Steuer J, Eriksson MO, Nyman R, Björck M, Wanhainen A. Early and long-term outcome after thoracic endovascular aortic repair (TEVAR) for acute complicated type B aortic dissection. Eur J Vasc Endovasc Surg 2011;41:318–23. https://doi.org/10.1016/j.ejvs.2010.11.024
Google ScholarCrossrefWorldCat 
1290	Zipfel B, Czerny M, Funovics M, Coppi G, Ferro C, Rousseau H, et al.  Endovascular treatment of patients with types A and B thoracic aortic dissection using Relay thoracic stent-grafts: results from the RESTORE patient registry. J Endovasc Ther 2011;18:131–43. https://doi.org/10.1583/10-3233mr.1
Google ScholarCrossrefWorldCat 
1291	Hanna JM, Andersen ND, Ganapathi AM, McCann RL, Hughes GC. Five-year results for endovascular repair of acute complicated type B aortic dissection. J Vasc Surg 2014;59:96–106. https://doi.org/10.1016/j.jvs.2013.07.001
Google ScholarCrossrefWorldCat 
1292	Stelzmueller ME, Nolz R, Mahr S, Beitzke D, Wolf F, Funovics M, et al.  Thoracic endovascular repair for acute complicated type B aortic dissections. J Vasc Surg 2019;69:318–26. https://doi.org/10.1016/j.jvs.2018.05.234
Google ScholarCrossrefWorldCat 
1293	Wilson-Smith AR, Muston B, Kamalanathan H, Yung A, Chen C-HJ, Sahai P, et al.  Endovascular repair of acute complicated type B aortic dissection-systematic review and meta-analysis of long-term survival and reintervention. Ann Cardiothorac Surg 2021;10:723–30. https://doi.org/10.21037/acs-2021-taes-17
Google ScholarCrossrefWorldCat 
1294	MacGillivray TE, Gleason TG, Patel HJ, Aldea GS, Bavaria JE, Beaver TM, et al.  The Society of Thoracic Surgeons/American Association for Thoracic Surgery clinical practice guidelines on the management of type B aortic dissection. J Thorac Cardiovasc Surg 2022;163:1231–49. https://doi.org/10.1016/j.jtcvs.2021.11.091
Google ScholarCrossrefWorldCat 
1295	Brunkwall J, Kasprzak P, Verhoeven E, Heijmen R, Taylor P, Alric P, et al.  Endovascular repair of acute uncomplicated aortic type B dissection promotes aortic remodelling: 1 year results of the ADSORB trial. Eur J Vasc Endovasc Surg 2014;48:285–91. https://doi.org/10.1016/j.ejvs.2014.05.012
Google ScholarCrossrefWorldCat 
1296	Hossack M, Patel S, Gambardella I, Neequaye S, Antoniou GA, Torella F. Endovascular vs. medical management for uncomplicated acute and sub-acute type B aortic dissection: a meta-analysis. Eur J Vasc Endovasc Surg 2020;59:794–807. https://doi.org/10.1016/j.ejvs.2019.08.003
Google ScholarCrossrefWorldCat 
1297	Sa MP, Jacquemyn X, Van den Eynde J, Chu D, Serna-Gallegos D, Singh MJ, et al.  Midterm outcomes of endovascular vs. medical therapy for uncomplicated type B aortic dissection: meta-analysis of reconstructed time to event data. Eur J Vasc Endovasc Surg 2023;66:609–19. https://doi.org/10.1016/j.ejvs.2023.07.004
Google ScholarCrossrefWorldCat 
1298	Sa MP, Jacquemyn X, Brown JA, Ahmad D, Serna-Gallegos D, Arnaoutakis GJ, et al.  Thoracic endovascular aortic repair for hyperacute, acute, subacute and chronic type B aortic dissection: meta-analysis of reconstructed time-to-event data. Trends Cardiovasc Med 2023:S1050-1738(23)00113-5. https://doi.org/10.1016/j.tcm.2023.12.005
Google ScholarWorldCat 
1299	Jubouri M, Al-Tawil M, Yip HCA, Bashir A, Tan SZCP, Bashir M, et al.  Mid- and long-term outcomes of thoracic endovascular aortic repair in acute and subacute uncomplicated type B aortic dissection. J Card Surg 2022;37:1328–39. https://doi.org/10.1111/jocs.16349
Google ScholarCrossrefWorldCat 
1300	Torrent DJ, McFarland GE, Wang G, Malas M, Pearce BJ, Aucoin V, et al.  Timing of thoracic endovascular aortic repair for uncomplicated acute type B aortic dissection and the association with complications. J Vasc Surg 2021;73:826–35. https://doi.org/10.1016/j.jvs.2020.05.073
Google ScholarCrossrefWorldCat 
1301	Schwartz SI, Durham C, Clouse WD, Patel VI, Lancaster RT, Cambria RP, et al.  Predictors of late aortic intervention in patients with medically treated type B aortic dissection. J Vasc Surg 2018;67:78–84. https://doi.org/10.1016/j.jvs.2017.05.128
Google ScholarCrossrefWorldCat 
1302	Onitsuka S, Akashi H, Tayama K, Okazaki T, Ishihara K, Hiromatsu S, et al.  Long-term outcome and prognostic predictors of medically treated acute type B aortic dissections. Ann Thorac Surg 2004;78:1268–73. https://doi.org/10.1016/j.athoracsur.2004.02.031
Google ScholarCrossrefWorldCat 
1303	Hughes GC, Ganapathi AM, Keenan JE, Englum BR, Hanna JM, Schechter MA, et al.  Thoracic endovascular aortic repair for chronic DeBakey IIIb aortic dissection. Ann Thorac Surg 2014;98:2092–7; discussion 2098. https://doi.org/10.1016/j.athoracsur.2014.06.066
Google ScholarCrossrefWorldCat 
1304	Jánosi RA, Tsagakis K, Bettin M, Kahlert P, Horacek M, Al-Rashid F, et al.  Thoracic aortic aneurysm expansion due to late distal stent graft-induced new entry. Catheter Cardiovasc Interv 2015;85:E43–53. https://doi.org/10.1002/ccd.25614
Google ScholarWorldCat 
1305	Cheng L, Xiang D, Zhang S, Zheng C, Wu X. Reintervention after thoracic endovascular aortic repair of uncomplicated type B aortic dissection. J Clin Med 2023;12:1418. https://doi.org/10.3390/jcm12041418
Google ScholarCrossrefWorldCat 
1306	Akutsu K, Nejima J, Kiuchi K, Sasaki K, Ochi M, Tanaka K, et al.  Effects of the patent false lumen on the long-term outcome of type B acute aortic dissection. Eur J Cardiothorac Surg 2004;26:359–66. https://doi.org/10.1016/j.ejcts.2004.03.026
Google ScholarCrossrefWorldCat 
1307	Tsai TT, Evangelista A, Nienaber CA, Myrmel T, Meinhardt G, Cooper JV, et al.  Partial thrombosis of the false lumen in patients with acute type B aortic dissection. N Engl J Med 2007;357:349–59. https://doi.org/10.1056/NEJMoa063232
Google ScholarCrossrefWorldCat 
1308	Dake MD, Thompson M, van Sambeek M, Vermassen F, Morales JP. DISSECT: a new mnemonic-based approach to the categorization of aortic dissection. Eur J Vasc Endovasc Surg 2013;46:175–90. https://doi.org/10.1016/j.ejvs.2013.04.029
Google ScholarCrossrefWorldCat 
1309	Wang J, Jin T, Chen B, Pan Y, Shao C. Systematic review and meta-analysis of current evidence in endograft therapy vs medical treatment for uncomplicated type B aortic dissection. J Vasc Surg 2022;76:1099–108.e3. https://doi.org/10.1016/j.jvs.2022.03.876
Google ScholarCrossrefWorldCat 
1310	Umaña JP, Lai DT, Mitchell RS, Moore KA, Rodriguez F, Robbins RC, et al.  Is medical therapy still the optimal treatment strategy for patients with acute type B aortic dissections? J Thorac Cardiovasc Surg 2002;124:896–910. https://doi.org/10.1067/mtc.2002.123131
Google ScholarCrossrefWorldCat 
1311	Umaña JP, Miller DC, Mitchell RS. What is the best treatment for patients with acute type B aortic dissections—medical, surgical, or endovascular stent-grafting? Ann Thorac Surg 2002;74:S1840–3; discussion S1857–63. https://doi.org/10.1016/s0003-4975(02)04140-1
Google ScholarCrossrefWorldCat 
1312	Morello F, Santoro M, Fargion AT, Grifoni S, Nazerian P. Diagnosis and management of acute aortic syndromes in the emergency department. Intern Emerg Med 2021;16:171–81. https://doi.org/10.1007/s11739-020-02354-8
Google ScholarCrossrefWorldCat 
1313	Marui A, Mochizuki T, Mitsui N, Koyama T, Kimura F, Horibe M. Toward the best treatment for uncomplicated patients with type B acute aortic dissection: a consideration for sound surgical indication. Circulation 1999;100:II275–80. https://doi.org/10.1161/01.cir.100.suppl_2.ii-275
Google ScholarCrossrefWorldCat 
1314	Crawford ES. The diagnosis and management of aortic dissection. JAMA 1990;264:2537–41.
Google ScholarCrossrefWorldCat 
1315	Hata M, Shiono M, Inoue T, Sezai A, Niino T, Negishi N, et al.  Optimal treatment of type B acute aortic dissection: long-term medical follow-up results. Ann Thorac Surg 2003;75:1781–4. https://doi.org/10.1016/s0003-4975(03)00113-9
Google ScholarCrossrefWorldCat 
1316	Oda T, Minatoya K, Sasaki H, Tanaka H, Seike Y, Itonaga T, et al.  Surgical indication for chronic aortic dissection in descending thoracic and thoracoabdominal aorta. Circ Cardiovasc Interv 2017;10:e004292. https://doi.org/10.1161/circinterventions.116.004292
Google ScholarCrossrefWorldCat 
1317	Conrad MF, Chung TK, Cambria MR, Paruchuri V, Brady TJ, Cambria RP. Effect of chronic dissection on early and late outcomes after descending thoracic and thoracoabdominal aneurysm repair. J Vasc Surg 2011;53:600–7; discussion 607. https://doi.org/10.1016/j.jvs.2010.09.053
Google ScholarCrossrefWorldCat 
1318	Crawford ES, Crawford JL, Safi HJ, Coselli JS, Hess KR, Brooks B, et al.  Thoracoabdominal aortic aneurysms: preoperative and intraoperative factors determining immediate and long-term results of operations in 605 patients. J Vasc Surg 1986;3:389–404. https://doi.org/10.1067/mva.1986.avs0030389
Google ScholarCrossrefWorldCat 
1319	Zoli S, Etz CD, Roder F, Mueller CS, Brenner RM, Bodian CA, et al.  Long-term survival after open repair of chronic distal aortic dissection. Ann Thorac Surg 2010;89:1458–66. https://doi.org/10.1016/j.athoracsur.2010.02.014
Google ScholarCrossrefWorldCat 
1320	Etz CD, Zoli S, Mueller CS, Bodian CA, Di Luozzo G, Lazala R, et al.  Staged repair significantly reduces paraplegia rate after extensive thoracoabdominal aortic aneurysm repair. J Thorac Cardiovasc Surg 2010;139:1464–72. https://doi.org/10.1016/j.jtcvs.2010.02.037
Google ScholarCrossrefWorldCat 
1321	Conrad MF, Ergul EA, Patel VI, Paruchuri V, Kwolek CJ, Cambria RP. Management of diseases of the descending thoracic aorta in the endovascular era: a Medicare population study. Ann Surg 2010;252:603–10. https://doi.org/10.1097/SLA.0b013e3181f4eaef
Google ScholarCrossrefWorldCat 
1322	Sobocinski J, Dias NV, Berger L, Midulla M, Hertault A, Sonesson B, et al.  Endograft repair of complicated acute type B aortic dissections. Eur J Vasc Endovasc Surg 2013;45:468–74. https://doi.org/10.1016/j.ejvs.2013.01.031
Google ScholarCrossrefWorldCat 
1323	Conrad MF, Carvalho S, Ergul E, Kwolek CJ, Lancaster RT, Patel VI, et al.  Late aortic remodeling persists in the stented segment after endovascular repair of acute complicated type B aortic dissection. J Vasc Surg 2015;62:600–5. https://doi.org/10.1016/j.jvs.2015.03.064
Google ScholarCrossrefWorldCat 
1324	Thrumurthy SG, Karthikesalingam A, Patterson BO, Holt PJE, Hinchliffe RJ, Loftus IM, et al.  A systematic review of mid-term outcomes of thoracic endovascular repair (TEVAR) of chronic type B aortic dissection. Eur J Vasc Endovasc Surg 2011;42:632–47. https://doi.org/10.1016/j.ejvs.2011.08.009
Google ScholarCrossrefWorldCat 
1325	Boufi M, Patterson BO, Loundou AD, Boyer L, Grima MJ, Loftus IM, et al.  Endovascular versus open repair for chronic type B dissection treatment: a meta-analysis. Ann Thorac Surg 2019;107:1559–70. https://doi.org/10.1016/j.athoracsur.2018.10.045
Google ScholarCrossrefWorldCat 
1326	Conway AM, Qato K, Mondry LR, Stoffels GJ, Giangola G, Carroccio A. Outcomes of thoracic endovascular aortic repair for chronic aortic dissections. J Vasc Surg 2018;67:1345–52. https://doi.org/10.1016/j.jvs.2017.08.098
Google ScholarCrossrefWorldCat 
1327	Tenorio ER, Oderich GS, Farber MA, Schneider DB, Timaran CH, Schanzer A, et al.  Outcomes of endovascular repair of chronic postdissection compared with degenerative thoracoabdominal aortic aneurysms using fenestrated-branched stent grafts. J Vasc Surg 2020;72:822–36.e9. https://doi.org/10.1016/j.jvs.2019.10.091
Google ScholarCrossrefWorldCat 
1328	Marques De Marino P, Ibraheem A, Gafur N, Verhoeven EL, Katsargyris A. Outcomes of fenestrated and branched endovascular aortic repair for chronic post-dissection thoracoabdominal aortic aneurysms. J Cardiovasc Surg 2020;61:427–34. https://doi.org/10.23736/s0021-9509.20.11367-3
Google ScholarCrossrefWorldCat 
1329	Gallitto E, Faggioli G, Melissano G, Fargion A, Isernia G, Bertoglio L, et al.  Fenestrated and branched endografts for post-dissection thoraco-abdominal aneurysms: results of a national multicentre study and literature review. Eur J Vasc Endovasc Surg 2022;64:630–8. https://doi.org/10.1016/j.ejvs.2022.06.019
Google ScholarCrossrefWorldCat 
1330	Geisbüsch S, Kuehnl A, Salvermoser M, Reutersberg B, Trenner M, Eckstein H-H. Editor’s choice—hospital incidence, treatment, and in hospital mortality following open and endovascular surgery for thoraco-abdominal aortic aneurysms in Germany from 2005 to 2014: secondary data analysis of the Nationwide German DRG microdata. Eur J Vasc Endovasc Surg 2019;57:488–98. https://doi.org/10.1016/j.ejvs.2018.10.030
Google ScholarCrossrefWorldCat 
1331	Genoni M, Paul M, Jenni R, Graves K, Seifert B, Turina M. Chronic beta-blocker therapy improves outcome and reduces treatment costs in chronic type B aortic dissection. Eur J Cardiothorac Surg 2001;19:606–10. https://doi.org/10.1016/s1010-7940(01)00662-5
Google ScholarCrossrefWorldCat 
1332	Chen SW, Chan YH, Lin CP, Wu VC-C, Cheng Y-T, Chen D-Y, et al.  Association of long-term use of antihypertensive medications with late outcomes among patients with aortic dissection. JAMA Netw Open 2021;4:e210469. https://doi.org/10.1001/jamanetworkopen.2021.0469
Google ScholarCrossrefWorldCat 
1333	Smedberg C, Hultgren R, Leander K, Steuer J. Pharmacological treatment in patients with aortic dissection. Open Heart 2022;9:e002082. https://doi.org/10.1136/openhrt-2022-002082
Google ScholarCrossrefWorldCat 
1334	Xiong J, Jiang B, Guo W, Wang SM, Tong XY. Endovascular stent graft placement in patients with type B aortic dissection: a meta-analysis in China. J Thorac Cardiovasc Surg 2009;138:865–72.e1. https://doi.org/10.1016/j.jtcvs.2009.02.005
Google ScholarCrossrefWorldCat 
1335	Zhu JM, Ma WG, Peterss S, Wang L-F, Qiao Z-Y, Ziganshin BA, et al.  Aortic dissection in pregnancy: management strategy and outcomes. Ann Thorac Surg 2017;103:1199–206. https://doi.org/10.1016/j.athoracsur.2016.08.089
Google ScholarCrossrefWorldCat 
1336	Yates MT, Soppa G, Smelt J, Fletcher N, van Besouw J-P, Thilaganathan B, et al.  Perioperative management and outcomes of aortic surgery during pregnancy. J Thorac Cardiovasc Surg 2015;149:607–10. https://doi.org/10.1016/j.jtcvs.2014.10.038
Google ScholarCrossrefWorldCat 
1337	Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, De Bonis M, et al.  2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018;39:3165–241. https://doi.org/10.1093/eurheartj/ehy340
Google ScholarCrossrefWorldCat 
1338	DeMartino RR, Sen I, Huang Y, Bower TC, Oderich GS, Pochettino A, et al.  Population-based assessment of the incidence of aortic dissection, intramural hematoma, and penetrating ulcer, and its associated mortality from 1995 to 2015. Circ Cardiovasc Qual Outcomes 2018;11:e004689. https://doi.org/10.1161/circoutcomes.118.004689
Google ScholarCrossrefWorldCat 
1339	Evangelista A, Dominguez R, Sebastia C, Salas A, Permanyer-Miralda G, Avegliano G, et al.  Long-term follow-up of aortic intramural hematoma: predictors of outcome. Circulation 2003;108:583–9. https://doi.org/10.1161/01.Cir.0000081776.49923.5a
Google ScholarCrossrefWorldCat 
1340	Moral S, Ballesteros E, Roque M, Carrato C, Vilardell P, Brugada R, et al.  Intimal disruption in type B aortic intramural hematoma. Does size matter? A systematic review and meta-analysis. Int J Cardiol 2018;269:298–303. https://doi.org/10.1016/j.ijcard.2018.07.111
Google ScholarCrossrefWorldCat 
1341	Moral S, Ballesteros E, Evangelista A. Conservative vs surgical treatment in type A intramural hematoma. What is new? J Card Surg 2020;35:1758–60. https://doi.org/10.1111/jocs.14739
Google ScholarCrossrefWorldCat 
1342	Ishizu K, Kaji S, Nakashima M, Kitai T, Kim K, Ehara N, et al.  Focal intimal disruption size at multidetector CT and disease progression in type B aortic intramural hematoma. Radiology 2021;301:311–9. https://doi.org/10.1148/radiol.2021204385
Google ScholarCrossrefWorldCat 
1343	Chou AS, Ziganshin BA, Charilaou P, Tranquilli M, Rizzo JA, Elefteriades JA. Long-term behavior of aortic intramural hematomas and penetrating ulcers. J Thorac Cardiovasc Surg 2016;151:361–72, 373.e1. https://doi.org/10.1016/j.jtcvs.2015.09.012
Google ScholarCrossrefWorldCat 
1344	Evangelista A, Mukherjee D, Mehta RH, O’Gara PT, Fattori R, Cooper JV, et al.  Acute intramural hematoma of the aorta: a mystery in evolution. Circulation 2005;111:1063–70. https://doi.org/10.1161/01.Cir.0000156444.26393.80
Google ScholarCrossrefWorldCat 
1345	Song JK. Update in acute aortic syndrome: intramural hematoma and incomplete dissection as new disease entities. J Cardiol 2014;64:153–61. https://doi.org/10.1016/j.jjcc.2014.05.005
Google ScholarCrossrefWorldCat 
1346	Song JK, Kim HS, Kang DH, Lim T-H, Song M-G, Park S-W, et al.  Different clinical features of aortic intramural hematoma versus dissection involving the ascending aorta. J Am Coll Cardiol 2001;37:1604–10. https://doi.org/10.1016/s0735-1097(01)01184-6
Google ScholarCrossrefWorldCat 
1347	Evangelista A, Maldonado G, Moral S, Teixido-Tura G, Lopez A, Cuellar H, et al.  Intramural hematoma and penetrating ulcer in the descending aorta: differences and similarities. Ann Cardiothorac Surg 2019;8:456–70. https://doi.org/10.21037/acs.2019.07.05
Google ScholarCrossrefWorldCat 
1348	Wee I, Varughese RS, Syn N, Choong A. Non-operative management of type A acute aortic syndromes: a systematic review and meta-analysis. Eur J Vasc Endovasc Surg 2019;58:41–51. https://doi.org/10.1016/j.ejvs.2018.10.015
Google ScholarCrossrefWorldCat 
1349	Chow SCY, Wong RHL, Lakhani I, Wong MV, Tse G, Yu PSY, et al.  Management of acute type A intramural hematoma: upfront surgery or individualized approach? A retrospective analysis and meta-analysis. J Thorac Dis 2020;12:680–9. https://doi.org/10.21037/jtd.2019.12.109
Google ScholarCrossrefWorldCat 
1350	Evangelista A, Czerny M, Nienaber C, Schepens M, Rousseau H, Cao P, et al.  Interdisciplinary expert consensus on management of type B intramural haematoma and penetrating aortic ulcer. Eur J Cardiothorac Surg 2015;47:209–17. https://doi.org/10.1093/ejcts/ezu386
Google ScholarCrossrefWorldCat 
1351	Sa MP, Jacquemyn X, Tasoudis P, Dufendach K, Singh MJ, de la Cruz KI, et al.  Five year results of endovascular versus medical therapy in acute type B aortic intramural haematoma: meta-analysis of reconstructed time to event data. Eur J Vasc Endovasc Surg 2024;67:584–92. https://doi.org/10.1016/j.ejvs.2023.12.024
Google ScholarCrossrefWorldCat 
1352	Moral S, Cuéllar H, Avegliano G, Ballesteros E, Salcedo MT, Ferreira-González I, et al.  Clinical implications of focal intimal disruption in patients with type B intramural hematoma. J Am Coll Cardiol 2017;69:28–39. https://doi.org/10.1016/j.jacc.2016.10.045
Google ScholarCrossrefWorldCat 
1353	Chakos A, Twindyawardhani T, Evangelista A, Maldonado G, Piffaretti G, Yan TD, et al.  Endovascular versus medical management of type B intramural hematoma: a meta-analysis. Ann Cardiothorac Surg 2019;8:447–55. https://doi.org/10.21037/acs.2019.06.11
Google ScholarCrossrefWorldCat 
1354	Song JK, Yim JH, Ahn JM, Kim D-H, Kang JW, Lee TY, et al.  Outcomes of patients with acute type a aortic intramural hematoma. Circulation 2009;120:2046–52. https://doi.org/10.1161/circulationaha.109.879783
Google ScholarCrossrefWorldCat 
1355	Ahn JM, Kim H, Kwon O, Om SY, Heo R, Lee S, et al.  Differential clinical features and long-term prognosis of acute aortic syndrome according to disease entity. Eur Heart J 2019;40:2727–36. https://doi.org/10.1093/eurheartj/ehz153
Google ScholarCrossrefWorldCat 
1356	Kitamura T, Torii S, Miyamoto T, Mishima T, Ohkubo H, Fujioka S, et al.  Watch-and-wait strategy for type A intramural haematoma and acute aortic dissection with thrombosed false lumen of the ascending aorta: a Japanese single-centre experience. Eur J Cardiothorac Surg 2020;58:590–7. https://doi.org/10.1093/ejcts/ezaa080
Google ScholarCrossrefWorldCat 
1357	Jánosi RA, Gorla R, Tsagakis K, Kahlert P, Horacek M, Bruckschen F, et al.  Thoracic endovascular repair of complicated penetrating aortic ulcer: an 11-year single-center experience. J Endovasc Ther 2016;23:150–9. https://doi.org/10.1177/1526602815613790
Google ScholarCrossrefWorldCat 
1358	Nguyen VX, Nguyen BD. PET/CT imaging of abdominal aorta with intramural hematomas, penetrating ulcer, and saccular pseudoaneurysm. Clin Nucl Med 2014;39:467–9. https://doi.org/10.1097/RLU.0b013e318292f152
Google ScholarCrossrefWorldCat 
1359	Gorla R, Erbel R, Kuehl H, Kahlert P, Tsagakis K, Jakob H, et al.  Prognostic value of (18)F-fluorodeoxyglucose PET-CT imaging in acute aortic syndromes: comparison with serological biomarkers of inflammation. Int J Cardiovasc Imaging 2015;31:1677–85. https://doi.org/10.1007/s10554-015-0725-8
Google ScholarCrossrefWorldCat 
1360	Eggebrecht H, Plicht B, Kahlert P, Erbel R. Intramural hematoma and penetrating ulcers: indications to endovascular treatment. Eur J Vasc Endovasc Surg 2009;38:659–65. https://doi.org/10.1016/j.ejvs.2009.09.001
Google ScholarCrossrefWorldCat 
1361	Salim S, Locci R, Martin G, Gibbs R, Jenkins M, Hamady M, et al.  Short- and long-term outcomes in isolated penetrating aortic ulcer disease. J Vasc Surg 2020;72:84–91. https://doi.org/10.1016/j.jvs.2019.09.039
Google ScholarCrossrefWorldCat 
1362	Überall MA, Elling C, Eibl C, Müller-Schwefe GHH, Lefeber C, Heine M, et al.  Tapentadol prolonged release in patients with chronic low back pain: real-world data from the German Pain eRegistry. Pain Manag 2022;12:211–27. https://doi.org/10.2217/pmt-2021-0058
Google ScholarCrossrefWorldCat 
1363	Ganaha F, Miller DC, Sugimoto K, Do YS, Minamiguchi H, Saito H, et al.  Prognosis of aortic intramural hematoma with and without penetrating atherosclerotic ulcer: a clinical and radiological analysis. Circulation 2002;106:342–8. https://doi.org/10.1161/01.cir.0000022164.26075.5a
Google ScholarCrossrefWorldCat 
1364	DeCarlo C, Latz CA, Boitano LT, Waller HD, Kim Y, Sumpio BJ, et al.  Natural history of penetrating atherosclerotic ulcers in aortic branch vessels. J Vasc Surg 2021;74:1904–9. https://doi.org/10.1016/j.jvs.2021.06.035
Google ScholarCrossrefWorldCat 
1365	Piazza M, Squizzato F, Porcellato L, Casali E, Grego F, Antonello M. Predictors of intervention in acute type B aortic penetrating ulcer and intramural hematoma. Semin Thorac Cardiovasc Surg 2022;36:1–10. https://doi.org/10.1053/j.semtcvs.2022.07.009
Google ScholarCrossrefWorldCat 
1366	Kotsis T, Spyropoulos BG, Asaloumidis N, Christoforou P, Katseni K, Papaconstantinou I. Penetrating atherosclerotic ulcers of the abdominal aorta: a case report and review of the literature. Vasc Specialist Int 2019;35:152–9. https://doi.org/10.5758/vsi.2019.35.3.152
Google ScholarCrossrefWorldCat 
1367	DeCarlo C, Latz CA, Boitano LT, Kim Y, Tanious A, Schwartz SI, et al.  Prognostication of asymptomatic penetrating aortic ulcers: a modern approach. Circulation 2021;144:1091–101. https://doi.org/10.1161/circulationaha.121.054710
Google ScholarCrossrefWorldCat 
1368	Demetriades D, Velmahos GC, Scalea TM, Jurkovich GJ, Karmy-Jones R, Teixeira PG, et al.  Operative repair or endovascular stent graft in blunt traumatic thoracic aortic injuries: results of an American Association for the Surgery of Trauma Multicenter Study. J Trauma 2008;64:561–70; discussion 570–1. https://doi.org/10.1097/TA.0b013e3181641bb3
Google ScholarWorldCat 
1369	Katzenschlager R, Ugurluoglu A, Ahmadi A, Hülsmann M, Koppensteiner R, Larch E, et al.  Incidence of pseudoaneurysm after diagnostic and therapeutic angiography. Radiology 1995;195:463–6. https://doi.org/10.1148/radiology.195.2.7724767
Google ScholarCrossrefWorldCat 
1370	Mulder EJ, van Bockel JH, Maas J, van den Akker PJ, Hermans J. Morbidity and mortality of reconstructive surgery of noninfected false aneurysms detected long after aortic prosthetic reconstruction. Arch Surg 1998;133:45–9. https://doi.org/10.1001/archsurg.133.1.45
Google ScholarCrossrefWorldCat 
1371	Chaud GJ, Mohammadi S, Cervetti MR, Guimaron S, Sebestyen A, Dagenais F, et al.  Aortic pseudoaneurysm after type A aortic dissection: results of conservative management. Semin Thorac Cardiovasc Surg 2022;35:457–64. https://doi.org/10.1053/j.semtcvs.2022.04.004
Google ScholarCrossrefWorldCat 
1372	Richens D, Kotidis K, Neale M, Oakley C, Fails A. Rupture of the aorta following road traffic accidents in the United Kingdom 1992–1999. The results of the co-operative crash injury study. Eur J Cardiothorac Surg 2003;23:143–8. https://doi.org/10.1016/s1010-7940(02)00720-0
Google ScholarCrossrefWorldCat 
1373	Harky A, Bleetman D, Chan JSK, Eriksen P, Chaplin G, MacCarthy-Ofosu B, et al.  A systematic review and meta-analysis of endovascular versus open surgical repair for the traumatic ruptured thoracic aorta. J Vasc Surg 2020;71:270–82. https://doi.org/10.1016/j.jvs.2019.05.011
Google ScholarCrossrefWorldCat 
1374	Heneghan RE, Aarabi S, Quiroga E, Gunn ML, Singh N, Starnes BW. Call for a new classification system and treatment strategy in blunt aortic injury. J Vasc Surg 2016;64:171–6. https://doi.org/10.1016/j.jvs.2016.02.047
Google ScholarCrossrefWorldCat 
1375	Januzzi JL, Sabatine MS, Eagle KA, Evangelista A, Bruckman D, Fattori R, et al.  Iatrogenic aortic dissection. Am J Cardiol 2002;89:623–6. https://doi.org/10.1016/s0002-9149(01)02312-8
Google ScholarCrossrefWorldCat 
1376	Gómez-Moreno S, Sabaté M, Jiménez-Quevedo P, Vázquez P, Alfonso F, Angiolillo DJ, et al.  Iatrogenic dissection of the ascending aorta following heart catheterisation: incidence, management and outcome. EuroIntervention 2006;2:197–202.
Google ScholarWorldCat 
1377	Dunning DW, Kahn JK, Hawkins ET, O’Neill W. Iatrogenic coronary artery dissections extending into and involving the aortic root. Catheter Cardiovasc Interv 2000;51:387–93. https://doi.org/10.1002/1522-726x(200012)51:4<387::aid-ccd3>3.0.co;2-b
Google ScholarCrossrefWorldCat 
1378	Bekkers JA, te Riele RJ, Takkenberg JJ, Bol Raap G, Hofland J, Roos-Hesselink JW, et al.  Thoracic aortic surgery: an overview of 40 years clinical practice. J Thorac Cardiovasc Surg 2014;147:332–43. https://doi.org/10.1016/j.jtcvs.2012.11.036
Google ScholarCrossrefWorldCat 
1379	Meena RA, Benarroch-Gampel J, Leshnower BG, Escobar GA, Duwayri Y, Jordan WD, et al.  Surveillance recommendations after thoracic endovascular aortic repair should be based on initial indication for repair. Ann Vasc Surg 2019;57:51–9. https://doi.org/10.1016/j.avsg.2018.11.001
Google ScholarCrossrefWorldCat 
1380	Giles KA, Beck AW, Lala S, Patterson S, Back M, Fatima J, et al.  Implications of secondary aortic intervention after thoracic endovascular aortic repair for acute and chronic type B dissection. J Vasc Surg 2019;69:1367–78. https://doi.org/10.1016/j.jvs.2018.07.080
Google ScholarCrossrefWorldCat 
1381	Kimura N, Itoh S, Yuri K, Adachi K, Matsumoto H, Yamaguchi A, et al.  Reoperation for enlargement of the distal aorta after initial surgery for acute type A aortic dissection. J Thorac Cardiovasc Surg 2015;149:S91–8.e1. https://doi.org/10.1016/j.jtcvs.2014.08.008
Google ScholarCrossrefWorldCat 
1382	Ameli-Renani S, Das R, Morgan RA. Thoracic endovascular aortic repair for the treatment of aortic dissection: post-operative imaging, complications and secondary interventions. Cardiovasc Intervent Radiol 2015;38:1391–404. https://doi.org/10.1007/s00270-015-1072-9
Google ScholarCrossrefWorldCat 
1383	Fleischmann D, Afifi RO, Casanegra AI, Elefteriades JA, Gleason TG, Hanneman K, et al.  Imaging and surveillance of chronic aortic dissection: a scientific statement from the American Heart Association. Circ Cardiovasc Imaging 2022;15:e000075. https://doi.org/10.1161/hci.0000000000000075
Google ScholarCrossrefWorldCat 
1384	Colacchio EC, Squizzato F, Piazza M, Menegolo M, Grego F, Antonello M. Clinical and imaging predictors of disease progression in type B aortic intramural hematomas and penetrating aortic ulcers: a systematic review. Diagnostics (Basel) 2022;12:2727. https://doi.org/10.3390/diagnostics12112727
Google ScholarCrossrefWorldCat 
1385	Vapnik JS, Kim JB, Isselbacher EM, Ghoshhajra BB, Cheng Y, Sundt TM, et al.  Characteristics and outcomes of ascending versus descending thoracic aortic aneurysms. Am J Cardiol 2016;117:1683–90. https://doi.org/10.1016/j.amjcard.2016.02.048
Google ScholarCrossrefWorldCat 
1386	Gökalp AL, Takkenberg JJM. Decision-making in thoracic aortic aneurysm surgery-clinician and patient view. Semin Thorac Cardiovasc Surg 2019;31:638–42. https://doi.org/10.1053/j.semtcvs.2019.05.032
Google ScholarCrossrefWorldCat 
1387	Treasure T, King A, Hidalgo Lemp L, Golesworthy T, Pepper J, Takkenberg JJM. Developing a shared decision support framework for aortic root surgery in Marfan syndrome. Heart 2018;104:480–6. https://doi.org/10.1136/heartjnl-2017-311598
Google ScholarCrossrefWorldCat 
1388	Jondeau G, Ropers J, Regalado E, Braverman A, Evangelista A, Teixedo G, et al.  International registry of patients carrying TGFBR1 or TGFBR2 mutations: results of the MAC (Montalcino Aortic Consortium). Circ Cardiovasc Genet 2016;9:548–58. https://doi.org/10.1161/circgenetics.116.001485
Google ScholarCrossrefWorldCat 
1389	Thakker PD, Braverman AC. Cardiogenetics: genetic testing in the diagnosis and management of patients with aortic disease. Heart 2021;107:619–26. https://doi.org/10.1136/heartjnl-2020-317036
Google ScholarCrossrefWorldCat 
1390	Loeys BL, Schwarze U, Holm T, Callewaert BL, Thomas GH, Pannu H, et al.  Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med 2006;355:788–98. https://doi.org/10.1056/NEJMoa055695
Google ScholarCrossrefWorldCat 
1391	Regalado ES, Morris SA, Braverman AC, Hostetler EM, De Backer J, Li R, et al.  Comparative risks of initial aortic events associated with genetic thoracic aortic disease. J Am Coll Cardiol 2022;80:857–69. https://doi.org/10.1016/j.jacc.2022.05.054
Google ScholarCrossrefWorldCat 
1392	Huguenard AL, Johnson GW, Desai RR, Osbun JW, Dacey RG, Braverman AC. Relationship between phenotypic features in Loeys-Dietz syndrome and the presence of intracranial aneurysms. J Neurosurg 2022;138:1385–92. https://doi.org/10.3171/2022.9.Jns221373
Google ScholarWorldCat 
1393	Lopez-Sainz A, Mila L, Rodriguez-Palomares J, Limeres J, Granato C, La Mura L, et al.  Aortic branch aneurysms and vascular risk in patients with Marfan syndrome. J Am Coll Cardiol 2021;77:3005–12. https://doi.org/10.1016/j.jacc.2021.04.054
Google ScholarCrossrefWorldCat 
1394	Kaw A, Kaw K, Hostetler EM, Beleza-Meireles A, Smith-Collins A, Armstrong C, et al.  Expanding ACTA2 genotypes with corresponding phenotypes overlapping with smooth muscle dysfunction syndrome. Am J Med Genet A 2022;188:2389–96. https://doi.org/10.1002/ajmg.a.62775
Google ScholarCrossrefWorldCat 
1395	Velvin G, Wilhelmsen JE, Johansen H, Bathen T, Geirdal AO. Systematic review of quality of life in persons with hereditary thoracic aortic aneurysm and dissection diagnoses. Clin Genet 2019;95:661–76. https://doi.org/10.1111/cge.13522
Google ScholarCrossrefWorldCat 
1396	Mariscalco G, Debiec R, Elefteriades JA, Samani NJ, Murphy GJ. Systematic review of studies that have evaluated screening tests in relatives of patients affected by nonsyndromic thoracic aortic disease. J Am Heart Assoc 2018;7:e009302. https://doi.org/10.1161/jaha.118.009302
Google ScholarCrossrefWorldCat 
1397	Cecchi AC, Boerio ML, Marin I, Pinard A, Milewicz DM. Preventing acute aortic dissections: the power of familial screening and risk assessment. J Am Heart Assoc 2022;11:e025441. https://doi.org/10.1161/jaha.122.025441
Google ScholarCrossrefWorldCat 
1398	Abbasciano RG, Mariscalco G, Barwell J, Owens G, Zakkar M, Joel-David L, et al.  Evaluating the feasibility of screening relatives of patients affected by nonsyndromic thoracic aortic diseases: the REST study. J Am Heart Assoc 2022;11:e023741. https://doi.org/10.1161/jaha.121.023741
Google ScholarCrossrefWorldCat 
1399	Musunuru K, Hershberger RE, Day SM, Klinedinst NJ, Landstrom AP, Parikh VN, et al.  Genetic testing for inherited cardiovascular diseases: a scientific statement from the American Heart Association. Circ Genom Precis Med 2020;13:e000067. https://doi.org/10.1161/hcg.0000000000000067
Google ScholarCrossrefWorldCat 
1400	Albornoz G, Coady MA, Roberts M, Davies RR, Tranquilli M, Rizzo JA, et al.  Familial thoracic aortic aneurysms and dissections—incidence, modes of inheritance, and phenotypic patterns. Ann Thorac Surg 2006;82:1400–5. https://doi.org/10.1016/j.athoracsur.2006.04.098
Google ScholarCrossrefWorldCat 
1401	Biddinger A, Rocklin M, Coselli J, Milewicz DM. Familial thoracic aortic dilatations and dissections: a case control study. J Vasc Surg 1997;25:506–11. https://doi.org/10.1016/s0741-5214(97)70261-1
Google ScholarCrossrefWorldCat 
1402	Robertson EN, van der Linde D, Sherrah AG, Vallely MP, Wilson M, Bannon PG, et al.  Familial non-syndromal thoracic aortic aneurysms and dissections—incidence and family screening outcomes. Int J Cardiol 2016;220:43–51. https://doi.org/10.1016/j.ijcard.2016.06.086
Google ScholarCrossrefWorldCat 
1403	De Backer J, Bondue A, Budts W, Evangelista A, Gallego P, Jondeau G, et al.  Genetic counselling and testing in adults with congenital heart disease: a consensus document of the ESC Working Group of Grown-Up Congenital Heart Disease, the ESC Working Group on Aorta and Peripheral Vascular Disease and the European Society of Human Genetics. Eur J Prev Cardiol 2020;27:1423–35. https://doi.org/10.1177/2047487319854552
Google ScholarCrossrefWorldCat 
1404	Wolford BN, Hornsby WE, Guo D, Zhou W, Lin M, Farhat L, et al.  Clinical implications of identifying pathogenic variants in individuals with thoracic aortic dissection. Circ Genom Precis Med 2019;12:e002476. https://doi.org/10.1161/circgen.118.002476
Google ScholarCrossrefWorldCat 
1405	Renard M, Francis C, Ghosh R, Scott AF, Witmer PD, Adès LC, et al.  Clinical validity of genes for heritable thoracic aortic aneurysm and dissection. J Am Coll Cardiol 2018;72:605–15. https://doi.org/10.1016/j.jacc.2018.04.089
Google ScholarCrossrefWorldCat 
1406	De Backer J, Jondeau G, Boileau C. Genetic testing for aortopathies: primer for the nongeneticist. Curr Opin Cardiol 2019;34:585–93. https://doi.org/10.1097/hco.0000000000000669
Google ScholarCrossrefWorldCat 
1407	Milewicz DM, Guo D, Hostetler E, Marin I, Pinard AC, Cecchi AC, et al.  Update on the genetic risk for thoracic aortic aneurysms and acute aortic dissections: implications for clinical care. J Cardiovasc Surg 2021;62:203–10. https://doi.org/10.23736/s0021-9509.21.11816-6
Google ScholarCrossrefWorldCat 
1408	Chou EL, Lindsay ME. The genetics of aortopathies: hereditary thoracic aortic aneurysms and dissections. Am J Med Genet C Semin Med Genet 2020;184:136–48. https://doi.org/10.1002/ajmg.c.31771
Google ScholarCrossrefWorldCat 
1409	Harris SL, Lindsay ME. Role of clinical genetic testing in the management of aortopathies. Curr Cardiol Rep 2021;23:10. https://doi.org/10.1007/s11886-020-01435-6
Google ScholarCrossrefWorldCat 
1410	Regalado ES, Guo DC, Prakash S, Bensend TA, Flynn K, Estrera A, et al.  Aortic disease presentation and outcome associated with ACTA2 mutations. Circ Cardiovasc Genet 2015;8:457–64. https://doi.org/10.1161/circgenetics.114.000943
Google ScholarCrossrefWorldCat 
1411	Teixidó-Tura G, Franken R, Galuppo V, Gutiérrez García-Moreno L, Borregan M, Mulder BJM, et al.  Heterogeneity of aortic disease severity in patients with Loeys-Dietz syndrome. Heart 2016;102:626–32. https://doi.org/10.1136/heartjnl-2015-308535
Google ScholarCrossrefWorldCat 
1412	Baudhuin LM, Kotzer KE, Lagerstedt SA. Increased frequency of FBN1 truncating and splicing variants in Marfan syndrome patients with aortic events. Genet Med 2015;17:177–87. https://doi.org/10.1038/gim.2014.91
Google ScholarCrossrefWorldCat 
1413	Franken R, Teixido-Tura G, Brion M, Forteza A, Rodriguez-Palomares J, Gutierrez L, et al.  Relationship between fibrillin-1 genotype and severity of cardiovascular involvement in Marfan syndrome. Heart 2017;103:1795–9. https://doi.org/10.1136/heartjnl-2016-310631
Google ScholarCrossrefWorldCat 
1414	Wallace SE, Regalado ES, Gong L, Janda AL, Guo D, Russo CF, et al.  MYLK pathogenic variants aortic disease presentation, pregnancy risk, and characterization of pathogenic missense variants. Genet Med 2019;21:144–51. https://doi.org/10.1038/s41436-018-0038-0
Google ScholarCrossrefWorldCat 
1415	Seike Y, Matsuda H, Ishibashi-Ueda H, Morisaki H, Morisaki T, Minatoya K, et al.  Surgical outcome and histological differences between individuals with TGFBR1 and TGFBR2 mutations in Loeys-Dietz syndrome. Ann Thorac Cardiovasc Surg 2021;27:56–63. https://doi.org/10.5761/atcs.oa.20-00223
Google ScholarCrossrefWorldCat 
1416	Arnaud P, Milleron O, Hanna N, Ropers J, Ould Ouali N, Affoune A, et al.  Clinical relevance of genotype-phenotype correlations beyond vascular events in a cohort study of 1500 Marfan syndrome patients with FBN1 pathogenic variants. Genet Med 2021;23:1296–304. https://doi.org/10.1038/s41436-021-01132-x
Google ScholarCrossrefWorldCat 
1417	Silberbach M, Roos-Hesselink JW, Andersen NH, Braverman AC, Brown N, Collins RT, et al.  Cardiovascular health in Turner syndrome: a scientific statement from the American Heart Association. Circ Genom Precis Med 2018;11:e000048. https://doi.org/10.1161/hcg.0000000000000048
Google ScholarCrossrefWorldCat 
1418	Gravholt CH, Andersen NH, Conway GS, Dekkers OM, Geffner ME, Klein KO, et al.  Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol 2017;177:G1–70. https://doi.org/10.1530/eje-17-0430
Google ScholarCrossrefWorldCat 
1419	van den Hoven AT, Chelu RG, Duijnhouwer AL, Demulier L, Devos D, Nieman K, et al.  Partial anomalous pulmonary venous return in Turner syndrome. Eur J Radiol 2017;95:141–6. https://doi.org/10.1016/j.ejrad.2017.07.024
Google ScholarCrossrefWorldCat 
1420	Carlson M, Airhart N, Lopez L, Silberbach M. Moderate aortic enlargement and bicuspid aortic valve are associated with aortic dissection in Turner syndrome: report of the international Turner syndrome aortic dissection registry. Circulation 2012;126:2220–6. https://doi.org/10.1161/circulationaha.111.088633
Google ScholarCrossrefWorldCat 
1421	Matura LA, Ho VB, Rosing DR, Bondy CA. Aortic dilatation and dissection in Turner syndrome. Circulation 2007;116:1663–70. https://doi.org/10.1161/circulationaha.106.685487
Google ScholarCrossrefWorldCat 
1422	Schoemaker MJ, Swerdlow AJ, Higgins CD, Wright AF, Jacobs PA. Mortality in women with Turner syndrome in Great Britain: a national cohort study. J Clin Endocrinol Metab 2008;93:4735–42. https://doi.org/10.1210/jc.2008-1049
Google ScholarCrossrefWorldCat 
1423	Duijnhouwer AL, Bons LR, Timmers H, van Kimmenade RRL, Snoeren M, Timmermans J, et al.  Aortic dilatation and outcome in women with Turner syndrome. Heart 2019;105:693–700. https://doi.org/10.1136/heartjnl-2018-313716
Google ScholarCrossrefWorldCat 
1424	Donadille B, Tuffet S, Cholet C, Nedelcu M, Bourcigaux N, Iserin L, et al.  Prevalence and progression of aortic dilatation in adult patients with Turner syndrome: a cohort study. Eur J Endocrinol 2020;183:463–70. https://doi.org/10.1530/eje-20-0284
Google ScholarCrossrefWorldCat 
1425	Meccanici F, Schotte MH, Snoeren M, Bons LR, van den Hoven AT, Kardys I, et al.  Aortic dilation and growth in women with Turner syndrome. Heart 2023;109:102–10. https://doi.org/10.1136/heartjnl-2022-320922
Google ScholarCrossrefWorldCat 
1426	Galian-Gay L, Rodriguez-Palomares JF. Turner syndrome and aortic complications: more benign than previously thought. Heart 2022;109:82–3. https://doi.org/10.1136/heartjnl-2022-321330
Google ScholarCrossrefWorldCat 
1427	Silberbach M, Braverman AC, Prakash SK, Roos-Hesselink JW, Quezada E, Scurlock C. Preventing aortic dissection in Turner syndrome: who faces the risk? Int J Cardiol 2023;377:44. https://doi.org/10.1016/j.ijcard.2023.01.075
Google ScholarCrossrefWorldCat 
1428	Prakash S, Gen TACRI, Milewicz D. Turner syndrome-specific and general population Z-scores are equivalent for most adults with Turner syndrome. Am J Med Genet A 2017;173:1094–6. https://doi.org/10.1002/ajmg.a.38100
Google ScholarCrossrefWorldCat 
1429	Corbitt H, Maslen C, Prakash S, Morris SA, Silberbach M. Allometric considerations when assessing aortic aneurysms in Turner syndrome: implications for activity recommendations and medical decision-making. Am J Med Genet A 2018;176:277–82. https://doi.org/10.1002/ajmg.a.38584
Google ScholarCrossrefWorldCat 
1430	Quigley CA, Fechner PY, Geffner ME, Eugster EA, Ross JL, Habiby RL, et al.  Prevention of growth failure in Turner syndrome: long-term results of early growth hormone treatment in the “Toddler Turner” Cohort. Horm Res Paediatr 2021;94:18–35. https://doi.org/10.1159/000513788
Google ScholarCrossrefWorldCat 
1431	Klein KO, Rosenfield RL, Santen RJ, Gawlik AM, Backeljauw PF, Gravholt CH, et al.  Estrogen replacement in Turner syndrome: literature review and practical considerations. J Clin Endocrinol Metab 2018;103:1790–803. https://doi.org/10.1210/jc.2017-02183
Google ScholarCrossrefWorldCat 
1432	Quigley CA, Wan X, Garg S, Kowal K, Cutler GB, Ross JL. Effects of low-dose estrogen replacement during childhood on pubertal development and gonadotropin concentrations in patients with Turner syndrome: results of a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 2014;99:E1754–1764. https://doi.org/10.1210/jc.2013-4518
Google ScholarCrossrefWorldCat 
1433	Davenport ML, Crowe BJ, Travers SH, Rubin K, Ross JL, Fechner PY, et al.  Growth hormone treatment of early growth failure in toddlers with Turner syndrome: a randomized, controlled, multicenter trial. J Clin Endocrinol Metab 2007;92:3406–16. https://doi.org/10.1210/jc.2006-2874
Google ScholarCrossrefWorldCat 
1434	Stephure DK; Canadian Growth Hormone Advisory Committee. Impact of growth hormone supplementation on adult height in Turner syndrome: results of the Canadian randomized controlled trial. J Clin Endocrinol Metab 2005;90:3360–6. https://doi.org/10.1210/jc.2004-2187
Google ScholarWorldCat 
1435	Campens L, Baris L, Scott NS, Broberg CS, Bondue A, Jondeau G, et al.  Pregnancy outcome in thoracic aortic disease data from the registry of pregnancy and cardiac disease. Heart 2021;107:1704–9. https://doi.org/10.1136/heartjnl-2020-318183
Google ScholarCrossrefWorldCat 
1436	Grewal J, Valente AM, Egbe AC, Wu FM, Krieger EV, Sybert VP, et al.  Cardiovascular outcomes of pregnancy in Turner syndrome. Heart 2021;107:61–6. https://doi.org/10.1136/heartjnl-2020-316719
Google ScholarCrossrefWorldCat 
1437	Thompson T, Zieba B, Howell S, Karakash W, Davis S. A mixed methods study of physical activity and quality of life in adolescents with Turner syndrome. Am J Med Genet A 2020;182:386–96. https://doi.org/10.1002/ajmg.a.61439
Google ScholarCrossrefWorldCat 
1438	Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med 2000;342:673–80. https://doi.org/10.1056/nejm200003093421001
Google ScholarCrossrefWorldCat 
1439	Byers PH, Belmont J, Black J, De Backer J, Frank M, Jeunemaitre X, et al.  Diagnosis, natural history, and management in vascular Ehlers-Danlos syndrome. Am J Med Genet C Semin Med Genet 2017;175:40–7. https://doi.org/10.1002/ajmg.c.31553
Google ScholarCrossrefWorldCat 
1440	Oderich GS, Panneton JM, Bower TC, Lindor NM, Cherry KJ, Noel AA, et al.  The spectrum, management and clinical outcome of Ehlers-Danlos syndrome type IV: a 30-year experience. J Vasc Surg 2005;42:98–106. https://doi.org/10.1016/j.jvs.2005.03.053
Google ScholarCrossrefWorldCat 
1441	Frank M, Adham S, Seigle S, Legrand A, Mirault T, Henneton P, et al.  Vascular Ehlers-Danlos syndrome: long-term observational study. J Am Coll Cardiol 2019;73:1948–57. https://doi.org/10.1016/j.jacc.2019.01.058
Google ScholarCrossrefWorldCat 
1442	Pepin MG, Schwarze U, Rice KM, Liu M, Leistritz D, Byers PH. Survival is affected by mutation type and molecular mechanism in vascular Ehlers-Danlos syndrome (EDS type IV). Genet Med 2014;16:881–8. https://doi.org/10.1038/gim.2014.72
Google ScholarCrossrefWorldCat 
1443	van de Laar I, Baas AF, De Backer J, Blankenstein JD, Dulfer E, Helderman-van den Enden ATJM, et al.  Surveillance and monitoring in vascular Ehlers-Danlos syndrome in European reference network for rare vascular diseases (VASCERN). Eur J Med Genet 2022;65:104557. https://doi.org/10.1016/j.ejmg.2022.104557
Google ScholarCrossrefWorldCat 
1444	Baderkhan H, Wanhainen A, Stenborg A, Stattin EL, Bjorck M. Celiprolol treatment in patients with vascular Ehlers-Danlos syndrome. Eur J Vasc Endovasc Surg 2021;61:326–31. https://doi.org/10.1016/j.ejvs.2020.10.020
Google ScholarCrossrefWorldCat 
1445	Ong KT, Perdu J, De Backer J, Bozec E, Collignon P, Emmerich J, et al.  Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet 2010;376:1476–84. https://doi.org/10.1016/s0140-6736(10)60960-9
Google ScholarCrossrefWorldCat 
1446	Murray ML, Pepin M, Peterson S, Byers PH. Pregnancy-related deaths and complications in women with vascular Ehlers-Danlos syndrome. Genet Med 2014;16:874–80. https://doi.org/10.1038/gim.2014.53
Google ScholarCrossrefWorldCat 
1447	Loeys BL, Dietz HC, Braverman AC, Callewaert BL, De Backer J, Devereux RB, et al.  The revised Ghent nosology for the Marfan syndrome. J Med Genet 2010;47:476–85. https://doi.org/10.1136/jmg.2009.072785
Google ScholarCrossrefWorldCat 
1448	Yildiz M, Nucera M, Jungi S, Heinisch PP, Mosbahi S, Becker D, et al.  Outcome of Stanford type B dissection in patients with Marfan syndrome. Eur J Cardiothorac Surg 2023;64:ezad178. https://doi.org/10.1093/ejcts/ezad178
Google ScholarCrossrefWorldCat 
1449	Narula N, Devereux RB, Arbustini E, Ma X, Weinsaft JW, Girardi L, et al.  Risk of type B dissection in Marfan syndrome: the Cornell aortic aneurysm registry. J Am Coll Cardiol 2023;82:2009–17. https://doi.org/10.1016/j.jacc.2023.08.055
Google ScholarCrossrefWorldCat 
1450	Senemaud J, Gaudry M, Jouve E, Blanchard A, Milleron O, Dulac Y, et al.  Primary non-aortic lesions are not rare in Marfan syndrome and are associated with aortic dissection independently of age. J Clin Med 2023;12:2902. https://doi.org/10.3390/jcm12082902
Google ScholarCrossrefWorldCat 
1451	Judge DP, Rouf R, Habashi J, Dietz HC. Mitral valve disease in Marfan syndrome and related disorders. J Cardiovasc Transl Res 2011;4:741–7. https://doi.org/10.1007/s12265-011-9314-y
Google ScholarCrossrefWorldCat 
1452	Demolder A, Bianco L, Caruana M, Cervi E, Evangelista A, Jondeau G, et al.  Arrhythmia and impaired myocardial function in heritable thoracic aortic disease: an international retrospective cohort study. Eur J Med Genet 2022;65:104503. https://doi.org/10.1016/j.ejmg.2022.104503
Google ScholarCrossrefWorldCat 
1453	Pyeritz RE. Marfan syndrome: improved clinical history results in expanded natural history. Genet Med 2019;21:1683–90. https://doi.org/10.1038/s41436-018-0399-4
Google ScholarCrossrefWorldCat 
1454	Jondeau G, Detaint D, Tubach F, Arnoult F, Milleron O, Raoux F, et al.  Aortic event rate in the Marfan population: a cohort study. Circulation 2012;125:226–32. https://doi.org/10.1161/circulationaha.111.054676
Google ScholarCrossrefWorldCat 
1455	Requejo-Garcia L, Martinez-Lopez R, Plana-Andani E, Medina-Badenes P, Hernándiz-Martínez A, Torres-Blanco A, et al.  Extrathoracic aneurysms in Marfan syndrome: a systematic review of the literature. Ann Vasc Surg 2022;87:548–59. https://doi.org/10.1016/j.avsg.2022.08.005
Google ScholarCrossrefWorldCat 
1456	Guala A, Teixidó-Tura G, Rodríguez-Palomares J, Ruiz-Muñoz A, Dux-Santoy L, Villalva N, et al.  Proximal aorta longitudinal strain predicts aortic root dilation rate and aortic events in Marfan syndrome. Eur Heart J 2019;40:2047–55. https://doi.org/10.1093/eurheartj/ehz191
Google ScholarCrossrefWorldCat 
1457	Teixido-Tura G, Redheuil A, Rodríguez-Palomares J, Gutiérrez L, Sánchez V, Forteza A, et al.  Aortic biomechanics by magnetic resonance: early markers of aortic disease in Marfan syndrome regardless of aortic dilatation? Int J Cardiol 2014;171:56–61. https://doi.org/10.1016/j.ijcard.2013.11.044
Google ScholarCrossrefWorldCat 
1458	Kuijpers JM, Mulder BJ. Aortopathies in adult congenital heart disease and genetic aortopathy syndromes: management strategies and indications for surgery. Heart 2017;103:952–66. https://doi.org/10.1136/heartjnl-2015-308626
Google ScholarCrossrefWorldCat 
1459	Milewicz DM, Braverman AC, De Backer J, Morris SA, Boileau C, Maumenee IH, et al.  Marfan syndrome. Nat Rev Dis Primers 2021;7:64. https://doi.org/10.1038/s41572-021-00298-7
Google ScholarCrossrefWorldCat 
1460	Doyle JJ, Doyle AJ, Wilson NK, Habashi JP, Bedja D, Whitworth RE, et al.  A deleterious gene-by-environment interaction imposed by calcium channel blockers in Marfan syndrome. Elife 2015;4:e08648. https://doi.org/10.7554/eLife.08648
Google ScholarCrossrefWorldCat 
1461	Lacro RV, Dietz HC, Sleeper LA, Yetman AT, Bradley TJ, Colan SD, et al.  Atenolol versus losartan in children and young adults with Marfan’s syndrome. N Engl J Med 2014;371:2061–71. https://doi.org/10.1056/NEJMoa1404731
Google ScholarCrossrefWorldCat 
1462	Teixido-Tura G, Forteza A, Rodríguez-Palomares J, González Mirelis J, Gutiérrez L, Sánchez V, et al.  Losartan versus atenolol for prevention of aortic dilation in patients with Marfan syndrome. J Am Coll Cardiol 2018;72:1613–8. https://doi.org/10.1016/j.jacc.2018.07.052
Google ScholarCrossrefWorldCat 
1463	Pitcher A, Spata E, Emberson J, Davies K, Halls H, Holland L, et al.  Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials. Lancet 2022;400:822–31. https://doi.org/10.1016/s0140-6736(22)01534-3
Google ScholarCrossrefWorldCat 
1464	Groenink M, den Hartog AW, Franken R, Radonic T, de Waard V, Timmermans J, et al.  Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J 2013;34:3491–500. https://doi.org/10.1093/eurheartj/eht334
Google ScholarCrossrefWorldCat 
1465	Nucera M, Kreibich M, Yildiz M, Berger T, Kolb RK, Kondov S, et al.  Endovascular aortic repair in patients with Marfan and Loeys-Dietz syndrome is safe and durable when employed by a multi-disciplinary aortic team. Eur J Cardiothorac Surg 2024;65:ezae069. https://doi.org/10.1093/ejcts/ezae069
Google ScholarCrossrefWorldCat 
1466	Czerny M, Grabenwoger M, Berger T, Aboyans V, Della Corte A, Chen EP, et al.  EACTS/STS Guidelines for diagnosing and treating acute and chronic syndromes of the aortic organ. Eur J Cardiothorac Surg 2024;65:ezad426. https://doi.org/10.1093/ejcts/ezad426
Google ScholarCrossrefWorldCat 
1467	Milleron O, Arnoult F, Delorme G, Detaint D, Pellenc Q, Raffoul R, et al.  Pathogenic FBN1 genetic variation and aortic dissection in patients with Marfan syndrome. J Am Coll Cardiol 2020;75:843–53. https://doi.org/10.1016/j.jacc.2019.12.043
Google ScholarCrossrefWorldCat 
1468	Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller G-P, et al.  2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J 2021;42:563–645. https://doi.org/10.1093/eurheartj/ehaa554
Google ScholarCrossrefWorldCat 
1469	Martín C, Evangelista A, Serrano-Fiz S, Villar S, Ospina V, Martínez D, et al.  Aortic complications in Marfan syndrome: should we anticipate preventive aortic root surgery? Ann Thorac Surg 2020;109:1850–7. https://doi.org/10.1016/j.athoracsur.2019.08.096
Google ScholarCrossrefWorldCat 
1470	Roman MJ, Pugh NL, Hendershot TP, Devereux RB, Dietz H, Holmes K, et al.  Aortic complications associated with pregnancy in Marfan syndrome: the NHLBI national registry of genetically triggered thoracic aortic aneurysms and cardiovascular conditions (GenTAC). J Am Heart Assoc 2016;5:e004052. https://doi.org/10.1161/jaha.116.004052
Google ScholarCrossrefWorldCat 
1471	Braverman AC, Mittauer E, Harris KM, Evangelista A, Pyeritz RE, Brinster D, et al.  Clinical features and outcomes of pregnancy-related acute aortic dissection. JAMA Cardiol 2021;6:58–66. https://doi.org/10.1001/jamacardio.2020.4876
Google ScholarWorldCat 
1472	Narula N, Devereux RB, Malonga GP, Hriljac I, Roman MJ. Pregnancy-related aortic complications in women with Marfan syndrome. J Am Coll Cardiol 2021;78:870–9. https://doi.org/10.1016/j.jacc.2021.06.034
Google ScholarCrossrefWorldCat 
1473	Davis MB, Arendt K, Bello NA, Brown H, Briller J, Epps K, et al.  Team-based care of women with cardiovascular disease from pre-conception through pregnancy and postpartum: JACC focus seminar 1/5. J Am Coll Cardiol 2021;77:1763–77. https://doi.org/10.1016/j.jacc.2021.02.033
Google ScholarCrossrefWorldCat 
1474	Meijboom LJ, Vos FE, Timmermans J, Boers GH, Zwinderman AH, Mulder BJM. Pregnancy and aortic root growth in the Marfan syndrome: a prospective study. Eur Heart J 2005;26:914–20. https://doi.org/10.1093/eurheartj/ehi103
Google ScholarCrossrefWorldCat 
1475	Kuperstein R, Cahan T, Yoeli-Ullman R, Ben Zekry S, Shinfeld A, Simchen MJ. Risk of aortic dissection in pregnant patients with the Marfan syndrome. Am J Cardiol 2017;119:132–7. https://doi.org/10.1016/j.amjcard.2016.09.024
Google ScholarCrossrefWorldCat 
1476	Roberts EA, Pistner A, Osobamiro O, Banning S, Shalhub S, Albright C, et al.  Beta-blocker use during pregnancy correlates with less aortic root dilatation in patients with Marfan’s syndrome. Aorta (Stamford) 2023;11:63–70. https://doi.org/10.1055/a-2072-0469
Google ScholarWorldCat 
1477	Roman MJ, Devereux RB. Aortic dissection risk in Marfan syndrome. J Am Coll Cardiol 2020;75:854–6. https://doi.org/10.1016/j.jacc.2019.12.042
Google ScholarCrossrefWorldCat 
1478	Quan A. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Hum Dev 2006;82:23–8. https://doi.org/10.1016/j.earlhumdev.2005.11.001
Google ScholarCrossrefWorldCat 
1479	Walfisch A, Al-maawali A, Moretti ME, Nickel C, Koren G. Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers. J Obstet Gynaecol 2011;31:465–72. https://doi.org/10.3109/01443615.2011.579197
Google ScholarCrossrefWorldCat 
1480	Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, et al.  Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006;354:2443–51. https://doi.org/10.1056/NEJMoa055202
Google ScholarCrossrefWorldCat 
1481	Mas-Stachurska A, Siegert AM, Batlle M, Gorbenko del Blanco D, Meirelles T, Rubies C, et al.  Cardiovascular benefits of moderate exercise training in Marfan syndrome: insights from an animal model. J Am Heart Assoc 2017;6:e006438. https://doi.org/10.1161/jaha.117.006438
Google ScholarCrossrefWorldCat 
1482	Gibson C, Nielsen C, Alex R, Cooper K, Farney M, Gaufin D, et al.  Mild aerobic exercise blocks elastin fiber fragmentation and aortic dilatation in a mouse model of Marfan syndrome associated aortic aneurysm. J Appl Physiol 2017;123:147–60. https://doi.org/10.1152/japplphysiol.00132.2017
Google ScholarCrossrefWorldCat 
1483	Selamet Tierney ES, Chung S, Stauffer KJ, Brabender J, Collins RT, Folk R, et al.  Can 10 000 healthy steps a day slow aortic root dilation in pediatric patients with Marfan syndrome? J Am Heart Assoc 2022;11:e027598. https://doi.org/10.1161/jaha.122.027598
Google ScholarCrossrefWorldCat 
1484	Jouini S, Milleron O, Eliahou L, Jondeau G, Vitiello D. Effects of a personalized home-based training program among patients suffering from Marfan syndrome: a pilot randomized and controlled study. Intractable Rare Dis Res 2021;10:263–8. https://doi.org/10.5582/irdr.2021.01080
Google ScholarCrossrefWorldCat 
1485	Benninghoven D, Hamann D, von Kodolitsch Y, Rybczynski M, Lechinger J, Schroeder F, et al.  Inpatient rehabilitation for adult patients with Marfan syndrome: an observational pilot study. Orphanet J Rare Dis 2017;12:127. https://doi.org/10.1186/s13023-017-0679-0
Google ScholarCrossrefWorldCat 
1486	Fuglsang S, Heiberg J, Hjortdal VE, Laustsen S. Exercise-based cardiac rehabilitation in surgically treated type-A aortic dissection patients. Scand Cardiovasc J 2017;51:99–105. https://doi.org/10.1080/14017431.2016.1257149
Google ScholarCrossrefWorldCat 
1487	Loeys BL, Chen J, Neptune ER, Judge DP, Podowski M, Holm T, et al.  A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 2005;37:275–81. https://doi.org/10.1038/ng1511
Google ScholarCrossrefWorldCat 
1488	MacCarrick G, Black JH, III, Bowdin S, El-Hamamsy I, Frischmeyer-Guerrerio PA, Guerrerio AL, et al.  Loeys-Dietz syndrome: a primer for diagnosis and management. Genet Med 2014;16:576–87. https://doi.org/10.1038/gim.2014.11
Google ScholarCrossrefWorldCat 
1489	Lindsay ME, Schepers D, Bolar NA, Doyle JJ, Gallo E, Fert-Bober J, et al.  Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm. Nat Genet 2012;44:922–7. https://doi.org/10.1038/ng.2349
Google ScholarCrossrefWorldCat 
1490	Boileau C, Guo DC, Hanna N, Regalado ES, Detaint D, Gong L, et al.  TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome. Nat Genet 2012;44:916–21. https://doi.org/10.1038/ng.2348
Google ScholarCrossrefWorldCat 
1491	van der Linde D, van de Laar IM, Bertoli-Avella AM, Oldenburg RA, Bekkers JA, Mattace-Raso FUS, et al.  Aggressive cardiovascular phenotype of aneurysms-osteoarthritis syndrome caused by pathogenic SMAD3 variants. J Am Coll Cardiol 2012;60:397–403. https://doi.org/10.1016/j.jacc.2011.12.052
Google ScholarCrossrefWorldCat 
1492	Hostetler EM, Regalado ES, Guo DC, Hanna N, Arnaud P, Muiño-Mosquera L, et al.  SMAD3 pathogenic variants: risk for thoracic aortic disease and associated complications from the Montalcino Aortic Consortium. J Med Genet 2019;56:252–60. https://doi.org/10.1136/jmedgenet-2018-105583
Google ScholarCrossrefWorldCat 
1493	Renard M, Callewaert B, Malfait F, Campens L, Sharif S, del Campo M, et al.  Thoracic aortic-aneurysm and dissection in association with significant mitral valve disease caused by mutations in TGFB2. Int J Cardiol 2013;165:584–7. https://doi.org/10.1016/j.ijcard.2012.09.029
Google ScholarCrossrefWorldCat 
1494	Bertoli-Avella AM, Gillis E, Morisaki H, Verhagen JMA, de Graaf BM, van de Beek G, et al.  Mutations in a TGF-beta ligand, TGFB3, cause syndromic aortic aneurysms and dissections. J Am Coll Cardiol 2015;65:1324–36. https://doi.org/10.1016/j.jacc.2015.01.040
Google ScholarCrossrefWorldCat 
1495	Marsili L, Overwater E, Hanna N, Baujat G, Baars MJH, Boileau C, et al.  Phenotypic spectrum of TGFB3 disease-causing variants in a Dutch-French cohort and first report of a homozygous patient. Clin Genet 2020;97:723–30. https://doi.org/10.1111/cge.13700
Google ScholarCrossrefWorldCat 
1496	Guo DC, Pannu H, Tran-Fadulu V, Papke CL, Yu RK, Avidan N, et al.  Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections. Nat Genet 2007;39:1488–93. https://doi.org/10.1038/ng.2007.6
Google ScholarCrossrefWorldCat 
1497	Guo DC, Papke CL, Tran-Fadulu V, Regalado ES, Avidan N, Johnson RJ, et al.  Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and Moyamoya disease, along with thoracic aortic disease. Am J Hum Genet 2009;84:617–27. https://doi.org/10.1016/j.ajhg.2009.04.007
Google ScholarCrossrefWorldCat 
1498	van de Laar I, Arbustini E, Loeys B, Björck E, Murphy L, Groenink M, et al.  European reference network for rare vascular diseases (VASCERN) consensus statement for the screening and management of patients with pathogenic ACTA2 variants. Orphanet J Rare Dis 2019;14:264. https://doi.org/10.1186/s13023-019-1186-2
Google ScholarCrossrefWorldCat 
1499	Brownstein AJ, Ziganshin BA, Kuivaniemi H, Body Simon, Bale A, Elefteriades J. Genes associated with thoracic aortic aneurysm and dissection: an update and clinical implications. Aorta (Stamford) 2017;5:11–20. https://doi.org/10.12945/j.aorta.2017.17.003
Google ScholarWorldCat 
1500	Bray JJH, Freer R, Pitcher A, Kharbanda R. Family screening for bicuspid aortic valve and aortic dilatation: a meta-analysis. Eur Heart J 2023;44:3152–64. https://doi.org/10.1093/eurheartj/ehad320
Google ScholarCrossrefWorldCat 
1501	Michelena HI, Vallabhajosyula S, Prakash SK. Nosology spectrum of the bicuspid aortic valve condition: complex-presentation valvulo-aortopathy. Circulation 2020;142:294–9. https://doi.org/10.1161/circulationaha.120.046892
Google ScholarCrossrefWorldCat 
1502	Prakash SK, Bosse Y, Muehlschlegel JD, Michelena HI, Limongelli G, Della Corte A, et al.  A roadmap to investigate the genetic basis of bicuspid aortic valve and its complications: insights from the International BAVCon (Bicuspid Aortic Valve Consortium). J Am Coll Cardiol 2014;64:832–9. https://doi.org/10.1016/j.jacc.2014.04.073
Google ScholarCrossrefWorldCat 
1503	Fulmer D, Toomer K, Guo L, Moore K, Glover J, Moore R, et al.  Defects in the exocyst-cilia machinery cause bicuspid aortic valve disease and aortic stenosis. Circulation 2019;140:1331–41. https://doi.org/10.1161/circulationaha.119.038376
Google ScholarCrossrefWorldCat 
1504	Luyckx I, Kumar AA, Reyniers E, Dekeyser E, Vanderstraeten K, Vandeweyer G, et al.  Copy number variation analysis in bicuspid aortic valve-related aortopathy identifies TBX20 as a contributing gene. Eur J Hum Genet 2019;27:1033–43. https://doi.org/10.1038/s41431-019-0364-y
Google ScholarCrossrefWorldCat 
1505	Xu YJ, Di RM, Qiao Q, Li X-M, Huang R-T, Xue S, et al.  GATA6 loss-of-function mutation contributes to congenital bicuspid aortic valve. Gene 2018;663:115–20. https://doi.org/10.1016/j.gene.2018.04.018
Google ScholarCrossrefWorldCat 
1506	Gehlen J, Stundl A, Debiec R, Fontana F, Krane M, Sharipova D, et al.  Elucidation of the genetic causes of bicuspid aortic valve disease. Cardiovasc Res 2023;119:857–66. https://doi.org/10.1093/cvr/cvac099
Google ScholarCrossrefWorldCat 
1507	Gago-Díaz M, Brion M, Gallego P, Calvo F, Robledo-Carmona J, Saura D, et al.  The genetic component of bicuspid aortic valve and aortic dilation. An exome-wide association study. J Mol Cell Cardiol 2017;102:3–9. https://doi.org/10.1016/j.yjmcc.2016.11.012
Google ScholarCrossrefWorldCat 
1508	Girdauskas E, Geist L, Disha K, Kazakbaev I, Groß T, Schulz S, et al.  Genetic abnormalities in bicuspid aortic valve root phenotype: preliminary results. Eur J Cardiothorac Surg 2017;52:156–62. https://doi.org/10.1093/ejcts/ezx065
Google ScholarCrossrefWorldCat 
1509	Mansoorshahi S, Yetman AT, Bissell MM, Kim YY, Michelena H, Hui DS, et al.  Whole exome sequencing uncovers the genetic complexity of bicuspid aortic valve in families with early onset complications. medRxiv 2024. https://doi.org/10.1101/2024.02.07.24302406.
1510	Michelena HI, Della Corte A, Evangelista A, Maleszewski JJ, Edwards WD, Roman MJ, et al.  International consensus statement on nomenclature and classification of the congenital bicuspid aortic valve and its aortopathy, for clinical, surgical, interventional and research purposes. Eur J Cardiothorac Surg 2021;60:448–76. https://doi.org/10.1093/ejcts/ezab038
Google ScholarCrossrefWorldCat 
1511	Verma S, Siu SC. Aortic dilatation in patients with bicuspid aortic valve. N Engl J Med 2014;370:1920–9. https://doi.org/10.1056/NEJMra1207059
Google ScholarCrossrefWorldCat 
1512	Yang LT, Ye Z, Wajih Ullah M, Maleszewski JJ, Scott CG, Padang R, et al.  Bicuspid aortic valve: long-term morbidity and mortality. Eur Heart J 2023;44:4549–62. https://doi.org/10.1093/eurheartj/ehad477
Google ScholarCrossrefWorldCat 
1513	Guo MH, Appoo JJ, Saczkowski R, Smith HN, Ouzounian M, Gregory AJ, et al.  Association of mortality and acute aortic events with ascending aortic aneurysm: a systematic review and meta-analysis. JAMA Netw Open 2018;1:e181281. https://doi.org/10.1001/jamanetworkopen.2018.1281
Google ScholarCrossrefWorldCat 
1514	Dayan V, Zuasnabar A, Citro R, Bossone E, Michelena HI, Parma G, et al.  Aortopathy and regurgitation in bicuspid valve patients increase the risk of aortopathy in relatives. Int J Cardiol 2019;286:117–20. https://doi.org/10.1016/j.ijcard.2019.03.031
Google ScholarCrossrefWorldCat 
1515	Galian-Gay L, Carro Hevia A, Teixido-Turà G, Rodríguez Palomares J, Gutiérrez-Moreno L, Maldonado G, et al.  Familial clustering of bicuspid aortic valve and its relationship with aortic dilation in first-degree relatives. Heart 2019;105:603–8. https://doi.org/10.1136/heartjnl-2018-313802
Google ScholarWorldCat 
1516	Tessler I, Leshno M, Shmueli A, Shpitzen S, Durst R, Gilon D. Cost-effectiveness analysis of screening for first-degree relatives of patients with bicuspid aortic valve. Eur Heart J Qual Care Clin Outcomes 2021;7:447–57. https://doi.org/10.1093/ehjqcco/qcab047
Google ScholarCrossrefWorldCat 
1517	Girdauskas E, Rouman M, Disha K, Espinoza A, Misfeld M, Borger MA, et al.  Aortic dissection after previous aortic valve replacement for bicuspid aortic valve disease. J Am Coll Cardiol 2015;66:1409–11. https://doi.org/10.1016/j.jacc.2015.07.022
Google ScholarCrossrefWorldCat 
1518	Masri A, Kalahasti V, Svensson LG, Alashi A, Schoenhagen P, Roselli EE, et al.  Aortic cross-sectional area/height ratio and outcomes in patients with bicuspid aortic valve and a dilated ascending aorta. Circ Cardiovasc Imaging 2017;10:e006249. https://doi.org/10.1161/circimaging.116.006249
Google ScholarCrossrefWorldCat 
1519	Della Corte A, Michelena HI, Citarella A, Votta E, Piatti F, Lo Presti F, et al.  Risk stratification in bicuspid aortic valve aortopathy: emerging evidence and future perspectives. Curr Probl Cardiol 2021;46:100428. https://doi.org/10.1016/j.cpcardiol.2019.06.002
Google ScholarCrossrefWorldCat 
1520	Ye Z, Lane C, Beachey JD. Clinical outcomes in patients with bicuspid aortic valves and ascending aorta ≥50 mm under surveillance. JACC: Advances 2023;2:100626. https://doi.org/10.1016/j.jacadv.2023.100626.
Google ScholarWorldCat 
1521	Michelena HI, Khanna AD, Mahoney D, Margaryan E, Topilsky Y, Suri RM, et al.  Incidence of aortic complications in patients with bicuspid aortic valves. JAMA 2011;306:1104–12. https://doi.org/10.1001/jama.2011.1286
Google ScholarCrossrefWorldCat 
1522	Michelena HI, Desjardins VA, Avierinos JF, Russo A, Nkomo VT, Sundt TM, et al.  Natural history of asymptomatic patients with normally functioning or minimally dysfunctional bicuspid aortic valve in the community. Circulation 2008;117:2776–84. https://doi.org/10.1161/CIRCULATIONAHA.107.740878
Google ScholarCrossrefWorldCat 
1523	Girdauskas E, Disha K, Secknus M, Borger M, Kuntze T. Increased risk of late aortic events after isolated aortic valve replacement in patients with bicuspid aortic valve insufficiency versus stenosis. J Cardiovasc Surg (Torino) 2013;54:653–9.
Google ScholarWorldCat 
1524	Cortenbach KRG, Yosofi B, Rodwell L, Meek J, Patel R, Prakash SK, et al.  Editor’s choice—therapeutic options and outcomes in midaortic syndrome: a systematic review and meta-analysis. Eur J Vasc Endovasc Surg 2023;65:120–30. https://doi.org/10.1016/j.ejvs.2022.10.017
Google ScholarCrossrefWorldCat 
1525	Teo LL, Cannell T, Babu-Narayan SV, Hughes M, Mohiaddin RH. Prevalence of associated cardiovascular abnormalities in 500 patients with aortic coarctation referred for cardiovascular magnetic resonance imaging to a tertiary center. Pediatr Cardiol 2011;32:1120–7. https://doi.org/10.1007/s00246-011-9981-0
Google ScholarCrossrefWorldCat 
1526	Spaziani G, Girolami F, Arcieri L, Calabri GB, Porcedda G, Di Filippo C, et al.  Bicuspid aortic valve in children and adolescents: a comprehensive review. Diagnostics (Basel) 2022;12:1751. https://doi.org/10.3390/diagnostics12071751
Google ScholarCrossrefWorldCat 
1527	Raissadati A, Nieminen H, Haukka J, Sairanen H, Jokinen E. Late causes of death after pediatric cardiac surgery: a 60-year population-based study. J Am Coll Cardiol 2016;68:487–98. https://doi.org/10.1016/j.jacc.2016.05.038
Google ScholarCrossrefWorldCat 
1528	Panzer J, Bové T, Vandekerckhove K, De Wolf D. Hypertension after coarctation repair–a systematic review. Transl Pediatr 2022;11:270–9. https://doi.org/10.21037/tp-21-418
Google ScholarCrossrefWorldCat 
1529	Batlivala SP, Goldstein BH. Current transcatheter approaches for the treatment of aortic coarctation in children and adults. Interv Cardiol Clin 2019;8:47–58. https://doi.org/10.1016/j.iccl.2018.08.001
Google ScholarWorldCat 
1530	Egbe AC, Miranda WR, Bonnichsen CR, Warnes CA, Connolly HM. Potential benefits of ambulatory blood pressure monitoring in coarctation of aorta. J Am Coll Cardiol 2020;75:2089–90. https://doi.org/10.1016/j.jacc.2020.02.053
Google ScholarCrossrefWorldCat 
1531	Luitingh TL, Lee MGY, Jones B, Kowalski R, Weskamp Aguero S, Koleff J, et al.  A cross-sectional study of the prevalence of exercise-induced hypertension in childhood following repair of coarctation of the aorta. Heart Lung Circ 2019;28:792–9. https://doi.org/10.1016/j.hlc.2018.03.015
Google ScholarCrossrefWorldCat 
1532	Brown ML, Burkhart HM, Connolly HM, Dearani JA, Cetta F, Li Z, et al.  Coarctation of the aorta: lifelong surveillance is mandatory following surgical repair. J Am Coll Cardiol 2013;62:1020–5. https://doi.org/10.1016/j.jacc.2013.06.016
Google ScholarCrossrefWorldCat 
1533	Somers T, Nies H, van Kimmenade RRJ, Bosboom DGH, Geuzebroek GSC, Morshuis WJ. Necessity of life-long follow-up after surgery for coarctation of the aorta: a case series of very late false aneurysm formation. Eur Heart J Case Rep 2022;6:ytac073. https://doi.org/10.1093/ehjcr/ytac073
Google ScholarCrossrefWorldCat 
1534	Padang R, Dennis M, Semsarian C, Bannon PG, Tanous DJ, Celermajer DS, et al.  Detection of serious complications by MR imaging in asymptomatic young adults with repaired coarctation of the aorta. Heart Lung Circ 2014;23:332–8. https://doi.org/10.1016/j.hlc.2013.10.055
Google ScholarCrossrefWorldCat 
1535	Bhatt AB, Lantin-Hermoso MR, Daniels CJ, Jaquiss R, Landis BJ, Marino BS, et al.  Isolated coarctation of the aorta: current concepts and perspectives. Front Cardiovasc Med 2022;9:817866. https://doi.org/10.3389/fcvm.2022.817866
Google ScholarCrossrefWorldCat 
1536	Erben Y, Oderich GS, Verhagen HJM, Witsenburg M, van den Hoven AT, Debus ES, et al.  Multicenter experience with endovascular treatment of aortic coarctation in adults. J Vasc Surg 2019;69:671–9.e1. https://doi.org/10.1016/j.jvs.2018.06.209
Google ScholarCrossrefWorldCat 
1537	Meijs TA, Warmerdam EG, Slieker MG, Krings GJ, Molenschot MMC, Meijboom FJ, et al.  Medium-term systemic blood pressure after stenting of aortic coarctation: a systematic review and meta-analysis. Heart 2019;105:1464–70. https://doi.org/10.1136/heartjnl-2019-314965
Google ScholarCrossrefWorldCat 
1538	Layton KF, Kallmes DF, Cloft HJ, Lindell EP, Cox VS. Bovine aortic arch variant in humans: clarification of a common misnomer. AJNR Am J Neuroradiol 2006;27:1541–2.
Google ScholarWorldCat 
1539	Berko NS, Jain VR, Godelman A, Stein EG, Ghosh S, Haramati LB. Variants and anomalies of thoracic vasculature on computed tomographic angiography in adults. J Comput Assist Tomogr 2009;33:523–8. https://doi.org/10.1097/RCT.0b013e3181888343
Google ScholarCrossrefWorldCat 
1540	Dumfarth J, Peterss S, Kofler M, Plaikner M, Ziganshin BA, Schachner T, et al.  In DeBakey type I aortic dissection, bovine aortic arch is associated with arch tears and stroke. Ann Thorac Surg 2017;104:2001–8. https://doi.org/10.1016/j.athoracsur.2017.05.026
Google ScholarCrossrefWorldCat 
1541	Hornick M, Moomiaie R, Mojibian H, Ziganshin B, Almuwaqqat Z, Lee ES, et al.  ‘Bovine’ aortic arch—a marker for thoracic aortic disease. Cardiology 2012;123:116–24. https://doi.org/10.1159/000342071
Google ScholarCrossrefWorldCat 
1542	Yousef S, Singh S, Alkukhun A, Alturkmani B, Mori M, Chen J, et al.  Variants of the aortic arch in adult general population and their association with thoracic aortic aneurysm disease. J Card Surg 2021;36:2348–54. https://doi.org/10.1111/jocs.15563
Google ScholarCrossrefWorldCat 
1543	Tanaka A, Milner R, Ota T. Kommerell’s diverticulum in the current era: a comprehensive review. Gen Thorac Cardiovasc Surg 2015;63:245–59. https://doi.org/10.1007/s11748-015-0521-3
Google ScholarCrossrefWorldCat 
1544	Upchurch GR, Jr, Escobar GA, Azizzadeh A, Beck AW, Conrad MF, Matsumura JS, et al.  Society for Vascular Surgery clinical practice guidelines of thoracic endovascular aortic repair for descending thoracic aortic aneurysms. J Vasc Surg 2021;73:55s–83s. https://doi.org/10.1016/j.jvs.2020.05.076
Google ScholarCrossrefWorldCat 
1545	Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, et al.  Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001;286:1317–24. https://doi.org/10.1001/jama.286.11.1317
Google ScholarCrossrefWorldCat 
1546	Suárez C, Zeymer U, Limbourg T, Baumgartner I, Cacoub P, Poldermans D, et al.  Influence of polyvascular disease on cardiovascular event rates. Insights from the REACH registry. Vasc Med 2010;15:259–65. https://doi.org/10.1177/1358863x10373299
Google ScholarCrossrefWorldCat 
1547	Alberts MJ, Bhatt DL, Mas JL, Ohman EM, Hirsch AT, Rother J, et al.  Three-year follow-up and event rates in the international REduction of atherothrombosis for continued health registry. Eur Heart J 2009;30:2318–26. https://doi.org/10.1093/eurheartj/ehp355
Google ScholarCrossrefWorldCat 
1548	van den Berg MJ, Bhatt DL, Kappelle LJ, de Borst GJ, Cramer MJ, van der Graaf Y, et al.  Identification of vascular patients at very high risk for recurrent cardiovascular events: validation of the current ACC/AHA very high risk criteria. Eur Heart J 2017;38:3211–8. https://doi.org/10.1093/eurheartj/ehx102
Google ScholarCrossrefWorldCat 
1549	Subherwal S, Bhatt DL, Li S, Wang TY, Thomas L, Alexander KP, et al.  Polyvascular disease and long-term cardiovascular outcomes in older patients with non-ST-segment-elevation myocardial infarction. Circ Cardiovasc Qual Outcomes 2012;5:541–9. https://doi.org/10.1161/circoutcomes.111.964379
Google ScholarCrossrefWorldCat 
1550	van der Meer MG, Cramer MJ, van der Graaf Y, Appelman Y, Doevendans PA, Nathoe HM. The impact of polyvascular disease on long-term outcome in percutaneous coronary intervention patients. Eur J Clin Invest 2014;44:231–9. https://doi.org/10.1111/eci.12222
Google ScholarCrossrefWorldCat 
1551	Steinvil A, Sadeh B, Arbel Y, Justo D, Belei A, Borenstein N, et al.  Prevalence and predictors of concomitant carotid and coronary artery atherosclerotic disease. J Am Coll Cardiol 2011;57:779–83. https://doi.org/10.1016/j.jacc.2010.09.047
Google ScholarCrossrefWorldCat 
1552	Ahmed B, Al-Khaffaf H. Prevalence of significant asymptomatic carotid artery disease in patients with peripheral vascular disease: a meta-analysis. Eur J Vasc Endovasc Surg 2009;37:262–71. https://doi.org/10.1016/j.ejvs.2008.10.017
Google ScholarCrossrefWorldCat 
1553	Mukherjee D, Eagle KA, Kline-Rogers E, Feldman LJ, Juliard J-M, Agnelli G, et al.  Impact of prior peripheral arterial disease and stroke on outcomes of acute coronary syndromes and effect of evidence-based therapies (from the global registry of acute coronary events). Am J Cardiol 2007;100:1–6. https://doi.org/10.1016/j.amjcard.2007.02.046
Google ScholarCrossrefWorldCat 
1554	Fowkes FG, Low LP, Tuta S, Kozak J. Ankle-brachial index and extent of atherothrombosis in 8891 patients with or at risk of vascular disease: results of the international AGATHA study. Eur Heart J 2006;27:1861–7. https://doi.org/10.1093/eurheartj/ehl114
Google ScholarCrossrefWorldCat 
1555	Durand DJ, Perler BA, Roseborough GS, Grega MA, Borowicz LM, Baumgartner WA, et al.  Mandatory versus selective preoperative carotid screening: a retrospective analysis. Ann Thorac Surg 2004;78:159–66; discussion 159–66. https://doi.org/10.1016/j.athoracsur.2004.02.024
Google ScholarCrossrefWorldCat 
1556	Naylor AR, Mehta Z, Rothwell PM, Bell PR. Carotid artery disease and stroke during coronary artery bypass: a critical review of the literature. Eur J Vasc Endovasc Surg 2002;23:283–94. https://doi.org/10.1053/ejvs.2002.1609
Google ScholarCrossrefWorldCat 
1557	Jens S, Koelemay MJ, Reekers JA, Bipat S. Diagnostic performance of computed tomography angiography and contrast-enhanced magnetic resonance angiography in patients with critical limb ischaemia and intermittent claudication: systematic review and meta-analysis. Eur Radiol 2013;23:3104–14. https://doi.org/10.1007/s00330-013-2933-8
Google ScholarCrossrefWorldCat 
1558	Illuminati G, Schneider F, Greco C, Mangieri E, Schiariti M, Tanzilli G, et al.  Long-term results of a randomized controlled trial analyzing the role of systematic pre-operative coronary angiography before elective carotid endarterectomy in patients with asymptomatic coronary artery disease. Eur J Vasc Endovasc Surg 2015;49:366–74. https://doi.org/10.1016/j.ejvs.2014.12.030
Google ScholarCrossrefWorldCat 
1559	Eikelboom JW, Bhatt DL, Fox KAA, Bosch J, Connolly SJ, Anand SS, et al.  Mortality benefit of rivaroxaban plus aspirin in patients with chronic coronary or peripheral artery disease. J Am Coll Cardiol 2021;78:14–23. https://doi.org/10.1016/j.jacc.2021.04.083
Google ScholarCrossrefWorldCat 
1560	Aboyans V, Lacroix P, Postil A, Guilloux J, Rollé F, Cornu E, et al.  Subclinical peripheral arterial disease and incompressible ankle arteries are both long-term prognostic factors in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol 2005;46:815–20. https://doi.org/10.1016/j.jacc.2005.05.066
Google ScholarCrossrefWorldCat 
1561	Rihal CS, Sutton-Tyrrell K, Guo P, Keller NM, Jandova R, Sellers MA, et al.  Increased incidence of periprocedural complications among patients with peripheral vascular disease undergoing myocardial revascularization in the bypass angioplasty revascularization investigation. Circulation 1999;100:171–7. https://doi.org/10.1161/01.cir.100.2.171
Google ScholarCrossrefWorldCat 
1562	Aboyans V, Lacroix P. Indications for carotid screening in patients with coronary artery disease. Presse Med 2009;38:977–86. https://doi.org/10.1016/j.lpm.2009.02.015
Google ScholarCrossrefWorldCat 
1563	Collet JP, Cayla G, Ennezat PV, Leclercq F, Cuisset T, Elhadad S, et al.  Systematic detection of polyvascular disease combined with aggressive secondary prevention in patients presenting with severe coronary artery disease: the randomized AMERICA study. Int J Cardiol 2018;254:36–42. https://doi.org/10.1016/j.ijcard.2017.11.081
Google ScholarCrossrefWorldCat 
1564	Neufang A, Dorweiler B, Espinola-Klein C, Savvidis S, Doemland M, Schotten S, et al.  Outcomes of complex femorodistal sequential autologous vein and biologic prosthesis composite bypass grafts. J Vasc Surg 2014;60:1543–53. https://doi.org/10.1016/j.jvs.2014.07.103
Google ScholarCrossrefWorldCat 
1565	Calvet D, Touzé E, Varenne O, Sablayrolles J-L, Weber S, Mas J-L. Prevalence of asymptomatic coronary artery disease in ischemic stroke patients: the PRECORIS study. Circulation 2010;121:1623–9. https://doi.org/10.1161/circulationaha.109.906958
Google ScholarCrossrefWorldCat 
1566	Hofmann R, Kypta A, Steinwender C, Kerschner K, Grund M, Leisch F. Coronary angiography in patients undergoing carotid artery stenting shows a high incidence of significant coronary artery disease. Heart 2005;91:1438–41. https://doi.org/10.1136/hrt.2004.050906
Google ScholarCrossrefWorldCat 
1567	Masabni K, Raza S, Blackstone EH, Gornik HL, Sabik JF, III. Does preoperative carotid stenosis screening reduce perioperative stroke in patients undergoing coronary artery bypass grafting? J Thorac Cardiovasc Surg 2015;149:1253–60. https://doi.org/10.1016/j.jtcvs.2015.02.003
Google ScholarCrossrefWorldCat 
1568	Klarin D, Patel VI, Zhang S, Xian Y, Kosinski A, Yerokun B, et al.  Concomitant carotid endarterectomy and cardiac surgery does not decrease postoperative stroke rates. J Vasc Surg 2020;72:589–96.e3. https://doi.org/10.1016/j.jvs.2019.10.072
Google ScholarCrossrefWorldCat 
1569	D'Agostino RS, Svensson LG, Neumann DJ, Balkhy HH, Williamson WA, Shahian DM. Screening carotid ultrasonography and risk factors for stroke in coronary artery surgery patients. Ann Thorac Surg 1996;62:1714–23. https://doi.org/10.1016/s0003-4975(96)00885-5
Google ScholarCrossrefWorldCat 
1570	Weissler EH, Jones WS, Desormais I, Debus S, Mazzolai L, Espinola-Klein C, et al.  Polyvascular disease: a narrative review of current evidence and a consideration of the role of antithrombotic therapy. Atherosclerosis 2020;315:10–7. https://doi.org/10.1016/j.atherosclerosis.2020.11.001
Google ScholarCrossrefWorldCat 
1571	Alkhalil M, Kuzemczak M, Whitehead N, Kavvouras C, Džavík V. Meta-analysis of intensive lipid-lowering therapy in patients with polyvascular disease. J Am Heart Assoc 2021;10:e017948. https://doi.org/10.1161/jaha.120.017948
Google ScholarCrossrefWorldCat 
1572	Ward RP, Goonewardena SN, Lammertin G, Lang RM. Comparison of the frequency of abnormal cardiac findings by echocardiography in patients with and without peripheral arterial disease. Am J Cardiol 2007;99:499–503. https://doi.org/10.1016/j.amjcard.2006.09.102
Google ScholarCrossrefWorldCat 
1573	Kelly R, Staines A, MacWalter R, Stonebridge P, Tunstall-Pedoe H, Struthers AD. The prevalence of treatable left ventricular systolic dysfunction in patients who present with noncardiac vascular episodes: a case-control study. J Am Coll Cardiol 2002;39:219–24. https://doi.org/10.1016/s0735-1097(01)01725-9
Google ScholarCrossrefWorldCat 
1574	Samsky MD, Hellkamp A, Hiatt WR, Fowkes FGR, Baumgartner I, Berger JS, et al.  Association of heart failure with outcomes among patients with peripheral artery disease: insights from EUCLID. J Am Heart Assoc 2021;10:e018684. https://doi.org/10.1161/jaha.120.018684
Google ScholarCrossrefWorldCat 
1575	Kahan T. The importance of myocardial fibrosis in hypertensive heart disease. J Hypertens 2012;30:685–7. https://doi.org/10.1097/HJH.0b013e328350e5db
Google ScholarCrossrefWorldCat 
1576	O'Rourke MF, Safar ME, Dzau V. The Cardiovascular Continuum extended: aging effects on the aorta and microvasculature. Vasc Med 2010;15:461–8. https://doi.org/10.1177/1358863x10382946
Google ScholarCrossrefWorldCat 
1577	Duscha BD, Annex BH, Green HJ, Pippen AM, Kraus WE. Deconditioning fails to explain peripheral skeletal muscle alterations in men with chronic heart failure. J Am Coll Cardiol 2002;39:1170–4. https://doi.org/10.1016/s0735-1097(02)01740-0
Google ScholarCrossrefWorldCat 
1578	Mancini DM, Walter G, Reichek N, Lenkinski R, McCully KK, Mullen JL, et al.  Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure. Circulation 1992;85:1364–73. https://doi.org/10.1161/01.cir.85.4.1364
Google ScholarCrossrefWorldCat 
1579	Hedberg P, Hammar C, Selmeryd J, Viklund J, Leppert J, Hellberg A, et al.  Left ventricular systolic dysfunction in outpatients with peripheral atherosclerotic vascular disease: prevalence and association with location of arterial disease. Eur J Heart Fail 2014;16:625–32. https://doi.org/10.1002/ejhf.95
Google ScholarCrossrefWorldCat 
1580	Sandesara PB, Hammadah M, Samman-Tahhan A, Kelli HM, O’Neal WT. Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clin Cardiol 2017;40:692–6. https://doi.org/10.1002/clc.22716
Google ScholarCrossrefWorldCat 
1581	Nakamura Y, Kunii H, Yoshihisa A, Takiguchi M, Shimizu T, Yamauchi H, et al.  Impact of peripheral artery disease on prognosis in hospitalized heart failure patients. Circ J 2015;79:785–93. https://doi.org/10.1253/circj.CJ-14-1280
Google ScholarCrossrefWorldCat 
1582	Inglis SC, Bebchuk J, Al-Suhaim SA, Case J, Pfeffer MA, Solomon SD, et al.  Peripheral artery disease and outcomes after myocardial infarction: an individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT. Int J Cardiol 2013;168:1094–101. https://doi.org/10.1016/j.ijcard.2012.11.033
Google ScholarCrossrefWorldCat 
1583	Jones WS, Clare R, Ellis SJ, Mills JS, Fischman DL, Kraus WE, et al.  Effect of peripheral arterial disease on functional and clinical outcomes in patients with heart failure (from HF-ACTION). Am J Cardiol 2011;108:380–4. https://doi.org/10.1016/j.amjcard.2011.03.057
Google ScholarCrossrefWorldCat 
1584	van Straten AH, Firanescu C, Soliman Hamad MA, Tan MESH, ter Woorst JFJ, Martens EJ, et al.  Peripheral vascular disease as a predictor of survival after coronary artery bypass grafting: comparison with a matched general population. Ann Thorac Surg 2010;89:414–20. https://doi.org/10.1016/j.athoracsur.2009.11.036
Google ScholarCrossrefWorldCat 
1585	Goto S, Bhatt DL, Rother J, Alberts M, Hill MD, Ikeda Y, et al.  Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J 2008;156:855–63, 863.e2. https://doi.org/10.1016/j.ahj.2008.06.029
Google ScholarCrossrefWorldCat 
1586	Olesen JB, Gislason GH, Torp-Pedersen C, Lip GY. Atrial fibrillation and vascular disease—a bad combination. Clin Cardiol 2012;35:15–20. https://doi.org/10.1002/clc.20955
Google ScholarWorldCat 
1587	Parvar SL, Thiyagarajah A, Nerlekar N, King P, Nicholls SJ. A systematic review and meta-analysis of gender differences in long-term mortality and cardiovascular events in peripheral artery disease. J Vasc Surg 2021;73:1456–65.e7. https://doi.org/10.1016/j.jvs.2020.09.039
Google ScholarCrossrefWorldCat 
1588	Depta JP, Bhatt DL. Atherothrombosis and atrial fibrillation: important and often overlapping clinical syndromes. Thromb Haemost 2010;104:657–63. https://doi.org/10.1160/th10-05-0332
Google ScholarCrossrefWorldCat 
1589	Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2n–9n. https://doi.org/10.1016/s0002-9149(98)00583-9
Google ScholarCrossrefWorldCat 
1590	Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham heart study. JAMA 1994;271:840–4.
Google ScholarCrossrefWorldCat 
1591	Zhu J, Tan X, Zhou JZ. Peripheral artery disease and clinical outcomes in patients with atrial fibrillation: a systematic review and meta-analysis. Clin Cardiol 2021;44:1050–7. https://doi.org/10.1002/clc.23678
Google ScholarCrossrefWorldCat 
1592	Olesen JB, Lip GY, Lane DA, Køber L, Hansen ML, Karasoy D, et al.  Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study. Am J Med 2012;125:826.e13–23. https://doi.org/10.1016/j.amjmed.2011.11.024
Google ScholarCrossrefWorldCat 
1593	Skelding KA, Yakubov SJ, Kleiman NS, Reardon MJ, Adams DH, Huang J, et al.  Transcatheter aortic valve replacement versus surgery in women at high risk for surgical aortic valve replacement (from the CoreValve US High Risk Pivotal Trial). Am J Cardiol 2016;118:560–6. https://doi.org/10.1016/j.amjcard.2016.05.051
Google ScholarCrossrefWorldCat 
1594	Gilard M, Eltchaninoff H, Iung B, Donzeau-Gouge P, Chevreul K, Fajadet J, et al.  Registry of transcatheter aortic-valve implantation in high-risk patients. N Engl J Med 2012;366:1705–15. https://doi.org/10.1056/NEJMoa1114705
Google ScholarCrossrefWorldCat 
1595	Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al.  Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010;363:1597–607. https://doi.org/10.1056/NEJMoa1008232
Google ScholarCrossrefWorldCat 
1596	Reindl M, Lechner I, Holzknecht M, Tiller C, Fink P, Oberhollenzer F, et al.  Cardiac magnetic resonance imaging versus computed tomography to guide transcatheter aortic valve replacement (TAVR-CMR): a randomized, open-label, non-inferiority trial. Circulation 2023;148:1220–30. https://doi.org/10.1161/CIRCULATIONAHA.123.066498
Google ScholarCrossrefWorldCat 
1597	Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al.  2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42:373–498. https://doi.org/10.1093/eurheartj/ehaa612
Google ScholarCrossrefWorldCat 
1598	Fanaroff AC, Manandhar P, Holmes DR, Cohen DJ, Harrison JK, Hughes GC, et al.  Peripheral artery disease and transcatheter aortic valve replacement outcomes: a report from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Therapy Registry. Circ Cardiovasc Interv 2017;10:e005456. https://doi.org/10.1161/CIRCINTERVENTIONS.117.005456
Google ScholarCrossrefWorldCat 

## Author notes

Lucia Mazzolai and Jose F Rodriguez-Palomares Chairpersons contributed equally to the document and are joint corresponding authors.

Gisela Teixido-Tura and Stefano Lanzi Task Force Co-ordinators contributed equally to the document.

**Author/Task Force Member affiliations are listed in author information.**

Representing the European Society of Vascular Medicine (ESVM)

Representing the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN)

**ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.**

**ESC subspecialty communities having participated in the development of this document:**

**Associations:** Association for Acute CardioVascular Care (ACVC), Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of Cardiovascular Imaging (EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), Heart Failure Association (HFA).

**Councils:** Council for Cardiology Practice, Council on Hypertension.

**Working Groups:** Adult Congenital Heart Disease, Aorta and Peripheral Vascular Diseases, Cardiovascular Surgery, Thrombosis.

**Patient Forum**

![graphic](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/m_ehae179il3.jpeg?Expires=1728479087&Signature=ES4FBNAEPlskBJTQSnOwRQxGBs99LYJB4Nj1m2~jWc49x6Vjr0kwbZ9rvllg8UdO83BzH429yc~2R7W~6BEx3bsxb6rALJAu7blt12KK0amfYOskcZuCKJHUV0TzSrzR-odwJ6nIwJ2r~IS03Bu0advi9EUCkwCvRZk95rkYRoN9B0ND4v5AI6ZHAcWvDItoxkARNEqVifv3Io8XFt1RIjmdtYl~pDDz9ebJZeeUnZapXymeV9uNUewESI8c9f6pxkiaeAt4YcjZ1YoPld-dmlWEZHH4~Q3-K4S4vPlTiP3iRQlJM68n26ZDVIJGKIAW5PD2xaEkvaVFY1F7tkKHZw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)**All experts involved in the development of these guidelines have submitted declarations of interest which are reported in a supplementary document to the guidelines. See the _European Heart Journal_ online or [https://www.escardio.org/Guidelines](https://www.escardio.org/Guidelines) for supplementary documents as well as evidence tables**

**Disclaimer**. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription. The ESC warns readers that the technical language may be misinterpreted and declines any responsibility in this respect.

**Permissions**. The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permissions can be obtained upon submission of a written request to Oxford University Press, the publisher of the _European Heart Journal_ and the party authorized to handle such permissions on behalf of the ESC ([journals.permissions@oup.com](mailto:journals.permissions@oup.com)).

© The European Society of Cardiology 2024. All rights reserved. For permissions, please email: journals.permissions@oup.com.

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ([https://academic.oup.com/pages/standard-publication-reuse-rights](https://academic.oup.com/pages/standard-publication-reuse-rights))

## Supplementary data

[ehae179\_Supplementary\_Data](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/ehae179_supplementary_data.pdf?Expires=1728479089&Signature=AdqRXDap7pdhltwNvunHQTU9t2lmBaZZaNqVP9gLkMGaFltmT19j0YvANk~7KN3YLYNbrQW0qtmcV8DQoLV9HwWR1qn5B6KAW2JGb~nfbGlfKNDbzfic3F5Eoj1RcONPXWhwLpV6nC5LOVC5q1WFBYg7d4GqlmV8m1uUshcbshSUFtSqlScxq2fxqCI~7EoU7OP~jiPBlnqYgVEwcKsFfPdsAOBRRZHBXT-dUl9Q4pe8-jjlMchu74aup9t97hKnVoOnazXzin3yFH-ce6YmanNQFN3O9hBhwFx~pDNU11EJUsFnbJtjbru0VuI9bM00qWnL9rQhGAwSonYvunh1lQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) - pdf file

[2024\_ESC\_Guidelines\_PAAD\_EvidenceTables](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/2024_esc_guidelines_paad_evidencetables.pdf?Expires=1728479089&Signature=SLIVsv~-0hyc7-LKJ2wgY1RaNsCbT-m2nrUwVSiHhzRbrP9zXqPJ3ELZsNl763UJIgbwNFFAZJ7bRMlsGMmcpett4AcAkIiQTX3W4OJYbDEDRI484TqnzFQlG7A3LYEZxlVkziF6A~0H~9F2zvGvbgrmrWPhW7I2cmvpAcUsH1yhevwnuhnoBEKb2S-ngtzkusj3p6RoutekUXOBdx8ojXHxNbHnpRMO~cXxVR-JCM24Bjq3VdxjUa4hSARhcr-9Ppl4XJhbdVw4RRbGtNPlIqqY7XppqUWmjw5t7CUPxCTfNd9PkDj3RSOigo6asO~K0mgCJUcVIiwAqM0HVLIEng__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) - pdf file

[DOI\_summary\_2024\_ESC\_Guidelines\_PAAD\_ehae179](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae179/5/doi_summary_2024_esc_guidelines_paad_ehae179.pdf?Expires=1728479089&Signature=xICJTjuKPtcP5tLLegiAoxtNBNSQUxZ~EB09uJwQt-uKVnjvXwRk2OA~x94RLx2m7qxTotjKpmuoLngqblhE62pwyOoRUVKKIle8IXsbj5IE7QZ3pVdxtLdehg69ozjN5pmAiBBnPOaJ0Y00r509e-XMeaaVdtpoOJPSb~UuvIdMqy0PVO2jx04FaDbDgNcBORD1212zpT3DOJl961GIshhavEgiHTR4DXPtGNis~MfJVHcTueWNv7vHCg3-7k-n9ol9sAFjdj65xL2ReAOcxvEMLcm8RME9-mnApAkRkIWnDq8ASDA~fu57lk3ne-kwe9M7fPIAxG562VqHuyxj~Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) - pdf file
